The|O paternal|O uncle|O (|O patient|O number|O 7107|O ;|O P4|O ,|O II|O ,|O 3|O )|O ,|O although|O not|O tested|O ,|O has|O a|O presentation|O evocating|O a|O GATA2|O mutation|O with|O recurrent|O warts|O associated|O with|O mild|O neutropenia|O and|O monocytopenia|O .|O
Patients|O with|O CMML|O -|O 2|O were|O more|O likely|O to|O have|O lower|O hemoglobin|O levels|O (|O P|O =|O 0|O .|O 04|O )|O ,|O higher|O AMC|O (|O P|O =|O 0|O .|O 03|O )|O ,|O lower|O platelet|O counts|O (|O P|O =|O 0|O .|O 0007|O )|O ,|O higher|O likelihood|O of|O circulating|O blasts|O and|O IMC|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O and|O higher|O risk|O of|O karyotypic|O abnormalities|O (|O P|O <|O 0|O .|O 0001|O )|O .|O
Patients|O with|O t|O (|O 15|O ;|O 17|O )|O were|O excluded|O from|O any|O analyses|O .|O
During|O this|O transition|O from|O the|O FAB|O system|O to|O the|O WHO|O classification|O ,|O the|O percent|O blasts|O threshold|O for|O defining|O high|O -|O grade|O MDS|O and|O AML|O was|O lowered|O .|O
Presumably|O ,|O these|O results|O reflect|O differences|O in|O analytical|O sensitivity|O among|O the|O participating|O laboratories|O .|O
Moreover|O ,|O knockdown|O of|O Asxl1|O using|O shRNA|O in|O vivo|O in|O a|O mouse|O model|O of|O haematopoietic|O NrasG12D|O overexpression|O resulted|O in|O accelerated|O disease|O latency|O and|O increased|O disease|O burden|O in|O vivo|O ,|O with|O concomitant|O loss|O of|O Asxl1|O (|O REF|O .|O 86|O )|O .|O
Before|O the|O evolution|O to|O MDS|O or|O AML|O ,|O a|O median|O of|O 4|O blood|O counts|O were|O available|O per|O patient|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
Using|O a|O mammalian|O suppressor|O mutation|O approach|O ,|O the|O functional|O importance|O of|O the|O GATA1|O /|O FOG1|O interaction|O was|O established|O ,|O showing|O that|O physical|O association|O of|O GATA1|O with|O FOG1|O is|O required|O for|O erythroid|O differentiation|O .|O
Moreover|O ,|O it|O has|O been|O reported|O in|O a|O zebrafish|O model|O that|O GATA2|O is|O regulated|O by|O the|O microRNA|O (|O miRNA|O )|O miR|O -|O 451|O .|O
Somatic|O deletions|O and|O inactivating|O mutations|O in|O TET2|O were|O identified|O in|O MPN|O and|O MDS|O based|O on|O mapping|O of|O loss|O -|O of|O -|O heterozygosity|O and|O microdeletions|O within|O a|O minimal|O region|O of|O chromosome|O 4q24|O (|O REFS|O 25|O ,|O 26|O )|O .|O
Kaplan|O -|O Meier|O survival|O curves|O corresponding|O to|O the|O 5|O score|O categories|O were|O significantly|O different|O by|O log|O rank|O -|O test|O (|O Figure|O 6|O ,|O P|O <|O .|O 001|O )|O .|O
Karyotype|O .|O
Clinical|O parameters|O studied|O included|O age|O ,|O gender|O ,|O overall|O survival|O (|O OS|O )|O ,|O and|O blood|O counts|O .|O
As|O indicated|O above|O ,|O GATA2|O expression|O is|O critical|O throughout|O various|O stages|O of|O hematopoiesis|O ,|O and|O its|O levels|O partly|O determine|O the|O fate|O along|O different|O myeloid|O cell|O lineages|O ;|O for|O this|O reason|O ,|O GATA2|O expression|O is|O tightly|O regulated|O .|O
At|O present|O ,|O only|O limited|O information|O is|O available|O about|O the|O distribution|O of|O BCOR|O and|O BCORL1|O mutations|O across|O the|O main|O cytogenetic|O /|O molecular|O AML|O categories|O .|O
Although|O obtaining|O a|O remission|O is|O the|O first|O step|O in|O controlling|O the|O disease|O ,|O it|O is|O also|O important|O for|O patients|O to|O emerge|O from|O the|O induction|O phase|O in|O a|O condition|O to|O tolerate|O subsequent|O ,|O more|O intensive|O treatments|O during|O consolidation|O to|O achieve|O durable|O disease|O control|O .|O
In|O addition|O ,|O HLA|O testing|O should|O be|O performed|O promptly|O in|O those|O who|O may|O be|O candidates|O for|O either|O fully|O ablative|O or|O reduced|O -|O intensity|O allogeneic|O HSCT|O from|O a|O matched|O sibling|O or|O an|O unrelated|O donor|O ,|O which|O constitutes|O the|O best|O option|O for|O long|O -|O term|O disease|O control|O .|O
We|O and|O other|O groups|O recently|O identified|O a|O variety|O of|O new|O mutations|O present|O at|O distinct|O frequencies|O in|O subgroups|O of|O patients|O with|O MDS|O .|O
However|O ,|O more|O than|O half|O of|O patients|O with|O myelodysplastic|O syndromes|O have|O a|O normal|O karyotype|O ,|O and|O patients|O with|O identical|O chromosomal|O abnormalities|O are|O often|O clinically|O heterogeneous|O .|O
The|O first|O reported|O pegylated|O INF|O -|O alpha|O (|O 90|O mug|O /|O week|O )|O induced|O hematologic|O remission|O in|O approximately|O 80|O %|O of|O patients|O with|O PV|O and|O 81|O %|O of|O patients|O with|O ET|O (|O complete|O remission|O in|O 70|O %|O with|O PV|O and|O 76|O %|O with|O ET|O )|O and|O molecular|O remission|O in|O 54|O %|O of|O patients|O with|O PV|O and|O 38|O %|O with|O ET|O .|O
OS|O was|O estimated|O using|O the|O Kaplan|O -|O Meier|O product|O limit|O method|O ,|O and|O survival|O curves|O of|O different|O subgroups|O (|O JAK2|O -|O mutant|O ,|O CALR|O -|O mutant|O ,|O MPL|O -|O mutant|O ,|O and|O triple|O -|O negative|O patients|O )|O were|O compared|O by|O the|O log|O -|O rank|O test|O .|O
Studies|O are|O now|O needed|O to|O specifically|O compare|O triple|O -|O negative|O PMF|O with|O the|O myelodysplastic|O syndrome|O associated|O with|O bone|O marrow|O fibrosis|O ,|O but|O a|O nonnegligible|O overlap|O between|O the|O 2|O conditions|O is|O predictable|O .|O
We|O identified|O additional|O somatic|O mutations|O in|O spliceosomal|O genes|O ,|O including|O SF3B1|O ,|O U2AF1|O ,|O and|O SRSF2|O .|O
The|O serious|O and|O usually|O sudden|O infections|O occurring|O in|O 4|O patients|O led|O to|O their|O deaths|O .|O
Notably|O ,|O the|O regulatory|O elements|O responsible|O for|O GATA2|O gene|O expression|O also|O harbor|O GATA|O motifs|O .|O
These|O tended|O to|O be|O low|O positive|O when|O tested|O in|O laboratories|O using|O quantitative|O assays|O ,|O so|O it|O is|O likely|O that|O these|O specimens|O had|O JAK2|O V617F|O levels|O that|O were|O below|O the|O limit|O of|O detection|O for|O most|O laboratories|O .|O
SNP|O array|O analysis|O revealed|O chromosome|O 7|O deletions|O in|O 14|O out|O of|O 102|O subjects|O and|O loss|O of|O heterozygosity|O due|O to|O uniparental|O disomy|O (|O UPD|O )|O in|O two|O subjects|O (|O Fig|O .|O 1a|O )|O .|O
Each|O laboratory|O was|O asked|O to|O provide|O three|O DNA|O specimens|O :|O one|O known|O to|O be|O JAK2|O V617F|O positive|O ,|O one|O weakly|O positive|O ,|O and|O one|O from|O a|O patient|O suspected|O to|O have|O a|O MPN|O but|O that|O was|O found|O to|O be|O JAK2|O V617F|O negative|O .|O
Recently|O ,|O Simon|O et|O al|O reported|O that|O GATA2|O acts|O as|O a|O regulator|O of|O the|O angiopoietin|O -|O 2|O (|O ANG2|O )|O transcription|O ,|O a|O gene|O crucial|O for|O angiogenesis|O .|O
The|O high|O frequency|O of|O mutations|O in|O different|O components|O of|O the|O RNA|O splicing|O machinery|O in|O MDS|O suggests|O that|O abnormal|O RNA|O splicing|O is|O the|O common|O consequence|O of|O these|O mutations|O ,|O which|O is|O relevant|O to|O the|O pathogenesis|O of|O MDS|O .|O
We|O propose|O limiting|O the|O use|O of|O hematopoietic|O growth|O factors|O and|O implementing|O intensive|O treatment|O such|O as|O allograft|O in|O patients|O with|O neutropenia|O and|O GATA2|O mutations|O as|O soon|O as|O an|O unrelated|O donor|O has|O been|O identified|O .|O
The|O MD|O Anderson|O Prognostic|O Scoring|O System|O (|O MDAPS|O )|O was|O developed|O in|O a|O cohort|O of|O 213|O CMML|O patients|O and|O identified|O a|O hemoglobin|O level|O <|O 12|O g|O /|O dl|O ,|O presence|O of|O circulating|O immature|O myeloid|O cells|O (|O IMCs|O )|O ,|O absolute|O lymphocyte|O count|O (|O ALC|O )|O >|O 2|O .|O 5|O x|O 109|O /|O l|O and|O >|O 10|O %|O BM|O blasts|O as|O independent|O predictors|O for|O inferior|O survival|O .|O
Based|O on|O their|O analysis|O ,|O three|O cytogenetic|O risk|O categories|O were|O identified|O :|O low|O risk|O (|O diploid|O karyotype|O or|O loss|O of|O chromosome|O Y|O as|O a|O single|O anomaly|O )|O ,|O intermediate|O risk|O (|O all|O other|O abnormalities|O except|O those|O mentioned|O in|O low|O -|O and|O high|O -|O risk|O categories|O )|O and|O high|O risk|O (|O trisomy|O 8|O ,|O abnormalities|O of|O chromosome|O 7|O or|O complex|O karyotype|O )|O ;|O with|O 5|O -|O year|O OS|O for|O the|O three|O groups|O being|O 35|O %|O ,|O 26|O %|O and|O 4|O %|O ,|O respectively|O (|O P|O <|O 0|O .|O 001|O )|O .|O
Mutations|O in|O six|O genes|O -|O ASXL1|O ,|O RUNX1|O ,|O TP53|O ,|O EZH2|O ,|O CBL|O ,|O and|O ETV6|O -|O were|O significant|O predictors|O of|O poor|O overall|O survival|O ,|O after|O adjustment|O for|O IPSS|O risk|O group|O ,|O and|O were|O found|O in|O 74|O of|O 255|O samples|O (|O 29|O .|O 0|O %|O )|O with|O normal|O cytogenetic|O features|O .|O
Further|O ,|O we|O performed|O cox|O multivariable|O analysis|O of|O myeloid|O malignancy|O subtypes|O and|O identified|O that|O presence|O of|O the|O STAG2|O mutation|O predicted|O poor|O survival|O independent|O of|O age|O ,|O sex|O ,|O and|O IPSS|O scores|O in|O high|O -|O and|O low|O -|O risk|O MDS|O patients|O (|O hazard|O ratio|O [|O HR|O ]|O =|O 1|O .|O 5|O [|O 0|O .|O 9|O ,|O 2|O .|O 6|O ]|O ;|O P|O =|O .|O 11|O )|O and|O in|O patients|O with|O MDS|O who|O survived|O beyond|O 12|O months|O (|O HR|O =|O 2|O .|O 1|O [|O 1|O .|O 1|O ,|O 3|O .|O 8|O ]|O ;|O P|O =|O .|O 017|O ;|O Figure|O 3|O )|O .|O
Recent|O studies|O have|O shown|O that|O the|O placement|O of|O 5|O -|O hmC|O leads|O to|O active|O demethylation|O through|O the|O activation|O -|O induced|O cytidine|O deaminase|O (|O AID|O )|O -|O APOBEC|O DNA|O repair|O pathway|O (|O FIG|O .|O 1|O )|O .|O
In|O the|O current|O work|O ,|O we|O studied|O a|O large|O population|O of|O patients|O with|O PMF|O followed|O at|O 4|O different|O centers|O and|O analyzed|O the|O impact|O of|O driver|O mutations|O of|O JAK2|O ,|O CALR|O ,|O or|O MPL|O on|O clinical|O course|O ,|O risk|O of|O leukemic|O transformation|O ,|O and|O OS|O .|O
In|O addition|O ,|O the|O discovery|O of|O these|O mutations|O ,|O particularly|O if|O pathogenic|O or|O initiating|O ,|O will|O provide|O important|O avenues|O for|O exploring|O novel|O therapeutic|O approaches|O toward|O modulating|O their|O effectors|O '|O activity|O .|O
The|O mutational|O status|O for|O cohesin|O complex|O genes|O (|O STAG2|O ,|O STAG1|O ,|O RAD21|O ,|O SMC3|O ,|O SMC1A|O ,|O PDS5B|O ,|O WAPAL|O ,|O MAU2|O ,|O REC8|O ,|O NIPBL|O ,|O SMC5|O ,|O and|O ESCO2|O )|O were|O analyzed|O in|O bone|O marrow|O and|O blood|O specimens|O of|O 1060|O patients|O with|O MDS|O (|O n|O =|O 386|O )|O ,|O MPNs|O (|O n|O =|O 55|O )|O ,|O MDS|O /|O MPNs|O (|O n|O =|O 169|O )|O ,|O and|O sAML|O (|O n|O =|O 149|O )|O that|O evolved|O from|O these|O conditions|O and|O pAML|O (|O n|O =|O 301|O )|O ,|O including|O 200|O patients|O in|O The|O Cancer|O Genome|O Atlas|O (|O TCGA|O )|O AML|O cohort|O (|O see|O supplemental|O Table|O 1|O ,|O available|O at|O the|O Blood|O Web|O site|O )|O .|O
Principles|O of|O AML|O Treatment|O .|O
RNA|O splicing|O is|O accomplished|O by|O recruitment|O and|O disengagement|O of|O multiple|O snRNP|O complexes|O and|O other|O protein|O factors|O to|O newly|O transcribed|O pre|O -|O mRNA|O ,|O through|O which|O exon|O -|O intron|O boundaries|O are|O recognized|O and|O intronic|O sequences|O were|O correctly|O spliced|O out|O to|O generate|O mature|O mRNA|O .|O
In|O contrast|O ,|O in|O various|O malignancies|O ,|O overexpression|O of|O EZH2|O has|O been|O reported|O ,|O suggesting|O that|O EZH2|O might|O also|O act|O as|O an|O oncogene|O .|O
By|O contrast|O ,|O the|O use|O of|O Illumina|O Infinium|O 27k|O methylation|O arrays|O to|O examine|O samples|O from|O patients|O with|O MDS|O and|O other|O chronic|O myeloid|O malignancies|O with|O TET2|O mutations|O suggested|O that|O there|O was|O no|O significant|O difference|O in|O DNA|O methylation|O between|O bone|O marrow|O samples|O from|O patients|O with|O high|O 5|O -|O hmC|O levels|O versus|O healthy|O controls|O .|O
Additional|O exon|O 12|O mutations|O have|O been|O reported|O ,|O but|O their|O clinical|O significance|O is|O unknown|O .|O
We|O found|O that|O among|O the|O initially|O screened|O cohort|O of|O patients|O with|O myeloid|O malignancies|O ,|O mutations|O were|O highly|O recurrent|O in|O U2AF1|O ,|O SF3B1|O ,|O and|O SRSF2|O ,|O whereas|O mutations|O of|O other|O spliceosomal|O genes|O were|O each|O detected|O in|O 1|O of|O 120|O cases|O ,|O indicating|O a|O frequency|O of|O <|O 1|O %|O .|O
These|O observations|O indicate|O that|O driver|O mutations|O define|O distinct|O disease|O entities|O within|O PMF|O .|O
These|O observations|O were|O validated|O in|O the|O Mayo|O Clinic|O cohort|O where|O mutation|O and|O survival|O analyses|O were|O performed|O from|O time|O of|O referral|O .|O
ASXL1|O (|O additional|O sex|O combs|O -|O like|O 1|O gene|O )|O is|O the|O key|O regulator|O in|O histone|O modification|O via|O its|O interaction|O with|O PRC2|O (|O polycomb|O complex|O 2|O )|O ,|O which|O methylates|O the|O 27th|O lysine|O residue|O of|O histone|O H3|O (|O H3K27|O )|O .|O
These|O results|O establish|O fundamental|O principles|O underlying|O GATA|O factor|O mechanisms|O in|O chromatin|O and|O illustrate|O a|O complex|O network|O of|O considerable|O importance|O for|O the|O control|O of|O hematopoiesis|O .|O
Thrombotic|O complications|O occurred|O in|O 76|O of|O 617|O patients|O (|O 12|O %|O )|O with|O PMF|O .|O
Further|O work|O in|O mice|O and|O humans|O is|O needed|O for|O the|O identification|O and|O functional|O validation|O of|O collaborating|O genetic|O events|O that|O cooperate|O with|O TET2|O mutations|O in|O myeloid|O malignancies|O .|O
Mutations|O in|O ASXL1|O ,|O EZH2|O ,|O and|O UTX|O have|O been|O identified|O in|O MDS|O and|O appear|O to|O alter|O histone|O biology|O ,|O resulting|O in|O dysregulation|O of|O gene|O expression|O in|O MDS|O .|O
During|O the|O past|O decade|O ,|O there|O have|O been|O major|O efforts|O to|O better|O define|O the|O genetic|O lesions|O underlying|O the|O large|O group|O of|O AML|O with|O normal|O cytogenetics|O (|O CN|O -|O AML|O )|O that|O accounts|O for|O 40|O -|O 50|O %|O of|O all|O AML|O cases|O .|O
The|O 10|O -|O year|O cumulative|O incidence|O of|O leukemic|O transformation|O was|O 19|O .|O 4|O %|O (|O 95|O %|O CI|O ,|O 13|O .|O 9|O -|O 25|O .|O 6|O )|O in|O JAK2|O -|O mutant|O ,|O 9|O .|O 4|O %|O (|O 95|O %|O CI|O ,|O 4|O .|O 3|O -|O 16|O .|O 8|O )|O in|O CALR|O -|O mutant|O ,|O 16|O .|O 9|O %|O (|O 95|O %|O CI|O ,|O 4|O .|O 1|O -|O 37|O .|O 1|O )|O in|O MPL|O -|O mutant|O ,|O and|O 34|O .|O 4|O %|O (|O 95|O %|O CI|O ,|O 16|O .|O 8|O -|O 52|O .|O 8|O )|O in|O triple|O -|O negative|O subjects|O (|O Figure|O 3|O )|O .|O
Comparison|O among|O the|O 12|O laboratories|O performing|O quantitative|O JAK2|O V617F|O assays|O was|O complicated|O by|O the|O various|O ways|O in|O which|O the|O laboratories|O reported|O their|O results|O .|O
Immunoglobulin|O levels|O were|O almost|O in|O the|O normal|O range|O .|O
The|O molecular|O basis|O of|O the|O '|O GATA|O factor|O switching|O '|O resides|O in|O a|O gene|O expression|O regulatory|O network|O utilizing|O the|O cis|O -|O acting|O GATA|O motifs|O in|O the|O GATA1|O and|O GATA2|O genes|O .|O
Therefore|O ,|O the|O importance|O of|O obtaining|O adequate|O samples|O of|O marrow|O or|O peripheral|O blood|O at|O diagnosis|O for|O full|O karyotyping|O and|O fluorescence|O in|O situ|O hybridization|O (|O FISH|O )|O cytogenetic|O analysis|O for|O the|O most|O common|O abnormalities|O cannot|O be|O overemphasized|O .|O
The|O authors|O also|O noted|O that|O a|O survival|O benefit|O was|O not|O observed|O in|O the|O subgroup|O of|O patients|O undergoing|O allogeneic|O HSCT|O in|O first|O CR|O because|O of|O an|O increased|O incidence|O of|O nonrelapse|O mortality|O .|O
The|O prospectively|O defined|O cut|O -|O off|O point|O for|O data|O analysis|O occurred|O when|O half|O the|O patients|O remaining|O in|O the|O study|O had|O completed|O the|O week|O 36|O visit|O and|O when|O all|O the|O patients|O had|O completed|O the|O week|O 24|O evaluation|O or|O discontinued|O treatment|O .|O
Use|O of|O both|O the|O HpaII|O tiny|O fragment|O enrichment|O by|O ligation|O -|O mediated|O PCR|O assay|O (|O HELP|O assay|O )|O and|O LC|O -|O MS|O to|O detect|O global|O levels|O of|O DNA|O methylation|O in|O AML|O patient|O samples|O with|O TET2|O mutations|O revealed|O hypermethylation|O as|O well|O as|O lower|O global|O 5|O -|O hmC|O levels|O .|O
Others|O have|O demonstrated|O that|O patients|O with|O SF3B1|O -|O mutated|O RARS|O had|O abnormal|O splicing|O of|O ABCB7|O in|O mitochondria|O ,|O further|O strengthening|O the|O hypothesis|O of|O mitochondrial|O dysregulation|O .|O
To|O determine|O the|O functional|O effect|O of|O spliceosomal|O mutations|O ,|O we|O evaluated|O pre|O -|O mRNA|O splicing|O profiles|O by|O RNA|O deep|O sequencing|O .|O
When|O the|O survival|O benefit|O of|O SF3B1|O mutations|O was|O examined|O in|O patients|O with|O MDS|O with|O increased|O RS|O ,|O the|O presence|O of|O SF3B1|O mutations|O was|O associated|O with|O better|O OS|O and|O LFS|O in|O univariate|O analysis|O ;|O however|O ,|O significance|O was|O completely|O accounted|O for|O by|O the|O World|O Health|O Organization|O categorization|O for|O morphologic|O risk|O ,|O and|O no|O additional|O prognostic|O value|O from|O the|O presence|O or|O absence|O of|O SF3B1|O mutations|O was|O observed|O when|O RARS|O and|O RCMD|O -|O RS|O were|O analyzed|O separately|O .|O
The|O G|O -|O MDAPS|O was|O validated|O in|O 176|O patients|O with|O CMML|O and|O leukocytosis|O (|O >|O 12|O x|O 109|O /|O l|O )|O ,|O with|O median|O survivals|O in|O the|O four|O risk|O categories|O being|O 33|O ,|O 19|O ,|O 12|O and|O 8|O months|O ,|O respectively|O (|O P|O <|O 0|O .|O 01|O )|O ;|O limitations|O for|O G|O -|O MDAPS|O included|O the|O inclusion|O of|O patients|O with|O upto|O 30|O %|O BM|O blasts|O (|O oligoblastic|O AML|O )|O .|O
Anemia|O and|O thrombocytopenia|O were|O more|O common|O in|O patients|O who|O received|O ruxolitinib|O than|O in|O patients|O who|O received|O placebo|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
Leukemia|O -|O free|O survival|O was|O significantly|O shorter|O in|O the|O mutationally|O high|O -|O risk|O group|O (|O P|O <|O 0|O .|O 0001|O )|O and|O the|O cumulative|O risk|O of|O leukemia|O using|O competitive|O risk|O analysis|O was|O significantly|O increased|O (|O HR|O :|O 2|O .|O 96|O ;|O 95|O %|O CI|O :|O 1|O .|O 85|O -|O 4|O .|O 76|O ;|O P|O <|O 0|O .|O 0001|O )|O compared|O with|O mutationally|O low|O -|O risk|O (|O Figure|O 2d|O )|O ;|O this|O was|O confirmed|O by|O multivariable|O analysis|O that|O included|O IPSS|O (|O P|O <|O 0|O .|O 001|O )|O ,|O unfavorable|O karyotype|O (|O P|O <|O 0|O .|O 007|O )|O or|O both|O (|O P|O =|O 0|O .|O 024|O )|O (|O Supplementary|O Table|O S3|O )|O .|O
The|O observation|O that|O most|O mutations|O are|O nonsense|O and|O frameshift|O types|O suggests|O that|O cohesin|O mutations|O lead|O to|O decreased|O function|O of|O the|O cohesin|O complex|O .|O
DIAGNOSIS|O .|O
Seventeen|O patients|O who|O received|O ruxolitinib|O (|O 11|O .|O 0|O %|O )|O and|O 16|O patients|O who|O received|O placebo|O (|O 10|O .|O 6|O %|O )|O discontinued|O the|O study|O treatment|O because|O of|O adverse|O events|O (|O of|O any|O grade|O )|O .|O
In|O the|O aforementioned|O EORTC|O /|O GIMEMA|O trial|O ,|O the|O 4|O -|O year|O DFS|O rate|O among|O patients|O with|O intermediate|O -|O risk|O AML|O was|O 48|O .|O 5|O %|O for|O the|O nodonor|O group|O (|O n|O =|O 104|O ;|O 62|O .|O 5|O %|O underwent|O HSCT|O )|O and|O 45|O %|O for|O the|O donor|O group|O (|O n|O =|O 61|O ;|O 75|O %|O underwent|O HSCT|O )|O .|O
In|O our|O study|O ,|O 87|O (|O 49|O %|O )|O patients|O had|O an|O ASXL1|O mutation|O ,|O with|O 47|O (|O 28|O %|O )|O of|O these|O being|O c|O .|O 1934dupG|O ;|O p|O .|O Gly646TrpfsX12|O .|O
The|O latter|O has|O been|O shown|O to|O reduce|O the|O incidence|O of|O life|O -|O threatening|O pancytopenia|O .|O
Other|O indications|O for|O JAK2|O mutation|O analysis|O include|O splanchnic|O vein|O thrombosis|O and|O the|O provisional|O entity|O refractory|O anemia|O with|O ring|O sideroblasts|O and|O thrombocytosis|O (|O RARS|O -|O T|O )|O .|O
A|O heterogeneous|O group|O of|O malignant|O haematopoietic|O disorders|O that|O are|O characterized|O by|O dysplastic|O and|O ineffective|O blood|O cell|O production|O and|O a|O variable|O risk|O of|O transformation|O to|O acute|O leukaemia|O .|O
Both|O translocations|O and|O mutations|O of|O ETV6|O have|O been|O identified|O in|O acute|O myeloid|O leukemia|O ,|O and|O translocations|O have|O been|O described|O in|O rare|O cases|O of|O myelodysplastic|O syndromes|O ,|O but|O ETV6|O mutations|O have|O not|O previously|O been|O reported|O in|O myelodysplastic|O syndromes|O .|O
Therefore|O ,|O whether|O GATA2|O influences|O prognosis|O in|O patients|O with|O AML|O has|O not|O been|O determined|O .|O
Also|O in|O the|O Mayo|O cohort|O ,|O ASXL1|O mutations|O were|O more|O likely|O to|O occur|O in|O the|O presence|O of|O normal|O karyotype|O (|O 37|O %|O versus|O 19|O %|O ;|O P|O =|O 0|O .|O 003|O )|O and|O were|O not|O different|O between|O favorable|O and|O unfavorable|O cytogenetic|O categories|O .|O
The|O specific|O diagnostic|O criteria|O are|O presented|O below|O .|O
Our|O survey|O of|O more|O than|O 900|O mutations|O in|O 111|O cancer|O -|O associated|O genes|O identified|O only|O 6|O mutated|O oncogenes|O ,|O which|O were|O present|O in|O less|O than|O 10|O %|O of|O samples|O .|O
The|O findings|O of|O this|O study|O clearly|O indicate|O that|O the|O genetic|O basis|O of|O disease|O and|O ,|O more|O specifically|O ,|O the|O driver|O mutation|O responsible|O for|O clinical|O phenotype|O is|O an|O independent|O predictor|O of|O clinical|O course|O and|O outcomes|O ,|O and|O that|O accounting|O for|O that|O can|O improve|O the|O risk|O stratification|O provided|O by|O IPSS|O .|O
Each|O potential|O mutation|O was|O compared|O against|O databases|O of|O known|O SNPs|O ,|O including|O Entrez|O Gene|O and|O the|O Ensembl|O Genome|O Browser|O .|O
In|O both|O reports|O ,|O the|O authors|O revealed|O that|O the|O oncogenicity|O of|O IDH1|O mutants|O in|O neural|O and|O haematopoietic|O cells|O may|O depend|O on|O the|O increased|O activity|O of|O the|O EGLN|O family|O ,|O which|O are|O alpha|O -|O ketoglutarate|O -|O dependent|O prolyl|O hydroxylases|O that|O normally|O mark|O the|O oxygen|O -|O labile|O subunit|O of|O the|O transcription|O factor|O hypoxia|O -|O inducible|O factor|O (|O HIF|O )|O for|O proteasomal|O degradation|O .|O
Paired|O -|O end|O 90|O -|O bp|O reads|O were|O generated|O and|O subjected|O to|O data|O analysis|O with|O the|O use|O of|O the|O platform|O provided|O by|O DNAnexus|O .|O
In|O the|O EORTC|O /|O GIMEMA|O trial|O comparing|O outcomes|O between|O patients|O aged|O 45|O or|O younger|O in|O no|O -|O donor|O (|O patients|O in|O CR|O planned|O for|O autologous|O HSCT|O )|O versus|O donor|O groups|O (|O patients|O in|O CR|O with|O matched|O sibling|O donor|O planned|O for|O allogeneic|O HSCT|O )|O on|O an|O intent|O -|O to|O -|O treat|O basis|O ,|O the|O 4|O -|O year|O DFS|O rate|O for|O the|O subgroup|O with|O good|O -|O risk|O cytogenetics|O [|O eg|O ,|O t|O (|O 8|O ;|O 21|O )|O or|O inv|O (|O 16|O )|O ]|O was|O 66|O %|O for|O the|O no|O -|O donor|O group|O (|O n|O =|O 73|O ;|O 63|O %|O underwent|O HSCT|O )|O and|O 62|O %|O for|O the|O donor|O group|O (|O n|O =|O 50|O ;|O 72|O %|O underwent|O HSCT|O )|O .|O
The|O long|O concatenated|O DNA|O was|O then|O sheared|O into|O 100|O to|O 250|O bp|O fragments|O using|O the|O Covaris|O System|O (|O Covaris|O ,|O Woburn|O ,|O MA|O )|O to|O obtain|O randomly|O fragmented|O sequences|O ,|O and|O was|O size|O selected|O for|O 200|O bp|O fragments|O using|O Agencourt|O AMPure|O XP|O reagent|O (|O Agencourt|O Bioscience|O Corp|O .|O ,|O Beverly|O ,|O MA|O )|O .|O
Exclusionary|O criteria|O include|O no|O evidence|O of|O a|O reactive|O neutrophilia|O ,|O other|O MPN|O ,|O MDS|O ,|O or|O overlap|O MDS|O /|O MPN|O disorder|O .|O
Mutations|O of|O SETBP1|O (|O at|O 18q12|O .|O 3|O )|O are|O found|O in|O 2|O .|O 2|O %|O to|O 4|O .|O 3|O %|O of|O MDS|O patients|O and|O 6|O .|O 2|O %|O to|O 15|O %|O of|O CMML|O patients|O .|O
The|O genetic|O subtypes|O of|O PMF|O differ|O substantially|O as|O regards|O clinical|O course|O ,|O disease|O progression|O ,|O and|O overall|O survival|O .|O
Dickinson|O '|O s|O group|O observed|O the|O signs|O of|O disease|O progression|O in|O patients|O with|O GATA2|O mutation|O as|O elevated|O FLT3L|O ,|O loss|O of|O bone|O marrow|O progenitors|O ,|O depletion|O of|O transitional|O B|O cells|O ,|O naive|O T|O cells|O ,|O and|O NK|O cells|O ,|O as|O well|O as|O clonal|O myelopoiesis|O .|O
These|O distinct|O mechanisms|O may|O contribute|O to|O the|O differential|O downstream|O signaling|O and|O drug|O sensitivity|O of|O truncation|O vs|O membrane|O proximal|O mutations|O .|O
Notably|O ,|O genome|O -|O wide|O GATA1|O and|O GATA2|O occupancy|O of|O GATA|O motifs|O has|O been|O also|O investigated|O by|O ChIP|O -|O sequencing|O analysis|O .|O
MPL|O and|O JAK2|O mutations|O are|O not|O mutually|O exclusive|O ,|O and|O rare|O cases|O of|O concurrent|O MPL|O mutation|O and|O JAK2|O V617F|O mutation|O have|O been|O reported|O .|O
Perturbation|O of|O other|O functions|O of|O cohesin|O complex|O genes|O may|O contribute|O to|O hematopoietic|O transformation|O ,|O particularly|O through|O their|O role|O in|O regulating|O gene|O expression|O and|O DNA|O -|O loop|O formation|O .|O
Subsequent|O analysis|O identified|O the|O MPLW515L|O mutation|O that|O resulted|O in|O a|O MPN|O -|O like|O disorder|O in|O a|O murine|O bone|O marrow|O transplant|O assay|O .|O
Primary|O myelofibrosis|O (|O PMF|O )|O is|O a|O myeloproliferative|O neoplasm|O whose|O cardinal|O features|O include|O extensive|O extramedullary|O hematopoiesis|O ,|O associated|O with|O marked|O hepatosplenomegaly|O ,|O anemia|O that|O is|O often|O transfusion|O -|O dependent|O and|O profound|O constitutional|O symptoms|O .|O
8|O .|O 2|O .|O OVEREXPRESSION|O OF|O GATA2|O IN|O ACUTE|O MYELOID|O LEUKEMIA|O .|O
ASXL1|O mutations|O are|O generally|O frameshift|O ,|O resulting|O in|O truncation|O and|O loss|O -|O of|O -|O function|O ,|O with|O subsequent|O loss|O of|O PRC2|O -|O mediated|O histone|O lysine|O 27|O methylation|O .|O
Because|O of|O their|O often|O protracted|O course|O ,|O MDSs|O recapitulate|O the|O stages|O of|O acquisition|O of|O a|O malignant|O phenotype|O ,|O thereby|O offering|O insights|O into|O leukemogenesis|O .|O
IDH1|O functions|O in|O the|O cytoplasm|O and|O in|O peroxisomes|O ,|O whereas|O IDH2|O functions|O in|O the|O mitochondria|O .|O
In|O this|O analysis|O of|O 389|O well|O -|O characterized|O patients|O with|O AML|O ,|O we|O identified|O somatic|O mutations|O in|O the|O cohesin|O complex|O in|O 5|O .|O 9|O %|O of|O patients|O .|O
Moreover|O ,|O loss|O of|O PRC2|O components|O in|O mouse|O models|O of|O APL|O results|O in|O differentiation|O of|O APL|O cells|O .|O
Only|O 17|O %|O of|O patients|O were|O assigned|O to|O an|O IPSS|O risk|O group|O that|O differed|O from|O the|O group|O assigned|O at|O the|O time|O of|O diagnosis|O .|O
This|O prognostic|O significance|O was|O observed|O when|O IDH1|O and|O IDH2|O mutations|O were|O separately|O analyzed|O ,|O although|O patient|O numbers|O were|O small|O for|O each|O subgroup|O and|O statistical|O significance|O was|O reached|O only|O for|O the|O relapse|O -|O free|O survival|O analysis|O .|O
As|O an|O international|O collaborative|O effort|O ,|O we|O are|O currently|O analyzing|O clinical|O ,|O hematologic|O ,|O and|O molecular|O data|O of|O a|O large|O population|O of|O PMF|O patients|O with|O the|O aim|O of|O developing|O a|O clinically|O useful|O prognostic|O tool|O .|O
Of|O the|O 617|O PMF|O patients|O ,|O the|O clinical|O -|O molecular|O risk|O was|O very|O low|O in|O 71|O patients|O ,|O low|O in|O 150|O patients|O ,|O intermediate|O in|O 202|O patients|O ,|O high|O in|O 141|O patients|O ,|O and|O very|O high|O in|O 53|O patients|O .|O
Accumulating|O evidence|O supports|O that|O lineage|O -|O specific|O transcription|O factors|O actively|O maintain|O homeostasis|O within|O the|O hematopoietic|O system|O through|O the|O accurate|O orchestration|O of|O cellular|O proliferation|O ,|O differentiation|O and|O survival|O .|O
This|O is|O particularly|O true|O of|O elderly|O patients|O with|O AML|O .|O
In|O patients|O with|O the|O favorable|O -|O risk|O CBF|O AML|O [|O eg|O ,|O t|O (|O 8|O ;|O 21|O )|O or|O inv|O (|O 16|O )|O ]|O ,|O the|O presence|O of|O a|O mutation|O in|O c|O -|O KIT|O significantly|O increased|O the|O risk|O of|O relapse|O .|O
Figure|O 1|O .|O (|O a|O )|O Frequencies|O and|O distribution|O of|O mutations|O .|O Frequencies|O are|O given|O for|O molecular|O mutations|O in|O EZH2|O ,|O TET2|O ,|O ASXL1|O ,|O CBL|O ,|O NRAS|O ,|O KRAS|O ,|O JAK2|O ,|O RUNX1|O ,|O IDH1|O ,|O IDH2|O ,|O NPM1|O and|O MPL|O .|O Each|O patient|O is|O represented|O by|O a|O colored|O box|O .|O The|O patient|O cohort|O is|O further|O annotated|O according|O to|O karyotype|O and|O diagnostic|O category|O .|O Kaplan|O -|O Meier|O survival|O estimates|O of|O 81|O CMML|O cases|O .|O (|O b|O )|O Data|O are|O shown|O for|O overall|O survival|O of|O CMML|O patients|O including|O EZH2|O -|O mutated|O patients|O (|O n|O =|O 9|O )|O and|O EZH2|O wild|O -|O type|O patients|O (|O n|O =|O 72|O ;|O alive|O at|O 3|O years|O :|O 33|O .|O 3|O versus|O 69|O .|O 9|O %|O )|O .|O (|O c|O )|O Data|O are|O shown|O for|O overall|O survival|O of|O CMML|O patients|O including|O EZH2|O -|O mutated|O patients|O (|O n|O =|O 9|O )|O ,|O EZH2|O /|O TET2|O wild|O -|O type|O patients|O (|O n|O =|O 40|O )|O and|O TET2|O -|O mutated|O patients|O with|O EZH2|O wild|O -|O type|O (|O n|O =|O 32|O ;|O alive|O at|O 3|O years|O :|O 33|O .|O 9|O versus|O 49|O .|O 7|O versus|O 89|O .|O 8|O %|O )|O .|O
Results|O .|O
A|O clonal|O disorder|O of|O haematopoiesis|O that|O is|O characterized|O by|O the|O expansion|O of|O monocytes|O within|O the|O bone|O marrow|O and|O /|O or|O peripheral|O blood|O ,|O as|O well|O as|O dysplasia|O of|O myeloid|O -|O precursor|O cellular|O elements|O .|O
Radiation|O or|O surgical|O resection|O may|O be|O incorporated|O with|O systemic|O chemotherapy|O in|O emergent|O situations|O ;|O however|O ,|O these|O modalities|O ,|O if|O needed|O at|O all|O ,|O should|O be|O optimally|O deferred|O until|O count|O recovery|O to|O avoid|O excess|O toxicity|O .|O
To|O assess|O whether|O mutations|O were|O acquired|O ,|O T|O cells|O from|O the|O same|O individuals|O were|O analyzed|O or|O allelic|O discrimination|O assays|O were|O applied|O to|O show|O that|O the|O mutations|O were|O absent|O in|O a|O cohort|O of|O 250|O unaffected|O donors|O (|O Supplementary|O Methods|O ,|O Supplementary|O Table|O 2|O and|O Supplementary|O Fig|O .|O 5|O )|O .|O Detected|O SNPs|O are|O summarized|O in|O Supplementary|O Table|O 3|O .|O
In|O some|O cases|O these|O mutations|O occur|O in|O genes|O with|O known|O roles|O in|O regulating|O chromatin|O and|O /|O or|O methylation|O states|O in|O haematopoietic|O progenitors|O ,|O and|O in|O other|O cases|O genetic|O and|O functional|O studies|O have|O elucidated|O a|O role|O for|O specific|O mutations|O in|O altering|O epigenetic|O patterning|O in|O myeloid|O malignancies|O .|O
DISCUSSION|O .|O
Best|O supportive|O care|O is|O always|O an|O option|O for|O patients|O who|O cannot|O tolerate|O or|O do|O not|O wish|O to|O pursue|O further|O intensive|O treatment|O .|O
Similar|O results|O were|O obtained|O when|O considering|O NPM1|O -|O mutated|O CN|O -|O AML|O patients|O or|O when|O looking|O at|O the|O different|O prognostic|O groups|O in|O the|O European|O LeukemiaNet|O classification|O (|O data|O not|O shown|O )|O .|O
DNMT3A|O (|O DNA|O (|O cytosine|O -|O 5|O )|O -|O methyltransferase|O 3|O alpha|O gene|O ;|O located|O at|O 2p23|O )|O encodes|O a|O DNA|O methyltransferase|O that|O catalyzes|O the|O incorporation|O of|O methyl|O groups|O to|O the|O cytosine|O residue|O of|O CpG|O dinucleotides|O ,|O effectively|O controlling|O epigenetically|O manipulated|O gene|O expression|O .|O
EZH2|O encodes|O the|O catalytic|O subunit|O of|O the|O polycomb|O repressive|O complex|O 2|O ,|O a|O highly|O conserved|O histone|O H3|O lysine|O 27|O methyltransferase|O that|O influences|O stem|O cell|O renewal|O by|O epigenetic|O modification|O .|O
S4|O in|O the|O Supplementary|O Appendix|O )|O .|O
In|O the|O European|O cohort|O ,|O leukemia|O -|O free|O survival|O was|O negatively|O affected|O by|O IDH1|O /|O 2|O ,|O SRSF2|O and|O ASXL1|O mutations|O and|O in|O the|O Mayo|O cohort|O by|O IDH1|O and|O SRSF2|O mutations|O .|O
Do|O BCOR|O and|O BCORL1|O mutations|O have|O any|O clinical|O impact|O in|O AML|O ?|O
Statistical|O analysis|O .|O
All|O the|O cases|O were|O AML|O de|O novo|O ,|O from|O 18|O to|O 76|O years|O old|O .|O
Ling|O Zhang|O ;|O Eric|O Padron|O ;|O Jeffrey|O Lancet|O .|O
JAK2V617F|O is|O the|O best|O characterized|O mutation|O in|O BCR|O -|O ABL1|O -|O negative|O neoplasms|O ,|O with|O an|O estimated|O prevalence|O of|O more|O than|O 95|O %|O in|O PV|O ,|O 50|O %|O in|O ET|O ,|O and|O 50|O %|O in|O PMF|O .|O
In|O the|O last|O year|O ,|O genes|O in|O the|O cohesin|O complex|O have|O been|O described|O as|O novel|O mutations|O occurring|O in|O 13|O %|O of|O AML|O patients|O ,|O suggesting|O that|O the|O cohesin|O -|O complex|O presents|O an|O important|O pathway|O in|O the|O pathogenesis|O of|O AML|O .|O
Mutation|O of|O R882|O occurred|O in|O nearly|O 60|O %|O of|O the|O DNMT3A|O -|O mutant|O samples|O (|O 37|O of|O 62|O mutations|O )|O and|O has|O been|O shown|O to|O decrease|O catalytic|O activity|O and|O DNA|O binding|O affinity|O .|O
Taken|O together|O ,|O our|O data|O suggest|O that|O cohesin|O mutations|O do|O not|O affect|O patient|O prognosis|O .|O
Most|O patients|O with|O EZH2|O or|O ASXL1|O mutations|O had|O low|O or|O intermediate|O -|O 1|O risk|O according|O to|O the|O IPSS|O (|O 86|O %|O and|O 73|O %|O ,|O respectively|O )|O .|O
We|O applied|O nextgeneration|O amplicon|O deep|O -|O sequencing|O using|O the|O small|O volume|O Titanium|O assay|O (|O 454|O Life|O Sciences|O ,|O Branford|O ,|O CT|O ,|O USA|O )|O .|O
In|O fact|O ,|O in|O erythroid|O cells|O ,|O it|O activates|O erythroid|O -|O specific|O genes|O and|O also|O contributes|O to|O the|O repression|O of|O genes|O associate|O with|O a|O proliferative|O state|O .|O
Srdan|O Verstovsek|O ;|O Ruben|O A|O .|O Mesa|O ;|O Jason|O Gotlib|O ;|O Richard|O S|O .|O Levy|O ;|O Vikas|O Gupta|O ;|O John|O F|O .|O DiPersio|O ;|O John|O V|O .|O Catalano|O ;|O Michael|O Deininger|O ;|O Carole|O Miller|O ;|O Richard|O T|O .|O Silver|O ;|O Moshe|O Talpaz|O ;|O Elliott|O F|O .|O Winton|O ;|O Jimmie|O H|O .|O Harvey|O ;|O Jr|O .|O ;|O Murat|O O|O .|O Arcasoy|O ;|O Elizabeth|O Hexner|O ;|O Roger|O M|O .|O Lyons|O ;|O Ronald|O Paquette|O ;|O Azra|O Raza|O ;|O Kris|O Vaddi|O ;|O Susan|O Erickson|O -|O Viitanen|O ;|O Iphigenia|O L|O .|O Koumenis|O ;|O M|O .|O S|O .|O ;|O William|O Sun|O ;|O Victor|O Sandor|O ;|O Hagop|O M|O .|O Kantarjian|O .|O
In|O the|O HOVON|O trial|O ,|O the|O benefit|O in|O OS|O outcomes|O for|O the|O dose|O -|O escalated|O daunorubicin|O group|O was|O observed|O only|O in|O patients|O aged|O 65|O years|O and|O younger|O or|O in|O those|O with|O CBF|O translocations|O .|O
As|O previously|O mentioned|O ,|O the|O Gata2|O knock|O -|O out|O mouse|O has|O profound|O defects|O in|O definitive|O hematopoiesis|O :|O Gata2|O -|O deficient|O embryos|O are|O anemic|O ,|O have|O moderately|O reduced|O numbers|O of|O primitive|O erythroid|O cells|O and|O HPCs|O ,|O and|O die|O at|O day|O 10|O -|O 11|O of|O gestation|O ,|O demonstrating|O that|O GATA2|O is|O essential|O in|O the|O earliest|O stages|O of|O hematopoiesis|O .|O
When|O presented|O with|O rare|O cases|O such|O as|O acute|O leukemias|O of|O ambiguous|O lineage|O (|O including|O mixed|O phenotype|O acute|O leukemias|O ,|O as|O defined|O by|O the|O 2008|O WHO|O classification|O )|O ,|O consultation|O with|O an|O experienced|O hematopathologist|O should|O be|O sought|O .|O
Although|O studies|O in|O the|O Swedish|O Leukemia|O Registry|O documented|O improvement|O in|O outcomes|O for|O patients|O younger|O than|O 60|O years|O over|O the|O past|O 3|O decades|O ,|O no|O similar|O improvement|O was|O observed|O for|O the|O older|O population|O .|O
Multivariable|O analysis|O ,|O using|O IDH1|O ,|O transfusion|O dependence|O ,|O and|O risk|O parameter|O variables|O from|O the|O revised|O International|O Prognostic|O Scoring|O System|O (|O R|O -|O IPSS|O )|O ,|O showed|O that|O presence|O of|O mutant|O IDH1|O ,|O but|O not|O IDH2|O ,|O was|O the|O single|O variable|O associated|O with|O inferior|O leukemia|O -|O free|O survival|O .|O
The|O rate|O of|O discontinuation|O of|O the|O study|O drug|O because|O of|O adverse|O events|O was|O 11|O .|O 0|O %|O in|O the|O ruxolitinib|O group|O and|O 10|O .|O 6|O %|O in|O the|O placebo|O group|O .|O
The|O normal|O role|O of|O CSF3R|O in|O promoting|O neutrophil|O production|O is|O biologically|O consistent|O with|O our|O observation|O of|O CSF3R|O activating|O mutations|O in|O hematologic|O malignancies|O characterized|O by|O high|O levels|O of|O neutrophils|O .|O
Mutations|O associated|O with|O CN|O -|O AML|O include|O those|O affecting|O NPM1|O ,|O FLT3|O ,|O MLL|O ,|O CEBPA|O ,|O TET2|O ,|O ASXL1|O ,|O IDH1|O ,|O IDH2|O ,|O DNMT3A|O ,|O RUNX1|O and|O other|O genes|O .|O
Third|O ,|O mutations|O with|O a|O quality|O score|O of|O <|O 8000|O or|O an|O allele|O frequency|O of|O <|O 15|O %|O were|O excluded|O .|O
Mutations|O in|O other|O exons|O include|O V501A|O ,|O Y252H|O ,|O and|O S204P|O (|O Figure|O 2|O )|O .|O
Thirteen|O deaths|O occurred|O in|O the|O ruxolitinib|O group|O as|O compared|O with|O 24|O deaths|O in|O the|O placebo|O group|O (|O hazard|O ratio|O ,|O 0|O .|O 50|O ;|O 95|O %|O confidence|O interval|O ,|O 0|O .|O 25|O to|O 0|O .|O 98|O ;|O P|O =|O 0|O .|O 04|O )|O .|O
The|O risk|O of|O transformation|O at|O the|O age|O of|O 10|O ,|O 20|O ,|O or|O 30|O was|O ,|O respectively|O ,|O 6|O %|O ,|O 54|O %|O ,|O and|O 63|O %|O (|O Figure|O 2B|O )|O .|O
Granulocytic|O dysplasia|O is|O not|O present|O ,|O and|O there|O is|O no|O monocytosis|O ,|O eosinophilia|O ,|O or|O basophilia|O .|O
Rare|O mutations|O in|O TET2|O ,|O ASXL1|O ,|O IDH1|O /|O IDH2|O ,|O EZH2|O ,|O DNMT3A|O ,|O and|O CBL|O have|O been|O described|O ,|O although|O the|O precise|O roles|O of|O these|O mutations|O in|O the|O pathogenesis|O of|O ET|O and|O PMF|O are|O unknown|O .|O
As|O of|O their|O prognostic|O relevance|O in|O the|O European|O cohort|O (|O see|O below|O )|O ,|O mutation|O analyses|O in|O the|O Mayo|O cohort|O were|O focused|O on|O ASXL1|O ,|O SRSF2|O ,|O EZH2|O ,|O IDH1|O and|O IDH2|O ;|O the|O corresponding|O mutational|O frequencies|O were|O 31|O %|O (|O 85|O out|O of|O 279|O studied|O cases|O )|O ,|O 15|O %|O (|O 52|O of|O 358|O )|O ,|O 6|O %|O (|O 15|O of|O 270|O )|O ,|O 3|O %|O (|O 10|O of|O 374|O )|O and|O 2|O %|O (|O 7|O of|O 374|O )|O .|O
C|O -|O terminal|O mutations|O of|O RUNX1|O were|O detected|O in|O nine|O patients|O with|O CMML|O ;|O they|O would|O have|O been|O overlooked|O had|O the|O mutation|O analysis|O not|O included|O exons|O 7b|O and|O 8|O of|O the|O RUNX1|O gene|O .|O
MDS|O may|O occur|O de|O novo|O or|O arise|O years|O after|O exposure|O to|O mutagens|O (|O including|O radiation|O and|O some|O types|O of|O chemotherapy|O )|O .|O
Abbreviations|O :|O AVWS|O =|O acute|O von|O Willebrand|O syndrome|O ;|O ET|O =|O essential|O thrombocythemia|O ;|O Hct|O =|O hematocrit|O .|O
Histopathologic|O and|O clinical|O features|O of|O CNL|O and|O aCML|O .|O
Recently|O ,|O we|O characterized|O 81|O cases|O according|O to|O cytogenetics|O and|O mutations|O in|O seven|O candidate|O genes|O ,|O detecting|O an|O overall|O mutation|O rate|O of|O 72|O .|O 8|O %|O .|O
TET2|O mutations|O were|O not|O exclusive|O of|O abnormalities|O in|O other|O epigenetic|O regulators|O such|O as|O the|O chromatin|O -|O modifying|O genes|O ASXL1|O and|O EZH2|O .|O
Findings|O were|O similar|O for|O each|O individual|O mutation|O ,|O with|O clonal|O expansion|O in|O 7|O of|O 8|O patients|O with|O STAG2|O mutations|O (|O P|O =|O .|O 05|O )|O ,|O 2|O of|O 4|O SMC3|O mutant|O patients|O ,|O as|O well|O as|O in|O the|O single|O patient|O with|O a|O RAD21|O mutation|O .|O
We|O compared|O the|O allelic|O burden|O of|O mutations|O in|O the|O cohesin|O complex|O with|O the|O allelic|O burden|O of|O NPM1|O mutations|O ,|O as|O the|O level|O of|O the|O allelic|O burden|O can|O indicate|O clonal|O hierarchy|O of|O different|O mutations|O .|O
Atypical|O chronic|O myeloid|O leukemia|O (|O aCML|O )|O is|O an|O uncommon|O myelodysplastic|O /|O myeloproliferative|O (|O MDS|O /|O MPN|O )|O neoplasm|O ,|O with|O a|O relative|O incidence|O estimated|O at|O 1|O to|O 2|O cases|O for|O every|O 100|O patients|O with|O BCR|O -|O ABL1|O -|O positive|O chronic|O myeloid|O leukemia|O (|O CML|O )|O .|O
Indeed|O ,|O U2AF1|O and|O SRSF2|O mutations|O were|O associated|O with|O worse|O survival|O in|O CMML|O and|O low|O -|O risk|O MDS|O ,|O respectively|O .|O
On|O the|O other|O hand|O ,|O GATA1|O activates|O known|O erythroid|O and|O megakaryocyte|O specific|O genes|O and|O functions|O as|O a|O repressor|O of|O genes|O that|O mark|O the|O immature|O state|O of|O erythroid|O precursor|O cells|O ,|O including|O GATA2|O and|O KIT|O .|O
Dawson|O et|O al|O showed|O that|O JAK2|O localizes|O to|O the|O nucleus|O and|O phosphorylates|O Y41|O of|O histone|O H3|O .|O
Mutations|O and|O translocations|O involving|O mixed|O -|O lineage|O leukaemia|O (|O MLL|O )|O as|O well|O as|O mutations|O in|O Polycomb|O repressive|O complex|O (|O PRC|O )|O components|O and|O interacting|O proteins|O affect|O histone|O modifications|O and|O can|O promote|O myeloid|O transformation|O .|O
The|O lymphocyte|O count|O was|O also|O low|O ,|O with|O a|O median|O at|O 1|O .|O 1|O G|O /|O L|O (|O 25th|O percentile|O :|O 1|O .|O 0|O ;|O 75th|O percentile|O :|O 1|O .|O 7|O )|O ;|O with|O B|O cells|O and|O NK|O cells|O were|O also|O low|O .|O
Treatment|O -|O related|O mortality|O frequently|O exceeds|O any|O expected|O transient|O response|O in|O this|O group|O ,|O particularly|O in|O patients|O older|O than|O 75|O years|O or|O in|O those|O who|O have|O significant|O comorbid|O conditions|O or|O ECOG|O performance|O status|O greater|O than|O 2|O .|O
A|O subsequent|O study|O investigated|O whether|O the|O acquisition|O of|O the|O above|O factors|O during|O follow|O -|O up|O predicted|O survival|O of|O PMF|O patients|O ,|O and|O eventually|O led|O to|O the|O development|O of|O the|O dynamic|O IPSS|O (|O DIPSS|O )|O .|O
Mutations|O in|O IDH2|O have|O been|O reported|O in|O 8|O %|O to|O 12|O %|O of|O patients|O with|O AML|O ,|O with|O a|O frequency|O of|O 19|O %|O reported|O among|O those|O with|O normal|O karyotype|O .|O
Tagged|O next|O -|O generation|O amplicon|O deep|O -|O sequencing|O primer|O sequences|O are|O available|O online|O (|O Supplementary|O Table|O 3|O )|O .|O
Analysis|O of|O copy|O number|O state|O was|O done|O using|O BRLMM|O -|O PPlus|O algorithm|O with|O regional|O GC|O correction|O ,|O embedded|O in|O Genotyping|O Console|O Version|O 2|O .|O 0|O and|O Chromosome|O Analysis|O Suite|O software|O (|O Affymetrix|O )|O .|O
This|O technique|O can|O reliably|O detect|O mutations|O present|O at|O a|O frequency|O of|O 10|O %|O or|O higher|O .|O
The|O majority|O of|O patients|O receiving|O placebo|O had|O spleen|O growth|O .|O
The|O approach|O to|O validation|O differs|O between|O qualitative|O and|O quantitative|O assays|O .|O
Moreover|O ,|O no|O homozygous|O mutations|O were|O found|O in|O patients|O with|O UPD21q|O (|O n|O =|O 8|O )|O .|O
JAK2V617F|O remains|O the|O best|O clinical|O marker|O of|O disease|O despite|O the|O identification|O of|O numerous|O other|O mutations|O prevalent|O in|O subsets|O of|O MPN|O .|O
Initial|O Evaluation|O .|O
Notably|O ,|O in|O each|O model|O published|O to|O date|O ,|O there|O was|O a|O considerable|O latency|O before|O mice|O developed|O overt|O myeloid|O leukaemias|O ,|O which|O suggests|O that|O secondary|O events|O are|O required|O for|O specific|O disease|O phenotypes|O .|O
Paired|O BM|O mononuclear|O cells|O and|O CD3|O +|O peripheral|O blood|O lymphocytes|O were|O used|O as|O germline|O controls|O .|O
Based|O on|O retrospective|O analysis|O of|O data|O from|O large|O cooperative|O group|O studies|O ,|O 40|O %|O to|O 50|O %|O of|O patients|O with|O de|O novo|O AML|O have|O normal|O karyotype|O ,|O which|O is|O associated|O with|O an|O intermediate|O risk|O in|O terms|O of|O survival|O outcomes|O .|O
Thus|O ,|O success|O in|O these|O trials|O may|O be|O assessed|O using|O indirect|O measures|O ,|O such|O as|O hematologic|O improvement|O or|O decreased|O transfusion|O requirements|O and|O survival|O ,|O without|O actually|O achieving|O CR|O .|O
For|O the|O European|O cohort|O ,|O survival|O was|O measured|O from|O the|O date|O of|O diagnosis|O to|O the|O date|O of|O death|O or|O last|O follow|O -|O up|O and|O for|O the|O Mayo|O cohort|O from|O time|O of|O referral|O to|O date|O of|O death|O or|O last|O follow|O -|O up|O .|O
TREATMENT|O .|O
No|O buccal|O sample|O was|O available|O for|O the|O sole|O patient|O with|O a|O mutation|O in|O FLNB|O (|O R566Q|O )|O ,|O so|O this|O mutation|O could|O not|O be|O assumed|O to|O be|O somatic|O .|O
Overall|O Survival|O .|O
Patients|O with|O STAG2|O /|O RAD21|O mutations|O were|O more|O likely|O to|O respond|O to|O treatment|O with|O HMAs|O compared|O with|O WT|O cases|O (|O 79|O %|O vs|O 47|O %|O ;|O P|O =|O .|O 04|O )|O and|O were|O comparable|O in|O age|O and|O IPSS|O scores|O with|O the|O nonresponders|O .|O
All|O the|O authors|O contributed|O to|O subsequent|O drafts|O and|O made|O the|O decision|O to|O submit|O the|O article|O for|O publication|O .|O
The|O CR|O (|O including|O CRp|O )|O rate|O was|O significantly|O higher|O with|O decitabine|O (|O 18|O %|O vs|O .|O 8|O %|O ;|O P|O =|O .|O 001|O )|O .|O
Recent|O studies|O have|O also|O demonstrated|O the|O independent|O prognostic|O value|O of|O SETBP1|O in|O CMML|O by|O disclosing|O the|O close|O associations|O between|O the|O mutation|O and|O higher|O white|O blood|O cell|O counts|O (|O P|O =|O 0|O .|O 03|O )|O ,|O frequent|O extramedullary|O disease|O (|O P|O =|O 0|O .|O 03|O )|O ,|O dismal|O OS|O (|O hazard|O ratio|O =|O 2|O .|O 23|O ,|O 95|O %|O CI|O :|O 1|O .|O 07|O -|O 4|O .|O 26|O )|O (|O P|O =|O 0|O .|O 028|O )|O ,|O and|O AML|O -|O free|O survival|O (|O hazard|O ratio|O =|O 2|O .|O 05|O ,|O 95|O %|O CI|O :|O 1|O .|O 01|O -|O 4|O .|O 65|O )|O (|O P|O =|O 0|O .|O 049|O )|O .|O
The|O RUNX|O proteins|O are|O critical|O regulators|O of|O myeloid|O differentiation|O in|O all|O vertebrates|O .|O
Another|O option|O for|O this|O group|O is|O 1|O to|O 2|O cycles|O of|O high|O -|O dose|O cytarabine|O -|O based|O consolidation|O followed|O by|O autologous|O HSCT|O (|O category|O 2B|O )|O .|O
With|O respect|O to|O ASXL1|O mutations|O ,|O Sanger|O sequencing|O indicated|O a|O burden|O of|O ~|O 50|O %|O .|O
The|O majority|O of|O patients|O had|O improvements|O in|O symptoms|O ,|O which|O occurred|O even|O in|O patients|O who|O did|O not|O have|O a|O reduction|O in|O spleen|O volume|O of|O 35|O %|O or|O more|O .|O
In|O this|O assay|O ,|O mutant|O transduced|O stem|O cells|O showed|O lower|O repopulating|O capacity|O compared|O to|O mock|O -|O or|O wild|O -|O type|O U2AF35|O -|O transduced|O cells|O ,|O as|O determined|O by|O the|O chimerism|O in|O peripheral|O blood|O 6|O weeks|O after|O transplantation|O ,|O indicating|O that|O both|O U2AF35|O mutants|O could|O disturb|O normal|O hematopoiesis|O .|O
To|O further|O evaluate|O the|O efficacy|O and|O safety|O of|O ruxolitinib|O ,|O we|O conducted|O the|O Controlled|O Myelofibrosis|O Study|O with|O Oral|O JAK|O Inhibitor|O Treatment|O I|O (|O COMFORT|O -|O I|O )|O ,|O a|O randomized|O ,|O double|O -|O blind|O ,|O placebo|O -|O controlled|O trial|O involving|O patients|O with|O intermediate|O -|O 2|O or|O high|O -|O risk|O myelofibrosis|O .|O
STAG2|O was|O associated|O with|O higher|O -|O risk|O disease|O (|O P|O =|O .|O 0023|O )|O ,|O and|O RAD21|O and|O SMC3|O defects|O were|O most|O frequently|O identified|O in|O sAML|O (|O 3|O .|O 5|O %|O and|O 4|O %|O ,|O respectively|O ;|O supplemental|O Figure|O 1|O )|O .|O
Mutations|O have|O been|O identified|O in|O myeloid|O malignancies|O and|O have|O been|O demonstrated|O to|O dysregulate|O RNA|O splicing|O (|O Fig|O .|O 2|O )|O .|O
Patients|O in|O both|O treatment|O arms|O received|O only|O 2|O cycles|O of|O standard|O -|O dose|O cytarabine|O ,|O daunorubicin|O ,|O and|O etoposide|O for|O consolidation|O therapy|O .|O
Candidate|O genes|O identified|O were|O validated|O using|O 2|O external|O validation|O cohorts|O .|O
The|O karyotype|O was|O normal|O .|O
Consonant|O with|O the|O genetic|O data|O showing|O that|O mutations|O in|O epigenetic|O modifiers|O occur|O in|O concert|O with|O class|O I|O and|O class|O II|O mutations|O ,|O functional|O studies|O have|O revealed|O that|O perturbations|O of|O these|O epigenetic|O modifiers|O alone|O can|O confer|O self|O -|O renewal|O and|O lead|O to|O myeloid|O transformation|O .|O
However|O ,|O this|O capacity|O for|O GATA|O factors|O to|O functionally|O substitute|O each|O other|O is|O limited|O and|O suggests|O that|O the|O cellular|O context|O in|O which|O each|O GATA|O factor|O is|O expressed|O is|O important|O .|O
Thus|O ,|O azacitidine|O would|O be|O expected|O to|O have|O greater|O efficacy|O in|O cohesin|O -|O deficient|O patients|O .|O
Somatic|O point|O mutations|O are|O common|O in|O myelodysplastic|O syndromes|O and|O are|O associated|O with|O specific|O clinical|O features|O .|O
Notch1|O and|O Gata2|O are|O coexpressed|O in|O endothelial|O cells|O lining|O the|O floor|O of|O the|O aorta|O at|O E10|O .|O 5|O ,|O and|O NOTCH1|O binds|O the|O Gata2|O promoter|O and|O acts|O as|O an|O upstream|O regulator|O of|O Gata2|O expression|O during|O the|O onset|O of|O definitive|O hematopoiesis|O in|O the|O mouse|O embryo|O .|O
GATA1|O and|O GATA2|O are|O essential|O for|O the|O development|O of|O the|O erythroid|O and|O megakaryocyte|O lineages|O .|O
Most|O TSG|O mutations|O are|O not|O canonical|O ,|O though|O ,|O making|O systematic|O clinical|O diagnostics|O more|O difficult|O .|O
Of|O note|O ,|O thus|O far|O ,|O we|O sequenced|O 463|O cases|O of|O various|O myeloid|O malignancies|O and|O detected|O the|O corresponding|O putative|O ASXL1|O mutation|O 1900|O _|O 1922del|O (|O Glu635ArgfsX16|O )|O in|O 21|O patients|O overall|O (|O Supplementary|O Table|O 4|O )|O .|O
These|O latter|O showed|O a|O particularly|O high|O risk|O at|O 3|O years|O (|O >|O 30|O %|O ,|O Figure|O 1C|O )|O .|O
SETBP1|O mutations|O .|O
Therefore|O ,|O in|O vivo|O experiments|O indicate|O that|O the|O hematopoietic|O GATA|O factors|O are|O functionally|O redundant|O with|O regard|O to|O erythropoiesis|O ,|O while|O the|O GATA1|O protein|O exerts|O a|O unique|O function|O in|O megakaryopoiesis|O .|O
A|O rational|O bioanalytic|O algorithm|O was|O applied|O to|O identify|O candidate|O nonsynonymous|O alterations|O .|O
They|O hypothesized|O that|O the|O FOG1|O antagonist|O activity|O in|O this|O process|O could|O be|O to|O some|O extend|O caused|O by|O a|O '|O GATA|O switch|O '|O at|O the|O GATA2|O locus|O .|O
In|O low|O -|O risk|O MDS|O ,|O mutations|O of|O any|O 1|O of|O these|O 3|O genes|O were|O found|O in|O 39|O %|O of|O patients|O ,|O and|O further|O analysis|O found|O that|O mutations|O in|O SF3B1|O were|O highly|O associated|O with|O RARS|O .|O
In|O addition|O to|O the|O known|O numerical|O and|O structural|O chromosomal|O abnormalities|O ,|O with|O novel|O genomic|O sequencing|O technologies|O ,|O approximately|O 80|O %|O of|O MDS|O patients|O have|O been|O shown|O to|O harbor|O somatic|O or|O acquired|O gene|O mutations|O .|O
Several|O key|O mutations|O are|O associated|O with|O distinct|O clinical|O phenotypes|O ,|O which|O are|O discussed|O below|O .|O
All|O of|O these|O were|O found|O to|O have|O low|O JAK2|O V617F|O allele|O burden|O when|O tested|O by|O quantitative|O assays|O .|O
Inferior|O predictors|O of|O survival|O in|O PMF|O secondary|O to|O PV|O and|O ET|O are|O similar|O for|O de|O novo|O disease|O ,|O and|O patients|O may|O be|O risk|O stratified|O in|O a|O comparable|O manner|O .|O
The|O somatic|O or|O germline|O status|O of|O mutations|O in|O genes|O of|O the|O cohesin|O complex|O was|O established|O by|O evaluating|O remission|O samples|O or|O T|O cells|O (|O CD3|O +|O CD11b|O -|O CD14|O -|O CD3|O +|O )|O purified|O from|O diagnostic|O samples|O by|O flow|O
The|O median|O OS|O among|O patients|O with|O FLT3|O -|O ITD|O in|O the|O absence|O of|O a|O wild|O -|O type|O FLT3|O was|O only|O 7|O months|O compared|O with|O 46|O months|O among|O both|O the|O patient|O subgroups|O with|O wild|O -|O type|O FLT3|O with|O or|O without|O FLT3|O -|O ITD|O .|O
Standardization|O .|O
In|O CMML|O ,|O recent|O data|O suggest|O that|O EZH2|O is|O a|O negative|O prognostic|O factor|O ,|O with|O shorter|O OS|O ,|O particularly|O in|O the|O CMML|O II|O subtype|O .|O
Further|O work|O to|O study|O the|O in|O vivo|O effects|O of|O conditional|O PRC2|O loss|O or|O overexpression|O is|O crucial|O to|O advance|O our|O understanding|O of|O PRC2|O function|O in|O HSCs|O and|O in|O myeloid|O leukaemogenesis|O .|O
RA|O with|O excess|O blasts|O (|O RAEB1|O and|O RAEB2|O )|O cases|O were|O considered|O as|O high|O -|O risk|O MDS|O .|O
The|O Stat|O View|O (|O SAS|O Institute|O ,|O Cary|O ,|O NC|O ,|O USA|O )|O statistical|O package|O was|O used|O for|O all|O calculations|O .|O
As|O illustrated|O in|O Figures|O 4|O -|O 5|O ,|O the|O prognosis|O of|O a|O triple|O -|O negative|O patient|O is|O markedly|O worse|O than|O that|O of|O a|O CALR|O -|O mutant|O patient|O :|O in|O these|O cases|O ,|O therapeutic|O decisions|O may|O span|O from|O a|O watchful|O waiting|O strategy|O to|O allogeneic|O stem|O cell|O transplantation|O .|O
Somatic|O cohesin|O defects|O were|O detected|O in|O 12|O %|O of|O patients|O with|O myeloid|O malignancies|O ,|O whereas|O low|O expression|O of|O these|O genes|O was|O present|O in|O an|O additional|O 15|O %|O of|O patients|O .|O Mutations|O of|O cohesin|O genes|O were|O mutually|O exclusive|O and|O mostly|O resulted|O in|O predicted|O loss|O of|O function|O .|O
After|O secondary|O causes|O of|O polycythemia|O have|O been|O ruled|O out|O ,|O JAK2|O analysis|O (|O first|O for|O exon|O 14|O V617F|O ,|O and|O then|O ,|O if|O findings|O are|O negative|O ,|O for|O exon|O 12|O )|O is|O indicated|O to|O support|O the|O diagnosis|O of|O PV|O .|O
Thirteen|O patients|O (|O nos|O .|O 10|O -|O 13|O and|O 17|O -|O 25|O )|O carrying|O N|O -|O terminal|O mutants|O resulting|O in|O frameshift|O and|O /|O or|O truncation|O of|O RUNX1|O proteins|O in|O the|O middle|O of|O the|O RHD|O are|O expected|O to|O lose|O the|O ability|O of|O the|O RHD|O to|O bind|O to|O DNA|O sequences|O and|O lack|O transcriptional|O activities|O .|O
JAK2|O protein|O kinase|O activity|O is|O activated|O by|O phosphorylation|O of|O its|O kinase|O domain|O .|O Activation|O of|O JAK2|O induces|O signal|O transduction|O from|O both|O type|O 1|O and|O type|O 2|O cytokine|O receptors|O .|O Constitutive|O activation|O of|O JAK2|O by|O either|O point|O mutation|O or|O fusion|O protein|O causes|O activation|O of|O the|O JAK|O /|O STAT|O pathway|O .|O
At|O least|O one|O mutation|O was|O present|O in|O 226|O of|O the|O 439|O samples|O (|O 51|O .|O 5|O %|O )|O .|O (|O Missense|O mutations|O of|O KDM6A|O were|O found|O in|O three|O samples|O ,|O but|O the|O mutations|O could|O not|O be|O confirmed|O as|O somatic|O and|O are|O not|O included|O in|O the|O totals|O listed|O above|O .|O )|O
The|O TET|O enzymes|O can|O also|O convert|O 5|O -|O mC|O to|O 5|O -|O formylcytosine|O (|O 5|O -|O fC|O )|O and|O 5|O -|O carboxylcytosine|O (|O 5|O -|O caC|O )|O ;|O 5|O -|O caC|O can|O be|O directly|O recognized|O and|O repaired|O by|O TDG|O -|O mediated|O BER|O (|O an|O enzymatic|O activity|O that|O is|O unable|O to|O excise|O 5|O -|O hmC|O or|O 5|O -|O mC|O )|O .|O
These|O mutations|O are|O specific|O for|O PV|O and|O are|O observed|O in|O predominantly|O patients|O who|O are|O JAK2V617F|O negative|O ,|O with|O an|O overall|O frequency|O of|O 3|O %|O .|O
Genetic|O counseling|O should|O also|O be|O considered|O for|O patients|O with|O GATA2|O mutations|O because|O of|O the|O high|O clinical|O penetrance|O and|O poor|O survival|O rates|O .|O
The|O comparison|O of|O cumulative|O incidence|O curves|O in|O different|O groups|O of|O patients|O was|O carried|O out|O using|O the|O Pepe|O -|O Mori|O test|O ,|O whereas|O the|O effect|O of|O quantitative|O covariates|O was|O estimated|O by|O applying|O the|O Fine|O -|O Gray|O regression|O model|O .|O
In|O addition|O ,|O most|O of|O the|O aberrant|O transcripts|O of|O PTEN|O /|O MMAC1|O were|O caused|O by|O intragenic|O deletions|O .|O
Based|O on|O the|O 2008|O World|O Health|O Organization|O (|O WHO|O )|O classification|O system|O ,|O CMML|O is|O further|O subcategorized|O into|O CMML|O -|O 1|O (|O <|O 5|O %|O circulating|O blasts|O and|O <|O 10|O %|O BM|O blasts|O )|O and|O CMML|O -|O 2|O (|O 5|O -|O 19|O %|O circulating|O blasts|O ,|O 10|O -|O 19|O %|O BM|O blasts|O or|O when|O Auer|O rods|O are|O present|O irrespective|O of|O the|O blast|O count|O )|O ,|O with|O median|O overall|O survivals|O (|O OSs|O )|O of|O approximately|O 20|O and|O 15|O months|O ,|O respectively|O .|O
However|O ,|O none|O of|O these|O drugs|O have|O been|O shown|O to|O either|O reverse|O bone|O marrow|O fibrosis|O or|O induce|O genetic|O remissions|O and|O their|O effect|O on|O survival|O is|O uncertain|O .|O
Research|O has|O primarily|O focused|O on|O the|O prognostic|O implication|O of|O cytogenetics|O in|O BCR|O -|O ABL1|O -|O negative|O MPNs|O .|O
Swapna|O Thota|O ;|O Aaron|O D|O .|O Viny|O ;|O Hideki|O Makishima|O ;|O Barbara|O Spitzer|O ;|O Tomas|O Radivoyevitch|O ;|O Bartlomiej|O Przychodzen|O ;|O Mikkael|O A|O .|O Sekeres|O ;|O Ross|O L|O .|O Levine|O ;|O Jaroslaw|O P|O .|O Maciejewski|O .|O
The|O cohort|O harboring|O EZH2|O aberrations|O was|O too|O small|O to|O detect|O a|O clear|O association|O with|O a|O specific|O French|O -|O American|O -|O British|O ,|O International|O Prognostic|O Scoring|O System|O or|O World|O Health|O Organization|O classification|O of|O MDS|O (|O Table|O 1|O )|O .|O
Although|O EZH2|O mutations|O are|O sufficient|O to|O induce|O an|O MDS|O /|O MPN|O murine|O phenotype|O ,|O a|O concomitant|O TET2|O mutation|O accelerates|O this|O phenotype|O and|O leads|O to|O progressive|O disease|O .|O
Staining|O was|O performed|O in|O a|O Gene|O Stain|O Automated|O Gel|O Stainer|O using|O PlusOne|O Silver|O Staining|O Kit|O (|O Pharmacia|O Biotech|O )|O .|O
Only|O the|O mutation|O R396Q|O in|O P1|O has|O been|O described|O previously|O in|O 1|O case|O of|O MonoMAC|O syndrome|O .|O
Table|O 4|O .|O Methods|O in|O Detecting|O JAK2|O Mutations|O .|O
At|O the|O opposite|O ,|O triple|O -|O negative|O patients|O had|O higher|O incidence|O of|O leukemic|O transformation|O compared|O with|O either|O CALR|O -|O mutant|O or|O JAK2|O -|O mutant|O patients|O .|O
Over|O the|O past|O 10|O years|O ,|O significant|O advances|O have|O been|O made|O in|O our|O understanding|O of|O the|O molecular|O pathogenesis|O of|O MDS|O and|O other|O myelodysplasias|O ,|O including|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O and|O atypical|O chronic|O myeloid|O leukemia|O ,|O through|O identification|O of|O common|O gene|O mutations|O found|O in|O these|O neoplasms|O .|O
This|O subclonal|O architecture|O occurs|O in|O the|O setting|O of|O cooccurring|O genetic|O and|O molecular|O abnormalities|O ,|O including|O mutations|O in|O chromatin|O modifiers|O (|O ASXL1|O )|O and|O key|O transcriptional|O regulators|O (|O RUNX1|O ,|O Ras|O family|O genes|O ,|O and|O BCOR|O )|O .|O
Mutations|O in|O a|O subset|O of|O epigenetic|O regulators|O ,|O including|O TET2|O ,|O ASXL1|O and|O DNMT3A|O ,|O are|O associated|O with|O poor|O overall|O survival|O ;|O as|O such|O ,|O these|O mutant|O alleles|O define|O a|O subset|O of|O high|O -|O risk|O leukaemia|O that|O is|O in|O need|O of|O novel|O ,|O mechanism|O -|O based|O therapies|O .|O
In|O univariate|O analysis|O ,|O CALR|O -|O mutant|O patients|O had|O a|O better|O OS|O than|O JAK2|O -|O mutant|O (|O hazard|O ratio|O [|O HR|O ]|O 2|O .|O 3|O ,|O P|O <|O .|O 001|O )|O ,|O MPL|O -|O mutant|O (|O HR|O 2|O .|O 6|O ,|O P|O =|O .|O 009|O )|O ,|O and|O triple|O -|O negative|O patients|O (|O HR|O 6|O .|O 2|O ,|O P|O <|O .|O 001|O )|O .|O
In|O the|O previously|O discussed|O SWOG|O /|O ECOG|O trial|O ,|O the|O 5|O -|O year|O survival|O rates|O (|O from|O time|O of|O CR|O )|O for|O patients|O with|O intermediate|O -|O risk|O cytogenetics|O were|O 36|O %|O for|O the|O autologous|O HSCT|O group|O (|O n|O =|O 37|O ;|O 59|O %|O underwent|O HSCT|O )|O and|O 52|O %|O for|O the|O allogeneic|O HSCT|O group|O (|O n|O =|O 47|O ;|O 66|O %|O underwent|O HSCT|O )|O .|O
To|O assess|O the|O prevalence|O of|O EZH2|O mutations|O in|O individuals|O with|O MDS|O ,|O we|O sequenced|O the|O gene|O in|O all|O 102|O subjects|O from|O the|O initial|O cohort|O and|O in|O 24|O additional|O individuals|O with|O MDS|O (|O Supplementary|O Table|O 1|O )|O .|O
A|O DNA|O binding|O defective|O form|O of|O SCL|O maintains|O its|O association|O with|O a|O subset|O of|O active|O GATA|O elements|O ,|O indicating|O that|O GATA1|O is|O a|O key|O determinant|O for|O SCL|O recruitment|O .|O
Moreover|O ,|O screening|O of|O whole|O exome|O sequencing|O results|O for|O AML|O available|O through|O the|O Cancer|O Genome|O Atlas|O showed|O the|O presence|O of|O mutations|O in|O genes|O encoding|O other|O components|O of|O the|O spliceosome|O ,|O including|O mutations|O in|O HCFC1|O (|O P72L|O )|O ,|O SAP130|O (|O T247I|O )|O ,|O SRSF6|O (|O W123S|O )|O ,|O SON|O (|O M1024V|O )|O ,|O and|O U2AF26|O (|O C116X|O ;|O supplemental|O Figure|O 1|O )|O .|O
Overall|O ,|O the|O response|O rates|O for|O INF|O -|O alpha|O are|O promising|O but|O remain|O comparable|O with|O those|O already|O achieved|O by|O hydroxyurea|O .|O
Median|O survival|O is|O estimated|O at|O <|O 6|O years|O with|O causes|O of|O death|O ,|O including|O leukemic|O transformation|O ,|O progressive|O cachexia|O ,|O vascular|O events|O and|O infections|O .|O
Allelic|O Losses|O of|O PTEN|O /|O MMAC1|O Gene|O Characterized|O by|O Loss|O of|O Heterozygosity|O Analysis|O
In|O this|O review|O ,|O we|O describe|O all|O novel|O key|O mutations|O in|O MDS|O and|O their|O significance|O in|O pathophysiology|O and|O clinical|O practice|O .|O
Fourteen|O months|O after|O the|O transplantation|O ,|O no|O severe|O infection|O was|O noted|O and|O immunologic|O recovery|O was|O obtained|O .|O
Management|O of|O AML|O in|O Patients|O Older|O Than|O 60|O Years|O .|O
These|O supportive|O care|O measures|O are|O tailored|O to|O address|O the|O specific|O needs|O and|O infection|O susceptibility|O of|O each|O individual|O patient|O .|O
The|O median|O follow|O -|O up|O of|O the|O cohort|O was|O 18|O months|O (|O 1|O -|O 168|O months|O )|O .|O
10|O .|O CONCLUSIONS|O AND|O FUTURE|O PERSPECTIVES|O .|O
Therefore|O ,|O more|O detailed|O expression|O studies|O in|O bone|O marrow|O subfractions|O from|O individuals|O with|O MDS|O are|O warranted|O .|O
No|O standard|O of|O care|O exists|O for|O CNL|O or|O aCML|O .|O
Background|O .|O
It|O is|O particularly|O important|O to|O identify|O the|O gene|O targets|O of|O possible|O splicing|O defects|O .|O
In|O addition|O ,|O we|O identified|O 8|O deletions|O involving|O STAG2|O (|O chromosome|O X|O )|O or|O RAD21|O (|O chromosome|O 8|O )|O (|O supplemental|O Figure|O 3|O and|O supplemental|O Table|O 3|O )|O .|O
GATA2|O also|O plays|O a|O critical|O role|O in|O the|O decision|O of|O stem|O cells|O to|O commit|O to|O erythroid|O versus|O myeloid|O lineages|O interacting|O with|O PU|O .|O 1|O and|O repressing|O its|O expression|O .|O
Mutations|O of|O RNA|O -|O splicing|O genes|O are|O the|O most|O frequently|O observed|O mutations|O in|O MDS|O ,|O occurring|O in|O up|O to|O 50|O %|O of|O cases|O ,|O the|O most|O common|O of|O which|O include|O mutations|O of|O U2AF1|O (|O U2AF35|O )|O ,|O SRSF2|O (|O SC35|O )|O ,|O SF3B1|O (|O SF3B155|O or|O SAP155|O )|O ,|O and|O ZRSR2|O (|O URP|O )|O .|O
This|O enhancer|O activity|O requires|O both|O WGATAR|O and|O E|O -|O box|O motifs|O .|O
Physicians|O taking|O care|O of|O patients|O with|O PMF|O are|O often|O faced|O with|O therapeutic|O decisions|O that|O include|O the|O indication|O and|O timing|O of|O allogeneic|O stem|O cell|O transplantation|O or|O investigational|O drug|O therapy|O .|O
Clinicohematological|O characteristics|O and|O outcome|O of|O patients|O with|O CMML|O and|O RUNX1|O mutations|O .|O
There|O were|O no|O significant|O associations|O with|O cytogenetic|O risk|O groups|O .|O
MPL|O mutation|O analysis|O is|O not|O indicated|O in|O the|O consideration|O of|O PV|O ,|O because|O no|O MPL|O mutations|O have|O been|O described|O for|O this|O entity|O .|O
In|O addition|O ,|O 85|O .|O 3|O %|O of|O patients|O whose|O MDS|O harbored|O an|O SRSF2|O had|O at|O least|O 1|O additional|O mutation|O ,|O including|O RUNX1|O ,|O IDH2|O ,|O and|O ASXL1|O (|O P|O <|O 0|O .|O 001|O )|O .|O
She|O had|O 3|O children|O ,|O 1|O of|O whom|O developed|O MDS|O detected|O in|O the|O evaluation|O of|O asthenia|O at|O the|O age|O of|O 12|O (|O patient|O number|O 5834|O ;|O P3|O ,|O III|O ,|O 3|O )|O .|O
The|O N|O -|O and|O C|O -|O ZnFs|O of|O GATA2|O are|O encoded|O by|O exons|O 4|O and|O 5|O ,|O respectively|O .|O
In|O lower|O -|O risk|O MDS|O ,|O IDH2|O mutations|O were|O shown|O to|O co|O -|O occur|O with|O mutations|O in|O DNMT3A|O ,|O ASXL1|O ,|O and|O SRSF2|O and|O to|O be|O an|O adverse|O prognostic|O factor|O for|O OS|O .|O
In|O addition|O ,|O high|O -|O dose|O cytarabine|O ,|O if|O not|O previously|O used|O as|O treatment|O for|O persistent|O disease|O at|O day|O 15|O ,|O with|O or|O without|O anthracycline|O may|O also|O be|O considered|O in|O the|O salvage|O setting|O .|O
Assays|O that|O are|O not|O allele|O specific|O ,|O such|O as|O melting|O curve|O analysis|O ,|O offer|O the|O potential|O to|O detect|O rare|O variants|O ,|O but|O have|O a|O significantly|O lower|O sensitivity|O (|O typically|O 5|O %|O to|O 10|O %|O mutant|O alleles|O )|O .|O
They|O found|O an|O in|O -|O frame|O deletion|O of|O 6|O amino|O acids|O (|O 341|O -|O 346|O ,|O found|O in|O one|O case|O )|O and|O a|O L359V|O substitution|O (|O found|O in|O 8|O cases|O )|O ,|O located|O in|O the|O N|O -|O ZnF|O and|O C|O -|O ZnF|O ,|O respectively|O .|O
Patient|O population|O BM|O aspirates|O or|O blood|O samples|O were|O collected|O from|O 315|O patients|O with|O MDS|O (|O n|O =|O 88|O )|O ,|O MDS|O /|O myeloproliferative|O neoplasms|O (|O MDS|O /|O MPNs|O ;|O n|O =|O 66|O )|O ,|O MPN|O (|O n|O =|O 52|O )|O ,|O secondary|O AML|O (|O sAML|O ;|O n|O =|O 54|O )|O that|O evolved|O from|O these|O conditions|O and|O primary|O AML|O (|O pAML|O ;|O n|O =|O 55|O )|O seen|O at|O Cleveland|O Clinic|O or|O Nagoya|O University|O between|O 2003|O and|O 2010|O (|O Table|O 1|O )|O .|O
Although|O clonality|O has|O been|O demonstrated|O in|O CNL|O ,|O the|O majority|O of|O patients|O exhibit|O normal|O cytogenetics|O .|O
The|O samples|O were|O then|O sequenced|O on|O an|O Illumina|O HiSeq2000|O that|O generated|O paired|O end|O reads|O of|O 100|O nucleotides|O .|O
The|O MDAPS|O was|O subsequently|O applied|O to|O 212|O CMML|O patients|O in|O the|O Dusseldorf|O registry|O ;|O in|O a|O univariate|O analysis|O ,|O circulating|O IMC|O had|O no|O prognostic|O impact|O ,|O whereas|O on|O multivariable|O analysis|O ,|O elevated|O lactate|O dehydrogenase|O ,|O BM|O blast|O count|O >|O 10|O %|O ,|O male|O gender|O ,|O hemoglobin|O <|O 12|O g|O /|O dl|O and|O ALC|O >|O 2|O .|O 5|O x|O 109|O /|O l|O were|O independently|O prognostic|O .|O
If|O the|O relapse|O occurs|O after|O a|O relatively|O "|O long|O "|O (|O >|O 12|O months|O )|O period|O of|O remission|O ,|O retreatment|O with|O the|O previously|O successful|O induction|O regimen|O is|O an|O option|O .|O
ET|O .|O
Although|O HSCT|O was|O associated|O with|O a|O significantly|O higher|O rate|O of|O nonrelapse|O mortality|O (|O 21|O %|O vs|O .|O 3|O %|O ;|O P|O <|O .|O 001|O )|O ,|O the|O 3|O -|O year|O OS|O rate|O showed|O a|O survival|O benefit|O with|O HSCT|O (|O 62|O %|O vs|O .|O 51|O %|O ;|O P|O =|O .|O 012|O )|O .|O
The|O SRSF2|O gene|O encodes|O a|O member|O of|O the|O serine|O /|O arginine|O -|O rich|O family|O critical|O for|O pre|O -|O mRNA|O splicing|O .|O
Survival|O analysis|O confirmed|O the|O prognostic|O validity|O of|O the|O IPSS|O risk|O recalculation|O in|O our|O sample|O set|O (|O Table|O 3|O in|O the|O Supplementary|O Appendix|O )|O .|O
The|O molecular|O basis|O and|O clinical|O significance|O of|O genetic|O mutations|O identified|O in|O myelodysplastic|O syndromes|O .|O
RESULTS|O .|O
In|O our|O study|O ,|O although|O the|O G|O -|O MDAPS|O stratified|O patients|O into|O four|O risk|O categories|O ,|O the|O Mayo|O prognostic|O model|O was|O more|O effective|O and|O was|O able|O to|O risk|O stratify|O within|O each|O of|O the|O G|O -|O MDAPS|O risk|O groups|O .|O
Overall|O and|O leukemia|O -|O free|O survivals|O were|O inter|O -|O independently|O predicted|O by|O ASXL1|O ,|O SRSF2|O or|O EZH2|O mutations|O and|O ASXL1|O ,|O SRSF2|O and|O IDH1|O or|O 2|O mutations|O ,|O respectively|O .|O
Among|O the|O patients|O who|O received|O high|O -|O dose|O cytarabine|O consolidation|O ,|O the|O 5|O -|O year|O relapse|O -|O free|O survival|O rate|O was|O 78|O %|O for|O CBF|O AML|O ,|O 40|O %|O for|O normal|O karyotype|O ,|O and|O 21|O %|O for|O other|O cytogenetic|O categories|O .|O
The|O clinical|O value|O of|O the|O mutation|O in|O MDS|O is|O uncertain|O .|O
Significantly|O ,|O multivariate|O analyses|O demonstrated|O that|O GATA2|O overexpression|O was|O an|O unfavorable|O independent|O factor|O associated|O with|O overall|O survival|O when|O adjusted|O for|O age|O and|O cytogenetic|O prognostic|O group|O .|O
Unfavorable|O karyotype|O indicates|O any|O of|O the|O following|O :|O +|O 8|O ,|O -|O 7|O /|O 7q|O -|O ,|O i|O (|O 17q|O )|O ,|O inv|O (|O 3|O )|O ,|O -|O 5|O /|O 5q|O ,|O 12p|O -|O ,|O or|O 11q23|O rearrangements|O .|O
Abbreviations|O :|O ASXL1|O ,|O additional|O sex|O combs|O 1|O gene|O ;|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O ;|O SF3B1|O ,|O splicing|O factor|O 3B|O subunit|O 1|O ;|O SRSF2|O ,|O serine|O /|O arginine|O -|O rich|O splicing|O factor|O 2|O ;|O U2AF35|O ,|O U2|O small|O -|O nuclear|O RNA|O auxiliary|O factor|O 1|O ;|O WHO|O ,|O World|O Health|O Organization|O .|O
Some|O of|O these|O RNAs|O code|O for|O key|O proteins|O involved|O in|O malignant|O transformation|O .|O
A|O recent|O study|O addressed|O this|O issue|O by|O breeding|O a|O Gata2|O transgene|O onto|O a|O Gata1|O null|O background|O whose|O protein|O levels|O and|O spatiotemporal|O patterns|O of|O GATA2|O expression|O closely|O recapitulated|O those|O of|O normal|O GATA1|O .|O
In|O that|O way|O ,|O these|O three|O factors|O could|O then|O maintain|O expression|O of|O each|O other|O in|O HSC|O after|O BMP4|O and|O NOTCH1|O signaling|O ceases|O .|O
Further|O work|O may|O identify|O additional|O readers|O of|O 5|O -|O hmC|O and|O evaluate|O the|O function|O of|O MBD3|O in|O other|O cellular|O contexts|O .|O
The|O genes|O encoding|O RAS|O proteins|O are|O small|O GTPases|O involved|O in|O the|O regulation|O of|O cell|O proliferation|O ,|O survival|O ,|O and|O differentiation|O .|O
At|O least|O part|O of|O the|O difference|O is|O likely|O due|O to|O the|O fact|O that|O ,|O in|O the|O Mayo|O Clinic|O study|O ,|O OS|O was|O estimated|O from|O the|O date|O of|O diagnosis|O or|O first|O referral|O ,|O whereas|O in|O this|O study|O it|O was|O always|O estimated|O from|O the|O date|O of|O diagnosis|O .|O
The|O induction|O therapy|O of|O AML|O was|O complicated|O by|O lung|O aspergillosis|O in|O 2|O patients|O of|O 4|O who|O have|O received|O this|O therapeutic|O approach|O ,|O and|O 1|O additional|O patient|O (|O patient|O number|O 5593|O )|O suffered|O from|O lung|O aspergillosis|O along|O with|O genital|O cancer|O .|O
Other|O methods|O used|O to|O detect|O V617F|O include|O restriction|O fragment|O length|O polymorphism|O ,|O denaturing|O high|O -|O performance|O liquid|O chromatography|O ,|O high|O -|O resolution|O melting|O -|O curve|O analysis|O ,|O pyrosequencing|O ,|O and|O various|O allele|O -|O specific|O PCR|O systems|O with|O electrophoretic|O analysis|O of|O the|O products|O .|O
ASSOCIATIONS|O FROM|O THE|O MULTIVARIABLE|O SURVIVAL|O MODEL|O .|O
6|O .|O 2|O .|O LEVELS|O OF|O GATA2|O EXPRESSION|O DETERMINE|O THE|O FATE|O ALONG|O ERYTHROID|O AND|O MEGAKARYOCYTE|O DIFFERENTIATION|O PATHWAYS|O .|O
It|O has|O been|O postulated|O that|O STAG2|O mutations|O and|O resultant|O resultant|O depletion|O of|O cohesin|O may|O increase|O RUNX1|O expression|O ,|O forming|O the|O basis|O of|O leukemogenesis|O in|O these|O patients|O .|O
Patients|O .|O
CCAAT|O enhancer|O binding|O protein|O alpha|O (|O CEBPA|O )|O is|O mutated|O in|O familial|O AML|O with|O an|O autosomaldominant|O transmission|O and|O a|O high|O penetrance|O .|O
Some|O cases|O may|O still|O show|O evidence|O of|O both|O myeloid|O and|O lymphoid|O antigen|O expression|O on|O the|O leukemic|O cells|O .|O
A|O treatment|O decision|O -|O making|O algorithm|O for|O previously|O untreated|O ,|O medically|O fit|O ,|O elderly|O patients|O (|O age|O >|O =|O 60|O years|O )|O with|O AML|O was|O recently|O developed|O by|O the|O German|O AML|O cooperative|O group|O .|O
In|O subject|O 87|O ,|O one|O allele|O was|O deleted|O and|O the|O other|O contained|O a|O point|O mutation|O .|O
Treatment|O strategies|O for|O relapse|O are|O categorized|O according|O to|O patient|O age|O .|O
In|O a|O study|O of|O patients|O with|O MDS|O and|O chronic|O myelomonocytic|O leukaemia|O (|O CMML|O )|O ,|O mutations|O in|O TET2|O were|O identified|O in|O CD34|O +|O cells|O (|O which|O include|O HSCs|O )|O ,|O and|O some|O patients|O had|O more|O than|O one|O TET2|O mutation|O .|O
As|O summarized|O in|O this|O review|O ,|O only|O a|O few|O direct|O GATA2|O target|O genes|O have|O been|O described|O ,|O the|O most|O prominent|O of|O these|O being|O GATA2|O itself|O .|O
Myeloproliferative|O neoplasms|O (|O MPN|O )|O that|O do|O not|O contain|O the|O BCR|O -|O ABL1|O mutation|O include|O polycythemia|O vera|O (|O PV|O )|O ,|O essential|O thrombocythemia|O (|O ET|O )|O ,|O and|O primary|O myelofibrosis|O (|O PMF|O )|O .|O
Diagnosis|O was|O confirmed|O at|O each|O institution|O according|O to|O World|O Health|O Organization|O classification|O criteria|O .|O
The|O role|O of|O myeloablative|O allogeneic|O HSCT|O is|O limited|O in|O older|O patients|O because|O of|O significant|O comorbidities|O ;|O however|O ,|O ongoing|O interest|O has|O been|O shown|O in|O reduced|O -|O intensity|O conditioning|O (|O RIC|O )|O allogeneic|O HSCT|O as|O consolidation|O therapy|O .|O
Unlike|O the|O FOG1|O /|O GATA1|O binding|O ,|O these|O molecular|O interactions|O are|O still|O not|O fully|O understood|O .|O
The|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O identified|O 163|O (|O 72|O %|O )|O patients|O in|O the|O low|O -|O risk|O category|O ,|O 31|O (|O 14|O %|O )|O in|O the|O intermediate|O -|O risk|O category|O and|O 32|O (|O 14|O %|O )|O in|O the|O high|O -|O risk|O category|O ,|O respectively|O .|O
When|O dichotomized|O using|O a|O threshold|O expression|O of|O <|O mean|O -|O 2|O standard|O deviations|O (|O 95|O %|O confidence|O interval|O )|O as|O a|O cutoff|O value|O ,|O 10|O %|O to|O 20|O %|O of|O cases|O showed|O decreased|O cohesin|O expression|O (|O Figure|O 5A|O -|O B|O )|O .|O
As|O expected|O ,|O age|O and|O IPSS|O risk|O group|O were|O strongly|O associated|O with|O overall|O survival|O (|O Table|O 2|O )|O .|O
The|O GATA|O family|O of|O nuclear|O regulatory|O proteins|O serves|O as|O a|O prototype|O for|O the|O action|O of|O lineage|O -|O restricted|O transcription|O factors|O .|O
The|O latest|O iteration|O replaced|O the|O term|O myeloproliferative|O disorders|O with|O "|O myeloproliferative|O neoplasms|O "|O (|O MPN|O )|O and|O incorporated|O systemic|O mastocytosis|O ,|O chronic|O eosinophilic|O leukemia|O -|O not|O otherwise|O specified|O ,|O chronic|O neutrophilic|O leukemia|O ,|O and|O MPN|O -|O unclassifiable|O into|O the|O existing|O MPD|O category|O .|O
If|O available|O ,|O results|O of|O prior|O serial|O testing|O may|O be|O provided|O .|O
Because|O a|O relatively|O small|O number|O of|O CN|O -|O AML|O cases|O has|O been|O analyzed|O for|O BCORL1|O mutations|O and|O cases|O of|O s|O -|O AML|O have|O not|O been|O investigated|O for|O BCOR|O mutations|O ,|O it|O is|O not|O yet|O clear|O whether|O or|O not|O mutations|O of|O these|O two|O homologous|O genes|O may|O occur|O in|O the|O same|O clinical|O -|O genetic|O AML|O backgrounds|O .|O
Furthermore|O ,|O analysis|O of|O the|O mutant|O -|O allele|O burden|O in|O samples|O with|O mutations|O of|O TET2|O and|O other|O genes|O showed|O that|O TET2|O mutations|O are|O not|O always|O present|O at|O the|O greatest|O frequency|O ,|O which|O would|O be|O expected|O if|O they|O were|O exclusively|O involved|O in|O early|O pathogenic|O events|O (|O Fig|O .|O 7|O in|O the|O Supplementary|O Appendix|O )|O .|O
Myelopoiesis|O .|O
Our|O results|O are|O also|O different|O from|O McGlynn|O study|O and|O Padua|O study|O of|O RAS|O ,|O FMS|O ,|O and|O p53|O ,|O in|O which|O the|O loss|O of|O FMS|O gene|O ,|O mutation|O of|O RAS|O ,|O FMS|O ,|O and|O p53|O were|O common|O in|O AML|O and|O myelodysplasias|O .|O
There|O are|O several|O reasons|O why|O blood|O is|O the|O preferred|O type|O of|O specimen|O ,|O including|O convenience|O and|O the|O fact|O that|O the|O diagnosis|O of|O PV|O can|O in|O most|O cases|O be|O made|O without|O a|O bone|O marrow|O evaluation|O .|O
We|O investigated|O a|O family|O in|O which|O the|O mother|O (|O patient|O number|O 6227|O ;|O P1|O ,|O II|O ,|O 4|O )|O developed|O at|O 35|O years|O of|O age|O an|O AML|O M2|O associated|O with|O myelodysplasia|O -|O related|O changes|O .|O
Mutations|O of|O BCOR|O mainly|O clustered|O with|O CN|O -|O AML|O ,|O were|O virtually|O mutually|O exclusive|O with|O NPM1|O and|O FLT3|O -|O ITD|O mutations|O and|O showed|O an|O association|O with|O DNMT3A|O and|O RUNX1|O mutations|O .|O
Therefore|O ,|O we|O performed|O exome|O sequencing|O on|O the|O AML|O diagnosis|O sample|O of|O the|O second|O son|O (|O patient|O number|O 6225|O )|O .|O
Krebs|O cycle|O .|O
Dynamic|O DNA|O methylation|O and|O demethylation|O balance|O occur|O via|O 5|O -|O hydroxymethylcytosine|O (|O 5hmC|O )|O -|O dependent|O active|O demethylation|O ,|O which|O controls|O DNA|O replication|O and|O cancer|O development|O in|O mammalian|O cells|O .|O
To|O detect|O allelic|O losses|O ,|O the|O polymorphic|O short|O tandem|O repeat|O markers|O used|O were|O D10S215|O ,|O D10S541|O ,|O D10S579|O ,|O and|O AFM086|O .|O
Mutations|O in|O RUNX1|O ,|O TP53|O ,|O and|O NRAS|O were|O most|O strongly|O associated|O with|O severe|O thrombocytopenia|O (|O P|O <|O 0|O .|O 001|O for|O all|O comparisons|O )|O and|O an|O increased|O proportion|O of|O bone|O marrow|O blasts|O (|O P|O <|O 0|O .|O 006|O for|O all|O comparisons|O )|O .|O
To|O determine|O the|O relative|O contribution|O of|O mutation|O status|O to|O overall|O survival|O ,|O we|O generated|O a|O multivariable|O Cox|O model|O ,|O using|O a|O stepwise|O variable|O -|O selection|O procedure|O incorporating|O age|O ,|O sex|O ,|O IPSS|O classification|O ,|O and|O mutation|O status|O for|O the|O 13|O most|O frequently|O mutated|O genes|O identified|O in|O this|O study|O .|O
If|O a|O quantitative|O cutoff|O is|O used|O to|O define|O a|O positive|O result|O ,|O this|O value|O should|O be|O stated|O as|O part|O of|O the|O methodology|O summary|O ,|O and|O a|O limit|O of|O sensitivity|O must|O also|O be|O included|O .|O
We|O compared|O the|O characteristics|O of|O the|O study|O patients|O with|O mutations|O ,|O using|O the|O appropriate|O statistical|O methods|O ,|O as|O detailed|O in|O the|O Methods|O section|O in|O the|O Supplementary|O Appendix|O .|O
However|O ,|O due|O to|O the|O low|O frequency|O of|O the|O mutation|O ,|O additional|O studies|O are|O necessary|O to|O confirm|O these|O findings|O .|O
The|O FERM|O domain|O ,|O which|O resides|O at|O the|O amino|O terminus|O ,|O functions|O as|O a|O binding|O protein|O transducing|O signals|O from|O JAK2|O to|O other|O transmembrane|O cytokine|O receptors|O (|O Figure|O 1|O )|O .|O
ZRSR2|O /|O URP|O .|O
More|O than|O 50|O %|O of|O patients|O in|O each|O arm|O had|O already|O experienced|O a|O CR|O when|O they|O received|O cycle|O 2|O .|O
These|O SCN|O patients|O harbor|O germ|O -|O line|O mutations|O in|O neutrophil|O elastase|O or|O other|O genes|O necessary|O for|O production|O of|O neutrophils|O .|O
Myelodysplastic|O syndromes|O are|O clinically|O heterogeneous|O disorders|O characterized|O by|O clonal|O hematopoiesis|O ,|O impaired|O differentiation|O ,|O peripheral|O -|O blood|O cytopenias|O ,|O and|O a|O risk|O of|O progression|O to|O acute|O myeloid|O leukemia|O .|O
In|O contrast|O ,|O mutations|O of|O EZH2|O ,|O which|O lies|O on|O the|O distal|O portion|O of|O chromosome|O 7q|O ,|O were|O not|O associated|O with|O 7q|O deletions|O .|O
Collaboration|O of|O other|O genetic|O or|O epigenetic|O alterations|O in|O the|O great|O majority|O of|O patients|O with|O CMML|O and|O RUNX1|O mutations|O ,|O especially|O at|O AML|O transformation|O ,|O requires|O further|O investigation|O .|O
During|O erythroid|O differentiation|O ,|O expression|O of|O GATA1|O is|O upregulated|O and|O GATA1|O replaces|O GATA2|O at|O the|O same|O motifs|O ,|O resulting|O in|O the|O inhibition|O of|O GATA2|O transcription|O .|O
One|O complicating|O issue|O is|O that|O the|O GATA2|O protein|O is|O much|O less|O stable|O than|O GATA1|O ,|O raising|O questions|O about|O the|O relevance|O of|O mRNA|O levels|O .|O
ABSTRACT|O .|O
Most|O mutated|O patients|O had|O a|O normal|O karyotype|O ,|O suggesting|O that|O cohesin|O gene|O mutations|O do|O not|O act|O through|O destabilization|O of|O chromosomal|O integrity|O in|O AML|O ,|O but|O rather|O alternative|O mechanisms|O such|O as|O transcriptional|O control|O .|O
When|O stratifying|O by|O normal|O /|O abnormal|O karyotype|O ,|O no|O particular|O genetic|O lesion|O was|O enriched|O based|O on|O karyotype|O ,|O although|O 5|O out|O of|O 9|O patients|O (|O 55|O %|O )|O with|O RUNX1|O mutations|O and|O abnormal|O karyotype|O had|O trisomy|O 8|O .|O
ABSTRACT|O .|O
Thus|O ,|O transcription|O of|O GATA2|O mRNAs|O is|O initiated|O from|O two|O first|O exons|O :|O the|O distal|O first|O exon|O of|O GATA2|O (|O IS|O exon|O )|O is|O specific|O of|O hematopoietic|O and|O neuronal|O cells|O ,|O whereas|O the|O proximal|O first|O exon|O (|O IG|O exon|O )|O is|O utilized|O in|O all|O tissues|O that|O express|O GATA2|O (|O Fig|O .|O 1|O )|O .|O
Cytokine|O -|O driven|O neutrophilia|O accompanying|O plasma|O cell|O neoplasms|O is|O a|O well|O -|O described|O association|O .|O
TP53|O as|O a|O therapeutic|O target|O has|O also|O been|O investigated|O in|O del|O (|O 5q|O )|O MDS|O .|O
Several|O methods|O have|O been|O used|O to|O detect|O JAK2|O and|O MPL|O mutations|O .|O
If|O there|O is|O doubt|O ,|O a|O peripheral|O blood|O or|O a|O bone|O marrow|O specimen|O collected|O at|O a|O later|O time|O point|O may|O be|O used|O to|O confirm|O the|O finding|O .|O
OVERVIEW|O .|O
Although|O there|O are|O no|O FDA|O -|O cleared|O tests|O ,|O a|O number|O of|O methods|O have|O been|O developed|O for|O detecting|O JAK2|O V617F|O mutation|O .|O
Survival|O rates|O were|O 77|O %|O (|O at|O 20|O years|O )|O and|O 62|O %|O (|O at|O 30|O years|O )|O in|O this|O series|O of|O 14|O patients|O with|O GATA2|O mutations|O (|O Figure|O 2A|O )|O .|O
Current|O recommendations|O support|O the|O use|O of|O aspirin|O as|O first|O -|O line|O therapy|O in|O all|O risk|O classes|O unless|O contraindicated|O .|O
Reductions|O in|O spleen|O volume|O were|O durable|O ;|O 67|O .|O 0|O %|O of|O patients|O with|O a|O response|O had|O this|O response|O for|O 48|O weeks|O or|O longer|O with|O continued|O therapy|O .|O
Together|O ,|O except|O for|O the|O two|O patients|O carrying|O biallelic|O heterozygous|O mutations|O ,|O the|O remaining|O were|O monoallelic|O heterozygous|O mutations|O .|O
Transformation|O to|O AML|O occurred|O in|O 2|O patients|O in|O this|O study|O ;|O both|O patients|O received|O ruxolitinib|O and|O had|O baseline|O characteristics|O that|O placed|O them|O at|O increased|O risk|O for|O transformation|O .|O
GATA2|O transcription|O is|O regulated|O by|O several|O transcription|O factors|O such|O as|O ETS1|O ,|O BMP4|O ,|O NOTCH1|O ,|O PU|O .|O 1|O and|O EVI1|O ,|O and|O by|O the|O cytokines|O IL|O -|O 1|O and|O TNFalpha|O .|O
On|O a|O univariate|O analysis|O ,|O factors|O adversely|O influencing|O OS|O included|O high|O WBC|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O high|O absolute|O neutrophil|O count|O (|O P|O =|O 0|O .|O 0005|O )|O ,|O high|O ALC|O (|O P|O =|O 0|O .|O 005|O )|O ,|O high|O AMC|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O low|O platelet|O count|O (|O P|O =|O 0|O .|O 012|O )|O ,|O presence|O of|O circulating|O IMC|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O PB|O blasts|O (|O P|O =|O 0|O .|O 002|O )|O ,|O BM|O blasts|O (|O P|O =|O 0|O .|O 005|O )|O ,|O BM|O cellularity|O (|O P|O =|O 0|O .|O 01|O )|O ,|O WHO|O morphological|O categories|O (|O P|O =|O 0|O .|O 02|O )|O ,|O MDAPS|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O G|O -|O MDAPS|O (|O P|O =|O 0|O .|O 01|O )|O and|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O (|O P|O =|O 0|O .|O 04|O )|O (|O Table|O 3|O )|O .|O
At|O least|O 18|O clones|O were|O subsequently|O sequenced|O .|O
As|O seen|O from|O the|O earlier|O discussions|O ,|O patients|O with|O NK|O -|O AML|O may|O present|O with|O multiple|O molecular|O lesions|O .|O
GATA1|O is|O present|O in|O the|O more|O differentiated|O cells|O of|O the|O erythroid|O ,|O megakaryocytic|O ,|O eosinophilic|O and|O mast|O lineages|O ,|O and|O is|O an|O essential|O transcription|O factor|O for|O the|O maturation|O of|O erythroid|O and|O megakaryocytic|O cells|O .|O
The|O most|O relevant|O question|O ,|O both|O biologically|O and|O clinically|O ,|O is|O which|O other|O gene|O mutations|O are|O associated|O with|O the|O mutation|O status|O of|O individual|O spliceosomal|O genes|O .|O
GATA2|O is|O expressed|O in|O adult|O endothelial|O cells|O ,|O where|O it|O plays|O key|O roles|O in|O the|O transcriptional|O regulation|O of|O endothelial|O -|O specific|O genes|O containing|O GATA|O -|O binding|O sites|O in|O their|O promoter|O regions|O :|O eNOS|O ,|O von|O Willebrand|O factor|O ,|O KDR|O and|O PECAM|O .|O
The|O interaction|O between|O the|O TP53|O mutations|O and|O the|O genes|O more|O recently|O reported|O to|O be|O mutated|O in|O patients|O with|O myelodysplastic|O syndromes|O have|O not|O been|O studied|O in|O a|O large|O enough|O number|O of|O patients|O to|O establish|O their|O independent|O prognostic|O significance|O .|O
Another|O recent|O study|O also|O showed|O that|O in|O younger|O patients|O (|O age|O <|O 60|O years|O )|O with|O NK|O -|O AML|O ,|O DNMT3A|O mutation|O was|O associated|O with|O significantly|O decreased|O DFS|O (|O 3|O -|O year|O rate|O ,|O 20|O %|O vs|O .|O 49|O %|O ;|O P|O =|O .|O 007|O )|O and|O a|O trend|O toward|O decreased|O OS|O .|O
In|O this|O study|O ,|O samples|O with|O abnormal|O sequencing|O results|O were|O subjected|O to|O repeated|O analyses|O by|O DNA|O PCR|O using|O alternative|O primer|O pairs|O to|O confirm|O the|O presence|O of|O unequivocal|O mutations|O .|O
The|O majority|O of|O abnormalities|O in|O PV|O were|O associated|O with|O age|O >|O =|O 60|O years|O .|O
Treatment|O with|O antimetabolites|O ,|O such|O as|O the|O purine|O analog|O fludarabine|O ,|O has|O also|O been|O associated|O with|O therapy|O -|O related|O MDS|O /|O AML|O in|O patients|O with|O lymphoproliferative|O disorders|O ,|O particularly|O when|O administered|O in|O combination|O with|O alkylating|O agents|O .|O
Allogeneic|O HSCT|O in|O first|O CR|O was|O associated|O with|O a|O significantly|O lower|O 3|O -|O year|O cumulative|O relapse|O rate|O (|O 22|O %|O vs|O .|O 62|O %|O ;|O P|O <|O .|O 001|O )|O and|O higher|O 3|O -|O year|O relapse|O -|O free|O survival|O rate|O (|O 56|O %|O vs|O .|O 29|O %|O ;|O P|O <|O .|O 001|O )|O compared|O with|O the|O non|O -|O HSCT|O group|O .|O
This|O splicing|O abnormality|O of|O RUNX1|O is|O also|O observed|O in|O cases|O with|O SRSF2|O mutations|O but|O not|O in|O SF3B1|O mutants|O .|O
In|O the|O context|O of|O hematopoiesis|O ,|O available|O data|O demonstrate|O that|O either|O quantitative|O or|O qualitative|O dysfunction|O of|O GATA|O hematopoietic|O factors|O contribute|O to|O the|O malignant|O phenotype|O of|O several|O types|O of|O leukemias|O .|O
GATA2|O mutations|O are|O identified|O in|O chronic|O neutropenia|O .|O
Careful|O analysis|O of|O the|O methylome|O in|O HSCs|O revealed|O that|O deletion|O of|O Dnmt3a|O resulted|O in|O both|O hypermethylation|O and|O hypomethylation|O of|O different|O loci|O ;|O notably|O ,|O they|O observed|O hypomethylation|O and|O increased|O expression|O of|O a|O core|O set|O of|O genes|O that|O are|O crucial|O for|O regulating|O HSC|O self|O -|O renewal|O and|O promoting|O malignancy|O .|O
One|O control|O had|O a|O deletion|O of|O nucleotides|O (|O nt|O )|O 1064|O through|O 1814|O ,|O the|O others|O had|O deletion|O of|O nt|O 1180|O -|O 2142|O ,|O nt|O 1244|O -|O 1526|O ,|O nt|O 1296|O -|O 2013|O ,|O and|O nt|O 1835|O -|O 1877|O .|O
The|O second|O objective|O focuses|O on|O patient|O -|O specific|O factors|O ,|O including|O assessment|O of|O comorbid|O conditions|O ,|O which|O may|O affect|O an|O individual|O '|O s|O ability|O to|O tolerate|O chemotherapy|O .|O
A|O screening|O assay|O may|O be|O warranted|O in|O patients|O with|O thrombocytosis|O >|O 1000|O x|O 109|O /|O L|O because|O the|O risk|O of|O acquired|O von|O Willebrand|O syndrome|O increases|O with|O increasing|O platelets|O levels|O .|O
In|O AML|O ,|O the|O BCOR|O gene|O is|O targeted|O by|O both|O translocations|O and|O mutations|O .|O
Conditioning|O regimes|O and|O graft|O -|O versus|O -|O host|O disease|O (|O GVHD|O )|O prophylaxis|O was|O variable|O ,|O and|O significant|O differences|O were|O not|O found|O between|O protocols|O .|O
However|O ,|O we|O found|O several|O specific|O genes|O in|O which|O the|O splicing|O pattern|O was|O altered|O .|O
Chromosomal|O abnormalities|O were|O described|O according|O to|O the|O International|O System|O for|O Human|O Cytogenetic|O Nomenclature|O .|O
Because|O of|O the|O decreased|O probability|O of|O achieving|O remission|O through|O induction|O chemotherapy|O ,|O transplantation|O without|O induction|O chemotherapy|O may|O be|O considered|O for|O patients|O with|O antecedent|O myelodysplasia|O or|O treatment|O -|O related|O leukemia|O who|O have|O an|O available|O sibling|O donor|O and|O who|O have|O a|O relatively|O low|O percentage|O of|O marrow|O involvement|O .|O
Furthermore|O ,|O GATA2|O directly|O upregulates|O BMP4|O expression|O ,|O binding|O to|O the|O regulatory|O elements|O present|O at|O the|O BMP4|O promoter|O .|O
At|O several|O points|O during|O the|O course|O of|O treatment|O ,|O response|O is|O assessed|O based|O on|O bone|O marrow|O morphology|O and|O cytogenetic|O and|O molecular|O responses|O (|O see|O pages|O 997|O and|O 998|O for|O definitions|O of|O complete|O and|O partial|O response|O and|O disease|O relapse|O )|O .|O
Cytogenetic|O and|O molecular|O abnormalities|O associated|O with|O cohesin|O defects|O .|O
RT|O -|O PCR|O and|O cDNA|O Sequencing|O .|O
At|O both|O the|O 3|O '|O and|O 5|O '|O splice|O sites|O of|O RUNX1|O intron|O 6|O ,|O unspliced|O reads|O were|O more|O frequent|O than|O spliced|O reads|O (|O Figure|O 3B|O )|O .|O
She|O died|O from|O CMV|O pneumonia|O without|O achieving|O complete|O remission|O .|O
Adverse|O effects|O may|O be|O attenuated|O with|O prophylactic|O cytoreduction|O when|O using|O hydroxyurea|O .|O
Table|O 1|O .|O Baseline|O Characteristics|O of|O the|O Patients|O .|O
The|O PTEN|O /|O MMAC1|O protein|O is|O a|O dual|O -|O specificity|O phosphatase|O containing|O a|O protein|O tyrosine|O phosphatases|O catalytic|O domain|O and|O a|O region|O homology|O with|O the|O cytoskeletal|O proteins|O tensin|O and|O auxillin|O .|O
A|O recent|O in|O vitro|O study|O showed|O that|O loss|O of|O BAP1|O ,|O a|O tumor|O suppressor|O gene|O ,|O is|O linked|O to|O myeloid|O neoplasm|O by|O loss|O of|O interacting|O with|O the|O polycomb|O group|O proteins|O ASXL1|O and|O ASXL2|O ,|O as|O well|O as|O host|O cell|O factor|O -|O 1|O and|O O|O -|O linked|O N|O -|O acetylglucosamine|O transferase|O ,|O which|O could|O provide|O an|O alternative|O mechanism|O in|O dysregulation|O of|O epigenesis|O .|O
Fig|O .|O 4|O .|O A|O model|O for|O human|O erythroid|O and|O megakaryocyte|O development|O .|O (|O A|O )|O Scheme|O outlining|O the|O early|O stages|O of|O maturation|O of|O erythroid|O differentiation|O .|O Important|O transcriptional|O and|O signaling|O regulators|O that|O are|O required|O for|O the|O initial|O stages|O of|O erythropoiesis|O are|O indicated|O (|O inside|O grey|O boxes|O )|O .|O Transcription|O factors|O and|O activation|O of|O signaling|O proteins|O aberrantly|O expressed|O in|O human|O and|O /|O or|O murine|O erythroleukemia|O are|O highlighted|O in|O red|O .|O (|O B|O )|O Megakaryocyte|O maturation|O proceeds|O in|O an|O ordered|O manner|O from|O the|O BFU|O -|O Mk|O through|O proplatelet|O -|O producing|O cells|O .|O Important|O transcriptional|O and|O signaling|O regulators|O that|O are|O required|O for|O the|O initial|O stages|O of|O megakaryopoiesis|O are|O also|O indicated|O (|O inside|O grey|O boxes|O )|O .|O Genes|O aberrantly|O expressed|O in|O human|O megakaryocytic|O disorders|O are|O highlighted|O in|O red|O .|O
Table|O 1|O .|O Features|O of|O the|O BCOR|O and|O BCORL1|O transcriptional|O corepressors|O .|O
When|O considering|O the|O otherwise|O favorable|O prognostic|O group|O of|O patients|O with|O mutated|O NPM1|O ,|O but|O wild|O -|O type|O FLT3|O ,|O no|O significant|O difference|O for|O OS|O and|O RFS|O between|O patients|O with|O our|O without|O mutations|O in|O the|O cohesin|O complex|O was|O identified|O (|O OS|O :|O HR|O 0|O .|O 65|O ;|O 95|O %|O CI|O ,|O 0|O .|O 2|O -|O 2|O .|O 14|O ;|O P|O =|O .|O 48|O ;|O supplemental|O Figure|O 3E|O )|O and|O (|O RFS|O :|O HR|O 0|O .|O 32|O ;|O 95|O %|O CI|O ,|O 0|O .|O 07|O -|O 1|O .|O 39|O ;|O P|O =|O .|O 13|O ;|O supplemental|O Figure|O 3F|O )|O .|O
The|O biological|O functions|O of|O GATA2|O in|O hematopoiesis|O and|O the|O importance|O of|O its|O balanced|O expression|O led|O to|O the|O suggestion|O that|O it|O might|O be|O involved|O in|O leukemogenesis|O .|O
Although|O allele|O burden|O has|O been|O shown|O to|O decrease|O after|O use|O of|O some|O inhibitors|O ,|O there|O is|O no|O one|O -|O to|O -|O one|O correlation|O of|O allele|O burden|O with|O clinical|O response|O (|O eg|O ,|O reduction|O in|O splenomegaly|O )|O .|O
A|O 1|O -|O muL|O aliquot|O of|O cDNA|O was|O used|O for|O the|O first|O PCR|O amplification|O for|O 30|O cycles|O ,|O using|O primers|O ,|O M1u|O and|O M1d|O .|O
The|O resulting|O risk|O categories|O were|O very|O low|O (|O score|O =|O 0|O )|O ,|O low|O (|O score|O =|O 1|O )|O ,|O intermediate|O (|O score|O 2|O or|O 3|O )|O ,|O high|O (|O score|O 4|O or|O 5|O )|O ,|O and|O very|O high|O (|O score|O >|O =|O 6|O )|O .|O
Statistical|O analyses|O were|O carried|O out|O using|O an|O SPSS|O software|O version|O 8|O .|O 0|O for|O Windows|O (|O SPSS|O Inc|O .|O ,|O Chicago|O ,|O IL|O ,|O USA|O )|O .|O
This|O study|O showed|O similar|O rates|O of|O 4|O -|O year|O nonrelapse|O mortality|O (|O 19|O %|O and|O 20|O %|O ,|O respectively|O )|O ,|O and|O no|O difference|O was|O seen|O in|O relapse|O and|O OS|O rates|O .|O
As|O reported|O by|O Ernst|O et|O al|O EZH2|O mutations|O were|O identified|O in|O 13|O %|O of|O CMML|O patients|O and|O myelodysplastic|O /|O myeloproliferative|O neoplasm|O patients|O mutated|O in|O EZH2|O had|O been|O associated|O with|O an|O inferior|O outcome|O (|O P|O =|O 0|O .|O 0006|O )|O .|O
The|O effect|O of|O these|O modifications|O most|O often|O involves|O variations|O in|O the|O transcriptional|O activity|O due|O to|O changes|O in|O nuclear|O localization|O ,|O DNA|O -|O binding|O ,|O protein|O stability|O ,|O and|O /|O or|O cofactor|O recruitment|O .|O
Traditional|O Sanger|O sequencing|O has|O been|O used|O extensively|O ,|O but|O it|O has|O relatively|O poor|O sensitivity|O .|O
Also|O in|O the|O Mayo|O cohort|O ASXL1|O and|O SRSF2|O mutations|O were|O more|O enriched|O in|O the|O DIPSS|O -|O plus|O high|O -|O risk|O category|O (|O 45|O %|O ,|O P|O =|O 0|O .|O 0002|O and|O 22|O %|O ,|O P|O =|O 0|O .|O 004|O ,|O respectively|O )|O ,|O with|O no|O difference|O for|O EZH2|O mutations|O .|O
Most|O of|O the|O mutations|O we|O detected|O were|O heterozygous|O ,|O indicating|O that|O homozygous|O mutations|O may|O lead|O to|O cell|O death|O or|O that|O some|O of|O the|O functional|O consequences|O are|O related|O to|O dominant|O negative|O effects|O .|O
Using|O these|O four|O independent|O risk|O factors|O ,|O we|O prepared|O a|O new|O prognostic|O risk|O model|O consisting|O of|O three|O risk|O categories|O :|O low|O risk|O (|O 0|O risk|O factors|O )|O ,|O intermediate|O risk|O (|O one|O risk|O factor|O )|O and|O high|O risk|O (|O two|O or|O more|O risk|O factors|O )|O ,|O with|O median|O survivals|O of|O 32|O ,|O 18|O .|O 5|O and|O 10|O months|O ,|O respectively|O (|O Figure|O 2|O )|O .|O
In|O the|O majority|O of|O affected|O individuals|O ,|O a|O cure|O for|O the|O disease|O cannot|O be|O achieved|O ,|O and|O most|O die|O from|O severe|O cytopenias|O .|O
Notwithstanding|O case|O reports|O of|O JAK2|O V617F|O positivity|O in|O selected|O cases|O of|O CNL|O and|O aCML|O ,|O no|O other|O recurrent|O genetic|O mutations|O had|O been|O identified|O in|O these|O diseases|O until|O the|O recent|O discoveries|O of|O mutant|O SETBP1|O and|O CSF3R|O .|O
We|O recently|O reported|O that|O ~|O 50|O %|O to|O 60|O %|O of|O patients|O with|O CNL|O or|O aCML|O harbor|O mutations|O in|O the|O receptor|O for|O colony|O -|O stimulating|O factor|O 3|O (|O CSF3R|O ;|O GCSFR|O )|O .|O
They|O were|O also|O more|O likely|O to|O be|O assigned|O higher|O risk|O scores|O based|O on|O the|O MDAPS|O and|O the|O G|O -|O MDAPS|O .|O
No|O homozygous|O mutations|O have|O been|O reported|O for|O these|O three|O genes|O .|O
Mutational|O analysis|O was|O performed|O on|O bone|O marrow|O samples|O by|O direct|O sequencing|O of|O all|O reverse|O transcription|O PCR|O products|O amplified|O with|O three|O primer|O pairs|O that|O cover|O the|O entire|O coding|O sequences|O of|O RUNX1b|O .|O
Other|O potential|O prognostic|O biomarkers|O in|O PMF|O include|O nullizygosity|O for|O JAK2|O 46|O /|O 1|O haplotype|O ,|O low|O JAK2V617F|O allele|O burden|O ,|O increased|O serum|O IL|O -|O 8|O and|O IL|O -|O 2R|O levels|O and|O excess|O serum|O -|O free|O light|O chain|O levels|O .|O
The|O regimens|O represent|O purine|O analog|O (|O eg|O ,|O fludarabine|O ,|O cladribine|O ,|O clofarabine|O )|O -|O containing|O regimens|O ,|O which|O have|O shown|O remission|O rates|O of|O 30|O %|O to|O 45|O %|O in|O several|O clinical|O trials|O ,|O and|O those|O that|O have|O been|O used|O as|O the|O comparator|O arms|O in|O U|O .|O S|O .|O cooperative|O group|O trials|O in|O the|O past|O decade|O .|O
For|O patients|O with|O RUNX1|O mutations|O ,|O no|O significant|O difference|O was|O observed|O between|O the|O locations|O of|O mutations|O (|O N|O -|O terminal|O vs|O C|O -|O terminal|O )|O or|O between|O the|O patterns|O of|O mutations|O (|O missense|O vs|O frameshift|O /|O nonsense|O )|O with|O respect|O to|O the|O clinicohematological|O features|O ,|O overall|O survival|O or|O time|O to|O AML|O transformation|O (|O Supplementary|O Table|O 2|O )|O .|O
Notably|O ,|O germline|O cohesin|O mutations|O in|O NIBPL|O ,|O SMC1A|O ,|O SMC3|O ,|O and|O HDAC8|O occur|O in|O patients|O with|O Cornelia|O deLange|O syndrome|O ,|O hallmarked|O by|O craniofacial|O abnormalities|O and|O cognitive|O deficits|O .|O
The|O prognostic|O significance|O of|O some|O mutations|O in|O myelodysplastic|O syndromes|O has|O been|O described|O ,|O but|O prior|O studies|O have|O generally|O examined|O small|O sample|O sets|O ,|O have|O involved|O limited|O analyses|O of|O one|O or|O a|O small|O number|O of|O genes|O ,|O or|O have|O focused|O exclusively|O on|O a|O particular|O subtype|O of|O myelodysplastic|O syndrome|O .|O
Because|O of|O their|O distinct|O biological|O and|O clinical|O features|O ,|O "|O AML|O with|O mutated|O NPM1|O "|O and|O "|O AML|O with|O mutated|O CEBPA|O "|O are|O already|O recognized|O as|O provisional|O entities|O in|O the|O 2008|O WHO|O classification|O .|O
What|O Are|O the|O Needs|O for|O Standardization|O and|O Proficiency|O Testing|O ?|O
BCR|O -|O ABL1|O -|O Negative|O Myeloproliferative|O Neoplasms|O :|O A|O Review|O of|O Molecular|O Biology|O ,|O Diagnosis|O ,|O and|O Treatment|O .|O
This|O suggests|O that|O DNMT3A|O mutations|O may|O be|O an|O early|O event|O of|O clonal|O evolution|O .|O
In|O recent|O years|O ,|O a|O number|O of|O somatic|O mutations|O have|O been|O associated|O with|O various|O myeloid|O malignancies|O ,|O including|O MDS|O .|O
GATA1|O and|O GATA2|O regulate|O the|O expression|O of|O a|O number|O of|O erythroid|O genes|O ,|O and|O proper|O regulation|O of|O these|O genes|O is|O critical|O for|O the|O maintenance|O of|O erythroid|O homeostasis|O .|O
It|O is|O thus|O possible|O that|O functionally|O decreased|O expression|O may|O produce|O a|O clinical|O phenocopy|O of|O cohesin|O mutations|O .|O
The|O role|O of|O TET2|O in|O MPN|O was|O established|O while|O investigating|O a|O chromosomal|O rearrangement|O at|O locus|O 4q24|O previously|O described|O in|O patients|O with|O AML|O and|O MDS|O .|O
This|O consolidation|O therapy|O is|O based|O on|O a|O CALGB|O trial|O comparing|O 100|O mg|O /|O m2|O ,|O 400|O mg|O /|O m2|O ,|O and|O 3|O g|O /|O m2|O doses|O of|O cytarabine|O .|O
This|O latter|O observation|O generated|O the|O hypothesis|O of|O genetic|O "|O predestination|O ,|O "|O in|O which|O early|O driver|O mutations|O dictate|O future|O trajectories|O of|O subclonal|O evolution|O with|O distinct|O clinical|O outcomes|O .|O
Moreover|O ,|O recent|O studies|O have|O found|O that|O several|O class|O I|O and|O class|O II|O alterations|O that|O are|O central|O to|O the|O pathogenesis|O of|O myeloid|O malignancies|O have|O direct|O epigenetic|O functions|O in|O addition|O to|O their|O canonical|O roles|O in|O promoting|O haematopoietic|O cell|O proliferation|O .|O
This|O phosphorylation|O results|O in|O reduced|O binding|O of|O heterochromatin|O protein|O 1alpha|O (|O HP1alpha|O )|O ,|O a|O chromatin|O -|O binding|O protein|O that|O leads|O to|O transcriptional|O silencing|O (|O FIG|O .|O 3|O )|O .|O
The|O karyotype|O identified|O a|O trisomy|O 11|O and|O a|O partial|O deletion|O of|O chromosome|O 7|O .|O
BAALC|O expression|O was|O lower|O in|O patients|O with|O a|O mutation|O compared|O with|O patients|O without|O a|O mutation|O in|O a|O gene|O of|O the|O cohesin|O complex|O (|O P|O =|O .|O 033|O )|O (|O Table|O 1|O )|O .|O
Genotyping|O STR|O analysis|O demonstrated|O that|O the|O chromosome|O 3|O allele|O bearing|O the|O GATA2|O R396Q|O mutation|O came|O from|O the|O maternal|O grandfather|O ,|O although|O the|O mutation|O was|O not|O detected|O in|O his|O DNA|O sample|O (|O supplemental|O Figure|O 2|O )|O ,|O suggesting|O a|O de|O novo|O event|O in|O patient|O II|O -|O 4|O (|O patient|O number|O 6227|O )|O .|O
We|O also|O observed|O a|O subset|O of|O AML|O patients|O with|O marked|O reduction|O in|O STAG2|O and|O PDS5B|O expression|O in|O the|O absence|O of|O cohesin|O mutation|O .|O
These|O regimens|O are|O based|O on|O a|O backbone|O of|O cytarabine|O and|O an|O anthracycline|O ,|O and|O have|O changed|O little|O in|O the|O past|O 25|O years|O .|O
It|O is|O not|O clear|O whether|O BAP1|O or|O ASXL1|O mutations|O lead|O to|O alterations|O in|O H2AK119|O ubiquitylation|O in|O vivo|O .|O
Therapy|O has|O primarily|O consisted|O of|O hydroxyurea|O or|O other|O oral|O chemotherapeutics|O ,|O as|O well|O as|O interferon|O -|O a|O .|O
At|O a|O median|O follow|O -|O up|O of|O 15|O months|O ,|O 166|O (|O 73|O %|O )|O deaths|O and|O 33|O (|O 14|O .|O 5|O %|O )|O leukemic|O transformations|O were|O documented|O .|O
MPL|O mutations|O were|O less|O frequent|O (|O 0|O .|O 7|O %|O versus|O 12|O %|O ;|O P|O <|O 0|O .|O 001|O )|O in|O JAK2V617F|O -|O mutated|O patients|O ;|O IDH1|O and|O IDH2|O mutations|O ,|O which|O were|O mutually|O exclusive|O ,|O were|O more|O frequent|O in|O DNMT3A|O -|O (|O 27|O %|O versus|O 5|O %|O ;|O P|O =|O 0|O .|O 001|O )|O or|O SRSF2|O -|O (|O 36|O %|O versus|O 7|O %|O ;|O P|O <|O 0|O .|O 001|O )|O mutated|O patients|O .|O
Examination|O of|O the|O blood|O and|O the|O BM|O revealed|O a|O refractory|O cytopenia|O with|O multilineage|O dysplasia|O .|O
Set|O binding|O protein|O (|O SETBP1|O )|O interacts|O with|O SET|O ,|O a|O negative|O regulator|O of|O the|O tumor|O suppressor|O protein|O phosphatase|O 2A|O (|O PP2A|O )|O .|O
In|O addition|O ,|O the|O WHO|O classification|O system|O allows|O AML|O to|O be|O diagnosed|O regardless|O of|O the|O percentage|O of|O marrow|O blasts|O in|O patients|O with|O abnormal|O hematopoiesis|O and|O characteristic|O clonal|O structural|O cytogenetic|O abnormalities|O with|O t|O (|O 15|O ;|O 17|O )|O ,|O t|O (|O 8|O ;|O 21|O )|O ,|O and|O inv|O (|O 16|O )|O or|O t|O (|O 16|O ;|O 16|O )|O .|O
In|O U2AF35|O ,|O the|O mutations|O almost|O exclusively|O involved|O highly|O conserved|O two|O amino|O acid|O positions|O ,|O S34|O and|O Q157|O ,|O within|O the|O N|O -|O and|O C|O -|O terminal|O zinc|O finger|O domains|O ,|O while|O almost|O all|O SRSF2|O mutations|O are|O missense|O changes|O at|O P95|O or|O deletions|O involving|O this|O amino|O acid|O position|O .|O
The|O above|O difference|O in|O risk|O of|O thrombosis|O remained|O statistically|O significant|O after|O adjusting|O for|O age|O .|O
PTEN|O /|O MMAC1|O is|O a|O putative|O tumor|O suppressor|O gene|O recently|O identified|O at|O chromosome|O 10q23|O .|O 3|O ,|O which|O contains|O 9|O exons|O and|O encodes|O a|O 403|O amino|O acid|O protein|O .|O
Our|O results|O in|O the|O whole|O cohort|O of|O 310|O patients|O with|O MDS|O were|O generally|O consistent|O with|O those|O studies|O .|O
Clinically|O ,|O ASXL1|O mutations|O appear|O to|O be|O broadly|O adverse|O across|O many|O myeloid|O malignancies|O .|O
EZH2|O mutations|O constitute|O a|O novel|O poor|O prognostic|O risk|O group|O and|O ,|O moreover|O ,|O had|O the|O strongest|O clinical|O impact|O of|O all|O markers|O analyzed|O thus|O far|O .|O
The|O probability|O of|O 5|O -|O year|O disease|O -|O free|O survival|O was|O 33|O %|O ,|O 22|O %|O ,|O and|O 27|O %|O ,|O respectively|O .|O
Recent|O genomic|O studies|O have|O identified|O novel|O recurrent|O somatic|O mutations|O in|O patients|O with|O myeloid|O malignancies|O ,|O including|O myeloproliferative|O neoplasms|O (|O MPNs|O )|O ,|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O acute|O myeloid|O leukaemia|O (|O AML|O )|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
One|O -|O hundred|O and|O ninetyone|O patients|O (|O 84|O %|O )|O had|O CMML|O -|O 1|O with|O a|O median|O OS|O of|O 21|O months|O ,|O whereas|O 35|O patients|O had|O CMML|O -|O 2|O with|O a|O median|O OS|O of|O 15|O months|O .|O
Genomic|O DNA|O was|O extracted|O from|O BM|O or|O peripheral|O blood|O with|O the|O use|O of|O standard|O methods|O and|O subjected|O agarose|O gel|O and|O optical|O density|O ratio|O tests|O to|O confirm|O the|O purity|O and|O concentration|O before|O Covaris|O fragmentation|O .|O
No|O recurrent|O deletion|O ,|O amplification|O ,|O or|O uniparental|O disomy|O was|O detected|O by|O CGH|O (|O data|O not|O shown|O )|O .|O
In|O this|O study|O ,|O trisomy|O 13|O or|O trisomy|O 21|O was|O only|O present|O in|O one|O each|O of|O those|O harboring|O RUNX1|O mutations|O ,|O whereas|O they|O were|O not|O detected|O in|O mutation|O -|O negative|O patients|O .|O
The|O spectrum|O of|O infections|O associated|O with|O GATA2|O -|O deficient|O neutropenic|O patients|O encompasses|O bacterial|O and|O fungal|O infection|O with|O frequent|O skin|O or|O mucosal|O involvements|O and|O a|O higher|O risk|O of|O mycobacterial|O and|O viral|O infections|O ,|O reflecting|O either|O the|O profound|O deficit|O of|O NK|O cells|O in|O MonoMAC|O syndrome|O or|O the|O importance|O of|O the|O cooperation|O between|O neutrophils|O and|O NK|O cells|O .|O
However|O ,|O there|O is|O only|O one|O study|O reporting|O the|O prevalence|O of|O the|O GATA2|O high|O expression|O in|O AML|O ,|O performed|O by|O single|O -|O round|O RT|O -|O PCR|O .|O
Epigenetic|O modifications|O have|O long|O been|O known|O to|O govern|O genetic|O programming|O and|O cellular|O differentiation|O .|O
An|O interesting|O finding|O was|O the|O strong|O association|O between|O NPM1|O mutations|O and|O the|O mutations|O in|O cohesin|O genes|O ,|O as|O already|O indicated|O in|O the|O recent|O report|O of|O the|O Cancer|O Genome|O Atlas|O Research|O Network|O .|O
Cytogenetic|O and|O molecular|O lesions|O are|O the|O most|O significant|O prognostic|O indicators|O ,|O with|O failure|O to|O achieve|O remission|O after|O 1|O cycle|O of|O induction|O therapy|O and|O tumor|O burden|O (|O WBC|O >|O =|O 100|O ,|O 000|O /|O mcL|O )|O included|O as|O poor|O -|O risk|O factors|O for|O long|O -|O term|O remission|O .|O
Concluding|O remarks|O .|O
The|O protocol|O was|O approved|O by|O the|O institutional|O review|O board|O at|O each|O participating|O site|O .|O
Such|O mutations|O may|O lead|O to|O distinct|O phenotypes|O and|O ,|O because|O there|O is|O effect|O on|O survival|O ,|O their|O detection|O may|O have|O future|O diagnostic|O utility|O .|O
Interestingly|O ,|O small|O -|O molecule|O inhibitors|O of|O IDH|O mutants|O have|O been|O developed|O and|O are|O used|O in|O clinical|O trials|O for|O AML|O patients|O harboring|O these|O mutations|O .|O
In|O this|O large|O cohort|O study|O ,|O the|O prognostic|O value|O of|O such|O gene|O rearrangement|O in|O MDS|O was|O unable|O to|O be|O determined|O .|O
An|O alternative|O strategy|O for|O patients|O with|O antecedent|O myelodysplasia|O who|O have|O not|O received|O a|O hypomethylating|O agent|O would|O be|O a|O trial|O of|O either|O decitabine|O or|O azacytidine|O while|O a|O rapid|O donor|O search|O is|O initiated|O .|O
Mutations|O have|O been|O identified|O in|O R172|O and|O R140|O of|O the|O IDH2|O gene|O ,|O with|O R140|O mutation|O occurring|O more|O frequently|O .|O
Within|O "|O lower|O -|O risk|O "|O subjects|O (|O Figure|O 5A|O )|O ,|O CALR|O -|O mutant|O patients|O had|O a|O better|O OS|O compared|O with|O either|O JAK2|O (|O V617F|O )|O -|O mutant|O (|O P|O =|O .|O 011|O )|O or|O triple|O -|O negative|O patients|O (|O P|O <|O .|O 001|O )|O .|O
Patients|O with|O SNP|O -|O A|O lesions|O concordant|O with|O metaphase|O cytogenetics|O or|O typical|O lesions|O known|O to|O be|O recurrent|O required|O no|O further|O analysis|O .|O
Because|O most|O laboratories|O offer|O V617F|O and|O exon|O 12|O mutations|O as|O separate|O tests|O ,|O exon|O 12|O mutation|O may|O be|O mistakenly|O requested|O as|O the|O initial|O screening|O test|O instead|O of|O V617F|O mutation|O .|O
As|O such|O ,|O elucidating|O the|O impact|O of|O epigenetic|O mutations|O on|O leukaemogenesis|O and|O therapeutic|O response|O will|O be|O essential|O for|O advancing|O our|O understanding|O and|O treatment|O of|O myeloid|O malignancies|O .|O
Due|O to|O the|O strong|O association|O between|O NPM1|O mutations|O and|O mutations|O in|O the|O cohesin|O complex|O ,|O we|O studied|O the|O impact|O of|O cohesin|O mutations|O on|O OS|O and|O RFS|O in|O NPM1|O -|O mutated|O AML|O patients|O separately|O .|O
Recurrent|O mutations|O in|O JAK2|O and|O MPL|O genes|O are|O genetic|O hallmarks|O of|O BCR|O -|O ABL1|O -|O negative|O myeloproliferative|O neoplasms|O .|O
With|O quantitative|O assessment|O ,|O it|O has|O been|O reported|O that|O approximately|O 20|O %|O to|O 30|O %|O of|O PV|O patients|O have|O less|O than|O 25|O %|O JAK2|O V617F|O alleles|O .|O
Malcovati|O et|O al|O reported|O that|O regardless|O of|O disease|O type|O ,|O SF3B1|O mutations|O strongly|O predicted|O the|O presence|O of|O increased|O sideroblasts|O with|O 97|O .|O 7|O %|O positive|O predictive|O value|O ,|O although|O it|O did|O not|O necessarily|O satisfy|O the|O criteria|O for|O RARS|O or|O RCMD|O -|O RS|O (|O i|O .|O e|O .|O ,|O 15|O %|O of|O all|O erythroblasts|O )|O .|O
Preclinical|O studies|O have|O clearly|O shown|O that|O the|O development|O of|O MDS|O is|O derived|O from|O acquired|O genetic|O mutations|O independent|O of|O their|O phenotypic|O or|O morphologic|O presentation|O .|O
We|O found|O that|O several|O of|O these|O genetic|O lesions|O correlate|O strongly|O with|O features|O of|O the|O clinical|O phenotype|O ,|O including|O specific|O cytopenias|O ,|O blast|O percentage|O ,|O cytogenetic|O abnormalities|O ,|O and|O overall|O survival|O .|O
Notably|O ,|O expression|O of|O the|O entire|O cohesin|O complex|O was|O reduced|O in|O patients|O with|O STAG2|O mutations|O in|O a|O manner|O similar|O to|O that|O seen|O in|O patients|O with|O reduced|O cohesin|O expression|O in|O the|O absence|O of|O mutations|O (|O Figure|O 6B|O )|O .|O
No|O difference|O was|O seen|O in|O relapse|O rate|O ,|O EFS|O ,|O or|O OS|O outcomes|O between|O the|O treatment|O arms|O .|O
A|O recent|O study|O provided|O evidence|O of|O mutated|O CBL|O in|O enhancement|O of|O resistance|O to|O apoptosis|O in|O juvenile|O myelomonocytic|O leukemia|O via|O Src|O family|O kinase|O lyn|O -|O PI3K|O /|O AKT|O pathway|O ,|O suggesting|O a|O potential|O therapeutic|O strategy|O by|O using|O a|O Lyn|O -|O PI3K|O /|O AKT|O inhibitor|O to|O treat|O the|O chemoresistant|O CBL|O -|O mutant|O juvenile|O myelomonocytic|O leukemia|O or|O assumedly|O in|O CBL|O -|O mutated|O MDS|O .|O
Interestingly|O ,|O all|O mutations|O were|O mutually|O exclusive|O among|O each|O other|O .|O
These|O mutations|O block|O the|O expression|O of|O the|O full|O -|O length|O protein|O ,|O but|O allow|O for|O expression|O of|O a|O shorter|O isoform|O named|O GATA1s|O ,|O which|O retains|O the|O two|O ZnF|O and|O lacks|O the|O transactivation|O domain|O .|O
The|O improvement|O was|O rapid|O and|O was|O maintained|O over|O the|O 24|O -|O week|O period|O during|O which|O symptom|O data|O were|O collected|O (|O Fig|O .|O 2A|O )|O .|O
According|O to|O the|O 2008|O World|O Health|O Organization|O (|O WHO|O )|O diagnostic|O criteria|O for|O CNL|O ,|O the|O leukocytosis|O is|O >|O =|O 25|O x|O 109|O /|O L|O ;|O >|O 80|O %|O of|O leukocytes|O are|O segmented|O neutrophils|O /|O band|O forms|O ;|O and|O <|O 10|O %|O are|O immature|O granulocytes|O .|O
The|O extended|O cohort|O of|O patients|O was|O used|O to|O identify|O phenotype|O /|O genotype|O associations|O (|O supplemental|O Table|O 2|O )|O .|O
Perhaps|O additional|O emphasis|O should|O be|O placed|O on|O understanding|O the|O pathogenicity|O of|O these|O diseases|O to|O gain|O insight|O in|O other|O potential|O therapies|O .|O
The|O representative|O regimens|O included|O are|O :|O 1|O )|O cladribine|O ,|O cytarabine|O ,|O and|O granulocyte|O colony|O -|O stimulating|O factor|O (|O G|O -|O CSF|O )|O ,|O with|O or|O without|O mitoxantrone|O or|O idarubicin|O ;|O 2|O )|O fludarabine|O ,|O cytarabine|O ,|O and|O G|O -|O CSF|O (|O FLAG|O regimen|O )|O with|O or|O without|O idarubicin|O ;|O 3|O )|O etoposide|O and|O cytarabine|O ,|O with|O or|O without|O mitoxantrone|O ;|O or|O 4|O )|O clofarabine|O ,|O cytarabine|O and|O G|O -|O CSF|O .|O
The|O EZH2|O homologue|O EZH1|O also|O has|O similar|O enzymatic|O activity|O ,|O and|O the|O redundancy|O of|O these|O two|O proteins|O in|O controlling|O PRC2|O functionality|O probably|O differs|O according|O to|O cellular|O context|O .|O
Germline|O heterozygous|O mutations|O of|O RUNX1|O occur|O mostly|O in|O the|O Rel|O homology|O domain|O ,|O leading|O to|O the|O loss|O of|O its|O DNA|O -|O binding|O capacity|O and|O being|O associated|O with|O a|O familial|O platelet|O disorder|O and|O an|O autosomaldominant|O transmission|O .|O
Both|O IPSS|O and|O DIPSS|O use|O five|O adverse|O factors|O ,|O including|O age|O >|O 65|O years|O ,|O hemoglobin|O <|O 10|O g|O /|O dl|O ,|O leukocyte|O count|O >|O 25|O x|O 109|O /|O l|O ,|O circulating|O blasts|O >|O =|O 1|O %|O and|O presence|O of|O constitutional|O symptoms|O ,|O in|O order|O to|O distinguish|O among|O low|O ,|O intermediate|O -|O 1|O ,|O intermediate|O -|O 2|O and|O high|O -|O risk|O patients|O with|O respective|O median|O survivals|O of|O 11|O .|O 3|O ,|O 7|O .|O 9|O ,|O 4|O .|O 0|O and|O 2|O .|O 3|O years|O ,|O per|O IPSS|O ,|O or|O not|O reached|O ,|O 14|O .|O 2|O ,|O 4|O .|O 0|O and|O 1|O .|O 5|O years|O ,|O per|O DIPSS|O .|O
This|O study|O showed|O for|O the|O first|O time|O a|O high|O frequency|O of|O RUNX1|O mutations|O in|O CMML|O .|O
The|O patient|O died|O 5|O years|O later|O from|O an|O H1N1|O influenza|O infection|O in|O complete|O remission|O .|O
In|O principle|O ,|O the|O presence|O of|O additional|O exon|O 14|O mutations|O can|O interfere|O with|O binding|O of|O primers|O and|O probes|O in|O allele|O -|O specific|O assays|O ,|O but|O such|O mutations|O are|O exceptionally|O rare|O (|O <|O 1|O %|O of|O all|O JAK2|O mutations|O )|O .|O
Recent|O studies|O found|O SETBP1|O mutations|O in|O up|O to|O 9|O %|O of|O all|O MDS|O /|O MPN|O patients|O ,|O with|O especially|O high|O frequency|O (|O 24|O -|O 31|O .|O 7|O %|O )|O in|O atypical|O CML|O .|O
S5A|O and|O S5B|O in|O the|O Supplementary|O Appendix|O )|O .|O
For|O patients|O who|O are|O deemed|O unfit|O for|O standard|O induction|O or|O intermediate|O -|O intensity|O therapy|O such|O as|O clofarabine|O ,|O recent|O options|O have|O focused|O on|O epigenetic|O agents|O ,|O including|O hypomethylating|O drugs|O such|O as|O 5|O -|O azacytadine|O and|O decitabine|O ,|O alone|O or|O in|O combination|O with|O histone|O deacetylase|O inhibitors|O .|O
MPL|O was|O identified|O as|O a|O candidate|O for|O MPN|O pathogenesis|O when|O it|O was|O described|O in|O the|O downstream|O signaling|O pathway|O required|O for|O JAK2V617F|O -|O mediated|O transformation|O of|O myeloprogenitor|O cells|O .|O
Blood|O versus|O Bone|O Marrow|O Initial|O testing|O of|O JAK2|O and|O MPL|O mutations|O is|O most|O commonly|O performed|O on|O peripheral|O blood|O samples|O .|O
The|O mean|O coverage|O for|O cohesin|O genes|O (|O STAG2|O ,|O SMC3|O ,|O and|O RAD21|O )|O is|O 265X|O for|O the|O deepsequencing|O samples|O .|O
CSF3R|O mutations|O .|O
Therefore|O ,|O it|O is|O important|O for|O physicians|O to|O submit|O sufficient|O samples|O to|O reserve|O aliquots|O of|O cryopreserved|O marrow|O from|O the|O time|O of|O diagnosis|O to|O allow|O for|O molecular|O diagnostic|O tests|O in|O patients|O with|O normal|O karyotype|O .|O
Patients|O who|O received|O ruxolitinib|O had|O weight|O gain|O ,|O whereas|O those|O receiving|O placebo|O had|O weight|O loss|O (|O Fig|O .|O
During|O the|O past|O 3|O to|O 5|O years|O ,|O "|O normal|O "|O cytogenetics|O have|O been|O shown|O to|O encompass|O several|O molecular|O lesions|O with|O divergent|O risk|O behaviors|O .|O
The|O limited|O experience|O with|O induction|O -|O type|O chemotherapy|O for|O blastic|O transformation|O is|O generally|O poor|O with|O death|O related|O to|O resistant|O disease|O or|O regimen|O -|O related|O toxicities|O .|O
The|O immunologic|O standard|O evaluation|O ,|O even|O though|O it|O was|O not|O systemically|O performed|O ,|O revealed|O mild|O abnormalities|O (|O supplemental|O Table|O 2|O )|O .|O
There|O are|O few|O studies|O about|O the|O role|O of|O miRNAs|O in|O GATA2|O .|O
The|O high|O frequency|O with|O which|O cohesin|O mutations|O occur|O in|O myeloid|O disease|O and|O their|O presence|O in|O expanding|O subclones|O during|O disease|O progression|O suggests|O that|O the|O cohesin|O complex|O may|O represent|O an|O attractive|O therapeutic|O target|O for|O future|O preclinical|O and|O clinical|O studies|O .|O
According|O to|O recent|O large|O cohort|O studies|O of|O MDS|O patients|O ,|O 72|O -|O 90|O %|O of|O cases|O carried|O at|O least|O one|O mutation|O (|O average|O of|O 3|O /|O per|O case|O )|O .|O
Because|O the|O OS|O outcomes|O for|O the|O high|O -|O dose|O arm|O in|O the|O SWOG|O trial|O (|O high|O -|O dose|O cytarabine|O induction|O and|O 2|O cycles|O of|O high|O -|O dose|O cytarabine|O consolidation|O ;|O 4|O -|O year|O OS|O rate|O of|O 52|O %|O for|O patients|O age|O <|O 50|O years|O )|O is|O comparable|O to|O those|O of|O the|O CALGB|O trial|O with|O standard|O -|O dose|O infusional|O cytarabine|O induction|O and|O 4|O cycles|O of|O high|O -|O dose|O cytarabine|O consolidation|O (|O 4year|O OS|O rate|O of|O 52|O %|O for|O patients|O age|O <|O =|O 60|O years|O )|O ,|O the|O use|O of|O high|O -|O dose|O cytarabine|O in|O the|O induction|O phase|O outside|O of|O a|O clinical|O trial|O remains|O controversial|O .|O
PCR|O amplification|O conditions|O were|O the|O same|O for|O both|O U2AF35|O reactions|O and|O included|O a|O primary|O denaturation|O of|O 95|O -|O -|O Degree|O -|O -|O C|O for|O 2|O min|O ,|O followed|O by|O 35|O cycles|O of|O :|O 95|O -|O -|O Degree|O -|O -|O C|O for|O 30|O s|O ,|O 57|O -|O -|O Degree|O -|O -|O C|O for|O 45|O s|O and|O 72|O -|O -|O Degree|O -|O -|O C|O for|O 45|O s|O ,|O and|O ended|O with|O a|O final|O extension|O of|O 72|O -|O -|O Degree|O -|O -|O C|O for|O 5|O min|O .|O
Among|O patients|O with|O MDS|O /|O MPN|O ,|O SF3B1|O mutations|O were|O not|O common|O in|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O ,|O but|O they|O were|O frequent|O in|O patients|O with|O RARS|O -|O T|O ;|O thus|O ,|O the|O presence|O of|O RS|O was|O found|O to|O correlate|O highly|O with|O SF3B1|O mutations|O ,|O irrespective|O of|O other|O clinical|O or|O morphologic|O features|O (|O Figure|O 2A|O )|O .|O
ABSTRACT|O .|O
It|O is|O also|O known|O that|O the|O pro|O -|O inflammatory|O cytokines|O IL|O -|O 1|O and|O TNFalpha|O activate|O GATA2|O ,|O leading|O to|O the|O inhibition|O of|O erythroid|O differentiation|O in|O human|O erythropoietin|O -|O dependent|O cells|O .|O
Figure|O 1|O .|O Impact|O on|O OS|O of|O SRSF2|O ,|O ASXL1|O ,|O SF3B1|O and|O V2AK35|O mutations|O in|O patients|O with|O CMML|O .|O
Practice|O guidelines|O also|O serve|O to|O identify|O questions|O and|O suggest|O areas|O for|O future|O development|O .|O
He|O had|O a|O previous|O history|O of|O recurrent|O infections|O and|O mild|O neutropenia|O .|O
This|O complex|O initiates|O dimethylation|O and|O trimethylation|O of|O lysine|O 27|O of|O histone|O H3|O (|O H3K27|O )|O ,|O an|O epigenetic|O modification|O associated|O with|O gene|O silencing|O .|O
Zhang|O et|O al|O described|O two|O GATA2|O mutations|O in|O patients|O with|O chronic|O myeloid|O leukemia|O in|O blast|O crisis|O .|O
The|O investigations|O revealed|O no|O further|O significant|O associations|O ,|O with|O the|O exception|O of|O EZH2|O -|O mutated|O versus|O EZH2|O wild|O -|O type|O cases|O (|O Supplementary|O Table|O 5|O )|O .|O
Sample|O preparations|O and|O hybridizations|O were|O performed|O using|O Genome|O -|O wide|O Human|O SNP|O Nsp|O /|O Sty|O and|O CytoScan|O assay|O kits|O (|O Affymetrix|O )|O according|O to|O the|O manufacturer|O '|O s|O protocol|O .|O
DISCUSSION|O .|O
The|O oncogenic|O role|O of|O mutant|O JAK2V617F|O tyrosine|O kinase|O in|O patients|O with|O BCR|O -|O ABL1|O -|O negative|O MPN|O has|O not|O been|O fully|O established|O .|O
STATISTICAL|O ANALYSIS|O .|O
Informed|O consent|O for|O sample|O collection|O was|O obtained|O according|O to|O protocols|O approved|O by|O the|O institutional|O review|O boards|O and|O in|O accordance|O with|O the|O Declaration|O of|O Helsinki|O .|O
Cytogenetic|O and|O molecular|O analysis|O .|O
A|O post|O hoc|O analysis|O showed|O that|O patients|O who|O received|O ruxolitinib|O had|O improvement|O in|O each|O individual|O symptom|O assessed|O on|O the|O MFSAF|O (|O Fig|O .|O 2C|O )|O ,|O whereas|O symptoms|O worsened|O in|O the|O placebo|O group|O (|O P|O <|O 0|O .|O 01|O for|O all|O comparisons|O with|O placebo|O )|O .|O
The|O proportion|O of|O patients|O with|O a|O reduction|O of|O 50|O %|O or|O more|O in|O the|O total|O symptom|O score|O from|O baseline|O to|O week|O 24|O ,|O a|O prespecified|O secondary|O end|O point|O ,|O was|O significantly|O higher|O in|O the|O ruxolitinib|O group|O than|O in|O the|O placebo|O group|O (|O 45|O .|O 9|O %|O vs|O .|O 5|O .|O 3|O %|O ;|O odds|O ratio|O ,|O 15|O .|O 3|O ;|O 95|O %|O CI|O ,|O 6|O .|O 9|O to|O 33|O .|O 7|O ;|O P|O <|O 0|O .|O 001|O )|O .|O
In|O median|O ,|O the|O burden|O of|O EZH2|O mutations|O was|O 45|O %|O of|O bidirectional|O sequencing|O reads|O (|O range|O :|O 1|O .|O 4|O -|O 88|O %|O )|O per|O patient|O .|O
When|O GATA1|O is|O reestablished|O ,|O GATA1|O replaces|O GATA2|O at|O the|O PU|O .|O 1|O locus|O ,|O and|O PU|O .|O 1|O expression|O is|O extinguished|O .|O
Patients|O treated|O in|O the|O high|O -|O dose|O cytarabine|O arm|O received|O a|O second|O high|O -|O dose|O cycle|O for|O consolidation|O ,|O whereas|O patients|O in|O the|O standard|O -|O dose|O arm|O were|O randomized|O to|O receive|O consolidation|O therapy|O with|O either|O 2|O cycles|O of|O standard|O -|O dose|O cytarabine|O or|O 1|O cycle|O of|O high|O -|O dose|O cytarabine|O plus|O daunorubicin|O .|O
Although|O such|O testing|O is|O still|O not|O standard|O for|O diagnosing|O MPNs|O ,|O the|O findings|O from|O the|O sample|O exchange|O study|O provide|O hope|O that|O quantitative|O testing|O will|O be|O reliable|O when|O such|O testing|O becomes|O standard|O practice|O .|O
Only|O 3|O of|O these|O mutations|O (|O L359V|O ,|O T354M|O ,|O and|O M355del|O )|O have|O been|O functionally|O tested|O by|O gel|O -|O shift|O or|O luciferase|O assays|O .|O
Mutations|O in|O the|O cohesin|O -|O complex|O have|O already|O been|O described|O in|O colorectal|O cancer|O ,|O and|O there|O has|O been|O a|O link|O between|O these|O mutations|O and|O chromosomal|O instability|O .|O
Significant|O covariates|O were|O dichotomized|O at|O their|O medians|O ,|O and|O resulting|O 2|O -|O group|O log|O -|O rank|O test|O differences|O were|O visualized|O using|O Kaplan|O -|O Meier|O methods|O .|O
S9A|O and|O S9B|O in|O the|O Supplementary|O Appendix|O )|O .|O
Alternatively|O ,|O these|O mutations|O may|O modulate|O the|O ability|O of|O class|O I|O and|O class|O II|O alterations|O to|O alter|O the|O methylation|O and|O /|O or|O chromatin|O state|O and|O to|O contribute|O to|O leukaemogenesis|O .|O
Analysis|O for|O mutational|O burden|O after|O therapy|O demonstrated|O the|O STAG2|O and|O SMC3|O mutant|O clones|O in|O 2|O cases|O were|O undetectable|O and|O the|O third|O case|O had|O persistence|O of|O a|O small|O RAD21|O clone|O (|O 44|O %|O to|O 7|O %|O )|O .|O
Preanalytic|O components|O should|O include|O the|O tissue|O source|O (|O eg|O ,|O peripheral|O blood|O ,|O bone|O marrow|O ,|O paraffin|O -|O embedded|O tissue|O )|O and|O ,|O if|O available|O ,|O the|O clinical|O indication|O for|O testing|O .|O
Taken|O together|O ,|O our|O results|O indicate|O that|O GATA2|O overexpression|O could|O be|O a|O useful|O molecular|O marker|O for|O predicting|O clinical|O outcome|O in|O AML|O ,|O and|O would|O support|O the|O association|O between|O GATA2|O and|O both|O WT1|O and|O EVI1|O previously|O reported|O .|O
KEY|O POINTS|O .|O
Of|O note|O ,|O DNA|O methylation|O and|O direct|O DNA|O and|O DNA|O -|O associated|O histone|O modification|O represent|O critical|O mechanisms|O of|O altered|O epigenetic|O regulation|O in|O MDS|O (|O Fig|O .|O 1|O )|O .|O
Imagawa|O et|O al|O demonstrated|O that|O GATA2|O inhibits|O EPO|O transcription|O by|O binding|O to|O its|O promoter|O under|O normoxic|O conditions|O .|O
Nucleotide|O positions|O are|O determined|O based|O on|O the|O cited|O sources|O .|O
At|O 20|O years|O of|O age|O ,|O he|O underwent|O HSCT|O with|O an|O unrelated|O donor|O .|O
With|O less|O common|O mutations|O ,|O it|O is|O not|O clear|O what|O level|O of|O analytical|O sensitivity|O is|O needed|O .|O
The|O observation|O that|O about|O half|O the|O BCOR|O -|O mutated|O cases|O also|O carry|O mutations|O of|O the|O DNMT3A|O gene|O suggests|O that|O these|O two|O mutations|O may|O act|O synergistically|O to|O induce|O AML|O ,|O possibly|O interfering|O with|O epigenetic|O mechanisms|O .|O
These|O co|O -|O factors|O include|O the|O C|O -|O terminal|O binding|O protein|O (|O CtBP|O )|O and|O the|O NuRD|O chromatin|O remodelling|O complex|O .|O
Patients|O .|O
Statistical|O analysis|O .|O
Multivariable|O analyses|O of|O factors|O predicting|O progression|O to|O AML|O were|O also|O performed|O within|O the|O framework|O of|O competing|O risks|O by|O the|O sub|O -|O hazard|O regression|O method|O .|O
The|O first|O PCR|O products|O were|O 1476|O bp|O in|O length|O ,|O and|O the|O length|O of|O nested|O PCR|O products|O was|O 1344|O bp|O .|O Of|O the|O 62|O AML|O specimens|O analyzed|O ,|O 15|O (|O 24|O %|O )|O revealed|O the|O occurrence|O of|O aberrant|O PTEN|O /|O MMAC1|O transcripts|O ;|O a|O normalsized|O band|O was|O present|O in|O all|O specimens|O (|O Fig|O .|O 1A|O )|O .|O
Figure|O 2|O .|O Clinical|O evolution|O .|O (|O A|O )|O Kaplan|O -|O Meier|O survival|O curve|O of|O GATA2|O -|O mutated|O patients|O .|O Confidence|O intervals|O of|O 95|O %|O are|O indicated|O .|O (|O B|O )|O Evolution|O of|O GATA2|O -|O mutated|O patients|O to|O MDS|O or|O AML|O from|O birth|O to|O evolution|O to|O MDS|O or|O AML|O or|O last|O follow|O -|O up|O .|O Confidence|O intervals|O of|O 95|O %|O are|O indicated|O .|O
Of|O 5|O STAG2|O and|O SMC3|O mutated|O patients|O ,|O 3|O carried|O a|O mutation|O in|O NPM1|O ,|O respectively|O .|O
Given|O that|O IDH|O mutations|O lead|O to|O a|O gain|O -|O of|O -|O function|O mutation|O ,|O it|O may|O be|O possible|O to|O design|O small|O -|O molecule|O inhibitors|O that|O specifically|O block|O the|O synthesis|O of|O 2|O -|O HG|O ,|O with|O therapeutic|O response|O monitored|O through|O serum|O 2|O -|O HG|O levels|O and|O epigenetic|O patterning|O .|O
Management|O of|O AML|O .|O
Fig|O .|O 1|O .|O After|O the|O recognition|O of|O the|O 50|O splice|O site|O by|O U1|O snRNP|O complex|O ,|O a|O protein|O complex|O consisting|O of|O a|O U2AF|O heterodimer|O ,|O ZRSR2|O and|O SRSF1|O /|O 2|O was|O recruited|O to|O the|O 30|O splice|O boundary|O ,|O where|O the|O smaller|O subunit|O (|O U2AF35|O )|O of|O the|O U2AF|O heterodimer|O binds|O to|O the|O AG|O -|O dinucleotide|O ,|O while|O the|O larger|O subunits|O recognize|O a|O polypyrimidine|O tract|O .|O SRSF1|O and|O SRSF2|O belong|O to|O a|O SR|O family|O of|O proteins|O ,|O having|O one|O or|O more|O Serine|O -|O Arginine|O -|O rich|O domains|O ,|O and|O bind|O to|O splicing|O enhancer|O sequences|O and|O also|O interact|O with|O other|O proteins|O through|O its|O SR|O domain|O .|O To|O the|O 50|O upstream|O of|O the|O polypyrimidine|O tract|O lies|O a|O branchpoint|O sequence|O ,|O to|O which|O another|O splicing|O factor|O ,|O SF|O -|O 1|O ,|O binds|O and|O together|O with|O the|O U2AF|O heterodimer|O and|O other|O components|O ,|O participates|O in|O the|O establishment|O of|O the|O splicing|O E|O complex|O .|O Once|O the|O splicing|O E|O complex|O is|O established|O ,|O a|O U2|O snRNP|O complex|O replaces|O SF|O -|O 1|O to|O generate|O the|O splicing|O A|O complex|O .|O Prominently|O ,|O all|O the|O major|O components|O of|O these|O splicing|O complex|O are|O targets|O of|O gene|O mutations|O in|O MDS|O .|O
ABSTRACT|O .|O
Oligonucleotide|O primers|O for|O amplification|O of|O exons|O 1|O -|O 9|O of|O PTEN|O /|O MMAC1|O are|O shown|O in|O Table|O I|O .|O
We|O have|O performed|O deep|O sequencing|O of|O mRNA|O in|O hematopoietic|O cells|O derived|O from|O mutant|O cases|O and|O compared|O the|O results|O obtained|O in|O cells|O with|O a|O corresponding|O WT|O form|O of|O the|O gene|O .|O
In|O the|O presence|O of|O functional|O spliceosomal|O machinery|O ,|O sequencing|O reads|O are|O expected|O not|O to|O cross|O the|O intron|O /|O exon|O boundaries|O and|O therefore|O should|O not|O contain|O any|O intronic|O sequences|O .|O
In|O fact|O ,|O mutation|O of|O a|O subset|O of|O lysine|O residues|O causes|O a|O severe|O loss|O of|O the|O transactivation|O potential|O of|O GATA2|O protein|O .|O
As|O EZH2|O ,|O ASXL1|O and|O SRSF2|O mutations|O predicted|O overall|O survival|O ,|O while|O ASXL1|O ,|O SRSF2|O and|O IDH1|O or|O IDH2|O predicted|O leukemic|O transformation|O ,|O all|O independent|O of|O each|O other|O ,|O we|O considered|O the|O four|O mutations|O (|O ASXL1|O ,|O EZH2|O ,|O SRSF2|O and|O IDH1|O /|O 2|O )|O as|O being|O detrimental|O for|O disease|O outcome|O ,|O in|O general|O ,|O and|O accordingly|O classified|O the|O European|O patients|O into|O those|O who|O displayed|O at|O least|O one|O (|O '|O mutationally|O high|O -|O risk|O '|O )|O or|O none|O (|O '|O mutationally|O low|O -|O risk|O '|O )|O of|O the|O four|O mutations|O .|O
All|O mutations|O were|O detected|O by|O bidirectional|O sequencing|O and|O scored|O as|O pathogenic|O if|O not|O present|O in|O nonclonal|O paired|O CD3|O -|O derived|O DNA|O .|O
Figure|O 2|O .|O Cooccurring|O somatic|O mutations|O in|O cohesin|O mutant|O patients|O .|O (|O A|O )|O Mutually|O exclusive|O cohesin|O gene|O mutations|O and|O cooccurring|O somatic|O genetic|O events|O .|O (|O B|O )|O Somatic|O mutational|O correlation|O in|O cohesin|O mutant|O /|O deletion|O cases|O .|O
Mutations|O are|O numbered|O as|O recommended|O by|O the|O Human|O Genome|O Variation|O Society|O (|O http|O :|O /|O /|O www|O .|O hgvs|O .|O org|O /|O )|O using|O the|O reference|O sequence|O NM|O _|O 032638|O .|O 4|O .|O
Mayo|O Clinic|O cohort|O .|O
Table|O 2|O .|O Multivariate|O Cox|O proportional|O hazard|O regression|O analysis|O of|O driver|O mutations|O (|O JAK2|O ,|O CALR|O ,|O and|O MPL|O )|O and|O IPSS|O variables|O evaluated|O as|O risk|O factors|O for|O survival|O in|O patients|O with|O PMF|O .|O
The|O predictive|O model|O was|O subsequently|O validated|O in|O an|O independent|O cohort|O of|O elderly|O patients|O (|O N|O =|O 801|O )|O treated|O with|O 2|O courses|O of|O induction|O therapy|O with|O cytarabine|O and|O daunorubicin|O .|O
Despite|O the|O importance|O of|O BMI1|O in|O the|O regulation|O of|O stem|O cell|O self|O -|O renewal|O ,|O recurrent|O somatic|O mutations|O in|O PRC1|O members|O have|O not|O been|O described|O thus|O far|O in|O haematopoietic|O malignancies|O .|O
Taken|O together|O ,|O the|O above|O features|O conform|O to|O those|O of|O loss|O -|O of|O -|O function|O mutations|O in|O a|O tumor|O -|O suppressor|O gene|O .|O
RESULTS|O .|O
Mutations|O in|O IDH1|O have|O been|O reported|O in|O 6|O %|O to|O 9|O %|O of|O AML|O cases|O ,|O with|O a|O higher|O frequency|O reported|O among|O patients|O with|O NK|O -|O AML|O (|O 8|O %|O -|O 16|O %|O )|O .|O
A|O series|O of|O normal|O DNA|O samples|O should|O be|O analyzed|O to|O derive|O the|O threshold|O for|O a|O positive|O result|O .|O
Although|O allogeneic|O stem|O -|O cell|O transplantation|O may|O cure|O myelofibrosis|O ,|O few|O patients|O are|O eligible|O for|O this|O treatment|O .|O
The|O core|O proteins|O responsible|O for|O this|O pathway|O form|O the|O spliceosome|O complex|O (|O Fig|O .|O 2|O )|O .|O
RESULTS|O .|O
Sequencing|O results|O containing|O mutations|O were|O repeated|O using|O DNA|O samples|O .|O
The|O quality|O and|O quantity|O and|O the|O size|O distribution|O of|O the|O Illumina|O libraries|O were|O determined|O with|O an|O Agilent|O Bioanalyzer|O .|O
Expression|O of|O this|O enzyme|O has|O been|O reported|O to|O be|O reciprocal|O to|O the|O levels|O of|O UCK|O ,|O a|O rate|O -|O limiting|O enzyme|O for|O azacitidine|O metabolism|O .|O
Our|O comprehension|O of|O the|O biological|O consequences|O of|O these|O epigenetic|O changes|O is|O still|O at|O a|O nascent|O stage|O .|O
This|O pathway|O leads|O to|O the|O conversion|O of|O 5|O -|O hmC|O to|O 5|O -|O hydroxymethyluracil|O (|O 5|O -|O hmU|O )|O ,|O which|O activates|O the|O base|O -|O excision|O repair|O (|O BER|O )|O pathway|O that|O uses|O the|O thymine|O DNA|O glycosylase|O (|O TDG|O )|O or|O the|O single|O -|O strand|O -|O selective|O monofunctional|O uracil|O DNA|O glycosylase|O (|O SMUG1|O )|O to|O generate|O unmethylated|O cytosines|O .|O
Figure|O 5|O .|O Gene|O expression|O profile|O was|O analyzed|O in|O CD34|O +|O cells|O purified|O from|O mutationally|O high|O -|O risk|O (|O n|O =|O 9|O )|O and|O low|O -|O risk|O (|O n|O =|O 11|O )|O patients|O randomly|O selected|O in|O the|O European|O cohort|O .|O The|O heat|O map|O was|O computed|O on|O the|O gene|O list|O provided|O in|O Supplementary|O Table|O 4|O using|O the|O clustering|O algorithm|O included|O in|O the|O Partek|O GS|O package|O (|O Partek|O Incorporated|O ,|O St|O Louis|O ,|O MO|O ,|O USA|O )|O by|O means|O of|O euclidean|O distance|O and|O average|O linkage|O .|O Gene|O coloring|O is|O based|O on|O normalized|O signals|O ,|O as|O shown|O at|O the|O bottom|O of|O the|O figure|O ;|O green|O indicates|O reduced|O expression|O ,|O red|O increased|O expression|O .|O Gene|O symbol|O is|O indicated|O on|O the|O left|O .|O Low|O -|O risk|O and|O high|O -|O risk|O groups|O clustered|O separately|O in|O the|O dendrogram|O shown|O at|O the|O top|O of|O the|O heat|O map|O .|O
Although|O splenic|O irradiation|O and|O splenectomy|O may|O provide|O transient|O palliation|O of|O symptomatic|O splenomegaly|O ,|O the|O latter|O has|O been|O associated|O with|O anecdotal|O worsening|O of|O neutrophilic|O leukocytosis|O in|O CNL|O .|O
All|O other|O sequence|O variants|O were|O confirmed|O to|O be|O somatic|O by|O sequencing|O paired|O flow|O -|O sorted|O CD3|O +|O cells|O .|O
All|O mutations|O were|O heterozygous|O apart|O from|O STAG2|O and|O SMC1A|O mutations|O in|O male|O patients|O ,|O as|O both|O genes|O are|O X|O -|O linked|O .|O
Although|O complex|O karyotype|O (|O having|O >|O =|O 3|O clonal|O cytogenetic|O abnormalities|O )|O and|O -|O 5|O or|O -|O 7|O monosomies|O are|O categorized|O in|O the|O high|O -|O risk|O /|O unfavorable|O cytogenetics|O group|O ,|O the|O presence|O of|O a|O monosomal|O karyotype|O was|O found|O to|O confer|O further|O negative|O prognostic|O influence|O within|O the|O high|O -|O risk|O group|O .|O
Of|O the|O 15|O cases|O that|O showed|O aberrant|O transcripts|O ,|O 12|O cases|O displayed|O one|O abnormal|O transcript|O and|O 3|O had|O two|O abnormal|O transcripts|O (|O Fig|O .|O 1A|O )|O .|O
Although|O there|O is|O substantial|O interest|O in|O these|O technologies|O ,|O nonetheless|O there|O are|O limitations|O ,|O especially|O regarding|O sensitivity|O .|O
A|O total|O of|O 66|O specimens|O were|O shared|O among|O the|O 22|O laboratories|O that|O participated|O (|O 18|O in|O the|O United|O States|O ,|O 2|O in|O Canada|O ,|O and|O 2|O in|O Asia|O )|O .|O
MPL|O mutation|O detection|O was|O compared|O among|O the|O four|O participating|O laboratories|O .|O
Instead|O ,|O a|O better|O molecular|O characterization|O of|O MDS|O on|O the|O genomic|O ,|O epigenetic|O ,|O and|O genetic|O levels|O probably|O more|O objectively|O diagnoses|O conditions|O ,|O determines|O patients|O '|O prognosis|O and|O ,|O based|O on|O the|O underlying|O molecular|O defects|O ,|O directs|O the|O application|O of|O targeted|O therapies|O .|O
The|O median|O age|O of|O this|O cohort|O was|O 70|O years|O (|O range|O 30|O -|O 90|O )|O ;|O 185|O (|O 69|O %|O )|O were|O male|O and|O 227|O (|O 85|O %|O )|O patients|O met|O the|O 2008|O WHO|O criteria|O for|O CMML|O -|O 1|O .|O
To|O differentiate|O polymorphisms|O from|O somatic|O mutations|O ,|O we|O studied|O T|O -|O cells|O purified|O from|O diagnostic|O samples|O by|O flow|O cytometry|O .|O
Blood|O and|O medullar|O tests|O revealed|O a|O mild|O neutropenia|O and|O thrombocytopenia|O ,|O B|O -|O cell|O deficiencies|O ,|O and|O a|O very|O slightly|O hypoplastic|O BM|O with|O a|O normal|O karyotype|O .|O
The|O proteins|O of|O this|O family|O are|O critical|O for|O the|O hydroxylation|O of|O methylated|O cytosine|O residues|O .|O
Overall|O ,|O the|O main|O clinical|O features|O identified|O in|O these|O patients|O are|O the|O presence|O of|O warts|O at|O the|O initial|O diagnosis|O ,|O frequent|O infections|O ,|O and|O evolution|O to|O MDS|O and|O /|O or|O AML|O .|O
Among|O a|O total|O of|O 29|O patients|O ,|O 8|O of|O 9|O CNL|O (|O 89|O %|O )|O and|O 8|O of|O 20|O aCML|O (|O 40|O %|O )|O cases|O exhibited|O CSF3R|O mutations|O .|O
We|O included|O commonly|O used|O prognostic|O scoring|O systems|O such|O as|O MDAPS|O ,|O G|O -|O MDAPS|O and|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O .|O
Functional|O studies|O are|O needed|O to|O investigate|O this|O and|O the|O potential|O effects|O of|O GATA2|O mutations|O on|O dysfunction|O of|O the|O CXCR4|O pathway|O ,|O which|O account|O for|O the|O panleukopenia|O of|O WHIM|O patients|O .|O
The|O advantages|O and|O disadvantages|O of|O each|O technique|O ,|O including|O financial|O considerations|O associated|O with|O intellectual|O property|O rights|O ,|O must|O therefore|O be|O carefully|O weighed|O before|O deciding|O on|O the|O type|O of|O assay|O to|O implement|O (|O Table|O 4|O )|O .|O
This|O Special|O Article|O summarizes|O results|O from|O a|O nationwide|O laboratory|O survey|O of|O JAK2|O and|O MPL|O mutation|O analysis|O .|O
ASXL1|O .|O
The|O spectrum|O of|O GATA2|O mutations|O in|O MDS|O /|O AML|O ,|O Emberger|O ,|O or|O MonoMAC|O syndrome|O patients|O is|O large|O .|O
For|O two|O additional|O subjects|O who|O carried|O missense|O mutations|O (|O subjects|O 96|O and|O 97|O )|O ,|O we|O designed|O allelic|O discrimination|O assays|O (|O using|O PCR|O with|O allele|O -|O specific|O probes|O and|O high|O -|O resolution|O melting|O analysis|O ,|O HRM|O )|O and|O tested|O a|O cohort|O of|O 250|O unaffected|O individuals|O (|O controls|O )|O (|O Supplementary|O Methods|O and|O Supplementary|O Table|O 2|O )|O .|O
6|O .|O 3|O .|O GATA2|O IS|O A|O CRITICAL|O REGULATOR|O OF|O GRANULOCYTE|O DEVELOPMENT|O .|O
She|O had|O a|O history|O of|O recurrent|O gingivitis|O and|O skin|O infection|O consistent|O with|O chronic|O neutropenia|O (|O 12|O years|O before|O AML|O )|O and|O monocytopenia|O .|O
Intellectual|O property|O restrictions|O may|O influence|O the|O choice|O of|O a|O JAK2|O V617F|O assay|O ,|O given|O that|O Ipsogen|O (|O Marseille|O ,|O France|O )|O acquired|O a|O worldwide|O license|O on|O testing|O for|O this|O mutation|O in|O 2006|O .|O
The|O IPSS|O assigns|O patients|O to|O one|O of|O four|O groups|O of|O increasing|O prognostic|O risk|O (|O low|O ,|O intermediate|O 1|O ,|O intermediate|O 2|O ,|O and|O high|O )|O on|O the|O basis|O of|O the|O percentage|O of|O blasts|O in|O bone|O marrow|O ,|O the|O karyotype|O ,|O and|O the|O number|O of|O cytopenias|O present|O at|O the|O time|O of|O diagnosis|O (|O see|O Table|O 2|O in|O the|O Supplementary|O Appendix|O ,|O available|O with|O the|O full|O text|O of|O this|O article|O at|O NEJM|O .|O org|O )|O .|O
The|O diagnoses|O of|O CMML|O ,|O including|O subclassification|O into|O CMML|O -|O 1|O or|O CMML|O -|O 2|O ,|O and|O documentation|O regarding|O the|O presence|O or|O absence|O of|O ring|O sideroblasts|O and|O LT|O were|O according|O to|O the|O 2008|O WHO|O criteria|O .|O
In|O three|O individuals|O ,|O we|O examined|O whether|O the|O mutant|O mRNA|O was|O expressed|O (|O Supplementary|O Fig|O .|O 6|O and|O Supplementary|O Methods|O )|O .|O
For|O this|O reason|O ,|O the|O terms|O heterozygous|O and|O homozygous|O should|O generally|O be|O avoided|O in|O clinical|O reports|O .|O
Most|O laboratories|O reported|O their|O results|O as|O a|O JAK2|O V617|O percentage|O of|O unmutated|O alleles|O .|O
Ideally|O ,|O JAK2|O analysis|O for|O investigating|O the|O cause|O of|O neutrophilia|O and|O thrombocytosis|O would|O follow|O a|O determination|O of|O the|O absence|O of|O the|O BCR|O -|O ABL1|O translocation|O t|O (|O 9|O ;|O 22|O )|O .|O
For|O a|O qualitative|O assay|O ,|O the|O sensitivity|O must|O be|O defined|O .|O
The|O panel|O has|O included|O subcutaneous|O cytarabine|O ,|O 5|O -|O azacytidine|O ,|O and|O decitabine|O as|O low|O -|O intensity|O treatment|O options|O ,|O and|O clofarabine|O as|O an|O intermediate|O -|O intensity|O treatment|O option|O for|O patients|O with|O AML|O who|O are|O 60|O years|O or|O older|O .|O
Somatic|O mutations|O of|O the|O PTEN|O /|O MMAC1|O gene|O have|O been|O identified|O in|O a|O number|O of|O cancer|O cell|O lines|O and|O primary|O cancers|O .|O
For|O the|O remaining|O patients|O with|O mutations|O ,|O the|O somatic|O origin|O could|O not|O be|O confirmed|O due|O to|O lack|O of|O suitable|O material|O .|O
Subsequently|O ,|O a|O survival|O analysis|O based|O on|O a|O planned|O data|O cutoff|O with|O 4|O additional|O months|O of|O follow|O -|O up|O (|O median|O follow|O -|O up|O ,|O 51|O weeks|O )|O revealed|O a|O significant|O survival|O advantage|O for|O patients|O who|O received|O ruxolitinib|O ,|O with|O 13|O deaths|O in|O the|O ruxolitinib|O group|O (|O 8|O .|O 4|O %|O )|O and|O 24|O deaths|O in|O the|O placebo|O group|O (|O 15|O .|O 6|O %|O )|O (|O hazard|O ratio|O ,|O 0|O .|O 50|O ;|O 95|O %|O CI|O ,|O 0|O .|O 25|O to|O 0|O .|O 98|O ;|O P|O =|O 0|O .|O 04|O )|O (|O Fig|O .|O 3|O )|O .|O
In|O terms|O of|O understanding|O the|O effects|O of|O ASXL1|O loss|O in|O vivo|O ,|O Fisher|O et|O al|O reported|O the|O phenotype|O of|O mice|O with|O a|O germline|O gene|O -|O trap|O allele|O of|O Asxl1|O .|O
But|O mutations|O in|O TP53|O ,|O EZH2|O ,|O ETV6|O ,|O RUNX1|O ,|O and|O ASXL1|O also|O emerged|O as|O independent|O predictors|O of|O survival|O .|O
Individual|O disclosures|O for|O the|O NCCN|O Acute|O Myeloid|O Leukemia|O Panel|O members|O can|O be|O found|O on|O page|O 1021|O .|O (|O The|O most|O recent|O version|O of|O these|O guidelines|O and|O accompanying|O disclosures|O are|O available|O on|O the|O NCCN|O Web|O site|O at|O NCCN|O .|O org|O .|O )|O These|O guidelines|O are|O also|O available|O on|O the|O Internet|O .|O
These|O findings|O were|O confirmed|O in|O subsequent|O analyses|O from|O other|O large|O cooperative|O group|O studies|O .|O
The|O resulting|O list|O of|O candidate|O SNVs|O was|O filtered|O with|O R|O .|O
The|O '|O GATA|O switch|O '|O requires|O the|O interaction|O of|O GATA1|O with|O the|O transcriptional|O co|O -|O factor|O Friend|O of|O GATA1|O (|O FOG1|O )|O (|O Fig|O .|O 2|O )|O .|O
The|O monocytopenia|O ,|O together|O with|O the|O infectious|O spectrum|O composed|O by|O pyogenic|O or|O mycobacteria|O infections|O and|O HPV|O -|O related|O warts|O ,|O have|O some|O similarities|O to|O the|O MonoMAC|O syndrome|O .|O
As|O shown|O in|O Table|O 2|O ,|O all|O of|O these|O variables|O retained|O a|O significant|O independent|O prognostic|O effect|O on|O OS|O .|O
This|O data|O implements|O that|O cohesin|O mutations|O could|O be|O potentially|O used|O for|O minimal|O residual|O disease|O monitoring|O .|O
The|O significant|O difference|O in|O overall|O and|O leukemia|O -|O free|O survival|O between|O the|O mutationally|O high|O -|O and|O low|O -|O risk|O groups|O was|O apparent|O when|O lower|O -|O risk|O categories|O (|O low|O plus|O intermediate|O -|O 1|O risk|O patients|O )|O were|O considered|O separately|O from|O higher|O -|O risk|O categories|O (|O intermediate|O -|O 2|O plus|O high|O -|O risk|O patients|O )|O (|O Figures|O 3a|O and|O b|O )|O .|O
For|O all|O applicable|O variables|O ,|O however|O ,|O patients|O with|O missing|O baseline|O values|O were|O excluded|O from|O the|O analyses|O of|O change|O and|O percent|O change|O from|O baseline|O .|O
The|O median|O age|O of|O the|O cohort|O was|O 71|O years|O (|O range|O 20|O -|O 90|O years|O )|O ,|O with|O 67|O %|O of|O the|O patients|O being|O males|O .|O
ASXL1|O ,|O EZH2|O ,|O KDM6A|O ,|O IDH1|O exon|O 4|O ,|O IDH2|O exon|O 4|O ,|O and|O ETV6|O were|O analyzed|O by|O means|O of|O Sanger|O sequencing|O .|O
cytometry|O .|O
TABLE|O I|O .|O Oligonucleotide|O Primers|O for|O Studying|O the|O PTEN|O /|O MMAC1|O Gene|O .|O
This|O result|O differs|O from|O our|O previous|O studies|O of|O FHIT|O and|O TSG101|O ,|O in|O which|O deletions|O were|O located|O at|O the|O exon|O -|O intron|O junction|O region|O .|O
If|O the|O relapse|O is|O detected|O when|O the|O tumor|O burden|O is|O low|O and|O the|O patient|O has|O a|O previously|O identified|O sibling|O or|O unrelated|O donor|O ,|O salvage|O chemotherapy|O followed|O by|O allogeneic|O HSCT|O can|O be|O considered|O .|O
Future|O Directions|O for|O JAK2|O and|O MPL|O Mutation|O Testing|O .|O
RNA|O sequencing|O from|O TCGA|O patients|O was|O downloaded|O from|O the|O TCGA|O repository|O .|O
Death|O occurred|O in|O 176|O patients|O (|O 28|O .|O 5|O %|O )|O ,|O including|O 115|O of|O 399|O patients|O with|O JAK2|O (|O V617F|O )|O (|O 29|O %|O )|O ,|O 27|O of|O 140|O with|O a|O CALR|O exon|O 9|O indel|O (|O 19|O %|O )|O ,|O 10|O of|O 25|O (|O 40|O %|O )|O with|O an|O MPL|O (|O W515|O )|O mutation|O ,|O and|O 24|O of|O 53|O triple|O -|O negative|O patients|O (|O 45|O %|O )|O .|O
The|O most|O common|O CSF3R|O mutation|O in|O CNL|O /|O aCML|O is|O the|O membrane|O proximal|O mutation|O :|O T618I|O .|O
Mutations|O in|O DNMT3A|O have|O also|O been|O observed|O in|O patients|O with|O MDS|O ,|O as|O well|O as|O less|O commonly|O in|O patients|O with|O classic|O MPNs|O (|O BOX|O 1|O ;|O TABLE|O 1|O )|O .|O
For|O patients|O younger|O than|O 50|O years|O ,|O consolidation|O with|O high|O -|O dose|O cytarabine|O was|O associated|O with|O similar|O rates|O of|O treatment|O -|O related|O mortality|O (|O 2|O %|O vs|O .|O 0|O %|O )|O and|O grade|O 3|O or|O higher|O neurologic|O toxicity|O (|O 2|O %|O vs|O .|O 0|O %|O )|O compared|O with|O standard|O dose|O .|O
The|O presence|O (|O vs|O .|O the|O absence|O )|O of|O EZH2|O mutations|O was|O strongly|O associated|O with|O decreased|O overall|O survival|O in|O the|O stepwise|O ,|O multi|O -|O variable|O model|O that|O considered|O age|O ,|O sex|O ,|O IPSS|O risk|O group|O ,|O and|O the|O presence|O of|O other|O mutations|O (|O hazard|O ratio|O for|O death|O ,|O 2|O .|O 13|O [|O 95|O %|O CI|O ,|O 1|O .|O 36|O to|O 3|O .|O 33|O ]|O )|O .|O
Five|O laboratories|O had|O two|O or|O more|O false|O -|O negative|O results|O ,|O suggesting|O that|O the|O assays|O of|O these|O laboratories|O may|O have|O been|O of|O lower|O sensitivity|O than|O those|O of|O most|O participating|O laboratories|O .|O
RUNX1|O mutations|O have|O been|O found|O at|O a|O much|O higher|O frequency|O (|O 23|O .|O 6|O %|O )|O in|O patients|O with|O refractory|O anemia|O with|O excess|O blasts|O (|O RAEB|O )|O ,|O RAEB|O in|O transformation|O (|O RAEB|O -|O T|O )|O ,|O and|O AML|O following|O MDS|O with|O relative|O low|O blast|O count|O ,|O suggesting|O that|O it|O is|O associated|O with|O a|O high|O -|O risk|O phenotype|O .|O
Among|O all|O patients|O who|O received|O consolidation|O with|O high|O -|O dose|O cytarabine|O ,|O the|O rates|O of|O treatment|O -|O related|O deaths|O and|O serious|O neurotoxicity|O were|O 5|O %|O and|O 12|O %|O ,|O respectively|O .|O
An|O estimate|O of|O the|O relative|O abundance|O of|O mutant|O to|O wild|O -|O type|O alleles|O may|O be|O provided|O ;|O this|O is|O especially|O important|O for|O novel|O mutations|O ,|O which|O could|O represent|O previously|O unreported|O germline|O SNPs|O .|O
In|O contrast|O to|O previously|O reported|O findings|O in|O smaller|O sample|O sets|O ,|O neither|O monoallelic|O nor|O bi|O -|O allelic|O mutations|O were|O associated|O with|O IPSS|O risk|O group|O or|O overall|O survival|O (|O Fig|O .|O 6|O in|O the|O Supplementary|O Appendix|O )|O .|O
For|O patients|O whose|O clinical|O condition|O has|O deteriorated|O such|O that|O active|O treatment|O is|O no|O longer|O appropriate|O ,|O best|O supportive|O care|O should|O be|O continued|O .|O
Similar|O conclusions|O were|O reached|O in|O studies|O of|O patients|O with|O PV|O and|O ET|O treated|O with|O busulfan|O .|O
This|O interaction|O is|O given|O through|O a|O specific|O motif|O located|O at|O the|O FOG1|O N|O -|O terminus|O ,|O providing|O a|O mechanism|O for|O GATA1|O -|O dependent|O gene|O repression|O .|O
The|O population|O of|O HSCs|O that|O is|O capable|O of|O both|O self|O -|O renewal|O and|O the|O production|O of|O short|O -|O term|O haematopoietic|O stem|O or|O progenitor|O cells|O .|O
The|O findings|O of|O this|O study|O provide|O a|O proof|O of|O concept|O that|O a|O genetic|O classification|O of|O PMF|O is|O not|O only|O feasible|O but|O also|O highly|O relevant|O to|O clinical|O decision|O -|O making|O as|O regards|O diagnostic|O approach|O and|O prognostication|O .|O
Progression|O to|O blast|O phase|O according|O to|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O .|O
Rafael|O Bejar|O ;|O Kristen|O Stevenson|O ;|O M|O .|O S|O .|O ;|O Omar|O Abdel|O -|O Wahab|O ;|O Naomi|O Galili|O ;|O Bjorn|O Nilsson|O ;|O Guillermo|O Garcia|O -|O Manero|O ;|O Hagop|O Kantarjian|O ;|O Azra|O Raza|O ;|O Ross|O L|O .|O Levine|O ;|O Donna|O Neuberg|O ;|O Sc|O .|O D|O .|O ;|O Benjamin|O L|O .|O Ebert|O .|O
This|O is|O notable|O ,|O as|O both|O EZH2|O and|O the|O TET|O family|O of|O proteins|O have|O been|O implicated|O in|O epigenetic|O regulation|O of|O gene|O transcription|O .|O
The|O incidence|O of|O combined|O IDH1|O /|O 2|O mutations|O in|O MDS|O is|O variable|O ,|O ranging|O from|O 2|O .|O 2|O %|O to|O 12|O %|O .|O
However|O ,|O these|O GATA2|O mutations|O have|O not|O been|O detected|O in|O acute|O myeloid|O leukemia|O ,|O myelodysplastic|O syndrome|O ,|O acute|O lymphoid|O leukemia|O or|O chronic|O lymphoid|O leukemia|O patients|O .|O
There|O are|O no|O standard|O methods|O for|O detecting|O the|O rare|O JAK2|O mutations|O ,|O nor|O for|O MPL|O mutations|O .|O
The|O limited|O studies|O to|O date|O of|O IDH|O -|O mutant|O AML|O cells|O suggest|O that|O IDH2|O -|O R172|O mutations|O result|O in|O a|O higher|O level|O of|O 2|O -|O HG|O than|O IDH1|O -|O R132|O mutations|O .|O
However|O ,|O the|O genomic|O landscape|O of|O PMF|O has|O changed|O considerably|O since|O then|O .|O
All|O SF3B1|O mutations|O were|O located|O in|O exon|O 14|O or|O 15|O ,|O with|O the|O K700|O mutation|O being|O the|O most|O recurrent|O (|O Figure|O 1B|O )|O .|O
Because|O mutant|O CBL|O lacks|O E3|O ubiquitin|O ligase|O activity|O ,|O the|O protein|O is|O unable|O to|O act|O as|O a|O negative|O regulator|O to|O attenuate|O signaling|O function|O .|O
GATA|O factors|O constitute|O a|O family|O of|O evolutionarily|O conserved|O proteins|O that|O play|O crucial|O roles|O in|O the|O development|O and|O differentiation|O of|O eukaryotic|O organisms|O .|O
Laboratory|O Practice|O Guidelines|O for|O Detecting|O and|O Reporting|O JAK2|O and|O MPL|O Mutations|O in|O Myeloproliferative|O Neoplasms|O :|O A|O Report|O of|O the|O Association|O for|O Molecular|O Pathology|O .|O
In|O all|O ,|O 27|O of|O these|O 79|O cases|O (|O 34|O .|O 2|O %|O )|O harbored|O a|O mutation|O in|O ASXL1|O ,|O not|O including|O 14|O cases|O that|O harbored|O the|O putative|O c|O .|O 1934dupG|O germline|O variant|O .|O
Runt|O -|O related|O transcription|O factor|O 1|O (|O RUNX1|O )|O is|O essential|O for|O normal|O hematopoiesis|O .|O
Ruxolitinib|O ,|O a|O selective|O inhibitor|O of|O Janus|O kinase|O (|O JAK|O )|O 1|O and|O 2|O ,|O has|O clinically|O significant|O activity|O in|O myelofibrosis|O .|O
Myelofibrosis|O ,|O a|O myeloproliferative|O neoplasm|O ,|O is|O manifested|O by|O abnormal|O blood|O counts|O (|O anemia|O ,|O thrombocytosis|O or|O thrombocytopenia|O ,|O and|O leukocytosis|O or|O leukopenia|O )|O ,|O splenomegaly|O ,|O and|O debilitating|O symptoms|O (|O e|O .|O g|O .|O ,|O fatigue|O ,|O weakness|O ,|O abdominal|O pain|O ,|O cachexia|O ,|O weight|O loss|O ,|O pruritus|O ,|O night|O sweats|O ,|O and|O bone|O pain|O )|O ,|O which|O are|O thought|O to|O be|O caused|O by|O the|O combined|O effects|O of|O massive|O splenomegaly|O and|O elevated|O levels|O of|O proinflammatory|O cytokines|O .|O
Unexpectedly|O ,|O these|O mice|O ,|O and|O similar|O strains|O with|O GATA3|O replacement|O of|O GATA1|O ,|O showed|O almost|O complete|O rescue|O of|O erythropoiesis|O .|O
Figure|O 1|O .|O The|O frequency|O and|O the|O pair|O -|O wise|O co|O -|O occurrence|O of|O mutations|O in|O the|O 483|O PMF|O patients|O included|O in|O the|O European|O cohort|O are|O represented|O by|O a|O Circos|O diagram|O in|O (|O a|O )|O .|O Co|O -|O occurring|O mutations|O are|O indicated|O in|O the|O clockwise|O direction|O .|O In|O the|O Circos|O representation|O ,|O the|O length|O of|O the|O arc|O corresponds|O to|O the|O frequency|O of|O mutation|O in|O the|O first|O gene|O (|O color|O coded|O )|O and|O the|O width|O of|O the|O ribbon|O corresponds|O to|O the|O frequency|O of|O patients|O who|O also|O had|O a|O mutation|O in|O the|O second|O gene|O .|O The|O frequency|O of|O mutations|O in|O this|O cohort|O is|O shown|O on|O the|O right|O side|O .|O (|O b|O )|O shows|O the|O prevalence|O proportion|O of|O individual|O mutations|O in|O the|O four|O IPSS|O risk|O categories|O .|O
The|O current|O challenge|O is|O to|O develop|O a|O prognostic|O model|O that|O accounts|O for|O both|O clinical|O and|O molecular|O parameters|O ,|O including|O relevant|O subclonal|O mutations|O ,|O and|O that|O in|O perspective|O may|O be|O useful|O also|O for|O predicting|O response|O to|O different|O treatments|O .|O
ASXL1|O mutations|O were|O more|O frequent|O in|O EZH2|O -|O (|O 11|O %|O versus|O 3|O %|O ;|O P|O <|O 0|O .|O 002|O )|O ,|O TET2|O -|O (|O 11|O %|O versus|O 4|O %|O ;|O P|O =|O 0|O .|O 043|O )|O ,|O DNMT3A|O -|O (|O 11|O %|O versus|O 2|O %|O ;|O P|O =|O 0|O .|O 022|O )|O ,|O CBL|O -|O (|O 11|O %|O versus|O 2|O %|O ;|O P|O <|O 0|O .|O 001|O )|O and|O SRSF2|O -|O (|O 13|O .|O 5|O %|O versus|O 7|O %|O ;|O P|O =|O 0|O .|O 035|O )|O mutated|O patients|O .|O
RUNX1|O and|O CEBPA|O ,|O 2|O oncogenes|O encoding|O transcription|O factors|O ,|O have|O been|O linked|O to|O familial|O AML|O and|O MDS|O .|O
Lee|O Moffitt|O Cancer|O Center|O in|O Tampa|O ,|O Florida|O .|O
For|O instance|O ,|O the|O ASXL1|O mutation|O is|O associated|O with|O leukemic|O transformation|O in|O CMML|O .|O
As|O was|O the|O case|O in|O the|O current|O study|O ,|O SRSF2|O ,|O EZH2|O and|O IDH1|O mutations|O have|O previously|O been|O associated|O with|O poor|O outcome|O in|O MDS|O and|O IDH1|O in|O distinct|O subtypes|O of|O AML|O .|O
RESULTS|O .|O
Although|O no|O propensity|O to|O malignancy|O has|O been|O described|O ,|O these|O children|O have|O a|O markedly|O abbreviated|O lifespan|O ,|O abrogating|O the|O oncogenic|O propensity|O of|O these|O defects|O .|O
GATA3|O essentially|O contributes|O to|O the|O development|O of|O T|O lymphocytes|O .|O
Accounting|O for|O them|O is|O not|O only|O relevant|O to|O clinical|O decision|O -|O making|O ,|O but|O should|O also|O be|O considered|O in|O designing|O clinical|O trials|O .|O
Patients|O who|O experienced|O a|O CR|O after|O both|O treatment|O cycles|O were|O eligible|O to|O receive|O consolidation|O with|O a|O third|O cycle|O of|O chemotherapy|O or|O autologous|O or|O allogeneic|O HSCT|O .|O
Recent|O studies|O demonstrated|O the|O TET|O proteins|O (|O TET1|O -|O 3|O )|O are|O Fe|O (|O II|O )|O -|O and|O alpha|O -|O ketoglutarate|O -|O dependent|O enzymes|O that|O catalyse|O the|O conversion|O of|O 5|O -|O mC|O to|O 5|O -|O hydroxymethylcytosine|O (|O 5|O -|O hmC|O )|O in|O DNA24|O (|O FIG|O .|O 1|O )|O .|O
These|O mutations|O fall|O into|O 2|O classes|O :|O nonsense|O or|O frameshift|O mutations|O that|O lead|O to|O premature|O truncation|O of|O the|O cytoplasmic|O tail|O of|O the|O receptor|O (|O truncation|O mutations|O )|O and|O point|O mutations|O in|O the|O extracellular|O domain|O of|O CSF3R|O (|O membrane|O proximal|O mutations|O )|O .|O
So|O far|O ,|O risk|O stratification|O in|O PMF|O has|O been|O essentially|O based|O on|O demographic|O ,|O clinical|O ,|O and|O hematologic|O parameters|O .|O
The|O median|O follow|O -|O up|O of|O the|O cohort|O was|O 20|O .|O 4|O months|O (|O range|O ,|O 1|O -|O 282|O months|O )|O .|O
Mutations|O occurred|O throughout|O the|O genes|O without|O the|O presence|O of|O a|O mutational|O hotspot|O .|O
DISCUSSION|O .|O
Another|O conspicuous|O feature|O of|O splicing|O factor|O mutations|O is|O the|O presence|O of|O mutational|O hot|O spots|O in|O major|O mutational|O targets|O ,|O including|O SF3B1|O ,|O SRSF2|O and|O U2AF35|O .|O
Other|O options|O include|O an|O allogeneic|O HSCT|O if|O a|O matched|O sibling|O or|O alternative|O donor|O has|O been|O identified|O ,|O or|O participation|O in|O a|O clinical|O trial|O .|O
A|O total|O of|O 3|O mug|O of|O DNA|O extracted|O from|O the|O BM|O sample|O of|O patient|O number|O 6225|O (|O blast|O infiltration|O ,|O 30|O %|O )|O was|O fragmented|O by|O sonication|O to|O 150|O -|O 200|O bp|O and|O ligated|O to|O an|O oligonucleotide|O adaptor|O .|O
Coupled|O with|O genetic|O complementation|O analysis|O and|O transcriptional|O profiling|O ,|O this|O study|O revealed|O a|O rich|O collection|O of|O targets|O containing|O a|O characteristic|O binding|O motif|O of|O greater|O complexity|O than|O WGATAR|O .|O
Mutated|O allele|O frequencies|O were|O similar|O between|O NPM1|O and|O cohesin|O gene|O mutations|O .|O Overall|O survival|O (|O OS|O )|O ,|O relapse|O -|O free|O survival|O (|O RFS|O )|O ,|O and|O complete|O remission|O rates|O (|O CR|O )|O were|O not|O influenced|O by|O the|O presence|O of|O cohesin|O mutations|O (|O OS|O :|O hazard|O ratio|O [|O HR|O ]|O 0|O .|O 98|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 0|O .|O 56|O -|O 1|O .|O 72|O [|O P|O =|O .|O 94|O ]|O ;|O RFS|O :|O HR|O 0|O .|O 7|O ;|O 95|O %|O CI|O ,|O 0|O .|O 36|O -|O 1|O .|O 38|O [|O P|O =|O .|O 3|O ]|O ;|O CR|O :|O mutated|O 83|O %|O vs|O wild|O -|O type|O 76|O %|O [|O P|O =|O .|O 45|O ]|O )|O .|O
It|O is|O important|O to|O note|O that|O the|O development|O of|O HSCs|O from|O the|O hemogenic|O endothelium|O is|O a|O NOTCH1|O -|O regulated|O event|O and|O is|O impaired|O in|O NOTCH1|O deficient|O mouse|O embryos|O [|O 125|O ]|O .|O
The|O need|O for|O a|O cardiac|O evaluation|O should|O be|O determined|O by|O individual|O risk|O factors|O ,|O such|O as|O patient|O and|O family|O history|O or|O previous|O malignancy|O treated|O with|O cardiotoxic|O drugs|O or|O thoracic|O radiation|O .|O
Likewise|O ,|O enzymatic|O activities|O associated|O with|O genes|O involved|O in|O leukaemic|O transformation|O -|O including|O H3K79|O methyl|O transferase|O activity|O ,|O histone|O acetyltransferase|O activity|O and|O other|O chromatin|O enzymatic|O functions|O -|O have|O just|O recently|O been|O explored|O from|O a|O therapeutic|O standpoint|O .|O
More|O recently|O ,|O mutational|O profiling|O of|O a|O large|O cohort|O of|O patients|O with|O MDS|O reported|O that|O mutations|O in|O EZH2|O were|O associated|O with|O worsened|O overall|O survival|O ,|O independent|O of|O known|O clinical|O predictors|O of|O worsened|O survival|O in|O MDS|O such|O as|O the|O International|O Prognostic|O Scoring|O System|O (|O TABLE|O 1|O )|O .|O
Thus|O ,|O many|O phase|O I|O /|O II|O trials|O for|O AML|O in|O the|O older|O patient|O include|O categories|O such|O as|O CR|O incomplete|O (|O CRi|O )|O for|O patients|O who|O have|O fewer|O than|O 5|O %|O marrow|O blasts|O but|O mild|O residual|O cytopenia|O .|O
Direct|O sequencing|O of|O the|O aberrant|O band|O showed|O an|O insertion|O of|O 4|O bases|O (|O CCCG|O )|O at|O nt|O 1423|O of|O exon|O 5|O (|O Fig|O .|O 3B|O )|O .|O
The|O only|O described|O disease|O phenotype|O associated|O with|O TET2|O in|O MPN|O is|O older|O age|O .|O
Felicitas|O Thol|O ;|O Robin|O Bollin|O ;|O Marten|O Gehlhaar|O ;|O Carolin|O Walter|O ;|O Martin|O Dugas|O ;|O Karl|O Josef|O Suchanek|O ;|O Aylin|O Kirchner|O ;|O Liu|O Huang|O ;|O Anuhar|O Chaturvedi|O ;|O Martin|O Wichmann|O ;|O Lutz|O Wiehlmann|O ;|O Rabia|O Shahswar|O ;|O Frederik|O Damm|O ;|O Gudrun|O Gohring|O ;|O Brigitte|O Schlegelberger|O ;|O Richard|O Schlenk|O ;|O Konstanze|O Dohner|O ;|O Hartmut|O Dohner|O ;|O Jurgen|O Krauter|O ;|O Arnold|O Ganser|O ;|O Michael|O Heuser|O .|O
CALR|O -|O mutant|O patients|O were|O significantly|O younger|O ,|O had|O lower|O leukocyte|O count|O ,|O higher|O platelet|O count|O ,|O and|O lower|O IPSS|O risk|O .|O
This|O is|O based|O on|O the|O higher|O prevalence|O of|O unfavorable|O cytogenetics|O and|O antecedent|O myelodysplasia|O ,|O along|O with|O a|O higher|O incidence|O of|O multidrug|O resistance|O in|O patients|O older|O than|O 60|O years|O ,|O and|O an|O increased|O frequency|O of|O comorbid|O medical|O conditions|O that|O affect|O the|O patient|O '|O s|O ability|O to|O tolerate|O intensive|O treatment|O .|O
Although|O the|O CALGB|O trial|O did|O not|O show|O an|O overall|O benefit|O for|O higher|O doses|O of|O cytarabine|O consolidation|O in|O older|O patients|O ,|O a|O subset|O of|O patients|O with|O a|O good|O performance|O status|O ,|O normal|O renal|O function|O ,|O and|O a|O normal|O or|O low|O risk|O karyotype|O might|O be|O considered|O for|O a|O single|O cycle|O of|O cytarabine|O (|O 1|O .|O 0|O -|O 1|O .|O 5|O g|O /|O m2|O /|O d|O x|O 4|O -|O 6|O doses|O )|O without|O an|O anthracycline|O .|O
Because|O of|O the|O large|O numbers|O of|O diverse|O mutations|O ,|O large|O studies|O will|O be|O needed|O to|O fully|O evaluate|O the|O correlation|O between|O the|O mutation|O status|O of|O spliceosomal|O genes|O and|O other|O genes|O in|O a|O proper|O fashion|O .|O
We|O found|O a|O strong|O association|O between|O mutations|O affecting|O the|O cohesin|O complex|O and|O NPM1|O .|O
The|O proportion|O of|O patients|O with|O a|O reduction|O of|O 35|O %|O or|O more|O in|O spleen|O volume|O at|O week|O 24|O (|O primary|O end|O point|O )|O was|O 41|O .|O 9|O %|O in|O the|O ruxolitinib|O group|O as|O compared|O with|O 0|O .|O 7|O %|O in|O the|O placebo|O group|O (|O odds|O ratio|O ,|O 134|O .|O 4|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 18|O .|O 0|O to|O 1004|O .|O 9|O ;|O P|O <|O 0|O .|O 001|O )|O (|O Fig|O .|O 1A|O )|O .|O
This|O uses|O bone|O marrow|O blast|O percentage|O ,|O karyotype|O and|O the|O number|O of|O cytopenias|O to|O determine|O a|O risk|O score|O that|O is|O then|O used|O to|O predict|O median|O survival|O and|O time|O to|O transformation|O to|O acute|O myeloid|O leukaemia|O (|O AML|O )|O .|O
The|O prognostic|O relevance|O of|O IDH|O mutations|O depends|O on|O the|O mutation|O identified|O .|O
We|O did|O not|O find|O the|O patterns|O of|O mutations|O ,|O that|O is|O ,|O missense|O or|O nonsense|O /|O frameshift|O ,|O to|O have|O any|O influence|O on|O clinical|O outcome|O .|O
Among|O patients|O with|O unfavorable|O cytogenetics|O ,|O the|O 4|O -|O year|O OS|O rate|O in|O the|O subgroup|O of|O patients|O with|O monosomal|O karyotype|O was|O 3|O %|O compared|O with|O 13|O %|O in|O the|O subgroup|O without|O monosomal|O karyotype|O .|O
Early|O studies|O also|O suggest|O that|O HOXB|O genes|O may|O also|O be|O important|O targets|O of|O DNMT3A|O ,|O and|O the|O methylation|O of|O HOXB|O genes|O is|O altered|O in|O DNMT3A|O -|O mutant|O AML|O cells|O .|O
The|O most|O important|O results|O of|O this|O study|O of|O the|O effect|O of|O spliceosomal|O mutations|O on|O the|O transcriptome|O are|O that|O the|O associated|O splicing|O defects|O affect|O a|O specific|O subset|O of|O mRNAs|O (|O Figure|O 3|O ;|O supplemental|O Figures|O 8|O -|O 9|O )|O .|O
Patient|O number|O 5677|O (|O P5|O ,|O II|O ,|O 1|O )|O presented|O with|O WHIM|O -|O like|O syndrome|O with|O HPV|O -|O induced|O warts|O ,|O clinical|O features|O of|O extended|O sarcoidosis|O ,|O neutropenia|O ,|O lymphopenia|O ,|O monocytopenia|O ,|O and|O a|O severe|O defect|O in|O NK|O cells|O .|O
BCOR|O mutations|O were|O detected|O in|O about|O 4|O %|O (|O 10|O of|O 262|O )|O of|O an|O unselected|O cohort|O of|O de|O novo|O CN|O -|O AML|O .|O
When|O this|O laboratory|O was|O excluded|O ,|O there|O was|O complete|O concordance|O for|O 29|O specimens|O ,|O 18|O of|O which|O were|O in|O the|O high|O category|O ,|O 9|O were|O in|O the|O moderate|O category|O ,|O and|O 2|O were|O in|O the|O low|O category|O .|O
Affymetrix|O U133plus2|O CEL|O files|O for|O 183|O MDS|O patients|O and|O 17|O healthy|O controls|O in|O Gene|O Expression|O Omnibus|O GSE19429|O were|O pooled|O using|O Bioconductor|O '|O s|O gcrma|O tools|O for|O quantile|O normalization|O .|O
EVI1|O is|O predominantly|O expressed|O in|O HSCs|O ,|O suggesting|O a|O physiological|O role|O for|O this|O protein|O in|O these|O cells|O .|O
In|O a|O recent|O retrospective|O study|O that|O evaluated|O the|O prognostic|O impact|O of|O monosomal|O karyotype|O in|O older|O patients|O (|O age|O >|O 60|O years|O ;|O N|O =|O 186|O )|O with|O unfavorable|O cytogenetics|O treated|O on|O a|O GOELAMS|O trial|O ,|O the|O 2|O -|O year|O OS|O rate|O was|O significantly|O decreased|O among|O patients|O with|O monosomal|O karyotype|O compared|O with|O those|O without|O this|O abnormality|O (|O 7|O %|O vs|O .|O 22|O %|O ;|O P|O <|O .|O 0001|O )|O ;|O similar|O outcomes|O were|O observed|O within|O the|O subgroup|O of|O patients|O with|O complex|O karyotype|O .|O
A|O Double|O -|O Blind|O ,|O Placebo|O -|O Controlled|O Trial|O of|O Ruxolitinib|O for|O Myelofibrosis|O .|O
For|O example|O ,|O it|O is|O unclear|O how|O JAK2|O (|O or|O JAK1|O (|O REF|O .|O 95|O )|O )|O enters|O the|O nucleus|O ,|O as|O the|O JAKs|O do|O not|O contain|O known|O nuclear|O -|O localization|O sequences|O .|O
Immortalization|O of|O murine|O cells|O transduced|O with|O mutant|O SETBP1|O has|O been|O demonstrated|O ,|O highlighting|O the|O oncogenicity|O of|O this|O genetic|O lesion|O .|O
Frequency|O and|O distribution|O of|O mutations|O .|O
Besides|O alterations|O in|O TET2|O ,|O CBL|O ,|O ASXL1|O and|O the|O RAS|O pathway|O ,|O EZH2|O is|O targeted|O by|O various|O types|O of|O frameshift|O and|O point|O mutations|O .|O
Participation|O in|O clinical|O trials|O is|O especially|O encouraged|O .|O
On|O multivariable|O analysis|O that|O included|O the|O aforementioned|O variables|O ,|O only|O increased|O AMC|O (|O >|O 10|O x|O 109|O /|O l|O ,|O relative|O risk|O (|O RR|O )|O 2|O .|O 5|O ,|O 95|O %|O confidence|O interval|O (|O CI|O )|O 1|O .|O 7|O -|O 3|O .|O 8|O )|O ,|O presence|O of|O circulating|O IMC|O (|O RR|O 2|O .|O 0|O ,|O 95|O %|O CI|O 1|O .|O 4|O -|O 2|O .|O 7|O )|O ,|O decreased|O hemoglobin|O (|O <|O 10|O g|O /|O dl|O ,|O RR|O 1|O .|O 6|O ,|O 99|O %|O CI|O 1|O .|O 2|O -|O 2|O .|O 2|O )|O and|O decreased|O platelet|O count|O (|O <|O 100|O x|O 109|O /|O l|O ,|O RR|O 1|O .|O 4|O ,|O 99|O %|O CI|O 1|O .|O 0|O -|O 1|O .|O 9|O )|O retained|O significance|O .|O
Mutations|O were|O validated|O by|O Sanger|O sequencing|O and|O are|O only|O reported|O if|O they|O were|O detected|O by|O Sanger|O sequencing|O either|O in|O genomic|O DNA|O or|O in|O an|O independently|O whole|O genome|O -|O amplified|O DNA|O sample|O .|O
Earlier|O studies|O of|O RUNX1|O mutations|O in|O CMML|O were|O carried|O out|O by|O the|O PCR|O -|O single|O -|O strand|O conformational|O polymorphism|O approach|O ,|O and|O mainly|O focused|O on|O RHD|O (|O exons|O 3|O -|O -|O 5|O )|O .|O
Details|O of|O the|O treatment|O protocols|O have|O been|O previously|O reported|O .|O
Five|O mutants|O (|O nos|O .|O 26|O -|O -|O 30|O )|O with|O frameshift|O mutations|O located|O in|O exons|O 7b|O or|O 8|O producing|O stop|O codons|O downstream|O of|O the|O normal|O termination|O codon|O 453|O are|O expected|O to|O retain|O the|O DNA|O -|O binding|O potential|O but|O to|O lose|O transactivation|O ability|O ,|O and|O to|O act|O as|O dominant|O negative|O inhibitors|O of|O wild|O -|O type|O RUNX1|O ,|O as|O described|O by|O Harada|O et|O al|O .|O
The|O non|O -|O finger|O domains|O of|O the|O GATA|O proteins|O diverged|O substantially|O during|O molecular|O evolution|O ,|O suggesting|O that|O they|O may|O contribute|O to|O the|O unique|O functions|O of|O individual|O GATA|O factors|O .|O
EZH2|O missense|O ,|O donor|O -|O splice|O -|O site|O and|O frameshift|O mutations|O predicting|O truncated|O proteins|O were|O observed|O in|O 8|O out|O of|O 126|O subjects|O (|O 6|O %|O ;|O Table|O 1|O and|O Fig|O .|O 1b|O )|O .|O
The|O most|O frequent|O causes|O of|O death|O were|O intracranial|O hemorrhage|O ,|O progressive|O disease|O /|O blastic|O transformation|O ,|O and|O regimen|O -|O related|O toxicity|O from|O induction|O chemotherapy|O or|O transplantation|O .|O
Cloning|O analysis|O .|O
Key|O Point|O :|O Mutations|O of|O key|O transcription|O factor|O in|O myeloid|O malignancies|O .|O
The|O use|O of|O MPL|O analysis|O is|O best|O considered|O after|O pathology|O review|O of|O a|O bone|O marrow|O biopsy|O and|O aspirate|O .|O
Grade|O 4|O episodes|O of|O bleeding|O occurred|O in|O 1|O .|O 3|O %|O of|O patients|O who|O received|O ruxolitinib|O and|O in|O 1|O .|O 3|O %|O of|O patients|O who|O received|O placebo|O .|O
Genes|O encoding|O hematopoietic|O GATA|O factors|O usually|O contain|O two|O first|O exons|O that|O are|O tissue|O specific|O ,|O and|O have|O different|O 5|O -|O untranslated|O regions|O (|O UTR|O )|O .|O
The|O aim|O of|O this|O study|O was|O to|O investigate|O the|O frequency|O ,|O clinical|O implications|O ,|O and|O prognostic|O influence|O of|O mutations|O in|O the|O cohesin|O complex|O in|O the|O context|O of|O other|O prognostic|O markers|O in|O a|O cohort|O of|O 389|O uniformly|O treated|O AML|O patients|O .|O
The|O frequency|O of|O chromosomal|O changes|O in|O aCML|O is|O more|O variable|O ,|O ranging|O from|O 20|O %|O to|O 88|O %|O in|O 4|O series|O .|O
By|O examining|O the|O composition|O of|O GATA1|O -|O associated|O protein|O complexes|O in|O a|O conditional|O erythroid|O rescue|O system|O ,|O as|O well|O as|O through|O the|O use|O of|O tiling|O arrays|O ,|O they|O detected|O that|O the|O SCL|O complex|O was|O present|O at|O all|O activating|O GATA|O elements|O .|O
What|O Is|O the|O Current|O State|O of|O Practice|O in|O Clinical|O Laboratories|O for|O JAK2|O and|O MPL|O Mutation|O Testing|O ?|O
c|O -|O KIT|O mutations|O have|O been|O reported|O in|O approximately|O 20|O %|O of|O patients|O with|O CBF|O AML|O .|O
Polyclonal|O T|O -|O cell|O cultures|O were|O generated|O from|O viably|O frozen|O cells|O from|O subjects|O 10|O ,|O 40|O and|O 73|O (|O Supplementary|O Methods|O )|O .|O
Warts|O were|O considered|O when|O they|O numbered|O >|O =|O 10|O or|O when|O they|O presented|O as|O genital|O condylomata|O acuminata|O .|O
Cohesin|O gene|O mutations|O have|O no|O clear|O prognostic|O impact|O in|O AML|O patients|O .|O
Therapeutic|O response|O and|O clinical|O outcomes|O in|O patients|O with|O cohesin|O alterations|O .|O
Induction|O therapy|O with|O high|O -|O dose|O cytarabine|O was|O associated|O with|O significantly|O higher|O rates|O of|O treatment|O -|O related|O mortality|O (|O 14|O %|O vs|O .|O 5|O %|O for|O patients|O age|O <|O 50|O years|O ;|O 20|O %|O vs|O .|O 12|O %|O for|O patients|O age|O 50|O -|O 64|O years|O ;|O P|O =|O .|O 003|O )|O and|O grade|O 3|O or|O higher|O neurologic|O toxicity|O (|O 8|O %|O vs|O .|O 2|O %|O for|O patients|O <|O 50|O years|O ;|O 5|O %|O vs|O .|O 0|O .|O 5|O %|O for|O patients|O age|O 50|O -|O 64|O years|O ;|O P|O <|O .|O 0001|O )|O .|O
Increased|O response|O rates|O have|O also|O been|O reported|O when|O lenalidomide|O is|O used|O in|O patients|O with|O del|O (|O 5|O )|O (|O q31|O )|O .|O
Serial|O studies|O performed|O on|O patients|O from|O the|O initial|O diagnosis|O of|O low|O -|O risk|O MDS|O through|O subsequent|O transformation|O indicate|O that|O U2AF1|O mutations|O may|O represent|O early|O ancestral|O events|O .|O
We|O investigated|O its|O origin|O using|O 4|O highly|O polymorphic|O short|O tandem|O repeats|O ,|O 2|O centromeric|O to|O GATA2|O (|O D3S3606|O and|O D3S3607|O )|O and|O 2|O telomeric|O to|O GATA2|O (|O D3S1587|O and|O D3S1292|O )|O .|O
DNMT3A|O .|O
However|O ,|O the|O expression|O of|O these|O GATA|O factors|O is|O not|O limited|O to|O the|O hematopoietic|O compartment|O and|O they|O are|O also|O present|O in|O other|O tissues|O ,|O where|O they|O play|O important|O roles|O in|O development|O .|O
On|O multivariable|O analysis|O ,|O increased|O AMC|O (|O >|O 10|O x|O 109|O /|O l|O ,|O relative|O risk|O (|O RR|O )|O 2|O .|O 5|O ,|O 95|O %|O confidence|O interval|O (|O CI|O )|O 1|O .|O 7|O -|O 3|O .|O 8|O )|O ,|O presence|O of|O circulating|O IMC|O (|O RR|O 2|O .|O 0|O ,|O 95|O %|O CI|O 1|O .|O 4|O -|O 2|O .|O 7|O )|O ,|O decreased|O hemoglobin|O (|O <|O 10|O g|O /|O dl|O ,|O RR|O 1|O .|O 6|O ,|O 99|O %|O CI|O 1|O .|O 2|O -|O 2|O .|O 2|O )|O and|O decreased|O platelet|O count|O (|O <|O 100|O x|O 109|O /|O l|O ,|O RR|O 1|O .|O 4|O ,|O 99|O %|O CI|O 1|O .|O 0|O -|O 1|O .|O 9|O )|O remained|O significant|O .|O
Positive|O controls|O for|O MPL|O mutations|O are|O more|O difficult|O to|O obtain|O .|O
GATA2|O is|O a|O member|O of|O the|O GATA|O transcription|O factor|O family|O characterized|O by|O a|O 2|O zinc|O finger|O domains|O binding|O to|O the|O DNA|O sequence|O WGATAR|O and|O a|O transactivation|O domain|O .|O
Efficacy|O .|O
In|O addition|O to|O their|O association|O with|O sporadic|O MPN|O ,|O MPL|O mutations|O are|O also|O associated|O with|O familial|O diseases|O .|O
Figure|O 2|O .|O Prognostic|O impact|O of|O cohesin|O mutations|O in|O all|O investigated|O AML|O patients|O .|O (|O A|O )|O OS|O in|O AML|O patients|O with|O wild|O -|O type|O (|O WT|O )|O or|O mutated|O genes|O of|O the|O cohesin|O complex|O .|O (|O B|O )|O RFS|O in|O AML|O patients|O with|O WT|O or|O mutated|O genes|O of|O the|O cohesin|O complex|O .|O
All|O of|O these|O mutations|O were|O somatic|O as|O confirmed|O by|O sequencing|O of|O the|O corresponding|O germline|O -|O derived|O DNA|O .|O
As|O reported|O previously|O ,|O mutations|O of|O genes|O involved|O in|O tyrosinesignaling|O pathways|O (|O JAK2|O ,|O CBL|O ,|O and|O NRAS|O -|O KRAS|O -|O BRAF|O )|O were|O largely|O mutually|O exclusive|O (|O Fig|O .|O 1|O )|O .|O
Figure|O 2|O .|O Proposed|O Diagnostic|O Strategy|O for|O Myeloproliferative|O Neoplasms|O (|O MPN|O )|O .|O Initial|O Screening|O Should|O Be|O for|O BCR|O -|O ABL1|O .|O Positive|O Test|O is|O Diagnostic|O for|O Chronic|O Myeloid|O Leukemia|O (|O CML|O )|O .|O If|O Clinical|O Suspicion|O Exists|O for|O BCR|O -|O ABL1|O Negative|O MPN|O ,|O Then|O Screen|O for|O JAK2V617F|O Mutation|O .|O JAK2|O is|O Diagnostic|O for|O MPN|O .|O Bone|O Marrow|O (|O BM|O )|O Biopsy|O is|O Required|O for|O Diagnosis|O of|O Essential|O Thrombocythemia|O (|O ET|O )|O and|O Primary|O Myelofibrosis|O (|O PMF|O )|O ,|O and|O Can|O Be|O Helpful|O in|O JAK2|O Negative|O Polycythemia|O Vera|O (|O PV|O )|O .|O
All|O the|O mutations|O detected|O here|O disrupt|O highly|O conserved|O amino|O acids|O (|O Supplementary|O Fig|O .|O 8|O )|O .|O
Also|O known|O as|O the|O citric|O acid|O cycle|O or|O the|O tricarboxylic|O acid|O cycle|O .|O The|O Krebs|O cycle|O is|O a|O series|O of|O chemical|O reactions|O that|O is|O used|O by|O all|O aerobic|O organisms|O to|O generate|O NADH|O and|O certain|O amino|O acids|O through|O the|O oxidation|O of|O acetate|O .|O
The|O differences|O in|O phenotypes|O described|O among|O these|O reports|O may|O be|O attributable|O to|O the|O different|O approaches|O used|O to|O target|O Tet2|O .|O
However|O ,|O such|O significant|O effects|O seem|O less|O in|O each|O background|O -|O matched|O specific|O disease|O phenotype|O by|O multivariate|O analysis|O ,|O including|O ,|O for|O example|O ,|O International|O Prognostic|O Scoring|O System|O score|O .|O
Although|O data|O are|O emerging|O on|O the|O prognostic|O relevance|O of|O mutations|O in|O the|O IDH|O and|O DNMT3A|O genes|O (|O see|O earlier|O discussions|O )|O ,|O the|O role|O of|O these|O molecular|O lesions|O on|O the|O risk|O stratification|O of|O patients|O with|O AML|O remains|O to|O be|O defined|O .|O
Additionally|O ,|O we|O identified|O 4|O patients|O with|O mutations|O in|O RAD21|O and|O 2|O patients|O with|O mutations|O in|O SMC1A|O (|O Figure|O 1|O )|O .|O
Interestingly|O ,|O a|O study|O in|O patients|O with|O NK|O -|O AML|O showed|O that|O prognosis|O was|O worse|O among|O patients|O with|O FLT3|O -|O ITD|O without|O a|O wild|O -|O type|O FLT3|O ,|O compared|O with|O those|O with|O FLT3|O -|O ITD|O but|O having|O a|O wild|O -|O type|O FLT3|O in|O the|O second|O allele|O .|O
Our|O knowledge|O of|O the|O mechanisms|O that|O promote|O malignant|O myeloid|O transformation|O has|O evolved|O as|O a|O result|O of|O an|O improved|O understanding|O of|O the|O range|O of|O genetic|O events|O that|O are|O found|O in|O patients|O with|O these|O disorders|O .|O
The|O presence|O of|O overlapping|O features|O between|O MDS|O and|O myeloproliferative|O neoplasm|O has|O given|O rise|O to|O ambiguity|O with|O regard|O to|O diagnosis|O and|O prognostication|O of|O patients|O with|O CMML|O .|O
The|O Mayo|O prognostic|O model|O performed|O better|O than|O the|O MDAPS|O ,|O G|O -|O MDAPS|O and|O the|O Spanish|O cytogenetic|O risk|O models|O (|O Figure|O 2|O )|O .|O
On|O the|O other|O hand|O ,|O the|O implication|O of|O the|O impaired|O function|O of|O GATA2|O in|O solid|O tumors|O has|O only|O been|O studied|O in|O the|O pathogenesis|O of|O prostate|O cancer|O and|O neuroblastoma|O .|O
A|O series|O of|O small|O studies|O that|O involved|O 55|O patients|O with|O PMF|O ,|O 25|O patients|O with|O PMF|O ,|O and|O 104|O patients|O with|O PMF|O ,|O PV|O ,|O or|O ET|O reported|O a|O 47|O %|O 5|O -|O year|O probability|O of|O survival|O ,|O 41|O %|O projected|O 2|O -|O year|O overall|O survival|O ,|O and|O 58|O %|O 3|O -|O year|O survival|O ,|O respectively|O .|O
Whole|O exome|O sequencing|O has|O revealed|O the|O otherwise|O unexpected|O involvement|O of|O multiple|O components|O of|O the|O RNA|O splicing|O machinery|O by|O gene|O mutations|O that|O characterize|O MDS|O and|O related|O myeloid|O neoplasms|O and|O as|O such|O ,|O demonstrated|O the|O power|O of|O massively|O parallel|O sequencing|O technologies|O in|O cancer|O research|O .|O
Current|O Paradigms|O .|O
Similar|O results|O were|O reported|O for|O myelofibrosis|O .|O
However|O ,|O the|O strategies|O leading|O to|O the|O discovery|O of|O BCOR|O and|O BCORL1|O mutations|O in|O AML|O differed|O .|O
Karyotype|O was|O normal|O .|O
In|O late|O 2010|O ,|O a|O sample|O exchange|O for|O interlaboratory|O comparison|O of|O assays|O for|O MPNs|O was|O organized|O by|O the|O AMP|O .|O
Harada|O et|O al|O .|O did|O not|O find|O RUNX1|O mutations|O in|O four|O patients|O with|O CMML|O ,|O nor|O did|O Preudhomme|O et|O al|O .|O in|O 27|O CMML|O patients|O .|O
Disease|O phenotypes|O associated|O with|O JAK2|O exon|O 12|O mutations|O include|O younger|O age|O at|O diagnosis|O ,|O subnormal|O erythropoietin|O (|O EPO|O )|O levels|O ,|O and|O isolated|O erythrocytosis|O at|O clinical|O onset|O .|O
An|O ETV6|O gene|O rearrangement|O is|O associated|O with|O a|O good|O prognosis|O in|O a|O subtype|O of|O acute|O lymphoblastic|O leukemia|O with|O t|O (|O 11|O ;|O 22|O )|O .|O
This|O advance|O clearly|O illustrates|O the|O clinical|O relevance|O of|O defining|O the|O molecular|O basis|O of|O hematologic|O malignancies|O .|O
The|O presence|O of|O ASXL1|O mutations|O has|O also|O been|O independently|O associated|O with|O an|O inferior|O OS|O in|O low|O -|O and|O high|O -|O risk|O MDS|O patients|O .|O
Figure|O 2|O .|O The|O role|O of|O mutations|O and|O aberrant|O expression|O of|O chromatin|O modifiers|O in|O the|O pathogenesis|O of|O myeloid|O malignancies|O .|O In|O the|O hierarchical|O recruitment|O model|O ,|O transcriptional|O silencing|O begins|O with|O the|O recruitment|O of|O Polycomb|O repressive|O complex|O 2|O (|O PRC2|O )|O and|O the|O induction|O of|O enhancer|O of|O zeste|O homologue|O 2|O (|O EZH2|O )|O -|O mediated|O dimethylation|O (|O me2|O )|O and|O trimethylation|O (|O me3|O )|O of|O lysine|O 27|O of|O histone|O H3|O (|O H3K27|O )|O .|O PRC1|O recognizes|O H3K27me3|O through|O the|O chromodomain|O of|O Polycomb|O (|O PC|O )|O homologues|O .|O PRC1|O -|O mediated|O ubiquitylation|O (|O Ub|O )|O of|O lysine|O 119|O of|O histone|O H2A|O (|O H2AK119|O )|O follows|O ,|O leading|O to|O chromatin|O compaction|O and|O the|O recruitment|O by|O PRC2|O of|O DNA|O methyltransferases|O (|O DNMTs|O )|O to|O target|O -|O gene|O loci|O .|O Currently|O ,|O EZH2|O is|O known|O to|O be|O affected|O by|O loss|O -|O of|O -|O function|O mutations|O in|O myelodysplastic|O syndrome|O (|O MDS|O )|O ,|O myeloproliferative|O neoplasms|O (|O MPNs|O )|O ,|O and|O MDS|O /|O MPN|O overlap|O disorders|O .|O Other|O PRC2|O members|O are|O less|O commonly|O affected|O by|O loss|O -|O of|O -|O function|O mutations|O and|O copy|O -|O number|O loss|O ,|O including|O suppressor|O of|O zeste|O 12|O homologue|O (|O SUZ12|O )|O ,|O embryonic|O ectoderm|O development|O (|O EED|O )|O and|O JARID2|O .|O Overexpression|O of|O a|O PRC1|O component|O ,|O BMI1|O ,|O is|O known|O to|O result|O in|O increased|O haematopoietic|O stem|O cell|O self|O -|O renewal|O from|O mouse|O studies|O ,|O but|O BMI1|O overexpression|O is|O not|O known|O to|O be|O a|O recurrent|O alteration|O in|O human|O myeloid|O malignancy|O .|O PRC1|O activity|O recruits|O DNMTs|O ,|O including|O DNMT3A|O ,|O which|O is|O known|O to|O be|O affected|O by|O suspected|O loss|O -|O of|O -|O function|O mutations|O in|O all|O types|O of|O human|O myeloid|O malignancies|O .|O Removal|O of|O H2AK119|O ubiquitylation|O in|O Drosophila|O melanogaster|O and|O in|O mammalian|O cells|O in|O vitro|O occurs|O by|O the|O Polycomb|O -|O repressive|O deubiquitylase|O (|O PR|O -|O DUB|O )|O complex|O ,|O which|O consists|O of|O calypso|O (|O the|O D|O .|O melanogaster|O orthologue|O of|O BRCA1|O -|O associated|O protein|O 1|O (|O BAP1|O )|O )|O and|O addition|O of|O sex|O combs|O -|O like|O 1|O (|O ASXL1|O )|O .|O However|O ,|O the|O presence|O of|O this|O PR|O -|O DUB|O has|O not|O been|O demonstrated|O in|O mammalian|O cells|O in|O vivo|O ,|O and|O more|O recent|O data|O in|O mammalian|O myeloid|O leukaemia|O cells|O suggest|O that|O ASXL1|O expression|O is|O strongly|O correlated|O with|O an|O abundance|O of|O H3K27me3|O in|O addition|O to|O physically|O interacting|O with|O PRC2|O .|O Mixed|O -|O lineage|O leukaemia|O (|O MLL|O )|O is|O a|O member|O of|O a|O multiprotein|O complex|O that|O mediates|O methylation|O of|O H3K4|O within|O the|O promoter|O region|O of|O genes|O through|O its|O SET|O domain|O .|O MLL|O is|O known|O to|O be|O affected|O by|O mutations|O that|O result|O in|O a|O partial|O tandem|O -|O duplication|O (|O PTD|O )|O and|O by|O translocations|O that|O result|O in|O in|O -|O frame|O fusions|O of|O the|O amino|O -|O terminus|O of|O MLL|O to|O one|O of|O >|O 50|O different|O partners|O and|O loss|O of|O the|O H3K4|O methyltransferase|O SET|O domain|O .|O MLL|O -|O PTD|O has|O been|O shown|O to|O result|O in|O increased|O levels|O of|O H3K4me3|O ,|O whereas|O translocated|O MLL|O recruits|O the|O H3K79|O methyltransferase|O DOT1L|O .|O The|O multiple|O physical|O associations|O that|O MLL|O requires|O for|O its|O function|O has|O led|O to|O the|O development|O of|O various|O therapeutic|O approaches|O to|O abrogate|O the|O activity|O of|O mutant|O MLL|O .|O
Four|O patients|O were|O identified|O with|O missense|O mutations|O in|O SMC3|O and|O 1|O patient|O with|O the|O stop|O codon|O being|O changed|O to|O leucine|O (|O Figure|O 1|O and|O supplemental|O Table|O 4|O )|O .|O
Further|O evidence|O also|O supports|O that|O a|O wide|O spectrum|O of|O genetic|O aberrations|O has|O been|O implicated|O in|O the|O prognosis|O and|O behavior|O of|O individual|O MDS|O cases|O .|O
The|O methodology|O summary|O of|O sequencing|O assays|O should|O clearly|O state|O the|O regions|O covered|O by|O the|O assay|O .|O
Finally|O ,|O all|O patients|O require|O attentive|O supportive|O care|O related|O both|O to|O the|O underlying|O leukemia|O (|O ie|O ,|O tumor|O lysis|O syndrome|O )|O and|O the|O adverse|O effects|O of|O chemotherapy|O (|O see|O on|O page|O 996|O )|O .|O
Daunorubicin|O Pathway|O Interaction|O Database|O :|O http|O :|O /|O /|O pid|O .|O nci|O .|O nih|O .|O gov|O .|O
Comparisons|O of|O quantitative|O variables|O between|O groups|O of|O patients|O were|O carried|O out|O by|O the|O nonparametric|O Wilcoxon|O rank|O -|O sum|O test|O .|O
Background|O .|O
Patient|O outcome|O in|O primary|O myelofibrosis|O (|O PMF|O )|O is|O significantly|O influenced|O by|O karyotype|O .|O
Demographic|O and|O clinical|O characteristics|O of|O the|O study|O patients|O are|O detailed|O in|O Table|O 1|O in|O the|O Supplementary|O Appendix|O .|O
OS|O endpoints|O measured|O from|O the|O date|O of|O entry|O into|O one|O of|O the|O prospective|O studies|O were|O death|O (|O failure|O )|O and|O alive|O at|O last|O follow|O -|O up|O (|O censored|O )|O .|O
A|O complete|O review|O of|O other|O JAK2|O inhibitors|O is|O discussed|O elsewhere|O .|O
Similar|O to|O findings|O with|O IDH1|O mutations|O ,|O reports|O on|O the|O prognostic|O effect|O of|O IDH2|O mutations|O have|O also|O been|O inconsistent|O .|O
An|O accurate|O diagnosis|O is|O more|O likely|O when|O one|O or|O more|O of|O a|O JAK2V617F|O mutation|O ,|O cytogenetic|O abnormalities|O (|O +|O 9|O ,|O del|O [|O 13q|O ]|O )|O ,|O anemia|O ,|O elevated|O serum|O LDH|O ,|O and|O leukoerythroblastosis|O are|O present|O .|O
First|O ,|O mutations|O outside|O the|O coding|O region|O were|O excluded|O .|O
Table|O 2|O .|O Clinical|O characteristics|O of|O patients|O treated|O with|O HMAs|O .|O
The|O definition|O of|O complete|O remission|O (|O CR|O )|O ,|O overall|O survival|O (|O OS|O )|O ,|O and|O relapse|O -|O free|O survival|O (|O RFS|O )|O followed|O recommended|O criteria|O .|O
DATABASES|O .|O
After|O excluding|O all|O known|O single|O -|O nucleotide|O polymorphisms|O and|O filtering|O out|O alterations|O present|O in|O paired|O germline|O samples|O ,|O somatic|O alterations|O in|O cohesin|O complex|O genes|O were|O identified|O in|O 11|O .|O 6|O %|O of|O patients|O ,|O including|O STAG2|O (|O 5|O .|O 9|O %|O )|O ,|O RAD21|O (|O 2|O %|O )|O ,|O and|O SMC3|O (|O 2|O %|O )|O .|O
More|O recently|O ,|O mutant|O JAK2|O was|O shown|O to|O phosphorylate|O PRMT5|O ,|O an|O arginine|O methyltransferase|O ,|O much|O more|O effectively|O than|O wild|O -|O type|O JAK2|O (|O REF|O .|O 94|O )|O .|O
Grade|O 3|O episodes|O of|O bleeding|O (|O terms|O for|O bleeding|O events|O are|O described|O in|O the|O Supplementary|O Appendix|O )|O occurred|O in|O 2|O .|O 6|O %|O of|O patients|O who|O received|O ruxolitinib|O and|O in|O 2|O .|O 0|O %|O of|O patients|O who|O received|O placebo|O .|O
The|O model|O was|O generated|O from|O a|O stepwise|O Cox|O regression|O model|O that|O included|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O risk|O category|O (|O based|O on|O the|O percentage|O of|O blasts|O in|O bone|O marrow|O ,|O the|O karyotype|O ,|O and|O the|O number|O of|O cytopenias|O [|O see|O Table|O 2|O in|O the|O Supplementary|O Appendix|O ]|O )|O ,|O age|O ,|O sex|O ,|O and|O mutation|O status|O for|O genes|O that|O were|O mutated|O in|O 1|O %|O or|O more|O of|O the|O 428|O samples|O for|O which|O the|O IPSS|O classification|O was|O recalculated|O .|O Age|O was|O included|O in|O the|O analysis|O as|O a|O categorical|O variable|O on|O the|O basis|O of|O a|O best|O -|O split|O algorithm|O showing|O a|O significant|O difference|O in|O overall|O survival|O between|O patients|O less|O than|O 55|O years|O of|O age|O and|O those|O 55|O years|O of|O age|O or|O older|O (|O see|O Table|O 8|O in|O the|O Supplementary|O Appendix|O )|O .|O
Numerous|O studies|O have|O shown|O the|O negative|O prognostic|O influence|O of|O FLT3|O -|O ITD|O in|O patients|O with|O AML|O ,|O resulting|O in|O shorter|O remission|O durations|O (|O eg|O ,|O decreased|O diseasefree|O survival|O [|O DFS|O ]|O in|O patients|O with|O a|O CR|O )|O and|O poorer|O survival|O outcomes|O compared|O with|O patients|O with|O wild|O -|O type|O FLT3|O .|O
There|O was|O less|O reproducibility|O between|O laboratories|O in|O the|O lower|O ranges|O ,|O presumably|O because|O of|O greater|O variance|O of|O the|O method|O in|O the|O low|O range|O .|O
We|O identified|O a|O heterozygous|O nonsense|O GATA2|O E224X|O mutation|O (|O c|O .|O 670G|O >|O T|O ,|O supplemental|O Figure|O 1|O )|O that|O was|O not|O detected|O in|O the|O parents|O '|O samples|O .|O
Abnormal|O bands|O detected|O by|O SSCP|O analysis|O were|O analyzed|O for|O mutation|O by|O direct|O sequencing|O .|O
Diagnosis|O was|O confirmed|O and|O assigned|O according|O to|O World|O Health|O Organization|O classification|O criteria|O .|O
Ninety|O -|O three|O percent|O of|O patients|O with|O PMF|O showed|O a|O decrease|O in|O spleen|O size|O of|O >|O 20|O cm|O .|O
Two|O of|O the|O nine|O affected|O patients|O concomitantly|O harbored|O two|O different|O EZH2|O mutations|O ,|O however|O ,|O these|O were|O located|O on|O two|O separate|O amplicons|O not|O allowing|O to|O discriminate|O between|O a|O monoor|O biallelic|O state|O .|O
A|O group|O of|O clonal|O myeloid|O disorders|O that|O involve|O precursor|O cells|O with|O a|O reduced|O capacity|O to|O differentiate|O into|O more|O mature|O cellular|O elements|O and|O with|O increased|O proliferation|O and|O self|O -|O renewal|O .|O
In|O an|O analysis|O of|O data|O from|O patients|O treated|O on|O SWOG|O protocols|O (|O N|O =|O 1344|O ;|O age|O 16|O -|O 88|O years|O )|O ,|O 13|O %|O of|O patients|O were|O found|O to|O have|O monosomal|O karyotype|O ;|O nearly|O all|O of|O these|O cases|O (|O 98|O %|O )|O occurred|O within|O the|O unfavorable|O cytogenetics|O category|O .|O
Median|O survival|O is|O listed|O for|O specific|O mutations|O present|O in|O at|O least|O 4|O of|O the|O 439|O samples|O (|O 1|O %|O )|O .|O A|O patient|O could|O have|O multiple|O mutations|O .|O The|O P|O values|O are|O for|O median|O survival|O in|O the|O group|O of|O patients|O with|O a|O mutated|O gene|O versus|O the|O group|O of|O patients|O without|O a|O mutation|O in|O that|O gene|O .|O CI|O denotes|O confidence|O interval|O .|O
Sanger|O sequencing|O of|O 310|O patients|O was|O performed|O to|O assess|O phenotype|O /|O genotype|O associations|O .|O
Evaluation|O and|O Treatment|O of|O CNS|O Leukemia|O .|O
The|O 2008|O World|O Health|O Organization|O classification|O of|O hematopoietic|O neoplasms|O includes|O JAK2|O mutations|O as|O diagnostic|O criteria|O in|O PV|O and|O JAK2|O and|O MPL|O mutations|O in|O ET|O and|O PMF|O .|O
The|O prognostic|O relevance|O of|O the|O molecular|O consequence|O associated|O with|O TET2|O mutation|O has|O also|O been|O investigated|O in|O MDS|O .|O
At|O this|O point|O ,|O we|O will|O examine|O the|O switching|O profile|O that|O GATA1|O and|O GATA2|O shows|O during|O erythroid|O cell|O differentiation|O .|O
After|O crossover|O ,|O data|O for|O patients|O who|O were|O initially|O assigned|O to|O placebo|O were|O not|O included|O in|O the|O analyses|O ,|O except|O for|O the|O intention|O -|O to|O -|O treat|O analysis|O of|O overall|O survival|O .|O
Notably|O ,|O all|O three|O spliceosome|O mutations|O were|O mutually|O exclusive|O .|O
Recurrent|O DNMT3A|O mutations|O have|O been|O identified|O in|O de|O novo|O AML|O (|O 62|O of|O 281|O patients|O ,|O 22|O .|O 1|O %|O )|O and|O have|O been|O associated|O with|O an|O intermediate|O -|O risk|O cytogenetic|O profile|O .|O
These|O recommendations|O are|O based|O on|O a|O review|O of|O recently|O published|O clinical|O trials|O that|O have|O led|O to|O significant|O improvements|O in|O treatment|O or|O have|O yielded|O new|O information|O regarding|O biologic|O factors|O that|O may|O have|O prognostic|O importance|O .|O
Interestingly|O ,|O it|O has|O been|O recently|O reported|O that|O acetylation|O of|O EVI1|O at|O Lys564|O by|O P|O /|O CAF|O enhances|O the|O DNA|O -|O binding|O capacity|O of|O EVI1|O and|O thereby|O contributes|O to|O the|O transcriptional|O activation|O of|O GATA2|O .|O
The|O NCCN|O Clinical|O Practice|O Guidelines|O in|O Oncology|O (|O NCCN|O Guidelines|O )|O for|O AML|O provide|O recommendations|O on|O the|O diagnostic|O evaluation|O and|O workup|O for|O AML|O ,|O risk|O assessment|O based|O on|O cytogenetic|O and|O molecular|O features|O ,|O treatment|O options|O for|O induction|O and|O consolidation|O therapies|O for|O younger|O and|O older|O (|O age|O >|O =|O 65|O years|O )|O adult|O patients|O ,|O and|O key|O supportive|O care|O considerations|O .|O
Thus|O far|O ,|O in|O CMML|O ,|O loss|O -|O of|O -|O function|O gene|O mutations|O involving|O ASXL1|O and|O EZH2|O has|O been|O associated|O with|O poor|O outcome|O .|O
Ta|O -|O Chih|O Liu|O ;|O Pai|O -|O Mei|O Lin|O ;|O Jan|O -|O Gowth|O Chang|O ;|O Jing|O -|O Ping|O Lee|O ;|O Tyen|O -|O Po|O Chen|O ;|O Sheng|O -|O Fung|O Lin|O .|O
Thrombocytopenia|O rarely|O recurred|O at|O a|O grade|O 3|O or|O 4|O level|O after|O appropriate|O dose|O modifications|O and|O was|O not|O associated|O with|O an|O increase|O in|O bleeding|O events|O ,|O although|O bruising|O was|O more|O common|O in|O the|O ruxolitinib|O group|O .|O
The|O samples|O were|O from|O patients|O representative|O of|O the|O general|O population|O of|O patients|O with|O myelodysplastic|O syndromes|O (|O Table|O 1|O in|O the|O Supplementary|O Appendix|O )|O .|O
S3A|O ,|O S3B|O ,|O and|O S3C|O in|O the|O Supplementary|O Appendix|O )|O .|O
Considering|O the|O prognostic|O relevance|O of|O ASXL1|O mutations|O for|O survival|O and|O SRSF2|O and|O IDH1|O mutations|O for|O leukemia|O -|O free|O survival|O ,|O the|O Mayo|O cohort|O was|O divided|O into|O mutationally|O high|O (|O ASXL1|O ,|O SRSF2|O or|O IDH1|O mutated|O )|O and|O mutationally|O low|O (|O none|O of|O the|O above|O )|O risk|O categories|O ,|O which|O showed|O significant|O difference|O in|O both|O overall|O (|O multivariable|O HR|O accounting|O for|O DIPSS|O -|O plus|O :|O 1|O .|O 4|O ,|O 95|O %|O CI|O :|O 1|O .|O 0|O -|O 1|O .|O 9|O ;|O P|O =|O 0|O .|O 04|O )|O and|O leukemia|O -|O free|O (|O multivariable|O HR|O accounting|O for|O karyotype|O and|O thrombocytopenia|O :|O 3|O .|O 2|O ,|O 95|O %|O CI|O :|O 1|O .|O 6|O -|O 6|O .|O 4|O ;|O P|O =|O 0|O .|O 001|O )|O survival|O .|O
Marlene|O Pasquet|O ;|O Christine|O Bellanne|O -|O Chantelot|O ;|O Suzanne|O Tavitian|O ;|O Nais|O Prade|O ;|O Blandine|O Beaupain|O ;|O Olivier|O LaRochelle|O ;|O Arnaud|O Petit|O ;|O Pierre|O Rohrlich|O ;|O Christophe|O Ferrand|O ;|O Eric|O Van|O Den|O Neste|O ;|O Helene|O A|O .|O Poirel|O ;|O Thierry|O Lamy|O ;|O Marie|O Ouachee|O -|O Chardin|O ;|O Veronique|O Mansat|O -|O De|O Mas|O ;|O Jill|O Corre|O ;|O Christian|O Recher|O ;|O Genevieve|O Plat|O ;|O Francoise|O Bachelerie|O ;|O Jean|O Donadieu|O ;|O Eric|O Delabesse|O .|O
Leukemia|O -|O free|O survival|O was|O calculated|O from|O the|O date|O of|O first|O referral|O to|O the|O date|O of|O LT|O (|O uncensored|O )|O or|O death|O /|O last|O contact|O (|O censored|O )|O .|O
ECOG|O ,|O performance|O status|O of|O the|O Eastern|O Cooperative|O Oncology|O Group|O ;|O FAB|O ,|O French|O -|O American|O -|O British|O classification|O of|O AML|O ;|O FLT3|O -|O ITD|O ,|O internal|O tandem|O duplication|O of|O the|O FLT3|O gene|O ;|O no|O .|O ,|O number|O ;|O P|O ,|O P|O value|O from|O two|O -|O sided|O x|O -|O squared|O tests|O for|O categorical|O variables|O and|O from|O 2|O -|O sided|O Student|O t|O or|O Kolmogorov|O -|O Smirnov|O tests|O for|O continuous|O variables|O .|O
Figure|O 1|O .|O Schematic|O representation|O of|O the|O BCOR|O (|O top|O )|O and|O BCORL1|O (|O bottom|O )|O transcriptional|O corepressors|O with|O their|O respective|O domains|O and|O the|O location|O and|O type|O of|O mutations|O occurring|O in|O AML|O patients|O .|O The|O numbers|O above|O the|O arrows|O indicate|O the|O presence|O ,|O in|O more|O than|O one|O case|O ,|O of|O the|O same|O type|O of|O mutation|O occurring|O at|O the|O same|O exonic|O location|O or|O involving|O the|O splicing|O of|O the|O same|O intron|O .|O BCORL1|O mutations|O also|O include|O five|O mutations|O that|O were|O found|O in|O four|O AML|O cell|O lines|O and|O in|O the|O Jurkat|O T|O -|O lymphoblastic|O leukemia|O cell|O line|O .|O The|O specific|O type|O (|O i|O .|O e|O .|O frameshift|O ,|O nonsense|O ,|O missense|O or|O splice|O -|O site|O )|O of|O BCORL1|O mutations|O was|O inferred|O from|O Li|O et|O al|O .|O
Cox|O models|O were|O used|O to|O identify|O correlates|O with|O OS|O .|O
Commitment|O of|O hematopoietic|O stem|O cells|O /|O early|O progenitor|O cells|O (|O HSC|O /|O HPC|O )|O to|O specific|O lineages|O takes|O place|O within|O the|O bone|O marrow|O microenvironment|O under|O the|O influence|O of|O multiple|O regulatory|O factors|O .|O
An|O additional|O patient|O had|O a|O silent|O mutation|O (|O Ile87Ile|O )|O .|O
Insensitive|O molecular|O assays|O would|O cause|O an|O even|O bigger|O problem|O in|O ET|O ,|O in|O which|O up|O to|O 75|O %|O of|O cases|O have|O a|O JAK2|O V617F|O level|O of|O less|O than|O 25|O %|O and|O a|O considerable|O number|O (|O 40|O %|O of|O cases|O )|O have|O a|O JAK2|O V617F|O level|O of|O less|O than|O 10|O %|O .|O
However|O ,|O phlebotomy|O is|O still|O recommended|O with|O current|O guidelines|O that|O suggest|O an|O Hct|O target|O of|O <|O 50|O %|O .|O
By|O analyzing|O copy|O -|O number|O alterations|O with|O the|O use|O of|O SNP|O arrays|O and|O oncogene|O mutations|O ,|O by|O means|O of|O high|O -|O throughput|O genotyping|O ,|O we|O identified|O new|O mutations|O in|O ETV6|O and|O GNAS|O .|O
In|O the|O latter|O study|O from|O the|O UK|O MRC|O ,|O the|O 5|O -|O year|O OS|O rate|O among|O patients|O with|O and|O without|O FLT3|O -|O TKD|O mutations|O was|O 53|O %|O versus|O 37|O %|O ,|O respectively|O .|O
Isocitrate|O dehydrogenase|O 1|O and|O 2|O genes|O (|O IDH1|O /|O 2|O )|O encode|O isocitrate|O dehydrogenases|O (|O IDHs|O )|O ,|O which|O catalyze|O the|O NADP|O +|O -|O dependent|O decarboxylation|O of|O isocitrate|O to|O alpha|O -|O hetoglutarate|O (|O alpha|O -|O KG|O )|O or|O 2|O -|O oxoglutarate|O (|O 2OG|O )|O ,|O a|O key|O intermediate|O and|O an|O essential|O cofactor|O for|O a|O number|O of|O enzymes|O in|O the|O Kreb|O cycle|O (|O the|O tricarboxylic|O acid|O cycle|O )|O ,|O leading|O to|O the|O production|O of|O nicotinamide|O adenine|O dinucleotide|O phosphate|O (|O NADP|O )|O .|O
Using|O mass|O -|O spectrometric|O genotyping|O ,|O we|O examined|O these|O samples|O for|O 953|O recurrent|O mutations|O in|O 111|O cancer|O -|O associated|O genes|O .|O
We|O identified|O and|O validated|O mutations|O in|O 10|O genes|O :|O NRAS|O ,|O KRAS|O ,|O BRAF|O ,|O JAK2|O ,|O GNAS|O ,|O FLNB|O ,|O MET|O ,|O EGFR|O ,|O CDH1|O ,|O and|O PTPN11|O .|O
Notably|O ,|O PRC2|O associates|O only|O with|O the|O fusion|O oncoprotein|O and|O not|O with|O endogenous|O PML|O or|O RARalpha|O .|O
Although|O we|O could|O readily|O detect|O EZH2|O protein|O in|O cell|O lines|O and|O in|O primary|O T|O cells|O ,|O no|O EZH2|O protein|O expression|O could|O be|O measured|O in|O the|O total|O bone|O marrow|O of|O individuals|O with|O MDS|O irrespective|O of|O the|O presence|O or|O absence|O of|O EZH2|O mutations|O .|O
Notably|O ,|O the|O majority|O of|O somatic|O DNMT3A|O mutations|O result|O either|O in|O premature|O truncation|O of|O the|O protein|O product|O (|O nonsense|O or|O frameshift|O mutations|O )|O ,|O or|O occur|O at|O a|O single|O amino|O acid|O ,|O R882|O .|O
In|O subjects|O 10|O and|O 127|O ,|O mutant|O mRNA|O was|O detected|O ,|O but|O pyrosequencing|O and|O GeneScan|O analysis|O showed|O that|O the|O mutant|O sequences|O were|O expressed|O at|O lower|O levels|O than|O wild|O -|O type|O sequences|O ,|O suggesting|O a|O decreased|O stability|O of|O the|O mutant|O transcript|O .|O
SETBP1|O protects|O SET|O from|O protease|O cleavage|O ,|O thus|O increasing|O the|O amount|O of|O SET|O available|O to|O repress|O the|O activity|O of|O PP2A|O .|O
Five|O deaths|O were|O recorded|O ,|O 3|O as|O a|O direct|O consequence|O of|O the|O leukemic|O evolution|O (|O patient|O numbers|O 6227|O ,|O 5758|O ,|O and|O 5677|O )|O ,|O 1|O related|O to|O a|O flu|O -|O mediated|O pneumonia|O in|O a|O patient|O in|O complete|O remission|O of|O AML|O with|O immunodeficiency|O (|O patient|O number|O 6184|O )|O ,|O and|O 1|O in|O a|O patient|O who|O died|O from|O an|O aortic|O dissection|O at|O the|O age|O of|O 36|O (|O patient|O number|O 7107|O )|O .|O
However|O ,|O clinical|O outcome|O ,|O even|O in|O patients|O with|O normal|O karyotype|O AML|O (|O NK|O -|O AML|O )|O ,|O is|O heterogeneous|O .|O
The|O panel|O strongly|O recommends|O clinical|O trials|O as|O standard|O therapy|O for|O patients|O with|O poor|O prognostic|O features|O ,|O which|O include|O FLT3|O abnormalities|O in|O the|O setting|O of|O otherwise|O normal|O karyotype|O ,|O high|O WBC|O (|O >|O 50|O ,|O 000|O /|O mcL|O )|O at|O diagnosis|O ,|O or|O 2|O cycles|O of|O induction|O therapy|O needed|O to|O achieve|O CR|O .|O
These|O two|O novel|O classes|O of|O epigenetic|O mutations|O probably|O contribute|O to|O leukaemic|O transformation|O by|O affecting|O epigenetic|O regulation|O ,|O thus|O generating|O a|O chromatin|O landscape|O that|O can|O sustain|O ,|O and|O cooperate|O with|O ,|O the|O effect|O of|O class|O I|O and|O class|O II|O mutations|O .|O
All|O the|O authors|O vouch|O for|O the|O accuracy|O and|O completeness|O of|O the|O reported|O data|O and|O for|O the|O fidelity|O of|O this|O report|O to|O the|O protocol|O .|O
They|O found|O that|O DNMT3A|O mutations|O were|O present|O in|O 22|O %|O of|O adult|O cases|O of|O AML|O and|O were|O associated|O with|O an|O increased|O risk|O of|O relapse|O in|O a|O single|O -|O institution|O patient|O cohort|O (|O TABLE|O 1|O )|O .|O
Subsequent|O biochemical|O studies|O demonstrated|O that|O 2|O -|O HG|O inhibits|O TET|O family|O members|O as|O alpha|O -|O ketoglutarate|O is|O an|O essential|O cofactor|O of|O TET|O and|O its|O levels|O are|O reduced|O by|O the|O production|O of|O 2|O -|O HG|O .|O
After|O washing|O ,|O the|O eluate|O was|O amplified|O by|O PCR|O for|O 12|O cycles|O .|O
Compared|O to|O typical|O APL|O cases|O with|O t|O (|O 15|O ;|O 17|O )|O ,|O this|O patient|O showed|O distinct|O morphological|O features|O ,|O i|O .|O e|O .|O rectangular|O body|O inclusions|O in|O the|O cytoplasm|O of|O leukemic|O cells|O and|O an|O atypical|O clinical|O course|O characterized|O by|O multiple|O relapses|O following|O chemotherapy|O plus|O all|O -|O transretinoic|O acid|O .|O
For|O this|O subset|O of|O patients|O ,|O therapy|O with|O multiple|O cycles|O of|O high|O -|O dose|O cytarabine|O is|O a|O category|O 1|O option|O ,|O and|O allogeneic|O HSCT|O should|O be|O reserved|O until|O relapse|O .|O
Transcription|O factors|O are|O master|O regulators|O of|O development|O that|O control|O complex|O genetic|O networks|O .|O
Some|O karyotypic|O abnormalities|O ,|O such|O as|O deletion|O of|O chromosome|O 5q|O ,|O help|O establish|O the|O prognosis|O and|O may|O be|O associated|O with|O a|O specific|O clinical|O phenotype|O .|O
In|O a|O separate|O phase|O 3|O trial|O with|O a|O median|O follow|O -|O up|O of|O 61|O weeks|O ,|O there|O were|O no|O transformations|O to|O AML|O in|O 146|O patients|O who|O received|O ruxolitinib|O and|O two|O transformations|O in|O 73|O patients|O who|O received|O the|O best|O available|O therapy|O .|O
As|O indicated|O above|O ,|O the|O GATA2|O gene|O harbors|O two|O alternative|O untranslated|O first|O exons|O .|O
Rasburicase|O is|O a|O genetically|O engineered|O recombinant|O form|O of|O urate|O oxidase|O enzyme|O .|O
With|O respect|O to|O lenalidomide|O -|O treated|O patients|O (|O 8|O cohesin|O mutant|O and|O 84|O WT|O )|O ,|O we|O did|O not|O observe|O a|O significant|O difference|O in|O response|O rate|O in|O cohesin|O mutant|O (|O 50|O %|O )|O vs|O cohesin|O WT|O (|O 52|O %|O )|O patients|O .|O
TET2|O mutations|O were|O the|O most|O prevalent|O genetic|O abnormality|O identified|O in|O our|O sample|O set|O .|O
The|O L359V|O has|O an|O opposite|O effect|O to|O the|O T354M|O and|O M355del|O mutations|O ,|O with|O a|O gain|O of|O function|O effect|O for|O the|O former|O and|O a|O loss|O of|O function|O for|O the|O latter|O .|O
5|O -|O hmC|O is|O also|O more|O commonly|O enriched|O at|O gene|O exons|O compared|O with|O introns|O .|O
There|O was|O no|O difference|O in|O overall|O survival|O between|O patients|O with|O and|O without|O RUNX1|O mutations|O ,|O but|O a|O trend|O of|O higher|O risk|O of|O acute|O myeloid|O leukemia|O (|O AML|O )|O progression|O was|O observed|O in|O mutation|O -|O positive|O patients|O (|O 16|O /|O 30|O vs|O 17|O /|O 51|O ,|O P|O =|O 0|O .|O 102|O )|O ,|O especially|O in|O patients|O with|O C|O -|O terminal|O mutations|O (|O P|O =|O 0|O .|O 023|O )|O .|O
Numerous|O studies|O have|O identified|O BMI1|O ,|O a|O core|O member|O of|O the|O PRC1|O complex|O that|O is|O crucial|O for|O its|O H2AK119|O ubiquitin|O ligase|O activity|O (|O FIG|O .|O 2|O )|O ,|O as|O an|O important|O regulator|O of|O both|O HSC|O and|O leukaemia|O stem|O cell|O (|O LSC|O )|O self|O -|O renewal|O .|O
Thirty|O -|O two|O RUNX1|O mutations|O were|O detected|O in|O 30|O patients|O (|O 37|O %|O )|O ;|O 23|O mutants|O were|O located|O in|O the|O N|O -|O terminal|O part|O and|O 9|O in|O the|O C|O -|O terminal|O region|O .|O
Clinical|O presentations|O of|O pedigree|O 1|O .|O
The|O rate|O of|O evolution|O of|O patients|O with|O severe|O congenital|O neutropenia|O is|O 10|O .|O 8|O %|O at|O 20|O years|O increasing|O to|O 18|O .|O 8|O %|O in|O patients|O with|O SBDS|O mutations|O .|O
Taken|O together|O ,|O 16|O .|O 7|O %|O (|O 5|O /|O 30|O )|O of|O CMML|O patients|O carrying|O RUNX1|O mutations|O had|O cooperating|O mutations|O of|O FLT3|O or|O RAS|O genes|O .|O
These|O observations|O led|O to|O the|O notion|O that|O a|O key|O function|O of|O GATA2|O is|O to|O maintain|O the|O proliferative|O progenitor|O -|O cell|O phenotype|O ,|O and|O that|O its|O downregulation|O is|O necessary|O for|O differentiation|O .|O
STAG1|O ,|O STAG2|O ,|O SMC3|O ,|O and|O RAD21|O mutations|O had|O no|O influence|O on|O OS|O and|O RFS|O ,|O whereas|O the|O analysis|O was|O not|O performed|O for|O SMC1A|O due|O to|O the|O low|O mutation|O frequency|O (|O Table|O 2|O )|O .|O
The|O presence|O of|O IDH2|O mutations|O was|O mutually|O exclusive|O with|O IDH1|O mutation|O in|O nearly|O all|O cases|O .|O
The|O occurrence|O of|O subclonal|O driver|O mutations|O might|O be|O closely|O related|O to|O the|O early|O initiating|O genetic|O lesions|O ,|O as|O recently|O observed|O in|O myelodysplastic|O syndromes|O .|O
The|O 2|O well|O -|O documented|O categories|O of|O cytotoxic|O agents|O associated|O with|O the|O development|O of|O therapy|O -|O related|O MDS|O /|O AML|O are|O alkylating|O agents|O (|O eg|O ,|O cyclophosphamide|O ,|O melphalan|O )|O and|O topoisomerase|O inhibitors|O /|O agents|O that|O interact|O with|O topoisomerase|O (|O eg|O ,|O etoposide|O ,|O doxorubicin|O ,|O mitoxantrone|O )|O .|O
He|O is|O still|O in|O hematologic|O and|O cytogenetic|O remission|O 2|O years|O after|O HSCT|O .|O
Median|O follow|O -|O up|O time|O for|O all|O patients|O was|O 5|O .|O 1|O years|O (|O range|O ,|O 0|O .|O 19|O to|O 12|O .|O 2|O years|O )|O .|O
Figure|O 2|O .|O Hazard|O Ratios|O for|O Death|O from|O Any|O Cause|O ,|O According|O to|O Presence|O (|O vs|O .|O Absence|O )|O of|O Mutation|O in|O Each|O of|O Seven|O Genes|O .|O Results|O are|O shown|O ,|O on|O a|O log10|O scale|O ,|O for|O univariate|O analyses|O as|O well|O as|O for|O analyses|O with|O adjustment|O for|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O risk|O category|O (|O based|O on|O the|O percentage|O of|O blasts|O in|O bone|O marrow|O ,|O the|O karyotype|O ,|O and|O the|O number|O of|O cytopenias|O )|O (|O for|O details|O ,|O see|O Table|O 2|O in|O the|O Supplementary|O Appendix|O )|O .|O CI|O denotes|O confidence|O interval|O .|O
In|O MDS|O ,|O the|O rate|O of|O DNMT3A|O mutations|O appears|O to|O be|O lower|O ,|O in|O the|O range|O of|O 2|O -|O 8|O %|O .|O
The|O integrity|O and|O purity|O of|O total|O RNA|O were|O assessed|O with|O Agilent|O Bioanalyzer|O .|O cDNA|O (|O 1|O -|O 2|O mug|O )|O was|O generated|O with|O Clontech|O SmartPCR|O cDNA|O kit|O (|O Clontech|O Laboratories|O )|O from|O 100|O ng|O of|O total|O RNA|O .|O
We|O selected|O for|O GATA2|O by|O screening|O 14|O probands|O from|O a|O series|O of|O 544|O patients|O included|O in|O the|O registry|O .|O
In|O the|O aforementioned|O EORTC|O /|O GIMEMA|O trial|O ,|O a|O 43|O %|O 4|O -|O year|O DFS|O rate|O was|O reported|O in|O the|O donor|O group|O of|O patients|O with|O poor|O -|O risk|O cytogenetics|O (|O n|O =|O 64|O ;|O 73|O %|O underwent|O HSCT|O )|O ;|O this|O was|O significantly|O higher|O than|O the|O 4|O -|O year|O DFS|O rate|O (|O 18|O %|O ;|O P|O =|O .|O 008|O )|O among|O the|O no|O -|O donor|O group|O (|O n|O =|O 94|O ;|O 46|O %|O underwent|O HSCT|O )|O ,|O although|O only|O approximately|O half|O of|O the|O patients|O were|O able|O to|O proceed|O with|O the|O planned|O HSCT|O in|O the|O no|O -|O donor|O group|O .|O
The|O other|O GATA|O family|O members|O ,|O GATA4|O ,|O GATA5|O and|O GATA6|O ,|O are|O mainly|O expressed|O in|O tissues|O of|O mesodermal|O and|O endodermal|O origin|O such|O as|O the|O heart|O ,|O liver|O ,|O lung|O ,|O gut|O ,|O and|O gonads|O ,|O where|O they|O play|O critical|O roles|O in|O regulating|O tissue|O -|O specific|O gene|O expression|O .|O
In|O myelodysplastic|O syndromes|O (|O MDS|O )|O ,|O deletions|O of|O chromosome|O 7|O or|O 7q|O are|O common|O and|O correlate|O with|O a|O poor|O prognosis|O .|O The|O relevant|O genes|O on|O chromosome|O 7|O are|O unknown|O .|O
GERMLINE|O MUTATION|O ANALYSIS|O .|O
Of|O note|O ,|O ETV6|O fusion|O with|O PDGFRB|O or|O IL3|O may|O result|O in|O MPNs|O with|O eosinophilia|O .|O
Abbreviations|O :|O ALC|O ,|O absolute|O lymphocyte|O count|O ;|O AMC|O ,|O absolute|O monocyte|O count|O ;|O ANC|O ,|O absolute|O neutrophil|O count|O ;|O ASXL1|O ,|O additional|O sex|O combs|O 1|O gene|O ;|O BM|O ,|O bone|O marrow|O ;|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O ;|O PB|O ,|O peripheral|O blood|O ;|O SF3B1|O ,|O splicing|O factor|O 3B|O subunit|O 1|O ;|O SRSF2|O ,|O serine|O /|O arginine|O -|O rich|O splicing|O factor|O 2|O ;|O U2AF35|O ,|O U2|O small|O -|O nuclear|O RNA|O auxiliary|O factor|O 1|O ;|O WBC|O ,|O white|O blood|O cell|O count|O .|O
The|O recent|O identification|O of|O mutations|O in|O genes|O involved|O in|O epigenetic|O regulation|O has|O elucidated|O novel|O mechanisms|O of|O transformation|O .|O
The|O most|O common|O ASXL1|O mutation|O was|O c|O .|O 1934dupG|O ;|O p|O .|O Gly646TrpfsX12|O (|O n|O =|O 47|O ,|O 54|O %|O )|O ,|O followed|O by|O the|O 1900|O _|O 1922|O _|O del|O seen|O in|O 10|O (|O 11|O %|O )|O patients|O .|O
IDH1|O mutation|O was|O also|O associated|O with|O worse|O EFS|O and|O OS|O outcomes|O among|O the|O subgroup|O of|O patients|O with|O intermediate|O -|O risk|O NK|O -|O AML|O (|O wild|O -|O type|O NPM1|O without|O FLT3|O -|O ITD|O )|O .|O
Moreover|O ,|O it|O is|O known|O that|O GATA2|O overexpression|O in|O hematopoietic|O cell|O lines|O induces|O megakaryocytic|O differentiation|O (|O Fig|O .|O 4B|O )|O .|O
It|O has|O been|O recently|O reported|O that|O high|O GATA2|O expression|O is|O a|O common|O event|O in|O patients|O with|O prostate|O cancer|O (|O 83|O .|O 7|O %|O )|O ,|O and|O can|O influence|O the|O regulation|O of|O androgen|O -|O dependent|O genes|O ,|O such|O as|O KLK2|O and|O AZGP1|O .|O
These|O data|O are|O underscored|O by|O recent|O studies|O which|O suggest|O that|O alterations|O in|O these|O pathways|O have|O prognostic|O relevance|O in|O MDS|O and|O AML|O .|O
Table|O 1|O .|O Demographic|O and|O clinical|O features|O at|O diagnosis|O of|O 617|O patients|O with|O PMF|O subdivided|O according|O to|O their|O genotype|O (|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O )|O .|O
Because|O large|O segmental|O regions|O of|O UPD|O may|O harbor|O acquired|O homozygous|O mutations|O ,|O we|O sequenced|O EZH2|O in|O the|O bone|O marrow|O cells|O of|O the|O two|O subjects|O who|O showed|O UPD|O at|O 7q|O (|O Fig|O .|O 1a|O ;|O subjects|O 97|O and|O 103|O )|O .|O
In|O contrast|O ,|O patients|O with|O an|O isolated|O FLT3|O -|O ITD|O mutation|O and|O normal|O karyotype|O have|O an|O outlook|O similar|O to|O those|O with|O poor|O -|O risk|O cytogenetics|O and|O should|O be|O considered|O for|O a|O clinical|O trial|O or|O early|O allogeneic|O HSCT|O .|O
UTX|O mutations|O have|O been|O identified|O in|O a|O variety|O of|O cancers|O ,|O including|O some|O hematopoietic|O cell|O lines|O of|O myeloid|O origin|O ,|O e|O .|O g|O .|O ,|O CMML|O (|O 8|O %|O )|O ,|O but|O have|O been|O seldom|O found|O in|O MDS|O (|O 1|O %|O )|O .|O
Gene|O expression|O profiling|O was|O performed|O on|O total|O cellular|O RNA|O isolated|O from|O CD34|O +|O cells|O of|O a|O subset|O of|O patients|O from|O the|O European|O cohort|O ,|O randomly|O selected|O among|O those|O defined|O at|O '|O mutationally|O high|O -|O risk|O '|O or|O '|O mutationally|O low|O -|O risk|O '|O as|O described|O in|O Supplementary|O Methods|O .|O
For|O whole|O -|O exome|O sequencing|O ,|O the|O 50|O Mb|O of|O protein|O coding|O sequences|O was|O enriched|O from|O total|O genomic|O DNA|O by|O liquid|O -|O phase|O hybridization|O using|O SureSelect|O (|O version|O 4|O )|O (|O Agilent|O Technology|O ,|O Santa|O Clara|O ,|O CA|O )|O ,|O followed|O by|O massively|O parallel|O sequencing|O with|O HiSequation|O 2000|O (|O Illumina|O ,|O San|O Diego|O ,|O CA|O )|O .|O
None|O of|O these|O mutations|O were|O found|O in|O any|O of|O the|O unaffected|O subjects|O (|O Table|O 1|O and|O Supplementary|O Fig|O .|O 5|O )|O .|O
Further|O mutational|O screening|O in|O other|O malignancies|O might|O uncover|O the|O pathogenesis|O of|O common|O or|O unique|O tumorgenesis|O in|O various|O tissues|O .|O
Demonstration|O of|O a|O JAK2V617|O PB|O mutation|O confirms|O the|O presence|O of|O MPN|O and|O is|O highly|O suggestive|O of|O ET|O in|O the|O absence|O of|O erythrocytosis|O .|O
With|O the|O exception|O of|O refractory|O anemia|O with|O ring|O sideroblasts|O (|O RARS|O -|O T|O )|O ,|O higher|O frequencies|O (|O 38|O -|O 43|O %|O )|O appear|O to|O be|O associated|O with|O an|O MDS|O /|O MPN|O phenotype|O .|O
MPL|O .|O
In|O this|O double|O -|O blind|O trial|O ,|O we|O randomly|O assigned|O patients|O with|O intermediate|O -|O 2|O or|O high|O -|O risk|O myelofibrosis|O to|O twice|O -|O daily|O oral|O ruxolitinib|O (|O 155|O patients|O )|O or|O placebo|O (|O 154|O patients|O )|O .|O
One|O patient|O with|O acute|O promyelocytic|O leukemia|O (|O APL|O )|O has|O been|O reported|O to|O carry|O the|O 45|O ,|O -|O Y|O ,|O t|O (|O X|O ;|O 17|O )|O (|O p11|O ;|O q12|O )|O karyotype|O ,|O leading|O to|O the|O formation|O of|O a|O BCOR|O -|O RAR|O alpha|O fusion|O gene|O .|O
Mutations|O listed|O in|O the|O National|O Center|O for|O Biotechnology|O Information|O '|O s|O SNP|O database|O (|O dbSNP|O ,|O build|O 130|O )|O ,|O previously|O reported|O as|O germ|O line|O ,|O or|O present|O in|O the|O buccal|O sample|O from|O any|O patient|O in|O our|O cohort|O were|O considered|O to|O be|O germ|O line|O and|O were|O excluded|O from|O further|O analysis|O (|O Table|O 5|O in|O the|O Supplementary|O Appendix|O )|O .|O
A|O median|O of|O 498|O reads|O per|O amplicon|O (|O range|O 162|O -|O 740|O )|O were|O obtained|O for|O IDH1|O ,|O IDH2|O ,|O NPM1|O and|O EZH2|O ,|O thus|O yielding|O a|O sufficient|O coverage|O for|O mutation|O detection|O with|O high|O sensitivity|O .|O
In|O keeping|O with|O the|O prominent|O role|O of|O G|O -|O CSF|O in|O the|O production|O of|O neutrophils|O ,|O deletion|O of|O CSF3R|O leads|O to|O neutropenia|O in|O mouse|O models|O .|O
Epigenetic|O mutations|O are|O modifications|O that|O are|O reversible|O with|O therapy|O .|O
By|O definition|O ,|O mutations|O in|O this|O class|O of|O genes|O affect|O global|O chromatin|O landscapes|O and|O many|O genes|O and|O pathways|O are|O altered|O ;|O thus|O ,|O simple|O linear|O explanations|O are|O unlikely|O to|O precisely|O show|O how|O these|O mutations|O contribute|O to|O leukaemia|O development|O .|O
Illumina|O libraries|O were|O made|O from|O qualified|O fragmented|O gDNA|O with|O the|O use|O of|O NEBNext|O reagents|O (|O New|O England|O Biolabs|O )|O ,|O and|O the|O resulting|O libraries|O were|O subjected|O to|O exome|O enrichment|O with|O the|O use|O of|O NimbleGen|O SeqCap|O EZ|O Human|O Exome|O Library|O Version|O 2|O .|O 0|O (|O Roche|O NimbleGen|O )|O according|O to|O the|O manufacturer|O '|O s|O instructions|O .|O
These|O genotype|O -|O phenotype|O associations|O may|O reflect|O gene|O -|O specific|O functions|O of|O individual|O mutations|O .|O
Sanger|O sequencing|O analysis|O .|O
Figure|O 4|O .|O Kaplan|O -|O Meier|O analysis|O of|O survival|O of|O PMF|O patients|O stratified|O according|O to|O their|O driver|O mutation|O .|O Vertical|O tick|O marks|O indicate|O right|O -|O censored|O patients|O .|O In|O univariate|O analysis|O ,|O CALR|O -|O mutant|O patients|O had|O a|O better|O OS|O than|O JAK2|O -|O mutant|O (|O HR|O 2|O .|O 3|O ,|O P|O =|O .|O 001|O )|O ,|O MPL|O -|O mutant|O (|O HR|O 2|O .|O 6|O ,|O P|O =|O .|O 009|O )|O ,|O and|O triple|O -|O negative|O patients|O (|O HR|O 6|O .|O 2|O ,|O P|O =|O .|O 001|O )|O .|O Three|O JAK2|O -|O mutant|O patients|O had|O short|O follow|O -|O up|O and|O were|O not|O included|O in|O the|O analysis|O .|O
Hideki|O Makishima|O ;|O Valeria|O Visconte|O ;|O Hirotoshi|O Sakaguchi|O ;|O Anna|O M|O .|O Jankowska|O ;|O Sarah|O Abu|O Kar|O ;|O Andres|O Jerez|O ;|O Bartlomiej|O Przychodzen|O ;|O Manoj|O Bupathi|O ;|O Kathryn|O Guinta|O ;|O Manuel|O G|O .|O Afable|O ;|O Mikkael|O A|O .|O Sekeres|O ;|O Richard|O A|O .|O Padgett|O ;|O Ramon|O V|O .|O Tiu|O ;|O and|O Jaroslaw|O P|O .|O Maciejewski|O .|O
However|O ,|O these|O studies|O have|O used|O purified|O mutant|O protein|O alone|O ,|O and|O further|O studies|O of|O in|O vivo|O function|O in|O the|O presence|O of|O the|O wild|O -|O type|O allele|O are|O required|O to|O definitively|O establish|O the|O expression|O level|O and|O effect|O of|O R882|O and|O other|O mutations|O on|O normal|O enzymatic|O function|O .|O
Quantitative|O controls|O for|O the|O JAK2|O V617F|O mutation|O are|O commercially|O available|O (|O Horizon|O Discovery|O ,|O Cambridge|O ,|O UK|O ;|O Qiagen|O Marseille|O ,|O Marseille|O ,|O France|O )|O to|O serve|O as|O a|O quantitative|O or|O low|O -|O positive|O control|O .|O
The|O patient|O had|O 3|O sons|O and|O 2|O miscarriages|O .|O
Longer|O -|O term|O follow|O -|O up|O will|O be|O required|O to|O better|O define|O rates|O of|O AML|O transformation|O .|O
Mutations|O in|O other|O PRC2|O components|O are|O less|O common|O than|O EZH2|O mutations|O in|O patients|O with|O myeloid|O malignancies|O :|O 1|O .|O 4|O %|O of|O patients|O with|O PMF|O or|O MDS|O /|O MPN|O overlap|O disorders|O have|O SUZ12|O mutations|O and|O less|O than|O 1|O %|O have|O EED|O deletions|O or|O mutations|O .|O
In|O the|O ruxolitinib|O group|O ,|O patients|O with|O new|O -|O onset|O grade|O 3|O or|O 4|O anemia|O had|O symptomatic|O improvement|O similar|O to|O that|O in|O patients|O without|O anemia|O .|O
It|O has|O been|O shown|O that|O granulocytic|O isolation|O achieves|O ,|O on|O average|O ,|O only|O 15|O %|O higher|O JAK2|O allele|O burden|O compared|O with|O that|O of|O whole|O white|O blood|O cells|O .|O
Methods|O .|O
A|O JAK2|O exon|O -|O 12|O mutation|O screen|O may|O be|O warranted|O in|O patients|O who|O were|O JAK2V617F|O negative|O ,|O particularly|O in|O those|O with|O subnormal|O EPO|O levels|O .|O
Further|O study|O will|O be|O needed|O to|O clarify|O these|O possibilities|O and|O to|O understand|O how|O different|O genotypic|O combinations|O of|O leukaemia|O -|O associated|O disease|O alleles|O result|O in|O biologically|O ,|O therapeutically|O and|O prognostically|O distinct|O myeloid|O leukaemia|O phenotypes|O .|O
We|O then|O examined|O whether|O the|O mutation|O status|O for|O each|O gene|O was|O associated|O with|O clinical|O variables|O ,|O including|O specific|O cytopenias|O ,|O the|O proportion|O of|O blasts|O ,|O and|O overall|O survival|O .|O
Despite|O the|O demonstrated|O role|O of|O cohesin|O in|O mitosis|O ,|O the|O mechanism|O by|O which|O altered|O cohesin|O function|O leads|O to|O clonal|O expansion|O and|O malignant|O transformation|O has|O not|O been|O elucidated|O .|O
In|O addition|O ,|O the|O 2|O -|O year|O death|O rate|O in|O CR|O was|O significantly|O lower|O in|O the|O ambulatory|O arm|O (|O 0|O %|O vs|O .|O 5|O %|O ;|O P|O =|O .|O 04|O )|O and|O no|O differences|O were|O observed|O in|O the|O cumulative|O relapse|O rate|O between|O arms|O .|O
Absence|O of|O both|O BCR|O -|O ABL1|O and|O rearrangement|O of|O PDGFRA|O ,|O PDGFRB|O ,|O or|O FGFR1|O are|O minimal|O diagnostic|O requirements|O for|O CNL|O and|O aCML|O .|O
Current|O prognostic|O scoring|O systems|O consider|O karyotypic|O abnormalities|O and|O certain|O clinical|O features|O to|O stratify|O patients|O with|O myelodysplastic|O syndromes|O into|O risk|O groups|O .|O
Women|O who|O are|O pregnant|O or|O who|O are|O likely|O to|O become|O pregnant|O can|O be|O managed|O with|O aspirin|O and|O venesection|O but|O should|O use|O interferon|O (|O INF|O )|O -|O alpha|O in|O place|O of|O hydroxyurea|O when|O the|O later|O is|O indicated|O .|O
Nearly|O all|O SF3B1|O mutations|O are|O located|O in|O exon|O 14|O or|O 15|O ,|O most|O commonly|O at|O K700E|O .|O
These|O results|O seem|O to|O suggest|O that|O in|O patients|O with|O NK|O -|O AML|O without|O FLT3|O -|O ITD|O ,|O NPM1|O mutations|O confer|O a|O survival|O benefit|O only|O in|O the|O presence|O of|O concurrent|O IDH|O mutations|O .|O
Base|O calling|O was|O performed|O using|O Illumina|O RTA|O Version|O 1|O .|O 8|O using|O default|O settings|O .|O
Affecting|O at|O least|O eight|O components|O of|O the|O RNA|O splicing|O machinery|O ,|O mutations|O were|O found|O in|O 130|O of|O 228|O MDS|O (|O 57|O %|O )|O ,|O 48|O of|O 88|O CMML|O (|O 55|O %|O )|O and|O 16|O of|O 62|O secondary|O AML|O (|O 25|O .|O 8|O %|O )|O cases|O ,|O but|O relatively|O rare|O in|O de|O novo|O AML|O (|O 10|O /|O 151|O ;|O 6|O .|O 6|O %|O )|O and|O MPNs|O (|O 5|O /|O 53|O ;|O 9|O .|O 4|O %|O )|O .|O
The|O Patient|O Global|O Impression|O of|O Change|O and|O other|O patient|O -|O reported|O outcomes|O mirrored|O changes|O in|O symptom|O scores|O (|O Fig|O .|O
Clonal|O hierarchy|O analysis|O was|O performed|O to|O determine|O if|O cohesin|O complex|O gene|O variants|O were|O ancestral|O or|O secondary|O genetic|O events|O .|O
ABSTRACT|O .|O
Cohesin|O mutations|O did|O not|O alter|O the|O IPSS|O cytogenetic|O risk|O of|O MDS|O patients|O (|O the|O average|O IPSS|O cytogenetics|O score|O was|O 0|O .|O 55|O points|O for|O cohesin|O mutant|O cohort|O and|O 0|O .|O 60|O points|O for|O WT|O )|O .|O
Fusion|O genes|O involving|O the|O PDGFb|O receptor|O gene|O at|O 5q33|O are|O characterized|O by|O a|O distinct|O phenotype|O of|O CMML|O -|O eos|O .|O
A|O technique|O that|O is|O used|O for|O determining|O the|O extent|O and|O pattern|O of|O DNA|O methylation|O within|O and|O around|O individual|O genes|O or|O an|O entire|O genome|O .|O
Each|O of|O the|O prognostically|O significant|O mutations|O most|O likely|O alters|O the|O biologic|O characteristics|O and|O phenotype|O of|O myelodysplastic|O syndromes|O in|O unique|O ways|O ,|O as|O is|O the|O case|O for|O cytogenetic|O abnormalities|O ,|O with|O complex|O interactions|O among|O combinations|O of|O genetic|O and|O epigenetic|O lesions|O .|O
ASXL1|O mutations|O were|O detected|O in|O 87|O (|O 49|O %|O )|O out|O of|O 179|O analyzed|O patients|O ,|O 72|O %|O (|O 63|O )|O being|O male|O ,|O with|O a|O median|O age|O of|O 70|O years|O (|O range|O 27|O -|O 86|O years|O )|O .|O
In|O addition|O to|O translocations|O ,|O gene|O deletions|O and|O somatic|O mutations|O of|O ETV6|O have|O been|O identified|O in|O myeloid|O malignancies|O ,|O including|O MDS|O and|O AML|O ,|O with|O evidence|O that|O deletion|O of|O ETV6|O was|O frequently|O accompanied|O by|O monosomy|O 7|O .|O
The|O clinical|O significance|O of|O SRSF2|O mutations|O has|O also|O been|O explored|O .|O
PCR|O -|O SSCP|O Analysis|O .|O
Mutation|O of|O NRAS|O ,|O previously|O reported|O as|O a|O marker|O of|O poor|O prognosis|O ,|O did|O not|O influence|O survival|O in|O this|O model|O ,|O most|O likely|O owing|O to|O strong|O associations|O between|O oncogenic|O NRAS|O mutations|O and|O components|O of|O the|O IPSS|O .|O
Jason|O Gotlib|O ;|O Julia|O E|O .|O Maxson|O ;|O Tracy|O I|O .|O George|O ;|O Jeffrey|O W|O .|O Tyner|O .|O
Given|O the|O molecular|O heterogeneity|O of|O myeloid|O neoplasms|O ,|O precise|O establishment|O of|O the|O clinical|O impact|O of|O these|O leukemia|O disease|O alleles|O and|O their|O relevance|O to|O clinical|O phenotype|O ,|O somatic|O genotype|O ,|O and|O clinical|O outcome|O requires|O large|O patient|O cohorts|O with|O detailed|O clinical|O annotation|O .|O
Cohesin|O gene|O family|O sequence|O alterations|O in|O myeloid|O neoplasms|O .|O
Preliminary|O trials|O incorporating|O FLT3|O inhibitors|O either|O as|O part|O of|O induction|O or|O postremission|O therapy|O (|O including|O post|O -|O HSCT|O )|O continue|O ;|O however|O ,|O the|O agents|O currently|O under|O investigation|O have|O shown|O only|O minimal|O impact|O .|O
Table|O 1|O .|O Comparison|O of|O pretreatment|O characteristics|O between|O patients|O with|O and|O without|O mutations|O in|O the|O cohesin|O complex|O genes|O .|O
We|O have|O demonstrated|O that|O somatic|O alterations|O in|O cohesin|O complex|O genes|O occur|O in|O 11|O .|O 6|O %|O of|O patients|O with|O myeloid|O neoplasms|O in|O our|O cohort|O ,|O consistent|O with|O recent|O reports|O in|O smaller|O patient|O cohorts|O .|O
The|O presence|O of|O SETBP1|O mutation|O often|O accompanies|O leukocytosis|O ,|O monosomy|O 7|O /|O deletion|O of|O 7q|O ,|O isochromosome|O of|O 17p|O ,|O and|O mutations|O of|O ASXL1|O ,|O EZH2|O ,|O and|O SRSF2|O .|O
These|O enzymes|O include|O prolyl|O hydroxylases|O and|O chromatin|O -|O modifying|O enzymes|O (|O e|O .|O g|O .|O ,|O histone|O demethylases|O and|O TET|O -|O 5mC|O hydroxylases|O )|O .|O
No|O mutation|O hotspot|O was|O identified|O in|O any|O of|O the|O genes|O (|O Figure|O 1|O and|O supplemental|O Tables|O 2|O -|O 6|O )|O .|O
Such|O mutations|O probably|O constitute|O a|O new|O class|O of|O TSGs|O ubiquitously|O involved|O in|O leukemogenesis|O .|O
She|O underwent|O treatment|O with|O intensive|O chemotherapy|O that|O was|O complicated|O by|O pulmonary|O aspergillosis|O .|O
Two|O principle|O studies|O have|O helped|O to|O establish|O INF|O -|O alpha|O as|O an|O effective|O therapy|O .|O
Interestingly|O ,|O we|O found|O a|O strong|O correlation|O between|O the|O cohesin|O gene|O and|O NPM1|O mutations|O (|O 57|O %|O of|O cohesin|O gene|O mutated|O patients|O had|O an|O NPM1|O mutation|O ;|O 9|O .|O 5|O %|O of|O NPM1|O mutated|O patients|O had|O a|O cohesin|O gene|O mutation|O compared|O with|O 4|O %|O of|O NPM1|O wild|O -|O type|O patients|O ;|O P|O =|O .|O 029|O )|O (|O Table|O 1|O )|O .|O
Ficoll|O density|O centrifugation|O should|O be|O avoided|O ,|O because|O it|O depletes|O the|O granulocytic|O population|O (|O which|O carries|O the|O mutations|O )|O .|O
Four|O of|O the|O 5|O cell|O lines|O (|O 80|O %|O )|O displayed|O the|O aberrant|O transcripts|O ;|O all|O 5|O displayed|O the|O normal|O transcript|O (|O Fig|O .|O 1B|O )|O .|O In|O addition|O ,|O four|O of|O the|O 30|O normal|O volunteers|O (|O 13|O %|O )|O exhibited|O both|O a|O normal|O and|O an|O aberrant|O fragments|O (|O Fig|O .|O 1A|O )|O .|O
Therapy|O -|O related|O myeloid|O leukemia|O (|O secondary|O MDS|O /|O AML|O )|O is|O a|O well|O -|O recognized|O consequence|O of|O cancer|O treatment|O in|O a|O proportion|O of|O patients|O receiving|O cytotoxic|O therapy|O for|O solid|O tumors|O or|O hematologic|O malignancies|O .|O
These|O mutations|O alter|O pre|O -|O mRNA|O splicing|O patterns|O .|O
Cytogenetics|O .|O
ABSTRACT|O .|O
In|O a|O European|O Group|O for|O Blood|O and|O Marrow|O Transplantation|O (|O EBMT|O )|O trial|O ,|O patients|O with|O high|O -|O risk|O myelodysplasia|O or|O AML|O evolving|O from|O myelodysplasia|O who|O received|O allogeneic|O HSCT|O without|O prior|O cytarabinebased|O chemotherapy|O had|O a|O 3|O -|O year|O DFS|O rate|O of|O 34|O %|O .|O
The|O clinical|O evolution|O in|O MDS|O or|O AML|O of|O patients|O with|O germline|O GATA2|O mutations|O is|O frequently|O associated|O with|O a|O partial|O or|O complete|O deletion|O of|O chromosome|O 7|O :|O 6|O of|O 11|O patients|O in|O our|O study|O (|O 2|O with|O the|O R330X|O mutation|O ,|O 1|O with|O the|O A372T|O mutation|O ,|O 2|O with|O the|O R396Q|O mutation|O ,|O and|O 1|O with|O deletion|O of|O GATA2|O locus|O )|O ,|O 4|O of|O 10|O patients|O in|O Kazenwadel|O et|O al|O (|O T354M|O ,|O 2|O distinct|O large|O deletions|O of|O GATA2|O locus|O and|O a|O frameshift|O starting|O from|O L332|O )|O ,|O 6|O of|O 28|O patients|O in|O Hahn|O et|O al|O (|O T354M|O or|O deletion|O of|O T355|O )|O ,|O and|O the|O case|O described|O by|O Bodor|O et|O al|O (|O T354M|O )|O ,|O suggesting|O that|O the|O monosomy|O 7q|O is|O a|O recurrent|O secondary|O event|O linked|O to|O the|O overt|O transformation|O .|O
At|O a|O median|O follow|O -|O up|O of|O 15|O months|O ,|O considering|O all|O 226|O patients|O ,|O 176|O (|O 78|O %|O )|O deaths|O and|O 32|O (|O 14|O %|O )|O LTs|O were|O documented|O .|O
Statistical|O analyses|O .|O
Mechanistic|O analyses|O provided|O evidence|O for|O crossregulatory|O and|O autoregulatory|O interactions|O among|O components|O of|O this|O complex|O ,|O including|O GATA2|O induction|O of|O the|O hematopoietic|O corepressor|O ETO2|O ,|O and|O an|O ETO2|O negative|O autoregulatory|O loop|O .|O
Genetic|O evaluation|O finally|O identified|O a|O heterozygous|O missense|O GATA2|O A372T|O mutation|O (|O c|O .|O 1114G|O >|O A|O ,|O supplemental|O Figure|O 1|O )|O .|O
Below|O is|O a|O summary|O of|O frequently|O mutated|O genes|O in|O MDS|O relevant|O to|O this|O pathway|O and|O their|O consequences|O .|O
Consequently|O ,|O we|O sequenced|O 120|O cases|O for|O ZRSR2|O ,|O LUC7L2|O ,|O and|O PRPF8|O and|O a|O total|O 310|O for|O SF3B1|O ,|O U2AF1|O ,|O and|O SRSF2|O .|O
Interestingly|O ,|O we|O found|O a|O similar|O mutation|O burden|O between|O NPM1|O and|O genes|O of|O the|O cohesin|O complex|O in|O most|O patients|O (|O supplemental|O Figure|O 1|O )|O ,|O suggesting|O that|O cohesin|O gene|O mutations|O occurred|O in|O the|O same|O clone|O as|O NPM1|O mutations|O .|O
We|O estimated|O the|O time|O to|O development|O of|O anemia|O (|O here|O defined|O as|O a|O hemoglobin|O level|O <|O 10|O g|O /|O dL|O )|O ,|O thrombocytopenia|O (|O platelet|O [|O PLT|O ]|O count|O <|O 100|O x|O 109|O /|O L|O )|O ,|O and|O marked|O leukocytosis|O (|O white|O blood|O cell|O [|O WBC|O ]|O count|O >|O 25|O x|O 109|O /|O L|O )|O using|O a|O competing|O risk|O approach|O .|O
Aspirin|O for|O thromboprophylaxis|O in|O PV|O was|O previously|O limited|O because|O of|O a|O documented|O risk|O of|O gastrointestinal|O bleeding|O with|O high|O doses|O (|O 900|O mg|O /|O day|O )|O .|O
The|O median|O time|O to|O AML|O progression|O was|O 6|O .|O 8|O months|O in|O patients|O with|O C|O -|O terminal|O mutations|O compared|O with|O 28|O .|O 3|O months|O in|O those|O without|O mutations|O (|O P|O =|O 0|O .|O 022|O )|O .|O
A|O quantitative|O assay|O or|O a|O reasonably|O sensitive|O qualitative|O assay|O is|O therefore|O essential|O for|O capturing|O the|O cases|O with|O low|O levels|O of|O the|O mutation|O .|O
P|O ,|O P|O value|O from|O univariate|O or|O multivariate|O Cox|O proportional|O hazards|O models|O .|O
N|O -|O ZnF|O contributes|O to|O the|O stabilization|O and|O specificity|O of|O DNA|O binding|O ,|O and|O mediates|O the|O formation|O of|O complexes|O with|O cofactors|O .|O
Dosing|O should|O aim|O to|O decrease|O platelets|O below|O 400|O x|O 109|O /|O L|O and|O maintain|O leukocytes|O above|O 2|O x|O 109|O /|O L|O .|O
Inclusion|O in|O the|O current|O study|O required|O the|O availability|O of|O demographic|O ,|O clinical|O ,|O and|O hematologic|O data|O at|O diagnosis|O (|O age|O ,|O evaluation|O of|O constitutional|O symptoms|O ,|O hemoglobin|O level|O ,|O white|O blood|O cell|O count|O ,|O and|O percentage|O of|O blasts|O in|O peripheral|O blood|O )|O that|O allow|O calculation|O of|O IPSS|O ,|O and|O at|O least|O 1|O DNA|O sample|O to|O assess|O mutation|O status|O of|O the|O 3|O driver|O genes|O :|O JAK2|O ,|O MPL|O ,|O and|O CALR|O .|O
Table|O 1|O .|O Clinical|O characteristics|O of|O patients|O with|O cohesin|O family|O gene|O defects|O .|O
These|O sites|O regulate|O the|O expression|O of|O specific|O genes|O that|O govern|O physiological|O cell|O identity|O and|O pluripotency|O /|O self|O -|O renewal|O in|O malignancy|O and|O in|O embryonic|O stem|O cells|O .|O
RNA|O splicing|O provides|O a|O basic|O cellular|O mechanism|O for|O expression|O of|O genetic|O information|O .|O
Three|O years|O later|O ,|O at|O age|O 14|O ,|O her|O second|O child|O (|O patient|O number|O 6225|O ;|O P1|O ,|O III|O ,|O 3|O )|O developed|O an|O AML|O M2|O associated|O with|O myelodysplasia|O -|O related|O changes|O with|O a|O similar|O cytologic|O presentation|O to|O his|O mother|O .|O
Two|O papers|O have|O provided|O new|O insights|O into|O GATA2|O regulatory|O networks|O by|O conducting|O a|O comprehensive|O analysis|O of|O GATA2|O binding|O sites|O by|O chromatin|O immunoprecipitation|O (|O ChIP|O )|O ,|O a|O powerful|O method|O for|O studying|O transcription|O factor|O function|O .|O
A|O higher|O allelic|O burden|O in|O PV|O is|O associated|O with|O pruritus|O and|O increased|O splenomegaly|O ,|O and|O has|O been|O implicated|O in|O myelofibrotic|O transformation|O .|O
As|O EZH2|O functions|O as|O a|O histone|O methyltransferase|O ,|O abnormal|O histone|O modification|O may|O contribute|O to|O epigenetic|O deregulation|O in|O MDS|O .|O
In|O addition|O ,|O another|O study|O indicated|O that|O BCOR|O mutations|O were|O more|O frequently|O found|O in|O AML|O with|O normal|O karyotype|O (|O 17|O .|O 1|O %|O )|O than|O in|O unselected|O cases|O (|O 3|O .|O 8|O %|O )|O ,|O but|O with|O no|O differences|O among|O low|O -|O or|O high|O -|O risk|O MDS|O subgroups|O according|O to|O IPSS|O score|O .|O
Given|O the|O essential|O role|O of|O the|O GATA2|O transcription|O factor|O in|O hematopoiesis|O ,|O it|O is|O crucial|O to|O elucidate|O its|O mechanisms|O and|O the|O full|O spectrum|O of|O target|O genes|O that|O mediate|O its|O activity|O .|O
Methylation|O of|O CpG|O islands|O and|O '|O shores|O '|O within|O promoter|O regions|O leads|O to|O transcriptional|O silencing|O through|O binding|O of|O methyl|O -|O DNA|O -|O binding|O proteins|O and|O chromatin|O modifying|O enzymes|O .|O
In|O patients|O who|O have|O symptomatic|O splenomegaly|O ,|O hydroxyurea|O (|O 500|O mg|O t|O .|O i|O .|O d|O .|O )|O should|O be|O used|O .|O
Mutation|O was|O absent|O in|O a|O cohort|O of|O 250|O unaffected|O donors|O .|O
In|O the|O analysis|O of|O prognostic|O factors|O ,|O variables|O included|O were|O age|O ,|O sex|O ,|O hemoglobin|O ,|O white|O blood|O cell|O count|O (|O WBC|O )|O ,|O absolute|O neutrophil|O count|O ,|O absolute|O monocyte|O count|O (|O AMC|O )|O ,|O ALC|O ,|O platelet|O count|O ,|O PB|O and|O BM|O blasts|O ,|O circulating|O IMC|O ,|O BM|O cellularity|O ,|O percentage|O of|O BM|O ring|O sideroblasts|O ,|O WHO|O morphological|O subcategories|O (|O CMML|O -|O 1|O vs|O CMML|O -|O 2|O )|O ,|O karyotype|O groups|O based|O on|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O ,|O MDAPS|O and|O G|O -|O MDAPS|O prognostic|O risk|O categories|O ,|O ASXL1|O mutations|O and|O spliceosome|O component|O mutations|O ,|O involving|O SF3B1|O ,|O SRSF2|O and|O U2AF35|O (|O also|O referred|O to|O as|O U2AF1|O )|O .|O
ABSTRACT|O .|O
Their|O results|O suggest|O that|O the|O study|O of|O this|O transcription|O factor|O and|O its|O downstream|O targets|O may|O uncover|O a|O regulatory|O network|O important|O for|O coronary|O artery|O disease|O inheritance|O .|O
Occasionally|O ,|O patients|O with|O both|O myeloid|O and|O lymphoid|O markers|O at|O diagnosis|O (|O biphenotypic|O leukemia|O )|O may|O experience|O response|O to|O ALL|O therapy|O if|O an|O AML|O induction|O regimen|O failed|O .|O
3|O .|O STRUCTURE|O AND|O PROPERTIES|O OF|O GATA2|O .|O
To|O ensure|O that|O more|O than|O 90|O %|O of|O cases|O are|O detected|O ,|O the|O adequate|O analytical|O sensitivity|O of|O a|O clinical|O JAK2|O assay|O should|O be|O at|O least|O 1|O %|O .|O
Representations|O generated|O by|O HpaII|O and|O by|O MspI|O restriction|O enzyme|O digestion|O of|O the|O genome|O followed|O by|O ligation|O -|O mediated|O PCR|O are|O compared|O to|O generate|O maps|O of|O methylation|O abundance|O and|O distribution|O .|O
Mayo|O prognostic|O model|O for|O WHO|O -|O defined|O chronic|O myelomonocytic|O leukemia|O :|O ASXL1|O and|O spliceosome|O component|O mutations|O and|O outcomes|O .|O
Although|O one|O study|O has|O described|O this|O as|O a|O PCR|O artefact|O ,|O as|O it|O is|O not|O found|O in|O germline|O DNAs|O ,|O control|O DNAs|O or|O other|O studied|O types|O of|O cancers|O ,|O it|O is|O generally|O considered|O to|O be|O a|O bona|O fide|O mutation|O .|O
The|O frequent|O evolution|O to|O MDS|O and|O AML|O in|O these|O patients|O reveals|O the|O importance|O of|O screening|O GATA2|O in|O chronic|O neutropenia|O associated|O with|O monocytopenia|O because|O of|O the|O frequent|O hematopoietic|O transformation|O ,|O variable|O clinical|O expression|O at|O onset|O ,|O and|O the|O need|O for|O aggressive|O therapy|O in|O patients|O with|O poor|O clinical|O outcome|O .|O
Conversely|O ,|O high|O FOG1|O levels|O in|O maturing|O erythroid|O /|O megakaryocytic|O cells|O inhibit|O GATA2|O expression|O ,|O leading|O to|O further|O elevation|O of|O FOG1|O and|O reduced|O GATA2|O expression|O .|O
Precise|O spatio|O -|O temporal|O control|O of|O GATA1|O and|O GATA2|O expression|O is|O required|O in|O early|O hematopoietic|O progenitors|O to|O determine|O erythroid|O /|O megakaryocyte|O versus|O granulocyte|O /|O monocyte|O lineage|O output|O ,|O as|O well|O as|O in|O the|O subsequent|O differentiation|O of|O erythroid|O cells|O and|O megakaryocytes|O .|O
As|O mentioned|O above|O ,|O ASXL1|O and|O spliceosome|O component|O mutations|O had|O no|O impact|O on|O OS|O .|O
These|O patients|O were|O entered|O into|O the|O multicenter|O treatment|O trial|O AML|O SHG|O 0199|O (|O #|O NCT00209833|O ,|O June|O 1999|O to|O September|O 2004|O ,|O n|O =|O 276|O )|O or|O AML|O SHG|O 0295|O (|O February|O 1995|O to|O May|O 1999|O ,|O n|O =|O 113|O )|O for|O whom|O pretreatment|O cell|O samples|O were|O available|O .|O
One|O approach|O to|O improving|O the|O IPSS|O would|O be|O to|O include|O one|O additional|O variable|O :|O the|O presence|O or|O absence|O of|O a|O mutation|O in|O any|O of|O the|O five|O genes|O with|O independent|O prognostic|O significance|O .|O
Therefore|O ,|O ASXL1|O mutations|O represent|O a|O relatively|O frequent|O and|O independent|O prognostic|O biomarker|O in|O myeloid|O malignancies|O .|O
DNMT3A|O also|O forms|O complexes|O with|O DNMT3L|O ,|O a|O DNMT|O family|O member|O that|O lacks|O a|O methyltransferase|O catalytic|O domain|O ;|O formation|O of|O the|O DNMT3A|O -|O DNMT3L|O complex|O results|O in|O increased|O DNMT3A|O activity|O .|O
Patnaik|O et|O al|O identified|O JAK2|O mutations|O in|O 6|O .|O 4|O %|O of|O patients|O with|O isolated|O del|O (|O 5q|O )|O MDS|O (|O 5|O of|O 77|O patients|O )|O ,|O with|O JAK2|O V617F|O allele|O burden|O ranging|O from|O 1|O %|O to|O 10|O %|O .|O
PCR|O products|O were|O separated|O by|O electrophoresis|O at|O 70|O W|O for|O 2|O hr|O in|O 6|O %|O denaturing|O polyacrylamide|O gels|O containing|O 7|O M|O urea|O .|O Gels|O were|O dried|O and|O autoradiographed|O for|O 6|O -|O 18|O hr|O .|O
The|O process|O of|O haematopoietic|O differentiation|O from|O haematopoietic|O stem|O cells|O to|O mature|O granulocytes|O ,|O monocytes|O ,|O erythroid|O cells|O and|O megakaryocytes|O .|O
Cohesin|O defects|O were|O associated|O with|O poor|O overall|O survival|O (|O 27|O .|O 2|O vs|O 40|O months|O ;|O P|O =|O .|O 023|O )|O ,|O especially|O in|O STAG2|O mutant|O MDS|O patients|O surviving|O >|O 12|O months|O (|O median|O survival|O 35|O vs|O 50|O months|O ;|O P|O =|O .|O 017|O )|O .|O
Although|O germline|O mutations|O in|O SMC1A|O ,|O SMC3|O ,|O and|O RAD21|O have|O been|O associated|O with|O cohesinopathies|O ,|O pathogenic|O STAG1|O germline|O mutations|O have|O not|O been|O reported|O .|O
These|O are|O then|O cleaved|O by|O an|O endonuclease|O ,|O and|O the|O resulting|O single|O -|O strand|O break|O can|O then|O be|O processed|O by|O either|O short|O -|O patch|O BER|O (|O through|O which|O a|O single|O nucleotide|O is|O replaced|O )|O or|O long|O -|O patch|O BER|O (|O through|O which|O 2|O -|O 10|O new|O nucleotides|O are|O synthesized|O )|O .|O
The|O selected|O observations|O were|O validated|O by|O targeted|O deep|O sequencing|O using|O MiSeq|O .|O
Table|O 1|O .|O Clinicohematological|O characteristics|O and|O mutation|O patterns|O of|O patients|O with|O RUNX1|O mutations|O at|O initial|O diagnosis|O of|O CMML|O .|O
Imai|O et|O al|O .|O found|O that|O one|O of|O five|O CMML|O patients|O examined|O had|O V105X|O mutation|O and|O Nakao|O et|O al|O .|O reported|O that|O one|O out|O of|O eight|O patients|O with|O CMML|O had|O RUNX1|O mutation|O .|O
Figure|O 4|O .|O Analysis|O of|O clonal|O hierarchy|O points|O toward|O cohesin|O as|O a|O secondary|O mutation|O .|O (|O A|O -|O B|O )|O Exemplary|O serial|O samples|O illustrating|O clonal|O architecture|O of|O cohesin|O family|O genes|O .|O (|O C|O )|O VAFs|O of|O STAG2|O mutations|O by|O deep|O sequencing|O in|O serial|O samples|O .|O For|O each|O STAG2|O mutant|O patient|O with|O available|O serial|O samples|O ,|O the|O VAF|O in|O each|O sampling|O is|O shown|O .|O Although|O only|O 2|O patients|O were|O found|O to|O harbor|O a|O STAG2|O mutation|O in|O the|O dominant|O clone|O at|O the|O first|O time|O point|O ,|O 7|O out|O of|O 8|O patients|O (|O 87|O .|O 5|O %|O )|O who|O were|O initially|O found|O to|O have|O a|O subclonal|O STAG2|O mutation|O underwent|O clonal|O expansion|O ,|O becoming|O the|O dominant|O clone|O at|O the|O time|O of|O transformation|O (|O P|O =|O .|O 05|O )|O .|O (|O D|O )|O VAFs|O of|O SMC3|O and|O RAD21|O mutations|O by|O deep|O sequencing|O in|O serial|O samples|O .|O For|O 4|O patients|O with|O SMC3|O mutations|O and|O the|O 1|O patient|O with|O a|O RAD21|O mutation|O with|O available|O serial|O samples|O ,|O the|O VAF|O in|O each|O sampling|O is|O shown|O .|O All|O of|O these|O 5|O patients|O harbored|O subclonal|O cohesin|O mutations|O at|O the|O first|O time|O point|O ,|O with|O 2|O out|O of|O 4|O (|O 50|O %|O )|O of|O the|O SMC3|O mutant|O patients|O and|O the|O 1|O out|O of|O 1|O RAD21|O mutant|O patient|O undergoing|O clonal|O expansion|O ,|O becoming|O the|O dominant|O clone|O at|O the|O time|O of|O transformation|O .|O
Splenic|O irradiation|O when|O using|O either|O 100|O -|O 500|O cGy|O in|O 5|O -|O 10|O fractions|O or|O 100|O cGy|O in|O 4|O fractions|O may|O help|O transiently|O reduce|O spleen|O size|O .|O
The|O first|O JAK2|O mutation|O (|O JAK2|O -|O V617F|O )|O was|O identified|O in|O patients|O with|O MPN|O and|O was|O found|O to|O be|O an|O activating|O mutation|O within|O the|O JH2|O pseudokinase|O domain|O (|O reviewed|O in|O REF|O .|O 92|O )|O .|O
Within|O our|O cohort|O ,|O we|O analyzed|O response|O to|O therapeutic|O interventions|O of|O lenalidomide|O (|O n|O =|O 92|O ;|O supplemental|O Table|O 7|O )|O or|O the|O hypomethylating|O agents|O (|O HMAs|O )|O decitabine|O and|O azacitidine|O (|O n|O =|O 140|O ;|O Table|O 2|O )|O .|O
The|O panel|O uniformly|O endorsed|O allogeneic|O HSCT|O with|O matched|O sibling|O or|O matched|O unrelated|O donor|O (|O including|O cord|O blood|O )|O or|O clinical|O trial|O as|O consolidation|O therapy|O for|O patients|O with|O poor|O -|O risk|O cytogenetics|O or|O molecular|O abnormalities|O .|O
The|O discovery|O that|O the|O TET|O family|O of|O enzymes|O places|O novel|O modifications|O on|O cytosine|O -|O methylated|O DNA|O has|O led|O to|O rapidly|O increasing|O insight|O into|O the|O biological|O function|O of|O modified|O DNA|O cytosine|O residues|O .|O
The|O starting|O dose|O of|O ruxolitinib|O depended|O on|O the|O baseline|O platelet|O count|O :|O 15|O mg|O twice|O daily|O for|O a|O platelet|O count|O of|O 100x109|O to|O 200x109|O per|O liter|O and|O 20|O mg|O twice|O daily|O for|O a|O count|O that|O exceeded|O 200x109|O per|O liter|O .|O
Clinical|O and|O biologic|O annotations|O of|O the|O samples|O have|O been|O declared|O to|O the|O Comite|O National|O Informatique|O et|O Libertes|O .|O
In|O addition|O to|O regulating|O normal|O neutrophil|O homeostasis|O ,|O G|O -|O CSF|O levels|O rapidly|O increase|O during|O infection|O ,|O resulting|O in|O elevated|O levels|O of|O neutrophils|O as|O a|O component|O of|O the|O immune|O response|O .|O
Direct|O Sanger|O sequencing|O or|O pyrosequencing|O has|O been|O used|O for|O assessment|O of|O JAK2|O and|O MPL|O mutations|O .|O
The|O PcG|O member|O that|O has|O been|O most|O frequently|O implicated|O in|O the|O pathogenesis|O of|O human|O malignancies|O is|O EZH2|O ,|O the|O enzymatic|O component|O of|O the|O PRC2|O complex|O .|O
A|O multivariable|O analysis|O that|O included|O all|O three|O mutations|O as|O covariates|O confirmed|O their|O inter|O -|O independent|O prognostic|O value|O :|O HR|O was|O 1|O .|O 91|O (|O 95|O %|O CI|O :|O 1|O .|O 1|O -|O 3|O .|O 36|O ;|O P|O =|O 0|O .|O 025|O )|O for|O EZH2|O ,|O 2|O .|O 21|O (|O 95|O %|O CI|O :|O 1|O .|O 57|O -|O 3|O .|O 11|O ;|O P|O <|O 0|O .|O 0001|O )|O for|O ASXL1|O and|O 2|O .|O 6|O (|O 95|O %|O CI|O :|O 1|O .|O 63|O -|O 41|O .|O 6|O ;|O P|O <|O 0|O .|O 0001|O )|O for|O SRSF2|O mutations|O .|O
Initial|O analysis|O was|O performed|O on|O 483|O European|O patients|O studied|O within|O 1|O year|O of|O diagnosis|O ;|O the|O seminal|O observations|O were|O subsequently|O validated|O in|O an|O independent|O cohort|O of|O 396|O patients|O studied|O at|O time|O of|O referral|O (|O including|O both|O newly|O and|O previously|O diagnosed|O patients|O )|O to|O the|O Mayo|O Clinic|O and|O receiving|O treatment|O according|O to|O current|O practice|O .|O
No|O aberrant|O splice|O variants|O were|O detected|O using|O primers|O from|O exon|O 11|O to|O exon|O 13|O or|O when|O exon|O 11|O to|O exon|O 20|O primers|O were|O used|O (|O Supplementary|O Methods|O )|O .|O
Outcomes|O were|O poor|O for|O patients|O with|O monosomal|O karyotype|O at|O baseline|O (|O n|O =|O 83|O )|O ,|O although|O the|O high|O -|O dose|O regimen|O was|O associated|O with|O significantly|O improved|O rates|O of|O 5|O -|O year|O EFS|O (|O 13|O %|O vs|O .|O 0|O %|O ;|O P|O =|O .|O 02|O )|O and|O OS|O (|O 16|O %|O vs|O .|O 0|O %|O ;|O P|O =|O .|O 02|O )|O compared|O with|O those|O of|O the|O intermediate|O -|O dose|O in|O this|O subgroup|O .|O
Given|O the|O controversy|O surrounding|O the|O c|O .|O 1934dupG|O ;|O p|O .|O Gly646TrpfsX12|O ASXL1|O mutation|O ,|O we|O reanalyzed|O our|O cohort|O after|O excluding|O these|O patients|O and|O found|O no|O differences|O in|O our|O observations|O .|O
Since|O GATA2|O levels|O decreased|O with|O differentiation|O in|O each|O of|O the|O various|O hematopoietic|O sub|O -|O lineages|O ,|O this|O pattern|O might|O reflect|O the|O ability|O of|O overexpressed|O or|O activated|O GATA2|O to|O suppress|O normal|O differentiation|O and|O promote|O leukemic|O transformation|O .|O
Recently|O ,|O Ayala|O et|O al|O detected|O GATA2|O expression|O by|O quantitative|O real|O -|O time|O PCR|O in|O 52|O %|O (|O 21|O /|O 41|O )|O cases|O ;|O however|O ,|O their|O data|O referred|O to|O patients|O that|O express|O GATA2|O ,|O instead|O of|O patients|O with|O GATA2|O overexpression|O .|O
When|O transfusion|O support|O is|O required|O ,|O leukocyte|O -|O depleted|O blood|O products|O should|O be|O used|O for|O transfusion|O .|O
The|O mechanism|O by|O which|O this|O occurs|O and|O the|O presumed|O targets|O of|O epigenetic|O modification|O remain|O elusive|O .|O
These|O data|O suggest|O that|O somatic|O alterations|O in|O epigenetic|O regulators|O are|O a|O common|O genetic|O event|O in|O myeloid|O malignancies|O and|O contribute|O to|O haematopoietic|O transformation|O .|O
The|O molecular|O consequences|O of|O the|O mutations|O identified|O here|O can|O be|O classified|O in|O 2|O distinct|O groups|O ,|O the|O first|O with|O mutations|O located|O in|O or|O close|O to|O the|O second|O GATA2|O zinc|O finger|O (|O A372T|O mutation|O in|O P2|O located|O between|O the|O third|O [|O C370|O ]|O and|O fourth|O [|O C373|O ]|O cysteines|O of|O the|O zinc|O finger|O ,|O M388V|O in|O P3|O and|O R396Q|O in|O P1|O )|O and|O the|O second|O with|O the|O complete|O loss|O of|O 1|O allele|O of|O GATA2|O (|O P7|O )|O or|O creation|O of|O a|O stop|O codon|O leading|O to|O the|O loss|O of|O the|O second|O zinc|O finger|O (|O R330X|O mutation|O in|O P4|O located|O in|O the|O first|O zinc|O finger|O ,|O R204X|O [|O P5|O ]|O and|O E224X|O [|O P6|O ]|O mutations|O leading|O to|O the|O loss|O of|O the|O 2|O zinc|O fingers|O )|O .|O
This|O will|O also|O be|O informative|O regarding|O the|O extent|O to|O which|O CSF3R|O mutation|O is|O a|O primary|O driver|O of|O disease|O .|O
Interestingly|O ,|O the|O IDH2|O -|O R172|O mutation|O seemed|O to|O be|O mutually|O exclusive|O with|O NPM1|O mutations|O and|O FLT3|O -|O ITD|O .|O
Minor|O infections|O were|O defined|O as|O those|O for|O which|O patients|O did|O not|O seek|O medical|O attention|O (|O eg|O ,|O stomatologic|O ,|O ear|O ,|O nose|O ,|O and|O throat|O infections|O )|O .|O
This|O phosphorylation|O causes|O downregulation|O of|O PRMT5|O activity|O and|O blocks|O the|O specific|O interaction|O of|O PRMT5|O with|O methylosome|O protein|O 50|O (|O MEP50|O )|O .|O
Median|O overall|O survival|O was|O 17|O .|O 7|O years|O in|O CALR|O -|O mutant|O ,|O 9|O .|O 2|O years|O in|O JAK2|O -|O mutant|O ,|O 9|O .|O 1|O years|O in|O MPL|O -|O mutant|O ,|O and|O 3|O .|O 2|O years|O in|O triple|O -|O negative|O patients|O .|O
Figure|O 6|O .|O Kaplan|O -|O Meier|O analysis|O of|O survival|O of|O PMF|O patients|O stratified|O according|O to|O the|O risk|O categories|O defined|O by|O a|O clinical|O -|O molecular|O prognostic|O model|O .|O This|O model|O includes|O the|O variables|O reported|O in|O Table|O 2|O ,|O that|O is|O ,|O IPSS|O variables|O plus|O CALR|O ,|O JAK2|O ,|O and|O MPL|O mutation|O status|O .|O We|O assigned|O each|O factor|O an|O integer|O weight|O according|O to|O the|O corresponding|O HR|O in|O the|O multivariable|O -|O Cox|O regression|O of|O Table|O 2|O .|O Scores|O were|O then|O recoded|O into|O the|O 5|O risk|O categories|O shown|O in|O this|O figure|O :|O details|O are|O reported|O in|O the|O last|O section|O of|O "|O Results|O .|O "|O Based|O on|O the|O Akaike|O information|O criterion|O ,|O which|O compares|O quality|O of|O models|O ,|O the|O clinical|O -|O molecular|O model|O provided|O a|O better|O stratification|O than|O the|O IPSS|O .|O This|O analysis|O serves|O as|O a|O proof|O of|O concept|O that|O accounting|O for|O driver|O mutations|O improves|O the|O risk|O stratification|O provided|O by|O IPSS|O .|O
These|O mutations|O have|O been|O reported|O to|O result|O in|O a|O decreased|O global|O 5hmC|O level|O with|O a|O concomitant|O increase|O in|O 5mC|O genomic|O DNA|O .|O
The|O highest|O frequency|O (|O 33|O .|O 7|O %|O )|O of|O mutations|O was|O found|O in|O patients|O with|O cytogenetically|O normal|O AML|O .|O
We|O identified|O a|O heterozygous|O missense|O GATA2|O M388V|O mutation|O (|O c|O .|O 1162A|O >|O G|O ,|O supplemental|O Figure|O 1|O )|O .|O
Recent|O studies|O have|O also|O identified|O subclonal|O mutations|O in|O genes|O like|O ASXL1|O ,|O SRSF2|O ,|O EZH2|O ,|O IDH1|O ,|O and|O IDH2|O ,|O which|O are|O commonly|O associated|O with|O disease|O progression|O and|O identify|O PMF|O patients|O at|O high|O risk|O for|O leukemic|O transformation|O or|O premature|O death|O .|O
Examination|O of|O log|O (|O 2log|O )|O survival|O plots|O and|O partial|O residuals|O confirmed|O that|O the|O underlying|O assumption|O of|O proportional|O hazards|O was|O met|O except|O in|O the|O case|O wherein|O survival|O curves|O are|O equal|O during|O the|O first|O 12|O months|O and|O separate|O drastically|O thereafter|O (|O Figure|O 3|O )|O ;|O we|O therefore|O dichotomized|O follow|O -|O up|O into|O before|O and|O after|O 12|O months|O .|O
Multivariate|O analysis|O consisting|O of|O age|O ,|O IPSS|O score|O ,|O transfusion|O dependency|O ,|O and|O mutational|O status|O indicated|O that|O the|O presence|O of|O a|O BCOR|O mutation|O was|O an|O independent|O unfavorable|O prognostic|O factor|O for|O OS|O .|O
However|O ,|O the|O lower|O repopulation|O of|O mutant|O -|O transduced|O stem|O cells|O raises|O a|O serious|O difficulty|O to|O our|O understanding|O of|O how|O U2AF35|O mutated|O cells|O achieve|O clonal|O dominance|O over|O the|O remaining|O normal|O hematopoietic|O cells|O ,|O although|O some|O oncogenes|O ,|O such|O as|O oncogenic|O RAS|O ,|O have|O been|O shown|O to|O induce|O apoptosis|O rather|O than|O transformation|O and|O promotion|O of|O cell|O growth|O depending|O on|O cell|O contexts|O .|O
In|O vitro|O data|O suggest|O that|O DNA|O methyltransferase|O inhibitors|O (|O DNMTIs|O ;|O e|O .|O g|O .|O ,|O decitabine|O and|O azacitidine|O )|O suppress|O the|O protein|O expression|O of|O DNMT1|O and|O DNMT3A|O ,|O followed|O by|O suppression|O of|O growth|O and|O methylation|O in|O leukemic|O cell|O lines|O ,|O whereas|O DNMT3B|O mutations|O have|O been|O identified|O in|O inherited|O immunodeficiency|O ,|O centrosome|O instability|O ,|O and|O facial|O anomalies|O (|O ICF|O syndrome|O )|O .|O
The|O National|O Comprehensive|O Cancer|O Network|O (|O NCCN|O )|O makes|O no|O representation|O or|O warranties|O of|O any|O kind|O regarding|O their|O content|O ,|O use|O ,|O or|O application|O and|O disclaims|O any|O responsibility|O for|O their|O applications|O or|O use|O in|O any|O way|O .|O
Another|O gene|O recently|O described|O to|O be|O mutated|O in|O clonal|O hematological|O diseases|O is|O ASXL1|O on|O chromosome|O 20q11|O .|O 1|O .|O
Taken|O together|O ,|O these|O data|O suggest|O that|O the|O classical|O twohit|O model|O of|O myeloid|O malignancy|O pathogenesis|O must|O be|O modified|O to|O account|O for|O novel|O classes|O of|O mutant|O disease|O alleles|O ,|O most|O notably|O mutations|O in|O epigenetic|O modifiers|O .|O
In|O the|O present|O study|O ,|O we|O describe|O the|O initial|O identification|O by|O exome|O sequencing|O of|O GATA2|O mutation|O in|O a|O mother|O and|O her|O 3|O children|O associated|O with|O a|O prior|O history|O of|O chronic|O mild|O neutropenia|O evolving|O to|O AML|O and|O /|O or|O MDS|O .|O
ASSOCIATIONS|O OF|O MUTATIONS|O WITH|O OVERALL|O SURVIVAL|O .|O
Although|O targeting|O of|O BCORL1|O mutations|O to|O the|O expressed|O allele|O in|O female|O AML|O patients|O was|O not|O formally|O demonstrated|O by|O Li|O et|O al|O ,|O the|O above|O findings|O again|O point|O to|O BCORL1|O as|O a|O tumor|O -|O suppressor|O gene|O that|O is|O inactivated|O by|O mutations|O in|O a|O subset|O of|O AML|O .|O
A|O previously|O unrecognized|O translational|O isoform|O of|O FOG1|O has|O been|O identified|O .|O
In|O contrast|O to|O the|O irreversible|O nature|O of|O somatic|O mutations|O ,|O epigenetic|O modifications|O are|O theoretically|O alterable|O and|O thus|O a|O potential|O target|O for|O therapeutic|O interventions|O .|O
Another|O 16|O specimens|O yielded|O false|O -|O positive|O results|O .|O
These|O findings|O may|O also|O lend|O more|O specificity|O to|O the|O WHO|O diagnostic|O criteria|O for|O CNL|O and|O aCML|O ,|O which|O are|O variably|O applied|O in|O routine|O clinical|O practice|O .|O
In|O the|O UK|O MRC|O AML|O 10|O trial|O ,|O significant|O benefit|O with|O allogeneic|O HSCT|O was|O observed|O for|O the|O subgroup|O of|O patients|O with|O intermediate|O -|O risk|O cytogenetics|O (|O but|O not|O for|O those|O with|O favorable|O or|O high|O -|O risk|O cytogenetics|O )|O ;|O in|O this|O subgroup|O ,|O the|O DFS|O (|O 50|O %|O vs|O .|O 39|O %|O ;|O P|O =|O .|O 004|O )|O and|O OS|O rates|O (|O 55|O %|O vs|O .|O 44|O %|O ;|O P|O =|O .|O 02|O )|O were|O significantly|O higher|O among|O the|O donor|O groups|O than|O the|O nodonor|O groups|O .|O
Most|O laboratories|O reported|O analytical|O sensitivities|O in|O the|O 1|O %|O to|O 5|O %|O range|O ;|O only|O two|O laboratories|O indicated|O analytical|O sensitivities|O of|O less|O than|O 1|O %|O .|O
8|O .|O IMPAIRED|O GATA2|O FUNCTION|O IN|O LEUKEMIA|O .|O
When|O both|O cohorts|O were|O subjected|O to|O multivariable|O analysis|O that|O included|O recently|O developed|O prognostic|O models|O for|O survival|O in|O PMF|O (|O IPSS3|O in|O the|O European|O cohort|O and|O DIPSS|O -|O plus|O in|O the|O Mayo|O cohort|O )|O ,|O only|O ASXL1|O mutations|O retained|O their|O significance|O .|O
In|O patients|O who|O have|O received|O standard|O -|O dose|O cytarabine|O induction|O and|O have|O residual|O blasts|O without|O hypoplasia|O ,|O additional|O therapy|O with|O standard|O -|O dose|O cytarabine|O and|O anthracycline|O should|O be|O considered|O .|O
Nevertheless|O ,|O studies|O have|O implicated|O the|O MDS|O phenotype|O in|O a|O broad|O spectrum|O of|O genetic|O abnormalities|O .|O
Although|O we|O may|O understand|O the|O specific|O activity|O of|O an|O individual|O gene|O and|O /|O or|O have|O derived|O general|O models|O of|O how|O epigenetic|O modifications|O affect|O transcription|O ,|O we|O do|O not|O yet|O have|O a|O grasp|O of|O the|O crucial|O components|O that|O are|O altered|O by|O these|O epigenetic|O mutations|O and|O how|O this|O affects|O epigenetic|O patterning|O ,|O gene|O expression|O and|O phenotypic|O alterations|O in|O haematopoietic|O cells|O .|O
Of|O greatest|O diagnostic|O effect|O are|O recurrent|O mutations|O found|O in|O specific|O genes|O .|O
The|O induction|O strategy|O is|O influenced|O by|O individual|O patient|O characteristics|O such|O as|O age|O ,|O presence|O of|O comorbid|O conditions|O affecting|O performance|O status|O ,|O and|O preexisting|O myelodysplasia|O .|O
Moreover|O ,|O it|O has|O been|O demonstrated|O that|O GATA1|O and|O /|O or|O GATA2|O bind|O to|O a|O GATA|O motif|O located|O at|O the|O 3|O '|O enhancer|O region|O of|O WT1|O ,|O playing|O an|O important|O role|O in|O the|O regulation|O of|O WT1|O gene|O expression|O .|O
A|O recent|O study|O in|O 354|O patients|O with|O MDS|O showed|O that|O mutations|O of|O BCOR|O and|O BCORL1|O were|O identified|O in|O 4|O .|O 8|O %|O and|O 0|O .|O 8|O %|O of|O these|O patients|O ,|O respectively|O ,|O with|O higher|O frequency|O in|O patients|O with|O CMML|O and|O AML|O (|O 7|O .|O 4|O %|O and|O 9|O .|O 1|O %|O ,|O respectively|O )|O .|O
Although|O some|O mutations|O in|O these|O factors|O are|O activating|O ,|O most|O are|O loss|O -|O of|O -|O function|O or|O hypomorphic|O mutations|O and|O affect|O bona|O fide|O tumor|O suppressor|O genes|O (|O TSGs|O )|O .|O
In|O our|O series|O ,|O none|O of|O the|O patients|O bearing|O GATA2|O mutations|O exhibit|O lymphedema|O or|O deafness|O .|O
TET2|O mutations|O ,|O in|O contrast|O ,|O overlapped|O with|O lesions|O in|O nearly|O every|O other|O mutated|O gene|O ,|O suggesting|O that|O TET2|O mutations|O have|O a|O pathogenic|O role|O that|O is|O at|O least|O partially|O independent|O of|O other|O abnormalities|O .|O
Disease|O phenotypes|O associated|O with|O JAK2V617F|O mutations|O include|O older|O age|O ,|O higher|O hemoglobin|O levels|O ,|O leukocytosis|O ,|O and|O lower|O platelet|O count|O .|O
TP53|O is|O a|O tumor|O suppressor|O gene|O with|O a|O critical|O role|O in|O both|O cell|O cycle|O regulation|O and|O DNA|O repair|O .|O
However|O ,|O other|O studies|O demonstrated|O that|O the|O presence|O of|O cohesin|O mutations|O did|O not|O have|O a|O negative|O impact|O on|O survival|O or|O response|O to|O treatment|O in|O AML|O .|O
Patients|O with|O t|O (|O 8|O ;|O 21|O )|O or|O inv|O (|O 16|O )|O /|O t|O (|O 16|O ;|O 16|O )|O with|O c|O -|O KIT|O mutation|O are|O categorized|O as|O having|O intermediate|O risk|O AML|O (|O see|O "|O Risk|O Status|O Based|O on|O Cytogenetics|O and|O Molecular|O Abnormalities|O ,|O "|O on|O page|O 995|O )|O .|O
Despite|O recent|O major|O advances|O in|O our|O understanding|O of|O the|O genetics|O of|O myeloid|O malignancies|O ,|O there|O have|O been|O far|O fewer|O examples|O of|O how|O these|O insights|O have|O translated|O to|O novel|O therapies|O .|O
1|O .|O INTRODUCTION|O .|O
ASXL1|O ,|O SF3B1|O and|O SRSF2|O mutation|O analysis|O was|O performed|O according|O to|O previously|O published|O methods|O .|O
The|O proportion|O of|O patients|O with|O unfavorable|O cytogenetics|O tends|O to|O be|O higher|O in|O the|O population|O with|O therapy|O -|O related|O AML|O .|O
RUNX1|O mutations|O are|O frequent|O in|O chronic|O myelomonocytic|O leukemia|O and|O mutations|O at|O the|O C|O -|O terminal|O region|O might|O predict|O acute|O myeloid|O leukemia|O transformation|O .|O
Efforts|O are|O continuously|O being|O made|O to|O identify|O additional|O genetic|O aberrations|O involved|O in|O the|O development|O of|O CMML|O .|O
Limitations|O of|O the|O Ipsogen|O qualitative|O assay|O (|O MutaScreen|O assay|O )|O were|O highlighted|O in|O a|O report|O that|O described|O two|O MPNs|O containing|O variant|O JAK2|O mutations|O ,|O each|O with|O the|O typical|O codon|O 617|O (|O 1849G|O >|O T|O )|O mutation|O ,|O and|O in|O one|O case|O an|O additional|O codon|O 617|O (|O 1851C|O >|O T|O )|O substitution|O and|O a|O codon|O 618|O (|O 1852T|O >|O C|O )|O mutation|O ,|O and|O in|O the|O other|O case|O an|O additional|O codon|O 618|O (|O 1853G|O >|O T|O )|O mutation|O .|O
Analysis|O of|O clonal|O dynamics|O in|O patients|O in|O whom|O serial|O samples|O are|O obtained|O at|O various|O time|O points|O along|O their|O disease|O course|O provides|O important|O insight|O into|O the|O timing|O and|O effect|O of|O cohesin|O loss|O of|O function|O on|O leukemia|O initiation|O and|O progression|O .|O
The|O CR|O rates|O were|O equivalent|O in|O both|O arms|O (|O 71|O %|O and|O 74|O %|O ,|O respectively|O )|O ,|O with|O significantly|O higher|O 5|O -|O year|O relapse|O -|O free|O survival|O rates|O with|O high|O -|O dose|O cytarabine|O (|O 48|O %|O vs|O .|O 25|O %|O ;|O P|O =|O .|O 007|O )|O .|O
The|O u|O white|O blood|O count|O is|O >|O 13|O x|O 109|O /|O L|O ,|O with|O immature|O granulocytes|O >|O 10|O %|O of|O leukocytes|O and|O <|O 20|O %|O blasts|O in|O the|O blood|O and|O marrow|O .|O
According|O to|O a|O recent|O report|O ,|O knock|O down|O of|O U2AF1|O expression|O leads|O to|O the|O skipping|O of|O a|O specific|O exon|O of|O FECH|O during|O splicing|O .|O
INTRODUCTION|O .|O
If|O the|O LP|O is|O negative|O ,|O the|O patient|O can|O be|O followed|O with|O a|O repeat|O LP|O if|O symptoms|O persist|O .|O
All|O of|O the|O deletions|O in|O aberrant|O transcripts|O involved|O exon|O 5|O that|O contains|O the|O PTPase|O core|O motif|O .|O
If|O the|O marrow|O is|O hypoplastic|O (|O defined|O as|O cellularity|O <|O 10|O %|O -|O 20|O %|O and|O residual|O blasts|O <|O 5|O %|O -|O 10|O %|O )|O ,|O additional|O treatment|O selection|O may|O be|O deferred|O until|O marrow|O recovery|O ,|O when|O the|O remission|O status|O can|O be|O assessed|O .|O
Recently|O ,|O the|O transcription|O factor|O GATA2|O has|O been|O identified|O as|O a|O new|O predisposing|O gene|O for|O familial|O AML|O /|O MDS|O .|O
Data|O from|O the|O North|O American|O Association|O of|O Central|O Cancer|O Registries|O and|O the|O Surveillance|O ,|O Epidemiology|O ,|O and|O End|O Results|O program|O have|O estimated|O the|O annual|O age|O -|O adjusted|O incidence|O of|O BCR|O -|O ABL1|O -|O negative|O MPD|O to|O be|O 2|O .|O 1|O per|O 100|O ,|O 000|O ,|O with|O an|O overall|O 3|O -|O year|O survival|O rate|O of|O 80|O %|O .|O
HCT|O may|O be|O warranted|O in|O intermediate|O -|O 2|O -|O risk|O or|O high|O -|O risk|O patients|O in|O which|O median|O survival|O is|O expected|O to|O be|O <|O 5|O years|O .|O
With|O the|O use|O of|O this|O targeted|O approach|O ,|O we|O identified|O mutations|O in|O ZRSR2|O (|O W153X|O )|O and|O SRSF2|O (|O P95R|O ;|O Figure|O 1D|O -|O E|O )|O .|O
Furthermore|O ,|O increased|O BFU|O -|O E|O ,|O CFU|O -|O E|O ,|O and|O CFU|O -|O GM|O colony|O formations|O were|O observed|O in|O primary|O cells|O with|O ASXL1|O mutations|O .|O
Metaphase|O cytogenetics|O details|O were|O retrieved|O from|O 892|O patients|O .|O
To|O minimize|O false|O positives|O and|O focus|O on|O the|O most|O prevalent|O or|O relevant|O somatic|O events|O ,|O we|O implemented|O a|O rational|O bioanalytic|O filtering|O approach|O and|O applied|O heuristic|O bioanalytic|O pipelines|O .|O
One|O laboratory|O found|O an|O S505N|O mutation|O that|O was|O not|O detected|O by|O the|O other|O laboratories|O .|O
These|O genetic|O and|O epigenetic|O data|O suggested|O that|O IDH|O and|O TET2|O mutations|O affect|O the|O same|O pathway|O .|O
Using|O genome|O -|O wide|O microarray|O analysis|O coupled|O with|O ChIP|O ,|O Huang|O et|O al|O revealed|O that|O GATA2|O regulates|O cell|O cycle|O regulators|O and|O megakaryocyte|O -|O specific|O genes|O .|O
The|O presence|O of|O reactive|O thrombosis|O does|O not|O exclude|O a|O diagnosis|O of|O essential|O thrombocytosis|O in|O the|O presence|O of|O 3|O other|O major|O criteria|O .|O
New|O genetic|O findings|O in|O CNL|O and|O aCML|O .|O
Bruising|O (|O bleeding|O events|O related|O to|O skin|O and|O subcutaneous|O tissue|O )|O (|O see|O the|O Supplementary|O Appendix|O )|O was|O assessed|O separately|O .|O
Secondary|O efficacy|O variables|O were|O tested|O in|O a|O fixed|O -|O sequence|O testing|O procedure|O at|O an|O alpha|O level|O of|O 0|O .|O 05|O .|O
An|O assay|O that|O detects|O less|O than|O 0|O .|O 1|O %|O of|O JAK2|O allele|O ,|O therefore|O ,|O is|O more|O likely|O to|O produce|O false|O -|O positive|O results|O in|O the|O diagnostic|O setting|O .|O
When|O Should|O JAK2|O and|O MPL|O Mutational|O Analysis|O Be|O Performed|O ?|O
To|O elucidate|O the|O exact|O impacts|O of|O splicing|O factor|O mutations|O ,|O a|O well|O -|O designed|O control|O study|O should|O be|O required|O taking|O other|O common|O mutations|O also|O into|O account|O .|O
To|O detect|O germline|O variants|O of|O cohesin|O genes|O ,|O our|O strategy|O was|O to|O select|O nonsynonymous|O variants|O present|O in|O both|O somatic|O and|O germline|O samples|O that|O are|O possibly|O deleterious|O .|O
A|O missense|O mutation|O within|O the|O pseudokinase|O domain|O of|O JAK2|O (|O a|O change|O of|O valine|O to|O phenylalanine|O at|O the|O 617|O position|O )|O causes|O constitutional|O activation|O of|O the|O tyrosine|O kinase|O in|O the|O absence|O of|O ligand|O stimulation|O (|O e|O .|O g|O .|O ,|O interferon|O ,|O GM|O -|O CSF|O ,|O erythropoietin|O ,|O and|O thrombopoietin|O )|O .|O
In|O addition|O ,|O patients|O with|O unfavorable|O karyotypes|O ,|O such|O as|O -|O 7|O ,|O -|O 5|O ,|O 11q23|O abnormalities|O or|O complex|O cytogenetic|O abnormalities|O ,|O are|O also|O considered|O poor|O -|O risk|O .|O
Figure|O 4|O .|O The|O contribution|O of|O Polycomb|O -|O mediated|O gene|O repression|O to|O the|O pathophysiology|O of|O APL|O .|O Fusion|O of|O the|O promyelocytic|O leukaemia|O (|O PML|O )|O gene|O to|O the|O retinoic|O acid|O receptor|O -|O alpha|O (|O RARA|O )|O gene|O results|O in|O a|O hallmark|O of|O acute|O promyelocytic|O leukaemia|O (|O APL|O )|O :|O the|O PML|O -|O RARA|O fusion|O .|O Polycomb|O repressive|O complex|O 2|O (|O PRC2|O )|O has|O been|O found|O to|O directly|O associate|O with|O the|O PML|O -|O RARalpha|O fusion|O protein|O but|O not|O to|O either|O endogenous|O protein|O alone|O .|O PRC2|O -|O mediated|O transcriptional|O repression|O is|O thought|O to|O have|O a|O role|O in|O the|O leukaemogenic|O activity|O of|O PML|O -|O RARalpha|O ,|O and|O the|O loss|O of|O PRC2|O components|O in|O mouse|O models|O of|O APL|O results|O in|O the|O differentiation|O of|O APL|O cells|O .|O A|O variant|O RARalpha|O translocation|O is|O the|O promyelocytic|O leukaemia|O zinc|O finger|O (|O PLZF|O )|O -|O RARalpha|O fusion|O ,|O which|O results|O in|O a|O form|O of|O APL|O that|O is|O insensitive|O to|O all|O -|O trans|O retinoic|O acid|O (|O ATRA|O )|O ,|O the|O main|O therapeutic|O modality|O used|O to|O treat|O patients|O with|O APL|O .|O Interestingly|O ,|O it|O has|O been|O shown|O that|O unlike|O PML|O -|O RARalpha|O ,|O PLZF|O -|O RARalpha|O also|O interacts|O with|O PRC1|O via|O direct|O association|O with|O BMI1|O (|O REF|O .|O 98|O )|O .|O Treatment|O with|O ATRA|O results|O in|O a|O loss|O of|O PRC2|O recruitment|O by|O PLZF|O -|O RARalpha|O ,|O whereas|O PRC1|O -|O mediated|O gene|O repression|O persists|O in|O an|O ATRA|O -|O insensitive|O manner|O .|O This|O explains|O ,|O at|O least|O in|O part|O ,|O the|O lack|O of|O efficacy|O of|O ATRA|O in|O PLZF|O -|O RARalpha|O -|O positive|O APL|O .|O CBX4|O ,|O chromobox|O protein|O homologue|O 4|O ;|O EED|O ,|O embryonic|O ectoderm|O development|O ;|O EZH2|O ,|O enhancer|O of|O zeste|O homologue|O 2|O ;|O H2AK119Ub|O ,|O histone|O H2A|O ubiquitylated|O on|O lysine|O 119|O ;|O H3K27me3|O ,|O histone|O H3|O trimethylated|O on|O lysine|O 27|O ;|O PH1|O ,|O polyhomeotic|O -|O like|O protein|O 1|O ;|O SUZ12|O ,|O suppressor|O of|O zeste|O 12|O homologue|O .|O
The|O PCR|O amplification|O was|O performed|O in|O a|O volume|O of|O 25|O muL|O containing|O 0|O .|O 5|O mug|O of|O genomic|O DNA|O ,|O 2|O .|O 5|O pmol|O each|O of|O the|O primers|O ,|O 5|O muCi|O 35SdATP|O ,|O 0|O .|O 2|O mM|O each|O of|O dNTPs|O ,|O 1|O .|O 25U|O AmpliTaq|O Gold|O DNA|O polymerase|O ,|O and|O 1x|O PCR|O buffer|O .|O
Of|O the|O 617|O subjects|O studied|O ,|O 399|O (|O 64|O .|O 7|O %|O )|O carried|O JAK2|O (|O V617F|O )|O ,|O 140|O (|O 22|O .|O 7|O %|O )|O had|O a|O CALR|O exon|O 9|O indel|O ,|O 25|O (|O 4|O .|O 0|O %|O )|O carried|O an|O MPL|O (|O W515|O )|O mutation|O ,|O and|O 53|O (|O 8|O .|O 6|O %|O )|O had|O nonmutated|O JAK2|O ,|O CALR|O ,|O and|O MPL|O (|O so|O -|O called|O triple|O -|O negative|O PMF|O )|O .|O
Patients|O with|O CALR|O mutation|O had|O a|O lower|O risk|O of|O developing|O anemia|O ,|O thrombocytopenia|O ,|O and|O marked|O leukocytosis|O compared|O with|O other|O subtypes|O .|O
These|O findings|O show|O that|O the|O association|O of|O some|O mutations|O with|O poor|O survival|O may|O be|O indirectly|O captured|O by|O the|O IPSS|O because|O of|O their|O associations|O with|O cytopenias|O ,|O blast|O percentage|O ,|O and|O karyotype|O .|O
Acute|O myeloid|O leukaemia|O (|O AML|O )|O .|O
The|O primers|O ,|O M2u|O ,|O M2d|O ,|O and|O M3u|O ,|O as|O described|O in|O Table|O I|O ,|O were|O used|O for|O sequencing|O analysis|O .|O
All|O patients|O were|O followed|O up|O until|O death|O or|O for|O up|O to|O 88|O months|O .|O
In|O a|O study|O of|O 137|O patients|O with|O PV|O ,|O 11|O %|O displayed|O abnormal|O genotypes|O ,|O with|O Y|O -|O (|O 7|O %|O of|O male|O patients|O )|O ,|O +|O 8|O ,|O +|O 9|O ,|O 20q|O -|O ,|O and|O abnormalities|O of|O chromosome|O 1|O ,|O 13q|O -|O ,|O 11q|O -|O ,|O 3p|O -|O ,|O and|O dup13|O were|O observed|O with|O the|O highest|O frequency|O .|O
Currently|O ,|O the|O interactions|O of|O both|O IDH1|O or|O IDH2|O and|O DNMT3|O mutations|O with|O other|O molecular|O changes|O require|O further|O investigation|O to|O determine|O the|O prognostic|O value|O in|O patients|O with|O NK|O -|O AML|O .|O
About|O two|O -|O thirds|O of|O mutations|O were|O either|O nonsense|O or|O frameshift|O changes|O ,|O causing|O a|O premature|O stop|O codon|O .|O
The|O presence|O of|O an|O isolated|O NPM1|O or|O CEBPA|O mutation|O improves|O prognosis|O only|O slightly|O less|O than|O for|O patients|O with|O CBF|O translocations|O (|O see|O "|O Initial|O Evaluation|O "|O on|O page|O 999|O )|O .|O
Normal|O cytogenetics|O were|O present|O in|O 48|O %|O of|O mutant|O cases|O ,|O whereas|O 10|O %|O had|O complex|O cytogenetics|O ,|O a|O distribution|O comparable|O to|O WT|O patients|O .|O
Although|O initial|O reports|O (|O 354|O patients|O )|O suggested|O SF3B1|O mutations|O convey|O significantly|O longer|O OS|O ,|O leukemia|O -|O free|O survival|O (|O LFS|O )|O ,|O and|O event|O -|O free|O survival|O in|O their|O cohort|O ,|O subsequent|O analysis|O of|O 323|O MDS|O cases|O ,|O patients|O carrying|O an|O SF3B1|O mutation|O showed|O a|O significantly|O better|O OS|O and|O no|O effect|O on|O LFS|O in|O RARS|O and|O refractory|O cytopenia|O with|O multilineage|O dysplasia|O with|O ringed|O sideroblasts|O (|O RCMD|O -|O RS|O )|O .|O
An|O ECOG|O -|O led|O phase|O III|O trial|O is|O currently|O in|O progress|O ,|O which|O will|O compare|O induction|O therapy|O with|O single|O -|O agent|O clofarabine|O versus|O cytarabine|O /|O daunorubicin|O in|O patients|O older|O than|O 60|O years|O .|O
In|O terms|O of|O clinical|O features|O ,|O triple|O -|O negative|O PMF|O is|O similar|O to|O the|O myelodysplastic|O syndrome|O associated|O with|O bone|O marrow|O fibrosis|O that|O we|O described|O previously|O .|O
There|O is|O no|O difference|O in|O analytical|O performance|O using|O peripheral|O blood|O or|O bone|O marrow|O samples|O for|O testing|O for|O JAK2|O mutations|O ,|O because|O granulocytes|O constitute|O the|O predominant|O population|O in|O both|O specimens|O .|O
For|O the|O European|O cohort|O ,|O the|O Sanger|O technique|O was|O used|O to|O detect|O mutations|O across|O the|O entire|O coding|O region|O of|O EZH2|O and|O TET2|O ,|O and|O regions|O previously|O described|O as|O mutational|O hotspots|O for|O DNMT3A|O ,|O CBL|O ,|O ASXL1|O ,|O IDH1|O ,|O IDH2|O ,|O SRSF2|O and|O MPL|O ;|O JAK2V617F|O was|O detected|O by|O real|O -|O time|O PCR|O (|O RT|O -|O PCR|O )|O .|O
METHODS|O .|O
A|O total|O of|O 155|O patients|O in|O the|O ruxolitinib|O group|O and|O 151|O in|O the|O placebo|O group|O received|O at|O least|O one|O dose|O of|O the|O study|O medication|O and|O were|O included|O in|O the|O analysis|O of|O safety|O .|O
Here|O ,|O the|O same|O cohort|O was|O used|O to|O identify|O affected|O genes|O on|O chromosome|O 7|O .|O
Which|O Methodologies|O Are|O Used|O to|O Detect|O JAK2|O and|O MPL|O Mutations|O ?|O
To|O address|O these|O issues|O from|O the|O laboratory|O perspective|O ,|O here|O we|O present|O practice|O guidelines|O for|O JAK2|O and|O MPL|O mutation|O testing|O and|O reporting|O .|O
In|O multivariable|O analysis|O that|O included|O the|O four|O mutations|O as|O covariates|O ,|O ASXL1|O (|O HR|O :|O 2|O .|O 5|O ,|O 95|O %|O CI|O :|O 1|O .|O 5|O -|O 4|O .|O 1|O ;|O P|O <|O 0|O .|O 0001|O )|O ,|O SRSF2|O (|O HR|O :|O 2|O .|O 73|O ,|O 95|O %|O CI|O :|O 1|O .|O 34|O -|O 5|O .|O 55|O ;|O P|O =|O 0|O .|O 005|O )|O and|O IDH1|O or|O IDH2|O (|O HR|O :|O 2|O .|O 66|O ,|O 95|O %|O CI|O :|O 1|O .|O 10|O -|O 6|O .|O 47|O ;|O P|O =|O 0|O .|O 03|O )|O ,|O but|O not|O EZH2|O (|O HR|O :|O 1|O .|O 98|O ,|O 95|O %|O CI|O :|O 0|O .|O 88|O -|O 4|O .|O 46|O )|O ,|O mutations|O remained|O significant|O .|O
In|O univariate|O analysis|O ,|O the|O presence|O of|O SRSF2|O ,|O SF3B1|O or|O U2AF35|O mutations|O had|O no|O prognostic|O impact|O on|O OS|O or|O leukemia|O free|O survival|O (|O Table|O 3|O and|O Figure|O 1|O )|O .|O
If|O the|O clinical|O utility|O of|O mutations|O in|O other|O genes|O (|O eg|O ,|O TET2|O ,|O ASXL1|O ,|O and|O EZH2|O )|O is|O established|O for|O MPNs|O ,|O next|O -|O generation|O sequencing|O provides|O a|O way|O to|O expand|O the|O scope|O of|O the|O assay|O without|O significantly|O increasing|O the|O work|O required|O to|O perform|O the|O test|O .|O
Nevertheless|O ,|O a|O simplified|O prognostic|O scoring|O scheme|O has|O great|O clinical|O value|O .|O
Table|O 3|O .|O 2008|O World|O Health|O Organization|O Diagnostic|O Criteria|O for|O Primary|O Myelofibrosis|O .|O
Seven|O (|O 3|O %|O )|O patients|O had|O an|O abnormality|O of|O chromosome|O 7|O (|O monosomy|O 7|O -|O 6|O and|O del7q|O -|O 1|O )|O ,|O 16|O (|O 7|O %|O )|O had|O +|O 8|O (|O 9|O as|O a|O single|O abnormality|O and|O 7|O with|O an|O additional|O structural|O abnormality|O )|O ,|O 8|O (|O 4|O %|O )|O had|O a|O monosomal|O karyotype|O and|O 2|O (|O 1|O %|O )|O patients|O had|O a|O complex|O karyotype|O without|O monosomies|O .|O
In|O addition|O ,|O an|O increase|O in|O immature|O thymic|O T|O cells|O and|O mature|O splenic|O B|O cells|O was|O observed|O in|O at|O least|O one|O Tet2|O -|O knockout|O mouse|O model|O ,|O consistent|O with|O effects|O on|O lymphoid|O fate|O commitment|O .|O
In|O a|O post|O hoc|O analysis|O of|O subgroups|O ,|O mean|O changes|O in|O spleen|O volume|O among|O patients|O with|O the|O JAK2V617F|O mutation|O were|O -|O 34|O .|O 6|O %|O in|O the|O ruxolitinib|O group|O and|O 8|O .|O 1|O %|O in|O the|O placebo|O group|O ;|O the|O corresponding|O changes|O among|O patients|O without|O the|O mutation|O were|O -|O 23|O .|O 8|O %|O and|O 8|O .|O 4|O %|O (|O P|O value|O for|O interaction|O ,|O 0|O .|O 07|O )|O .|O
Spliceosome|O component|O (|O P|O =|O 0|O .|O 4|O )|O and|O ASXL1|O mutations|O (|O P|O =|O 0|O .|O 37|O )|O had|O no|O impact|O survival|O .|O
The|O intent|O of|O traditional|O induction|O chemotherapy|O is|O to|O produce|O a|O major|O reduction|O in|O the|O leukemic|O burden|O and|O to|O restore|O normal|O hematopoiesis|O .|O
GATA1|O inhibits|O PU|O .|O 1|O by|O preventing|O its|O interaction|O with|O the|O co|O -|O activator|O c|O -|O JUN|O ,|O whereas|O PU|O .|O 1|O blocks|O GATA1|O function|O by|O inhibiting|O its|O ability|O to|O bind|O to|O DNA|O .|O
In|O patients|O older|O than|O 60|O years|O ,|O the|O proportion|O of|O those|O with|O favorable|O CBF|O translocations|O decreases|O ,|O as|O does|O the|O number|O with|O isolated|O NPM1|O mutations|O ,|O whereas|O the|O number|O of|O those|O with|O unfavorable|O karyotypes|O and|O mutations|O increases|O .|O
These|O neutropenias|O may|O be|O isolated|O or|O associated|O with|O immunologic|O defects|O or|O extra|O -|O hematopoietic|O manifestations|O .|O
Clinical|O parameters|O studied|O included|O age|O ,|O sex|O ,|O overall|O survival|O (|O OS|O )|O ,|O blood|O counts|O ,|O and|O metaphase|O cytogenetics|O .|O
The|O precise|O pathogenetic|O mechanisms|O associated|O with|O facilitation|O of|O clonal|O evolution|O remain|O unclear|O .|O
Figure|O 3|O .|O Unsplicing|O of|O specific|O genes|O because|O of|O spliceosomal|O mutations|O as|O detected|O by|O deep|O RNA|O sequencing|O .|O Next|O -|O generation|O -|O based|O RNA|O deep|O sequencing|O was|O used|O to|O quantitatively|O study|O splicing|O patterns|O .|O (|O A|O )|O The|O top|O panel|O shows|O the|O intron|O 5|O and|O exon|O 6|O boundary|O of|O TET2|O (|O dotted|O line|O )|O .|O Five|O reads|O correspond|O to|O transcripts|O that|O were|O not|O spliced|O (|O unspliced|O )|O and|O 4|O were|O spliced|O at|O this|O boundary|O .|O The|O bottom|O panel|O shows|O read|O counts|O at|O the|O 5|O '|O and|O 3|O '|O splice|O sites|O of|O each|O intron|O (|O 3|O -|O 10|O )|O of|O TET2|O .|O White|O and|O black|O bars|O indicate|O the|O number|O of|O spliced|O and|O unspliced|O reads|O ,|O respectively|O .|O In|O a|O case|O of|O AML|O with|O a|O U2AF1|O mutation|O ,|O more|O unspliced|O than|O spliced|O reads|O were|O observed|O at|O the|O 3|O '|O splice|O site|O of|O intron|O 5|O (|O left|O panel|O )|O ,|O probably|O because|O of|O a|O loss|O of|O spliceosome|O function|O .|O However|O ,|O unspliced|O RNAs|O were|O less|O frequent|O than|O spliced|O RNAs|O in|O WT|O RNA|O sequencing|O (|O right|O panel|O )|O .|O (|O B|O )|O At|O both|O the|O 3|O '|O and|O 5|O '|O splice|O sites|O of|O RUNX1|O intron|O 6|O ,|O unspliced|O reads|O were|O more|O frequent|O than|O spliced|O reads|O in|O AML|O cases|O with|O U2AF1|O and|O SRSF2|O mutations|O .|O However|O ,|O there|O were|O fewer|O unspliced|O transcripts|O at|O the|O same|O site|O in|O WT|O and|O SF3B1|O mutant|O samples|O .|O Splicing|O abnormalities|O in|O the|O selected|O genes|O are|O summarized|O (|O bottom|O right|O )|O ,|O including|O the|O results|O presented|O in|O detail|O in|O supplemental|O Figures|O 7|O and|O 8|O .|O
In|O the|O past|O 5|O years|O ,|O the|O presence|O of|O autosomal|O chromosome|O monosomies|O in|O AML|O has|O emerged|O as|O an|O important|O prognostic|O factor|O associated|O with|O extremely|O poor|O prognosis|O .|O
Discovery|O of|O frequent|O mutations|O of|O splicing|O machinery|O in|O myelodysplasia|O .|O
Conflicting|O data|O exist|O regarding|O the|O prognostic|O impact|O of|O TET2|O mutations|O in|O MDS|O .|O
The|O current|O study|O seeks|O to|O improve|O upon|O these|O prognostic|O models|O by|O incorporating|O recently|O described|O molecular|O markers|O (|O somatic|O mutations|O )|O ,|O some|O of|O which|O have|O already|O been|O shown|O useful|O in|O the|O prognostic|O assessment|O of|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
Samples|O were|O acquired|O from|O adult|O patients|O ,|O who|O provided|O written|O informed|O consent|O ,|O between|O 1994|O and|O 2008|O according|O to|O protocols|O approved|O by|O the|O institutional|O review|O board|O at|O each|O institution|O .|O
No|O correlation|O was|O observed|O between|O genes|O in|O the|O cohesin|O complex|O and|O other|O mutations|O such|O as|O FLT3|O -|O ITD|O ,|O IDH1|O ,|O IDH2|O ,|O or|O NRAS|O mutations|O .|O
These|O analyses|O were|O performed|O using|O JMP9|O (|O SAS|O ,|O Cary|O ,|O NC|O )|O and|O R|O -|O statistical|O language|O .|O
In|O STAG2|O ,|O we|O detected|O mutations|O in|O 17|O females|O (|O 14|O heterozygous|O and|O 3|O homozygous|O )|O and|O in|O 44|O males|O (|O hemizygous|O )|O .|O
Association|O between|O mutations|O and|O clinical|O and|O biological|O features|O was|O assessed|O by|O the|O X2|O test|O .|O
Informed|O consent|O was|O obtained|O according|O to|O protocols|O approved|O by|O the|O institutional|O review|O boards|O and|O in|O accordance|O with|O the|O Declaration|O of|O Helsinki|O .|O
Exome|O sequencing|O .|O
Disease|O -|O free|O survival|O was|O 51|O %|O for|O related|O HLA|O -|O matched|O donors|O and|O 67|O %|O for|O unrelated|O donors|O .|O
In|O all|O patients|O except|O those|O at|O highest|O risk|O ,|O the|O presence|O of|O these|O mutations|O is|O associated|O with|O an|O overall|O survival|O similar|O to|O that|O of|O patients|O in|O the|O next|O -|O highest|O IPSS|O risk|O group|O .|O
Using|O target|O gene|O sequencing|O technology|O ,|O Gelsi|O -|O Boyer|O et|O al|O first|O identified|O ASXL1|O mutations|O in|O 11|O %|O of|O MDS|O patients|O and|O 43|O %|O of|O patients|O with|O CMML|O .|O
The|O 2|O -|O year|O OS|O rate|O was|O 50|O %|O and|O 16|O %|O ,|O respectively|O (|O P|O =|O .|O 001|O )|O .|O
The|O human|O GATA2|O gene|O (|O 13|O ,|O 760|O kb|O )|O ,|O cloned|O by|O Lee|O et|O al|O is|O located|O on|O 3q21|O and|O has|O 6|O exons|O .|O
However|O ,|O in|O AML|O ,|O cohesin|O mutations|O have|O not|O been|O associated|O with|O aneuploidy|O or|O complex|O cytogenetics|O ,|O suggesting|O an|O alternate|O mechanism|O of|O transformation|O .|O
Next|O -|O generation|O pyrosequencing|O of|O PCR|O -|O amplified|O exons|O of|O TET2|O ,|O RUNX1|O ,|O TP53|O ,|O CDKN2A|O ,|O PTEN|O ,|O NPM1|O exon|O 11|O ,|O and|O CBL|O exons|O 8|O and|O 9|O was|O performed|O with|O the|O use|O of|O a|O next|O -|O generation|O sequencing|O platform|O (|O 454|O Life|O Sciences|O )|O .|O
Studies|O have|O shown|O that|O c|O -|O KIT|O mutations|O are|O associated|O with|O decreased|O remission|O duration|O (|O eg|O ,|O EFS|O and|O relapse|O -|O free|O survival|O )|O and|O decreased|O OS|O in|O both|O groups|O of|O patients|O with|O t|O (|O 8|O ;|O 21|O )|O or|O inv|O (|O 16|O )|O .|O
In|O MDS|O /|O MPN|O ,|O SRSF2|O mutations|O were|O more|O common|O than|O U2AF1|O ;|O however|O ,|O U2AF1|O mutations|O were|O associated|O with|O shorter|O survival|O (|O Figure|O 2B|O )|O .|O
First|O ,|O not|O all|O patients|O have|O mutations|O in|O class|O I|O or|O class|O II|O genes|O ;|O as|O one|O example|O ,|O class|O I|O mutations|O are|O only|O present|O in|O approximately|O 50|O %|O of|O patients|O with|O AML|O and|O ,|O to|O date|O ,|O genetic|O studies|O have|O not|O identified|O additional|O class|O I|O mutations|O in|O the|O remaining|O cases|O of|O AML|O .|O
Treatment|O of|O acute|O leukemia|O has|O been|O divided|O into|O induction|O chemotherapy|O and|O postremission|O (|O or|O consolidation|O )|O therapy|O .|O
Several|O studies|O demonstrate|O a|O mutation|O rate|O in|O de|O novo|O MDS|O of|O 6|O .|O 4|O -|O 12|O %|O .|O
Figure|O 1|O .|O Change|O in|O Spleen|O Volume|O .|O Panel|O A|O shows|O the|O results|O of|O the|O intention|O -|O to|O -|O treat|O analysis|O of|O the|O percentage|O of|O patients|O in|O each|O study|O group|O who|O reached|O the|O primary|O end|O point|O of|O a|O reduction|O of|O 35|O %|O or|O more|O in|O spleen|O volume|O as|O assessed|O by|O means|O of|O magnetic|O resonance|O imaging|O (|O MRI|O )|O or|O computed|O tomography|O (|O CT|O )|O .|O Patients|O who|O discontinued|O the|O study|O drug|O before|O week|O 24|O or|O crossed|O over|O before|O week|O 24|O were|O counted|O as|O not|O having|O had|O a|O response|O .|O Only|O patients|O with|O baseline|O data|O were|O included|O in|O this|O analysis|O .|O I|O bars|O denote|O 95|O %|O confidence|O intervals|O .|O CI|O denotes|O confidence|O interval|O .|O Panel|O B|O shows|O the|O percent|O change|O from|O baseline|O in|O spleen|O volume|O at|O week|O 24|O (|O in|O 139|O patients|O in|O the|O ruxolitinib|O group|O and|O 106|O in|O the|O placebo|O group|O )|O or|O at|O the|O last|O evaluation|O before|O week|O 24|O (|O in|O 16|O patients|O in|O the|O ruxolitinib|O group|O and|O 47|O in|O the|O placebo|O group|O )|O .|O Data|O for|O 1|O patient|O with|O a|O missing|O baseline|O value|O are|O not|O included|O on|O the|O graph|O .|O Most|O patients|O in|O the|O ruxolitinib|O group|O (|O 150|O of|O 155|O )|O had|O a|O reduction|O in|O spleen|O volume|O ,|O whereas|O most|O patients|O in|O the|O placebo|O group|O had|O either|O an|O increase|O in|O spleen|O volume|O (|O 102|O of|O 153|O patients|O )|O or|O no|O change|O (|O 15|O of|O 153|O patients|O )|O .|O Panel|O C|O shows|O the|O median|O percent|O change|O in|O spleen|O volume|O as|O assessed|O by|O means|O of|O MRI|O or|O CT|O over|O time|O .|O Reductions|O in|O spleen|O volume|O were|O apparent|O at|O the|O first|O on|O -|O study|O measurement|O at|O 12|O weeks|O and|O were|O maintained|O over|O the|O course|O of|O the|O study|O .|O The|O upper|O edge|O of|O each|O I|O bar|O corresponds|O to|O the|O 75th|O percentile|O ,|O and|O the|O lower|O edge|O to|O the|O 25th|O percentile|O .|O
These|O drugs|O are|O expected|O to|O be|O more|O effective|O in|O the|O chronic|O phase|O of|O disease|O before|O increasing|O genetic|O complexity|O associated|O with|O disease|O transformation|O supervenes|O ,|O and|O therapeutic|O inhibition|O of|O CSF3R|O -|O related|O signaling|O may|O be|O less|O relevant|O .|O
Although|O these|O mutations|O were|O common|O and|O found|O in|O a|O wide|O spectrum|O of|O myeloid|O diseases|O ,|O some|O are|O strongly|O associated|O with|O specific|O phenotypic|O features|O ,|O such|O as|O SF3B1|O mutations|O with|O MDS|O or|O MDS|O /|O MPN|O with|O RS|O and|O SRSF2|O mutations|O with|O CMML|O and|O advanced|O forms|O of|O MDS|O such|O as|O sAML|O and|O RA|O with|O excess|O blasts|O .|O
A|O 5|O -|O muL|O aliquot|O of|O each|O sample|O was|O loaded|O ,|O and|O electrophoresis|O was|O carried|O out|O in|O a|O GenePhor|O Electrophoresis|O Unit|O using|O the|O GeneGel|O Excel|O 12|O .|O 5|O /|O 24|O Kit|O .|O
Interestingly|O ,|O prior|O to|O gene|O repression|O by|O GATA1|O ,|O the|O SCL|O complex|O was|O frequently|O found|O to|O correlate|O with|O the|O presence|O of|O GATA2|O ,|O suggesting|O that|O GATA2|O might|O function|O via|O SCL|O to|O activate|O KIT|O and|O GATA2|O expression|O in|O immature|O erythroid|O cells|O .|O
Chromosome|O 3|O microsatellite|O genotyping|O .|O
We|O performed|O a|O survival|O analysis|O utilizing|O multiple|O clinical|O ,|O pathological|O and|O molecular|O variables|O .|O
Figure|O 4|O .|O Three|O -|O tiered|O dynamic|O DIPSS|O -|O plus|O stratified|O survival|O data|O in|O 279|O patients|O with|O PMF|O sub|O -|O stratified|O according|O to|O ASXL1|O mutation|O status|O (|O a|O )|O and|O according|O to|O ASXL1|O /|O SRSF2|O /|O IDH1|O mutation|O status|O (|O b|O )|O .|O
Cohesin|O is|O a|O multiprotein|O complex|O that|O has|O an|O established|O role|O as|O an|O effector|O of|O sister|O -|O chromatid|O cohesin|O during|O metaphase|O .|O
In|O this|O cross|O -|O sectional|O analysis|O of|O the|O cohesin|O mutant|O cohort|O ,|O STAG2|O and|O SMC3|O mutant|O clones|O were|O ancestral|O in|O only|O 18|O %|O of|O the|O cases|O .|O
International|O Prognostic|O Scoring|O System|O .|O
When|O the|O JAK2|O V617F|O level|O of|O a|O particular|O patient|O falls|O below|O 1|O %|O ,|O however|O ,|O caution|O must|O be|O exercised|O ,|O because|O very|O low|O levels|O of|O JAK2|O V617F|O mutations|O (|O usually|O <|O 0|O .|O 1|O %|O )|O have|O been|O described|O in|O peripheral|O blood|O of|O unaffected|O individuals|O .|O
Our|O clinical|O trial|O protocol|O allowed|O an|O intent|O -|O to|O -|O treat|O analysis|O on|O the|O basis|O of|O donor|O availability|O in|O patients|O with|O CN|O -|O AML|O .|O
Mutation|O Analysis|O of|O PTEN|O /|O MMAC1|O in|O Acute|O Myeloid|O Leukemia|O .|O
Genomic|O DNA|O samples|O from|O 62|O AML|O patients|O and|O 5|O cell|O lines|O were|O examined|O .|O PCR|O -|O SSCP|O analysis|O of|O exon|O 5|O showed|O abnormal|O bands|O in|O the|O cell|O line|O U937|O (|O Fig|O .|O 3A|O )|O .|O
To|O simplify|O the|O implementation|O of|O the|O score|O ,|O we|O recoded|O it|O into|O 5|O broader|O categories|O of|O adequate|O numerosity|O by|O pooling|O consecutive|O score|O values|O .|O
Postinduction|O Therapy|O :|O To|O judge|O the|O efficacy|O of|O the|O induction|O therapy|O ,|O a|O bone|O marrow|O aspirate|O and|O biopsy|O should|O be|O performed|O 7|O to|O 10|O days|O after|O completion|O of|O induction|O therapy|O .|O
Her|O brother|O and|O parents|O are|O healthy|O .|O
This|O case|O ,|O although|O anecdotal|O ,|O provides|O a|O strong|O rationale|O for|O the|O investigation|O of|O tyrosine|O kinase|O inhibitors|O (|O TKIs|O )|O in|O CNL|O and|O aCML|O patients|O .|O
In|O a|O patient|O with|O sAML|O ,|O we|O identified|O a|O somatic|O mutation|O (|O M1307I|O )|O in|O PRPF8|O and|O a|O heterozygous|O mutation|O (|O R27X|O )|O in|O LUC7L2|O ,|O respectively|O (|O Figure|O 1C|O )|O .|O
When|O considering|O the|O type|O of|O CALR|O mutation|O ,|O patients|O carrying|O a|O type|O 1|O CALR|O mutation|O had|O a|O better|O OS|O compared|O with|O patients|O carrying|O JAK2|O (|O V617F|O )|O (|O P|O <|O .|O 001|O )|O .|O
Fig|O .|O 2|O .|O '|O GATA|O factor|O switching|O '|O and|O '|O GATA|O switch|O '|O in|O erythropoiesis|O .|O GATA2|O has|O a|O role|O in|O the|O regulation|O of|O its|O own|O transcription|O binding|O to|O its|O promoter|O and|O working|O as|O an|O enhancer|O of|O its|O transcription|O .|O During|O erythroid|O differentiation|O ,|O expression|O of|O GATA1|O is|O up|O -|O regulated|O and|O GATA1|O replaces|O GATA2|O at|O the|O same|O motifs|O and|O ,|O as|O a|O result|O ,|O inhibits|O GATA2|O transcription|O .|O The|O '|O GATA|O switch|O '|O requires|O the|O interaction|O of|O different|O proteins|O ,|O such|O as|O GATA1|O -|O FOG1|O and|O FOG1|O -|O NuRD|O binding|O .|O
We|O reasoned|O that|O an|O integrated|O and|O comprehensive|O mutational|O analysis|O of|O the|O most|O commonly|O occurring|O mutations|O ,|O performed|O in|O large|O well|O -|O characterized|O cohort|O of|O subjects|O with|O PMF|O ,|O could|O allow|O to|O identify|O mutationally|O defined|O subgroups|O of|O patients|O resulting|O in|O improved|O prognosis|O assessment|O and|O providing|O a|O background|O for|O the|O interpretation|O of|O results|O obtained|O with|O conventional|O therapy|O ,|O including|O allogeneic|O stem|O cell|O transplantation|O and|O particularly|O novel|O drugs|O .|O
Analysis|O of|O cohesin|O mutations|O .|O
The|O adverse|O prognostic|O value|O conferred|O by|O these|O factors|O was|O validated|O by|O the|O Dusseldorf|O model|O ,|O with|O the|O exception|O of|O circulating|O IMC|O .|O
The|O father|O (|O patient|O number|O 7106|O ;|O P4|O ,|O II|O ,|O 2|O )|O has|O the|O same|O mutation|O .|O
There|O was|O no|O difference|O in|O age|O (|O P|O =|O 0|O .|O 6|O )|O ,|O gender|O (|O P|O =|O 0|O .|O 23|O )|O ,|O hemoglobin|O values|O (|O P|O =|O 0|O .|O 07|O )|O ,|O platelet|O count|O (|O P|O =|O 0|O .|O 09|O )|O ,|O ALC|O (|O P|O =|O 0|O .|O 79|O )|O ,|O PB|O (|O P|O =|O 0|O .|O 5|O )|O and|O BM|O (|O 0|O .|O 27|O )|O blasts|O ,|O WHO|O histological|O categories|O (|O P|O =|O 0|O .|O 3|O )|O and|O the|O incidence|O of|O SRSF2|O (|O P|O =|O 0|O .|O 57|O )|O and|O SF3B1|O (|O P|O =|O 0|O .|O 43|O )|O mutations|O .|O
Overall|O survival|O was|O measured|O from|O the|O time|O of|O sample|O collection|O to|O the|O time|O of|O death|O from|O any|O cause|O ;|O data|O were|O censored|O at|O the|O time|O patients|O were|O last|O known|O to|O be|O alive|O .|O
Thrombotic|O events|O were|O defined|O as|O described|O in|O detail|O by|O the|O CYTO|O -|O PV|O Collaborative|O Group|O .|O
Their|O role|O in|O the|O classification|O and|O diagnosis|O is|O yet|O to|O be|O established|O .|O
The|O C|O -|O terminal|O missense|O mutation|O has|O not|O been|O reported|O earlier|O and|O all|O of|O the|O earlier|O identified|O C|O -|O terminal|O mutations|O resulted|O in|O frameshifts|O .|O
Radiotherapy|O ,|O especially|O in|O the|O context|O of|O myeloablative|O therapy|O (|O eg|O ,|O total|O -|O body|O irradiation|O or|O radioimmunotherapy|O )|O given|O before|O autologous|O stem|O cell|O transplantation|O ,|O may|O also|O increase|O the|O risk|O of|O therapy|O -|O related|O MDS|O /|O AML|O .|O
An|O explosion|O in|O the|O discovery|O and|O understanding|O of|O novel|O mutations|O in|O MDS|O has|O provided|O an|O important|O pathophysiologic|O and|O prognostic|O insight|O into|O this|O extraordinarily|O heterogeneous|O disease|O .|O
Conventional|O cytogenetic|O techniques|O detect|O large|O chromosomal|O aberrations|O in|O 40|O -|O 60|O %|O of|O individuals|O with|O MDS|O ,|O of|O which|O deletions|O of|O chromosome|O 5|O or|O 5q|O (|O 15|O %|O )|O and|O 7|O or|O 7q|O (|O 10|O %|O )|O are|O the|O most|O frequent|O .|O
In|O the|O ruxolitinib|O group|O ,|O patients|O with|O new|O -|O onset|O grade|O 3|O or|O 4|O anemia|O had|O improvements|O in|O symptoms|O and|O reductions|O in|O spleen|O volume|O that|O were|O similar|O to|O those|O in|O patients|O without|O anemia|O (|O Fig|O .|O 9C|O and|O 9D|O in|O the|O Supplementary|O Appendix|O )|O .|O
Multivariate|O analysis|O of|O OS|O was|O carried|O out|O by|O Cox|O regression|O .|O
Table|O 2|O .|O Univariate|O analysis|O for|O OS|O and|O RFS|O in|O AML|O patients|O (|O n|O =|O 389|O )|O according|O to|O cohesin|O gene|O mutation|O status|O .|O
In|O this|O analysis|O ,|O median|O OS|O between|O the|O Intermediate|O I|O and|O Intermediate|O II|O groups|O were|O not|O as|O widely|O separated|O among|O patients|O aged|O 60|O years|O and|O younger|O (|O 13|O .|O 6|O vs|O .|O 18|O .|O 7|O months|O ,|O respectively|O )|O ;|O in|O patients|O older|O than|O 60|O years|O ,|O median|O OS|O was|O similar|O between|O the|O 2|O intermediate|O groups|O (|O 9|O .|O 5|O vs|O .|O 9|O .|O 2|O months|O ,|O respectively|O )|O .|O
Besides|O ,|O a|O cell|O -|O cycle|O -|O dependent|O regulation|O of|O both|O GATA2|O expression|O and|O degradation|O has|O been|O demonstrated|O through|O its|O phosphorylation|O by|O CDK|O /|O cyclin|O systems|O at|O CDK|O consensus|O motifs|O (|O S|O /|O T0P|O +|O 1|O )|O ,|O suggesting|O that|O hematopoietic|O -|O cell|O proliferation|O may|O be|O modulated|O by|O expression|O of|O GATA2|O in|O tandem|O with|O cell|O -|O cycle|O regulators|O .|O
CtBP1|O and|O -|O 2|O interact|O specifically|O with|O FOG1|O through|O a|O motif|O located|O in|O the|O C|O -|O terminal|O half|O of|O FOG1|O ;|O however|O ,|O although|O transient|O transfection|O assays|O suggested|O that|O the|O FOG1|O /|O CtBP|O interaction|O is|O important|O for|O mediating|O transcriptional|O repression|O ,|O mice|O harboring|O a|O mutant|O FOG1|O with|O a|O disrupted|O CtBP|O -|O binding|O motif|O showed|O normal|O hematopoietic|O development|O ,|O indicating|O that|O the|O FOG1|O /|O CtBP|O interaction|O is|O not|O required|O for|O FOG1|O function|O in|O vivo|O .|O
JAK2V617|O is|O present|O in|O more|O than|O 95|O %|O of|O patients|O with|O PV|O ,|O and|O serum|O EPO|O levels|O are|O appropriately|O subnormal|O in|O more|O than|O 90|O %|O of|O patients|O .|O
To|O understand|O the|O role|O of|O these|O mutations|O in|O MDS|O pathogenesis|O ,|O the|O effects|O of|O the|O mutant|O alleles|O on|O RNA|O splicing|O should|O be|O evaluated|O in|O more|O physiological|O conditions|O using|O primary|O hematopoietic|O cells|O .|O
A|O recent|O paper|O described|O a|O case|O of|O a|O SCN|O patient|O who|O acquired|O a|O CSF3R|O truncation|O mutation|O followed|O by|O a|O T618I|O point|O mutation|O (|O reported|O as|O T595I|O using|O the|O traditional|O CSF3R|O numbering|O system|O that|O does|O not|O include|O the|O signal|O peptide|O )|O .|O
C|O -|O terminal|O mutations|O might|O be|O associated|O with|O a|O more|O frequent|O and|O rapid|O AML|O transformation|O .|O
Total|O white|O blood|O cells|O from|O the|O peripheral|O blood|O are|O the|O preferred|O type|O of|O cell|O population|O for|O these|O analyses|O .|O
Somatic|O mutations|O of|O SRSF2|O (|O mainly|O at|O the|O proline|O 95|O position|O )|O have|O been|O reported|O in|O MDS|O patients|O with|O an|O incidence|O of|O 11|O -|O 15|O %|O .|O
For|O the|O purpose|O of|O this|O study|O ,|O nonsynonymous|O variants|O known|O to|O be|O pathogenic|O ,|O rare|O ,|O or|O with|O unknown|O genotypic|O frequency|O variants|O in|O general|O population|O are|O included|O .|O
INTRODUCTION|O .|O
Large|O splenomegaly|O was|O defined|O as|O a|O spleen|O tip|O extending|O >|O 10|O cm|O from|O left|O costal|O margin|O ,|O as|O previously|O reported|O .|O
Comparisons|O of|O proportions|O were|O performed|O by|O the|O x2|O test|O and|O by|O Fisher|O '|O s|O exact|O test|O ,|O and|O differences|O in|O values|O and|O in|O ranks|O were|O assessed|O by|O Student|O t|O tests|O and|O Mann|O -|O Whitney|O U|O tests|O ,|O respectively|O .|O
Age|O >|O 65|O ,|O hemoglobin|O <|O 10|O g|O /|O dL|O ,|O leukocytosis|O >|O 25|O x|O 109|O /|O L|O ,|O circulating|O blasts|O >|O 1|O %|O ,|O and|O presence|O of|O constitutional|O symptoms|O .|O
The|O gene|O encoded|O GATA|O binding|O protein|O 2|O (|O globin|O transcription|O factor|O 2|O )|O (|O GATA2|O )|O is|O a|O transcription|O factor|O that|O is|O crucial|O for|O the|O proliferation|O and|O survival|O of|O hematopoietic|O cells|O .|O
The|O study|O design|O adhered|O to|O the|O tenets|O of|O the|O Declaration|O of|O Helsinki|O and|O was|O approved|O by|O our|O institutional|O review|O board|O before|O its|O initiation|O .|O
In|O contrast|O to|O earlier|O studies|O ,|O our|O result|O ,|O which|O included|O the|O largest|O cohort|O of|O CMML|O patients|O who|O had|O no|O earlier|O history|O of|O chemotherapy|O or|O radiotherapy|O ,|O showed|O for|O the|O first|O time|O a|O very|O high|O frequency|O of|O RUNX1|O mutations|O ,|O which|O was|O comparable|O with|O those|O reported|O in|O atomic|O bomb|O survivors|O or|O in|O chemotherapy|O -|O related|O MDS|O .|O
In|O both|O cases|O ,|O copy|O -|O number|O data|O and|O sequencing|O data|O reveal|O that|O these|O are|O loss|O -|O of|O -|O function|O ,|O frequently|O heterozygous|O alterations|O that|O often|O occur|O in|O concert|O in|O the|O same|O patient|O sample|O .|O
Interestingly|O ,|O the|O rate|O of|O CBL|O mutation|O was|O found|O to|O be|O significantly|O higher|O in|O secondary|O MDS|O compared|O with|O de|O novo|O MDS|O (|O 11|O .|O 7|O %|O versus|O 0|O .|O 6|O %|O ,|O respectively|O )|O .|O
Individual|O parameters|O of|O independent|O significance|O for|O LT|O included|O PB|O blast|O count|O and|O AMC|O >|O 10|O x|O 109|O /|O l|O .|O
In|O a|O phase|O II|O study|O in|O patients|O aged|O 60|O years|O and|O older|O (|O N|O =|O 55|O ;|O median|O age|O ,|O 74|O years|O )|O ,|O the|O CR|O rate|O with|O this|O agent|O (|O 20|O mg|O /|O m2|O /|O d|O for|O 5|O days|O )|O was|O 24|O %|O (|O including|O 6|O /|O 24|O patients|O [|O 24|O %|O ]|O with|O poor|O -|O risk|O cytogenetics|O )|O ,|O and|O the|O median|O EFS|O and|O OS|O were|O 6|O and|O 8|O months|O ,|O respectively|O .|O
The|O loss|O of|O function|O for|O PTEN|O /|O MMAC1|O appears|O to|O occur|O during|O the|O progression|O of|O multiple|O human|O cancers|O .|O PTEN|O /|O MMAC1|O has|O also|O been|O identified|O as|O the|O gene|O responsible|O for|O Cowden|O disease|O ,|O a|O rare|O familial|O syndrome|O associated|O with|O an|O elevated|O risk|O for|O tumors|O of|O the|O breast|O ,|O thyroid|O ,|O and|O skin|O ,|O and|O BannayanZonana|O syndrome|O ,|O a|O related|O harmartomatous|O polyposis|O syndrome|O .|O
The|O frequency|O of|O coexisting|O somatic|O mutations|O can|O yield|O insights|O into|O the|O molecular|O circuitry|O of|O a|O cancer|O .|O
Myelodysplastic|O syndromes|O (|O MDS|O )|O are|O a|O heterogeneous|O cluster|O of|O clonal|O hematopoietic|O neoplasms|O manifested|O by|O peripheral|O cytopenias|O ,|O lineage|O dysplasia|O ,|O and|O a|O predisposition|O to|O acute|O myeloid|O leukemia|O .|O
5hmC|O ,|O an|O oxidation|O product|O of|O 5mC|O by|O the|O TET|O family|O of|O iron|O (|O II|O )|O /|O alpha|O -|O ketoglutarate|O -|O dependent|O dioxygenases|O ,|O is|O considered|O a|O novel|O and|O important|O epigenetic|O marker|O that|O constitutes|O the|O initial|O process|O of|O DNA|O demethylation|O pathway|O (|O Fig|O .|O 1|O )|O .|O
Changes|O in|O symptoms|O recorded|O with|O the|O MFSAF|O were|O directionally|O consistent|O with|O the|O assessments|O made|O with|O other|O validated|O and|O common|O patient|O -|O reported|O outcome|O instruments|O used|O in|O this|O study|O .|O
Similarly|O ,|O in|O a|O retrospective|O review|O of|O adult|O patients|O with|O AML|O treated|O on|O CALGB|O protocols|O (|O N|O =|O 1213|O )|O ,|O the|O 5|O -|O year|O survival|O rates|O for|O those|O with|O favorable|O ,|O intermediate|O -|O risk|O ,|O and|O poor|O -|O risk|O cytogenetics|O were|O 55|O %|O ,|O 24|O %|O ,|O and|O 5|O %|O ,|O respectively|O .|O
Most|O patients|O with|O MDS|O have|O a|O detectable|O gene|O mutation|O ,|O making|O its|O clinical|O implementation|O broadly|O applicable|O .|O
HLA|O typing|O of|O family|O members|O is|O recommended|O for|O patients|O younger|O than|O 60|O years|O who|O do|O not|O have|O favorable|O -|O risk|O cytogenetics|O .|O
In|O the|O high|O -|O risk|O group|O ,|O a|O donor|O search|O should|O begin|O while|O the|O patient|O is|O recovering|O from|O induction|O chemotherapy|O rather|O than|O waiting|O for|O remission|O to|O be|O achieved|O .|O
The|O decision|O to|O use|O high|O -|O versus|O standard|O -|O dose|O cytarabine|O for|O induction|O might|O be|O influenced|O by|O consolidation|O strategies|O ;|O fewer|O high|O -|O dose|O consolidation|O cycles|O may|O be|O needed|O for|O patients|O induced|O with|O high|O -|O dose|O cytarabine|O or|O for|O those|O who|O will|O undergo|O early|O autologous|O HSCT|O .|O
Several|O in|O vivo|O experimental|O approaches|O have|O been|O explored|O to|O assess|O GATA2|O function|O in|O hematopoiesis|O .|O
Similarly|O ,|O the|O presence|O of|O SRSF2|O or|O IDH1|O mutations|O appears|O to|O predict|O leukemia|O independent|O of|O currently|O known|O risk|O factors|O including|O thrombocytopenia|O and|O unfavorable|O karyotype|O .|O
Among|O patients|O in|O whom|O the|O study|O drug|O was|O interrupted|O ,|O symptoms|O (|O assessed|O by|O means|O of|O the|O total|O symptom|O score|O )|O returned|O to|O baseline|O levels|O over|O a|O period|O of|O approximately|O 1|O week|O (|O Fig|O .|O
More|O recently|O ,|O a|O large|O series|O of|O patients|O with|O MDS|O (|O N|O =|O 317|O )|O showed|O that|O the|O SF3B1|O mutation|O status|O was|O not|O associated|O with|O time|O to|O AML|O progression|O or|O OS|O ,|O regardless|O if|O all|O patients|O or|O only|O the|O subgroup|O of|O patients|O with|O RS|O were|O included|O in|O the|O analyses|O .|O
We|O therefore|O studied|O a|O cohort|O of|O 1060|O patients|O with|O MDS|O ,|O myeloproliferative|O neoplasms|O (|O MPNs|O )|O ,|O MDS|O /|O MPN|O overlap|O syndromes|O ,|O and|O primary|O and|O secondary|O AML|O (|O pAML|O and|O sAML|O ,|O respectively|O )|O to|O elucidate|O the|O clinical|O characteristics|O of|O patients|O with|O myeloid|O neoplasms|O harboring|O cohesin|O mutations|O with|O respect|O to|O disease|O phenotype|O ,|O genetic|O background|O ,|O therapeutic|O response|O ,|O and|O clinical|O outcome|O .|O
Over|O the|O last|O decade|O ,|O genetic|O alterations|O in|O patients|O with|O MDS|O /|O CMML|O have|O been|O a|O subject|O of|O investigations|O .|O
Therefore|O ,|O lower|O -|O risk|O patients|O with|O myelodysplastic|O syndromes|O who|O have|O EZH2|O and|O ASXL1|O mutations|O may|O require|O more|O aggressive|O treatment|O than|O would|O be|O predicted|O by|O the|O IPSS|O .|O
Based|O on|O data|O from|O a|O large|O study|O in|O elderly|O patients|O (|O N|O =|O 1406|O )|O ,|O patient|O and|O disease|O factors|O significantly|O associated|O with|O CR|O and|O /|O or|O early|O death|O were|O identified|O and|O risk|O scores|O were|O developed|O based|O on|O multivariate|O regression|O analysis|O .|O
Patient|O number|O 6183|O (|O P7|O ,|O II|O ,|O 1|O )|O is|O a|O young|O girl|O with|O an|O initial|O presentation|O of|O neutropenia|O evolving|O to|O MDS|O associated|O with|O the|O loss|O of|O chromosome|O 7|O (|O Table|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
Among|O patients|O in|O the|O European|O cohort|O ,|O 382|O (|O 79|O %|O )|O displayed|O at|O least|O one|O somatic|O mutation|O (|O see|O Supplementary|O Figure|O S4|O for|O details|O )|O ;|O the|O frequency|O of|O individual|O mutations|O and|O their|O interrelationships|O are|O shown|O in|O Figure|O 1a|O .|O
MDS|O indicates|O myelodysplastic|O syndromes|O ;|O RCUD|O ,|O refractory|O cytopenia|O with|O unilineage|O dysplasia|O ;|O RCMD|O ,|O refractory|O cytopenia|O with|O multilineage|O dysplasia|O ;|O MDS|O -|O U|O ,|O MDS|O unclassifiable|O ;|O RARS|O ,|O refractory|O anemia|O with|O ring|O sideroblasts|O ;|O RAEB|O ,|O refractory|O anemia|O with|O excess|O blasts|O ;|O MDS|O /|O MPN|O ,|O MDS|O /|O myeloproliferative|O neoplasms|O ;|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O ;|O aCML|O ,|O atypical|O chronic|O myeloid|O leukemia|O ;|O JMML|O ,|O juvenile|O myelomonocytic|O leukemia|O ;|O RARS|O -|O T|O ,|O RARS|O associated|O with|O marked|O thrombocytosis|O ;|O PV|O ,|O polycythemia|O vera|O ;|O PMF|O ,|O primary|O myelofibrosis|O ;|O ET|O ,|O essential|O thrombocythemia|O ;|O and|O AML|O ,|O acute|O myeloid|O leukemia|O .|O
Thirty|O -|O six|O patients|O in|O the|O placebo|O group|O (|O 23|O .|O 4|O %|O )|O crossed|O over|O to|O ruxolitinib|O (|O 16|O before|O and|O 20|O after|O week|O 24|O ;|O see|O the|O Supplementary|O Appendix|O .|O )|O
Summarizing|O this|O data|O and|O taking|O our|O previously|O published|O data|O into|O account|O we|O were|O able|O to|O detect|O at|O least|O one|O molecular|O mutation|O in|O 61|O /|O 81|O (|O 75|O .|O 3|O %|O )|O patients|O (|O Figure|O 1a|O )|O .|O
Older|O adults|O with|O intact|O functional|O status|O (|O ie|O ,|O ECOG|O score|O 0|O -|O 2|O )|O ,|O minimal|O comorbidity|O ,|O and|O favorable|O cytogenetic|O or|O molecular|O mutations|O ,|O may|O benefit|O from|O standard|O therapies|O regardless|O of|O chronologic|O age|O .|O
Studies|O have|O shown|O significantly|O decreased|O OS|O outcomes|O among|O patients|O with|O DNMT3A|O mutations|O compared|O with|O those|O with|O the|O wild|O -|O type|O gene|O (|O median|O OS|O ,|O 12|O -|O 21|O vs|O .|O 40|O -|O 41|O months|O )|O .|O
In|O follow|O -|O up|O sequencing|O of|O an|O expanded|O cohort|O of|O 29|O patients|O from|O the|O New|O England|O Journal|O of|O Medicine|O report|O ,|O 21|O %|O have|O exhibited|O both|O CSF3R|O and|O SETBP1|O mutations|O ,|O with|O 31|O %|O of|O samples|O having|O CSF3R|O mutations|O only|O and|O 7|O %|O with|O SETBP1|O mutations|O only|O (|O Figure|O 1|O )|O .|O
Over|O the|O last|O several|O years|O ,|O our|O knowledge|O of|O genes|O being|O mutated|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O patients|O has|O not|O only|O expanded|O due|O to|O the|O results|O of|O next|O generation|O and|O whole|O genome|O sequencing|O efforts|O ,|O but|O we|O have|O also|O learned|O that|O mutations|O in|O AML|O occur|O in|O specific|O pathways|O .|O
In|O first|O complete|O remission|O ,|O he|O received|O a|O matched|O unrelated|O donor|O hematopoietic|O stem|O cell|O transplantation|O (|O HSCT|O )|O and|O is|O still|O in|O remission|O 18|O months|O after|O the|O allograft|O .|O
The|O presence|O of|O large|O hyperlobulated|O and|O mature|O -|O appearing|O megakaryocytes|O without|O erythroid|O or|O granulocyte|O proliferation|O is|O diagnostic|O for|O ET|O according|O to|O the|O WHO|O guidelines|O ,|O but|O reliability|O may|O depend|O on|O skilled|O hematopathologists|O .|O
The|O median|O spleen|O volume|O was|O more|O than|O 2500|O cm3|O (|O >|O 10|O times|O the|O median|O normal|O spleen|O volume|O of|O 200|O cm3|O )|O .|O
DFS|O rate|O (|O for|O patients|O with|O a|O CR|O )|O and|O OS|O rate|O (|O for|O all|O patients|O )|O at|O 4|O years|O was|O not|O significantly|O different|O between|O treatment|O arms|O .|O
The|O primary|O end|O point|O was|O the|O proportion|O of|O patients|O with|O a|O reduction|O of|O 35|O %|O or|O more|O in|O spleen|O volume|O from|O baseline|O to|O week|O 24|O ,|O measured|O by|O means|O of|O magnetic|O resonance|O imaging|O or|O computed|O tomography|O .|O
His|O younger|O brother|O (|O patient|O number|O 6331|O ;|O P4|O ,|O III|O ,|O 2|O )|O presented|O recurrent|O otitis|O during|O infancy|O and|O had|O a|O long|O period|O of|O extensive|O warts|O since|O the|O age|O of|O 12|O .|O
These|O results|O are|O also|O consistent|O with|O previous|O suggestions|O that|O mutations|O affecting|O epigenetic|O regulation|O might|O be|O prognostically|O more|O relevant|O than|O those|O involved|O with|O JAK|O -|O STAT|O signaling|O .|O
It|O is|O known|O that|O germline|O mutations|O lead|O to|O cohesinopathies|O that|O are|O characterized|O by|O growth|O and|O developmental|O disorders|O in|O regard|O to|O the|O role|O of|O cohesin|O genes|O in|O the|O pathogenesis|O of|O human|O disease|O .|O
PATIENTS|O ,|O MATERIALS|O ,|O AND|O METHODS|O .|O
The|O karyotype|O identified|O a|O translocation|O involving|O MLL|O along|O with|O a|O monosomy|O 7|O .|O
He|O presented|O with|O an|O Aspergillus|O infection|O during|O induction|O therapy|O and|O died|O from|O severe|O respiratory|O distress|O .|O
In|O subject|O 87|O ,|O we|O found|O a|O monoallelic|O microdeletion|O of|O 130|O kb|O at|O 7q36|O .|O 1|O .|O
Median|O remission|O duration|O was|O 45|O months|O for|O the|O high|O -|O dose|O arm|O ,|O compared|O with|O 12|O months|O for|O the|O standard|O treatment|O arm|O .|O
Whether|O the|O same|O set|O of|O genes|O is|O subject|O to|O altered|O epigenetic|O patterning|O in|O DNMT3A|O -|O mutant|O AML|O cells|O has|O not|O been|O investigated|O .|O
However|O ,|O other|O studies|O demonstrated|O that|O the|O presence|O of|O cohesin|O mutations|O did|O not|O have|O a|O negative|O impact|O on|O survival|O or|O response|O to|O treatment|O in|O AML|O .|O
This|O Special|O Article|O also|O points|O to|O future|O directions|O for|O genomic|O testing|O in|O BCR|O -|O ABL1|O -|O negative|O myeloproliferative|O neoplasms|O .|O
We|O next|O investigated|O associations|O of|O distinct|O mutations|O ,|O however|O ,|O no|O specific|O pattern|O was|O observed|O ,|O that|O is|O ,|O EZH2|O mutations|O were|O detected|O in|O combination|O with|O TET2|O alterations|O (|O 4|O /|O 10|O )|O ,|O ASXL1|O (|O 3|O /|O 10|O )|O ,|O RUNX1|O (|O 3|O /|O 10|O )|O ,|O CBL|O (|O 2|O /|O 10|O )|O ,|O JAK2|O (|O 2|O /|O 10|O )|O ,|O NRAS|O (|O 2|O /|O 10|O )|O ,|O KRAS|O (|O 1|O /|O 10|O )|O and|O IDH2|O (|O 1|O /|O 10|O )|O ,|O respectively|O (|O Figure|O 1a|O )|O .|O
A|O matched|O unrelated|O donor|O search|O (|O including|O cord|O blood|O )|O should|O be|O initiated|O for|O high|O -|O risk|O patients|O who|O would|O be|O candidates|O for|O HSCT|O in|O first|O CR|O ,|O or|O considered|O at|O first|O relapse|O in|O appropriate|O patients|O concomitant|O with|O initiation|O of|O reinduction|O therapy|O .|O
In|O addition|O ,|O the|O recent|O discovery|O of|O frequent|O mutations|O of|O epigenetic|O regulators|O engaged|O in|O DNA|O methylation|O (|O DNMT3A|O ,|O TET2|O ,|O and|O IDH1|O /|O 2|O )|O and|O histone|O modifications|O (|O ASXL1|O and|O EZH2|O and|O other|O components|O of|O Polycomb|O complex|O 2|O )|O in|O MDS|O suggested|O a|O central|O role|O of|O a|O compromised|O epigenetic|O regulation|O in|O their|O pathogenesis|O .|O
Greater|O efforts|O in|O this|O regard|O ,|O coupled|O with|O advances|O in|O epigenomic|O platforms|O ,|O will|O help|O to|O gain|O greater|O insight|O into|O the|O role|O of|O these|O mutations|O in|O MDS|O ,|O MPN|O and|O AML|O .|O
Table|O 1|O .|O Mutations|O in|O epigenetic|O modifiers|O in|O myeloid|O malignancies|O .|O
Heterozygous|O mutations|O largely|O present|O with|O a|O mutually|O exclusive|O pattern|O .|O
Mortality|O for|O splenectomy|O in|O PMF|O is|O 5|O %|O -|O 10|O %|O .|O
SF3B1|O .|O
In|O addition|O to|O RUNX1|O and|O CEBPA|O mutations|O ,|O monosomy|O 7|O was|O associated|O with|O pure|O familial|O MDS|O /|O AML|O in|O 14|O pedigrees|O with|O an|O autosomal|O -|O dominant|O transmission|O and|O a|O young|O age|O (|O <|O 18|O years|O )|O .|O
The|O reaction|O was|O then|O stopped|O by|O heat|O inactivation|O at|O 95|O -|O -|O degrees|O -|O -|O C|O for|O 5|O min|O .|O
MATERIALS|O AND|O METHODS|O .|O
A|O number|O of|O conclusions|O can|O be|O reached|O ,|O taking|O these|O data|O together|O .|O
JAK2FV617F|O allelic|O burden|O was|O only|O decreased|O 13|O %|O in|O bone|O marrow|O and|O 9|O %|O in|O peripheral|O blood|O from|O baseline|O .|O
Data|O were|O analyzed|O using|O our|O in|O -|O house|O pipeline|O for|O somatic|O mutation|O calling|O (|O Genomon|O )|O as|O previously|O described|O (|O http|O :|O /|O /|O genomon|O .|O hgc|O .|O jp|O /|O exome|O /|O en|O /|O index|O .|O html|O )|O .|O
INTRODUCTION|O .|O
Although|O there|O are|O small|O -|O molecule|O inhibitors|O for|O JAK2|O ,|O such|O as|O ruxolitinib|O [|O approved|O by|O the|O U|O .|O S|O .|O Food|O and|O Drug|O Administration|O (|O FDA|O )|O for|O myelofibrosis|O ]|O ,|O these|O target|O the|O JAK2|O and|O often|O the|O JAK1|O proteins|O ,|O and|O thus|O are|O not|O specific|O for|O the|O V617F|O mutation|O .|O
A|O subsequent|O post|O hoc|O analysis|O of|O OS|O with|O additional|O follow|O -|O up|O time|O showed|O the|O same|O median|O OS|O with|O a|O statistically|O significant|O advantage|O associated|O with|O decitabine|O (|O HR|O ,|O 0|O .|O 82|O ;|O 95|O %|O CI|O ,|O 0|O .|O 68|O -|O 0|O .|O 99|O ;|O P|O =|O .|O 03|O )|O .|O
In|O subject|O 73|O (|O who|O harbored|O a|O heterozygous|O splice|O -|O donor|O -|O site|O mutation|O in|O intron|O 12|O )|O ,|O only|O wild|O -|O type|O mRNA|O was|O detected|O .|O
The|O second|O most|O frequently|O mutated|O genes|O in|O the|O cohesin|O complex|O were|O SMC3|O and|O STAG2|O ,|O and|O we|O found|O 5|O patients|O with|O these|O mutations|O ,|O respectively|O .|O
The|O primary|O end|O point|O was|O the|O proportion|O of|O patients|O with|O a|O reduction|O in|O spleen|O volume|O of|O 35|O %|O or|O more|O at|O 24|O weeks|O ,|O assessed|O by|O means|O of|O magnetic|O resonance|O imaging|O .|O
Patients|O with|O nonmutated|O JAK2|O and|O MPL|O were|O studied|O for|O CALR|O exon|O 9|O mutations|O as|O reported|O in|O our|O original|O article|O or|O by|O Sanger|O sequencing|O ,|O as|O described|O elsewhere|O .|O
Significantly|O decreased|O OS|O with|O DNMT3A|O mutations|O has|O also|O been|O reported|O in|O the|O subgroup|O of|O patients|O with|O NK|O -|O AML|O with|O wild|O -|O type|O NPM1|O with|O or|O without|O FLT3|O -|O ITD|O or|O NPM1|O mutation|O in|O the|O presence|O of|O FLT3|O -|O ITD|O ,|O but|O not|O in|O the|O favorable|O subgroup|O with|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O .|O
Association|O between|O categorical|O variables|O (|O 2|O -|O way|O tables|O )|O was|O tested|O by|O the|O Fisher|O exact|O test|O .|O
Mutational|O analysis|O of|O the|O entire|O 9|O coding|O exons|O showed|O that|O only|O one|O cell|O line|O (|O U937|O )|O had|O a|O frameshift|O mutation|O resulting|O in|O premature|O termination|O of|O the|O PTEN|O /|O MMAC1|O protein|O .|O
Aberrant|O expression|O of|O differentiation|O antigens|O present|O at|O diagnosis|O may|O allow|O tracking|O of|O residual|O blasts|O through|O flow|O cytometry|O in|O follow|O -|O up|O samples|O that|O may|O appear|O normal|O according|O to|O conventional|O morphology|O .|O
All|O candidate|O mutations|O identified|O on|O mass|O -|O spectrometric|O genotyping|O were|O validated|O with|O the|O use|O of|O redesigned|O assays|O in|O nonamplified|O or|O independently|O amplified|O DNA|O specimens|O from|O the|O study|O patients|O with|O the|O use|O of|O homogeneous|O Mass|O -|O Extend|O (|O hME|O )|O chemistry|O ,|O as|O described|O previously|O .|O
Our|O results|O indicate|O that|O the|O PTEN|O /|O MMAC1|O gene|O may|O play|O a|O role|O in|O a|O small|O percentage|O of|O AML|O ,|O but|O its|O significance|O needs|O to|O be|O further|O evaluated|O .|O
Clinically|O verified|O MPL|O mutations|O are|O listed|O in|O Table|O 2|O .|O
Notably|O ,|O the|O prognostic|O relevance|O of|O ASXL1|O mutations|O was|O mostly|O restricted|O to|O patients|O with|O either|O intermediate|O -|O 2|O risk|O (|O P|O =|O 0|O .|O 03|O )|O or|O intermediate|O -|O 1|O plus|O low|O -|O risk|O disease|O (|O P|O =|O 0|O .|O 07|O )|O unlike|O high|O -|O risk|O disease|O (|O P|O =|O 0|O .|O 78|O )|O (|O Figure|O 4a|O )|O .|O
The|O presence|O of|O JAK2|O V617F|O mutation|O did|O not|O affect|O blood|O counts|O or|O clinical|O outcomes|O between|O patients|O with|O and|O without|O JAK2|O V617F|O .|O
The|O PRC2|O protein|O complex|O is|O an|O essential|O regulator|O of|O embryonic|O and|O hematopoietic|O stem|O cells|O ,|O required|O during|O cell|O differentiation|O ,|O for|O maintaining|O cell|O identity|O and|O proliferation|O ,|O and|O for|O stem|O -|O cell|O plasticity|O .|O
Affymetrix|O 250K|O and|O 6|O .|O 0|O Kit|O (|O Affymetrix|O )|O were|O used|O .|O
JAK2V617F|O is|O the|O best|O characterized|O mutation|O in|O BCR|O -|O ABL1|O -|O negative|O MPN|O .|O
No|O significant|O differences|O were|O observed|O in|O EFS|O ,|O DFS|O ,|O or|O OS|O outcomes|O between|O treatment|O arms|O .|O
Known|O single|O -|O nucleotide|O polymorphisms|O (|O SNPs|O )|O ,|O intronic|O polymorphisms|O more|O than|O six|O bases|O from|O a|O splice|O junction|O ,|O and|O silent|O mutations|O were|O excluded|O from|O further|O analysis|O .|O
Cox|O proportional|O hazard|O regression|O model|O was|O used|O for|O multivariable|O analysis|O .|O
IPSS|O and|O DIPSS|O risks|O were|O estimated|O as|O previously|O described|O .|O
DNA|O METHYLATION|O .|O
Another|O hypomethylating|O agent|O ,|O decitabine|O ,|O has|O also|O been|O evaluated|O as|O remission|O induction|O therapy|O for|O older|O patients|O with|O AML|O .|O
Evidence|O that|O accounting|O for|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O improves|O the|O risk|O stratification|O provided|O by|O IPSS|O .|O
Both|O azacytidine|O and|O decitabine|O are|O approved|O by|O the|O FDA|O as|O treatment|O for|O patients|O with|O MDS|O .|O
In|O all|O cases|O ,|O hematologic|O parameters|O fluctuated|O with|O time|O ,|O except|O for|O monocytes|O ,|O which|O remained|O low|O .|O
An|O identical|O mutational|O variant|O of|O SETBP1|O has|O also|O been|O described|O in|O Schinzel|O -|O Giedion|O midface|O retraction|O syndrome|O .|O
The|O exon|O 12|O mutations|O and|O the|O V617F|O mutation|O are|O mutually|O exclusive|O ;|O either|O V617F|O or|O exon|O 12|O mutations|O are|O present|O in|O virtually|O all|O cases|O of|O PV|O .|O
UTX|O ,|O in|O conjunction|O with|O the|O other|O epigenetic|O genes|O (|O e|O .|O g|O .|O ,|O EZH2|O )|O ,|O regulates|O histone|O methylation|O .|O
RNA|O Extraction|O and|O Reverse|O Transcription|O .|O
RARS|O -|O T|O :|O refractory|O anemia|O with|O ring|O sideroblasts|O with|O thrombocytosis|O ,|O a|O subtype|O of|O mixed|O myelodysplasia|O and|O myeloproliferative|O neoplasm|O .|O
Patients|O with|O ET|O are|O risk|O stratified|O in|O the|O same|O manner|O as|O those|O with|O PV|O (|O Table|O 5|O )|O .|O
RESULTS|O .|O
This|O criterion|O provides|O a|O measure|O of|O the|O relative|O goodness|O of|O fit|O of|O a|O statistical|O model|O and|O a|O means|O for|O comparison|O among|O models|O ,|O a|O lower|O AIC|O value|O indicating|O a|O better|O tradeoff|O between|O fit|O and|O complexity|O .|O
The|O role|O of|O cytogenetics|O in|O the|O classification|O of|O MPN|O is|O less|O defined|O than|O for|O the|O pathognomonic|O t|O (|O 9|O ;|O 22|O )|O karyotype|O of|O CML|O .|O
In|O 1951|O ,|O Dameshek|O organized|O chronic|O myelogenous|O leukemia|O (|O CML|O )|O ,|O polycythemia|O vera|O (|O PV|O )|O ,|O essential|O thrombocythemia|O (|O ET|O )|O ,|O and|O primary|O myelofibrosis|O (|O PMF|O )|O into|O an|O inclusive|O disease|O category|O that|O he|O termed|O "|O myeloproliferative|O disorders|O "|O (|O MPD|O )|O .|O
Workup|O .|O
The|O DNMT3A|O mutations|O have|O been|O reported|O in|O 18|O %|O to|O 22|O %|O of|O patients|O with|O AML|O ,|O with|O a|O frequency|O of|O 29|O %|O to|O 34|O %|O in|O those|O with|O NK|O -|O AML|O .|O
To|O better|O understand|O the|O role|O of|O GATA2|O ,|O further|O studies|O addressed|O to|O identify|O the|O downstream|O targets|O that|O mediate|O the|O effects|O of|O this|O transcription|O factor|O would|O be|O needed|O .|O
JAK2|O .|O
Therefore|O ,|O deregulation|O of|O these|O processes|O is|O intimately|O linked|O to|O hematopoietic|O disorders|O and|O may|O result|O in|O leukemia|O .|O
Only|O the|O mutation|O in|O R381Q|O of|O SMC3|O was|O recurrent|O in|O 2|O patients|O ,|O whereas|O all|O other|O mutations|O were|O only|O identified|O once|O (|O Figure|O 1|O and|O supplemental|O Table|O 4|O )|O .|O
A|O diagnosis|O of|O PV|O can|O be|O made|O when|O JAK2|O V617F|O or|O exon|O 12|O mutation|O is|O detected|O ,|O along|O with|O increased|O hemoglobin|O and|O low|O or|O normal|O levels|O of|O erythropoietin|O .|O
Unlike|O granulocyte|O isolation|O ,|O optimization|O in|O a|O PCR|O procedure|O does|O not|O increase|O time|O ,|O labor|O ,|O or|O cost|O on|O a|O routine|O basis|O .|O
Anemia|O and|O thrombocytopenia|O were|O the|O most|O frequent|O hematologic|O adverse|O events|O (|O overall|O and|O grade|O 3|O or|O 4|O events|O )|O (|O Table|O 2|O )|O and|O a|O reason|O for|O treatment|O discontinuation|O in|O one|O patient|O in|O each|O study|O -|O drug|O group|O for|O each|O event|O .|O
In|O our|O cohort|O ,|O we|O identified|O mutations|O in|O genes|O of|O the|O cohesin|O complex|O in|O 23|O AML|O patients|O (|O 5|O .|O 9|O %|O )|O .|O
Because|O the|O allele|O burden|O varies|O between|O MPN|O entities|O or|O between|O patients|O at|O diagnosis|O and|O after|O treatment|O ,|O samples|O with|O a|O low|O allelic|O frequency|O should|O be|O included|O .|O
CSF3R|O truncation|O mutations|O result|O in|O a|O loss|O of|O a|O portion|O of|O the|O cytoplasmic|O domain|O of|O the|O receptor|O ,|O suggesting|O possible|O molecular|O mechanisms|O for|O receptor|O activation|O .|O
Within|O "|O higher|O -|O risk|O "|O subjects|O (|O Figure|O 5B|O )|O ,|O CALR|O -|O mutant|O patients|O had|O a|O better|O OS|O compared|O with|O all|O the|O remaining|O genetic|O subgroups|O (|O P|O =|O .|O 023|O compared|O with|O JAK2|O -|O mutant|O ,|O P|O =|O .|O 003|O compared|O with|O MPL|O -|O mutant|O ,|O and|O P|O =|O .|O 001|O compared|O with|O triple|O -|O negative|O patients|O )|O .|O
For|O the|O purposes|O of|O comparison|O ,|O results|O were|O grouped|O as|O high|O (|O >|O 50|O %|O )|O ,|O moderate|O (|O 5|O %|O to|O 50|O %|O )|O ,|O low|O (|O 2|O %|O to|O 5|O %|O )|O ,|O and|O negative|O (|O <|O 2|O %|O )|O .|O
In|O line|O with|O other|O studies|O ,|O cohesin|O mutations|O were|O not|O associated|O with|O an|O increase|O in|O the|O frequency|O of|O complex|O cytogenetic|O abnormalities|O .|O
The|O strongest|O correlation|O was|O found|O in|O PMF|O ,|O where|O 33|O %|O of|O 109|O patients|O had|O cytogenetic|O abnormalities|O ,|O including|O +|O 8|O ,|O 13q|O -|O ,|O 20q|O -|O ,|O and|O abnormalities|O of|O chromosomes|O 1|O ,|O 7|O ,|O and|O 9|O .|O
Figure|O 1|O .|O EZH2|O is|O recurrently|O affected|O in|O individuals|O with|O MDS|O .|O (|O a|O )|O Genomic|O aberrations|O of|O chromosome|O 7|O detected|O in|O 102|O individuals|O with|O MDS|O by|O high|O -|O resolution|O SNP|O arrays|O .|O Numbers|O on|O the|O right|O are|O unique|O patient|O numbers|O .|O Two|O subjects|O carried|O large|O areas|O of|O UPD|O (|O blue|O bars|O )|O ,|O 14|O carried|O deletions|O (|O red|O bars|O )|O and|O 6|O showed|O duplications|O (|O green|O bars|O ,|O asterisk|O represents|O four|O different|O subjects|O )|O .|O Subject|O 87|O showed|O a|O 130|O -|O kb|O microdeletion|O at|O 7q36|O .|O 1|O ,|O which|O contains|O CUL1|O and|O EZH2|O .|O CNA|O ,|O copy|O number|O alterations|O ;|O UPD|O ,|O uniparental|O disomy|O .|O (|O b|O )|O Protein|O localization|O of|O ten|O different|O EZH2|O point|O mutations|O found|O in|O 8|O out|O of|O 126|O subjects|O with|O MDS|O .|O The|O ruler|O indicates|O amino|O acids|O .|O The|O catalytic|O SET|O domain|O ,|O a|O C|O -|O rich|O domain|O and|O the|O two|O SANT|O domains|O are|O indicated|O .|O Numbers|O in|O the|O boxes|O indicate|O unique|O patent|O numbers|O (|O UPN|O )|O
Subgroups|O .|O
In|O the|O placebo|O group|O ,|O patients|O with|O and|O those|O without|O grade|O 3|O or|O 4|O anemia|O had|O worsening|O of|O symptoms|O ,|O which|O was|O greater|O in|O patients|O with|O anemia|O .|O
Five|O patients|O had|O more|O than|O one|O episode|O of|O grade|O 3|O or|O 4|O thrombocytopenia|O .|O
Postremission|O or|O Consolidation|O Therapy|O :|O Although|O successful|O induction|O therapy|O clears|O the|O visible|O signs|O of|O leukemia|O in|O the|O marrow|O and|O restores|O normal|O hematopoiesis|O in|O patients|O with|O de|O novo|O AML|O ,|O additional|O postremission|O therapy|O (|O ie|O ,|O consolidation|O )|O is|O needed|O to|O reduce|O the|O residual|O abnormal|O cells|O to|O a|O level|O that|O can|O be|O contained|O by|O immune|O surveillance|O .|O
French|O Severe|O Chronic|O Neutropenia|O Registry|O .|O
Mutation|O descriptors|O are|O not|O translated|O into|O the|O standard|O Human|O Genome|O Variation|O Society|O (|O HGVS|O )|O nomenclature|O ,|O to|O avoid|O misinterpretation|O .|O
On|O the|O basis|O of|O these|O findings|O ,|O we|O screened|O other|O rationally|O selected|O genes|O within|O the|O spliceosomal|O machinery|O in|O patients|O with|O MDS|O and|O related|O disorders|O (|O n|O =|O 120|O )|O .|O
Undoubtedly|O ,|O cell|O division|O is|O one|O of|O the|O key|O processes|O for|O every|O tumor|O cell|O including|O AML|O blasts|O due|O to|O the|O increased|O proliferation|O potential|O of|O malignant|O cells|O .|O
Study|O Design|O And|O treatment|O .|O
GATA2|O is|O degraded|O through|O ubiquitination|O -|O proteasome|O -|O dependent|O systems|O and|O three|O regions|O located|O in|O the|O non|O -|O finger|O areas|O (|O amino|O acids|O 1|O -|O -|O 70|O ,|O 153|O -|O -|O 256|O and|O 412|O -|O -|O 480|O )|O appear|O to|O be|O important|O for|O its|O degradation|O .|O
Until|O these|O recent|O results|O were|O obtained|O ,|O spliceosomal|O dysfunction|O was|O only|O rarely|O associated|O with|O malignant|O transformation|O .|O
NPM1|O mutations|O can|O occur|O concurrently|O with|O FLT3|O -|O ITD|O ,|O and|O patients|O who|O have|O both|O genetic|O lesions|O have|O an|O outcome|O more|O similar|O to|O those|O with|O isolated|O FLT3|O -|O ITD|O mutations|O .|O
These|O results|O were|O confirmed|O after|O adjusting|O for|O time|O -|O dependent|O DIPSS|O ,|O with|O a|O better|O OS|O of|O patients|O with|O type|O 1|O CALR|O mutation|O compared|O with|O those|O with|O JAK2|O (|O V617F|O )|O (|O HR|O 2|O .|O 01|O ,|O P|O =|O .|O 04|O )|O ,|O and|O no|O difference|O between|O patients|O with|O type|O 1|O and|O those|O with|O type|O 2|O CALR|O mutation|O ,|O as|O well|O as|O between|O patients|O with|O type|O 2|O CALR|O mutation|O and|O those|O with|O JAK2|O (|O V617F|O )|O .|O
Quantitative|O real|O time|O PCR|O (|O qPCR|O )|O testing|O for|O monitoring|O JAK2|O V617F|O allele|O burden|O has|O been|O limited|O to|O patients|O enrolled|O in|O clinical|O trials|O such|O as|O the|O peg|O -|O IFN|O -|O a|O -|O 2a|O and|O MF|O -|O TG101348|O -|O 001|O trials|O .|O
These|O findings|O show|O that|O ruxolitinib|O is|O an|O effective|O therapy|O for|O myelofibrosis|O .|O
The|O disease|O course|O of|O therapy|O -|O related|O MDS|O /|O AML|O is|O generally|O progressive|O and|O may|O be|O more|O resistant|O to|O conventional|O cytotoxic|O therapies|O than|O de|O novo|O cases|O of|O MDS|O /|O AML|O .|O
INTRODUCTION|O .|O
Recently|O ,|O a|O more|O diverse|O range|O of|O missense|O ,|O nonsense|O and|O frameshift|O mutations|O in|O EZH2|O were|O identified|O in|O patients|O with|O myeloid|O malignancies|O ,|O most|O commonly|O PRC2|O complex|O in|O MDS|O ,|O CMML|O and|O primary|O myelofibrosis|O (|O PMF|O )|O and|O rarely|O in|O other|O chronic|O or|O acute|O myeloid|O malignancies|O (|O FIG|O .|O 2|O ;|O TABLE|O 1|O )|O .|O
CBL|O .|O
The|O deficiency|O of|O ABCB7|O protein|O is|O related|O to|O mitochondrial|O iron|O overload|O ,|O reduced|O heme|O synthesis|O at|O earlier|O phase|O of|O erythroid|O precursors|O ,|O and|O ineffective|O erythropoiesis|O .|O
These|O patients|O should|O be|O considered|O for|O a|O clinical|O trial|O ,|O allogeneic|O HSCT|O with|O matched|O sibling|O or|O matched|O unrelated|O donor|O ,|O or|O best|O supportive|O care|O .|O
The|O presence|O of|O STAG2|O mutation|O appeared|O to|O be|O associated|O with|O adverse|O clinical|O outcome|O and|O an|O increase|O in|O bone|O marrow|O blasts|O .|O
Besides|O ,|O an|O essential|O contribution|O of|O GATA2|O to|O urogenital|O development|O has|O been|O shown|O .|O
The|O mutant|O enzymes|O are|O not|O catalytically|O inactive|O .|O
Chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O is|O classified|O as|O one|O of|O the|O subtypes|O of|O myelodysplastic|O syndrome|O (|O MDS|O )|O in|O the|O French|O -|O American|O -|O British|O system|O ,|O whereas|O according|O to|O the|O World|O Health|O Organization|O classification|O ,|O CMML|O is|O categorized|O to|O be|O an|O MDS|O /|O myeloproliferative|O disease|O rather|O than|O MDS|O per|O se|O .|O
SURVEY|O OF|O MUTATIONS|O IN|O THE|O STUDY|O SAMPLES|O .|O
In|O general|O ,|O high|O ALC|O have|O been|O associated|O with|O favorable|O outcomes|O in|O hematological|O malignancies|O ,|O and|O its|O inclusion|O as|O an|O adverse|O prognosticator|O in|O the|O MDAPS|O is|O perplexing|O .|O
The|O period|O taken|O into|O account|O was|O the|O time|O interval|O from|O birth|O to|O the|O first|O date|O when|O the|O event|O was|O observed|O or|O when|O no|O event|O occurred|O to|O the|O last|O examination|O .|O
A|O '|O two|O -|O hit|O '|O model|O of|O leukemogenesis|O of|O AML|O ,|O that|O is|O ,|O cooperation|O of|O class|O I|O mutations|O that|O drive|O proliferation|O and|O class|O II|O mutations|O that|O lead|O to|O differentiation|O block|O in|O leukemic|O cells|O ,|O has|O been|O proposed|O .|O
Besides|O ,|O it|O is|O known|O that|O an|O E|O -|O box|O -|O WGATAR|O composite|O element|O residing|O within|O a|O GATA2|O intron|O (|O 9|O .|O 5|O kb|O downstream|O of|O the|O transcription|O start|O site|O )|O confers|O strong|O enhancer|O activity|O in|O GATA2|O -|O expressing|O cells|O in|O vitro|O and|O in|O the|O vasculature|O and|O fetal|O liver|O of|O mouse|O embryos|O .|O
Recently|O ,|O other|O common|O molecular|O lesions|O with|O prognostic|O impact|O have|O been|O identified|O in|O patients|O with|O AML|O .|O
Similar|O results|O were|O obtained|O when|O only|O considering|O patients|O with|O de|O novo|O AML|O (|O n|O =|O 348|O )|O with|O the|O exclusion|O of|O patients|O with|O secondary|O AML|O (|O OS|O :|O HR|O 0|O .|O 96|O ;|O 95|O %|O CI|O ,|O 0|O .|O 54|O -|O 1|O .|O 73|O ;|O P|O =|O .|O 89|O ;|O supplemental|O Figure|O 2A|O )|O ,|O (|O RFS|O :|O HR|O 0|O .|O 62|O ;|O 95|O %|O CI|O ,|O 0|O .|O 3|O -|O 1|O .|O 25|O ;|O P|O =|O .|O 18|O ;|O supplemental|O Figure|O 2B|O )|O ,|O and|O (|O CR|O :|O mutated|O 82|O %|O vs|O wild|O -|O type|O 78|O %|O ;|O P|O =|O .|O 65|O )|O .|O
Management|O of|O AML|O in|O Patients|O Younger|O Than|O 60|O Years|O .|O
A|O total|O of|O 617|O patients|O with|O PMF|O were|O recruited|O from|O 4|O centers|O :|O 187|O from|O the|O Department|O of|O Hematology|O Oncology|O and|O 171|O from|O the|O Center|O for|O the|O Study|O of|O Myelofibrosis|O (|O Pavia|O ,|O Italy|O )|O ,|O 163|O from|O the|O University|O Hospital|O (|O Florence|O ,|O Italy|O )|O ,|O and|O 96|O from|O the|O Hospital|O Clinic|O (|O Barcelona|O ,|O Spain|O )|O .|O
In|O subject|O 97|O ,|O a|O point|O mutation|O was|O found|O that|O was|O homozygous|O due|O to|O UPD|O ,|O and|O in|O subject|O 96|O ,|O two|O different|O point|O mutations|O were|O found|O that|O resided|O on|O two|O different|O alleles|O (|O Supplementary|O Fig|O .|O 4|O )|O .|O
Additionally|O ,|O similar|O to|O our|O observations|O in|O CNL|O /|O aCML|O ,|O SCN|O patients|O can|O acquire|O compound|O CSF3R|O mutations|O .|O
The|O estimated|O 2|O -|O year|O AML|O transformation|O free|O was|O 21|O %|O for|O mutation|O -|O positive|O patients|O and|O 55|O %|O for|O mutationnegative|O patients|O .|O
AT|O A|O GLANCE|O .|O
On|O the|O other|O hand|O ,|O it|O has|O been|O recently|O shown|O that|O the|O -|O 2|O .|O 8|O kb|O site|O confers|O maximal|O Gata2|O expression|O in|O HSCs|O and|O progenitors|O in|O specific|O contexts|O ,|O demonstrating|O that|O the|O -|O 2|O .|O 8|O kb|O site|O is|O not|O required|O for|O initiation|O or|O maintenance|O of|O Gata2|O repression|O during|O erythroid|O differentiation|O .|O
Induction|O Therapy|O :|O The|O creation|O of|O separate|O guidelines|O for|O patients|O older|O than|O 60|O years|O recognizes|O the|O poor|O outcomes|O in|O this|O group|O treated|O with|O standard|O cytarabine|O and|O an|O anthracycline|O .|O
However|O ,|O when|O each|O one|O of|O the|O four|O mutations|O was|O individually|O evaluated|O in|O the|O context|O of|O DIPSS|O -|O plus|O ,|O only|O ASXL1|O mutations|O remained|O significant|O (|O HR|O :|O 1|O .|O 4|O ,|O 95|O %|O CI|O :|O 1|O .|O 0|O -|O 1|O .|O 9|O ;|O P|O =|O 0|O .|O 04|O )|O .|O
What|O Are|O the|O Technical|O Issues|O Associated|O with|O JAK2|O and|O MPL|O Mutation|O Testing|O ?|O
When|O comparing|O patients|O with|O reduced|O expression|O or|O mutation|O of|O STAG2|O to|O patients|O with|O intact|O expression|O of|O WT|O STAG2|O ,|O we|O identified|O 28|O genes|O ,|O which|O were|O differentially|O expressed|O in|O patients|O with|O STAG2|O alterations|O regardless|O of|O whether|O this|O was|O due|O to|O somatic|O mutations|O or|O transcriptional|O downregulation|O (|O supplemental|O Table|O 13|O )|O .|O
Conclusions|O .|O
Moreover|O ,|O FLT3|O -|O TKD|O mutation|O as|O the|O sole|O genetic|O aberration|O or|O occurring|O concurrently|O with|O t|O (|O 15|O ;|O 17|O )|O /|O PML|O -|O RARA|O (|O underlying|O lesion|O in|O the|O APL|O subtype|O )|O or|O with|O FLT3|O -|O ITD|O (|O FLT3|O double|O mutation|O )|O has|O been|O associated|O with|O poorer|O outcomes|O .|O
This|O suggests|O that|O mutation|O in|O early|O stem|O cells|O may|O confer|O an|O advantage|O in|O clonal|O evolution|O .|O
RUNX1|O mutations|O have|O rarely|O been|O reported|O in|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O .|O
Hydroxyurea|O also|O has|O been|O shown|O to|O effectively|O reduce|O the|O JAK2V617|O allelic|O burden|O (|O molecular|O remission|O )|O ,|O although|O the|O long|O -|O term|O implications|O of|O this|O remain|O unclear|O .|O
Cytogenetic|O analysis|O was|O performed|O according|O to|O standard|O banding|O techniques|O on|O the|O basis|O of|O 20|O metaphases|O .|O
Adverse|O effects|O included|O thrombocytopenia|O ,|O anemia|O ,|O and|O a|O rapid|O return|O of|O symptoms|O after|O discontinuation|O of|O therapy|O .|O
RAS|O mutations|O are|O frequent|O events|O in|O CMML|O .|O
ABSTRACT|O .|O
Biomarkers|O .|O
The|O mutated|O genes|O are|O primarily|O engaged|O in|O the|O 3|O '|O -|O splice|O site|O recognition|O during|O pre|O -|O mRNA|O processing|O ,|O leading|O to|O abnormal|O RNA|O splicing|O and|O ineffective|O hematopoiesis|O .|O
The|O GATA1|O and|O GATA2|O genes|O are|O regulated|O through|O dynamic|O changes|O in|O the|O occupancy|O by|O GATA|O factors|O of|O GATA|O motifs|O in|O their|O regulatory|O regions|O ,|O so|O that|O there|O must|O be|O a|O switch|O controlled|O by|O GATA|O factors|O in|O GATA1|O and|O GATA2|O gene|O expression|O .|O
An|O early|O study|O showed|O detected|O missense|O point|O mutations|O of|O p53|O have|O been|O detected|O in|O 3|O of|O 44|O patients|O with|O high|O -|O grade|O MDS|O (|O 2|O RAEB|O and|O 1|O RAEB|O -|O T|O /|O AML|O )|O .|O
However|O ,|O a|O frameshift|O mutation|O in|O exon|O 7|O (|O 703delGinsAA|O ,|O nomenclature|O as|O described|O in|O ref|O .|O 5|O )|O introducing|O a|O premature|O stop|O codon|O was|O found|O in|O EZH2|O (|O Table|O 1|O ,|O Supplementary|O Figs|O .|O 2|O and|O 3|O )|O .|O
IPSS|O -|O or|O DIPSS|O -|O plus|O -|O independent|O prognostic|O value|O was|O also|O demonstrated|O by|O classifying|O patients|O into|O mutationally|O '|O high|O '|O or|O '|O low|O '|O risk|O groups|O defined|O as|O the|O respective|O presence|O or|O absence|O of|O at|O least|O one|O of|O the|O aforementioned|O mutations|O that|O were|O prognostically|O relevant|O for|O either|O overall|O or|O leukemia|O -|O free|O survival|O .|O
Moreover|O ,|O in|O our|O cases|O with|O normal|O karyotype|O AML|O ,|O GATA2|O overexpression|O was|O significantly|O associated|O with|O other|O molecular|O markers|O in|O AML|O as|O FLT3|O -|O ITD|O and|O NPM1|O mutations|O ,|O and|O EVI1|O and|O WT1|O overexpression|O .|O
EZH2|O mutations|O may|O also|O co|O -|O occur|O with|O TET2|O mutations|O and|O have|O been|O frequently|O found|O in|O high|O -|O grade|O MDS|O .|O
Similarly|O ,|O the|O Gata2|O knock|O -|O out|O mouse|O has|O profound|O defects|O in|O definitive|O hematopoiesis|O :|O Gata2|O -|O deficient|O embryos|O die|O of|O anemia|O at|O day|O 10|O -|O 11|O of|O gestation|O ,|O and|O show|O defects|O in|O the|O self|O -|O renewal|O and|O proliferation|O capacity|O of|O HSC|O .|O
Total|O RNA|O was|O purified|O as|O described|O previously|O or|O using|O a|O commercial|O kit|O (|O TRIzol|O Reagent|O ,|O GIBCOBRL|O ,|O NY|O )|O .|O The|O extracted|O RNA|O was|O treated|O with|O RNasefree|O DNase|O I|O .|O cDNA|O was|O synthesized|O from|O 1|O mug|O of|O total|O RNA|O .|O
In|O summary|O ,|O cohesin|O mutations|O ,|O which|O likely|O result|O in|O loss|O of|O function|O ,|O are|O recurrent|O molecular|O genetic|O events|O in|O both|O solid|O and|O hematopoietic|O tumors|O .|O
Additional|O MPL|O mutations|O have|O since|O been|O described|O at|O the|O same|O locus|O ,|O with|O an|O overall|O MPL515|O mutational|O frequency|O estimated|O at|O 4|O %|O for|O ET|O and|O 11|O %|O for|O PMF|O .|O
GATA2|O mutations|O are|O indicated|O as|O protein|O (|O first|O line|O )|O or|O nucleotide|O (|O second|O line|O )|O variations|O .|O Complete|O blood|O count|O was|O collected|O during|O routine|O at|O baseline|O before|O HSCT|O in|O absence|O of|O clonal|O hematopoiesis|O .|O
Five|O laboratories|O also|O offered|O JAK2|O exon|O 12|O assays|O ,|O two|O laboratories|O offered|O MPL|O mutation|O assays|O ,|O and|O another|O two|O provided|O MPL|O mutation|O results|O (|O although|O their|O assays|O were|O still|O being|O validated|O )|O .|O
The|O male|O patients|O had|O a|O functionally|O homozygous|O mutation|O for|O STAG2|O and|O SMC1A|O .|O
Although|O variations|O exist|O between|O institutional|O standards|O and|O practices|O ,|O several|O supportive|O care|O issues|O are|O important|O to|O consider|O in|O the|O management|O of|O patients|O with|O AML|O .|O
The|O TET|O family|O of|O proteins|O was|O first|O identified|O with|O the|O cloning|O of|O TET1|O as|O a|O fusion|O partner|O of|O MLL|O in|O patients|O with|O t|O (|O 10|O ;|O 11|O )|O (|O q22|O ;|O q23|O )|O AML|O .|O
Although|O several|O mutational|O studies|O of|O ASXL1|O have|O been|O impaired|O by|O the|O inclusion|O of|O nonsomatic|O variants|O ,|O mutations|O in|O ASXL1|O are|O associated|O with|O poor|O outcome|O in|O patients|O with|O MDS|O and|O in|O patients|O with|O AML|O .|O
This|O reversible|O modification|O is|O thought|O to|O be|O associated|O with|O transcriptional|O repression|O .|O
Thus|O JAK2|O -|O mediated|O tyrosine|O phosphorylation|O of|O PRMT5|O and|O histone|O H3|O -|O Y41|O can|O lead|O to|O direct|O alterations|O in|O epigenetic|O patterning|O .|O
The|O high|O -|O risk|O molecular|O group|O is|O defined|O as|O either|O NPM1|O -|O wild|O -|O type|O /|O FLT3|O -|O ITD|O -|O negative|O ,|O or|O NPM1|O -|O wild|O -|O type|O /|O FLT3|O -|O ITD|O -|O positive|O ,|O or|O NPM1|O -|O mutated|O /|O FLT3|O -|O ITD|O -|O positive|O .|O The|O low|O -|O risk|O molecular|O group|O is|O defined|O by|O the|O presence|O of|O an|O NPM1|O mutation|O and|O the|O absence|O of|O FLT3|O -|O ITD|O .|O
Although|O the|O results|O of|O clinical|O correlative|O studies|O have|O not|O been|O uniform|O ,|O in|O the|O largest|O series|O ,|O TET2|O mutations|O were|O associated|O with|O poorer|O prognosis|O in|O patients|O with|O favourable|O -|O risk|O ,|O cytogenetically|O normal|O AML|O (|O CN|O -|O AML|O )|O ,|O whereas|O studies|O have|O failed|O to|O demonstrate|O a|O consistent|O prognostic|O relevance|O of|O TET2|O mutations|O in|O patients|O with|O MPN|O or|O MDS|O .|O
This|O first|O involved|O variant|O allelic|O frequency|O (|O VAF|O )|O analyses|O of|O cooccurring|O mutations|O in|O samples|O ,|O adjusted|O for|O copy|O number|O .|O
The|O postanalytic|O components|O include|O interpretive|O comments|O ,|O if|O needed|O .|O
We|O identified|O 7|O different|O GATA2|O mutations|O in|O 14|O patients|O coming|O from|O 7|O pedigrees|O (|O Figure|O 1|O )|O .|O
Similarly|O ,|O 15|O out|O of|O 20|O RAD21|O sequence|O alterations|O were|O nonsense|O (|O n|O =|O 2|O )|O ,|O frameshift|O (|O n|O =|O 11|O )|O ,|O or|O splice|O site|O (|O n|O =|O 2|O )|O mutations|O causing|O low|O expression|O of|O the|O gene|O ;|O 5|O were|O missense|O mutations|O .|O
ETS1|O ,|O likewise|O involved|O in|O megakaryocyte|O development|O ,|O increases|O during|O megakaryocyte|O maturation|O ,|O and|O its|O overexpression|O is|O associated|O with|O enhanced|O differentiation|O and|O upregulation|O of|O GATA2|O and|O other|O megakaryocyte|O -|O specific|O genes|O .|O
No|O genome|O -|O wide|O increase|O in|O intron|O retention|O was|O observed|O in|O the|O patients|O with|O mutations|O .|O
Severe|O infections|O were|O defined|O as|O those|O that|O would|O be|O life|O -|O threatening|O without|O appropriate|O antibiotic|O or|O antifungal|O therapy|O .|O
Although|O the|O remission|O rates|O are|O similar|O for|O high|O -|O and|O standard|O -|O dose|O cytarabine|O ,|O 2|O studies|O have|O shown|O more|O rapid|O marrow|O blast|O clearance|O after|O 1|O cycle|O of|O high|O -|O dose|O therapy|O and|O a|O DFS|O advantage|O for|O patients|O aged|O 50|O years|O or|O younger|O who|O received|O the|O high|O -|O dose|O therapy|O .|O
Moreover|O ,|O GATA2|O is|O crucial|O for|O the|O proliferation|O and|O maintenance|O of|O hematopoietic|O stem|O cells|O and|O multipotential|O progenitors|O .|O
In|O mice|O ,|O Gata1|O null|O defects|O in|O erythroid|O cells|O can|O be|O partially|O rescued|O by|O knocking|O in|O Gata3|O into|O the|O endogenous|O Gata1|O locus|O .|O
A|O number|O of|O AML|O cell|O lines|O are|O positive|O for|O JAK2|O V617F|O ,|O including|O HEL|O ,|O MB|O -|O 02|O ,|O MUTZ|O -|O 8|O ,|O SET|O -|O 2|O ,|O UKE|O -|O 1|O .|O
RUNX1|O is|O also|O known|O as|O AML1|O and|O acts|O to|O regulate|O the|O expression|O of|O various|O genes|O specific|O for|O hematopoiesis|O ,|O including|O G|O -|O CSF|O ,|O IL|O -|O 3|O ,|O T|O -|O cell|O receptor|O and|O myeloperoxidase|O .|O
RNA|O SPLICING|O .|O
Complications|O may|O occur|O as|O infectious|O diseases|O ,|O but|O also|O less|O frequently|O as|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
ABSTRACT|O .|O
The|O libraries|O were|O then|O submitted|O for|O Illumina|O HiSeq2000|O sequencing|O according|O to|O standard|O procedures|O .|O
Instead|O ,|O Li|O et|O al|O found|O BCORL1|O to|O be|O mutated|O by|O searching|O for|O recurrent|O mutations|O in|O a|O discovery|O cohort|O of|O 8|O patients|O with|O secondary|O AML|O (|O s|O -|O AML|O )|O that|O were|O subjected|O to|O whole|O -|O exome|O sequencing|O .|O
The|O first|O is|O to|O characterize|O the|O disease|O process|O based|O on|O factors|O such|O as|O 1|O )|O prior|O toxic|O exposure|O ,|O 2|O )|O antecedent|O myelodysplasia|O ,|O and|O 3|O )|O karyotypic|O or|O molecular|O abnormalities|O ,|O which|O may|O provide|O prognostic|O information|O that|O could|O impact|O responsiveness|O to|O chemotherapy|O and|O risk|O of|O relapse|O .|O
Patients|O were|O registered|O in|O the|O French|O Severe|O Chronic|O Neutropenia|O Registry|O ,|O which|O was|O established|O in|O 1993|O to|O collect|O data|O from|O 35|O pediatric|O hematology|O -|O oncology|O clinical|O units|O .|O
MDS|O subtypes|O of|O refractory|O anemia|O (|O RA|O )|O ,|O RA|O with|O ringed|O sideroblasts|O ,|O and|O refractory|O cytopenia|O with|O multilineage|O dysplasia|O were|O classified|O as|O low|O -|O risk|O MDS|O .|O
For|O those|O with|O significant|O residual|O blasts|O or|O clear|O -|O cut|O induction|O failure|O ,|O escalation|O to|O high|O -|O dose|O cytarabine|O with|O or|O without|O an|O anthracycline|O is|O the|O most|O common|O salvage|O strategy|O .|O
PCR|O amplifications|O were|O carried|O out|O as|O described|O previously|O .|O
Differential|O expression|O analysis|O for|O this|O data|O set|O was|O performed|O using|O the|O Bioconductor|O DESeq2|O package|O .|O
As|O would|O be|O expected|O ,|O allogeneic|O HSCT|O was|O associated|O with|O a|O significantly|O higher|O rate|O of|O nonrelapse|O mortality|O (|O 36|O %|O vs|O .|O 4|O %|O ;|O P|O <|O .|O 001|O )|O at|O 3|O years|O ;|O the|O 3|O -|O year|O OS|O rate|O was|O not|O significantly|O different|O between|O the|O groups|O (|O 37|O %|O vs|O .|O 25|O %|O ;|O P|O =|O .|O 08|O )|O ,|O although|O a|O trend|O was|O seen|O favoring|O allogeneic|O HSCT|O .|O
The|O role|O of|O mutations|O in|O epigenetic|O regulators|O in|O myeloid|O malignancies|O .|O
Recent|O work|O demonstrated|O that|O ectopic|O overexpression|O of|O EZH2|O also|O results|O in|O myeloid|O transformation|O ,|O implying|O that|O EZH2|O may|O serve|O as|O both|O an|O oncogene|O and|O a|O tumour|O suppressor|O gene|O in|O the|O myeloid|O compartment|O .|O
The|O cumulative|O incidence|O of|O marked|O leukocytosis|O was|O significantly|O lower|O in|O CALR|O -|O mutant|O patients|O compared|O with|O JAK2|O -|O mutant|O (|O P|O =|O .|O 004|O )|O or|O triple|O -|O negative|O patients|O (|O P|O <|O .|O 001|O )|O .|O
DNMT3L|O binds|O to|O histone|O H3|O tails|O in|O the|O absence|O of|O K4|O methylation|O ,|O which|O leads|O to|O the|O recruitment|O of|O DNMT3A|O activity|O to|O specific|O loci|O .|O
Our|O results|O showed|O that|O 16|O .|O 7|O %|O of|O CMML|O patients|O with|O RUNX1|O mutations|O had|O FLT3|O or|O RAS|O mutations|O .|O
Many|O institutions|O also|O use|O HLA|O typing|O to|O select|O platelet|O donors|O for|O allogeneic|O HSCT|O .|O
Growth|O factors|O have|O no|O clear|O role|O in|O initial|O induction|O therapy|O ;|O however|O ,|O they|O may|O be|O considered|O as|O part|O of|O supportive|O care|O for|O postremission|O therapy|O .|O
In|O fact|O ,|O this|O identification|O has|O split|O PMF|O patients|O with|O nonmutated|O JAK2|O and|O MPL|O (|O about|O one|O -|O third|O of|O all|O patients|O with|O PMF|O )|O into|O 2|O distinct|O subtypes|O (|O Figure|O 7|O )|O :|O (|O 1|O )|O CALR|O -|O mutant|O PMF|O ,|O a|O condition|O with|O an|O indolent|O clinical|O course|O and|O (|O 2|O )|O PMF|O with|O nonmutated|O JAK2|O ,|O CALR|O ,|O and|O MPL|O ,|O a|O very|O aggressive|O myeloid|O neoplasm|O .|O
Previously|O ,|O we|O applied|O SNP|O arrays|O on|O a|O cohort|O of|O 102|O subjects|O to|O identify|O genomic|O aberrations|O in|O MDS|O .|O
Although|O detection|O of|O JAK2|O V617F|O and|O MPL|O mutations|O in|O the|O appropriate|O clinical|O settings|O confirms|O the|O diagnosis|O of|O ET|O or|O PMF|O ,|O absence|O of|O the|O mutations|O does|O not|O rule|O out|O disease|O .|O
The|O fragments|O were|O loaded|O and|O amplified|O with|O the|O SOLiD|O sequencing|O control|O beads|O during|O emulsion|O polymerase|O chain|O reaction|O .|O
4|O .|O 2|O .|O THE|O '|O GATA|O SWITCH|O '|O IN|O MAST|O CELLS|O .|O
Equivalent|O antithrombotic|O efficacy|O with|O low|O -|O dose|O aspirin|O (|O 100|O mg|O /|O day|O )|O has|O now|O been|O demonstrated|O and|O is|O currently|O recommended|O for|O all|O patients|O diagnosed|O with|O PV|O regardless|O of|O risk|O profile|O and|O in|O the|O absence|O of|O contraindications|O .|O
The|O Kaplan|O -|O Meier|O method|O was|O used|O to|O estimate|O survival|O rates|O .|O
For|O comparative|O genomic|O hybridization|O (|O CGH|O )|O analysis|O ,|O genomic|O DNA|O samples|O were|O analyzed|O for|O copy|O number|O changes|O using|O Affymetrix|O Genome|O -|O Wide|O Human|O SNP|O 6|O .|O 0|O arrays|O (|O for|O pedigree|O 1|O )|O or|O CytoScan|O HD|O arrays|O (|O for|O other|O pedigrees|O when|O material|O was|O available|O )|O .|O
Emberger|O (|O an|O autosomal|O dominant|O primary|O lymphedema|O with|O predisposition|O to|O AML|O )|O and|O MonoMAC|O (|O monocytopenia|O with|O Mycobacterium|O avium|O complex|O )|O syndromes|O are|O the|O two|O common|O inherited|O diseases|O that|O appear|O to|O be|O associated|O with|O GATA2|O mutations|O .|O
A|O multivariate|O analysis|O revealed|O that|O shorter|O survival|O was|O associated|O with|O older|O age|O (|O >|O 65|O years|O )|O ,|O female|O gender|O ,|O leukocyte|O count|O >|O 50|O x|O 109|O /|O L|O ,|O and|O the|O presence|O of|O immature|O circulating|O precursors|O .|O
It|O is|O responsible|O for|O removing|O small|O ,|O non|O -|O helix|O -|O distorting|O base|O lesions|O from|O the|O genome|O .|O
The|O model|O reported|O in|O Figure|O 6|O was|O developed|O with|O the|O only|O objective|O of|O showing|O ,|O as|O a|O proof|O of|O concept|O ,|O that|O genetic|O data|O can|O significantly|O improve|O prognostication|O of|O PMF|O .|O
Therefore|O ,|O if|O other|O World|O Health|O Organization|O major|O and|O minor|O diagnostic|O criteria|O are|O met|O ,|O finding|O such|O a|O low|O -|O positive|O JAK2|O mutation|O may|O still|O be|O clinically|O relevant|O .|O
CR|O ,|O complete|O remission|O ;|O HI|O -|O E|O ,|O hematologic|O improvement|O (|O erythroid|O )|O ;|O IWG|O ,|O International|O Working|O Group|O ;|O PR|O ,|O partial|O remission|O ;|O SD|O ,|O stable|O disease|O .|O
In|O 2|O cases|O of|O sAML|O that|O evolved|O from|O RAEB|O ,|O cohesin|O mutations|O were|O observed|O only|O after|O transformation|O to|O AML|O (|O Figure|O 4A|O -|O B|O )|O ,|O indicating|O these|O mutations|O can|O occur|O as|O a|O late|O event|O that|O is|O associated|O with|O AML|O transformation|O .|O
These|O studies|O revealed|O that|O deletion|O of|O Dnmt3a|O resulted|O in|O progressive|O expansion|O of|O the|O long|O -|O term|O haematopoietic|O stem|O cell|O (|O LT|O -|O HSC|O )|O pool|O without|O increasing|O HSC|O proliferation|O or|O altering|O haematopoietic|O differentiation|O .|O
The|O selection|O criteria|O were|O the|O absence|O of|O mutations|O for|O the|O major|O genes|O involved|O in|O congenital|O neutropenia|O (|O ELANE|O ,|O CXCR4|O ,|O SBDS|O ,|O HAX1|O ,|O and|O G6PC3|O ;|O n|O =|O 288|O patients|O )|O and|O the|O presence|O of|O clinical|O features|O associated|O with|O GATA2|O mutations|O :|O leg|O lymphedema|O ,|O warts|O ,|O and|O evolution|O to|O MDS|O /|O AML|O .|O
Similar|O studies|O that|O map|O 5|O -|O hmC|O localization|O in|O the|O haematopoietic|O system|O ,|O and|O the|O identity|O of|O specific|O TET2|O target|O genes|O in|O haematopoietic|O cells|O ,|O have|O not|O been|O reported|O to|O date|O .|O
Peroxisomes|O .|O
In|O the|O 2008|O WHO|O classification|O ,|O the|O category|O of|O AML|O with|O recurrent|O genetic|O abnormalities|O was|O expanded|O to|O include|O the|O following|O :|O t|O (|O 9|O ;|O 11|O )|O (|O p22|O ;|O q23|O )|O ,|O t|O (|O 6|O ;|O 9|O )|O (|O p23|O ;|O q34|O )|O (|O provisional|O entity|O )|O ,|O inv|O (|O 3|O )|O (|O q21|O ;|O q26|O .|O 2|O )|O or|O inv|O (|O 3|O ;|O 3|O )|O (|O q21|O ;|O q26|O .|O 2|O )|O (|O provisional|O entity|O )|O ,|O and|O t|O (|O 1|O ;|O 22|O )|O (|O p13|O ;|O q13|O )|O (|O provisional|O entity|O )|O ,|O in|O addition|O to|O the|O previously|O recognized|O t|O (|O 8|O ;|O 21|O )|O (|O q22|O ;|O q22|O )|O ;|O inv|O (|O 16|O )|O (|O p13|O ;|O 1q22|O )|O or|O t|O (|O 16|O ;|O 16|O )|O (|O p13|O .|O 1|O ;|O q22|O )|O ;|O and|O t|O (|O 15|O ;|O 17|O )|O (|O q22|O ;|O q12|O )|O [|O APL|O subtype|O ]|O .|O
Seishi|O Ogawa|O .|O
SETBP1|O is|O mutated|O at|O lower|O frequencies|O in|O unclassified|O MDS|O /|O MPN|O (|O 10|O %|O )|O and|O CMML|O (|O 4|O %|O )|O ,|O but|O no|O SETBP1|O mutations|O are|O found|O in|O AML|O ,|O acute|O lymphoblastic|O leukemia|O ,|O chronic|O lymphocytic|O leukemia|O ,|O or|O solid|O tumors|O .|O
Mutations|O in|O TP53|O ,|O NRAS|O ,|O RUNX1|O ,|O TET2|O ,|O and|O IDH1|O and|O IDH2|O have|O each|O been|O reported|O to|O influence|O overall|O survival|O in|O univariate|O analyses|O .|O
EZH2|O mutations|O ,|O which|O have|O not|O previously|O been|O associated|O with|O known|O prognostic|O markers|O ,|O retained|O a|O strong|O association|O with|O survival|O in|O our|O model|O .|O
The|O median|O OS|O for|O all|O patients|O was|O 17|O months|O .|O
In|O exploring|O the|O effects|O of|O cohesin|O downmodulation|O /|O mutations|O on|O expression|O pattern|O in|O cohort|O ,|O we|O noted|O a|O consistent|O down|O -|O modulation|O of|O DCK|O in|O patients|O with|O cohesin|O complex|O alterations|O .|O
U2AF1|O mutations|O are|O detected|O in|O approximately|O 8|O %|O of|O patients|O with|O MDS|O .|O
Sensitivity|O analyses|O were|O performed|O on|O CR|O and|O RFS|O ,|O and|O results|O are|O displayed|O for|O exploratory|O purposes|O .|O
This|O randomized|O ,|O double|O -|O blind|O ,|O placebo|O -|O controlled|O ,|O phase|O 3|O trial|O was|O conducted|O at|O 89|O sites|O in|O the|O United|O States|O ,|O Australia|O ,|O and|O Canada|O .|O
Figure|O 4|O .|O Overall|O Survival|O ,|O According|O to|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O Risk|O Category|O and|O Mutational|O Status|O .|O Panel|O A|O shows|O the|O overall|O survival|O of|O patients|O within|O each|O IPSS|O risk|O group|O .|O Panel|O B|O shows|O the|O overall|O survival|O of|O patients|O with|O mutations|O in|O one|O or|O more|O of|O the|O five|O prognostic|O genes|O (|O TP53|O ,|O EZH2|O ,|O ETV6|O ,|O RUNX1|O ,|O or|O ASXL1|O )|O as|O compared|O with|O patients|O without|O such|O mutations|O .|O Panels|O C|O through|O F|O show|O the|O overall|O survival|O of|O patients|O according|O to|O the|O presence|O and|O absence|O of|O prognostic|O mutations|O and|O according|O to|O IPSS|O risk|O group|O .|O In|O Panels|O C|O ,|O D|O ,|O and|O E|O ,|O the|O overall|O -|O survival|O curve|O for|O patients|O in|O the|O next|O -|O highest|O IPSS|O risk|O group|O is|O included|O for|O the|O purpose|O of|O comparison|O .|O In|O Panel|O F|O ,|O the|O comparison|O curve|O is|O for|O patients|O in|O the|O next|O -|O lowest|O IPSS|O risk|O group|O .|O P|O values|O were|O calculated|O for|O the|O log|O -|O rank|O comparison|O of|O overall|O survival|O between|O patients|O with|O mutations|O and|O those|O without|O mutations|O for|O the|O given|O IPSS|O risk|O group|O .|O The|O IPSS|O risk|O classification|O ,|O which|O is|O based|O on|O the|O percentage|O of|O blasts|O in|O bone|O marrow|O ,|O the|O karyotype|O ,|O and|O the|O number|O of|O cytopenias|O (|O Table|O 2|O in|O the|O Supplementary|O Appendix|O )|O ,|O was|O recalculated|O for|O 428|O of|O the|O 439|O samples|O at|O the|O time|O of|O bone|O marrow|O sample|O collection|O (|O the|O IPSS|O classification|O could|O not|O be|O recalculated|O for|O 11|O samples|O )|O .|O
The|O use|O of|O aspirin|O in|O reducing|O thrombotic|O complications|O in|O ET|O is|O less|O defined|O than|O for|O PV|O ,|O because|O no|O formal|O clinical|O trials|O have|O been|O conducted|O .|O
We|O subsequently|O screened|O a|O large|O cohort|O of|O patients|O (|O n|O =|O 310|O )|O with|O MDS|O and|O related|O disorders|O (|O including|O the|O initially|O screened|O 120|O cases|O )|O in|O a|O stepwise|O fashion|O to|O determine|O the|O frequency|O of|O spliceosomal|O mutations|O discovered|O in|O the|O index|O cases|O .|O
A|O recent|O study|O reported|O that|O in|O younger|O patients|O (|O age|O <|O 60|O years|O )|O with|O NK|O -|O AML|O ,|O presence|O of|O DNMT3A|O mutations|O was|O associated|O with|O significantly|O decreased|O OS|O compared|O with|O the|O wild|O -|O type|O gene|O (|O 5|O -|O year|O OS|O rate|O ,|O 23|O %|O vs|O .|O 45|O %|O ;|O P|O =|O .|O 02|O )|O .|O
Mutations|O in|O enzymatic|O modifiers|O represent|O attractive|O targets|O for|O directed|O therapy|O in|O myeloid|O malignancies|O .|O
Although|O this|O study|O was|O designed|O for|O evaluation|O of|O treatment|O in|O patients|O with|O high|O -|O risk|O MDS|O (|O based|O on|O FAB|O criteria|O )|O ,|O 113|O study|O patients|O (|O 32|O %|O )|O fulfilled|O criteria|O for|O AML|O using|O the|O 2008|O WHO|O classification|O ,|O with|O marrow|O -|O blast|O percentage|O between|O 20|O %|O and|O 30|O %|O .|O
In|O an|O open|O -|O label|O randomized|O phase|O III|O study|O ,|O decitabine|O was|O compared|O with|O physician|O '|O s|O choice|O (|O either|O low|O -|O dose|O cytarabine|O or|O supportive|O care|O )|O in|O older|O patients|O (|O age|O >|O =|O 65|O years|O )|O with|O newly|O diagnosed|O AML|O .|O
Patients|O had|O disease|O that|O was|O refractory|O to|O available|O therapies|O ,|O had|O side|O effects|O requiring|O their|O discontinuation|O ,|O or|O were|O not|O candidates|O for|O available|O therapies|O and|O had|O disease|O requiring|O treatment|O .|O
Although|O patients|O older|O than|O 75|O years|O with|O significant|O comorbidities|O generally|O do|O not|O benefit|O from|O conventional|O chemotherapy|O treatment|O ,|O the|O rare|O patient|O with|O favorable|O or|O normal|O karyotype|O and|O no|O significant|O comorbidities|O might|O be|O the|O exception|O to|O this|O dogma|O .|O
Moreover|O ,|O BCOR|O increases|O the|O repression|O of|O transcriptional|O activity|O by|O interacting|O with|O class|O I|O and|O II|O HDACs|O ,|O the|O polycomb|O group|O protein|O PCGF1|O /|O NSPC1|O and|O the|O histone|O demethylase|O FBXL10|O ,|O which|O implies|O BCOR|O may|O suppress|O gene|O transcription|O by|O epigenetic|O mechanisms|O .|O
Leptomeningeal|O involvement|O is|O much|O less|O frequent|O (|O <|O 3|O %|O )|O in|O patients|O with|O AML|O than|O in|O those|O with|O ALL|O ;|O therefore|O ,|O the|O panel|O does|O not|O recommend|O LP|O as|O part|O of|O the|O routine|O diagnostic|O workup|O .|O
The|O frequent|O evolution|O to|O MDS|O and|O AML|O of|O patients|O with|O GATA2|O mutations|O reveals|O the|O importance|O of|O screening|O for|O this|O mutation|O in|O chronic|O neutropenia|O ,|O especially|O when|O associated|O with|O monocytopenia|O because|O of|O frequent|O hematopoietic|O transformation|O ,|O variable|O clinical|O expression|O at|O onset|O ,|O and|O the|O need|O of|O aggressive|O strategy|O therapy|O in|O patients|O with|O poor|O clinical|O outcome|O .|O
DISCUSSION|O .|O
Acute|O myeloid|O leukemia|O (|O AML|O )|O is|O a|O disease|O characterized|O by|O high|O molecular|O heterogeneity|O .|O
Interestingly|O ,|O mutations|O in|O this|O complex|O were|O mutually|O exclusive|O ,|O similar|O to|O other|O mutations|O that|O belonged|O to|O 1|O pathway|O similar|O to|O genes|O of|O the|O spliceosome|O complex|O or|O mutations|O in|O IDH1|O ,|O IDH2|O ,|O and|O TET2|O .|O
Matched|O buccal|O DNA|O was|O available|O for|O 219|O (|O 49|O .|O 9|O %|O )|O of|O the|O 439|O samples|O analyzed|O in|O this|O study|O .|O
MOLECULAR|O BIOLOGY|O .|O
Thus|O ,|O for|O this|O subgroup|O of|O patients|O ,|O high|O -|O dose|O cytarabine|O followed|O by|O autologous|O HSCT|O should|O be|O the|O preferred|O HSCT|O option|O ,|O and|O allogeneic|O HSCT|O may|O be|O better|O reserved|O as|O salvage|O therapy|O or|O for|O those|O with|O c|O -|O KIT|O mutations|O .|O
Overall|O and|O leukemia|O -|O free|O survival|O curves|O were|O prepared|O by|O the|O Kaplan|O -|O Meier|O method|O and|O compared|O by|O the|O log|O -|O rank|O test|O .|O
A|O recent|O large|O cohort|O study|O of|O 430|O MDS|O patients|O also|O demonstrated|O that|O the|O mutation|O was|O associated|O with|O poor|O prognosis|O in|O MDS|O .|O
On|O the|O basis|O of|O such|O findings|O ,|O PTEN|O /|O MMAC1|O has|O been|O considered|O a|O candidate|O tumor|O suppressor|O gene|O that|O may|O play|O a|O role|O in|O varied|O malignancies|O .|O Chromosome|O 10q23|O .|O 3|O is|O deleted|O in|O a|O variety|O of|O primary|O tumors|O including|O myeloid|O leukemia|O .|O
Among|O patients|O who|O received|O ruxolitinib|O ,|O anemia|O and|O thrombocytopenia|O were|O the|O most|O common|O adverse|O events|O ,|O but|O they|O rarely|O led|O to|O discontinuation|O of|O the|O drug|O (|O in|O one|O patient|O for|O each|O event|O )|O .|O
Our|O data|O showed|O that|O the|O locations|O of|O RUNX1|O mutations|O in|O CMML|O patients|O were|O similar|O to|O those|O observed|O in|O therapy|O -|O related|O MDS|O /|O AML|O rather|O than|O in|O de|O novo|O MDS|O /|O AML|O .|O
Inappropriate|O expression|O of|O GATA2|O has|O been|O observed|O in|O patients|O with|O myelodysplastic|O syndrome|O ,|O related|O to|O severe|O dysplasia|O .|O
Patients|O .|O
There|O is|O a|O lack|O of|O well|O -|O established|O consensus|O concerning|O common|O analytical|O issues|O ,|O such|O as|O what|O specimen|O type|O should|O be|O tested|O ,|O whether|O it|O is|O clinically|O relevant|O to|O differentiate|O heterozygous|O from|O homozygous|O mutations|O ,|O whether|O granulocyte|O enrichment|O should|O be|O performed|O ,|O how|O to|O interpret|O a|O low|O level|O of|O a|O positive|O result|O ,|O and|O whether|O quantitative|O results|O should|O be|O used|O and|O reported|O (|O and|O ,|O if|O yes|O ,|O in|O which|O disease|O type|O and|O in|O what|O clinical|O condition|O )|O .|O
No|O mutations|O were|O observed|O in|O any|O of|O the|O AML|O or|O other|O tumor|O cell|O lines|O .|O
All|O except|O SET|O -|O 2|O are|O homozygous|O mutant|O ,|O but|O some|O (|O eg|O ,|O HEL|O )|O have|O more|O than|O two|O copies|O of|O JAK2|O and|O as|O such|O are|O not|O ideal|O as|O standards|O .|O
Of|O the|O 22|O laboratories|O ,|O 13|O used|O in|O -|O house|O tests|O for|O JAK2|O V617F|O and|O the|O remaining|O 9|O used|O commercial|O assays|O ;|O 14|O laboratories|O performed|O only|O qualitative|O assays|O ,|O 5|O performed|O only|O quantitative|O assays|O ,|O and|O 3|O performed|O both|O quantitative|O and|O qualitative|O assays|O .|O
Scores|O ranged|O from|O 0|O (|O "|O absent|O "|O symptoms|O )|O to|O 10|O (|O "|O worst|O imaginable|O "|O symptoms|O )|O ,|O and|O the|O total|O symptom|O score|O was|O the|O sum|O of|O the|O individual|O scores|O ,|O excluding|O inactivity|O .|O
Idarubicin|O ,|O which|O has|O a|O longer|O intracellular|O retention|O time|O ,|O used|O at|O doses|O of|O 12|O mg|O /|O m2|O x|O 3|O days|O ,|O has|O had|O comparable|O remission|O rates|O with|O fewer|O patients|O requiring|O additional|O therapy|O at|O day|O 15|O to|O achieve|O remission|O .|O
Samples|O from|O the|O European|O cohort|O ,|O collected|O at|O time|O of|O diagnosis|O ,|O were|O analyzed|O for|O mutations|O in|O ASXL1|O ,|O SRSF2|O ,|O EZH2|O ,|O TET2|O ,|O DNMT3A|O ,|O CBL|O ,|O IDH1|O ,|O IDH2|O ,|O MPL|O and|O JAK2|O .|O
One|O -|O hundred|O and|O fifty|O (|O 66|O %|O )|O patients|O had|O a|O diploid|O karyotype|O ,|O whereas|O 11|O (|O 5|O %|O )|O had|O no|O Y|O chromosome|O .|O
RARS|O :|O refractory|O anemia|O with|O ring|O sideroblasts|O .|O
Thirty|O -|O five|O percent|O of|O patients|O who|O received|O a|O low|O dose|O and|O 59|O %|O who|O received|O a|O high|O dose|O showed|O >|O 50|O %|O reduction|O in|O splenomegaly|O overall|O .|O
Acute|O Myeloid|O Leukemia|O :|O Clinical|O Practice|O Guidelines|O in|O Oncology|O .|O
The|O remarkable|O differences|O in|O clinical|O course|O and|O outcomes|O observed|O among|O the|O diverse|O genetic|O subtypes|O suggest|O that|O ,|O in|O spite|O of|O similar|O clinical|O features|O (|O bone|O marrow|O fibrosis|O ,|O abnormal|O stem|O cell|O trafficking|O ,|O and|O myeloid|O metaplasia|O )|O ,|O the|O disease|O biology|O varies|O considerably|O according|O to|O the|O different|O genetic|O lesions|O .|O
For|O survival|O analyses|O ,|O end|O points|O were|O death|O and|O the|O first|O episode|O of|O cancer|O .|O
Because|O the|O clinical|O presentation|O of|O pedigree|O 1|O was|O initially|O chronic|O neutropenia|O ,|O we|O investigated|O the|O presence|O of|O mutations|O of|O GATA2|O in|O the|O French|O Severe|O Chronic|O Neutropenia|O Registry|O .|O
Other|O relatively|O common|O mutations|O include|O R541|O _|O E543delinsK|O (|O approximately|O 10|O %|O )|O ,|O E543|O _|O D544del|O (|O approximately|O 10|O %|O )|O ,|O F537|O _|O K539delinsL|O (|O approximately|O 10|O %|O )|O ,|O K539L|O (|O approximately|O 10|O %|O )|O ,|O H538|O _|O K539delinsL|O (|O approximately|O 5|O %|O )|O ,|O and|O I540|O _|O E543delinsMK|O (|O approximately|O 5|O %|O )|O .|O
Bone|O marrow|O proliferation|O of|O pleomorphic|O ,|O loosely|O clustered|O megakaryocytes|O with|O unique|O stromal|O changes|O and|O without|O maturation|O defects|O is|O commonly|O seen|O in|O PV|O but|O is|O not|O diagnostic|O .|O
Conceivably|O ,|O inv|O ,|O i|O (|O 17q|O )|O or|O monosomal|O karyotype|O were|O identified|O as|O predictors|O of|O a|O >|O 80|O %|O 2|O -|O year|O mortality|O in|O PMF|O .|O
Clinical|O phenotypes|O that|O correspond|O to|O specific|O cytogenetic|O patterns|O were|O variable|O among|O the|O disease|O groups|O .|O
Most|O recently|O ,|O the|O creation|O of|O a|O conditional|O Idh1R132H|O knock|O -|O in|O mouse|O model|O reinforced|O the|O effect|O of|O IDH|O mutations|O on|O increasing|O the|O population|O of|O haematopoietic|O stem|O or|O progenitor|O cells|O and|O DNA|O cytosine|O and|O histone|O lysine|O methylation|O .|O
Acute|O myeloid|O leukemia|O (|O AML|O )|O is|O a|O heterogeneous|O hematologic|O malignancy|O characterized|O by|O the|O clonal|O expansion|O of|O myeloid|O blasts|O in|O the|O peripheral|O blood|O ,|O bone|O marrow|O ,|O and|O /|O or|O other|O tissues|O .|O
Loss|O of|O the|O long|O arm|O of|O chromosome|O 7|O is|O a|O frequent|O event|O in|O MDS|O and|O AML|O .|O
These|O benefits|O came|O at|O the|O cost|O of|O more|O frequent|O anemia|O and|O thrombocytopenia|O in|O the|O early|O part|O of|O the|O treatment|O period|O .|O
Moreover|O ,|O spliceosome|O -|O associated|O gene|O mutations|O were|O screened|O with|O whole|O exome|O sequencing|O results|O available|O through|O The|O Cancer|O Genome|O Atlas|O (|O National|O Cancer|O Institute|O )|O .|O
The|O most|O common|O of|O these|O include|O mutations|O in|O IDH1|O and|O IDH2|O genes|O ,|O which|O encode|O for|O isocitrate|O dehydrogenase|O 1|O and|O 2|O ,|O respectively|O ,|O and|O mutations|O in|O DNMT3A|O ,|O which|O encode|O for|O DNA|O methyltransferase|O 3A|O .|O
Current|O diagnostic|O strategies|O are|O increasingly|O reliant|O on|O molecular|O markers|O ,|O and|O their|O prognostic|O value|O continues|O to|O be|O investigated|O .|O
The|O percentage|O of|O BM|O blasts|O was|O 9|O .|O 5|O +|O =|O 1|O .|O 1|O %|O in|O patients|O with|O mutations|O compared|O with|O 7|O .|O 1|O +|O =|O 0|O .|O 7|O %|O in|O mutation|O -|O negative|O patients|O (|O P|O =|O 0|O .|O 073|O )|O .|O
Mutations|O in|O NPM1|O have|O been|O described|O in|O 6|O %|O (|O 6|O /|O 97|O )|O of|O CMML|O patients|O and|O were|O associated|O with|O a|O poor|O prognosis|O .|O
No|O data|O are|O available|O using|O more|O than|O 60|O mg|O /|O m2|O of|O daunorubicin|O or|O 12|O mg|O /|O m2|O of|O idarubicin|O with|O high|O -|O dose|O cytarabine|O .|O
Decreased|O levels|O of|O GATA2|O compromise|O the|O proliferation|O and|O survival|O of|O HSCs|O .|O
These|O two|O cases|O gave|O no|O signal|O and|O a|O wild|O -|O type|O result|O ,|O respectively|O ,|O by|O the|O Ipsogen|O assay|O ,|O but|O were|O detected|O as|O abnormal|O by|O melting|O curve|O analysis|O and|O subsequent|O Sanger|O sequencing|O .|O
It|O has|O been|O shown|O that|O GATA2|O inhibits|O erythroid|O differentiation|O through|O direct|O regulation|O of|O EPO|O activity|O .|O
TET1|O target|O genes|O can|O either|O be|O activated|O or|O repressed|O ,|O depending|O on|O the|O presence|O of|O PRC2|O or|O existing|O chromatin|O marks|O .|O
The|O expression|O levels|O of|O GATA2|O partially|O determine|O the|O fate|O along|O megakaryocyte|O -|O erythroid|O differentiation|O pathways|O .|O
High|O -|O dose|O cytarabine|O plus|O an|O anthracycline|O as|O induction|O therapy|O is|O considered|O a|O category|O 2B|O recommendation|O for|O patients|O younger|O than|O 60|O years|O .|O
On|O the|O other|O hand|O ,|O frameshift|O or|O nonsense|O mutations|O were|O distributed|O throughout|O the|O entire|O RUNX1|O gene|O in|O both|O N|O -|O terminal|O and|O C|O -|O terminal|O parts|O .|O
Cohesin|O mutant|O MDS|O patients|O were|O more|O likely|O to|O be|O associated|O with|O high|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O scores|O (|O Table|O 1|O )|O and|O were|O more|O prevalent|O in|O patients|O who|O transformed|O to|O sAML|O .|O
This|O review|O will|O focus|O on|O the|O latest|O developments|O in|O the|O molecular|O biology|O ,|O diagnosis|O ,|O and|O treatment|O of|O classic|O BCR|O -|O ABL1|O -|O negative|O MPNs|O .|O
The|O only|O relevant|O observation|O was|O the|O higher|O frequency|O of|O CALR|O type|O 1|O mutation|O in|O PMF|O compared|O with|O ET|O ,|O which|O may|O suggest|O a|O particularly|O active|O role|O of|O the|O 52|O -|O bp|O deletion|O in|O causing|O bone|O marrow|O fibrosis|O .|O
For|O example|O ,|O SF3B1|O was|O shown|O to|O participate|O in|O Hox|O gene|O regulation|O through|O functional|O interaction|O with|O polycomb|O and|O trithorax|O genes|O .|O
FOG1S|O is|O preferentially|O excluded|O from|O the|O nucleus|O by|O unknown|O mechanisms|O .|O
More|O recently|O ,|O somatic|O ,|O heterozygous|O activating|O mutations|O of|O EZH2|O that|O affect|O Y641|O have|O been|O identified|O in|O germinal|O -|O centre|O diffuse|O large|O -|O B|O -|O cell|O lymphomas|O .|O
In|O contrast|O with|O our|O incomplete|O understanding|O of|O the|O biological|O implications|O of|O EZH2|O mutations|O in|O myeloid|O malignancy|O pathogenesis|O ,|O correlative|O studies|O have|O demonstrated|O that|O EZH2|O mutations|O are|O a|O marker|O for|O adverse|O outcome|O in|O MDS|O and|O PMF|O .|O
Given|O the|O role|O of|O cohesin|O in|O alignment|O of|O sister|O chromatids|O during|O cellular|O replication|O ,|O cohesin|O mutations|O could|O theoretically|O lead|O to|O chromosomal|O instability|O .|O
The|O most|O frequent|O exon|O 12|O mutation|O involves|O an|O in|O -|O frame|O deletion|O of|O six|O nucleotides|O at|O codons|O 542|O and|O 543|O (|O N542|O _|O E543del|O )|O ;|O it|O is|O present|O in|O approximately|O 40|O %|O of|O V617F|O -|O negative|O PV|O .|O
Thus|O ,|O for|O routine|O clinical|O practice|O ,|O there|O is|O no|O recommended|O schedule|O for|O follow|O -|O up|O JAK2|O testing|O ,|O whether|O qualitative|O or|O quantitative|O .|O
CSF3R|O and|O SETBP1|O mutations|O are|O not|O mutually|O exclusive|O in|O CNL|O /|O aCML|O .|O
Approximately|O one|O -|O third|O of|O SCN|O patients|O eventually|O acquire|O truncation|O mutations|O in|O CSF3R|O (|O analogous|O to|O the|O truncation|O mutations|O we|O have|O observed|O in|O de|O novo|O CNL|O and|O aCML|O )|O ,|O which|O are|O associated|O with|O transformation|O to|O myelodysplasia|O or|O AML|O .|O
It|O contains|O three|O critical|O domains|O :|O JH1|O ,|O JH2|O ,|O and|O four|O -|O pointone|O ,|O ezrin|O ,|O radixin|O ,|O moesin|O (|O FERM|O )|O homolog|O domains|O .|O
Sequencing|O analysis|O of|O the|O aberrant|O fragments|O of|O the|O PTEN|O /|O MMAC1|O gene|O revealed|O the|O existence|O of|O eight|O types|O of|O RT|O -|O PCR|O products|O with|O losses|O of|O various|O exons|O of|O the|O published|O PTEN|O /|O MMAC1|O sequence|O from|O exons|O 1|O -|O 9|O (|O Fig|O .|O 2|O )|O .|O
High|O numbers|O of|O informative|O patients|O (|O those|O with|O mutations|O )|O are|O needed|O to|O establish|O correlations|O with|O response|O to|O specific|O drugs|O .|O
BCORL1a|O (|O an|O alternatively|O spliced|O form|O of|O BCORL1|O )|O contains|O additional|O 74|O amino|O acids|O (|O for|O a|O total|O of|O 1785|O )|O encoded|O by|O a|O further|O exon|O (|O exon|O 9|O )|O .|O BCOR|O and|O BCORL1|O localize|O in|O different|O subnuclear|O structures|O .|O Shown|O in|O the|O Bcor|O murine|O ortholog|O ;|O MLLT3|O is|O also|O known|O as|O AF9|O and|O is|O a|O fusion|O partner|O of|O MLL|O in|O acute|O leukemias|O .|O Direct|O or|O indirect|O .|O
Analogous|O to|O previously|O applied|O strategies|O that|O identified|O TET2|O ,|O CBL|O ,|O EZH2|O ,|O and|O other|O mutations|O ,|O we|O have|O identified|O mutations|O affecting|O ,|O in|O a|O recurrent|O fashion|O ,|O genes|O of|O the|O spliceosome|O machinery|O ,|O using|O a|O combination|O of|O targeted|O search|O approaches|O and|O unbiased|O mass|O sequencing|O .|O
2|O -|O HG|O ,|O 2|O hydroxyglutarate|O ;|O 5|O -|O hmC|O ,|O 5|O -|O hydroxymethylcytosine|O ;|O 5|O -|O mC|O ,|O 5|O -|O methylcytosine|O ;|O AML|O ,|O acute|O myeloid|O leukaemia|O ;|O ASXL1|O ,|O additional|O sex|O combs|O -|O like|O 1|O ;|O CMML|O ,|O chronic|O myelomonocytic|O leukaemia|O ;|O CN|O -|O AML|O ,|O cytogenetically|O normal|O AML|O ;|O CR|O ,|O complete|O response|O ;|O DNMT3A|O ,|O DNA|O methyltransferase|O 3A|O ;|O EZH2|O ,|O enhancer|O of|O zeste|O homologue|O 2|O ;|O H3K4me3|O ,|O trimethylation|O of|O lysine|O 4|O of|O histone|O H3|O ;|O HOX|O ,|O homeobox|O ;|O HSC|O ,|O haematopoietic|O stem|O cell|O ;|O IDH|O ,|O isocitrate|O dehydrogenase|O ;|O LSK|O ,|O lineage|O -|O SCA1|O +|O KIT|O +|O ;|O MDS|O ,|O myelodysplastic|O syndrome|O ;|O MLL|O ,|O mixed|O -|O lineage|O leukaemia|O ;|O MPN|O ,|O myeloproliferative|O neoplasm|O ;|O OS|O ,|O overall|O survival|O ;|O PMF|O ,|O primary|O myelofibrosis|O ;|O PRC2|O ,|O Polycomb|O repressive|O complex|O 2|O ;|O PTD|O ,|O partial|O tandem|O -|O duplication|O ;|O TET2|O ,|O tet|O methylcytosine|O dioxygenase|O 2|O .|O
In|O support|O of|O this|O possibility|O ,|O we|O found|O that|O both|O patients|O harbor|O heterozygous|O mutation|O of|O GATA2|O .|O
DISCUSSION|O .|O
However|O ,|O the|O diverse|O mutations|O likely|O involve|O additional|O abnormalities|O in|O other|O metabolic|O pathways|O ;|O for|O instance|O ,|O mutant|O calreticulin|O might|O have|O peculiar|O effects|O on|O megakaryocyte|O biology|O .|O
Given|O the|O high|O -|O toxicity|O profile|O of|O INF|O -|O alpha|O and|O the|O questionable|O benefit|O of|O its|O nonleukemogenic|O properties|O ,|O further|O research|O is|O needed|O to|O establish|O INF|O -|O alpha|O as|O a|O first|O -|O line|O therapy|O .|O
All|O other|O lesions|O were|O confirmed|O as|O somatic|O or|O germline|O by|O analysis|O of|O CD3|O -|O sorted|O cells|O .|O
Cohesin|O defects|O were|O found|O in|O 11|O %|O of|O lower|O -|O risk|O MDS|O patients|O and|O 4|O %|O of|O MDS|O /|O MPN|O overlap|O patients|O (|O supplemental|O Table|O 4|O )|O .|O
We|O also|O analyzed|O whether|O the|O locations|O and|O patterns|O of|O mutations|O had|O any|O clinical|O or|O prognostic|O effect|O on|O patients|O with|O CMML|O harboring|O RUNX1|O mutations|O .|O
In|O addition|O to|O clearly|O hypomorphic|O mutations|O ,|O splice|O site|O mutations|O were|O also|O identified|O (|O eg|O ,|O STAG2|O 5|O '|O of|O exon|O 4|O and|O 8|O )|O .|O
We|O first|O analyzed|O the|O entire|O cohort|O of|O patients|O (|O Table|O 1|O )|O and|O determined|O the|O survival|O of|O patients|O in|O whom|O the|O 3|O most|O common|O spliceosomal|O mutations|O were|O present|O .|O
OS|O according|O to|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O .|O
In|O both|O diseases|O ,|O trisomy|O 8|O and|O del|O (|O 20q|O )|O are|O the|O most|O common|O nonspecific|O chromosomal|O abnormalities|O observed|O at|O diagnosis|O or|O at|O the|O time|O of|O progressive|O disease|O .|O
That|O these|O mutations|O were|O not|O overlapping|O and|O also|O not|O found|O in|O cases|O with|O other|O spliceosomal|O defects|O suggests|O that|O the|O effect|O of|O a|O spliceosomal|O mutation|O on|O myeloid|O malignancies|O might|O be|O inhibited|O by|O mutation|O in|O another|O factor|O or|O that|O they|O might|O not|O have|O a|O synergetic|O effect|O on|O leukemogenesis|O .|O
Notably|O ,|O the|O features|O of|O BCOR|O mutations|O in|O AML|O closely|O resembled|O those|O of|O the|O germline|O BCOR|O disruptive|O mutations|O causing|O the|O oculo|O -|O facio|O -|O cardio|O -|O dental|O (|O OFCD|O )|O X|O -|O linked|O syndrome|O that|O is|O characterized|O by|O microphtalmia|O ,|O congenital|O cataracts|O ,|O dysmorphic|O appearance|O ,|O radiculomegaly|O ,|O and|O digital|O and|O cardiac|O defects|O .|O
Results|O from|O different|O methods|O may|O differ|O with|O respect|O to|O analytical|O sensitivity|O ,|O specificity|O ,|O and|O clinical|O relevance|O .|O
Recent|O studies|O suggest|O that|O the|O presence|O of|O U2AF1|O mutation|O may|O be|O higher|O in|O MDS|O patients|O harboring|O a|O deletion|O of|O del|O (|O 20q|O )|O (|O 20|O %|O )|O .|O
For|O patients|O with|O impaired|O cardiac|O function|O ,|O other|O regimens|O that|O combine|O nonanthracycline|O agents|O (|O eg|O ,|O fludarabine|O or|O topotecan|O )|O with|O cytarabine|O have|O been|O published|O .|O
As|O the|O main|O catalytic|O molecule|O of|O the|O PRCs|O ,|O EZH2|O (|O enhancer|O of|O zeste|O homologue|O 2|O )|O is|O responsible|O for|O mono|O -|O ,|O di|O -|O ,|O and|O trimethylation|O of|O H3K27|O .|O
DNA|O ,|O RNA|O extraction|O and|O cDNA|O preparation|O .|O
Granulocyte|O isolation|O is|O not|O necessary|O because|O granulocytes|O comprise|O approximately|O 45|O %|O to|O 75|O %|O of|O total|O white|O blood|O cells|O in|O normal|O individuals|O ,|O and|O this|O proportion|O is|O even|O higher|O in|O peripheral|O blood|O of|O MPN|O patients|O .|O
Whole|O RNA|O deep|O sequencing|O .|O
High|O -|O dose|O cytarabine|O should|O also|O be|O discontinued|O in|O patients|O with|O rapidly|O rising|O creatinine|O caused|O by|O tumor|O lysis|O .|O
She|O had|O a|O large|O monoallelic|O deletion|O of|O 61|O kb|O (|O Chr3|O :|O 128|O .|O 17|O -|O 128|O .|O 23|O Mb|O )|O completely|O encompassing|O GATA2|O and|O 2|O other|O genes|O ,|O DNAJB8|O and|O LOC90246|O (|O supplemental|O Figure|O 1|O )|O .|O
A|O routine|O blood|O test|O performed|O at|O 11|O years|O of|O age|O revealed|O a|O mild|O chronic|O neutropenia|O ,|O monocytopenia|O ,|O and|O mild|O lymphopenia|O with|O a|O profound|O B|O -|O cell|O defect|O (|O Table|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
Although|O CSF3R|O truncation|O mutations|O may|O exhibit|O sensitivity|O to|O JAK|O kinase|O inhibition|O in|O the|O context|O of|O high|O concentrations|O of|O the|O CSF3R|O ligand|O ,|O downstream|O signaling|O operates|O predominantly|O through|O SRC|O kinases|O and|O exhibits|O drug|O sensitivity|O to|O SRC|O kinase|O inhibitors|O such|O as|O dasatinib|O .|O
The|O SETBP1|O mutants|O disrupt|O this|O consensus|O b|O -|O TrCP|O motif|O ,|O leading|O to|O increased|O SETBP1|O and|O SET|O expression|O ,|O which|O lowers|O PP2A|O activity|O and|O increases|O proliferation|O of|O cells|O .|O
These|O elements|O have|O been|O identified|O using|O quantitative|O chromatin|O immunoprecipitation|O analyses|O .|O
The|O correlation|O between|O cooperating|O mutations|O and|O AML|O transformation|O is|O also|O shown|O in|O Table|O 1|O .|O Only|O one|O patient|O harboring|O a|O C|O -|O terminal|O mutation|O (|O no|O .|O 30|O )|O had|O a|O cooperating|O mutation|O with|O NRAS|O (|O Gly12Asp|O )|O .|O
However|O ,|O what|O we|O have|O learned|O is|O that|O mutations|O in|O epigenetic|O modifiers|O do|O not|O fit|O neatly|O into|O the|O established|O framework|O of|O class|O I|O and|O class|O II|O mutations|O in|O leukaemogenesis|O .|O
Furthermore|O ,|O Pase|O et|O al|O demonstrated|O that|O miR|O -|O 451|O regulates|O zebrafish|O erythroid|O maturation|O in|O vivo|O via|O downregulation|O of|O its|O target|O gata2|O .|O
We|O were|O unable|O to|O find|O any|O correlation|O between|O RAD21|O and|O RUNX1|O expression|O or|O between|O mutational|O status|O and|O expression|O in|O our|O patient|O cohorts|O ,|O suggesting|O that|O this|O interaction|O in|O humans|O may|O be|O subject|O to|O pathway|O redundancy|O .|O
The|O current|O study|O identifies|O mutations|O and|O mutational|O combinations|O that|O have|O clinical|O and|O prognostic|O correlates|O in|O PMF|O and|O could|O eventually|O prove|O useful|O for|O advancing|O the|O understanding|O of|O disease|O mechanisms|O ,|O as|O suggested|O by|O the|O association|O of|O a|O specific|O gene|O expression|O signature|O in|O the|O CD34|O +|O cells|O of|O an|O exploratory|O cohort|O of|O subjects|O with|O their|O mutational|O asset|O .|O
Patient|O population|O .|O
EZH2|O mutations|O were|O not|O detected|O in|O subject|O 103|O ,|O but|O a|O homozygous|O missense|O mutation|O was|O present|O in|O subject|O 97|O (|O Table|O 1|O )|O .|O
It|O is|O found|O in|O only|O 3|O %|O of|O patients|O with|O de|O novo|O acute|O myelogenous|O leukemia|O (|O AML|O )|O and|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O is|O not|O seen|O in|O nonmyeloid|O malignancies|O or|O reactive|O myeloproliferation|O .|O
The|O analysis|O of|O overall|O survival|O was|O updated|O at|O the|O time|O of|O a|O planned|O data|O -|O collection|O cutoff|O 4|O months|O after|O the|O primary|O analysis|O .|O
One|O study|O compared|O MDS|O and|O MPN|O with|O the|O corresponding|O secondary|O AMLs|O that|O had|O DNMT3A|O mutation|O and|O identified|O the|O same|O DNMT3A|O mutation|O in|O the|O antecedent|O disorder|O as|O in|O the|O secondary|O AML|O in|O all|O ten|O cases|O .|O
We|O identified|O mutations|O in|O 18|O genes|O (|O Table|O 1|O )|O .|O
The|O diagnostic|O value|O of|O JAK2|O and|O MPL|O mutations|O in|O MPN|O is|O well|O established|O .|O
Loss|O of|O heterozygosity|O (|O LOH|O )|O analysis|O and|O PCR|O -|O SSCP|O of|O the|O entire|O coding|O region|O showed|O that|O none|O of|O the|O AML|O cases|O had|O LOH|O or|O mutation|O .|O Only|O one|O frameshift|O mutation|O at|O codon|O 130|O (|O insertion|O of|O CCCG|O )|O with|O premature|O termination|O of|O coding|O sequence|O was|O observed|O in|O the|O U937|O cell|O line|O .|O
JAK2|O mutations|O are|O known|O to|O activate|O canonical|O cytokine|O signalling|O pathways|O through|O the|O phosphorylation|O of|O STAT|O proteins|O .|O
Other|O hematological|O neoplasms|O (|O eg|O ,|O myelodysplastic|O syndrome|O ,|O chronic|O myelomonocytic|O leukemia|O ,|O acute|O myeloid|O leukemia|O ,|O and|O acute|O lymphoblastic|O leukemia|O )|O may|O harbor|O JAK2|O and|O MPL|O mutations|O in|O low|O frequencies|O .|O
The|O guidelines|O recommend|O monitoring|O complete|O blood|O counts|O ,|O including|O platelets|O ,|O every|O 1|O to|O 3|O months|O for|O the|O first|O 2|O years|O after|O patients|O have|O completed|O consolidation|O therapy|O ,|O then|O every|O 3|O to|O 6|O months|O thereafter|O for|O a|O total|O of|O 5|O years|O .|O
The|O mechanism|O of|O this|O action|O seems|O to|O be|O the|O activation|O of|O SCL|O after|O the|O binding|O of|O GATA2|O to|O its|O promoter|O ,|O and|O the|O embryonic|O retinoid|O -|O BMP|O -|O GATA2|O signaling|O pathway|O ,|O that|O controls|O progenitor|O cell|O survival|O in|O primitive|O hematopoiesis|O .|O
Multivariable|O analyses|O were|O conducted|O with|O the|O Cox|O proportional|O hazards|O regression|O model|O .|O
In|O contrast|O ,|O GATA2|O overexpression|O is|O associated|O with|O the|O more|O favorable|O subtypes|O of|O neuroblastoma|O .|O
The|O risks|O for|O neurotoxicity|O and|O renal|O insufficiency|O are|O increased|O with|O high|O -|O dose|O cytarabine|O ;|O therefore|O ,|O both|O renal|O and|O neurologic|O function|O should|O be|O closely|O monitored|O in|O patients|O receiving|O this|O treatment|O .|O
Genomic|O sequence|O analysis|O of|O subject|O 87|O covering|O the|O coding|O region|O and|O splice|O sites|O of|O the|O remaining|O copy|O of|O CUL1|O and|O EZH2|O showed|O no|O aberrations|O in|O CUL1|O .|O
Recently|O ,|O several|O groups|O reported|O frequent|O mutations|O of|O multiple|O components|O of|O the|O RNA|O splicing|O machinery|O in|O MDS|O and|O related|O disorders|O .|O
Although|O various|O JAK2|O mutations|O have|O been|O reported|O in|O exons|O 12|O ,|O 13|O ,|O 14|O ,|O and|O 15|O ,|O in|O the|O vast|O majority|O of|O the|O cases|O mutations|O are|O found|O in|O codon|O 617|O ,|O resulting|O in|O the|O replacement|O of|O the|O amino|O acid|O valine|O with|O phenylalanine|O [|O V617F|O ,|O alias|O JAK2|O NM|O _|O 004972|O .|O 3|O :|O c|O .|O 1849G|O >|O T|O (|O p|O .|O Val617Phe|O )|O ]|O .|O
TET2|O enzymatically|O converts|O 5|O -|O methylcytosine|O (|O 5mC|O )|O to|O 5hydroxymethyl|O -|O cytosine|O (|O 5hmC|O )|O .|O
Because|O BCOR|O (|O and|O BCORL1|O )|O are|O ubiquitously|O expressed|O ,|O it|O will|O be|O crucial|O to|O define|O the|O key|O targets|O of|O their|O corepressive|O transcriptional|O activity|O specifically|O in|O AML|O cells|O ,|O in|O order|O to|O gain|O more|O precise|O insights|O into|O mechanistic|O role|O of|O BCOR|O and|O BCORL1|O mutations|O in|O leukemogenesis|O .|O
Fourteen|O unrelated|O proband|O cases|O were|O selected|O for|O the|O presence|O of|O a|O neutropenia|O ,|O a|O WHIM|O -|O like|O syndrome|O with|O possible|O evolution|O to|O MDS|O /|O AML|O ,|O and|O their|O negativity|O for|O mutations|O of|O the|O major|O genes|O involved|O in|O congenital|O neutropenia|O (|O ELANE|O ,|O CXCR4|O ,|O SBDS|O ,|O and|O G6PC3|O )|O .|O
Figure|O 2|O .|O Cumulative|O incidence|O of|O thrombosis|O in|O PMF|O patients|O stratified|O according|O to|O their|O driver|O mutation|O .|O Vertical|O tick|O marks|O indicate|O right|O -|O censored|O patients|O .|O JAK2|O -|O mutant|O patients|O had|O a|O higher|O incidence|O of|O thrombosis|O than|O those|O with|O CALR|O mutation|O (|O P|O =|O .|O 021|O )|O .|O This|O difference|O remained|O statistically|O significant|O after|O adjusting|O for|O age|O (|O SHR|O ,|O 2|O .|O 19|O ;|O 95|O %|O CI|O ,|O 1|O .|O 15|O -|O 4|O .|O 18|O ;|O P|O =|O .|O 017|O )|O ,|O the|O estimated|O risk|O of|O thrombosis|O being|O about|O 2|O -|O fold|O in|O JAK2|O -|O mutant|O compared|O with|O CALR|O -|O mutant|O patients|O .|O
Low|O -|O dose|O cytarabine|O resulted|O in|O a|O CR|O rate|O of|O 18|O %|O (|O vs|O .|O 1|O %|O with|O hydroxyurea|O )|O and|O a|O survival|O benefit|O compared|O with|O hydroxyurea|O in|O patients|O with|O favorable|O or|O normal|O karyotype|O .|O
The|O different|O genetic|O subtypes|O of|O PMF|O should|O also|O be|O considered|O in|O designing|O clinical|O trials|O on|O the|O use|O of|O novel|O drugs|O .|O
A|O reduction|O in|O spleen|O volume|O was|O maintained|O in|O patients|O who|O received|O ruxolitinib|O ;|O 67|O .|O 0|O %|O of|O the|O patients|O with|O a|O response|O had|O the|O response|O for|O 48|O weeks|O or|O more|O .|O
For|O U2AF35|O ,|O we|O amplified|O two|O areas|O with|O known|O mutations|O that|O included|O residues|O S34|O and|O Q157|O .|O
There|O were|O no|O significant|O differences|O between|O the|O two|O groups|O with|O the|O exception|O of|O age|O (|O P|O <|O 0|O .|O 05|O )|O .|O IPSS|O denotes|O International|O Prognostic|O Scoring|O System|O .|O
Cytogenetic|O /|O molecular|O features|O .|O
For|O this|O secondary|O end|O point|O ,|O among|O patients|O who|O had|O a|O reduction|O of|O 35|O %|O or|O more|O in|O spleen|O volume|O ,|O 67|O .|O 0|O %|O (|O 95|O %|O CI|O ,|O 46|O .|O 4|O to|O 81|O .|O 1|O )|O had|O a|O reduction|O in|O spleen|O volume|O that|O was|O maintained|O for|O 48|O weeks|O or|O more|O (|O loss|O of|O response|O was|O defined|O as|O a|O reduction|O of|O <|O 35|O %|O from|O baseline|O and|O an|O increase|O of|O >|O =|O 25|O %|O from|O the|O nadir|O )|O .|O
In|O addition|O ,|O two|O recent|O reports|O found|O that|O the|O (|O R|O )|O -|O enantiomer|O of|O 2|O -|O HG|O (|O (|O R|O )|O -|O 2HG|O )|O may|O actually|O serve|O as|O a|O cofactor|O for|O the|O activation|O of|O the|O EGLN|O family|O of|O prolyl|O hydroxylases|O (|O EGLN1|O -|O 3|O )|O .|O
Additional|O prespecified|O analyses|O showed|O that|O among|O the|O patients|O for|O whom|O baseline|O and|O week|O 24|O data|O were|O available|O ,|O the|O 129|O patients|O receiving|O ruxolitinib|O had|O a|O mean|O improvement|O of|O 46|O .|O 1|O %|O (|O median|O ,|O 56|O .|O 2|O %|O )|O in|O the|O total|O symptom|O score|O at|O week|O 24|O ;|O the|O 103|O patients|O receiving|O placebo|O had|O a|O mean|O worsening|O of|O 41|O .|O 8|O %|O (|O median|O ,|O 14|O .|O 6|O %|O )|O in|O the|O score|O (|O P|O <|O 0|O .|O 001|O )|O .|O
Moreover|O ,|O Yoshida|O et|O al|O analyzed|O 29|O cases|O with|O different|O subtypes|O of|O myelodysplasia|O and|O identified|O mutations|O of|O multiple|O components|O of|O the|O RNA|O splicing|O machinery|O ,|O including|O SF3B1|O ,|O U2AF35|O ,|O SRSF2|O ,|O ZRSR2|O ,|O SF3A1|O and|O PRPF40B|O ,|O in|O 16|O cases|O .|O
Twenty|O deaths|O occurred|O during|O the|O study|O or|O within|O 28|O days|O after|O the|O last|O dose|O was|O administered|O (|O 9|O deaths|O in|O the|O ruxolitinib|O group|O and|O 11|O deaths|O in|O the|O placebo|O group|O ,|O including|O 1|O death|O after|O crossover|O )|O (|O see|O the|O Supplementary|O Appendix|O for|O more|O detailed|O information|O )|O .|O
Median|O time|O to|O acute|O myeloid|O leukemia|O (|O AML|O )|O transformation|O was|O 21|O months|O (|O range|O ,|O 3|O -|O 94|O months|O )|O .|O
The|O first|O author|O and|O an|O author|O who|O was|O an|O employee|O of|O the|O sponsor|O wrote|O the|O initial|O draft|O of|O the|O manuscript|O ,|O with|O assistance|O from|O a|O medical|O writer|O who|O was|O paid|O by|O the|O sponsor|O .|O
Consistent|O with|O the|O mouse|O data|O ,|O TET2|O mutations|O are|O seen|O in|O up|O to|O 50|O %|O of|O cases|O of|O CMML|O .|O
As|O illustrated|O in|O Figure|O 7|O ,|O at|O least|O 3|O genetic|O subgroups|O should|O now|O be|O taken|O into|O account|O in|O the|O interpretation|O of|O results|O :|O CALR|O -|O mutant|O ,|O JAK2|O /|O MPL|O mutant|O ,|O and|O triple|O -|O negative|O patients|O .|O
Risk|O of|O development|O of|O anemia|O ,|O thrombocytopenia|O ,|O marked|O leukocytosis|O ,|O and|O large|O splenomegaly|O during|O the|O clinical|O course|O according|O to|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O .|O
Enrico|O Tiacci|O ;|O Vera|O Grossmann|O ;|O Maria|O Paola|O Martelli|O ;|O Alexander|O Kohlmann|O ;|O Torsten|O Haferlach|O ;|O and|O Brunangelo|O Falini|O .|O
According|O to|O the|O response|O criteria|O of|O the|O International|O Working|O Group|O for|O Myelofibrosis|O Research|O and|O Treatment|O ,|O 41|O .|O 2|O %|O of|O patients|O in|O the|O ruxolitinib|O group|O and|O 46|O .|O 9|O %|O of|O patients|O in|O the|O placebo|O group|O who|O were|O dependent|O on|O transfusions|O at|O baseline|O were|O classified|O as|O transfusion|O -|O independent|O during|O the|O study|O (|O Table|O S4|O in|O the|O Supplementary|O Appendix|O )|O .|O
Factors|O such|O as|O patient|O age|O ,|O comorbid|O conditions|O ,|O and|O features|O of|O the|O disease|O at|O diagnosis|O ,|O including|O elevated|O leukocyte|O counts|O (|O >|O =|O 50|O ,|O 000|O /|O mcL|O )|O or|O number|O of|O cycles|O of|O induction|O to|O achieve|O remission|O ,|O should|O play|O a|O role|O in|O choosing|O a|O consolidation|O strategy|O ,|O as|O should|O issues|O regarding|O fertility|O and|O salvage|O options|O .|O
An|O additional|O three|O patients|O had|O identical|O nonsense|O mutations|O at|O the|O transactivating|O domain|O (|O Arg293|O )|O .|O
Myelodysplastic|O syndromes|O are|O characterized|O by|O ineffective|O hematopoiesis|O and|O impaired|O differentiation|O ,|O leading|O to|O peripheral|O -|O blood|O cytopenias|O ,|O but|O the|O contribution|O of|O specific|O genotypes|O to|O particular|O cytopenias|O is|O unknown|O .|O
The|O mutation|O was|O retained|O during|O disease|O progression|O .|O
A|O well|O -|O thought|O -|O out|O plan|O for|O salvage|O therapy|O with|O either|O a|O matched|O sibling|O or|O unrelated|O donor|O HSCT|O should|O be|O an|O important|O part|O of|O the|O treatment|O decision|O for|O these|O patients|O .|O
PMF|O can|O be|O diagnosed|O by|O bone|O marrow|O biopsy|O that|O shows|O proliferation|O of|O hyperchromic|O megakaryocytes|O with|O large|O irregular|O nuclei|O ,|O in|O association|O with|O either|O reticulin|O or|O collagen|O fibrosis|O ,|O and|O in|O the|O absence|O of|O reactive|O fibrosis|O (|O Table|O 3|O )|O .|O
For|O instance|O ,|O U2AF1|O mutations|O were|O associated|O with|O defective|O splicing|O of|O intron|O 5|O of|O TET2|O at|O both|O splice|O sites|O (|O Figure|O 3A|O ;|O supplemental|O Figure|O 6|O )|O ,|O whereas|O splicing|O of|O other|O TET2|O introns|O were|O less|O affected|O .|O
INTRODUCTION|O .|O
For|O the|O secondary|O end|O point|O of|O overall|O survival|O ,|O at|O the|O time|O of|O data|O cutoff|O ,|O 10|O deaths|O were|O reported|O in|O the|O ruxolitinib|O group|O (|O 6|O .|O 5|O %|O )|O as|O compared|O with|O 14|O deaths|O in|O the|O placebo|O group|O (|O 9|O .|O 1|O %|O )|O (|O hazard|O ratio|O ,|O 0|O .|O 67|O ;|O 95|O %|O CI|O ,|O 0|O .|O 30|O to|O 1|O .|O 50|O ;|O P|O =|O 0|O .|O 33|O )|O .|O
The|O myelodysplastic|O syndromes|O (|O MDSs|O )|O are|O characterized|O by|O clonal|O hematopoiesis|O ,|O a|O variety|O of|O chromosomal|O abnormalities|O ,|O bone|O marrow|O (|O BM|O )|O failure|O ,|O and|O a|O propensity|O for|O evolution|O to|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
Subsequent|O clinical|O trials|O have|O not|O included|O maintenance|O as|O postremission|O therapy|O .|O
For|O each|O mutation|O ,|O we|O therefore|O compared|O the|O clinical|O characteristics|O of|O patients|O who|O had|O the|O mutation|O with|O those|O of|O patients|O who|O did|O not|O have|O the|O mutation|O .|O
An|O additional|O five|O specimens|O were|O positive|O in|O all|O laboratories|O where|O results|O were|O obtained|O ;|O some|O of|O the|O laboratories|O did|O not|O obtain|O a|O result|O with|O these|O specimens|O ,|O most|O likely|O because|O of|O low|O DNA|O concentration|O .|O
Mutations|O in|O TP53|O ,|O EZH2|O ,|O ETV6|O ,|O RUNX1|O ,|O and|O ASXL1|O are|O predictors|O of|O poor|O overall|O survival|O in|O patients|O with|O myelodysplastic|O syndromes|O ,|O independently|O of|O established|O risk|O factors|O .|O
These|O have|O also|O been|O reported|O to|O be|O associated|O with|O intermediate|O -|O 2|O /|O high|O -|O risk|O disease|O and|O increased|O risk|O of|O leukemic|O transformation|O .|O
The|O PCR|O product|O was|O run|O on|O a|O 2|O %|O agarose|O gel|O ,|O then|O cut|O from|O the|O gel|O ,|O purified|O and|O subcloned|O into|O the|O pCRII|O -|O TOPO|O vector|O (|O Invitrogen|O )|O .|O
Finally|O ,|O we|O used|O the|O Akaike|O information|O criterion|O as|O a|O measure|O of|O the|O relative|O quality|O of|O the|O clinical|O -|O molecular|O prognostic|O model|O compared|O with|O the|O IPSS|O .|O
The|O relationships|O between|O TET2|O mutations|O and|O other|O somatic|O events|O have|O also|O been|O explored|O .|O
During|O ontogeny|O of|O HSC|O ,|O GATA2|O plays|O at|O least|O two|O functionally|O distinct|O roles|O :|O the|O production|O and|O expansion|O of|O HSC|O in|O aorta|O -|O -|O gonad|O -|O -|O mesonephros|O ,|O and|O the|O proliferation|O and|O survival|O of|O HSC|O in|O adult|O bone|O marrow|O .|O
However|O ,|O for|O patients|O at|O high|O risk|O for|O CNS|O disease|O ,|O such|O as|O those|O with|O monocytic|O differentiation|O (|O M4|O or|O M5|O morphology|O )|O or|O high|O WBC|O count|O (|O >|O 100|O ,|O 000|O /|O mcL|O )|O at|O presentation|O ,|O a|O diagnostic|O LP|O should|O be|O considered|O as|O part|O of|O the|O documentation|O of|O remission|O status|O .|O
Clonal|O acquisition|O of|O cohesin|O complex|O gene|O mutations|O .|O
PU|O .|O 1|O is|O essential|O for|O monocytic|O ,|O granulocytic|O ,|O and|O lymphoid|O lineages|O .|O
In|O addition|O ,|O GATA1|O ,|O -|O 2|O ,|O -|O 3|O ,|O and|O -|O 4|O can|O all|O activate|O expression|O of|O IL4|O ,|O IL5|O and|O other|O target|O genes|O of|O GATA3|O in|O T|O -|O cells|O ,|O as|O well|O as|O repress|O IFNy|O .|O
Furthermore|O ,|O it|O is|O crucial|O for|O the|O proliferation|O and|O maintenance|O of|O HSC|O and|O HPC|O .|O
GATA1|O is|O expressed|O in|O the|O Sertoli|O cells|O of|O the|O testis|O ;|O GATA2|O is|O expressed|O in|O endothelial|O cells|O and|O in|O the|O central|O nervous|O system|O ,|O placenta|O ,|O fetal|O liver|O ,|O and|O fetal|O heart|O ;|O and|O GATA3|O is|O present|O in|O kidney|O ,|O central|O nervous|O system|O ,|O placenta|O ,|O skin|O and|O mammary|O gland|O .|O
Sequences|O were|O analyzed|O with|O Sequencher|O (|O Genescode|O )|O .|O
These|O pathways|O can|O be|O categorized|O according|O to|O their|O function|O .|O
MiRNAs|O are|O small|O non|O -|O coding|O RNAs|O that|O regulate|O gene|O expression|O at|O post|O -|O transcriptional|O level|O ,|O either|O by|O repressing|O translation|O or|O by|O inducing|O sequence|O -|O specific|O degradation|O of|O target|O mRNAs|O .|O
Genomic|O DNA|O was|O isolated|O and|O used|O to|O produce|O whole|O genome|O amplified|O DNA|O (|O by|O means|O of|O a|O kit|O [|O Qiagen|O ]|O )|O .|O
Principal|O causes|O of|O death|O in|O the|O ruxolitinib|O group|O were|O muscle|O weakness|O and|O general|O deterioration|O ,|O subdural|O hematoma|O ,|O renal|O failure|O ,|O non|O -|O small|O -|O cell|O lung|O cancer|O ,|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O pneumonia|O (|O in|O 2|O patients|O )|O ,|O and|O sepsis|O (|O in|O 2|O patients|O )|O .|O
Although|O all|O patients|O with|O AML|O are|O best|O managed|O within|O the|O context|O of|O an|O appropriate|O clinical|O trial|O ,|O this|O poor|O -|O risk|O group|O of|O patients|O ,|O in|O particular|O ,|O should|O be|O entered|O into|O a|O clinical|O trial|O (|O incorporating|O either|O chemotherapy|O or|O low|O -|O intensity|O therapy|O )|O ,|O if|O available|O ,|O because|O only|O 40|O %|O to|O 50|O %|O of|O these|O patients|O experience|O a|O CR|O with|O standard|O induction|O therapy|O .|O
Mutations|O in|O IDH1|O and|O IDH2|O that|O result|O in|O neomorphic|O enzymatic|O activity|O may|O represent|O novel|O ,|O tractable|O targets|O for|O this|O genetically|O defined|O subset|O of|O leukaemia|O patients|O .|O
Patients|O with|O a|O higher|O level|O of|O FLT3|O -|O TKD|O mutations|O (|O >|O 25|O %|O )|O had|O a|O significantly|O higher|O 5|O -|O year|O OS|O rate|O compared|O with|O those|O with|O lower|O levels|O of|O mutations|O ,|O which|O showed|O an|O OS|O rate|O similar|O to|O that|O of|O patients|O without|O FLT3|O -|O TKD|O mutations|O (|O 71|O %|O vs|O .|O 37|O %|O ;|O adjusted|O P|O =|O .|O 004|O )|O .|O
The|O expanded|O sample|O size|O of|O our|O cohort|O also|O enabled|O precise|O analysis|O of|O clinical|O associations|O .|O
In|O patients|O who|O have|O symptomatic|O anemia|O ,|O thalidomide|O or|O lenalidomide|O should|O be|O considered|O ,|O although|O therapy|O may|O be|O limited|O by|O toxicity|O .|O
Twenty|O -|O one|O patients|O had|O 23|O mutations|O (|O 72|O %|O )|O located|O in|O the|O N|O -|O terminal|O part|O and|O the|O remaining|O 9|O patients|O had|O single|O mutations|O located|O in|O the|O C|O -|O terminal|O region|O .|O
Interestingly|O ,|O these|O last|O two|O specimens|O were|O also|O found|O to|O be|O positive|O for|O JAK2|O V617F|O by|O many|O of|O the|O participating|O laboratories|O .|O
The|O sequencing|O of|O the|O exome|O was|O performed|O by|O IntegraGen|O using|O a|O HiSeq|O 2000|O (|O Illumina|O )|O .|O
Subsequent|O sequencing|O of|O this|O gene|O in|O other|O samples|O revealed|O several|O point|O mutations|O that|O were|O confirmed|O to|O be|O somatic|O on|O examination|O of|O matched|O buccal|O -|O swab|O DNA|O .|O
Overall|O survival|O was|O evaluated|O for|O all|O patients|O by|O means|O of|O unadjusted|O and|O adjusted|O Cox|O proportional|O -|O hazards|O regression|O modeling|O ;|O models|O were|O adjusted|O for|O the|O IPSS|O risk|O group|O assigned|O at|O the|O time|O of|O sample|O collection|O .|O
Cohesin|O complex|O mutations|O as|O a|O group|O had|O no|O prognostic|O impact|O in|O all|O and|O in|O cytogenetically|O normal|O AML|O patients|O .|O
We|O identified|O 6|O mutations|O of|O GATA2|O among|O these|O 14|O cases|O ,|O 5|O point|O mutations|O and|O a|O large|O deletion|O of|O 61|O kb|O completely|O overlapping|O the|O GATA2|O locus|O .|O
The|O clinical|O utility|O of|O quantification|O of|O V617F|O has|O not|O yet|O been|O established|O .|O
The|O guidelines|O provide|O a|O list|O of|O several|O commonly|O used|O salvage|O regimens|O (|O see|O page|O 998|O )|O .|O
ABSTRACT|O .|O
IDH1|O /|O 2|O .|O
Recent|O studies|O of|O cohesin|O dynamics|O at|O super|O enhancer|O sites|O are|O in|O line|O with|O these|O conclusions|O :|O cohesin|O localizes|O to|O sites|O of|O high|O mediator|O occupancy|O at|O the|O enhancer|O -|O promoter|O interaction|O sites|O in|O lymphoma|O and|O myeloma|O .|O
This|O enabled|O us|O to|O determine|O clonal|O architecture|O ,|O and|O we|O observed|O that|O cohesin|O mutant|O clones|O expanded|O or|O remained|O stable|O in|O all|O 13|O patients|O with|O a|O statistically|O significant|O increase|O in|O clone|O size|O (|O P|O =|O .|O 0032|O )|O .|O
6|O .|O EXPRESSION|O AND|O BIOLOGICAL|O FUNCTION|O OF|O GATA2|O IN|O HEMATOPOIESIS|O .|O
Cohesin|O mutations|O co|O -|O occur|O with|O other|O mutations|O known|O to|O be|O drivers|O of|O clonal|O evolution|O .|O
Gain|O -|O of|O -|O function|O of|O mutated|O C|O -|O CBL|O tumor|O suppressor|O plays|O an|O important|O role|O in|O development|O of|O myeloid|O malignancies|O .|O
A|O repeat|O bone|O marrow|O evaluation|O is|O performed|O in|O these|O patients|O and|O in|O those|O with|O hypoplasia|O after|O induction|O to|O document|O remission|O status|O .|O
An|O allele|O burden|O of|O greater|O than|O 50|O %|O suggests|O homozygosity|O ,|O which|O is|O most|O likely|O to|O occur|O in|O PV|O ;|O it|O is|O uncommon|O in|O ET|O .|O
Other|O genetic|O aberrations|O require|O identification|O .|O Runt|O -|O related|O transcription|O factor|O 1|O (|O RUNX1|O )|O is|O essential|O for|O normal|O hematopoiesis|O and|O differentiation|O .|O
The|O three|O risk|O groups|O had|O median|O survivals|O of|O 66|O (|O low|O risk|O )|O ,|O 36|O (|O intermediate|O risk|O )|O and|O 18|O (|O high|O risk|O )|O months|O ,|O respectively|O (|O P|O <|O 0|O .|O 0005|O )|O .|O
Ruxolitinib|O ,|O as|O compared|O with|O placebo|O ,|O provided|O significant|O clinical|O benefits|O in|O patients|O with|O myelofibrosis|O by|O reducing|O spleen|O size|O ,|O ameliorating|O debilitating|O myelofibrosis|O -|O related|O symptoms|O ,|O and|O improving|O overall|O survival|O .|O
Using|O standard|O curves|O for|O both|O the|O wild|O -|O type|O and|O mutant|O forms|O ,|O it|O is|O possible|O to|O perform|O this|O calculation|O ;|O however|O ,|O there|O is|O no|O standardization|O for|O measuring|O quantity|O .|O
In|O conclusion|O ,|O our|O study|O revealed|O mutations|O in|O 66|O /|O 81|O (|O 81|O .|O 5|O %|O )|O CMML|O patients|O providing|O new|O insights|O into|O the|O molecular|O heterogeneity|O of|O this|O disease|O .|O
DNAnexus|O software|O allowed|O visualization|O of|O reads|O derived|O from|O spliced|O mRNA|O and|O those|O that|O completely|O match|O the|O genome|O ,|O including|O both|O sense|O and|O antisense|O .|O
Initially|O ,|O the|O intrathecal|O therapy|O should|O be|O given|O twice|O weekly|O until|O the|O cytology|O shows|O no|O blasts|O ,|O and|O then|O weekly|O for|O 4|O to|O 6|O weeks|O .|O
Patients|O with|O RUNX1|O mutations|O had|O a|O trend|O of|O increased|O risk|O of|O AML|O transformation|O compared|O with|O that|O in|O mutation|O -|O negative|O patients|O ,|O but|O the|O difference|O did|O not|O reach|O statistical|O significance|O .|O
Such|O phenotypes|O would|O then|O be|O absent|O in|O myeloid|O cells|O lacking|O the|O corresponding|O transcripts|O .|O
We|O examined|O RUNX1|O mutations|O in|O 81|O patients|O with|O CMML|O at|O initial|O diagnosis|O .|O
Mutations|O in|O IDH1|O were|O first|O identified|O in|O glioblastoma|O through|O whole|O -|O exome|O sequencing|O ;|O this|O led|O to|O the|O identification|O of|O IDH1|O mutations|O in|O 12|O %|O of|O 149|O glioblastoma|O samples|O .|O
We|O then|O validated|O the|O results|O in|O an|O independent|O cohort|O of|O 268|O patients|O from|O the|O H|O .|O
There|O were|O no|O significant|O differences|O in|O the|O clinicohematological|O features|O between|O RUNX1|O mutationpositive|O and|O RUNX1|O mutation|O -|O negative|O groups|O .|O
The|O disease|O course|O of|O CNL|O is|O variable|O ,|O but|O acceleration|O is|O typically|O characterized|O by|O refractory|O neutrophilia|O ,|O worsening|O organomegaly|O ,|O and|O blastic|O transformation|O .|O
Besides|O ,|O mutations|O in|O sequences|O encoding|O the|O N|O -|O terminal|O transactivation|O domain|O of|O GATA1|O have|O been|O found|O in|O patients|O with|O Down|O syndrome|O who|O have|O a|O transient|O myeloproliferative|O disorder|O ,|O a|O clonal|O disease|O that|O is|O characterized|O by|O immature|O megakaryoblasts|O in|O the|O fetal|O liver|O and|O peripheral|O blood|O ,|O that|O can|O progress|O to|O acute|O megakaryocytic|O leukemia|O .|O
However|O ,|O if|O symptoms|O persist|O ,|O and|O bleeding|O and|O mass|O /|O lesions|O are|O excluded|O ,|O the|O patient|O should|O have|O a|O lumbar|O puncture|O (|O LP|O )|O for|O diagnostic|O and|O possible|O therapeutic|O purposes|O once|O coagulopathy|O has|O been|O corrected|O and|O adequate|O platelet|O support|O is|O available|O .|O
Organelles|O that|O are|O found|O in|O virtually|O all|O eukaryotic|O cells|O .|O They|O are|O involved|O in|O the|O catabolism|O of|O very|O -|O long|O -|O chain|O fatty|O acids|O ,|O branchedchain|O fatty|O acids|O ,|O d|O -|O amino|O acids|O ,|O polyamines|O and|O the|O biosynthesis|O of|O plasmalogens|O and|O etherphospholipids|O .|O
Study|O Oversight|O .|O
Thus|O ,|O as|O the|O population|O ages|O ,|O the|O incidence|O of|O AML|O ,|O along|O with|O myelodysplasia|O ,|O seems|O to|O be|O rising|O .|O
In|O this|O subgroup|O ,|O we|O did|O not|O identify|O a|O difference|O in|O OS|O and|O RFS|O for|O patients|O with|O or|O without|O mutations|O in|O the|O cohesin|O complex|O (|O OS|O :|O HR|O 0|O .|O 73|O ;|O 95|O %|O CI|O ,|O 0|O .|O 34|O -|O 1|O .|O 57|O ;|O P|O =|O .|O 42|O )|O and|O (|O RFS|O :|O HR|O 0|O .|O 47|O ;|O 95|O %|O CI|O ,|O 0|O .|O 19|O -|O 1|O .|O 16|O ;|O P|O =|O .|O 1|O ;|O supplemental|O Figure|O 3A|O -|O B|O )|O .|O
To|O the|O best|O of|O our|O knowledge|O ,|O this|O series|O is|O the|O largest|O one|O of|O CMML|O that|O has|O been|O examined|O for|O RUNX1|O mutations|O and|O we|O showed|O a|O high|O frequency|O of|O RUNX1|O mutations|O occurring|O preferentially|O at|O RHD|O with|O nonsense|O or|O frameshift|O patterns|O .|O
Both|O the|O NCCN|O and|O the|O European|O LeukemiaNet|O (|O ELN|O )|O classify|O patients|O with|O NK|O -|O AML|O and|O mutated|O NPM1|O or|O CEBPA|O (|O without|O FLT3|O -|O ITD|O )|O as|O having|O favorable|O risk|O .|O
This|O study|O identified|O age|O >|O 65|O years|O ,|O presence|O of|O constitutional|O symptoms|O ,|O hemoglobin|O level|O <|O 10|O g|O /|O dL|O ,|O leukocyte|O count|O >|O 25|O x|O 109|O /|O L|O ,|O and|O circulating|O blast|O cells|O 1|O %|O or|O greater|O as|O independent|O predictors|O of|O shortened|O survival|O at|O diagnosis|O .|O
A|O higher|O frequency|O of|O cohesin|O defects|O was|O found|O in|O sAML|O and|O high|O -|O risk|O MDS|O patients|O ,|O with|O somatic|O alterations|O in|O 20|O %|O and|O 17|O %|O of|O these|O disease|O phenotypes|O ,|O respectively|O (|O Figure|O 1C|O )|O .|O
Thus|O ,|O increased|O D|O -|O 2HG|O becomes|O a|O negative|O regulator|O of|O TET2|O (|O an|O alphaKG|O -|O dependent|O enzyme|O )|O ,|O resulting|O in|O abnormalities|O in|O global|O DNA|O methylation|O .|O
These|O SNPs|O have|O not|O been|O reported|O in|O dbSNP|O (|O version|O 137|O )|O and|O were|O not|O identified|O in|O peripheral|O blood|O mononuclear|O cells|O from|O 30|O healthy|O controls|O .|O
Germline|O deletion|O of|O the|O Gata1|O gene|O in|O mice|O leads|O to|O embryonic|O lethality|O caused|O by|O an|O arrest|O of|O erythroid|O development|O at|O the|O proerythroblast|O stage|O ,|O providing|O direct|O evidence|O that|O Gata1|O is|O essential|O for|O erythropoiesis|O .|O
These|O interactions|O can|O either|O involve|O only|O N|O -|O ZnF|O ,|O as|O in|O the|O case|O of|O FOG1|O ,|O or|O occur|O in|O collaboration|O with|O C|O -|O ZnF|O ,|O for|O example|O ,|O with|O Sp1|O ,|O EKLF|O and|O GATA1|O itself|O .|O
Mutations|O in|O CEBPA|O have|O been|O reported|O in|O 7|O %|O to|O 11|O %|O of|O patients|O with|O AML|O (|O or|O 13|O %|O -|O 15|O %|O of|O those|O with|O NK|O -|O AML|O )|O and|O has|O been|O associated|O with|O a|O favorable|O outcome|O (|O similar|O to|O patients|O with|O CBF|O translocations|O )|O with|O regard|O to|O increased|O remission|O duration|O and|O OS|O outcomes|O compared|O with|O wild|O -|O type|O CEBPA|O .|O
(|O Ipsogen|O became|O Qiagen|O Marseille|O in|O 2013|O .|O )|O
Subjects|O carrying|O 7|O or|O 7q|O deletions|O showed|O a|O significantly|O worse|O survival|O compared|O to|O individuals|O without|O any|O EZH2|O abnormalities|O (|O P|O <|O 0|O .|O 001|O ;|O Supplementary|O Fig|O .|O 7|O )|O .|O
In|O 10|O of|O 13|O cohesin|O mutant|O patients|O with|O serial|O samples|O ,|O the|O cohesin|O mutant|O clone|O achieved|O clonal|O dominance|O at|O the|O time|O of|O transformation|O .|O
Immunoprecipitation|O of|O methylated|O DNA|O followed|O by|O hybridization|O to|O DNA|O microarray|O chips|O (|O MeDIP|O -|O chip|O )|O revealed|O that|O AMLs|O with|O DNMT3AR882|O mutations|O had|O decreased|O methylation|O at|O 182|O specific|O genomic|O loci|O compared|O with|O DNMT3A|O -|O wild|O -|O type|O AML|O .|O
In|O all|O ,|O 10|O of|O 13|O patients|O had|O cohesin|O present|O in|O the|O dominant|O clone|O after|O transformation|O (|O supplemental|O Tables|O 10|O -|O 11|O )|O .|O
Taken|O together|O ,|O it|O is|O likely|O that|O NOTCH1|O and|O /|O or|O BMP4|O -|O signaling|O pathways|O initiate|O GATA2|O and|O FLI1|O expression|O ,|O which|O then|O autoregulate|O each|O other|O and|O combine|O to|O initiate|O SCL|O transcription|O (|O Fig|O .|O 3|O )|O .|O
APL|O uniquely|O responds|O to|O differentiation|O -|O inducing|O therapy|O with|O all|O -|O trans|O retinoic|O acid|O (|O ATRA|O )|O and|O /|O or|O arsenic|O trioxide|O .|O
This|O is|O most|O prominent|O for|O the|O association|O of|O SF3B1|O mutations|O with|O increased|O ring|O sideroblasts|O .|O
For|O detection|O of|O U2AF35|O mutations|O ,|O we|O applied|O the|O standard|O PCR|O techniques|O and|O bidirectional|O sequencing|O .|O
This|O discovery|O represents|O a|O significant|O advance|O in|O the|O field|O of|O MDS|O research|O ,|O providing|O a|O novel|O clue|O to|O understanding|O of|O the|O pathogenesis|O of|O MDS|O .|O
The|O PRC2|O complex|O consists|O of|O four|O core|O members|O :|O EZH1|O or|O EZH2|O ,|O embryonic|O ectoderm|O development|O (|O EED|O )|O ,|O suppressor|O of|O zeste|O 12|O homologue|O (|O SUZ12|O )|O and|O RBAP48|O (|O also|O known|O as|O RBBP4|O )|O (|O reviewed|O recently|O 61|O )|O .|O
In|O the|O ELN|O guidelines|O ,|O patients|O with|O NK|O -|O AML|O with|O both|O mutated|O NPM1|O and|O FLT3|O ,|O and|O those|O with|O wild|O -|O type|O NPM1|O and|O mutated|O FLT3|O or|O wild|O -|O type|O NPM1|O and|O FLT3|O are|O categorized|O as|O having|O intermediate|O -|O risk|O AML|O (|O "|O Intermediate|O I|O "|O group|O )|O .|O
In|O contrast|O ,|O U2AF1|O mutations|O were|O most|O frequent|O in|O the|O high|O -|O risk|O MDS|O /|O AML|O cohort|O (|O 11|O %|O )|O ,|O whereas|O SRSF2|O was|O most|O frequently|O mutated|O in|O MDS|O /|O MPN|O (|O 24|O %|O )|O particularly|O in|O CMML|O (|O 28|O %|O ;|O Figure|O 2A|O )|O .|O
Mutations|O of|O TET2|O were|O overrepresented|O in|O samples|O with|O normal|O cytogenetic|O features|O (|O P|O =|O 0|O .|O 005|O )|O (|O Table|O 7|O in|O the|O Supplementary|O Appendix|O )|O ,|O whereas|O TP53|O mutations|O were|O strongly|O associated|O with|O a|O complex|O karyotype|O (|O P|O <|O 0|O .|O 001|O )|O .|O
Induction|O Therapy|O :|O Standard|O induction|O regimens|O are|O appropriate|O for|O patients|O younger|O than|O age|O 60|O years|O .|O
There|O appears|O to|O be|O a|O low|O incidence|O rate|O of|O N|O -|O RAS|O (|O ~|O 4|O -|O 9|O %|O )|O in|O MDS|O patients|O .|O
In|O sum|O ,|O our|O studies|O found|O the|O widespread|O presence|O of|O mutations|O in|O genes|O involved|O in|O splicing|O in|O myeloid|O neoplasms|O .|O
In|O the|O European|O cohort|O ,|O JAK2V617F|O mutation|O was|O associated|O with|O older|O age|O (|O P|O =|O 0|O .|O 005|O )|O ,|O higher|O hemoglobin|O level|O (|O P|O =|O 0|O .|O 0001|O )|O and|O increased|O leukocyte|O count|O (|O P|O =|O 0|O .|O 001|O )|O ;|O EZH2|O mutations|O with|O leukocytosis|O (|O P|O =|O 0|O .|O 01|O )|O and|O >|O =|O 1|O %|O circulating|O blasts|O (|O P|O =|O 0|O .|O 02|O )|O ;|O ASXL1|O mutations|O with|O leukocytosis|O (|O P|O <|O 0|O .|O 001|O )|O ,|O >|O =|O 1|O %|O circulating|O blasts|O (|O P|O =|O 0|O .|O 001|O )|O ,|O anemia|O (|O P|O =|O 0|O .|O 01|O )|O ,|O splenomegaly|O (|O P|O =|O 0|O .|O 007|O )|O and|O constitutional|O symptoms|O (|O P|O <|O 0|O .|O 01|O )|O ;|O SRSF2|O mutations|O with|O older|O age|O (|O P|O <|O 0|O .|O 001|O )|O ,|O leukocytosis|O (|O P|O <|O 0|O .|O 01|O )|O ,|O >|O =|O 1|O %|O circulating|O blasts|O (|O P|O =|O 0|O .|O 012|O )|O and|O constitutional|O symptoms|O (|O P|O =|O 0|O .|O 009|O )|O .|O
The|O discovery|O of|O high|O -|O frequency|O CSF3R|O mutations|O in|O CNL|O ,|O and|O to|O a|O lesser|O extent|O in|O aCML|O ,|O identifies|O a|O new|O major|O diagnostic|O criterion|O for|O these|O diseases|O and|O suggests|O a|O close|O relationship|O between|O these|O neutrophilic|O leukemias|O .|O
The|O role|O of|O the|O GATA2|O transcription|O factor|O in|O normal|O and|O malignant|O hematopoiesis|O .|O
There|O are|O several|O studies|O on|O the|O characteristics|O and|O function|O of|O the|O GATA1|O protein|O domains|O ;|O however|O ,|O little|O is|O known|O about|O GATA2|O .|O
This|O mutation|O is|O present|O in|O approximately|O 96|O %|O of|O PV|O cases|O ,|O 55|O %|O of|O ET|O cases|O ,|O and|O 65|O %|O of|O PMF|O cases|O .|O
The|O integration|O of|O mutation|O assessment|O in|O diagnostic|O classification|O and|O prognostic|O scoring|O systems|O has|O the|O potential|O to|O parse|O diverse|O myelodysplastic|O syndromes|O into|O a|O set|O of|O discrete|O diseases|O with|O predictable|O clinical|O phenotypes|O ,|O prognosis|O ,|O and|O responses|O to|O therapy|O .|O
Different|O types|O of|O CALR|O exon|O 9|O mutations|O and|O their|O frequency|O .|O
These|O data|O reveal|O a|O novel|O mechanism|O for|O the|O regulation|O of|O GATA1|O interaction|O with|O FOG1|O -|O dependent|O protein|O complexes|O through|O the|O production|O of|O two|O translational|O isoforms|O with|O differential|O interaction|O profiles|O and|O independent|O nuclear|O localization|O control|O .|O
Recently|O ,|O two|O studies|O have|O shown|O that|O GATA1|O regulates|O erythropoiesis|O by|O controlling|O miRNAs|O .|O
Functional|O studies|O showed|O that|O the|O L359V|O mutant|O resulted|O in|O enhanced|O GATA2|O transactivation|O activity|O ,|O and|O that|O both|O GATA2|O mutations|O repressed|O PU|O .|O 1|O activity|O via|O aberrant|O protein|O -|O protein|O interaction|O .|O
Some|O published|O methods|O screen|O for|O mutations|O using|O denaturing|O high|O -|O performance|O liquid|O chromatography|O or|O high|O -|O resolution|O melting|O -|O curve|O analysis|O ,|O followed|O by|O direct|O sequencing|O to|O confirm|O that|O a|O mutation|O is|O present|O .|O
This|O mutation|O has|O also|O been|O observed|O in|O conjunction|O with|O NPM1|O mutations|O and|O FLT3|O mutations|O .|O
Somatic|O mutations|O of|O the|O histone|O methyltransferase|O gene|O EZH2|O in|O myelodysplastic|O syndromes|O .|O
Tissue|O typing|O should|O be|O broadened|O to|O include|O unrelated|O donor|O searches|O in|O patients|O younger|O than|O 60|O years|O with|O karyotypes|O or|O molecular|O abnormalities|O deemed|O highrisk|O .|O
INF|O -|O alpha|O .|O
Figure|O 1|O .|O Schematic|O representation|O of|O JAK2|O gene|O and|O mutation|O hot|O spots|O .|O Locations|O of|O reported|O mutations|O are|O indicated|O by|O colored|O triangles|O :|O red|O triangles|O for|O V617F|O ,|O black|O triangles|O for|O other|O SNP|O mutations|O ,|O and|O blue|O triangles|O for|O insertions|O /|O deletions|O .|O Representative|O codon|O numbers|O are|O marked|O above|O exon|O boxes|O .|O FERM|O ,|O four|O -|O point|O -|O one|O ,|O ezrin|O ,|O radixin|O ,|O moesin|O domain|O ;|O JH1|O ,|O kinase|O domain|O ;|O JH2|O ,|O pseudokinase|O domain|O ;|O SH2|O -|O like|O ,|O SH2|O -|O like|O domain|O .|O
To|O define|O a|O set|O of|O somatically|O mutated|O genes|O in|O bone|O marrow|O aspirates|O 5|O from|O patients|O with|O myelodysplastic|O syndromes|O ,|O we|O first|O examined|O 191|O samples|O for|O abnormalities|O in|O known|O oncogenes|O (|O Fig|O .|O 2|O in|O the|O Supplementary|O Appendix|O )|O .|O
Differences|O in|O the|O distribution|O of|O continuous|O variables|O between|O categories|O were|O analyzed|O by|O either|O Mann|O -|O Whitney|O (|O for|O comparison|O of|O two|O groups|O )|O or|O Kruskal|O -|O Wallis|O (|O comparison|O of|O three|O or|O more|O groups|O )|O test|O .|O
RESULTS|O .|O
The|O low|O frequencies|O of|O RUNX1|O mutations|O in|O the|O earlier|O studies|O were|O probably|O attributed|O to|O different|O patient|O populations|O along|O with|O the|O limited|O exons|O analyzed|O as|O well|O as|O the|O small|O number|O of|O CMML|O patients|O examined|O .|O
In|O more|O detail|O ,|O we|O observed|O 10|O novel|O different|O EZH2|O mutations|O in|O nine|O patients|O :|O 6|O missense|O ,|O 3|O frameshifts|O (|O 2|O deletions|O ,|O 1|O insertion|O )|O and|O 1|O splice|O mutation|O (|O Supplementary|O Table|O 4|O )|O .|O
Recent|O observations|O indicate|O that|O the|O JAK|O -|O STAT|O (|O Janus|O kinase|O -|O signal|O transducer|O and|O activator|O of|O transcription|O )|O pathway|O is|O activated|O in|O all|O MPNs|O regardless|O of|O founding|O driver|O mutations|O .|O
RNA|O was|O reversely|O transcribed|O to|O cDNA|O with|O the|O superscript|O II|O RNase|O H2|O reverse|O transcriptase|O kit|O (|O Invitrogen|O Corporation|O ,|O Carlsbad|O ,|O CA|O ,|O USA|O )|O .|O
The|O CR|O rates|O were|O similar|O ,|O with|O 55|O %|O for|O the|O high|O -|O dose|O arm|O compared|O with|O 58|O %|O for|O the|O standard|O -|O dose|O arm|O for|O patients|O younger|O than|O 50|O years|O ,|O and|O 45|O %|O for|O high|O -|O dose|O cytarabine|O versus|O 53|O %|O for|O standard|O -|O dose|O therapy|O for|O patients|O 50|O to|O 65|O years|O of|O age|O .|O
Studies|O have|O further|O shown|O that|O polycomb|O -|O based|O histone|O H3|O lysine|O 27|O trimethylation|O (|O H3K27triM|O )|O plays|O a|O critical|O role|O in|O epigenetic|O silencing|O in|O tumor|O cells|O .|O
Yet|O ,|O due|O to|O the|O limited|O number|O of|O EZH2|O -|O mutated|O cases|O ,|O we|O did|O not|O separate|O the|O cohort|O into|O these|O two|O categories|O in|O subsequent|O analyses|O .|O
The|O insertion|O resulted|O in|O the|O frameshift|O mutation|O of|O codon|O 130|O with|O premature|O termination|O of|O the|O coding|O sequence|O .|O
Spliceosomal|O genes|O are|O probably|O tumor|O suppressors|O ,|O and|O their|O mutations|O may|O constitute|O diagnostic|O biomarkers|O that|O could|O potentially|O serve|O as|O therapeutic|O targets|O .|O
These|O genes|O are|O located|O at|O disparate|O chromosomal|O locus|O but|O act|O together|O in|O control|O of|O cell|O division|O (|O centrosomes|O ,|O hetrochromatin|O ,|O DNA|O duplication|O ,|O gene|O expression|O ,|O and|O chromosome|O segregation|O )|O through|O regulating|O dissociation|O of|O sister|O chromatids|O in|O mitosis|O or|O meiosis|O (|O Fig|O .|O 3|O )|O .|O
Table|O 2|O .|O Adverse|O Events|O Observed|O in|O 10|O %|O or|O More|O of|O Patients|O Who|O Received|O Ruxolitinib|O .|O
Our|O sequence|O library|O for|O deep|O sequencing|O was|O generated|O by|O TruSeqCustom|O Amplicon|O (|O Illumina|O )|O .|O
GATA2|O mutation|O screening|O .|O
Therefore|O ,|O as|O a|O functionally|O relevant|O upstream|O regulator|O of|O GATA2|O ,|O NOTCH1|O is|O a|O potential|O initiator|O of|O the|O circuit|O .|O
Most|O clinical|O and|O disease|O characteristics|O of|O patients|O with|O mutations|O in|O the|O cohesin|O complex|O were|O similarly|O distributed|O ,|O as|O in|O patients|O with|O wild|O -|O type|O cohesin|O genes|O (|O Table|O 1|O )|O .|O
Expression|O array|O and|O RNA|O sequencing|O .|O
The|O estimated|O 2|O -|O year|O EFS|O and|O OS|O rates|O were|O 23|O .|O 5|O %|O and|O 38|O %|O ,|O respectively|O ,|O and|O estimated|O 4|O -|O year|O EFS|O and|O OS|O rates|O were|O 18|O %|O and|O 26|O .|O 5|O %|O ,|O respectively|O ;|O no|O differences|O were|O observed|O between|O treatment|O arms|O with|O regard|O to|O EFS|O ,|O OS|O ,|O and|O cumulative|O relapse|O rates|O .|O
Two|O laboratories|O reported|O results|O as|O one|O of|O six|O categories|O (|O >|O =|O 78|O %|O ,|O 50|O %|O to|O 78|O %|O ,|O .|O .|O .|O ,|O <|O 5|O %|O )|O ,|O and|O one|O laboratory|O reported|O results|O in|O three|O categories|O (|O homozygous|O ,|O heterozygous|O ,|O and|O low|O -|O level|O heterozygous|O )|O .|O
By|O contrast|O ,|O ASXL1|O loss|O did|O not|O result|O in|O significant|O changes|O in|O H2AK119|O ubiquitylation|O in|O myeloid|O haematopoietic|O cells|O .|O
Previous|O version|O of|O these|O guidelines|O have|O used|O cytogenetics|O as|O the|O major|O defining|O criteria|O for|O risk|O of|O relapse|O .|O
Recently|O ,|O several|O groups|O have|O reported|O whole|O exome|O sequencing|O of|O MDS|O and|O other|O myelodysplasias|O ,|O in|O which|O a|O common|O finding|O was|O frequent|O mutations|O of|O genes|O involved|O in|O RNA|O splicing|O in|O MDS|O and|O related|O myeloid|O neoplasms|O .|O
This|O stratification|O system|O did|O not|O predict|O leukemic|O transformation|O (|O LT|O )|O .|O
Figure|O 2|O .|O Frequency|O and|O phenotypic|O association|O of|O spliceosomal|O mutations|O in|O myeloid|O malignancies|O .|O (|O A|O )|O In|O the|O entire|O cohort|O (|O n|O =|O 310|O )|O ,|O a|O total|O of|O 88|O mutations|O in|O the|O spliceosome|O pathway|O components|O U2AF1|O ,|O SF3B1|O ,|O and|O SRSF2|O were|O observed|O in|O every|O subtype|O of|O myeloid|O malignancies|O ,|O except|O for|O MPN|O .|O In|O low|O -|O risk|O MDS|O ,|O SF3B1|O mutations|O were|O most|O frequent|O among|O the|O 3|O genes|O .|O In|O particular|O ,|O SF3B1|O was|O mutated|O in|O 15|O of|O 20|O cases|O of|O RARS|O (|O 60|O %|O )|O .|O In|O the|O high|O -|O risk|O MDS|O and|O AML|O group|O ,|O U2AF1|O mutations|O were|O most|O frequent|O (|O 15|O of|O 139|O ;|O 10|O .|O 8|O %|O )|O .|O In|O the|O MDS|O /|O MPN|O group|O ,|O SRSF2|O was|O most|O frequently|O mutated|O (|O 13|O of|O 46|O ;|O 28|O .|O 2|O %|O )|O ,|O whereas|O SF3B1|O is|O mutated|O at|O a|O high|O frequency|O in|O RARS|O -|O T|O (|O 10|O of|O 11|O ;|O 90|O .|O 1|O %|O )|O .|O (|O B|O )|O Effect|O of|O spliceosomal|O mutations|O on|O clinical|O outcomes|O .|O In|O the|O entire|O cohort|O ,|O patients|O with|O U2AF1|O mutations|O (|O MT|O )|O had|O worse|O OS|O ,|O compared|O with|O WT|O ,|O but|O SF3B1|O mutations|O made|O OS|O significantly|O shorter|O .|O In|O low|O -|O risk|O MDS|O ,|O mutation|O of|O SF3B1|O was|O a|O good|O prognostic|O factor|O ,|O but|O SRSF2|O mutations|O are|O associated|O with|O worse|O prognosis|O .|O In|O MDS|O /|O MPN|O ,|O patients|O with|O mutated|O U2AF1|O had|O a|O shorter|O OS|O ,|O but|O SF3B1|O mutations|O were|O associated|O with|O significantly|O better|O prognosis|O .|O In|O addition|O ,|O SRSF2|O mutations|O did|O not|O affect|O outcomes|O .|O
TET2|O mutations|O are|O primarily|O located|O in|O conserved|O functional|O domains|O and|O the|O N|O terminus|O that|O predict|O a|O loss|O -|O of|O -|O function|O .|O
Further|O work|O is|O crucial|O to|O validate|O this|O finding|O and|O to|O identify|O genetic|O targets|O of|O EZH2|O loss|O -|O of|O -|O function|O .|O
Conclusions|O .|O
Two|O specimens|O were|O found|O positive|O for|O the|O W515L|O mutation|O in|O all|O four|O laboratories|O .|O
The|O BCOR|O protein|O acts|O as|O corepressor|O of|O BCL6|O ,|O it|O can|O bind|O to|O other|O transcriptional|O factors|O and|O appears|O to|O play|O a|O key|O role|O in|O the|O regulation|O of|O early|O embryonic|O development|O ,|O mesenchymal|O stem|O cell|O function|O and|O hematopiesis|O .|O
The|O algorithm|O ,|O with|O or|O without|O knowledge|O of|O cytogenetic|O or|O molecular|O risk|O factors|O ,|O predicts|O the|O probability|O of|O achieving|O a|O CR|O and|O the|O risk|O for|O an|O early|O death|O for|O elderly|O patients|O with|O untreated|O AML|O ,|O who|O are|O medically|O fit|O and|O therefore|O considered|O eligible|O for|O intensive|O treatments|O .|O
In|O three|O individuals|O ,|O we|O could|O show|O that|O mutations|O were|O biallelic|O .|O
In|O the|O original|O study|O on|O the|O identification|O of|O calreticulin|O mutations|O in|O patients|O with|O ET|O or|O PMF|O ,|O a|O multivariate|O Cox|O regression|O analysis|O of|O overall|O survival|O (|O OS|O )|O showed|O that|O patients|O with|O a|O CALR|O mutation|O had|O a|O lower|O risk|O of|O death|O than|O those|O with|O JAK2|O (|O V617F|O )|O or|O an|O MPL|O mutation|O .|O
A|O large|O randomized|O phase|O III|O ECOG|O study|O reported|O a|O significant|O increase|O in|O CR|O rate|O (|O 71|O %|O vs|O .|O 57|O %|O ;|O P|O <|O .|O 001|O )|O and|O median|O OS|O (|O 24|O vs|O .|O 16|O months|O ;|O P|O =|O .|O 003|O )|O using|O daunorubicin|O 90|O mg|O /|O m2|O x|O 3|O days|O (|O n|O =|O 327|O )|O versus|O 45|O mg|O /|O m2|O x|O 3|O days|O (|O n|O =|O 330|O )|O in|O patients|O with|O previously|O untreated|O AML|O younger|O than|O 60|O years|O .|O
Total|O RNA|O was|O extracted|O from|O BM|O mononuclear|O cells|O with|O the|O use|O of|O the|O Nucleospin|O RNA|O II|O Kit|O (|O Macherey|O -|O Nagel|O )|O with|O DNAase|O treatment|O .|O
The|O Roche|O product|O was|O added|O with|O 0|O .|O 5|O mM|O dNTP|O ,|O 0|O .|O 75|O ml|O (|O 25|O mM|O )|O MgCl2|O ,|O 1|O .|O 6|O M|O Betaine|O and|O three|O primer|O pairs|O (|O 1|O mM|O /|O each|O primer|O )|O ,|O with|O the|O sequences|O of|O primers|O and|O their|O nucleotide|O position|O shown|O in|O Supplementary|O Table|O 1|O ,|O which|O cover|O the|O coding|O sequences|O from|O exons|O 3|O to|O 8|O of|O RUNX1b|O cDNA|O (|O GenBank|O accession|O number|O D43968|O )|O .|O
Point|O mutations|O have|O been|O also|O identified|O in|O diseases|O that|O overlap|O with|O familial|O AML|O /|O MDS|O ,|O such|O as|O Emberger|O and|O MonoMAC|O syndromes|O .|O
Tests|O for|O these|O molecular|O markers|O are|O becoming|O more|O common|O in|O commercial|O reference|O laboratories|O and|O in|O referral|O centers|O .|O
Homozygous|O deletion|O of|O the|O PTEN|O /|O MMAC1|O gene|O has|O also|O been|O reported|O in|O some|O tumor|O cell|O lines|O .|O
However|O ,|O chromosome|O wide|O analyses|O revealed|O that|O the|O vast|O majority|O of|O conserved|O composite|O elements|O are|O not|O occupied|O by|O these|O factors|O .|O
In|O the|O European|O cohort|O ASXL1|O ,|O SRSF2|O and|O EZH2|O mutations|O were|O significantly|O (|O P|O <|O 0|O .|O 05|O )|O enriched|O in|O the|O IPSS|O high|O -|O risk|O group|O with|O mutational|O frequencies|O of|O 42|O %|O ,|O 25|O %|O and|O 12|O %|O ,|O respectively|O (|O Figure|O 1b|O )|O .|O
Bone|O marrow|O evaluation|O is|O recommended|O only|O if|O the|O hemogram|O becomes|O abnormal|O ,|O rather|O than|O as|O routine|O surveillance|O at|O fixed|O intervals|O ,|O unless|O this|O is|O being|O performed|O as|O part|O of|O a|O clinical|O research|O protocol|O .|O
Deletions|O involving|O chromosome|O 7q|O ,|O which|O includes|O EZH2|O ,|O have|O long|O been|O incorporated|O into|O clinical|O cytogenetic|O prognostic|O schemas|O for|O patients|O with|O MDS|O or|O AML|O .|O
Bone|O marrow|O fibrosis|O secondary|O to|O PV|O or|O ET|O can|O be|O differentiated|O from|O PMF|O by|O bone|O marrow|O histology|O .|O
Binding|O of|O thrombopoietin|O to|O MPL|O leads|O to|O activation|O of|O JAK2|O ,|O which|O phosphorylates|O MPL|O and|O initiates|O a|O cascade|O of|O downstream|O signaling|O events|O that|O regulate|O cell|O survival|O ,|O proliferation|O ,|O and|O differentiation|O .|O
INTRODUCTION|O .|O
Although|O the|O exact|O incidence|O of|O therapy|O -|O related|O MDS|O /|O AML|O is|O unknown|O ,|O and|O varies|O depending|O on|O the|O types|O of|O treatment|O modalities|O used|O for|O a|O given|O primary|O tumor|O ,|O recent|O reports|O suggest|O that|O therapy|O -|O related|O MDS|O /|O AML|O may|O account|O for|O 5|O %|O to|O 20|O %|O of|O patients|O with|O MDS|O /|O AML|O .|O
RUNX1|O mutations|O were|O detected|O in|O 30|O of|O 81|O CMML|O patients|O (|O 37|O %|O )|O at|O initial|O diagnosis|O (|O Supplementary|O Figure|O 1|O )|O .|O
U2AF1|O and|O SRSF2|O are|O frequently|O mutated|O in|O high|O -|O risk|O MDS|O and|O CMML|O whereby|O RUNX1|O mutations|O are|O relevant|O ,|O which|O explains|O our|O theory|O that|O spliceosomal|O mutations|O results|O in|O similar|O phenotype|O to|O the|O corresponding|O loss|O -|O of|O -|O function|O mutations|O .|O
The|O impact|O of|O genetic|O lesions|O on|O survival|O was|O independent|O of|O current|O prognostic|O scoring|O systems|O .|O
The|O in|O vitro|O expression|O of|O JAK2V617F|O results|O in|O the|O constitutive|O activation|O of|O the|O JAK|O -|O STAT|O pathway|O and|O resultant|O cytokine|O -|O independent|O growth|O .|O
HLA|O typing|O should|O be|O performed|O in|O all|O patients|O with|O newly|O diagnosed|O AML|O for|O whom|O allogeneic|O hematopoietic|O stem|O cell|O transplantation|O (|O HSCT|O )|O would|O be|O considered|O .|O
This|O includes|O the|O discovery|O of|O the|O direct|O histone|O modifying|O activity|O of|O janus|O kinase|O 2|O (|O JAK2|O )|O ,|O as|O well|O as|O identification|O of|O interactions|O between|O the|O fusion|O oncoproteins|O that|O are|O characteristic|O of|O APL|O and|O PcG|O proteins|O .|O
In|O this|O review|O ,|O we|O highlight|O the|O recent|O understanding|O of|O GATA2|O in|O normal|O hematopoiesis|O and|O in|O leukemia|O .|O
Clinical|O suspicion|O of|O PMF|O may|O be|O raised|O in|O the|O context|O of|O nonspecific|O derangements|O in|O PB|O counts|O and|O evidence|O of|O extramedullary|O hematopoiesis|O (|O ie|O ,|O palpable|O splenomegaly|O )|O .|O
Another|O gene|O in|O which|O splicing|O was|O affected|O was|O RUNX1|O .|O
The|O observations|O in|O terms|O of|O overall|O survival|O were|O validated|O in|O an|O independent|O cohort|O of|O 396|O Mayo|O Clinic|O patients|O studied|O at|O the|O time|O of|O their|O referral|O ,|O whereas|O only|O SRSF2|O and|O IDH1|O mutations|O were|O associated|O with|O leukemic|O transformation|O in|O the|O Mayo|O cohort|O .|O
Moreover|O ,|O GATA2|O is|O expressed|O in|O adipocyte|O precursors|O and|O control|O the|O preadipocyte|O to|O adipocyte|O transition|O .|O
In|O contrast|O ,|O mutations|O in|O U2AF1|O affected|O exons|O 2|O and|O 6|O ,|O corresponding|O to|O the|O 2|O zinc|O finger|O domains|O of|O this|O protein|O (|O Figure|O 1A|O ;|O supplemental|O Figure|O 3|O )|O .|O
Univariate|O analysis|O disclosed|O significant|O correlations|O between|O shortened|O survival|O and|O EZH2|O (|O P|O =|O 0|O .|O 0003|O )|O ,|O ASXL1|O (|O P|O <|O 0|O .|O 0001|O )|O and|O SRSF2|O (|O P|O <|O 0|O .|O 0001|O )|O mutations|O (|O Figure|O 2a|O )|O .|O
SETBP1|O .|O
In|O this|O study|O ,|O we|O analyzed|O the|O frequency|O ,|O clinical|O ,|O and|O prognostic|O implications|O of|O mutations|O in|O STAG1|O ,|O STAG2|O ,|O SMC1A|O ,|O SMC3|O ,|O and|O RAD21|O ,|O all|O members|O of|O the|O cohesin|O complex|O ,|O in|O a|O cohort|O of|O 389|O uniformly|O treated|O AML|O patients|O by|O next|O generation|O sequencing|O .|O
ASXL1|O -|O mutated|O patients|O were|O found|O to|O have|O a|O higher|O WBC|O (|O P|O =|O 0|O .|O 009|O )|O ,|O higher|O AMC|O (|O P|O =|O 0|O .|O 008|O )|O ,|O higher|O prevalence|O of|O circulating|O IMC|O (|O P|O =|O 0|O .|O 03|O )|O and|O were|O more|O likely|O to|O have|O concomitant|O mutations|O of|O the|O U2AF35|O gene|O (|O P|O =|O 0|O .|O 03|O )|O .|O
However|O ,|O the|O functional|O contributions|O of|O these|O non|O -|O finger|O regions|O have|O not|O been|O fully|O described|O .|O
The|O prognostic|O significance|O of|O point|O mutations|O in|O patients|O with|O myelodysplastic|O syndromes|O may|O be|O driven|O by|O the|O association|O of|O these|O mutations|O with|O risk|O factors|O ,|O including|O karyotype|O ,|O blast|O proportion|O ,|O and|O cytopenias|O ,|O which|O are|O captured|O by|O existing|O clinical|O risk|O scoring|O systems|O such|O as|O the|O IPSS|O .|O
Epigenetics|O refers|O to|O heritable|O DNA|O -|O sequence|O -|O independent|O processes|O that|O regulate|O gene|O expression|O .|O
GATA|O factors|O occupied|O loci|O encoding|O multiple|O components|O of|O the|O SCL|O /|O TAL1|O complex|O ,|O a|O master|O regulator|O of|O hematopoiesis|O and|O leukemogenic|O target|O .|O
SF3B1|O mutations|O are|O associated|O with|O a|O favorable|O prognosis|O ,|O whereas|O U2AF1|O and|O SRSF2|O mutations|O are|O predictive|O for|O shorter|O survival|O .|O
Of|O the|O 259|O initial|O patients|O ,|O 99|O experienced|O a|O CR|O and|O were|O therefore|O eligible|O for|O HSCT|O evaluation|O ;|O of|O these|O patients|O ,|O only|O 14|O ultimately|O underwent|O transplantation|O because|O of|O illness|O ,|O lack|O of|O donor|O ,|O refusal|O ,|O or|O unspecified|O reasons|O .|O
Well|O -|O known|O examples|O of|O deregulated|O transcription|O factors|O are|O RUNX1|O /|O AML1|O and|O C|O /|O EBPA|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O SCL|O in|O T|O -|O cell|O acute|O lymphoblastic|O leukemia|O (|O T|O -|O ALL|O )|O ,|O and|O GATA1|O in|O Down|O syndrome|O -|O acute|O megakaryocytic|O leukemia|O .|O
The|O discovery|O of|O recurrent|O somatic|O mutations|O in|O various|O genes|O encoding|O spliceosomal|O proteins|O indicates|O that|O spliceosomal|O defects|O constitute|O an|O important|O and|O ubiquitous|O pathway|O in|O malignant|O transformation|O .|O
The|O corepressors|O BCOR|O and|O BCORL1|O :|O two|O novel|O players|O in|O acute|O myeloid|O leukemia|O .|O
STAG2|O and|O SMC1A|O are|O X|O -|O linked|O ,|O whereas|O the|O other|O 3|O genes|O are|O autosomal|O .|O
RESULTS|O .|O
BER|O is|O initiated|O by|O DNA|O glycosylases|O ,|O which|O recognize|O and|O remove|O specific|O inappropriate|O bases|O ,|O forming|O an|O abasic|O site|O .|O
Based|O on|O the|O current|O practice|O pattern|O and|O the|O literature|O ,|O this|O Special|O Article|O provides|O recommendations|O and|O guidelines|O for|O laboratory|O practice|O for|O detection|O of|O mutations|O in|O the|O JAK2|O and|O MPL|O genes|O ,|O including|O clinical|O manifestations|O for|O prompting|O the|O mutation|O analysis|O ,|O current|O and|O recommended|O methodologies|O for|O testing|O the|O mutations|O ,|O and|O standardization|O for|O reporting|O the|O test|O results|O .|O
The|O only|O potentially|O curative|O therapy|O is|O allogeneic|O hematopoietic|O stem|O cell|O transplantation|O ,|O but|O treatment|O -|O related|O mortality|O remains|O high|O .|O
In|O mice|O ,|O loss|O of|O Gata1|O expression|O in|O erythroid|O and|O megakaryocytic|O lineages|O leads|O to|O markedly|O increased|O Gata2|O mRNA|O levels|O ,|O reflecting|O the|O role|O of|O GATA1|O as|O a|O critical|O repressor|O of|O the|O GATA2|O locus|O .|O
JAK2|O Sanger|O sequencing|O assays|O ,|O such|O as|O those|O for|O exon|O 12|O mutations|O ,|O should|O report|O any|O detected|O mutations|O using|O standard|O Human|O Genome|O Variation|O Society|O (|O HGVS|O )|O nucleotide|O and|O amino|O acid|O nomenclature|O (|O HGVS|O ,|O http|O :|O /|O /|O www|O .|O hgvs|O .|O org|O /|O mutnomen|O ,|O last|O accessed|O February|O 19|O ,|O 2013|O )|O .|O
U2AF1|O /|O U2AF35|O .|O
Whole|O exome|O sequencing|O of|O 15|O patients|O with|O myeloid|O neoplasms|O was|O performed|O ,|O and|O somatic|O mutations|O in|O spliceosomal|O genes|O were|O identified|O .|O
A|O group|O of|O proteins|O that|O function|O in|O histone|O -|O modifiying|O complexes|O to|O activate|O gene|O expression|O by|O inducing|O trimethylation|O of|O lysine|O 4|O of|O histone|O H3|O (|O H3K4me3|O )|O at|O specific|O sites|O in|O chromatin|O that|O are|O recognized|O by|O the|O complex|O .|O
Advances|O in|O our|O knowledge|O of|O the|O genetics|O of|O myeloid|O malignancies|O ,|O coupled|O with|O an|O improved|O understanding|O of|O the|O role|O of|O specific|O epigenetic|O modifications|O in|O leukaemogenesis|O ,|O will|O probably|O lead|O to|O the|O development|O of|O additional|O therapies|O that|O improve|O outcomes|O for|O patients|O with|O MPN|O ,|O MDS|O and|O AML|O .|O
In|O fact|O ,|O when|O comparing|O JAK2|O -|O mutant|O and|O CALR|O -|O mutant|O patients|O ,|O the|O subdistribution|O hazard|O ratio|O (|O SHR|O )|O was|O 2|O .|O 19|O (|O 95|O %|O CI|O ,|O 1|O .|O 15|O -|O 4|O .|O 18|O ,|O P|O =|O .|O 017|O )|O ,|O indicating|O that|O the|O risk|O of|O thrombosis|O was|O about|O twofold|O in|O the|O former|O .|O
Gene|O expression|O and|O epigenomic|O analyses|O have|O identified|O a|O subset|O of|O downstream|O targets|O of|O epigenetic|O modifiers|O ,|O such|O as|O the|O HOX|O gene|O clusters|O ,|O that|O are|O essential|O for|O malignant|O transformation|O by|O specific|O epigenetic|O mutations|O .|O
One|O laboratory|O had|O a|O higher|O rate|O of|O discordance|O than|O the|O others|O ;|O it|O is|O possible|O that|O this|O laboratory|O was|O testing|O will|O be|O reliable|O when|O such|O testing|O becomes|O truly|O an|O outlier|O ,|O although|O it|O is|O also|O possible|O that|O there|O were|O clerical|O errors|O in|O reporting|O the|O results|O to|O the|O study|O .|O
DNAnexus|O software|O (|O DNAnexus|O Inc|O ;|O https|O :|O /|O /|O dnanexus|O .|O com|O )|O was|O used|O to|O visualize|O single|O nucleotide|O changes|O ,|O insertions|O ,|O and|O /|O or|O deletions|O at|O the|O gene|O ,|O exon|O ,|O and|O base|O pair|O levels|O .|O
However|O ,|O what|O importance|O amsacrine|O may|O have|O served|O in|O the|O outcomes|O of|O the|O HOVON|O /|O SAKK|O study|O is|O currently|O not|O known|O .|O
The|O reclassification|O of|O MPN|O by|O the|O WHO|O reflects|O the|O increasingly|O heterogenic|O character|O of|O MPDs|O .|O
Of|O these|O ,|O mutations|O involving|O ASXL1|O and|O EZH2|O have|O been|O associated|O with|O poor|O outcomes|O .|O
Several|O studies|O have|O confirmed|O that|O ,|O unlike|O mutations|O in|O splicing|O and|O cytokine|O signaling|O ,|O mutual|O exclusivity|O is|O not|O seen|O between|O TET2|O and|O other|O epigenetic|O modifiers|O ;|O TET2|O mutations|O appear|O to|O co|O -|O occur|O within|O the|O landscape|O of|O genetic|O events|O and|O are|O also|O frequently|O found|O in|O samples|O with|O normal|O cytogenetic|O features|O (|O P|O =|O 0|O .|O 005|O )|O .|O
These|O truncated|O receptors|O may|O also|O lack|O the|O binding|O site|O for|O suppressor|O of|O cytokine|O signaling|O 3|O ,|O which|O reduces|O trafficking|O of|O CSF3R|O to|O the|O lysosome|O .|O
The|O MPL|O gene|O maps|O to|O chromosome|O band|O 1p34|O and|O encodes|O the|O thrombopoietin|O receptor|O ,|O which|O binds|O to|O thrombopoietin|O ,|O the|O primary|O cytokine|O that|O regulates|O megakaryocyte|O development|O and|O platelet|O production|O ,|O as|O well|O as|O hematopoietic|O stem|O cell|O homeostasis|O .|O
Mutations|O in|O the|O cohesin|O complex|O in|O acute|O myeloid|O leukemia|O :|O clinical|O and|O prognostic|O implications|O .|O
SF3B1|O is|O a|O core|O component|O of|O the|O U2|O snRNP|O that|O recognizes|O the|O 3|O splice|O site|O at|O intron|O -|O exon|O junctions|O .|O
Although|O FISH|O studies|O for|O common|O cytogenetic|O abnormalities|O may|O provide|O a|O rapid|O screening|O to|O identify|O either|O favorable|O or|O unfavorable|O risk|O groups|O ,|O they|O do|O not|O provide|O a|O full|O picture|O of|O the|O genetic|O factors|O ,|O which|O contribute|O to|O risk|O .|O
A|O product|O with|O exons|O 4|O -|O 6|O missing|O and|O an|O insertion|O of|O 51|O bp|O was|O expressed|O in|O one|O specimen|O .|O
CR|O rates|O for|O patients|O who|O are|O 50|O years|O or|O younger|O have|O consistently|O been|O in|O the|O 60|O %|O to|O 70|O %|O range|O in|O most|O large|O cooperative|O group|O trials|O of|O infusional|O cytarabine|O and|O anthracycline|O .|O
If|O a|O clinical|O trial|O is|O not|O an|O option|O ,|O then|O low|O -|O intensity|O therapy|O or|O supportive|O care|O may|O be|O the|O appropriate|O choice|O .|O
Mechanistically|O ,|O defective|O splicing|O of|O specific|O genes|O may|O have|O similar|O consequences|O to|O loss|O of|O function|O mutations|O through|O the|O retention|O of|O introns|O (|O supplemental|O Figure|O 9|O )|O .|O
The|O participating|O laboratories|O tested|O the|O samples|O using|O a|O combination|O of|O quantitative|O and|O qualitative|O assays|O for|O JAK2|O mutations|O ,|O and|O several|O of|O the|O laboratories|O also|O performed|O MPL|O mutation|O assays|O .|O
In|O the|O subgroup|O of|O cytogenetically|O normal|O AML|O (|O CN|O -|O AML|O )|O ,|O additional|O mutation|O analyses|O were|O performed|O for|O CEBPA|O ,|O MLL|O -|O PTD|O ,|O WT1|O ,|O and|O WT1|O SNP|O rs16754|O ,|O NRAS|O ,|O and|O expression|O levels|O of|O BAALC|O ,|O ERG|O ,|O EVI1|O ,|O MN1|O ,|O MLL5|O ,|O and|O WT1|O were|O quantified|O as|O previously|O described|O using|O complementary|O DNA|O from|O the|O KG1A|O cell|O line|O (|O BAALC|O ,|O ERG|O ,|O MLL5|O )|O ,|O plasmids|O (|O MN1|O ,|O WT1|O )|O ,|O or|O from|O a|O patient|O sample|O (|O EVI1|O )|O to|O construct|O a|O relative|O standard|O curve|O using|O ABL|O as|O a|O housekeeping|O gene|O (|O Ipsogen|O ,|O Marseille|O ,|O France|O )|O .|O
In|O addition|O to|O RUNX1|O and|O CEBPA|O ,|O mutations|O in|O the|O telomerase|O RNA|O (|O TERC|O )|O or|O reverse|O transcriptase|O (|O TERT|O )|O subunits|O have|O also|O been|O identified|O .|O
Relative|O contribution|O of|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O to|O OS|O as|O predicted|O by|O IPSS|O or|O DIPSS|O .|O
Additional|O high|O -|O dose|O cytarabine|O at|O this|O time|O is|O unlikely|O to|O induce|O remission|O in|O these|O cases|O .|O
This|O study|O suggests|O that|O 2|O cycles|O of|O intermediate|O -|O dose|O cytarabine|O (|O 1|O g|O /|O m2|O every|O 12|O hours|O x|O 6|O days|O ;|O total|O dose|O 12|O g|O /|O m2|O per|O cycle|O )|O for|O each|O consolidation|O cycle|O may|O be|O a|O feasible|O alternative|O to|O the|O current|O NCCN|O recommendations|O of|O 3|O cycles|O of|O high|O -|O dose|O cytarabine|O (|O 3|O g|O /|O m2|O for|O 6|O doses|O ;|O total|O dose|O of|O 18|O g|O /|O m2|O per|O cycle|O )|O .|O
Survival|O outcomes|O between|O these|O groups|O were|O similar|O ,|O with|O a|O 3|O -|O year|O OS|O rates|O of|O 63|O %|O and|O 61|O %|O ,|O respectively|O .|O
In|O CMML|O ,|O ~|O 40|O %|O of|O patients|O have|O ASXL1|O mutations|O ,|O with|O the|O most|O frequent|O aberration|O being|O c|O .|O 1934dupG|O ;|O p|O .|O Gly646TrpfsX12|O .|O
Category|O 2B|O :|O Based|O upon|O lower|O -|O level|O evidence|O ,|O there|O is|O NCCN|O consensus|O that|O the|O intervention|O is|O appropriate|O .|O
In|O five|O out|O of|O eight|O subjects|O with|O an|O EZH2|O mutation|O ,|O a|O TET2|O was|O present|O (|O ref|O .|O 3|O and|O Supplementary|O Table|O 1|O )|O .|O
In|O a|O retrospective|O analysis|O comparing|O outcomes|O with|O RIC|O allogeneic|O HSCT|O and|O autologous|O HSCT|O in|O patients|O aged|O 50|O years|O and|O older|O based|O on|O large|O registry|O data|O ,|O allogeneic|O HSCT|O was|O associated|O with|O lower|O risk|O for|O relapse|O and|O superior|O DFS|O and|O OS|O relative|O to|O autologous|O HSCT|O .|O
Similarly|O ,|O as|O published|O by|O our|O group|O before|O ,|O spliceosome|O component|O mutations|O involving|O SF3B1|O ,|O SRSF2|O and|O U2AF35|O are|O common|O in|O CMML|O ,|O and|O do|O not|O have|O an|O impact|O on|O either|O the|O OS|O or|O the|O leukemia|O free|O survival|O .|O
On|O the|O opposite|O ,|O triple|O -|O negative|O patients|O were|O more|O likely|O to|O develop|O anemia|O compared|O with|O either|O CALR|O -|O mutant|O (|O P|O <|O .|O 001|O )|O or|O JAK2|O -|O mutant|O subjects|O (|O P|O =|O .|O 013|O )|O .|O
Somatic|O cohesin|O mutations|O have|O been|O reported|O in|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
To|O distinguish|O the|O independent|O contributions|O of|O mutations|O to|O the|O clinical|O phenotype|O and|O overall|O survival|O ,|O we|O examined|O a|O large|O set|O of|O samples|O obtained|O from|O patients|O with|O myelodysplastic|O syndromes|O for|O the|O presence|O of|O somatic|O mutations|O in|O a|O broad|O spectrum|O of|O cancer|O -|O associated|O genes|O .|O
In|O a|O literature|O review|O of|O 40|O patients|O meeting|O WHO|O criteria|O for|O true|O CNL|O ,|O the|O median|O survival|O was|O 23|O .|O 5|O months|O (|O range|O ,|O 1|O -|O 106|O months|O )|O .|O
Patients|O who|O do|O not|O receive|O postremission|O therapy|O will|O experience|O relapse|O ,|O usually|O within|O 6|O to|O 9|O months|O .|O
Moreover|O ,|O haploinsufficiency|O of|O GATA2|O in|O adult|O mice|O results|O in|O abnormal|O HSC|O homeostasis|O .|O
Two|O patients|O in|O our|O series|O (|O P1|O ,|O patient|O number|O 6227|O and|O P6|O ,|O patient|O number|O 7015|O )|O were|O treated|O with|O hematopoietic|O growth|O factors|O without|O benefits|O (|O lenograstim|O followed|O by|O sargramostim|O in|O one|O patient|O and|O filgrastim|O in|O the|O other|O )|O .|O
Further|O investigation|O in|O clinical|O trial|O settings|O will|O be|O required|O to|O determine|O whether|O JAK|O kinase|O inhibition|O in|O the|O setting|O of|O CSF3R|O mutation|O will|O lead|O to|O greater|O decreases|O in|O mutation|O allele|O burden|O compared|O with|O the|O responses|O observed|O in|O the|O setting|O of|O JAK2V617F|O .|O
CNL|O may|O be|O the|O archetype|O of|O an|O MPN|O whose|O pathogenesis|O is|O predominantly|O characterized|O by|O mutations|O of|O CSF3R|O ,|O whereas|O aCML|O may|O be|O more|O genetically|O heterogeneous|O .|O
Based|O on|O subgroup|O analyses|O ,|O however|O ,|O the|O survival|O benefit|O with|O high|O -|O dose|O daunorubicin|O was|O shown|O to|O be|O restricted|O to|O patients|O with|O favorable|O -|O and|O intermediate|O -|O risk|O cytogenetic|O profiles|O (|O median|O OS|O ,|O 34|O vs|O .|O 21|O months|O ;|O P|O =|O .|O 004|O )|O and|O those|O younger|O than|O 50|O years|O (|O median|O OS|O ,|O 34|O vs|O .|O 19|O months|O ;|O P|O =|O .|O 004|O )|O .|O
It|O may|O be|O difficult|O to|O accumulate|O JAK2|O exon|O 12|O or|O MPL|O mutant|O cases|O for|O validation|O ,|O given|O the|O low|O frequency|O of|O these|O variants|O .|O
GATA1|O and|O SCL|O /|O E2A|O mediate|O the|O anchoring|O of|O these|O proteins|O to|O the|O DNA|O ,|O while|O LMO2|O bridged|O them|O together|O .|O
We|O are|O not|O proposing|O it|O as|O clinical|O tool|O for|O several|O reasons|O ,|O including|O the|O fact|O that|O to|O this|O purpose|O it|O should|O be|O validated|O in|O an|O independent|O patient|O cohort|O .|O
However|O ,|O as|O a|O caveat|O ,|O a|O recent|O study|O indicated|O that|O the|O OS|O benefit|O with|O CEBPA|O was|O observed|O for|O patients|O with|O double|O mutations|O of|O CEBPA|O but|O not|O for|O those|O with|O a|O single|O mutation|O of|O the|O gene|O ;|O the|O 8|O -|O year|O OS|O rates|O reported|O in|O this|O study|O for|O patients|O with|O double|O -|O mutated|O CEBPA|O ,|O single|O mutation|O of|O CEBPA|O ,|O and|O wild|O -|O type|O gene|O were|O 54|O %|O ,|O 31|O %|O ,|O and|O 34|O %|O ,|O respectively|O .|O
The|O target|O genes|O (|O in|O total|O ,|O 1782|O amplicons|O )|O were|O successfully|O analyzed|O in|O all|O cases|O .|O
All|O recommendations|O are|O category|O 2A|O unless|O otherwise|O noted|O .|O
In|O the|O ruxolitinib|O group|O ,|O 41|O .|O 9|O %|O of|O patients|O met|O the|O defined|O response|O threshold|O of|O a|O reduction|O of|O 35|O %|O or|O more|O in|O spleen|O volume|O ,|O and|O nearly|O all|O the|O patients|O had|O some|O reduction|O in|O spleen|O volume|O .|O
Most|O mutations|O within|O the|O N|O -|O ZnF|O of|O GATA1|O disrupt|O its|O interaction|O with|O FOG1|O and|O are|O associated|O with|O several|O human|O hematological|O disorders|O ,|O including|O dyserythropoietic|O anemia|O ,|O thrombocytopenia|O ,|O and|O beta|O -|O thalassemia|O .|O
Whole|O exome|O sequencing|O .|O
Tet|O methylcytosine|O dioxygease|O 2|O (|O TET2|O )|O belongs|O to|O the|O TET|O oncogenic|O family|O and|O is|O mapped|O to|O 4q24|O .|O
High|O expression|O levels|O of|O GATA2|O were|O observed|O in|O brown|O preadipocytes|O before|O differentiation|O ,|O and|O rapidly|O diminished|O after|O the|O initiation|O of|O adipogenesis|O .|O
To|O assess|O the|O prognostic|O impact|O of|O the|O resulting|O score|O ,|O we|O included|O the|O score|O as|O a|O continuous|O covariate|O in|O a|O Cox|O survival|O regression|O model|O .|O
Furthermore|O ,|O patients|O receiving|O ruxolitinib|O had|O reductions|O in|O plasma|O levels|O of|O C|O -|O reactive|O protein|O and|O the|O proinflammatory|O cytokines|O tumor|O necrosis|O factor|O alpha|O and|O interleukin|O -|O 6|O ,|O and|O they|O had|O increases|O in|O levels|O of|O plasma|O leptin|O and|O erythropoietin|O (|O Fig|O .|O S7|O in|O the|O Supplementary|O Appendix|O )|O .|O
Unfavorable|O karyotype|O had|O an|O IPSS|O -|O independent|O detrimental|O effect|O on|O overall|O survival|O (|O HR|O :|O 6|O .|O 46|O ;|O 95|O %|O CI|O :|O 3|O .|O 4|O -|O 12|O .|O 5|O ;|O P|O <|O 0|O .|O 001|O )|O (|O Supplementary|O Figures|O S2A|O and|O B|O )|O and|O ,|O in|O univariate|O analysis|O ,|O on|O leukemia|O -|O free|O survival|O (|O HR|O :|O 3|O .|O 45|O ;|O 95|O %|O CI|O :|O 1|O .|O 03|O -|O 11|O .|O 6|O ;|O P|O =|O 0|O .|O 033|O )|O (|O Supplementary|O Figure|O S2C|O )|O ;|O the|O latter|O retained|O borderline|O significant|O in|O multivariable|O analysis|O (|O HR|O :|O 3|O .|O 3|O ;|O 95|O %|O CI|O :|O 0|O .|O 98|O -|O 11|O .|O 3|O ;|O P|O =|O 0|O .|O 053|O )|O .|O
Thirty|O -|O one|O patients|O (|O 6|O .|O 4|O %|O )|O displayed|O >|O 2|O mutations|O (|O Supplementary|O Table|O S2|O and|O Supplementary|O Figure|O S5|O )|O .|O
No|O differences|O were|O observed|O with|O respect|O to|O sex|O ,|O blood|O counts|O ,|O percentage|O of|O blasts|O in|O blood|O ,|O subtype|O of|O CMML|O ,|O cytogenetic|O risk|O group|O or|O International|O Prognostic|O Scoring|O System|O between|O CMML|O patients|O with|O RUNX1|O mutations|O and|O those|O without|O mutations|O .|O
Although|O the|O ATRA|O -|O insensitive|O PLZF|O -|O RARalpha|O oncoprotein|O also|O interacts|O with|O the|O PRC2|O complex|O ,|O PLZF|O -|O RARalpha|O also|O interacts|O with|O PRC1|O via|O its|O direct|O association|O with|O BMI1|O (|O REF|O .|O 98|O )|O .|O
Patients|O with|O significant|O CNS|O signs|O or|O symptoms|O at|O presentation|O should|O be|O evaluated|O using|O appropriate|O imaging|O techniques|O ,|O such|O as|O radiography|O ,|O CT|O ,|O or|O MRI|O for|O detection|O of|O intracranial|O bleeding|O ,|O leptomeningeal|O disease|O ,|O or|O mass|O lesions|O in|O either|O the|O brain|O or|O spinal|O cord|O .|O
Second|O ,|O known|O single|O nucleotide|O polymorphisms|O (|O SNPs|O )|O were|O removed|O (|O dbSNP|O ,|O version|O 137|O )|O .|O
The|O role|O of|O follow|O -|O up|O testing|O for|O JAK2|O and|O MPL|O mutations|O after|O therapy|O is|O not|O clearly|O established|O .|O
In|O contrast|O ,|O mutations|O of|O ZRSR2|O on|O X|O chromosome|O were|O distributed|O along|O the|O entire|O coding|O region|O .|O
Myelodysplastic|O syndromes|O (|O MDSs|O )|O are|O chronic|O and|O often|O progressive|O myeloid|O neoplasms|O associated|O with|O remarkable|O heterogeneity|O in|O the|O histomorphology|O and|O clinical|O course|O .|O
The|O use|O of|O high|O -|O throughput|O next|O -|O generation|O sequencing|O for|O somatic|O mutational|O profiling|O has|O led|O to|O the|O identification|O of|O recurrent|O somatic|O mutations|O within|O the|O cohesin|O complex|O in|O patients|O with|O acute|O myeloid|O leukemia|O (|O AML|O )|O ,|O myelodysplastic|O syndrome|O (|O MDS|O )|O ,|O glioblastoma|O multiforme|O ,|O Ewing|O sarcoma|O ,|O and|O colorectal|O and|O bladder|O carcinomas|O .|O
Therefore|O ,|O we|O investigated|O ASXL1|O exon|O 12|O mutations|O in|O 79|O /|O 81|O cases|O (|O no|O DNA|O available|O in|O two|O cases|O )|O .|O
Table|O 2|O .|O Hazard|O Ratios|O for|O Death|O in|O a|O Multivariable|O Model|O .|O
In|O marked|O contrast|O ,|O our|O patients|O with|O GATA2|O mutations|O presented|O with|O monocytopenia|O with|O a|O median|O of|O 0|O .|O 05|O G|O /|O L|O .|O
RUNX1|O .|O
Moreover|O ,|O cohesin|O gene|O mutations|O were|O screened|O using|O whole|O -|O exome|O sequencing|O results|O available|O through|O TCGA|O (|O http|O :|O /|O /|O tcga|O -|O data|O .|O nci|O .|O nih|O .|O gov|O /|O tcga|O /|O tcgaHome2|O .|O jsp|O )|O .|O
There|O was|O no|O difference|O in|O outcomes|O in|O a|O comparison|O between|O CMML|O patients|O with|O a|O monosomal|O karyotype|O and|O those|O with|O a|O complex|O karyotype|O without|O monosomies|O .|O
As|O with|O JAK2|O exon|O 12|O mutations|O ,|O these|O mutations|O occur|O predominantly|O in|O JAK2V617F|O -|O negative|O clones|O .|O
CR|O /|O complete|O response|O with|O incomplete|O platelet|O recovery|O (|O CRp|O )|O was|O achieved|O in|O 46|O %|O of|O patients|O ,|O with|O a|O 30day|O mortality|O rate|O of|O 10|O %|O .|O
Eight|O cases|O included|O with|O therapy|O -|O related|O myeloid|O malignancies|O .|O
2|O .|O THE|O GATA|O FAMILY|O OF|O TRANSCRIPTION|O FACTORS|O .|O
For|O these|O patients|O ,|O the|O panel|O feels|O it|O is|O reasonable|O to|O offer|O low|O -|O intensity|O therapy|O or|O best|O supportive|O care|O .|O
In|O comparison|O ,|O a|O 10|O -|O fold|O to|O 100|O -|O fold|O increase|O in|O assay|O sensitivity|O can|O be|O easily|O achieved|O by|O designing|O a|O sensitive|O PCR|O method|O .|O
Two|O patients|O had|O two|O mutations|O and|O one|O (|O no|O .|O 4|O )|O had|O two|O missense|O mutations|O in|O RHD|O ;|O cloning|O analysis|O showed|O that|O 14|O clones|O harbored|O 238|O C|O >|O T|O (|O Arg80Cys|O )|O and|O another|O 8|O clones|O harbored|O 251|O C|O >|O A|O (|O Thr84Asn|O )|O .|O
We|O analyzed|O RNA|O sequencing|O results|O in|O patients|O with|O mutations|O in|O U2AF1|O (|O n|O =|O 3|O )|O ,|O SRSF2|O (|O n|O =|O 2|O )|O ,|O SF3B1|O (|O n|O =|O 2|O )|O ,|O and|O U2AF26|O (|O n|O =|O 1|O )|O ,|O as|O well|O as|O in|O a|O healthy|O control|O and|O 1|O patients|O with|O MDS|O with|O a|O WT|O configuration|O of|O these|O genes|O .|O
Using|O deep|O sequencing|O and|O cross|O -|O sectional|O and|O serial|O analyses|O ,|O we|O found|O that|O cohesin|O mutations|O were|O not|O commonly|O present|O in|O the|O founder|O clone|O but|O rather|O promoted|O clonal|O expansion|O and|O transformation|O to|O more|O aggressive|O disease|O .|O
In|O the|O present|O study|O ,|O we|O describe|O the|O initial|O identification|O by|O exome|O sequencing|O of|O a|O GATA2|O R396Q|O mutation|O in|O a|O family|O with|O a|O history|O of|O chronic|O mild|O neutropenia|O evolving|O to|O AML|O and|O /|O or|O MDS|O .|O
Among|O SMC3|O alterations|O ,|O 8|O out|O of|O 19|O were|O nonsense|O (|O n|O =|O 1|O )|O ,|O frameshift|O (|O n|O =|O 1|O )|O ,|O or|O splice|O site|O (|O n|O =|O 6|O )|O mutations|O ,|O whereas|O 11|O out|O of|O 19|O were|O missense|O mutations|O .|O
The|O presence|O of|O TP53|O mutation|O has|O an|O independently|O negative|O impact|O on|O prognosis|O for|O all|O subtypes|O of|O MDS|O ,|O with|O a|O hazard|O ratio|O for|O death|O from|O any|O cause|O of|O 2|O .|O 48|O (|O 95|O %|O CI|O ,|O 1|O .|O 60|O -|O 3|O .|O 84|O )|O .|O
A|O retrospective|O study|O of|O 68|O patients|O with|O ET|O found|O that|O the|O risk|O of|O thrombotic|O events|O in|O patients|O who|O receive|O aspirin|O (|O 500|O mg|O /|O day|O )|O was|O 3|O .|O 6|O per|O 100|O person|O -|O years|O compared|O with|O 32|O .|O 3|O per|O 100|O person|O -|O years|O in|O patients|O under|O observation|O only|O .|O
An|O in|O vitro|O study|O also|O demonstrated|O that|O a|O transduction|O of|O C|O -|O CBL|O mutants|O into|O c|O -|O CBL|O (|O -|O /|O -|O )|O hematopoietic|O stem|O cells|O increased|O their|O senilities|O to|O stimulation|O of|O ligands|O (|O e|O .|O g|O .|O ,|O interleukin|O 3|O ,|O FLT3LG|O (|O FLT3|O ligand|O )|O ,|O thrombopoietin|O ,|O and|O stem|O cell|O factor|O )|O and|O had|O a|O long|O -|O term|O repopulating|O capacity|O .|O
FOG1|O has|O also|O been|O shown|O to|O interact|O with|O subunits|O of|O the|O nucleosome|O remodelling|O and|O histone|O deacetylase|O (|O NuRD|O )|O complex|O (|O Fig|O .|O 2|O )|O .|O
In|O the|O Mayo|O cohort|O ,|O ASXL1|O mutations|O clustered|O with|O older|O age|O (|O P|O =|O 0|O .|O 01|O )|O ,|O constitutional|O symptoms|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O leukocytosis|O (|O P|O =|O 0|O .|O 007|O )|O and|O >|O =|O 1|O %|O circulating|O blasts|O (|O P|O =|O 0|O .|O 02|O )|O ;|O SRSF2|O mutations|O with|O older|O age|O (|O P|O =|O 0|O .|O 002|O )|O and|O anemia|O /|O transfusion|O need|O (|O P|O <|O 0|O .|O 05|O )|O ;|O EZH2|O mutations|O with|O >|O =|O 1|O %|O circulating|O blasts|O (|O P|O =|O 0|O .|O 003|O )|O .|O
Single|O gene|O mutations|O are|O not|O currently|O used|O in|O prognostic|O scoring|O systems|O but|O are|O likely|O to|O be|O key|O drivers|O of|O clinical|O phenotypes|O and|O overall|O survival|O .|O
In|O addition|O ,|O unlike|O AML|O and|O MDS|O ,|O where|O a|O monosomal|O karyotype|O has|O been|O associated|O with|O worse|O outcomes|O compared|O with|O a|O complex|O karyotype|O ,|O this|O difference|O was|O not|O seen|O in|O our|O CMML|O cohort|O .|O
Although|O the|O biological|O ramifications|O of|O activating|O EZH2|O mutations|O in|O lymphomagenesis|O are|O not|O well|O understood|O ,|O biochemical|O studies|O have|O shown|O that|O Y641|O mutation|O increases|O dimethylation|O and|O trimethylation|O of|O H3K27|O despite|O impaired|O H3K27|O monomethylation|O .|O
Other|O treatment|O options|O are|O primarily|O palliative|O and|O include|O splenectomy|O ,|O involved|O field|O radiotherapy|O ,|O erythropoiesis|O stimulating|O agents|O ,|O androgen|O preparations|O and|O thalidomide|O and|O its|O analogs|O to|O treat|O anemia|O ,|O hydroxyurea|O and|O JAK|O inhibitors|O to|O treat|O splenomegaly|O or|O constitutional|O symptoms|O .|O
The|O physical|O interaction|O between|O GATA1|O and|O PU|O .|O 1|O is|O mutually|O antagonistic|O .|O
ASSOCIATIONS|O OF|O MUTATIONS|O WITH|O CYTOGENETIC|O FEATURES|O AND|O CYTOPENIAS|O .|O
Additional|O prespecified|O analyses|O showed|O that|O among|O the|O patients|O for|O whom|O baseline|O and|O week|O 24|O data|O were|O available|O ,|O the|O 139|O patients|O receiving|O ruxolitinib|O had|O a|O mean|O reduction|O in|O spleen|O volume|O of|O 31|O .|O 6|O %|O (|O median|O ,|O 33|O .|O 0|O %|O )|O at|O week|O 24|O ;|O the|O 106|O patients|O receiving|O placebo|O had|O a|O mean|O increase|O of|O 8|O .|O 1|O %|O (|O median|O ,|O 8|O .|O 5|O %|O )|O .|O
Figure|O 1|O .|O Pedigree|O description|O .|O P1|O to|O P7|O describes|O the|O pedigrees|O .|O Circles|O represent|O females|O and|O squares|O males|O .|O Parents|O are|O connected|O by|O a|O single|O horizontal|O line|O ,|O and|O vertical|O lines|O indicate|O their|O offspring|O .|O Offspring|O are|O connected|O by|O a|O horizontal|O line|O .|O Siblings|O are|O placed|O from|O left|O to|O right|O according|O to|O birth|O order|O and|O are|O labeled|O with|O Arabic|O numerals|O .|O Each|O generation|O is|O indicated|O by|O a|O Roman|O numeral|O .|O Circles|O and|O squares|O are|O black|O when|O neutropenias|O have|O been|O formally|O identified|O .|O If|O a|O patient|O is|O dead|O ,|O a|O diagonal|O line|O is|O placed|O over|O the|O circle|O or|O square|O .|O Smaller|O circles|O with|O a|O diagonal|O line|O indicate|O miscarriage|O (|O P1|O ,|O III|O ,|O 4|O ;|O P1|O ,|O III|O ,|O 6|O )|O or|O termination|O because|O of|O AML|O induction|O treatment|O (|O P1|O ,|O III|O ,|O 7|O )|O .|O Patients|O tested|O are|O indicated|O by|O the|O result|O of|O the|O GATA2|O screening|O and|O a|O number|O (|O patient|O number|O 7107|O was|O not|O analyzed|O )|O .|O The|O absence|O (|O wild|O -|O type|O ,|O WT|O )|O or|O presence|O of|O a|O GATA2|O mutation|O (|O protein|O variation|O or|O complete|O deletion|O indicated|O by|O Delta|O )|O is|O indicated|O below|O the|O symbol|O of|O the|O patient|O tested|O .|O
The|O structures|O of|O BCOR|O and|O BCORL1|O are|O shown|O in|O Figure|O 1|O and|O their|O main|O features|O are|O summarized|O in|O Table|O 1|O .|O
Unblinding|O of|O the|O study|O -|O drug|O assignments|O and|O crossover|O from|O placebo|O to|O ruxolitinib|O were|O permitted|O for|O protocol|O -|O defined|O worsening|O splenomegaly|O (|O see|O the|O Supplementary|O Appendix|O )|O .|O
Genomic|O DNA|O PCR|O amplification|O was|O performed|O using|O another|O exon|O -|O specific|O primer|O pair|O with|O earlier|O published|O sequences|O for|O mutation|O confirmation|O .|O
This|O model|O identified|O four|O prognostic|O groups|O with|O median|O survivals|O of|O 54|O (|O low|O )|O ,|O 25|O (|O intermediate|O 1|O )|O ,|O 14|O (|O intermediate|O 2|O )|O and|O 6|O months|O (|O high|O )|O ,|O respectively|O .|O
The|O diversity|O of|O PMF|O subtypes|O was|O not|O fully|O appreciated|O as|O long|O as|O the|O only|O known|O mutant|O genes|O associated|O with|O this|O condition|O were|O JAK2|O and|O MPL|O ,|O as|O illustrated|O in|O Figure|O 7|O .|O
The|O presence|O of|O hot|O spots|O and|O the|O absence|O of|O nonsense|O or|O frameshift|O changes|O strongly|O suggested|O that|O they|O could|O be|O associated|O with|O some|O gain|O of|O function|O rather|O than|O represented|O simple|O loss|O of|O functions|O .|O
Translocation|O is|O the|O most|O common|O genetic|O aberration|O identified|O in|O ETV6|O ,|O for|O which|O approximately|O 30|O partner|O genes|O have|O been|O reported|O and|O molecularly|O characterized|O .|O
However|O ,|O on|O a|O univariate|O analysis|O ,|O they|O had|O no|O impact|O on|O either|O the|O OS|O or|O the|O leukemia|O free|O survival|O .|O
Polycomb|O group|O (|O PcG|O )|O proteins|O are|O transcriptional|O repressors|O that|O are|O crucial|O for|O regulating|O cell|O differentiation|O and|O maintaining|O cell|O identity|O in|O different|O cellular|O contexts|O .|O
In|O addition|O to|O its|O role|O as|O an|O intermediate|O in|O DNA|O demethylation|O ,|O 5|O -|O hmC|O has|O recently|O been|O identified|O to|O have|O at|O least|O another|O specific|O gene|O regulatory|O function|O .|O
Cell|O fractionation|O .|O
Because|O of|O the|O question|O on|O whether|O c|O .|O 1934dupG|O ;|O p|O .|O Gly646TrpfsX12|O is|O truly|O an|O ASXL1|O gene|O mutation|O vs|O a|O somatic|O alteration|O ,|O we|O reanalyzed|O the|O entire|O cohort|O ,|O excluding|O the|O 47|O patients|O with|O this|O mutation|O and|O found|O no|O difference|O in|O our|O results|O (|O Supplementary|O figure|O one|O )|O .|O
Reads|O were|O assigned|O to|O their|O patient|O -|O specific|O barcode|O ,|O and|O sequences|O were|O analyzed|O twice|O separately|O using|O the|O 2010|O DNAnexus|O software|O and|O the|O following|O pipeline|O of|O bioinformatics|O software|O .|O
Additional|O cytogenic|O and|O molecular|O markers|O have|O since|O been|O characterized|O ,|O and|O their|O role|O continues|O to|O evolve|O .|O
Cutoffs|O for|O low|O expression|O of|O STAG2|O was|O considered|O the|O bottom|O 7|O .|O 5|O %|O transcript|O levels|O ,|O and|O high|O expressors|O were|O considered|O the|O top|O 25|O %|O .|O
Because|O long|O -|O term|O survival|O is|O high|O with|O PV|O and|O ET|O ,|O survival|O prediction|O may|O only|O be|O valuable|O if|O aggressive|O therapy|O is|O to|O be|O considered|O .|O
Mutations|O in|O isocitrate|O dehydrogenase|O 1|O (|O IDH1|O )|O ,|O IDH2|O or|O tet|O methylcytosine|O dioxygenase|O 2|O (|O TET2|O )|O affect|O 5|O -|O hydroxymethylcytosine|O modification|O of|O DNA|O ,|O which|O alters|O methylation|O and|O haematopoietic|O development|O .|O
All|O of|O the|O aberrant|O transcripts|O with|O intragenic|O deletion|O of|O exon|O 5|O contained|O the|O PTPase|O core|O motif|O .|O Aberrant|O transcripts|O from|O our|O normal|O controls|O all|O had|O the|O same|O deletion|O locations|O as|O the|O AML|O patients|O ,|O although|O aberrant|O transcripts|O occurred|O more|O frequently|O in|O the|O AML|O specimens|O and|O cell|O lines|O .|O
Outcomes|O from|O the|O earlier|O phase|O III|O SWOG|O /|O ECOG|O study|O in|O younger|O patients|O (|O age|O <|O =|O 55|O years|O )|O also|O suggested|O similar|O outcomes|O in|O those|O with|O favorable|O cytogenetics|O undergoing|O HSCT|O ;|O based|O on|O intent|O -|O to|O -|O treat|O analysis|O ,|O the|O 5|O -|O year|O survival|O rate|O (|O from|O time|O of|O CR|O )|O was|O 71|O %|O for|O the|O autologous|O HSCT|O group|O (|O n|O =|O 26|O ;|O 65|O %|O underwent|O HSCT|O )|O and|O 63|O %|O for|O the|O allogeneic|O HSCT|O group|O (|O n|O =|O 19|O ;|O 84|O %|O underwent|O HSCT|O )|O .|O
GATA2|O mutations|O in|O exons|O 2|O -|O 6|O were|O searched|O for|O by|O PCR|O and|O Sanger|O sequencing|O (|O primer|O sequences|O are|O listed|O in|O supplemental|O Table|O 1|O )|O .|O
She|O died|O from|O a|O refractory|O disease|O after|O several|O lines|O of|O chemotherapy|O .|O
Factors|O predicting|O the|O course|O of|O disease|O are|O poorly|O understood|O and|O rely|O on|O clinical|O parameters|O such|O as|O anemia|O ,|O splenomegaly|O or|O leukocytosis|O .|O
This|O result|O is|O different|O from|O Sakai|O '|O s|O study|O of|O lymphoid|O neoplasms|O ,|O in|O which|O the|O abnormalities|O of|O the|O PTEN|O /|O MMAC1|O gene|O may|O contribute|O to|O pathogenesis|O in|O a|O small|O percentage|O of|O malignant|O lymphoma|O .|O
Bone|O -|O marrow|O -|O aspirate|O mononuclear|O cells|O and|O buccal|O -|O swab|O samples|O from|O patients|O with|O myelodysplastic|O syndromes|O were|O obtained|O from|O Rush|O University|O Medical|O Center|O ,|O the|O University|O of|O Massachusetts|O Medical|O Center|O ,|O and|O the|O M|O .|O D|O .|O Anderson|O Cancer|O Center|O .|O
In|O these|O regions|O ,|O GATA2|O can|O be|O ubiquitinated|O at|O least|O when|O exogenously|O expressed|O in|O cells|O .|O
Together|O with|O our|O data|O ,|O this|O suggests|O that|O EZH2|O may|O act|O as|O a|O tumor|O suppressor|O .|O
It|O is|O noteworthy|O that|O GATA1|O controls|O hematopoietic|O development|O by|O activating|O and|O repressing|O gene|O transcription|O .|O
Although|O these|O recent|O studies|O have|O increased|O our|O understanding|O of|O the|O genetic|O drivers|O of|O CNL|O and|O aCML|O ,|O this|O knowledge|O is|O lacking|O in|O ~|O 30|O %|O of|O patients|O .|O
Investigation|O Drug|O Therapy|O .|O
DNMT3A|O is|O a|O member|O of|O the|O mammalian|O family|O of|O methyltransferases|O that|O enzymatically|O add|O a|O methyl|O group|O to|O cytosine|O in|O CpG|O dinucleotides|O in|O DNA|O .|O
R882|O is|O the|O most|O commonly|O mutated|O residue|O .|O
Through|O the|O whole|O exome|O sequencing|O of|O nine|O cases|O with|O low|O risk|O MDS|O ,|O of|O which|O eight|O were|O MDS|O with|O ring|O sideroblasts|O ,|O Papaemmanuil|O et|O al|O identified|O SF3B1|O mutations|O in|O six|O cases|O and|O in|O a|O subsequent|O large|O -|O scale|O mutation|O analysis|O ,|O confirmed|O the|O high|O frequency|O of|O SF3B1|O mutations|O in|O MDS|O (|O 72|O /|O 354|O ;|O 20|O %|O )|O ,|O which|O were|O rare|O in|O other|O myeloid|O neoplasms|O ,|O including|O AML|O (|O 3|O /|O 57|O ;|O 5|O %|O )|O ,|O CML|O (|O 0|O /|O 53|O )|O ,|O and|O MPNs|O (|O 12|O /|O 420|O ,|O 3|O %|O )|O .|O
The|O incidence|O of|O relapse|O was|O 47|O %|O and|O 35|O %|O ,|O respectively|O ,|O and|O the|O incidence|O of|O deaths|O in|O CRs|O was|O 5|O %|O and|O 20|O %|O ,|O respectively|O .|O
In|O patients|O with|O monosomy|O 7|O ,|O monosomal|O karyotype|O did|O not|O appear|O to|O influence|O outcomes|O (|O 4|O -|O year|O OS|O ,|O 0|O %|O -|O 3|O %|O )|O ;|O the|O 4|O -|O year|O OS|O rates|O for|O patients|O with|O inv|O (|O 3|O )|O /|O t|O (|O 3|O ;|O 3|O )|O and|O t|O (|O 6|O ;|O 9|O )|O and|O those|O without|O monosomal|O karyotype|O ,|O were|O 0|O %|O and|O 9|O %|O ,|O respectively|O .|O
Myelodysplastic|O syndromes|O are|O clinically|O heterogeneous|O disorders|O for|O which|O treatments|O are|O tailored|O to|O the|O predicted|O prognosis|O for|O each|O patient|O .|O
The|O Gata3|O null|O embryos|O die|O due|O to|O internal|O bleeding|O ,|O and|O display|O growth|O retardation|O ,|O deformities|O in|O the|O brain|O and|O spinal|O cord|O ,|O and|O gross|O aberrations|O in|O fetal|O liver|O hematopoiesis|O .|O
These|O include|O mutations|O in|O tet|O methylcytosine|O dioxygenase|O 2|O (|O TET2|O )|O ,|O isocitrate|O dehydrogenase|O 1|O (|O IDH1|O )|O ,|O IDH2|O ,|O additional|O sex|O combs|O -|O like|O 1|O (|O ASXL1|O )|O ,|O enhancer|O of|O zeste|O homologue|O 2|O (|O EZH2|O )|O and|O DNA|O methyltransferase|O 3A|O (|O DNMT3A|O )|O ,|O which|O have|O recently|O been|O shown|O to|O have|O biological|O ,|O clinical|O and|O potential|O therapeutic|O relevance|O in|O myeloid|O malignancies|O (|O TABLE|O 1|O )|O .|O
Analysis|O of|O knock|O -|O in|O mice|O ,|O where|O the|O FOG1|O /|O NuRD|O binding|O is|O disrupted|O ,|O revealed|O the|O importance|O of|O this|O interaction|O for|O regulating|O erythropoiesis|O and|O megakaryopoiesis|O .|O
As|O shown|O in|O the|O heat|O map|O in|O Figure|O 5|O ,|O the|O two|O mutational|O groups|O displayed|O a|O distinct|O molecular|O signature|O ,|O that|O was|O characterized|O by|O 39|O differentially|O expressed|O genes|O ,|O 27|O overexpressed|O and|O 12|O downregulated|O (|O Supplementary|O Table|O 4|O )|O .|O
Thus|O ,|O there|O is|O a|O functional|O convergence|O of|O diverse|O spliceosomal|O mutations|O toward|O effects|O on|O specific|O genes|O ,|O a|O phenomenon|O that|O explains|O the|O similar|O phenotypes|O of|O some|O of|O the|O different|O mutations|O .|O
Molecular|O abnormalities|O are|O detected|O in|O ~|O 90|O %|O of|O patients|O with|O CMML|O .|O
Over|O the|O past|O decade|O a|O series|O of|O studies|O has|O implicated|O PRC1|O activity|O in|O regulating|O HSC|O self|O -|O renewal|O and|O differentiation|O .|O
There|O is|O also|O reasonably|O good|O agreement|O among|O laboratories|O for|O quantitative|O testing|O .|O
Any|O clinician|O seeking|O to|O apply|O or|O consult|O the|O NCCN|O Guidelines|O is|O expected|O to|O use|O independent|O medical|O judgment|O in|O the|O context|O of|O individual|O clinical|O circumstances|O to|O determine|O any|O patient|O '|O s|O care|O or|O treatment|O .|O
Fragments|O were|O purified|O and|O amplified|O by|O PCR|O for|O 6|O cycles|O .|O
Based|O on|O the|O identification|O of|O IDH1|O mutations|O ,|O subsequent|O candidate|O -|O gene|O studies|O identified|O IDH2|O mutations|O in|O AML|O .|O
In|O patients|O with|O both|O anemia|O and|O splenomegaly|O ,|O erythropoietin|O stimulating|O agents|O are|O not|O recommended|O because|O increased|O extramedullary|O hematopoesis|O can|O lead|O to|O worsening|O splenomegaly|O .|O
Beginning|O in|O 1991|O ,|O 81|O patients|O with|O CMML|O were|O diagnosed|O and|O treated|O in|O the|O Division|O of|O Hematology|O -|O Oncology|O at|O Chang|O Gung|O Memorial|O Hospital|O ,|O Taipei|O ,|O Taiwan|O .|O
There|O are|O no|O studies|O about|O miRNAs|O and|O GATA2|O in|O human|O models|O ,|O although|O databases|O present|O many|O potential|O miRNAs|O with|O predicted|O binding|O sites|O in|O the|O 3|O '|O UTR|O of|O GATA2|O .|O
ChIP|O experiments|O revealed|O that|O CBP|O is|O not|O only|O found|O at|O active|O genes|O ,|O but|O also|O persists|O at|O several|O repressive|O GATA1|O elements|O in|O vivo|O .|O
Acetylation|O also|O represents|O an|O important|O post|O -|O translational|O modification|O that|O is|O crucial|O for|O the|O activity|O of|O GATA|O family|O members|O .|O
The|O French|O ALFA|O 98|O trial|O randomized|O patients|O aged|O 65|O years|O and|O older|O who|O achieved|O remission|O (|O n|O =|O 164|O randomized|O for|O postremission|O therapy|O )|O ,|O to|O consolidation|O with|O either|O 1|O additional|O course|O of|O standard|O -|O dose|O cytarabine|O (|O 200|O mg|O /|O m2|O x|O 7|O days|O )|O plus|O the|O anthracycline|O to|O which|O they|O had|O been|O randomized|O for|O induction|O (|O idarubicin|O ,|O 9|O mg|O /|O m2|O x|O 4|O days|O or|O daunorubicin|O ,|O 45|O mg|O /|O m2|O x|O 4|O days|O )|O or|O 6|O monthly|O courses|O of|O anthracycline|O (|O 1|O day|O only|O )|O at|O the|O above|O doses|O and|O 60|O mg|O /|O m2|O of|O cytarabine|O every|O 12|O hours|O as|O a|O subcutaneous|O infusion|O at|O home|O for|O 5|O days|O each|O month|O .|O
Myelodysplastic|O syndrome|O (|O MDS|O )|O .|O
Similarly|O ,|O all|O mutations|O in|O SRSF2|O affected|O position|O P95|O (|O Figure|O 1D|O )|O .|O
The|O current|O study|O was|O approved|O by|O the|O Mayo|O Clinic|O institutional|O review|O board|O .|O
Splenectomy|O is|O considered|O in|O refractory|O patients|O ,|O patients|O who|O require|O frequent|O transfusions|O or|O who|O have|O significant|O portal|O hypertension|O .|O
Microsatellite|O markers|O D10S215|O ,|O D10S541|O ,|O D10S579|O ,|O and|O AFM086|O displayed|O 10|O /|O 20|O ,|O 9|O /|O 20|O ,|O 12|O /|O 20|O ,|O and|O 8|O /|O 20|O heterozygosities|O ,|O respectively|O .|O But|O none|O of|O 20|O AML|O cases|O displayed|O LOH|O in|O these|O markers|O ,|O suggesting|O that|O the|O regions|O defined|O by|O these|O markers|O had|O both|O alleles|O intact|O in|O these|O cases|O .|O
When|O phosphorylated|O ,|O this|O mutational|O hotspot|O is|O bound|O by|O the|O E3|O ubiquitin|O ligase|O subunit|O b|O -|O TrCP1|O ,|O leading|O to|O ubiquitination|O of|O SETBP1|O and|O subsequent|O degradation|O .|O
Fragmented|O genomic|O DNA|O (|O 0|O .|O 5|O -|O 2|O .|O 5|O mug|O )|O was|O tested|O for|O size|O distribution|O and|O concentration|O with|O the|O use|O of|O an|O Agilent|O 2100|O Bioanalyzer|O (|O Agilent|O Technologies|O )|O .|O
The|O importance|O of|O cooperation|O with|O coexisting|O mutations|O and|O /|O or|O the|O effects|O of|O abnormal|O bone|O marrow|O environment|O represent|O possible|O explanations|O .|O
The|O accurate|O classification|O of|O AML|O requires|O multidisciplinary|O diagnostic|O studies|O (|O using|O immunohistochemistry|O ,|O cytochemistry|O ,|O or|O both|O ,|O in|O addition|O to|O molecular|O genetics|O analysis|O )|O in|O accordance|O with|O the|O 2008|O WHO|O classification|O .|O
The|O authors|O concluded|O that|O the|O prognostic|O relevance|O of|O DNMT3A|O mutations|O may|O depend|O on|O age|O and|O mutation|O type|O .|O
If|O no|O donor|O is|O immediately|O available|O ,|O patients|O should|O be|O considered|O for|O a|O clinical|O trial|O .|O
JAK2|O .|O
In|O the|O central|O nervous|O system|O ,|O GATA2|O is|O essential|O and|O sufficient|O for|O spinal|O cord|O interneuron|O generation|O [|O 175|O ]|O ,|O for|O the|O induction|O of|O ventral|O gonadotrope|O and|O thyrotrope|O fates|O in|O the|O pituitary|O ,|O and|O for|O the|O generation|O of|O serotonergic|O neurons|O in|O the|O rostral|O hindbrain|O .|O
Somatic|O cohesin|O mutations|O have|O been|O reported|O in|O several|O cohorts|O of|O patients|O with|O de|O novo|O AML|O .|O
The|O data|O presented|O above|O show|O that|O GATA2|O is|O an|O indispensable|O transcription|O factor|O for|O hematopoiesis|O .|O
Clinically|O ,|O epigenetic|O mutations|O occur|O in|O combination|O with|O both|O class|O I|O and|O class|O II|O genes|O and|O also|O occasionally|O with|O each|O other|O (|O FIG|O .|O 5|O )|O .|O
S11|O in|O the|O Supplementary|O Appendix|O )|O .|O
The|O IPSS|O risk|O (|O low|O ,|O intermediate|O 1|O ,|O intermediate|O 2|O ,|O or|O high|O )|O (|O Table|O 2|O in|O the|O Supplementary|O Appendix|O )|O had|O been|O ascertained|O at|O the|O time|O of|O diagnosis|O .|O
There|O have|O been|O promising|O results|O from|O clinical|O trials|O that|O involve|O the|O JAK|O tyrosine|O kinase|O inhibitors|O TG101384|O and|O INCB018424|O ,|O but|O their|O role|O in|O future|O therapy|O is|O yet|O to|O be|O established|O .|O
We|O identified|O a|O heterozygous|O GATA2|O R204X|O mutation|O (|O c|O .|O 610C|O >|O T|O ,|O supplemental|O Figure|O 1|O )|O .|O
Currently|O ,|O testing|O is|O based|O only|O on|O qualitative|O results|O ,|O but|O the|O accuracy|O and|O sensitivity|O of|O quantitative|O assays|O may|O be|O assessed|O in|O future|O iterations|O .|O
Clinically|O ,|O MDS|O patients|O harboring|O DNMT3A|O mutations|O demonstrate|O a|O more|O aggressive|O clinical|O course|O with|O shorter|O overall|O survival|O (|O OS|O )|O and|O increased|O rate|O of|O AML|O transformation|O .|O
Constitutional|O symptoms|O improved|O significantly|O in|O 40|O %|O -|O 60|O %|O ,|O and|O dose|O -|O dependent|O weight|O gain|O was|O reported|O in|O patients|O with|O low|O body|O mass|O index|O .|O
DISCUSSION|O .|O
These|O data|O suggest|O that|O TET2|O can|O function|O as|O a|O haploinsufficient|O tumour|O suppressor|O in|O most|O patients|O ;|O biallelic|O TET2|O inactivation|O occurs|O in|O <|O 10|O %|O of|O patients|O with|O leukaemia|O .|O
On|O the|O basis|O of|O the|O initial|O screen|O ,|O we|O noted|O that|O mutations|O in|O U2AF1|O ,|O SF3B1|O ,|O and|O SRSF2|O were|O the|O most|O frequent|O .|O
The|O BM|O smear|O did|O not|O identify|O myelokathexis|O features|O and|O the|O case|O was|O considered|O to|O be|O a|O WHIM|O -|O like|O syndrome|O .|O
The|O strong|O association|O with|O ASXL1|O indicates|O that|O epigenetic|O dysregulation|O may|O be|O synergistic|O in|O the|O mechanism|O of|O action|O exerted|O by|O cohesin|O haploinsufficiency|O .|O
Moreover|O ,|O a|O recent|O study|O demonstrated|O that|O high|O GATA2|O expression|O in|O human|O HSCs|O and|O HPCs|O confers|O increased|O quiescence|O ,|O an|O important|O hallmark|O property|O of|O HSCs|O .|O
We|O used|O a|O combination|O of|O genomic|O approaches|O ,|O including|O next|O -|O generation|O sequencing|O and|O mass|O spectrometry|O -|O -|O based|O genotyping|O ,|O to|O identify|O mutations|O in|O samples|O of|O bone|O marrow|O aspirate|O from|O 439|O patients|O with|O myelodysplastic|O syndromes|O .|O
It|O could|O be|O possible|O that|O a|O negative|O prognostic|O impact|O of|O cohesin|O mutations|O might|O have|O been|O missed|O because|O of|O the|O favorable|O prognostic|O impact|O of|O NPM1|O mutations|O and|O the|O strong|O association|O between|O these|O mutations|O .|O
Further|O analyses|O were|O performed|O using|O oncomine|O (|O https|O :|O /|O /|O www|O .|O oncomine|O .|O org|O /|O )|O .|O
In|O a|O multivariate|O analysis|O corrected|O for|O age|O ,|O CALR|O -|O mutant|O patients|O maintained|O a|O better|O OS|O compared|O with|O either|O JAK2|O -|O mutant|O (|O P|O =|O .|O 019|O )|O or|O triple|O -|O negative|O patients|O (|O P|O <|O .|O 001|O )|O .|O
BCOR|O mutations|O were|O demonstrated|O to|O be|O clonal|O ,|O somatic|O ,|O disruptive|O events|O involving|O the|O only|O functional|O allele|O ,|O not|O only|O in|O male|O but|O also|O in|O female|O AML|O patients|O .|O
A|O total|O of|O 70|O %|O of|O the|O patients|O were|O men|O (|O median|O age|O at|O the|O time|O of|O bone|O marrow|O aspirate|O collection|O ,|O 70|O years|O )|O ;|O 66|O %|O of|O the|O patients|O were|O in|O the|O IPSS|O low|O -|O risk|O or|O intermediate|O -|O 1|O -|O risk|O groups|O ,|O 58|O %|O had|O normal|O cytogenetic|O features|O ,|O and|O 13|O %|O had|O a|O complex|O karyotype|O .|O
The|O initial|O step|O in|O an|O accurate|O diagnosis|O must|O be|O the|O exclusion|O of|O the|O BCR|O -|O ABL1|O translocation|O in|O patients|O who|O present|O with|O signs|O ,|O symptoms|O ,|O or|O laboratory|O values|O consistent|O with|O PV|O ,|O ET|O ,|O or|O PMF|O .|O
METHODS|O .|O
ASXL1|O mutations|O were|O associated|O with|O a|O proliferative|O phenotype|O ,|O higher|O WBC|O ,|O higher|O AMC|O and|O presence|O of|O circulating|O IMC|O .|O
Somatic|O mutations|O ,|O such|O as|O V617F|O mutation|O in|O JH2|O ,|O disrupt|O the|O inhibitory|O function|O of|O the|O pseudokinase|O and|O thus|O lead|O to|O constitutive|O tyrosine|O phosphorylation|O activity|O that|O promotes|O cytokine|O hypersensitivity|O (|O UniProt|O ,|O http|O :|O /|O /|O www|O .|O uniprot|O .|O org|O /|O uniprot|O /|O O60674|O ,|O last|O accessed|O November|O 28|O ,|O 2012|O )|O .|O
The|O presence|O of|O this|O mutation|O implied|O that|O no|O intact|O copy|O of|O EZH2|O was|O left|O in|O the|O malignant|O bone|O marrow|O cells|O of|O this|O individual|O .|O
GATA2|O is|O acetylated|O at|O various|O lysine|O -|O rich|O motifs|O that|O are|O highly|O conserved|O among|O different|O species|O (|O lysines|O 102|O and|O 398|O and|O amino|O acids|O 281|O -|O 285|O ,|O 334|O -|O 336|O ,|O 389|O -|O 390|O and|O 402|O -|O 408|O )|O .|O
We|O also|O performed|O serial|O analyses|O for|O 12|O cases|O with|O STAG2|O and|O SMC3|O mutations|O and|O 1|O case|O with|O a|O mutation|O of|O RAD21|O (|O Figure|O 4C|O -|O D|O )|O .|O
Some|O presentations|O by|O other|O groups|O at|O the|O 2011|O meeting|O of|O the|O American|O Society|O of|O Hematology|O suggested|O a|O correlation|O between|O SF3B1|O and|O DNMT3A|O mutations|O and|O a|O favorable|O survival|O effect|O of|O RUNX1|O mutations|O in|O CMML|O with|O SRSF2|O .|O
Large|O numbers|O of|O genetic|O aberrations|O have|O been|O identified|O in|O patients|O with|O CMML|O .|O
A|O reasonable|O treatment|O regimen|O for|O these|O patients|O includes|O standard|O -|O dose|O cytarabine|O (|O 100|O -|O 200|O mg|O /|O m2|O by|O continuous|O infusion|O per|O day|O x|O 7|O days|O )|O along|O with|O 3|O days|O of|O anthracycline|O .|O
These|O agents|O can|O elicit|O improvement|O in|O blood|O counts|O but|O exhibit|O no|O proven|O disease|O -|O modifying|O benefit|O .|O
Clinical|O and|O laboratory|O characteristics|O of|O all|O 879|O study|O patients|O ,|O stratified|O into|O European|O (|O n|O =|O 483|O )|O and|O Mayo|O (|O n|O =|O 396|O )|O cohorts|O ,|O are|O outlined|O in|O Table|O 1|O .|O
When|O choosing|O among|O these|O options|O ,|O decisions|O are|O influenced|O by|O :|O 1|O )|O the|O expected|O relapse|O rate|O with|O high|O -|O dose|O cytarabine|O consolidation|O chemotherapy|O (|O which|O in|O turn|O is|O strongly|O influenced|O by|O cytogenetic|O and|O molecular|O abnormalities|O )|O ;|O 2|O )|O the|O additional|O morbidity|O and|O mortality|O associated|O with|O the|O transplant|O procedure|O ,|O which|O in|O turn|O are|O strongly|O influenced|O by|O patient|O -|O specific|O comorbidity|O ;|O and|O 3|O )|O salvage|O therapy|O options|O .|O
Some|O studies|O have|O reported|O the|O lack|O of|O prognostic|O value|O of|O IDH2|O mutations|O ,|O whereas|O others|O have|O reported|O favorable|O outcomes|O with|O IDH2|O mutations|O .|O
We|O have|O investigated|O FLT3|O and|O NRAS|O mutations|O in|O patients|O with|O CMML|O ,|O and|O we|O also|O examined|O the|O incidence|O of|O mutations|O in|O the|O CEBPa|O myeloid|O transcription|O factor|O in|O patients|O with|O CMML|O who|O later|O had|O acute|O myeloid|O leukemia|O (|O AML|O )|O transformation|O .|O
Although|O GATA|O members|O have|O a|O restricted|O expression|O pattern|O ,|O their|O functions|O are|O partially|O interchangeable|O .|O
Case|O series|O and|O analysis|O of|O registry|O data|O have|O reported|O encouraging|O results|O ,|O with|O 40|O %|O to|O 60|O %|O 2|O -|O year|O OS|O rates|O and|O 20|O %|O nonrelapse|O mortality|O for|O patients|O who|O underwent|O transplant|O in|O remission|O .|O
Complications|O may|O occur|O in|O congenital|O neutropenia|O ,|O essentially|O infectious|O diseases|O but|O also|O less|O frequently|O myelodysplastic|O syndrome|O (|O MDS|O )|O or|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
The|O HOVON|O /|O SAKK|O study|O compared|O a|O double|O -|O induction|O concept|O using|O intermediate|O -|O or|O high|O -|O dose|O cytarabine|O as|O part|O of|O an|O induction|O /|O consolidation|O regimen|O in|O a|O phase|O III|O randomized|O study|O in|O patients|O (|O age|O 18|O -|O 60|O years|O )|O with|O newly|O diagnosed|O AML|O (|O N|O =|O 860|O )|O .|O
Fig|O .|O 2|O .|O The|O results|O of|O sequencing|O of|O the|O isolated|O fragments|O from|O 7|O abnormal|O transcripts|O of|O the|O PTEN|O /|O MMAC1|O gene|O .|O (|O A|O )|O Deletion|O from|O nt|O 1064|O to|O 1814|O and|O 1835|O to|O 1877|O of|O cDNA|O .|O (|O B|O )|O Deletion|O from|O nt|O 1244|O to|O 1526|O of|O cDNA|O .|O (|O C|O )|O Deletion|O from|O nt|O 1296|O to|O 2013|O of|O cDNA|O .|O (|O D|O )|O Deletion|O from|O nt|O 1170|O to|O 2041|O of|O cDNA|O .|O (|O E|O )|O Deletion|O from|O nt|O 1180|O to|O 2142|O of|O cDNA|O .|O (|O F|O )|O Deletion|O from|O nt|O 1040|O to|O 2091|O of|O cDNA|O .|O (|O G|O )|O Deletion|O from|O nt|O 1035|O to|O 2165|O .|O Arrow|O indicates|O deletions|O .|O
The|O panel|O has|O provided|O the|O following|O options|O for|O consolidation|O therapy|O for|O patients|O with|O better|O risk|O cytogenetics|O (|O those|O with|O CBF|O leukemia|O ,|O without|O c|O -|O KIT|O mutations|O )|O :|O 1|O )|O 3|O to|O 4|O cycles|O of|O high|O -|O dose|O cytarabine|O (|O category|O 1|O )|O ;|O or|O 2|O )|O 1|O to|O 2|O cycles|O of|O high|O -|O dose|O cytarabine|O followed|O by|O autologous|O HSCT|O (|O category|O 2B|O )|O .|O
GATA2|O interacts|O with|O FOG1|O through|O the|O N|O -|O ZnF|O domain|O ,|O with|O PU|O .|O 1|O through|O the|O C|O -|O ZnF|O domain|O ,|O and|O needs|O both|O ZnF|O to|O interact|O with|O HDAC|O ,|O c|O -|O MYB|O ,|O RARalpha|O ,|O PLZF|O ,|O PPARy2|O ,|O and|O PIASy|O (|O Fig|O .|O 1|O )|O .|O
Preleukemic|O hematologic|O and|O immunologic|O parameters|O .|O
Again|O ,|O no|O difference|O was|O found|O in|O CR|O rates|O (|O mutated|O 88|O %|O vs|O wild|O -|O type|O 78|O %|O ;|O P|O =|O .|O 39|O )|O .|O
Tong|O et|O al|O reported|O that|O amino|O acids|O 381|O -|O 385|O ,|O covering|O the|O region|O adjacent|O to|O the|O C|O -|O terminal|O ZnF|O of|O GATA2|O ,|O are|O required|O for|O protein|O interaction|O with|O C|O /|O EBPA|O ,|O but|O not|O for|O DNA|O binding|O or|O nuclear|O localization|O .|O
Data|O were|O collected|O by|O the|O academic|O investigators|O and|O analyzed|O by|O the|O sponsor|O of|O the|O study|O ,|O Incyte|O .|O
Cooperating|O mutations|O of|O FLT3|O and|O RAS|O genes|O were|O also|O analyzed|O in|O CMML|O patients|O harboring|O RUNX1|O mutations|O (|O Table|O 1|O )|O ;|O one|O patient|O had|O FLT3|O -|O TKD|O (|O Asp835Tyr|O )|O ,|O three|O patients|O had|O NRAS|O mutations|O and|O one|O had|O a|O KRAS|O mutation|O .|O
Patients|O who|O experienced|O a|O remission|O continued|O to|O receive|O therapy|O every|O 4|O to|O 6|O weeks|O to|O maintain|O remission|O for|O up|O to|O 6|O additional|O treatment|O cycles|O .|O
As|O expected|O ,|O in|O sAML|O and|O pAML|O ,|O because|O of|O overall|O poor|O prognosis|O ,|O the|O presence|O of|O spliceosomal|O mutations|O did|O not|O further|O affect|O survival|O (|O supplemental|O Figure|O 4|O )|O .|O
The|O abnormal|O transcripts|O may|O result|O from|O aberrant|O RNA|O splicing|O ,|O as|O evidenced|O by|O the|O occurrence|O of|O aberrant|O transcripts|O in|O the|O AML|O specimens|O ,|O cell|O lines|O ,|O and|O normal|O controls|O ,|O and|O the|O simultaneous|O presence|O of|O normal|O full|O length|O transcripts|O in|O all|O tumor|O samples|O and|O cell|O lines|O examined|O .|O
Chronic|O myelomonocytic|O leukaemia|O (|O CMML|O )|O .|O
Cytogenetics|O and|O Risk|O Stratification|O :|O Although|O cytogenetic|O information|O is|O often|O unknown|O when|O treatment|O is|O initiated|O in|O patients|O with|O de|O novo|O AML|O ,|O karyotype|O represents|O the|O single|O most|O important|O prognostic|O factor|O for|O predicting|O remission|O rate|O ,|O relapse|O risks|O ,|O and|O overall|O survival|O (|O OS|O )|O outcomes|O .|O
Table|O 1|O .|O Summary|O of|O recurrent|O mutations|O in|O MDS|O .|O
The|O 4|O -|O year|O OS|O rate|O among|O intermediate|O -|O risk|O patients|O was|O 54|O %|O for|O the|O no|O -|O donor|O group|O and|O 53|O %|O for|O the|O donor|O group|O .|O
Patients|O with|O an|O ECOG|O performance|O status|O score|O of|O greater|O than|O 2|O or|O those|O with|O significant|O comorbidities|O (|O regardless|O of|O performance|O status|O score|O )|O are|O more|O likely|O to|O experience|O toxicity|O and|O less|O likely|O to|O benefit|O from|O standard|O -|O induction|O chemotherapy|O .|O
Besides|O ,|O despite|O a|O 5|O -|O fold|O increase|O in|O Gata2|O mRNA|O ,|O primary|O purified|O GATA1|O -|O deficient|O megakaryocytes|O manifest|O multiple|O abnormalities|O in|O growth|O control|O and|O differentiation|O .|O
In|O practice|O ,|O however|O ,|O clinicians|O find|O it|O easier|O to|O order|O both|O the|O BCR|O -|O ABL1|O and|O the|O JAK2|O assays|O at|O the|O same|O time|O in|O screening|O peripheral|O blood|O .|O
Nine|O of|O the|O 21|O patients|O (|O 43|O %|O )|O with|O N|O -|O terminal|O mutations|O had|O AML|O transformation|O compared|O with|O seven|O of|O nine|O patients|O with|O C|O -|O terminal|O mutations|O (|O P|O =|O 0|O .|O 118|O )|O .|O
Clinical|O associations|O and|O frequencies|O of|O spliceosomal|O mutations|O in|O myeloid|O malignancies|O .|O
Mutations|O in|O CSF3R|O have|O previously|O been|O identified|O in|O patients|O with|O severe|O congenital|O neutropenia|O (|O SCN|O )|O .|O
Additionally|O ,|O this|O study|O expands|O the|O current|O knowledge|O of|O cohesin|O mutations|O across|O the|O spectrum|O of|O myeloid|O diseases|O ,|O identifying|O cohesin|O mutation|O frequencies|O in|O different|O disease|O subtypes|O ,|O most|O prominently|O in|O sAML|O (|O 20|O %|O )|O .|O
Two|O missense|O point|O mutations|O in|O the|O middle|O of|O RHD|O (|O Arg80Cys|O and|O Arg139Gly|O )|O were|O described|O earlier|O .|O
The|O use|O of|O liposomal|O cytarabine|O ,|O which|O has|O a|O longer|O half|O -|O life|O ,|O for|O intrathecal|O use|O offers|O the|O benefit|O of|O less|O frequent|O (|O once|O weekly|O )|O administration|O .|O
Time|O to|O large|O splenomegaly|O could|O be|O estimated|O only|O in|O patients|O from|O the|O Pavia|O Center|O for|O the|O Study|O of|O Myelofibrosis|O .|O
A|O sequencing|O library|O was|O prepared|O for|O hotspot|O regions|O of|O IDH1|O (|O exon|O 4|O )|O ,|O IDH2|O (|O exon|O 4|O )|O ,|O NPM1|O (|O exon|O 11|O )|O and|O the|O complete|O coding|O region|O of|O EZH2|O (|O Supplementary|O Table|O 1|O )|O ,|O comprising|O a|O total|O of|O 22|O amplicons|O with|O a|O median|O size|O of|O 336|O bp|O .|O
More|O recently|O ,|O cohesin|O has|O been|O found|O to|O localize|O at|O superenhancers|O ,|O which|O are|O locus|O -|O control|O regions|O with|O broad|O peaks|O of|O H3K27|O acetylation|O .|O
Figure|O 3|O .|O Effect|O of|O cohesin|O mutational|O status|O on|O OS|O in|O MDS|O .|O Kaplan|O -|O Meier|O curves|O for|O patients|O with|O MDS|O are|O shown|O for|O (|O A|O )|O STAG2|O mutant|O patients|O and|O cohesin|O WT|O patients|O and|O (|O B|O )|O all|O cohesin|O mutant|O patients|O vs|O WT|O cohesin|O patients|O .|O Median|O OS|O of|O MDS|O patients|O with|O a|O STAG2|O mutation|O was|O 35|O months|O vs|O 50|O months|O (|O P|O =|O .|O 17|O ;|O HR|O :|O 1|O .|O 8|O CI|O [|O 1|O .|O 1|O -|O 3|O .|O 1|O ]|O )|O ,|O median|O survival|O for|O cohesin|O mutant|O MDS|O cases|O was|O inferior|O to|O WT|O MDS|O cases|O (|O 34|O .|O 2|O vs|O 48|O .|O 2|O ;|O P|O =|O .|O 21|O )|O ,|O and|O a|O significant|O survival|O difference|O was|O pronounced|O in|O patients|O with|O MDS|O who|O survived|O for|O at|O least|O 12|O months|O (|O P|O =|O .|O 01|O )|O .|O
Importantly|O ,|O most|O TET2|O mutations|O are|O heterozygous|O in|O leukaemia|O ,|O and|O the|O expression|O of|O the|O wild|O -|O type|O allele|O is|O retained|O .|O
In|O fact|O ,|O hematopoiesis|O is|O an|O elaborate|O regulatory|O network|O of|O transcription|O factors|O that|O coordinates|O the|O expression|O of|O multiple|O classes|O of|O downstream|O genes|O ,|O including|O cell|O cycle|O regulators|O and|O lineage|O -|O specific|O genes|O ,|O ensuring|O that|O the|O population|O of|O mature|O cells|O is|O proportioned|O appropriately|O and|O maintained|O at|O constant|O levels|O .|O
Despite|O cohesin|O '|O s|O role|O in|O alignment|O of|O sister|O chromatids|O during|O metaphase|O ,|O these|O data|O provide|O further|O evidence|O that|O the|O leukemogenic|O consequences|O of|O cohesin|O defects|O do|O not|O involve|O disrupted|O mitosis|O and|O global|O chromosomal|O instability|O .|O
In|O addition|O to|O the|O TET|O family|O ,|O there|O are|O other|O alpha|O -|O ketoglutarate|O -|O dependent|O enzymes|O that|O may|O be|O similarly|O inhibited|O by|O 2|O -|O HG|O .|O
There|O was|O no|O statistically|O significant|O difference|O ,|O among|O the|O three|O mutation|O groups|O (|O SRSF2|O vs|O SF3B1|O vs|O U2AF35|O )|O ,|O in|O prognostically|O relevant|O parameters|O .|O
MATERIALS|O AND|O METHODS|O .|O
We|O screened|O all|O 9|O coding|O exons|O for|O coding|O sequence|O changes|O that|O would|O result|O in|O a|O defect|O of|O the|O protein|O (|O small|O deletion|O ,|O insertion|O ,|O or|O point|O mutation|O )|O by|O PCR|O -|O SSCP|O and|O direct|O sequencing|O .|O
One|O patient|O had|O a|O baseline|O spleen|O length|O recorded|O as|O nonpalpable|O in|O error|O but|O had|O a|O prior|O measurement|O of|O 16|O cm|O and|O a|O baseline|O spleen|O volume|O of|O 2450|O cm3|O .|O
OS|O was|O calculated|O from|O the|O date|O of|O first|O referral|O to|O date|O of|O death|O (|O uncensored|O )|O or|O last|O contact|O (|O censored|O )|O .|O
Sequence|O Analysis|O .|O
Within|O 140|O CALR|O -|O mutant|O patients|O ,|O 101|O (|O 72|O %|O )|O had|O the|O 52|O -|O bp|O deletion|O (|O L367fs|O *|O 46|O ,|O type|O 1|O mutation|O )|O ,|O 22|O (|O 16|O %|O )|O had|O the|O 5|O -|O bp|O insertion|O (|O K385fs|O *|O 47|O ,|O type|O 2|O mutation|O )|O ,|O and|O 17|O (|O 12|O %|O )|O carried|O other|O less|O frequent|O indels|O .|O
Margaret|O R|O .|O O|O '|O Donnell|O ;|O Camille|O N|O .|O Abboud|O ;|O Jessica|O Altman|O ;|O Frederick|O R|O .|O Appelbaum|O ;|O Daniel|O A|O .|O Arber|O ;|O Eyal|O Attar|O ;|O Uma|O Borate|O ;|O Steven|O E|O .|O Coutre|O ;|O Lloyd|O E|O .|O Damon|O ;|O Salil|O Goorha|O ;|O Jeffrey|O Lancet|O ;|O Lori|O J|O .|O Maness|O ;|O Guido|O Marcucci|O ;|O Michael|O M|O .|O Millenson|O ;|O Joseph|O O|O .|O Moore|O ;|O Farhad|O Ravandi|O ;|O Paul|O J|O .|O Shami|O ;|O B|O .|O Douglas|O Smith|O ;|O Richard|O M|O .|O Stone|O ;|O Stephen|O A|O .|O Strickland|O ;|O Martin|O S|O .|O Tallman|O ;|O Eunice|O S|O .|O Wang|O ;|O Maoko|O Naganuma|O ;|O Kristina|O M|O .|O Gregory|O .|O
This|O mutation|O was|O found|O in|O the|O vast|O majority|O of|O patients|O with|O polycythemia|O vera|O (|O PV|O )|O and|O in|O approximately|O half|O of|O patients|O with|O essential|O thrombocythemia|O (|O ET|O )|O or|O primary|O myelofibrosis|O (|O PMF|O )|O .|O
6|O .|O 1|O .|O ROLE|O OF|O GATA2|O IN|O HEMATOPOIETIC|O STEM|O AND|O PROGENITOR|O CELLS|O .|O
Notably|O ,|O deletion|O of|O core|O ,|O non|O -|O enzymatic|O PRC2|O components|O in|O vivo|O results|O in|O myeloid|O transformation|O and|O /|O or|O increased|O HSC|O self|O -|O renewal|O .|O
These|O nonsense|O mutations|O are|O likely|O be|O sensitive|O to|O nonsense|O -|O mediated|O decay|O and|O would|O be|O null|O alleles|O similar|O in|O effect|O to|O whole|O gene|O deletions|O .|O
All|O P|O values|O were|O considered|O statistically|O significant|O when|O <|O .|O 05|O (|O 2|O -|O tailed|O )|O .|O
However|O ,|O due|O to|O the|O small|O number|O cases|O of|O our|O study|O and|O AML|O is|O a|O wide|O diversity|O disease|O which|O may|O differ|O in|O etiology|O ,|O pathology|O ,|O and|O behavior|O ,|O the|O potential|O role|O of|O PTEN|O /|O MMAC1|O in|O AML|O or|O in|O some|O subtypes|O of|O AML|O need|O further|O investigation|O .|O
Notably|O ,|O somatic|O mutations|O in|O BAP1|O ,|O a|O binding|O partner|O of|O ASXL1|O and|O a|O probable|O antagonist|O of|O PRC1|O activity|O ,|O have|O been|O described|O in|O mesothelioma|O ,|O melanoma|O and|O renal|O cell|O carcinoma|O but|O not|O to|O date|O in|O haematopoietic|O malignancies|O .|O
HR|O >|O 1|O or|O <|O 1|O indicate|O an|O increased|O or|O decreased|O risk|O ,|O respectively|O ,|O of|O an|O event|O for|O the|O first|O category|O listed|O .|O
Thirty|O -|O seven|O (|O 42|O %|O )|O ,|O 13|O (|O 14|O %|O )|O and|O 2|O (|O 2|O %|O )|O patients|O had|O concomitant|O ASXL1|O and|O SRSF2|O ,|O U2AF35|O and|O SF3B1|O mutations|O ,|O respectively|O .|O
Reticulin|O fibrosis|O is|O not|O significantly|O increased|O .|O
Detection|O of|O somatic|O spliceosomal|O mutations|O in|O myeloid|O malignancies|O .|O
However|O ,|O only|O ASXL1|O mutations|O (|O HR|O :|O 2|O .|O 02|O ;|O P|O <|O 0|O .|O 001|O )|O remained|O significant|O in|O the|O context|O of|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O .|O
Approximately|O 20|O -|O 40|O %|O of|O patients|O with|O CMML|O have|O an|O abnormal|O karyotype|O .|O
Written|O informed|O consent|O was|O obtained|O according|O to|O the|O Declaration|O of|O Helsinki|O ,|O and|O the|O studies|O were|O approved|O by|O the|O institutional|O review|O board|O of|O Hannover|O Medical|O School|O ,|O Hannover|O ,|O Germany|O .|O
The|O overall|O median|O survival|O was|O 25|O months|O compared|O with|O survivals|O ranging|O from|O 14|O to|O 30|O months|O gleaned|O from|O 3|O smaller|O studies|O .|O
Clinically|O ,|O EZH2|O mutations|O are|O also|O prognostically|O relevant|O in|O both|O low|O -|O and|O high|O -|O risk|O MDS|O and|O are|O associated|O with|O a|O worse|O OS|O compared|O with|O non|O -|O mutated|O EZH2|O .|O
The|O remaining|O mutations|O were|O validated|O by|O Sanger|O sequencing|O .|O
We|O also|O investigated|O expression|O signatures|O of|O genes|O associated|O with|O cohesin|O mutations|O or|O with|O reduced|O expression|O of|O STAG2|O /|O RAD21|O /|O SMC3|O .|O
Five|O were|O confirmed|O by|O classic|O Sanger|O sequencing|O :|O EPHB6|O T483P|O ,|O GATA2|O R396Q|O ,|O IMPG2|O P1161L|O ,|O NEK11|O D87Y|O ,|O and|O TTN|O P4737R|O (|O primer|O sequences|O are|O provided|O in|O supplemental|O Table|O 1|O ,|O available|O on|O the|O Blood|O Web|O site|O ;|O see|O the|O Supplemental|O Materials|O link|O at|O the|O top|O of|O the|O online|O article|O )|O .|O
Moreover|O ,|O patients|O with|O C|O -|O terminal|O mutations|O progressed|O to|O AML|O more|O rapidly|O .|O
Overall|O ,|O nonhematologic|O adverse|O events|O occurred|O at|O a|O similar|O rate|O in|O the|O two|O groups|O .|O
Because|O JAK2|O and|O MPL|O mutations|O are|O not|O completely|O specific|O for|O MPN|O ,|O finding|O of|O these|O mutations|O in|O isolation|O does|O not|O warrant|O a|O diagnosis|O of|O MPN|O .|O
The|O mutation|O W515L|O represents|O guanosine|O -|O to|O -|O thymidine|O substitution|O in|O MPL|O at|O nucleotide|O 1544|O ,|O which|O leads|O to|O exchange|O of|O leucine|O for|O tryptophan|O .|O
Taken|O together|O ,|O these|O data|O suggest|O that|O cohesin|O function|O is|O integral|O to|O expression|O of|O key|O cell|O -|O identity|O genes|O and|O that|O reduction|O in|O gene|O dose|O of|O cohesin|O alters|O cellular|O identity|O .|O
Frequently|O ,|O in|O these|O trials|O ,|O marrow|O examination|O is|O not|O performed|O until|O completion|O of|O 1|O to|O 2|O cycles|O of|O therapy|O .|O
Patients|O with|O low|O cohesin|O gene|O expression|O showed|O similar|O expression|O signatures|O as|O those|O with|O somatic|O cohesin|O mutations|O .|O
Molecular|O profiling|O is|O increasing|O the|O ability|O to|O identify|O mutations|O at|O the|O molecular|O level|O ,|O which|O carry|O prognostic|O impact|O .|O
Bone|O marrow|O (|O BM|O )|O samples|O were|O obtained|O with|O informed|O consent|O from|O all|O patients|O at|O initial|O presentation|O .|O
DNMT3A|O mutations|O were|O first|O reported|O in|O myeloid|O leukemias|O .|O
Using|O a|O cis|O -|O element|O knockout|O approach|O ,|O it|O has|O been|O demonstrated|O that|O the|O Gata2|O -|O 1|O .|O 8|O kb|O site|O is|O selectively|O required|O to|O maintain|O Gata2|O repression|O in|O late|O -|O stage|O erythroblasts|O in|O vivo|O .|O
9|O .|O OTHER|O IMPORTANT|O ROLES|O OF|O GATA2|O .|O
When|O considering|O all|O mutations|O in|O the|O cohesin|O complex|O as|O 1|O group|O ,|O OS|O and|O RFS|O were|O not|O influenced|O by|O the|O presence|O of|O cohesin|O mutations|O (|O OS|O :|O HR|O 0|O .|O 98|O ;|O 95|O %|O CI|O ,|O 0|O .|O 56|O -|O 1|O .|O 72|O ;|O P|O =|O .|O 94|O ;|O Figure|O 2A|O )|O (|O RFS|O :|O HR|O 0|O .|O 70|O ;|O 95|O %|O CI|O ,|O 0|O .|O 36|O -|O 1|O .|O 38|O ;|O P|O =|O .|O 3|O ,|O Figure|O 2B|O and|O Table|O 2|O )|O .|O
Patients|O with|O PMF|O are|O considered|O low|O risk|O if|O they|O have|O no|O risk|O factors|O ,|O intermediate|O -|O 1|O risk|O if|O they|O have|O 1|O risk|O factor|O ,|O intermediate|O -|O 2|O if|O they|O have|O 2|O risk|O factors|O ,|O and|O high|O risk|O if|O they|O have|O 3|O or|O more|O risk|O factors|O .|O
To|O determine|O the|O expression|O levels|O of|O EVI1|O ,|O relative|O quantification|O was|O calculated|O using|O the|O equation|O 2|O -|O Delta|O Delta|O Ct|O ,|O as|O previously|O described|O .|O
ABSTRACT|O .|O
This|O comparison|O between|O the|O -|O 2|O .|O 8|O kb|O and|O -|O 1|O .|O 8|O kb|O sites|O illustrates|O how|O GATA|O motifs|O function|O uniquely|O and|O collectively|O to|O achieve|O complex|O and|O dynamic|O transcriptional|O control|O at|O the|O GATA2|O locus|O during|O hematopoietic|O development|O .|O
Again|O ,|O if|O the|O patient|O '|O s|O clinical|O condition|O has|O deteriorated|O to|O a|O point|O at|O which|O active|O therapy|O would|O be|O detrimental|O ,|O best|O supportive|O care|O may|O be|O the|O most|O appropriate|O option|O .|O
The|O analytic|O components|O include|O the|O analytic|O result|O (|O mutation|O detected|O or|O not|O detected|O )|O and|O a|O brief|O description|O of|O the|O methodology|O used|O .|O
The|O ASXL1|O (|O additional|O sex|O combs|O like|O 1|O )|O gene|O ,|O contains|O 12|O exons|O and|O maps|O to|O chromosome|O 20q11|O ,|O regulating|O epigenetic|O functions|O and|O transcription|O .|O
Researchers|O should|O be|O prepared|O to|O take|O on|O this|O difficult|O task|O ,|O since|O in|O the|O future|O ,|O novel|O low|O frequency|O mutations|O in|O other|O genes|O are|O likely|O to|O emerge|O from|O the|O sequencing|O of|O additional|O AML|O genomes|O .|O
DISCUSSION|O .|O
In|O the|O 2|O cases|O studied|O (|O patient|O number|O 6165|O and|O 6184|O )|O ,|O the|O vaccine|O antigen|O response|O was|O normal|O (|O supplemental|O Table|O 2|O )|O .|O
In|O a|O multivariable|O Cox|O regression|O model|O ,|O the|O presence|O of|O mutations|O in|O five|O genes|O retained|O independent|O prognostic|O significance|O :|O TP53|O (|O hazard|O ratio|O for|O death|O from|O any|O cause|O ,|O 2|O .|O 48|O ;|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 1|O .|O 60|O to|O 3|O .|O 84|O )|O ,|O EZH2|O (|O hazard|O ratio|O ,|O 2|O .|O 13|O ;|O 95|O %|O CI|O ,|O 1|O .|O 36|O to|O 3|O .|O 33|O )|O ,|O ETV6|O (|O hazard|O ratio|O ,|O 2|O .|O 04|O ;|O 95|O %|O CI|O ,|O 1|O .|O 08|O to|O 3|O .|O 86|O )|O ,|O RUNX1|O (|O hazard|O ratio|O ,|O 1|O .|O 47|O ;|O 95|O %|O CI|O ,|O 1|O .|O 01|O to|O 2|O .|O 15|O )|O ,|O and|O ASXL1|O (|O hazard|O ratio|O ,|O 1|O .|O 38|O ;|O 95|O %|O CI|O ,|O 1|O .|O 00|O to|O 1|O .|O 89|O )|O .|O
MATERIALS|O AND|O METHODS|O .|O
Other|O genetic|O aberrations|O (|O e|O .|O g|O .|O ,|O loss|O of|O heterozygosity|O or|O deletion|O )|O may|O also|O result|O in|O inactivation|O or|O decreased|O gene|O function|O .|O
TP53|O mutations|O are|O ubiquitously|O mutated|O in|O human|O cancers|O and|O have|O been|O clearly|O identified|O to|O be|O oncogenic|O .|O
High|O -|O dose|O cytarabine|O therapy|O during|O induction|O was|O explored|O previously|O in|O 2|O large|O cooperative|O group|O trials|O .|O
NCCN|O Categories|O of|O Evidence|O and|O Consensus|O Category|O 1|O :|O Based|O upon|O high|O -|O level|O evidence|O ,|O there|O is|O uniform|O NCCN|O consensus|O that|O the|O intervention|O is|O appropriate|O .|O
Three|O AML|O cases|O with|O cohesin|O mutations|O (|O SMC3|O ,|O STAG2|O ,|O and|O RAD21|O )|O at|O diagnosis|O achieved|O remission|O with|O cytarabine|O and|O idarubicin|O treatment|O .|O
According|O to|O the|O NCCN|O AML|O Panel|O ,|O infusional|O cytarabine|O x|O 7|O days|O combined|O with|O either|O idarubicin|O or|O escalated|O daunorubicin|O is|O a|O category|O 1|O recommendation|O .|O
A|O total|O of|O 20|O AML|O patients|O were|O analyzed|O for|O LOH|O using|O four|O microsatellite|O markers|O near|O or|O within|O the|O PTEN|O /|O MMAC1|O gene|O locus|O .|O
The|O prevalence|O of|O EZH2|O mutations|O in|O MDS|O is|O variable|O .|O
The|O functional|O consequence|O of|O these|O truncations|O is|O altered|O and|O increased|O receptor|O activity|O conferring|O ligand|O hypersensitivity|O .|O
We|O suggest|O ,|O therefore|O ,|O that|O EZH2|O mutational|O status|O should|O be|O taken|O into|O account|O in|O future|O clinical|O studies|O of|O CMML|O .|O
All|O P|O values|O were|O calculated|O with|O the|O use|O of|O two|O -|O sided|O tests|O .|O
SRSF2|O has|O also|O been|O implicated|O in|O genetic|O stability|O ,|O and|O its|O defect|O could|O lead|O to|O hypermutability|O .|O
The|O factors|O included|O in|O the|O algorithm|O are|O the|O following|O :|O body|O temperature|O (|O <|O =|O 38|O -|O -|O degrees|O -|O -|O C|O ,|O >|O 38|O -|O -|O degrees|O -|O -|O C|O )|O ,|O hemoglobin|O levels|O (|O <|O =|O 10|O .|O 3|O ,|O >|O 10|O .|O 3|O g|O /|O dL|O )|O ,|O platelet|O counts|O (|O <|O =|O 28K|O ,|O >|O 28K|O -|O <|O =|O 53K|O ,|O >|O 53K|O -|O <|O =|O 10K|O ,|O >|O 10K|O counts|O /|O mcL|O )|O ,|O fibrinogen|O levels|O (|O <|O =|O 150|O ,|O >|O 150|O mg|O /|O dL|O )|O ,|O age|O at|O diagnosis|O (|O 60|O -|O 64|O ,|O >|O 64|O -|O 67|O ,|O >|O 67|O -|O 72|O ,|O >|O 72|O years|O )|O ,|O and|O type|O of|O leukemia|O (|O de|O novo|O ,|O secondary|O )|O .|O
None|O of|O the|O AML|O cases|O had|O mutations|O .|O
The|O UK|O MRC|O study|O (|O AML|O 10|O )|O also|O reported|O no|O DFS|O or|O OS|O advantage|O with|O allogeneic|O HSCT|O among|O patients|O (|O age|O <|O 55|O years|O )|O with|O favorable|O -|O risk|O cytogenetics|O .|O
Somatic|O TET2|O mutations|O were|O initially|O reported|O in|O myeloid|O neoplasms|O ,|O including|O MDS|O in|O 2009|O .|O
The|O FLT3|O -|O TKD|O mutations|O predominantly|O occur|O independently|O of|O FLT3|O -|O ITD|O ,|O and|O most|O frequently|O involve|O mutations|O in|O the|O D835|O residue|O of|O a|O tyrosine|O kinase|O domain|O .|O
The|O main|O genes|O involved|O in|O congenital|O neutropenia|O were|O characterized|O during|O the|O last|O decade|O ,|O with|O ELANE|O being|O involved|O in|O half|O of|O them|O (|O for|O review|O ,|O see|O Donadieu|O et|O al|O )|O .|O
Abbreviations|O :|O DIPSS|O -|O plus|O ,|O dynamic|O international|O prognostic|O scoring|O system|O -|O plus|O ;|O IPSS|O ,|O international|O prognostic|O scoring|O system|O .|O Mutation|O analysis|O and|O survival|O calculations|O in|O the|O European|O cohort|O were|O performed|O from|O the|O time|O of|O diagnosis|O and|O in|O the|O Mayo|O cohort|O from|O the|O time|O of|O referral|O to|O the|O Mayo|O Clinic|O .|O
The|O major|O chromosome|O aberrations|O in|O leukemia|O are|O specific|O translocations|O juxtaposing|O genes|O that|O activate|O oncogenes|O or|O create|O novel|O fusion|O genes|O .|O
Notably|O ,|O most|O of|O the|O mutated|O splicing|O factors|O in|O MDS|O belong|O to|O the|O A|O complex|O ,|O occurring|O largely|O in|O a|O mutually|O exclusive|O manner|O ,|O strongly|O indicating|O that|O the|O common|O functional|O target|O of|O these|O mutations|O should|O be|O the|O 30|O splice|O site|O recognition|O (|O Table|O 1|O )|O .|O
In|O addition|O to|O the|O 23|O somatic|O mutations|O ,|O we|O identified|O 3|O SNPs|O (|O 2|O in|O STAG1|O and|O 1|O in|O RAD21|O )|O ,|O which|O have|O not|O been|O described|O by|O dbSNP|O and|O were|O not|O found|O in|O mononuclear|O cells|O of|O 30|O healthy|O donors|O .|O
The|O prognostic|O effect|O of|O SF3B1|O mutations|O has|O been|O investigated|O in|O several|O studies|O .|O
We|O studied|O the|O impact|O of|O driver|O mutations|O of|O JAK2|O ,|O CALR|O ,|O (|O calreticulin|O gene|O )|O or|O MPL|O on|O clinical|O course|O ,|O leukemic|O transformation|O ,|O and|O survival|O of|O patients|O with|O primary|O myelofibrosis|O (|O PMF|O )|O .|O
For|O the|O latest|O update|O ,|O visit|O NCCN|O .|O org|O .|O
It|O is|O the|O most|O common|O form|O of|O acute|O leukemia|O among|O adults|O and|O accounts|O for|O the|O largest|O number|O of|O annual|O deaths|O from|O leukemias|O in|O the|O United|O States|O .|O
In|O 2|O of|O these|O 6|O pedigrees|O (|O P3|O and|O P4|O ,|O Figure|O 1|O )|O ,|O we|O identified|O a|O GATA2|O mutation|O in|O 4|O affected|O relatives|O ,|O 1|O in|O P3|O and|O 3|O in|O P4|O .|O
Effect|O of|O spliceosomal|O mutations|O on|O clinical|O outcomes|O .|O
There|O is|O increasing|O interest|O in|O INF|O -|O alpha|O due|O to|O its|O nonleukemogenic|O potential|O ;|O however|O ,|O the|O risk|O of|O leukemic|O transformation|O with|O hydroxyurea|O and|O busulfan|O therapies|O has|O likely|O been|O overstated|O .|O
Initial|O studies|O of|O the|O role|O of|O DNMT3A|O in|O mouse|O haematopoiesis|O demonstrated|O no|O overt|O phenotype|O unless|O both|O Dnmt3a|O and|O Dnmt3b|O were|O lost|O .|O
Products|O were|O purified|O before|O sequencing|O .|O
Figure|O 5|O .|O Analysis|O of|O cohesin|O expression|O identifies|O a|O discrete|O subset|O of|O low|O expressors|O .|O (|O A|O )|O Expression|O of|O STAG2|O in|O MDS|O and|O pAML|O subtypes|O .|O A|O discrete|O subset|O of|O patients|O exhibit|O low|O STAG2|O expression|O defined|O as|O <|O 2|O standard|O deviations|O below|O the|O mean|O as|O compared|O with|O 17|O healthy|O donors|O .|O This|O was|O more|O prevalent|O in|O patients|O with|O highrisk|O MDS|O and|O non|O -|O core|O binding|O factor|O AML|O without|O complex|O cytogenetics|O .|O (|O B|O )|O Percent|O of|O low|O expressors|O in|O cohesin|O genes|O .|O The|O frequency|O of|O cohesin|O low|O expressors|O for|O each|O cohesin|O complex|O gene|O (|O STAG2|O ,|O RAD21|O ,|O SMC1A|O ,|O SMC3|O ,|O STAG1|O ,|O and|O PDS5B|O )|O is|O shown|O by|O disease|O subtype|O .|O STAG2|O was|O most|O commonly|O underexpressed|O in|O high|O -|O risk|O MDS|O ,|O whereas|O RAD21|O was|O most|O commonly|O underexpressed|O in|O the|O remaining|O myeloid|O malignancies|O .|O SD|O ,|O standard|O deviation|O .|O
However|O ,|O with|O respect|O to|O the|O clinical|O data|O ,|O a|O poor|O outcome|O was|O observed|O for|O patients|O that|O carried|O EZH2|O mutations|O compared|O with|O EZH2|O wild|O -|O type|O cases|O (|O alive|O at|O 3|O years|O :|O 33|O .|O 3|O versus|O 69|O .|O 9|O %|O ;|O P|O =|O 0|O .|O 001|O )|O as|O shown|O in|O Figure|O 1b|O .|O
Although|O the|O gain|O -|O of|O -|O function|O mutation|O in|O the|O gene|O encoding|O Janus|O kinase|O (|O JAK|O )|O 2|O (|O JAK2V617F|O )|O is|O present|O in|O approximately|O 50|O %|O of|O patients|O with|O primary|O myelofibrosis|O ,|O other|O mechanisms|O of|O direct|O or|O indirect|O activation|O of|O the|O intracellular|O JAK|O -|O signal|O transducer|O and|O activator|O of|O transcription|O (|O STAT|O )|O pathway|O are|O known|O ,|O suggesting|O that|O dysregulation|O of|O this|O pathway|O is|O a|O central|O pathogenic|O component|O in|O myelofibrosis|O ,|O regardless|O of|O the|O mutational|O status|O of|O JAK2|O .|O
The|O reaction|O was|O first|O denatured|O for|O 5|O min|O at|O 95|O -|O -|O degrees|O -|O -|O C|O and|O incubated|O at|O 37|O -|O -|O degrees|O -|O -|O C|O for|O 60|O min|O .|O
This|O makes|O the|O accurate|O prediction|O of|O the|O prognosis|O an|O essential|O component|O of|O the|O care|O of|O patients|O .|O
BCORL1|O somatic|O mutations|O were|O found|O in|O about|O 6|O %|O of|O a|O series|O of|O 173|O AML|O patients|O which|O included|O cases|O with|O secondary|O leukemia|O (|O showing|O myelodysplasia|O -|O related|O changes|O or|O being|O therapy|O -|O related|O )|O and|O a|O high|O incidence|O (|O approx|O .|O 65|O %|O )|O of|O abnormal|O karyotypes|O .|O
In|O this|O regard|O ,|O it|O is|O hoped|O that|O further|O extensive|O studies|O in|O GATA1|O and|O GATA2|O -|O related|O leukemias|O could|O contribute|O to|O the|O development|O of|O new|O therapies|O for|O human|O leukemia|O .|O
In|O general|O ,|O our|O data|O support|O the|O idea|O that|O activating|O mutations|O of|O oncogenes|O are|O relatively|O infrequent|O in|O myelodysplastic|O syndromes|O .|O
An|O understanding|O of|O the|O clinical|O effects|O of|O mutations|O in|O various|O genes|O could|O improve|O the|O prediction|O of|O prognosis|O for|O patients|O with|O myelodysplastic|O syndromes|O and|O inform|O the|O selection|O of|O specific|O therapies|O .|O
No|O advantage|O was|O observed|O with|O the|O addition|O of|O ATRA|O .|O
ChIP|O for|O EZH2|O in|O the|O presence|O and|O absence|O of|O ASXL1|O revealed|O that|O EZH2|O recruitment|O was|O markedly|O reduced|O in|O the|O absence|O of|O ASXL1|O ,|O suggesting|O that|O ASXL1|O may|O be|O important|O for|O the|O recruitment|O and|O /|O or|O stability|O of|O the|O PRC2|O complex|O in|O myeloid|O haematopoietic|O cells|O .|O
Haematopoietic|O -|O specific|O conditional|O alleles|O are|O needed|O to|O delineate|O the|O effects|O of|O somatic|O Asxl1|O loss|O in|O the|O haematopoietic|O compartment|O ;|O preliminary|O studies|O suggest|O that|O these|O mice|O develop|O myeloid|O neoplasms|O that|O are|O most|O similar|O to|O human|O MDS|O in|O vivo|O .|O
Megakaryocytes|O are|O typically|O normal|O ,|O but|O can|O include|O some|O small|O hypolobated|O megakaryocytes|O .|O
Patients|O whose|O MDS|O harbors|O SF3B1|O mutations|O often|O have|O a|O higher|O platelet|O count|O ,|O increased|O ring|O sideroblasts|O ,|O fewer|O cytopenias|O ,|O and|O lower|O blast|O count|O ,|O when|O compared|O with|O patients|O without|O SF3B1|O mutations|O .|O
Similarly|O ,|O patients|O 60|O years|O or|O older|O who|O are|O physically|O fit|O and|O wish|O to|O pursue|O treatment|O after|O relapse|O may|O be|O offered|O the|O following|O options|O :|O 1|O )|O therapy|O on|O clinical|O trial|O (|O strongly|O preferred|O option|O by|O the|O panel|O )|O ;|O or|O 2|O )|O salvage|O chemotherapy|O followed|O by|O matched|O sibling|O or|O alternate|O donor|O HSCT|O (|O again|O ,|O transplant|O should|O be|O considered|O only|O if|O the|O patient|O has|O entered|O remission|O or|O in|O the|O context|O of|O a|O clinical|O trial|O )|O ;|O or|O 3|O )|O retreatment|O with|O the|O initial|O successful|O induction|O for|O a|O patients|O with|O a|O long|O initial|O remission|O duration|O (|O ie|O ,|O relapse|O >|O 12|O months|O )|O .|O
SF3B1|O mutations|O were|O found|O in|O 68|O -|O 82|O %|O of|O refractory|O anemia|O with|O ring|O sideroblasts|O (|O RSRS|O )|O and|O 57|O -|O 76|O %|O of|O refractory|O cytopenia|O with|O ring|O sideroblasts|O (|O RCMD|O -|O RS|O )|O .|O
The|O optimism|O for|O targeted|O JAK2|O tyrosine|O kinase|O inhibitors|O has|O been|O tempered|O with|O increasing|O data|O to|O suggest|O that|O the|O oncogenic|O role|O of|O JAK2|O mutations|O may|O be|O more|O complex|O than|O for|O BCR|O -|O ABL1|O in|O CML|O .|O
While|O compromised|O 30|O splice|O site|O recognition|O seems|O to|O be|O a|O common|O consequence|O of|O different|O splicing|O factor|O mutations|O ,|O there|O exist|O strong|O genotype|O and|O phenotype|O associations|O for|O splicing|O factor|O mutations|O .|O
Biallelic|O mutations|O were|O frequently|O observed|O in|O AML|O -|O M0|O and|O in|O myeloid|O malignancies|O with|O acquired|O trisomy|O 21|O and|O trisomy|O 13|O ,|O but|O were|O rarely|O found|O in|O other|O leukemia|O subtypes|O .|O
A|O subsequent|O study|O of|O 489|O AML|O samples|O also|O found|O that|O DNMT3A|O mutations|O conferred|O poor|O prognosis|O and|O decreased|O overall|O survival|O .|O
All|O samples|O were|O barcode|O -|O tagged|O using|O 48|O .|O 48|O Access|O Array|O technology|O (|O Fluidigm|O ,|O South|O San|O Francisco|O ,|O CA|O ,|O USA|O )|O ,|O starting|O with|O 50|O ng|O genomic|O DNA|O per|O sample|O (|O PCR|O amplification|O protocol|O ,|O Supplementary|O Table|O 2|O )|O .|O
Interestingly|O ,|O the|O latter|O genotype|O mimicked|O that|O of|O the|O AML|O index|O patient|O initially|O used|O for|O whole|O -|O exome|O sequencing|O .|O
In|O a|O large|O phase|O II|O study|O from|O the|O MD|O Anderson|O Cancer|O Center|O ,|O 112|O patients|O (|O age|O >|O 60|O years|O ;|O median|O age|O ,|O 71|O years|O )|O ,|O most|O of|O whom|O had|O additional|O risk|O factors|O ,|O received|O clofarabine|O ,|O 30|O mg|O /|O m2|O intravenously|O for|O 5|O days|O .|O
JAK2|O mutation|O has|O been|O identified|O in|O BCR|O -|O ABL|O -|O negative|O myeloproliferative|O neoplasm|O ,|O myelodysplastic|O and|O myeloproliferative|O neoplasms|O (|O e|O .|O g|O .|O ,|O RARS|O -|O T|O )|O ,|O and|O a|O subset|O of|O MDS|O with|O 5q|O -|O .|O
Diagnoses|O of|O PMF|O and|O that|O of|O leukemic|O transformation|O (|O blast|O phase|O )|O were|O performed|O in|O accordance|O with|O the|O 2008|O WHO|O criteria|O .|O
Adverse|O effects|O were|O reported|O in|O 96|O %|O of|O patients|O ,|O and|O treatment|O was|O stopped|O in|O 10|O %|O of|O these|O due|O to|O toxicity|O .|O
Box|O 1|O .|O Mutations|O in|O epigenetic|O modifiers|O and|O transformation|O of|O chronic|O myeloid|O malignancies|O Myeloproliferative|O neoplasms|O (|O MPNs|O )|O are|O clonal|O disorders|O of|O haematopoiesis|O that|O are|O characterized|O by|O an|O accumulation|O of|O mature|O -|O appearing|O cells|O in|O the|O bloodstream|O and|O include|O the|O breakpoint|O cluster|O region|O (|O BCR|O )|O -|O ABL1|O -|O translocated|O disorder|O chronic|O myeloid|O leukaemia|O (|O CML|O )|O ,|O as|O well|O as|O the|O '|O classic|O '|O BCR|O -|O ABL1|O -|O negative|O MPNs|O polycythemia|O vera|O (|O PV|O )|O ,|O essential|O thrombocytosis|O (|O ET|O )|O and|O primary|O myelofibrosis|O (|O PMF|O )|O .|O Patients|O with|O CML|O or|O with|O BCR|O -|O ABL1|O -|O negative|O classic|O MPNs|O are|O at|O increased|O risk|O of|O leukaemic|O transformation|O ,|O which|O is|O associated|O with|O dismal|O clinical|O prognosis|O .|O Prior|O work|O identifying|O the|O role|O of|O nucleoporin|O 98|O (|O NUP98|O )|O -|O homeobox|O A9|O (|O HOXA9|O )|O translocations|O as|O well|O as|O the|O overexpression|O of|O musashi|O homologue|O 2|O (|O MSI2|O )|O following|O the|O leukaemic|O transformation|O of|O CML|O suggested|O a|O potential|O role|O for|O alterations|O in|O genetic|O regulators|O of|O HOXA|O cluster|O genes|O in|O leukaemic|O transformation|O of|O MPNs|O .|O Notably|O ,|O mutations|O in|O TET2|O (|O REFS|O 29|O ,|O 103|O -|O 105|O )|O and|O isocitrate|O dehydrogenase|O 1|O (|O IDH1|O )|O and|O IDH2|O (|O REFS|O 106|O ,|O 107|O )|O occur|O in|O a|O significant|O subset|O of|O patients|O with|O MPN|O that|O undergoes|O leukaemic|O transformation|O to|O acute|O myeloid|O leukaemia|O (|O AML|O )|O (|O see|O the|O table|O )|O .|O Although|O there|O is|O evidence|O that|O TET2|O may|O regulate|O the|O HOXA|O cluster|O ,|O more|O work|O needs|O to|O be|O done|O to|O determine|O its|O functional|O relevance|O in|O disease|O transformation|O .|O The|O most|O common|O genetic|O alterations|O identified|O in|O AMLs|O that|O have|O developed|O from|O chronic|O myeloid|O malignancies|O include|O mutations|O in|O epigenetic|O modifying|O genes|O as|O well|O as|O genes|O without|O known|O direct|O chromatin|O -|O modifying|O functions|O such|O as|O TP53|O ,|O KRAS|O ,|O NRAS|O ,|O CBL|O ,|O Wilms|O tumour|O 1|O (|O WT1|O )|O and|O runt|O -|O related|O transcription|O factor|O 1|O (|O RUNX1|O )|O .|O Further|O comprehensive|O genomic|O and|O epigenomic|O characterization|O of|O paired|O chronic|O -|O and|O leukaemic|O -|O phase|O patient|O samples|O will|O be|O needed|O to|O further|O elucidate|O the|O mechanisms|O of|O transformation|O from|O MPN|O or|O myelodysplastic|O syndrome|O (|O MDS|O )|O to|O AML|O ,|O and|O how|O these|O alterations|O compare|O to|O those|O observed|O in|O classical|O ,|O de|O novo|O AML|O .|O
Mutational|O and|O methylation|O studies|O of|O a|O large|O cohort|O of|O patients|O with|O AML|O demonstrated|O that|O IDH|O mutations|O and|O TET2|O mutations|O are|O mutually|O exclusive|O in|O AML|O ,|O and|O patients|O with|O mutations|O in|O either|O TET2|O ,|O or|O IDH1|O or|O IDH2|O share|O similar|O methylation|O profiles|O that|O are|O characterized|O by|O global|O promoter|O hypermethylation|O .|O
SF3B1|O mutations|O are|O prevalent|O in|O low|O -|O risk|O MDS|O with|O ring|O sideroblasts|O ,|O whereas|O U2AF1|O and|O SRSF2|O mutations|O are|O frequent|O in|O chronic|O myelomonocytic|O leukemia|O and|O advanced|O forms|O of|O MDS|O .|O
In|O our|O analysis|O ,|O the|O prognostic|O implications|O of|O mutations|O in|O the|O cohesin|O complex|O were|O not|O significant|O when|O considering|O all|O mutations|O in|O the|O complex|O together|O or|O individually|O .|O
The|O sponsor|O ,|O in|O collaboration|O with|O the|O academic|O investigators|O ,|O interpreted|O the|O data|O .|O
SETBP1|O mutations|O in|O aCML|O were|O associated|O with|O higher|O white|O blood|O cell|O counts|O at|O diagnosis|O and|O poorer|O survival|O .|O
Therefore|O ,|O G|O -|O CSFs|O or|O granulocyte|O -|O macrophage|O colony|O -|O stimulating|O factors|O should|O be|O discontinued|O for|O a|O minimum|O of|O 7|O days|O before|O bone|O marrow|O samples|O are|O assessed|O when|O documenting|O remission|O status|O .|O
Clinical|O trials|O :|O NCCN|O believes|O that|O the|O best|O management|O for|O any|O cancer|O patient|O is|O in|O a|O clinical|O trial|O .|O
The|O impact|O on|O disease|O progression|O is|O unclear|O .|O
Our|O group|O has|O also|O analyzed|O a|O series|O of|O 225|O samples|O from|O patients|O with|O AML|O and|O found|O no|O GATA2|O mutations|O in|O any|O sample|O ,|O confirming|O this|O result|O .|O
Heterozygous|O point|O mutations|O located|O in|O the|O second|O zinc|O finger|O of|O GATA2|O have|O been|O identified|O initially|O in|O 4|O families|O with|O MDS|O and|O AML|O .|O
Figure|O 1|O .|O Cumulative|O incidence|O of|O anemia|O ,|O thrombocytopenia|O ,|O and|O marked|O leukocytosis|O in|O PMF|O patients|O stratified|O according|O to|O their|O driver|O mutation|O .|O The|O thresholds|O for|O hemoglobin|O level|O and|O WBC|O count|O are|O those|O of|O the|O IPSS|O ,|O whereas|O that|O for|O PLT|O count|O is|O the|O lower|O limit|O of|O normal|O range|O .|O Cumulative|O incidences|O were|O estimated|O with|O a|O competing|O risk|O approach|O ,|O considering|O death|O for|O any|O cause|O as|O a|O competing|O event|O .|O Vertical|O tick|O marks|O indicate|O right|O -|O censored|O patients|O .|O (|O A|O )|O Cumulative|O incidence|O of|O anemia|O (|O hemoglobin|O <|O 10|O g|O /|O dL|O )|O .|O CALR|O -|O mutant|O patients|O had|O a|O lower|O incidence|O of|O anemia|O compared|O with|O the|O remaining|O patients|O (|O maximum|O P|O value|O equal|O to|O .|O 004|O )|O .|O (|O B|O )|O Cumulative|O incidence|O of|O thrombocytopenia|O (|O PLT|O count|O <|O 100|O x|O 109|O /|O L|O )|O .|O The|O cumulative|O incidence|O of|O thrombocytopenia|O was|O significantly|O lower|O in|O CALR|O -|O mutant|O patients|O compared|O with|O the|O remaining|O ones|O (|O P|O =|O .|O 001|O in|O all|O comparisons|O )|O .|O (|O C|O )|O Cumulative|O incidence|O of|O marked|O leukocytosis|O (|O WBC|O count|O >|O 25|O x|O 109|O /|O L|O )|O .|O The|O cumulative|O incidence|O of|O marked|O leukocytosis|O was|O significantly|O lower|O in|O CALR|O -|O mutant|O patients|O compared|O with|O JAK2|O -|O mutant|O (|O P|O =|O .|O 004|O )|O or|O triple|O -|O negative|O patients|O (|O P|O =|O .|O 001|O )|O .|O
A|O single|O NPM1|O mutation|O ,|O which|O localizes|O to|O the|O cytoplasm|O ,|O confers|O a|O higher|O complete|O response|O (|O CR|O )|O rate|O and|O improved|O event|O -|O free|O survival|O (|O EFS|O )|O and|O OS|O compared|O with|O patients|O with|O NK|O -|O AML|O with|O wild|O -|O type|O NPM1|O ,|O resulting|O in|O outcomes|O similar|O to|O patients|O with|O favorable|O cytogenetics|O (|O eg|O ,|O CBF|O AML|O )|O .|O
Thus|O ,|O GATA2|O is|O crucial|O for|O the|O proliferation|O and|O expansion|O of|O HSC|O and|O progenitor|O cells|O .|O
Molecular|O Markers|O and|O Risk|O Stratification|O :|O The|O intermediate|O -|O risk|O cytogenetic|O category|O is|O the|O most|O heterogeneous|O group|O in|O AML|O ,|O because|O it|O encompasses|O both|O normal|O karyotype|O without|O gross|O structural|O abnormalities|O and|O those|O with|O structural|O changes|O that|O are|O considered|O neither|O poor|O -|O risk|O or|O favorable|O .|O
In|O addition|O ,|O there|O was|O no|O difference|O between|O CR|O rates|O of|O mutated|O and|O wild|O -|O type|O patients|O (|O mutated|O 83|O %|O vs|O wild|O -|O type|O 76|O %|O ;|O P|O =|O .|O 45|O )|O .|O
Analyses|O were|O conducted|O in|O accordance|O with|O the|O intention|O -|O to|O -|O treat|O principle|O .|O
Low|O -|O risk|O MDS|O was|O defined|O as|O patients|O having|O <|O 5|O %|O myeloblasts|O .|O
He|O developed|O ,|O at|O the|O age|O of|O 18|O ,|O AML|O with|O myelodysplastic|O features|O associated|O with|O a|O der|O (|O 1|O ;|O 7|O )|O (|O q10|O ;|O p10|O )|O leading|O to|O a|O monosomy|O 7q|O and|O a|O trisomy|O 1q|O .|O
A|O global|O immunologic|O defect|O was|O identified|O with|O a|O very|O low|O number|O of|O CD14|O +|O monocytes|O ,|O CD19|O +|O B|O -|O cell|O lymphocytes|O ,|O and|O CD3|O -|O /|O CD56|O +|O NK|O cells|O ,|O along|O with|O a|O normal|O CD3|O +|O T|O -|O cell|O lymphocyte|O count|O (|O supplemental|O Table|O 2|O )|O .|O
The|O most|O common|O partner|O gene|O is|O EVI|O ,|O as|O evidenced|O by|O the|O t|O (|O 3|O ;|O 12|O )|O (|O q26|O ;|O p13|O )|O /|O EVI|O -|O ETV6|O (|O TEL|O )|O translocation|O ,|O which|O was|O initially|O reported|O in|O 4|O patients|O with|O MDS|O /|O AML|O and|O 1|O patient|O with|O CML|O in|O blast|O phase|O .|O
Clinically|O ,|O IDH|O mutations|O may|O be|O more|O commonly|O seen|O in|O older|O patients|O with|O higher|O platelet|O counts|O .|O
Notably|O ,|O the|O SET|O domain|O ,|O essential|O for|O the|O methyltransferase|O activity|O of|O EZH2|O (|O refs|O .|O 8|O -|O 10|O )|O ,|O was|O either|O altered|O or|O truncated|O in|O at|O least|O one|O allele|O in|O all|O affected|O subjects|O (|O Fig|O .|O 1b|O and|O Supplementary|O Fig|O .|O 8|O )|O .|O
No|O significant|O differences|O were|O observed|O between|O the|O intermediate|O -|O and|O high|O -|O dose|O arms|O in|O rates|O of|O CR|O (|O 80|O %|O vs|O .|O 82|O %|O )|O ,|O 5|O -|O year|O EFS|O (|O 34|O %|O vs|O .|O 35|O %|O )|O ,|O or|O 5|O -|O year|O OS|O (|O 40|O %|O vs|O .|O 42|O %|O )|O ,|O results|O that|O seem|O comparable|O to|O those|O from|O the|O CALGB|O study|O with|O high|O -|O dose|O cytarabine|O .|O
IDH1|O mutation|O was|O found|O to|O occur|O concurrently|O with|O NK|O -|O AML|O and|O NPM1|O mutations|O .|O
Mutational|O profiling|O for|O ASXL1|O ,|O EZH2|O ,|O SRSF2|O and|O IDH|O identifies|O PMF|O patients|O who|O are|O at|O risk|O for|O premature|O death|O or|O leukemic|O transformation|O .|O
The|O presence|O of|O hypomorphic|O mutations|O suggests|O that|O somatic|O alterations|O of|O cohesin|O lead|O to|O loss|O of|O function|O .|O
All|O exons|O of|O selected|O genes|O were|O amplified|O and|O underwent|O direct|O genomic|O sequencing|O by|O standard|O techniques|O on|O the|O ABI|O 3730xl|O DNA|O analyzer|O (|O Applied|O Biosystems|O )|O as|O previously|O described|O .|O
The|O reported|O DNA|O concentrations|O for|O the|O 66|O specimens|O ranged|O from|O 0|O .|O 3|O to|O 318|O ng|O /|O mL|O .|O
DIPSS|O was|O recently|O modified|O into|O DIPSS|O -|O plus|O by|O incorporating|O three|O additional|O DIPSS|O -|O independent|O risk|O factors|O :|O platelet|O count|O <|O 100|O x|O 109|O /|O l|O ,|O red|O cell|O transfusion|O need|O and|O unfavorable|O karyotype|O ;|O median|O survival|O for|O the|O low|O ,|O intermediate|O -|O 1|O ,|O intermediate|O -|O 2|O and|O high|O -|O risk|O categories|O were|O 15|O .|O 4|O ,|O 6|O .|O 5|O ,|O 2|O .|O 9|O and|O 1|O .|O 3|O years|O .|O
The|O main|O objective|O was|O to|O evaluate|O the|O prognostic|O relevance|O of|O recently|O discovered|O mutations|O in|O PMF|O in|O the|O context|O of|O currently|O used|O prognostic|O models|O .|O
RFS|O endpoints|O measured|O from|O the|O date|O of|O documented|O CR|O were|O relapse|O (|O failure|O )|O ,|O death|O in|O CR|O (|O failure|O )|O ,|O and|O alive|O in|O CR|O at|O last|O follow|O -|O up|O (|O censored|O )|O .|O
The|O most|O promising|O JAK2|O inhibitors|O are|O TG101348|O and|O INCB018424|O .|O
Similarly|O ,|O the|O benefit|O in|O OS|O outcomes|O seen|O with|O CEBPA|O mutations|O seems|O to|O be|O lost|O in|O the|O presence|O of|O concurrent|O FLT3|O -|O ITD|O .|O
To|O further|O examine|O the|O impact|O of|O driver|O mutations|O on|O the|O clinical|O course|O of|O the|O disease|O ,|O we|O subdivided|O PMF|O patients|O into|O 2|O subgroups|O according|O to|O their|O IPSS|O risk|O :|O the|O "|O lower|O -|O risk|O "|O subgroup|O included|O patients|O with|O low|O or|O intermediate|O -|O 1|O IPSS|O risk|O ,|O whereas|O the|O "|O higher|O -|O risk|O "|O subgroup|O included|O patients|O with|O intermediate|O -|O 2|O or|O high|O IPSS|O risk|O .|O
The|O same|O held|O true|O when|O all|O four|O mutations|O and|O DIPSS|O -|O plus|O were|O included|O in|O the|O multivariable|O model|O as|O covariates|O (|O HR|O :|O 1|O .|O 4|O ,|O 95|O %|O CI|O :|O 1|O .|O 0|O -|O 2|O .|O 0|O ;|O P|O =|O 0|O .|O 046|O )|O .|O
However|O ,|O preliminary|O evidence|O suggests|O that|O further|O work|O along|O these|O lines|O will|O probably|O yield|O greater|O predictive|O value|O in|O the|O near|O future|O .|O
Blood|O and|O medullar|O tests|O revealed|O mild|O neutropenia|O ;|O monocytopenia|O ;|O B|O -|O ,|O NK|O -|O ,|O and|O dendritic|O -|O cell|O deficiencies|O ;|O and|O an|O hypoplastic|O BM|O with|O a|O karyotype|O harboring|O the|O same|O chromosomal|O alteration|O observed|O in|O the|O BM|O of|O his|O brother|O ,|O a|O der|O (|O 1|O ;|O 7|O )|O (|O q10|O ;|O p10|O )|O leading|O to|O a|O partial|O monosomy|O 7q|O .|O
Significance|O was|O determined|O at|O a|O 1|O -|O sided|O alpha|O level|O of|O 0|O .|O 05|O .|O
SF3B1|O mutations|O have|O been|O commonly|O identified|O in|O MDS|O (|O 20|O %|O ,|O 72|O of|O 354|O patients|O )|O ,|O with|O particularly|O high|O frequency|O in|O patients|O with|O ring|O sideroblasts|O (|O 65|O %|O )|O and|O less|O commonly|O in|O other|O WHO|O subtypes|O .|O
The|O largest|O series|O of|O WHO|O -|O defined|O aCML|O consists|O of|O 55|O cases|O from|O an|O Italian|O cohort|O .|O
The|O NCCN|O AML|O Panel|O suggests|O that|O complementary|O diagnostic|O techniques|O can|O be|O used|O at|O the|O discretion|O of|O the|O pathology|O departments|O of|O the|O individual|O institutions|O .|O
Nichols|O et|O al|O described|O a|O family|O with|O X|O -|O linked|O dyserythropoietic|O anemia|O and|O thrombocytopenia|O due|O to|O a|O substitution|O of|O methionine|O for|O valine|O at|O amino|O acid|O 205|O of|O GATA1|O .|O
DISCUSSION|O .|O
MM|O Patnaik|O ;|O E|O Padron|O ;|O RR|O LaBorde|O ;|O TL|O Lasho|O ;|O CM|O Finke|O ;|O CA|O Hanson|O ;|O JM|O Hodnefield|O ;|O RA|O Knudson|O ;|O RP|O Ketterling|O ;|O A|O Al|O -|O kali|O ;|O A|O Pardanani|O ;|O NA|O Ali|O ;|O RS|O Komroji|O ;|O A|O Tefferi|O .|O
The|O hemoglobin|O and|O platelet|O counts|O were|O at|O the|O lower|O range|O of|O normal|O values|O with|O a|O median|O of|O 12|O .|O 5|O g|O /|O dL|O (|O 25th|O percentile|O :|O 11|O .|O 2|O ;|O 75th|O percentile|O 13|O .|O 4|O )|O and|O 152|O G|O /|O L|O (|O 25th|O percentile|O :|O 125|O ;|O 75th|O percentile|O :|O 180|O )|O ,|O respectively|O .|O
Somatic|O mutations|O may|O influence|O the|O clinical|O phenotype|O but|O are|O not|O included|O in|O current|O prognostic|O scoring|O systems|O .|O
Exon|O 12|O mutations|O are|O far|O less|O common|O ,|O present|O in|O only|O approximately|O 3|O %|O of|O PV|O cases|O .|O
A|O prospective|O phase|O II|O study|O evaluated|O the|O efficacy|O of|O reduced|O intensity|O conditioning|O followed|O by|O HCT|O in|O 103|O patients|O with|O PMF|O or|O post|O -|O PV|O /|O ET|O MF|O .|O
We|O screened|O the|O whole|O cDNA|O of|O RUNX1b|O by|O direct|O sequencing|O for|O each|O of|O the|O three|O PCR|O products|O ,|O which|O cover|O the|O entire|O coding|O sequences|O of|O RUNX1b|O .|O
Previously|O identified|O mutations|O ,|O such|O as|O janus|O kinase|O 2|O (|O JAK2|O )|O -|O V617F|O and|O fusion|O proteins|O involving|O translocation|O of|O the|O promyelocytic|O leukaemia|O (|O PML|O )|O gene|O ,|O also|O contribute|O to|O epigenetic|O modifications|O in|O myeloid|O malignancies|O .|O
Prognostic|O significance|O was|O sustained|O for|O all|O but|O IDH1|O mutations|O in|O multivariable|O analysis|O that|O included|O all|O four|O mutations|O .|O
Overall|O ,|O in|O this|O cohort|O of|O 81|O CMML|O patients|O 32|O variants|O (|O 17|O different|O )|O were|O detected|O in|O 13|O /|O 81|O cases|O (|O 16|O .|O 0|O %|O )|O for|O these|O four|O genes|O .|O
Single|O -|O nucleotide|O variants|O (|O SNVs|O )|O were|O filtered|O using|O COSMIC|O v53|O and|O dbSNP135|O databases|O for|O nonsynonymous|O variants|O with|O a|O reading|O call|O higher|O than|O 5|O ,|O leading|O to|O the|O identification|O of|O 8|O SNVs|O :|O EPHB6|O T483P|O ,|O ERN|O V458G|O ,|O GATA2|O R396Q|O ,|O IMPG2|O P1161L|O ,|O KDM5C|O V858G|O ,|O MAST4|O K2422E|O ,|O NEK11|O D87Y|O ,|O and|O TTN|O P4737R|O .|O
The|O mutation|O was|O also|O subsequently|O reported|O in|O MDS|O and|O CMML|O .|O
The|O most|O commonly|O mutated|O gene|O in|O this|O complex|O was|O STAG1|O with|O 7|O patients|O harboring|O a|O mutation|O in|O this|O gene|O .|O
As|O reference|O standards|O for|O quantitative|O JAK2|O testing|O are|O made|O available|O ,|O comparable|O results|O across|O laboratories|O can|O be|O achieved|O in|O monitoring|O treatment|O response|O and|O minimal|O residual|O disease|O .|O
Largely|O specific|O to|O myelodysplastic|O phenotypes|O ,|O these|O splicing|O factor|O mutations|O provide|O a|O potential|O clue|O to|O better|O understanding|O of|O the|O pathogenesis|O of|O MDS|O .|O
Two|O of|O our|O CMML|O patients|O had|O biallelic|O heterozygous|O mutations|O ,|O one|O carrying|O two|O missense|O mutations|O and|O the|O other|O carrying|O two|O frameshift|O mutations|O on|O separate|O alleles|O by|O cloning|O analysis|O .|O
Recently|O ,|O a|O recurring|O monoallelic|O EZH2|O point|O mutation|O in|O the|O SET|O domain|O (|O Tyr641|O ;|O Tyr646|O in|O NM|O _|O 004456|O .|O 3|O )|O leading|O to|O loss|O of|O function|O has|O been|O described|O in|O lymphomas|O .|O
Briefly|O ,|O two|O separate|O PCR|O reactions|O were|O performed|O and|O the|O primers|O used|O were|O as|O follows|O :|O (|O for|O S34|O )|O Forward|O :|O 5|O '|O -|O GGTGCTTAATACCACGGAAAA|O -|O 3|O '|O ,|O Reverse|O :|O 5|O '|O -|O AGTCGATCACCTG|O CCTCACT|O -|O 3|O '|O ;|O (|O for|O Q157|O )|O Forward|O :|O 5|O '|O -|O GCCTCGTGTGCATTCTCTG|O -|O 3|O '|O ,|O Reverse|O :|O 5|O '|O -|O CTTTTCAGTTTCGCCGTGAG|O -|O 3|O '|O .|O
In|O this|O study|O ,|O ruxolitinib|O therapy|O was|O significantly|O more|O effective|O than|O placebo|O with|O respect|O to|O all|O primary|O and|O secondary|O efficacy|O end|O points|O ,|O as|O well|O as|O in|O an|O updated|O analysis|O of|O overall|O survival|O .|O
Primary|O myelofibrosis|O (|O PMF|O )|O is|O a|O Philadelphia|O -|O negative|O myeloproliferative|O neoplasm|O (|O MPN|O )|O characterized|O by|O abnormal|O proliferation|O of|O megakaryocytes|O ,|O deposition|O of|O fibrous|O connective|O tissues|O in|O the|O bone|O marrow|O ,|O abnormal|O stem|O cell|O trafficking|O ,|O and|O extramedullary|O hematopoiesis|O (|O myeloid|O metaplasia|O )|O .|O
EZH2|O is|O an|O H3K27|O methyltransferase|O .|O
Patients|O should|O be|O monitored|O and|O assessed|O for|O nystagmus|O ,|O dysmetria|O ,|O slurred|O speech|O ,|O and|O ataxia|O before|O each|O dose|O of|O high|O -|O dose|O cytarabine|O ;|O patients|O exhibiting|O any|O neurologic|O signs|O should|O discontinue|O high|O -|O dose|O cytarabine|O ,|O and|O all|O subsequent|O cytarabine|O therapy|O must|O be|O administered|O as|O standard|O dose|O .|O
A|O larger|O study|O leveraged|O next|O -|O generation|O sequencing|O technology|O and|O determined|O the|O overall|O rate|O of|O TP53|O mutations|O to|O be|O 7|O .|O 5|O -|O 9|O .|O 4|O %|O ,|O with|O a|O much|O higher|O incidence|O in|O patients|O with|O isolated|O del|O (|O 5q|O )|O (|O 19|O %|O )|O as|O well|O as|O in|O those|O with|O complex|O cytogenetic|O abnormalities|O including|O monosomy|O 5|O and|O /|O or|O del|O (|O 5q|O )|O (|O 72|O %|O )|O .|O
C|O -|O terminal|O mutations|O have|O recently|O been|O described|O in|O a|O large|O series|O of|O MDS|O /|O AML|O in|O which|O no|O patient|O with|O CMML|O was|O included|O .|O
Additionally|O ,|O 5|O -|O hmC|O may|O lead|O to|O passive|O demethylation|O as|O DNMT1|O is|O unable|O to|O recognize|O 5|O -|O hmC|O ;|O methylation|O marks|O thus|O become|O lost|O in|O succeeding|O DNA|O replication|O cycles|O ,|O as|O newly|O incorporated|O cytosines|O in|O the|O daughter|O strand|O fail|O to|O become|O methylated|O .|O
They|O were|O aligned|O to|O hg19|O using|O STAR|O .|O
The|O identification|O of|O somatic|O mutations|O of|O calreticulin|O has|O substantially|O modified|O our|O knowledge|O of|O PMF|O .|O
Gene|O set|O enrichment|O analysis|O of|O expression|O data|O from|O DNMT3A|O -|O mutant|O compared|O with|O DNMT3A|O -|O wild|O -|O type|O AML|O patient|O samples|O identified|O altered|O expression|O of|O genes|O in|O key|O metabolic|O and|O apoptosis|O pathways|O .|O
Multiple|O steps|O were|O performed|O to|O reduce|O the|O false|O -|O positive|O rate|O within|O reported|O results|O .|O
Enriched|O libraries|O were|O tested|O for|O enrichment|O by|O quantitative|O PCR|O and|O for|O size|O distribution|O and|O concentration|O by|O an|O Agilent|O 2100|O Bioanalyzer|O .|O
In|O 2013|O ,|O somatic|O mutations|O of|O CALR|O ,|O the|O gene|O encoding|O calreticulin|O ,|O have|O been|O found|O in|O 20|O %|O to|O 25|O %|O of|O patients|O with|O essential|O thrombocythemia|O (|O ET|O )|O or|O PMF|O .|O
Even|O BRG1|O is|O present|O at|O GATA1|O regulated|O genes|O prior|O to|O their|O activation|O by|O GATA1|O .|O
Toxic|O effects|O were|O generally|O managed|O with|O dose|O modification|O .|O
n|O =|O 116|O (|O mutants|O )|O ,|O 776|O (|O WT|O )|O .|O
We|O analyzed|O the|O effect|O of|O allogeneic|O transplantation|O on|O OS|O of|O patients|O with|O cohesin|O mutations|O .|O
We|O observed|O decreased|O expression|O of|O DCK|O and|O increased|O expression|O of|O UCK|O in|O patients|O with|O cohesin|O mutations|O or|O with|O nonmutational|O suppression|O of|O cohesin|O expression|O ,|O indicating|O common|O alterations|O of|O downstream|O pathways|O (|O supplemental|O Table|O 12|O )|O .|O
In|O a|O recent|O German|O study|O that|O included|O 305|O MDS|O patients|O with|O del|O (|O 20q|O )|O ,|O 16|O .|O 3|O %|O had|O the|O ASXL1|O mutation|O ,|O which|O was|O associated|O with|O a|O shorter|O 2|O -|O year|O survival|O rate|O .|O
Fisher|O '|O s|O exact|O test|O ,|O the|O X2|O analysis|O ,|O the|O unpaired|O t|O -|O test|O and|O Wilcoxon|O '|O s|O rank|O -|O sum|O test|O were|O used|O whenever|O appropriate|O to|O make|O comparisons|O between|O groups|O .|O
Systematic|O recording|O of|O infectious|O episodes|O was|O obtained|O from|O the|O patients|O '|O written|O medical|O history|O .|O
In|O another|O study|O ,|O SRSF2|O mutations|O also|O co|O -|O occurred|O with|O RUNX1|O and|O IDH1|O mutations|O .|O
Approximately|O half|O the|O grade|O 3|O or|O 4|O thrombocytopenia|O events|O (|O 11|O of|O 20|O )|O occurred|O during|O the|O first|O 8|O weeks|O of|O treatment|O (|O Fig|O .|O S10|O in|O the|O Supplementary|O Appendix|O )|O and|O led|O to|O dose|O adjustments|O or|O brief|O treatment|O interruptions|O .|O
If|O an|O HLA|O -|O matched|O sibling|O or|O matched|O unrelated|O donor|O has|O been|O identified|O ,|O an|O allogeneic|O HSCT|O may|O salvage|O 25|O %|O to|O 30|O %|O of|O patients|O with|O induction|O failure|O .|O
METHODS|O .|O
BCOR|O and|O BCORL1|O (|O at|O Xp11|O .|O 4|O )|O encode|O a|O protein|O that|O functions|O as|O the|O corepressor|O of|O BCL6|O .|O
JH1|O ,|O the|O catalytic|O phosphokinase|O domain|O ,|O is|O located|O at|O the|O carboxyl|O terminus|O and|O induces|O phosphorylation|O of|O target|O proteins|O .|O
Currently|O ,|O mutations|O in|O DNMT3A|O ,|O IDH1|O ,|O IDH2|O or|O TET2|O seem|O to|O have|O clinical|O relevance|O to|O risk|O stratification|O and|O /|O or|O therapeutic|O relevance|O in|O patients|O with|O AML|O .|O
Adverse|O effects|O were|O mild|O and|O included|O nausea|O ,|O vomiting|O ,|O diarrhea|O ,|O anemia|O ,|O and|O asymptomatic|O increases|O in|O serum|O amylase|O ,|O lipase|O ,|O and|O transaminases|O .|O
UPN|O ,|O unique|O patient|O number|O ;|O FAB|O ,|O French|O -|O American|O -|O British|O classification|O ;|O WHO|O ,|O World|O Health|O Organization|O classification|O ;|O IPSS|O ,|O International|O Prognostic|O Scoring|O System|O ;|O N|O /|O A|O ,|O not|O analyzed|O ;|O chr|O .|O ,|O chromosome|O .|O
Follow|O -|O Up|O Testing|O .|O
Two|O patients|O with|O mutations|O in|O STAG2|O had|O missense|O mutations|O ,|O 2|O patients|O had|O frameshift|O mutations|O ,|O and|O 1|O patient|O had|O a|O nonsense|O mutation|O in|O this|O gene|O (|O Figure|O 1|O and|O supplemental|O Table|O 3|O )|O .|O
Below|O we|O will|O summarize|O some|O of|O the|O major|O functions|O of|O GATA2|O in|O this|O biological|O process|O .|O
Several|O studies|O have|O demonstrated|O an|O inferior|O overall|O survival|O in|O SRSF2|O -|O mutated|O myeloid|O neoplasms|O (|O P|O =|O 0|O .|O 01|O )|O .|O
Disease|O phenotypes|O associated|O ET|O PMF|O with|O MPL|O mutations|O include|O older|O age|O ,|O female|O gender|O ,|O lower|O hemoglobin|O level|O ,|O and|O higher|O platelet|O count|O .|O
CHROMATIN|O /|O HISTONE|O MODIFICATION|O .|O
In|O a|O European|O trial|O that|O compared|O idarubicin|O 12|O mg|O /|O m2|O x|O 3|O or|O 4|O days|O versus|O daunorubicin|O 80|O mg|O /|O m|O x|O 3|O days|O in|O patients|O between|O ages|O 50|O and|O 70|O years|O ,|O CR|O rates|O were|O 83|O %|O and|O 70|O %|O ,|O respectively|O (|O P|O =|O .|O 024|O )|O .|O
We|O used|O 2|O independent|O pipelines|O for|O identifying|O somatic|O and|O germline|O alterations|O .|O
SETBP1|O mutations|O have|O also|O been|O demonstrated|O to|O occur|O at|O the|O time|O of|O disease|O transformation|O ,|O suggesting|O that|O these|O mutations|O could|O be|O a|O mechanism|O that|O results|O in|O myeloid|O leukemic|O transformation|O from|O MDS|O and|O CMML|O .|O
To|O investigate|O whether|O these|O mutations|O were|O somatically|O acquired|O ,|O we|O analyzed|O DNA|O of|O non|O -|O neoplastic|O T|O cells|O from|O the|O same|O individuals|O .|O
Table|O 2|O .|O MPL|O Mutations|O in|O Myeloproliferative|O Neoplasms|O .|O
Conversely|O ,|O the|O use|O of|O the|O distal|O first|O exon|O (|O IS|O exon|O )|O is|O restricted|O to|O hematopoietic|O and|O neural|O tissues|O .|O
The|O trial|O protocol|O ,|O which|O describes|O in|O detail|O the|O inclusion|O and|O exclusion|O criteria|O and|O other|O information|O about|O the|O trial|O design|O ,|O as|O well|O as|O the|O statistical|O analysis|O plan|O ,|O is|O available|O at|O NEJM|O .|O org|O .|O
All|O statistical|O analyses|O considered|O clinical|O and|O laboratory|O parameters|O obtained|O at|O the|O time|O of|O referral|O to|O the|O Mayo|O Clinic|O ,|O which|O in|O most|O instances|O coincided|O with|O time|O of|O BM|O biopsy|O at|O the|O Mayo|O Clinic|O and|O study|O sample|O collection|O .|O
No|O OS|O advantage|O was|O observed|O despite|O the|O increased|O response|O to|O HMAs|O .|O
The|O CALGB|O trial|O also|O included|O maintenance|O chemotherapy|O following|O the|O consolidation|O phase|O ;|O however|O ,|O not|O all|O patients|O in|O remission|O received|O maintenance|O (|O 55|O %|O of|O patients|O in|O CR|O )|O following|O high|O -|O dose|O cytarabine|O consolidation|O .|O
Moreover|O ,|O GATA2|O directly|O upregulates|O BMP4|O expression|O ,|O binding|O to|O the|O regulatory|O elements|O present|O at|O the|O BMP4|O promoter|O .|O
No|O treatment|O is|O indicated|O for|O low|O -|O risk|O patients|O .|O
All|O these|O findings|O point|O to|O mutational|O targeting|O of|O corepressors|O as|O a|O new|O mechanism|O of|O leukemogenesis|O .|O
In|O addition|O ,|O the|O guidelines|O can|O serve|O as|O a|O reference|O guide|O for|O clinical|O practitioners|O and|O other|O health|O care|O professionals|O in|O interpretation|O and|O utilization|O of|O the|O results|O .|O
Because|O complete|O remission|O rates|O rarely|O exceed|O 70|O %|O in|O younger|O patients|O and|O 50|O %|O in|O older|O patients|O ,|O substantial|O opportunity|O exists|O for|O innovative|O clinical|O trials|O involving|O both|O patient|O populations|O .|O
Mutations|O in|O the|O cohesin|O complex|O are|O novel|O ,|O genetic|O lesions|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O that|O are|O not|O well|O characterized|O .|O
Rasburicase|O should|O be|O considered|O as|O initial|O treatment|O in|O patients|O with|O rapidly|O increasing|O blast|O counts|O ,|O high|O uric|O acid|O ,|O or|O evidence|O of|O impaired|O renal|O function|O .|O
Extrapolation|O from|O studies|O conducted|O in|O patients|O with|O PV|O may|O suggest|O commensurate|O efficacy|O of|O aspirin|O in|O patients|O with|O ET|O .|O
These|O findings|O also|O highlight|O the|O cost|O and|O the|O huge|O amount|O of|O time|O involved|O to|O investigate|O the|O functional|O and|O clinical|O aspects|O of|O genetic|O lesions|O that|O occur|O at|O a|O relatively|O low|O frequency|O in|O AML|O .|O
By|O contrast|O ,|O the|O overexpression|O of|O wildtype|O EZH2|O is|O commonly|O observed|O in|O various|O epithelial|O malignancies|O ,|O and|O increased|O EZH2|O expression|O has|O been|O shown|O to|O be|O caused|O ,|O at|O least|O in|O part|O ,|O by|O the|O loss|O of|O transcriptional|O repression|O by|O specific|O microRNAs|O including|O miR|O -|O 101|O (|O REF|O .|O 64|O )|O .|O
Figure|O 1|O .|O Mutations|O in|O CSF3R|O and|O SETBP1|O are|O common|O in|O CNL|O and|O aCML|O .|O Percentages|O of|O CSF3R|O ,|O SETBP1|O ,|O and|O JAK2|O V617F|O mutations|O in|O 29|O patients|O with|O CNL|O or|O aCML|O are|O shown|O .|O CSF3R|O mutations|O arise|O in|O 2|O classes|O ,|O nonsense|O or|O frameshift|O mutations|O that|O truncate|O the|O cytoplasmic|O tail|O (|O truncation|O mutations|O )|O and|O point|O mutations|O in|O the|O extracellular|O domain|O (|O membrane|O proximal|O mutation|O )|O ,|O and|O some|O cases|O exhibit|O both|O classes|O of|O mutations|O on|O the|O same|O allele|O (|O compound|O mutations|O )|O .|O These|O mutations|O can|O occur|O in|O isolation|O or|O in|O combination|O with|O other|O mutant|O genes|O ,|O with|O 21|O %|O of|O patients|O having|O both|O CSF3R|O and|O SETBP1|O mutations|O .|O One|O patient|O exhibited|O mutations|O in|O both|O CSF3R|O (|O G683R|O )|O and|O JAK2|O (|O V617F|O )|O ;|O however|O ,|O the|O clonality|O of|O this|O double|O mutation|O could|O not|O be|O established|O due|O to|O limited|O material|O ,|O presenting|O the|O possibility|O of|O polyclonal|O populations|O of|O tumor|O cells|O with|O distinct|O mutational|O profiles|O .|O The|O frequencies|O of|O each|O class|O of|O CSF3R|O mutation|O alone|O or|O in|O combination|O with|O SETBP1|O or|O JAK2|O are|O shown|O for|O a|O combined|O cohort|O of|O CNL|O and|O aCML|O (|O n|O =|O 29|O )|O ,|O the|O CNL|O cases|O only|O (|O n|O =|O 9|O )|O ,|O and|O the|O aCML|O cases|O only|O (|O n|O =|O 20|O )|O .|O
Events|O that|O occurred|O more|O frequently|O in|O the|O ruxolitinib|O group|O were|O ecchymosis|O ,|O dizziness|O ,|O and|O headache|O (|O predominantly|O grade|O 1|O or|O 2|O )|O (|O Table|O 2|O )|O .|O
JAK2|O (|O Janus|O kinase|O 2|O )|O ,|O located|O at|O 9p24|O ,|O belongs|O to|O the|O Janus|O kinase|O family|O and|O is|O the|O sentinel|O kinase|O in|O many|O hematopoietic|O signaling|O cascades|O .|O
The|O mammalian|O PRC1|O complex|O is|O thought|O to|O be|O composed|O of|O only|O two|O core|O members|O consisting|O of|O RING1A|O and|O RING1B|O together|O with|O one|O of|O the|O following|O :|O BMI1|O ,|O MEL18|O (|O also|O known|O as|O PCGF2|O )|O or|O NSPC1|O (|O also|O known|O as|O PCGF1|O )|O .|O
Patients|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
In|O patients|O with|O t|O (|O 8|O ;|O 21|O )|O ,|O c|O -|O KIT|O mutations|O were|O also|O associated|O with|O a|O higher|O incidence|O of|O relapse|O at|O 5|O years|O (|O 70|O %|O vs|O .|O 36|O %|O :|O P|O =|O .|O 017|O )|O ,|O but|O no|O differences|O were|O observed|O in|O 5|O -|O year|O OS|O (|O 42|O %|O vs|O .|O 48|O %|O )|O .|O
In|O our|O study|O ,|O 76|O (|O 34|O %|O )|O had|O an|O abnormal|O karyotype|O ,|O with|O prominent|O aberrations|O being|O 11|O (|O 5|O %|O )|O with|O -|O Y|O ,|O 7|O (|O 3|O %|O )|O with|O abnormalities|O of|O chromosome|O 7|O (|O monosomy|O 7|O -|O 6|O and|O del7q|O -|O 1|O )|O ,|O 16|O (|O 7|O %|O )|O with|O +|O 8|O ,|O 8|O (|O 4|O %|O )|O with|O a|O monosomal|O karyotype|O and|O 2|O (|O 1|O %|O )|O with|O a|O complex|O karyotype|O .|O
Significant|O differences|O in|O survival|O between|O the|O mutationally|O high|O -|O and|O low|O -|O risk|O disease|O groups|O were|O again|O not|O apparent|O in|O DIPSSplus|O high|O -|O risk|O disease|O (|O P|O =|O 0|O .|O 39|O )|O but|O were|O restricted|O to|O low|O plus|O intermediate|O -|O 1|O risk|O disease|O categories|O (|O P|O =|O 0|O .|O 02|O ;|O Figure|O 4b|O )|O .|O
4|O .|O TRANSCRIPTIONAL|O REGULATION|O OF|O GATA2|O .|O
Participation|O in|O a|O clinical|O trial|O investigating|O novel|O agents|O may|O also|O be|O appropriate|O for|O patients|O with|O a|O performance|O status|O score|O of|O greater|O than|O 2|O without|O significant|O comorbid|O conditions|O .|O
In|O a|O recent|O report|O of|O 122|O patients|O treated|O with|O high|O -|O dose|O cytarabine|O and|O daunorubicin|O ,|O the|O remission|O rates|O were|O strongly|O influenced|O by|O cytogenetics|O ,|O with|O CR|O rates|O of|O 87|O %|O ,|O 79|O %|O ,|O and|O 62|O %|O for|O favorable|O -|O ,|O intermediate|O -|O ,|O and|O poor|O -|O risk|O groups|O ,|O respectively|O .|O
Mutations|O in|O ASXL1|O and|O EZH2|O had|O associations|O with|O clinical|O phenotypes|O ,|O including|O overall|O survival|O ,|O that|O differed|O from|O those|O of|O TET2|O mutations|O ,|O suggesting|O that|O these|O genes|O drive|O distinct|O and|O additive|O aspects|O of|O cellular|O transformation|O to|O myelodysplastic|O syndromes|O .|O
Both|O disease|O -|O specific|O and|O individual|O patient|O factors|O are|O taken|O into|O consideration|O when|O deciding|O treatment|O .|O
Such|O decisions|O rely|O upon|O currently|O available|O prognostic|O scoring|O systems|O ,|O recently|O developed|O by|O the|O International|O Working|O Group|O for|O myeloproliferative|O neoplasm|O Research|O and|O Treatment|O (|O IWG|O -|O MRT|O )|O ,|O including|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O ,|O which|O is|O applicable|O at|O time|O of|O diagnosis|O ,|O and|O the|O dynamic|O IPSS|O (|O DIPSS|O )|O that|O can|O be|O applied|O at|O any|O time|O during|O the|O disease|O course|O .|O
This|O allows|O for|O broad|O multigene|O coverage|O in|O a|O single|O assay|O ,|O thereby|O interrogating|O all|O of|O the|O targets|O deemed|O relevant|O for|O a|O particular|O clinical|O entity|O .|O
At|O least|O 3|O functional|O domains|O have|O been|O identified|O within|O the|O GATA1|O protein|O :|O the|O N|O -|O terminal|O transactivation|O domain|O ,|O N|O -|O ZnF|O ,|O and|O C|O -|O ZnF|O .|O
Fujiwara|O et|O al|O used|O ChIP|O -|O sequencing|O to|O define|O GATA1|O and|O GATA2|O occupancy|O genome|O -|O wide|O in|O erythroid|O cells|O .|O
Studies|O regarding|O the|O importance|O of|O JAK2|O mutation|O in|O clinical|O outcomes|O in|O MDS|O are|O limited|O .|O
A|O higher|O cross|O -|O sectional|O prevalence|O among|O advanced|O cases|O suggests|O that|O both|O U2AF1|O and|O SRSF2|O constitute|O high|O -|O risk|O defects|O .|O
Presenting|O hematologic|O and|O clinical|O features|O of|O PMF|O patients|O according|O to|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O Of|O the|O 617|O patients|O studied|O ,|O 399|O (|O 64|O .|O 7|O %|O )|O carried|O JAK2|O (|O V617F|O )|O ,|O 140|O (|O 22|O .|O 7|O %|O )|O a|O CALR|O exon|O 9|O indel|O ,|O 25|O (|O 4|O .|O 0|O %|O )|O an|O MPL|O (|O W515|O )|O mutation|O ,|O and|O 53|O (|O 8|O .|O 6|O %|O )|O had|O nonmutated|O JAK2|O ,|O MPL|O ,|O and|O CALR|O (|O ie|O ,|O triple|O -|O negative|O subjects|O )|O .|O
Patients|O with|O PMF|O may|O carry|O JAK2|O (|O V617F|O )|O ,|O a|O CALR|O exon|O 9|O indel|O ,|O an|O MPL|O exon|O 10|O mutation|O ,|O or|O none|O of|O these|O genetic|O lesions|O .|O
JAK2|O .|O
We|O postulate|O that|O changes|O in|O epigenetic|O modifications|O caused|O by|O defective|O EZH2|O may|O result|O in|O tumor|O promotion|O by|O different|O mechanisms|O depending|O on|O the|O cellular|O context|O and|O the|O oncogenic|O pathways|O that|O are|O activated|O .|O
Nonetheless|O ,|O overall|O IPSS|O risk|O was|O higher|O in|O cohesin|O -|O mutated|O patients|O ,|O driven|O by|O high|O blast|O count|O ,|O suggesting|O a|O stem|O cell|O defect|O in|O the|O mutant|O clone|O .|O
Multivariate|O analysis|O has|O demonstrated|O that|O age|O ,|O complex|O karyotype|O ,|O MLL|O -|O PTD|O ,|O and|O RUNX1|O mutations|O are|O independently|O associated|O with|O poorer|O prognosis|O in|O MDS|O ,|O a|O finding|O confirmed|O in|O subsequent|O studies|O .|O
Functional|O genomic|O studies|O will|O permit|O a|O more|O comprehensive|O understanding|O of|O the|O molecular|O complexity|O of|O these|O diseases|O .|O
In|O multivariate|O analysis|O corrected|O for|O age|O ,|O CALR|O -|O mutant|O patients|O had|O better|O overall|O survival|O than|O either|O JAK2|O -|O mutant|O or|O triple|O -|O negative|O patients|O .|O
The|O second|O study|O was|O a|O phase|O II|O clinical|O trial|O that|O reported|O complete|O hematologic|O remission|O in|O 94|O .|O 6|O %|O of|O patients|O who|O received|O pegylated|O INF|O -|O alpha|O (|O 90|O -|O 135|O mu|O /|O week|O )|O after|O 31|O .|O 4|O months|O of|O median|O follow|O -|O up|O and|O 21|O .|O 4|O %|O of|O patients|O in|O complete|O molecular|O remission|O .|O
In|O this|O process|O ,|O GATA1|O and|O GATA2|O show|O dynamic|O changes|O in|O their|O expression|O profiles|O and|O these|O patterns|O are|O reciprocal|O during|O erythroid|O differentiation|O (|O Fig|O .|O 2|O )|O .|O
We|O conclude|O that|O EZH2|O is|O targeted|O by|O various|O types|O of|O deletions|O and|O mutations|O in|O MDS|O ,|O probably|O leading|O to|O loss|O of|O function|O of|O the|O gene|O .|O
Similarly|O to|O mutations|O of|O BCOR|O ,|O most|O of|O the|O alterations|O affecting|O BCORL1|O were|O nonsense|O mutations|O ,|O out|O -|O of|O -|O frame|O insertions|O /|O deletions|O or|O splice|O site|O mutations|O that|O ,|O although|O not|O resulting|O in|O clearly|O diminished|O mRNA|O levels|O of|O BCORL1|O ,|O were|O predicted|O to|O encode|O truncated|O proteins|O lacking|O the|O last|O C|O -|O terminal|O LXXLL|O nuclear|O receptor|O recruitment|O motif|O .|O
Table|O 1|O outlines|O the|O presenting|O clinical|O and|O laboratory|O features|O and|O subsequent|O events|O in|O the|O 226|O study|O patients|O with|O CMML|O ,|O stratified|O by|O PB|O and|O BM|O blasts|O .|O
In|O RAD21|O ,|O we|O found|O 2|O patients|O with|O missense|O mutations|O ,|O 1|O patient|O with|O a|O frameshift|O mutation|O ,|O and|O 1|O with|O a|O nonsense|O mutation|O (|O Figure|O 1|O and|O supplemental|O Table|O 5|O )|O .|O
Changes|O reported|O in|O our|O internal|O or|O publicly|O available|O (|O Database|O of|O Genomic|O Variants|O )|O copy|O number|O variation|O databases|O were|O considered|O nonsomatic|O and|O excluded|O .|O
We|O performed|O a|O multivariate|O Cox|O proportional|O hazard|O regression|O considering|O type|O of|O mutation|O (|O CALR|O ,|O JAK2|O ,|O MPL|O ,|O or|O none|O of|O the|O previous|O mutations|O )|O and|O each|O single|O variable|O included|O in|O the|O IPSS|O score|O at|O diagnosis|O (|O age|O >|O 65|O years|O ,|O hemoglobin|O <|O 10|O g|O /|O dL|O ,|O WBC|O count|O >|O 25|O x|O 109|O /|O L|O ,|O peripheral|O blood|O blasts|O >|O =|O 1|O %|O ,|O and|O presence|O of|O constitutional|O symptoms|O )|O .|O
However|O ,|O many|O of|O these|O mutations|O in|O MDS|O are|O observed|O to|O some|O extent|O in|O other|O myeloid|O neoplasms|O ,|O including|O AML|O and|O other|O myelproliferative|O neoplasms|O (|O MPNs|O )|O ,|O indicating|O the|O presence|O of|O common|O mechanisms|O among|O different|O myeloid|O neoplasms|O .|O
An|O estimated|O 13780|O people|O will|O be|O diagnosed|O with|O AML|O in|O 2012|O ,|O and|O 10200|O patients|O will|O die|O of|O the|O disease|O .|O
Principal|O causes|O of|O death|O in|O the|O placebo|O group|O were|O staphylococcal|O infection|O ,|O gastrointestinal|O hemorrhage|O ,|O intestinal|O perforation|O ,|O multiorgan|O failure|O ,|O pneumonia|O ,|O sepsis|O (|O in|O 2|O patients|O )|O ,|O and|O disease|O progression|O (|O in|O 4|O patients|O )|O .|O
These|O data|O suggest|O that|O in|O the|O favorablerisk|O subgroup|O of|O patients|O with|O AML|O ,|O the|O potential|O advantage|O with|O allogeneic|O HSCT|O in|O preventing|O relapse|O may|O be|O offset|O by|O high|O rates|O of|O transplant|O -|O related|O deaths|O .|O
Although|O they|O present|O overlapping|O expression|O patterns|O ,|O GATA2|O is|O expressed|O in|O HSCs|O ,|O early|O HPCs|O ,|O as|O well|O as|O erythroid|O precursor|O cells|O ,|O controlling|O early|O stages|O of|O hematopoiesis|O ,|O whereas|O GATA1|O is|O required|O for|O terminal|O maturation|O .|O
In|O the|O HOVON|O trial|O ,|O which|O randomized|O patients|O aged|O 60|O years|O and|O older|O to|O induction|O therapy|O with|O standard|O -|O dose|O cytarabine|O combined|O with|O either|O standard|O -|O dose|O daunorubicin|O (|O 45|O mg|O /|O m2|O x|O 3|O days|O ;|O n|O =|O 411|O )|O or|O dose|O -|O escalated|O daunorubicin|O (|O 90|O mg|O /|O m2|O x|O 3|O days|O ;|O n|O =|O 402|O )|O ,|O the|O CR|O rate|O was|O 54|O %|O and|O 64|O %|O ,|O respectively|O (|O P|O =|O .|O 002|O )|O .|O
In|O 1999|O ,|O the|O WHO|O developed|O a|O newer|O classification|O system|O ,|O which|O incorporates|O information|O from|O cytogenetics|O and|O evidence|O of|O dysplasia|O to|O refine|O prognostic|O subgroups|O that|O may|O define|O treatment|O strategies|O .|O
Table|O 1|O .|O Splicing|O factor|O mutations|O in|O myeloid|O neoplasms|O .|O
The|O L359V|O mutation|O and|O the|O deletion|O of|O codons|O 341|O -|O 346|O have|O been|O exclusively|O identified|O in|O myeloid|O transformation|O of|O chronic|O myeloid|O leukemias|O and|O are|O acquired|O .|O
This|O study|O was|O approved|O by|O the|O institutional|O ethics|O committee|O (|O Comitato|O di|O Bioetica|O ,|O Fondazione|O Istituto|O di|O Ricovero|O e|O Cura|O a|O Carattere|O Scientifico|O [|O IRCCS|O ]|O Policlinico|O ,|O San|O Matteo|O ,|O Pavia|O ,|O Italy|O )|O ,|O and|O by|O the|O institutional|O review|O boards|O of|O the|O remaining|O centers|O .|O
Older|O adults|O with|O newly|O diagnosed|O AML|O with|O ECOG|O performance|O status|O score|O of|O 0|O to|O 2|O ,|O with|O or|O without|O adverse|O features|O (|O such|O as|O therapy|O -|O related|O AML|O /|O prior|O MDS|O or|O unfavorable|O cytogenic|O or|O molecular|O markers|O )|O may|O be|O managed|O with|O one|O of|O the|O following|O options|O :|O clinical|O trial|O ,|O standard|O infusional|O cytarabine|O and|O anthracycline|O ;|O low|O -|O intensity|O therapy|O (|O eg|O ,|O subcutaneous|O cytarabine|O ,|O azacitidine|O ,|O or|O decitabine|O )|O ;|O or|O intermediate|O -|O intensity|O therapy|O with|O clofarabine|O (|O category|O 2B|O )|O .|O
Two|O major|O classes|O of|O activating|O FLT3|O mutations|O have|O been|O identified|O in|O patients|O with|O AML|O ,|O which|O include|O the|O internal|O tandem|O duplications|O (|O ITD|O )|O and|O tyrosine|O kinase|O domain|O (|O TKD|O )|O point|O mutations|O .|O
In|O 2006|O ,|O mutations|O in|O a|O second|O gene|O ,|O myeloproliferative|O leukemia|O virus|O oncogene|O (|O MPL|O )|O ,|O were|O identified|O in|O both|O ET|O and|O PMF|O patients|O .|O
In|O summary|O ,|O our|O results|O show|O that|O mutations|O in|O the|O cohesin|O complex|O are|O recurrent|O mutations|O in|O AML|O .|O
Frequencies|O and|O patterns|O of|O RUNX1|O mutations|O in|O patients|O with|O CMML|O .|O
For|O U2AF1|O and|O U2AF26|O we|O found|O that|O accumulation|O of|O unspliced|O transcripts|O rather|O than|O abnormal|O alternative|O splicing|O is|O the|O main|O consequence|O of|O the|O mutations|O .|O
It|O is|O hoped|O and|O expected|O that|O prospective|O therapeutic|O trials|O will|O be|O launched|O in|O the|O coming|O months|O to|O years|O to|O exploit|O these|O various|O genetic|O pathways|O ,|O in|O order|O to|O optimize|O the|O use|O of|O current|O drugs|O ,|O but|O also|O to|O develop|O unique|O ,|O patient|O -|O specific|O new|O treatments|O in|O a|O disease|O with|O a|O great|O unmet|O need|O for|O more|O effective|O therapy|O .|O
Most|O frequently|O ,|O MDS|O and|O AML|O are|O sporadic|O and|O affect|O primarily|O elderly|O patients|O with|O a|O median|O age|O more|O than|O 65|O years|O .|O
This|O then|O leads|O to|O subsequent|O activation|O of|O downstream|O tyrosine|O kinases|O and|O activation|O of|O transcription|O factors|O STAT3|O and|O STAT5|O ,|O which|O in|O turn|O leads|O to|O transformation|O of|O hematopoietic|O cells|O into|O cytokine|O -|O independent|O clones|O ,|O resulting|O in|O megakaryocytic|O hyperplasia|O and|O marrow|O fibrosis|O .|O
Interestingly|O ,|O spliceosome|O mutations|O ,|O specific|O in|O SF3B1|O ,|O were|O reported|O in|O chronic|O lymphocytic|O leukemia|O .|O
A|O low|O -|O positive|O control|O should|O be|O included|O in|O each|O run|O ,|O to|O demonstrate|O that|O the|O assay|O is|O performing|O at|O the|O level|O of|O the|O measured|O sensitivity|O .|O
Throughout|O ,|O 2|O -|O sided|O tests|O were|O used|O with|O significance|O defined|O as|O a|O <|O .|O 05|O .|O
Recently|O ,|O a|O similar|O '|O GATA|O switch|O '|O has|O been|O described|O in|O mast|O cells|O ,|O showing|O that|O it|O might|O occur|O in|O different|O cellular|O systems|O .|O
Allele|O Burden|O .|O
Cooperativity|O between|O GATA1|O and|O SCL|O occurs|O at|O regulatory|O regions|O containing|O juxtaposed|O GATA|O and|O E|O -|O box|O elements|O that|O assemble|O higher|O order|O protein|O networks|O .|O
Because|O many|O older|O patients|O have|O some|O evidence|O of|O antecedent|O myelodysplasia|O ,|O full|O normalization|O of|O peripheral|O blood|O counts|O often|O does|O not|O occur|O even|O if|O therapy|O clears|O the|O marrow|O blasts|O .|O
Technical|O details|O about|O sample|O processing|O for|O SNP|O -|O As|O were|O previously|O described|O .|O
For|O patients|O who|O present|O with|O solitary|O extramedullary|O disease|O (|O often|O referred|O to|O as|O myeloid|O sarcoma|O ,|O granulocytic|O sarcoma|O ,|O or|O chloroma|O )|O without|O overt|O marrow|O disease|O ,|O the|O initial|O treatment|O should|O still|O be|O based|O on|O systemic|O induction|O chemotherapy|O .|O
These|O likely|O include|O patient|O genetic|O background|O ,|O characteristics|O of|O the|O distinct|O CSF3R|O mutation|O (|O eg|O ,|O hematopoietic|O cell|O of|O origin|O ,|O allele|O burden|O ,|O activation|O of|O distinct|O signaling|O cascades|O )|O ,|O and|O the|O accompanying|O clonal|O architecture|O of|O these|O neoplasms|O (|O eg|O ,|O mutations|O of|O SETBP1|O ,|O JAK2|O V617F|O ,|O or|O other|O genes|O )|O .|O
Numerous|O prognostic|O models|O have|O attempted|O to|O risk|O stratify|O patients|O with|O CMML|O .|O
There|O is|O longstanding|O ,|O yet|O debatable|O evidence|O that|O a|O reduction|O in|O hematocrit|O (|O Hct|O )|O level|O to|O <|O 45|O %|O reduces|O the|O risk|O of|O vaso|O -|O occlusive|O events|O .|O
BCORL1|O mutations|O mostly|O occurred|O in|O patients|O with|O s|O -|O AML|O and|O /|O or|O with|O abnormal|O karyotype|O ,|O and|O carried|O germline|O TP53|O ,|O CEBPA|O and|O NPM1|O genes|O .|O
In|O the|O latest|O versions|O of|O these|O guidelines|O ,|O the|O panel|O has|O endeavored|O to|O incorporate|O emerging|O data|O on|O the|O influence|O of|O mutations|O in|O specific|O genes|O such|O as|O c|O -|O KIT|O ,|O FLT3|O ,|O CEBPA|O ,|O and|O NPM1|O on|O subsets|O of|O patients|O within|O a|O cytogenetic|O category|O (|O see|O "|O Risk|O Status|O Based|O on|O Cytogenetics|O and|O Molecular|O Abnormalities|O ,|O "|O on|O page|O 995|O )|O .|O
Presence|O of|O mutational|O hot|O spot|O in|O SF3B1|O ,|O SRSF2|O ,|O and|O U2AF35|O .|O
Patient|O groups|O with|O nominal|O variables|O were|O compared|O by|O X2|O -|O test|O .|O
Mechanistic|O studies|O to|O understand|O their|O functional|O and|O pathophysiological|O role|O are|O currently|O underway|O ,|O but|O our|O genetic|O data|O suggest|O that|O cohesin|O mutations|O do|O not|O contribute|O to|O hematopoietic|O transformation|O through|O altered|O chromosomal|O instability|O .|O
Table|O 1|O .|O Clinical|O and|O laboratory|O characteristics|O of|O 879|O patients|O with|O PMF|O stratified|O into|O European|O (|O n|O =|O 483|O )|O and|O Mayo|O Clinic|O (|O n|O =|O 396|O )|O cohorts|O .|O
These|O markers|O include|O FMS|O -|O like|O tyrosine|O kinase|O 3|O (|O FLT3|O )|O ,|O c|O -|O KIT|O ,|O nucleophosmin|O (|O NPM1|O )|O ,|O and|O CEBPA|O gene|O mutations|O .|O
Several|O groups|O have|O generated|O mouse|O models|O of|O TET2|O loss|O ,|O and|O in|O each|O study|O to|O date|O TET2|O loss|O resulted|O in|O disruption|O of|O haematopoietic|O differentiation|O with|O progressive|O expansion|O of|O the|O lineage|O -|O SCA1|O +|O KIT|O +|O (|O LSK|O )|O population|O ,|O which|O includes|O HSCs|O and|O multipotent|O progenitor|O cells|O .|O
To|O date|O ,|O mutation|O or|O alterations|O in|O expression|O of|O EZH1|O have|O not|O been|O found|O in|O human|O malignancies|O .|O
The|O hotspot|O region|O of|O ASXL1|O exon|O 12|O (|O n|O =|O 6|O amplicons|O )|O was|O investigated|O by|O conventional|O Sanger|O sequencing|O using|O primer|O sequences|O as|O published|O by|O Gelsi|O -|O Boyer|O et|O al|O
The|O 2|O most|O frequent|O molecular|O lesions|O with|O prognostic|O impact|O in|O patients|O with|O AML|O are|O mutations|O of|O the|O FLT3|O gene|O (|O 37|O %|O -|O 46|O %|O of|O patients|O )|O encoding|O a|O receptor|O tyrosine|O kinase|O involved|O in|O hematopoiesis|O ,|O and|O mutations|O of|O the|O NPM1|O gene|O (|O 28|O %|O -|O 35|O %|O )|O encoding|O a|O shuttling|O protein|O within|O the|O nucleolus|O .|O
Coagulopathy|O is|O fairly|O common|O at|O presentation|O in|O many|O leukemias|O ;|O it|O is|O therefore|O standard|O clinical|O practice|O to|O screen|O for|O coagulopathy|O by|O evaluating|O prothrombin|O time|O ,|O partial|O thromboplastin|O time|O ,|O and|O fibrinogen|O as|O part|O of|O the|O initial|O workup|O and|O before|O performing|O any|O invasive|O procedure|O .|O
In|O vitro|O analyses|O of|O several|O of|O these|O EZH2|O mutants|O suggest|O that|O these|O mutations|O confer|O loss|O -|O of|O -|O function|O .|O
Abbreviations|O :|O AML|O ,|O acute|O myeloid|O leukemia|O ;|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O ;|O ND|O ,|O not|O done|O .|O
Multivariable|O analysis|O confirmed|O the|O independent|O prognostic|O value|O for|O survival|O of|O distinguishing|O mutationally|O low|O from|O high|O -|O risk|O groups|O in|O the|O context|O of|O IPSS|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O cytogenetic|O risk|O stratification|O (|O P|O <|O 0|O .|O 0001|O )|O or|O both|O (|O P|O =|O 0|O .|O 04|O )|O .|O
Menghini|O et|O al|O presented|O evidence|O that|O GATA2|O is|O phosphorylated|O and|O blocked|O by|O the|O PI3K|O /|O Akt|O signal|O transduction|O pathway|O ,|O leading|O to|O an|O increase|O of|O adipose|O tissue|O differentiation|O and|O a|O reduction|O of|O adipose|O tissue|O -|O related|O inflammation|O .|O
The|O majority|O of|O the|O MPL|O mutations|O are|O found|O in|O exon|O 10|O codon|O 515|O ;|O W515L|O is|O the|O most|O common|O ,|O followed|O by|O W515K|O .|O
None|O of|O the|O four|O mutations|O detected|O in|O the|O malignant|O cells|O were|O found|O in|O these|O T|O cells|O ,|O confirming|O that|O these|O were|O acquired|O mutations|O (|O Table|O 1|O )|O .|O
This|O suggests|O that|O cohesin|O mutations|O may|O occur|O at|O a|O similarly|O early|O time|O point|O of|O leukemogenesis|O .|O
When|O taking|O into|O account|O the|O type|O of|O CALR|O mutation|O ,|O both|O patients|O with|O type|O 1|O and|O those|O with|O type|O 2|O mutation|O had|O a|O lower|O risk|O of|O thrombosis|O compared|O with|O patients|O carrying|O JAK2|O (|O V617F|O )|O (|O P|O =|O .|O 042|O and|O P|O =|O .|O 021|O ,|O respectively|O )|O .|O
However|O ,|O changes|O in|O methylation|O were|O not|O correlated|O with|O robust|O changes|O in|O gene|O expression|O .|O
Although|O karyotype|O and|O molecular|O markers|O are|O powerful|O predictors|O of|O DFS|O outcomes|O ,|O induction|O chemotherapy|O will|O be|O initiated|O before|O this|O information|O is|O available|O in|O most|O instances|O .|O
In|O addition|O ,|O the|O Dusseldorf|O scoring|O system|O identified|O elevated|O lactate|O dehydrogenase|O and|O male|O gender|O as|O negative|O prognosticators|O for|O survival|O .|O
The|O clinical|O significance|O of|O the|O majority|O of|O genetic|O events|O has|O been|O validated|O based|O on|O a|O large|O cohort|O study|O that|O identified|O mutations|O as|O predictors|O for|O risk|O stratification|O in|O MDS|O patients|O and|O biomarkers|O for|O potential|O targeted|O therapies|O .|O
Minegishi|O et|O al|O reported|O an|O inhibitory|O function|O of|O GATA2|O in|O the|O differentiation|O of|O hematopoietic|O precursor|O cells|O ,|O and|O suggested|O that|O GATA2|O may|O act|O to|O preserve|O the|O pool|O of|O immature|O cells|O .|O
Individual|O reads|O were|O 75|O bp|O long|O .|O
RNA|O splicing|O is|O a|O necessary|O process|O such|O that|O pre|O -|O messenger|O RNA|O (|O pre|O -|O mRNA|O )|O transcripts|O are|O processed|O so|O that|O introns|O are|O removed|O and|O exons|O are|O joined|O to|O form|O mature|O RNA|O .|O
The|O mutation|O L359V|O of|O GATA2|O was|O found|O in|O about|O 10|O %|O of|O the|O patients|O at|O the|O progression|O phase|O of|O chronic|O myeloid|O leukemia|O ,|O including|O accelerated|O phase|O and|O blast|O crisis|O .|O
RUNX1|O and|O CEBPA|O were|O not|O mutated|O in|O any|O member|O of|O this|O family|O (|O data|O not|O shown|O )|O .|O
The|O effect|O of|O the|O S34F|O and|O Q157P|O /|O R|O U2AF35|O mutants|O was|O also|O tested|O in|O competitive|O repopulation|O assays|O ,|O in|O which|O highly|O purified|O mouse|O hematopoietic|O stem|O cells|O (|O CD34|O -|O c|O -|O Kit|O +|O ScaI|O +|O Lin|O -|O )|O were|O transduced|O with|O each|O mutant|O and|O together|O with|O normal|O competitors|O ,|O transplanted|O into|O lethally|O irradiated|O mice|O .|O
Karyotyping|O and|O cytogenic|O profiling|O is|O increasingly|O important|O in|O evaluating|O patients|O with|O BCR|O -|O ABL1|O -|O negative|O MPN|O .|O
The|O identification|O of|O GATA2|O mutations|O in|O patients|O with|O mild|O chronic|O neutropenia|O subsequently|O evolving|O to|O MDS|O /|O AML|O suggests|O that|O it|O may|O be|O an|O early|O finding|O in|O disease|O initiation|O .|O
Figure|O 1|O .|O The|O World|O Health|O Organization|O (|O WHO|O )|O 2008|O Classification|O of|O Myeloid|O Malignancies|O and|O Associated|O Genotypic|O Abnormalities|O :|O Acute|O Myeloid|O Leukemia|O (|O AML|O )|O ;|O Myelopreliferative|O Neoplasm|O Associated|O Esosinophilia|O (|O MPN|O -|O eos|O )|O ;|O Myelodysplatic|O Syndrome|O (|O MDS|O )|O .|O MDS|O /|O MPN|O Includes|O Subtypes|O Chronic|O Myelomonocytic|O Leukemia|O (|O CMML|O )|O ,|O Juvenile|O Myelomonocytic|O Leukemia|O (|O JMML|O )|O ,|O Atypical|O Chronic|O Myeloid|O Leukemia|O -|O BCR|O -|O ABL1|O Negative|O (|O aCML|O )|O ,|O MDS|O /|O MPN|O Unspecified|O (|O MDS|O /|O MPN|O -|O u|O )|O ,|O Which|O Includes|O the|O Refractory|O Anemia|O With|O Ring|O Sideblasts|O and|O Thrombocytosis|O (|O RARS|O -|O T|O )|O .|O MPN|O Includes|O Nonclassic|O Subtypes|O Chronic|O Neutrophilic|O Leukemia|O (|O CNL|O )|O ,|O Chronic|O Eosinophilic|O Leukemia|O (|O CEL|O )|O ,|O Systemic|O Mastocytosis|O (|O SM|O )|O ,|O and|O MPN|O Unspecified|O (|O MPN|O -|O u|O )|O .|O Classic|O Subtypes|O Include|O Chronic|O Myeloid|O Leukemia|O -|O BCR|O -|O ABL1|O positive|O (|O CML|O )|O ,|O Polycythemia|O Vera|O (|O PV|O )|O ,|O Essential|O Thrombocythemia|O (|O ET|O )|O ,|O and|O Primary|O Myelofibrosis|O (|O PMF|O )|O .|O
Consequently|O ,|O one|O might|O predict|O that|O GATA2|O and|O the|O SCL|O /|O TAL1|O complex|O commonly|O co|O -|O occupy|O and|O function|O through|O such|O composite|O elements|O in|O vivo|O .|O
APL|O is|O a|O genetically|O distinct|O subtype|O of|O AML|O that|O is|O most|O commonly|O associated|O with|O a|O recurrent|O chromosomal|O translocation|O fusing|O the|O promyelocytic|O leukaemia|O (|O PML|O )|O gene|O to|O retinoic|O acid|O receptor|O -|O alpha|O (|O RARA|O )|O .|O
We|O examined|O the|O other|O members|O of|O the|O family|O (|O mother|O ,|O father|O ,|O the|O 2|O other|O sons|O ,|O maternal|O grandfather|O ,|O maternal|O grandmother|O ,|O and|O maternal|O cousins|O )|O for|O the|O presence|O of|O these|O variations|O .|O
If|O a|O diagnosis|O of|O PMF|O or|O ET|O is|O entertained|O ,|O then|O MPL|O analysis|O should|O be|O performed|O in|O the|O setting|O of|O a|O negative|O JAK2|O V617F|O assay|O ,|O if|O required|O to|O meet|O World|O Health|O Organization|O diagnostic|O criteria|O .|O
Mutations|O in|O ASXL1|O ,|O IDH1|O ,|O IDH2|O ,|O CBL|O ,|O IKAROS|O ,|O and|O LNK|O genes|O have|O all|O been|O described|O with|O variable|O frequencies|O in|O MPN|O .|O
The|O activated|O JAK2|O causes|O phosphorylation|O of|O STATs|O ,|O which|O then|O dimerize|O and|O translocate|O to|O the|O nucleus|O ,|O where|O they|O regulate|O gene|O transcription|O .|O
DNA|O REPAIR|O /|O TUMOR|O SUPPRESSOR|O .|O
Several|O non|O -|O finger|O domains|O of|O GATA2|O have|O been|O described|O :|O two|O transactivation|O domains|O (|O TAD|O )|O ,|O located|O in|O the|O N|O -|O and|O C|O -|O terminal|O regions|O ;|O a|O nuclear|O localization|O signal|O (|O NLS|O )|O ;|O a|O negative|O regulatory|O domain|O (|O NRD|O )|O ;|O and|O regions|O that|O appear|O to|O be|O important|O for|O its|O degradation|O .|O
We|O included|O the|O information|O as|O to|O SF3B1|O mutation|O status|O of|O 39|O cases|O reported|O in|O our|O previous|O study|O .|O
However|O ,|O several|O lines|O of|O evidence|O suggest|O that|O there|O are|O leukaemia|O disease|O alleles|O that|O cannot|O be|O classified|O into|O this|O widely|O accepted|O two|O -|O hit|O model|O of|O myeloid|O leukaemogenesis|O .|O
PCR|O products|O were|O electrophoresed|O on|O a|O 2|O %|O agarose|O gel|O ,|O gel|O -|O purified|O with|O a|O MinElute|O Gel|O Extraction|O kit|O (|O Qiagen|O ,|O Hilden|O ,|O Germany|O )|O and|O sequenced|O in|O both|O directions|O with|O BigDye|O Terminators|O v3|O .|O 1|O Cycle|O Sequencing|O kits|O on|O an|O automated|O ABI|O PRISM|O 3730|O DNA|O Analyzer|O (|O Applied|O Biosystems|O Inc|O .|O ,|O Foster|O City|O ,|O CA|O ,|O USA|O )|O ,|O according|O to|O the|O manufacturer|O '|O s|O instructions|O .|O
Table|O 1|O .|O Frequency|O of|O Mutation|O and|O Association|O with|O Median|O Survival|O .|O
No|O specimen|O was|O negative|O for|O all|O 12|O laboratories|O ,|O again|O presumably|O reflecting|O poorer|O reproducibility|O at|O the|O low|O end|O and|O possibly|O indicating|O high|O sensitivity|O (|O which|O could|O result|O in|O false|O -|O positive|O results|O )|O .|O
These|O data|O underscore|O the|O importance|O of|O aberrant|O epigenetic|O programming|O in|O the|O biology|O of|O myeloid|O malignancies|O .|O
INTRODUCTION|O .|O
All|O patients|O studied|O during|O remission|O lost|O the|O mutation|O at|O this|O time|O point|O .|O
On|O the|O contrary|O ,|O despite|O the|O fact|O that|O calreticulin|O mutations|O involve|O high|O platelet|O counts|O also|O in|O PMF|O ,|O the|O risk|O of|O thrombosis|O of|O these|O patients|O is|O relatively|O low|O ,|O at|O least|O compared|O with|O that|O of|O JAK2|O -|O mutant|O patients|O .|O
Both|O BCOR|O and|O BCORL1|O genes|O are|O located|O on|O the|O X|O -|O chromosome|O and|O encode|O for|O large|O nuclear|O proteins|O that|O are|O ubiquitously|O expressed|O in|O human|O tissues|O .|O
Such|O an|O indirect|O alteration|O of|O key|O proteins|O known|O to|O be|O involved|O in|O malignant|O transformation|O could|O explain|O the|O leukemogenic|O effects|O of|O spliceosomal|O mutations|O ,|O in|O particular|O how|O spliceosomal|O mutations|O may|O result|O in|O a|O phenocopy|O of|O features|O associated|O with|O known|O TSG|O mutations|O .|O
The|O amino|O terminus|O of|O DNMT3A|O contains|O both|O PWWP|O and|O ADD|O domains|O that|O recognize|O histone|O H3|O lysine|O modifications|O and|O recruit|O the|O protein|O to|O specific|O gene|O targets|O (|O reviewed|O in|O REF|O .|O 19|O )|O .|O
Moreover|O ,|O mutations|O and|O in|O -|O frame|O translocations|O of|O MLL|O are|O now|O known|O to|O result|O in|O malignant|O transformation|O directly|O through|O alterations|O in|O post|O -|O translational|O histone|O modification|O (|O see|O REF|O .|O 91|O for|O an|O excellent|O review|O on|O MLL|O )|O .|O
Alan|O H|O .|O Shih|O ;|O Omar|O Abdel|O -|O Wahab|O ;|O Jay|O P|O .|O Patel|O ;|O Ross|O L|O .|O Levine|O .|O
DNMT3A|O and|O its|O homologue|O DNMT3B|O are|O responsible|O for|O initiating|O de|O novo|O DNA|O methylation|O ;|O by|O contrast|O ,|O DNMT1|O maintains|O methylation|O through|O cell|O division|O .|O
Two|O large|O cohort|O studies|O have|O indicated|O that|O TET2|O mutations|O do|O not|O impact|O overall|O survival|O while|O another|O study|O showed|O that|O patients|O with|O mutant|O TET2|O experienced|O a|O superior|O overall|O survival|O when|O compared|O with|O well|O -|O matched|O wild|O -|O type|O controls|O .|O
BCOR|O and|O BCORL1|O .|O
Outcomes|O from|O multiple|O cycles|O of|O high|O -|O dose|O cytarabine|O consolidation|O are|O comparable|O to|O results|O with|O autologous|O HSCT|O .|O
We|O also|O screened|O for|O homozygous|O deletion|O at|O PTEN|O /|O MMAC1|O gene|O by|O PCR|O amplification|O of|O all|O exons|O ,|O but|O no|O homozygous|O deletion|O was|O observed|O in|O any|O of|O the|O AML|O cases|O or|O 5|O cell|O lines|O .|O
The|O conflicting|O findings|O from|O the|O above|O studies|O require|O further|O investigation|O .|O
As|O expected|O ,|O promoters|O of|O genes|O that|O are|O required|O for|O specific|O haematopoietic|O cell|O fates|O are|O often|O demethylated|O as|O progenitor|O cells|O differentiate|O ,|O whereas|O genes|O that|O are|O responsible|O for|O maintaining|O a|O stem|O or|O progenitor|O state|O such|O as|O meis|O homeobox|O 1|O (|O MEIS1|O )|O and|O homeobox|O A9|O (|O HOXA9|O )|O become|O increasingly|O methylated|O with|O differentiation|O .|O
Differentiation|O of|O HPCs|O is|O highly|O dependent|O on|O the|O precise|O timing|O and|O levels|O of|O expression|O of|O GATA|O factors|O and|O combinations|O of|O different|O regulators|O ,|O such|O as|O PU|O .|O 1|O ,|O EPO|O ,|O and|O ETS1|O .|O
INTRODUCTION|O .|O
When|O cells|O /|O DNA|O are|O exposed|O to|O carcinogens|O ,|O acquisition|O of|O 5hmC|O and|O loss|O of|O 5mC|O occur|O in|O the|O promoter|O regions|O of|O these|O genes|O ,|O ultimately|O resulting|O in|O an|O aberrant|O methylation|O pattern|O found|O in|O tumor|O cells|O .|O
Identical|O somatic|O activating|O mutations|O of|O GNAS|O have|O been|O identified|O in|O several|O types|O of|O solid|O tumors|O but|O not|O in|O hematologic|O cancers|O .|O
With|O either|O high|O -|O or|O standard|O -|O dose|O cytarabinebased|O induction|O for|O younger|O patients|O ,|O between|O 20|O %|O and|O 45|O %|O of|O these|O patients|O will|O not|O enter|O remission|O .|O
We|O also|O found|O that|O missense|O mutations|O of|O RUNX1|O preferentially|O (|O 89|O %|O )|O located|O in|O the|O RHD|O .|O
Somatic|O mutations|O in|O other|O cohesin|O genes|O (|O SMC1A|O ,|O PDS5B|O ,|O WAPAL|O ,|O MAU2|O ,|O REC8|O ,|O NIPBL|O ,|O SMC5|O ,|O and|O ESCO2|O )|O were|O present|O in|O <|O .|O %|O of|O our|O cohort|O (|O Figure|O 1|O and|O supplemental|O Tables|O 2|O -|O 4|O )|O .|O
To|O date|O ,|O biological|O consequences|O of|O splicing|O factor|O mutations|O have|O been|O tested|O only|O for|O U2AF35|O mutants|O .|O
All|O final|O reports|O must|O address|O preanalytic|O ,|O analytic|O ,|O and|O postanalytic|O components|O .|O
All|O cohesin|O mutations|O were|O heterozygous|O in|O nature|O except|O for|O mutations|O in|O STAG2|O and|O SMC1A|O ,|O which|O are|O located|O on|O chromosome|O X|O and|O thus|O result|O in|O the|O absence|O of|O expression|O of|O a|O wild|O -|O type|O (|O WT|O )|O allele|O .|O
With|O the|O availability|O of|O a|O broad|O selection|O of|O test|O methods|O ,|O laboratories|O may|O find|O it|O challenging|O to|O select|O the|O methodology|O and|O platform|O most|O suitable|O for|O their|O practice|O .|O
However|O ,|O there|O is|O a|O concern|O that|O some|O laboratories|O may|O have|O had|O a|O high|O true|O false|O -|O positive|O rate|O ,|O because|O one|O laboratory|O had|O a|O positive|O result|O that|O was|O not|O detected|O by|O any|O other|O laboratory|O .|O
Rarely|O ,|O double|O MPL|O mutations|O occurring|O in|O cis|O of|O exon|O 10|O have|O been|O identified|O .|O
Clinical|O trials|O conducted|O by|O the|O Polycythemia|O Vera|O Study|O Group|O support|O the|O use|O of|O hydroxyurea|O in|O conjunction|O with|O aspirin|O in|O patients|O with|O high|O -|O risk|O PV|O .|O
The|O incidence|O of|O acute|O GVHD|O all|O grades|O was|O 38|O %|O and|O chronic|O GVHD|O was|O 49|O %|O .|O
These|O patients|O appear|O to|O also|O have|O a|O longer|O event|O -|O free|O survival|O .|O
Other|O candidate|O genes|O currently|O being|O evaluated|O for|O prognostic|O importance|O include|O TET2|O and|O RUNX1|O .|O
STRs|O were|O amplified|O by|O PCR|O (|O primer|O sequences|O are|O provided|O in|O supplemental|O Table|O 1|O )|O and|O analyzed|O by|O GeneScan|O analysis|O performed|O on|O an|O Applied|O Biosystems|O 3130XL|O .|O
In|O addition|O ,|O contrary|O to|O the|O aforementioned|O models|O ,|O we|O found|O that|O a|O high|O AMC|O was|O independently|O associated|O with|O a|O shortened|O OS|O .|O
Figure|O 6|O .|O Unsupervised|O hierarchical|O clustering|O of|O gene|O expression|O with|O annotation|O by|O cohesin|O mutational|O status|O and|O cohesin|O expression|O .|O (|O A|O )|O Unsupervised|O hierarchical|O clustering|O of|O TCGA|O AML|O patients|O with|O annotation|O of|O STAG2|O low|O expression|O and|O STAG2|O mutation|O .|O Patients|O with|O STAG2|O mutations|O and|O low|O STAG2|O expression|O cluster|O show|O a|O unique|O expression|O profile|O and|O cluster|O separately|O from|O patients|O with|O WT|O STAG2|O and|O high|O expression|O .|O (|O B|O )|O Cohesin|O complex|O expression|O in|O STAG2|O (|O i|O )|O ,|O RAD21|O (|O ii|O )|O ,|O and|O SMC3|O (|O iii|O )|O low|O expressors|O .|O Within|O each|O group|O of|O cohesin|O low|O expressors|O ,|O the|O entire|O cohesin|O family|O gene|O complex|O has|O similarly|O decreased|O expression|O .|O
Initial|O treatment|O based|O on|O G|O -|O CSF|O and|O corticosteroids|O showed|O a|O moderate|O efficacy|O on|O neutropenia|O .|O
JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O analysis|O .|O
It|O has|O been|O found|O that|O an|O N|O -|O terminally|O truncated|O version|O of|O FOG1|O is|O produced|O from|O an|O internal|O ATG|O ,|O and|O that|O this|O isoform|O (|O designated|O FOG1S|O )|O lacks|O the|O NuRD|O -|O binding|O domain|O ,|O altering|O the|O complexes|O with|O which|O it|O interacts|O .|O
ASXL1|O mutations|O had|O no|O effect|O on|O the|O OS|O (|O P|O =|O 0|O .|O 37|O )|O or|O leukemia|O free|O survival|O (|O 0|O .|O 09|O )|O (|O Table|O 3|O and|O Figure|O 1|O )|O .|O
However|O ,|O all|O these|O mutations|O accounted|O for|O a|O minor|O proportion|O of|O patients|O with|O CMML|O .|O
EZH2|O mutations|O were|O spread|O over|O several|O exons|O ,|O but|O predominantly|O were|O located|O in|O the|O four|O conserved|O regions|O and|O ,|O in|O particular|O ,|O 6|O /|O 10|O mutations|O were|O located|O in|O the|O conserved|O catalytic|O SET|O (|O enhancer|O of|O zeste|O and|O trithorax|O )|O domain|O (|O amino|O acids|O 618|O -|O 751|O )|O ,|O essential|O for|O the|O methyltransferase|O activity|O of|O EZH2|O (|O Supplementary|O Table|O 4|O )|O .|O
All|O together|O ,|O these|O data|O suggest|O that|O PRC2|O alterations|O seem|O to|O be|O haploinsufficient|O in|O the|O pathogenesis|O of|O myeloid|O malignancies|O .|O
We|O did|O not|O identify|O any|O other|O clinically|O relevant|O differences|O in|O the|O distribution|O of|O cohesin|O defects|O .|O
IDH1|O and|O IDH2|O mutations|O were|O initially|O identified|O in|O patients|O with|O low|O -|O grade|O glioma|O and|O a|O subpopulation|O of|O glioblastoma|O multiforme|O (|O GBM|O )|O ,|O in|O which|O a|O more|O favorable|O prognosis|O may|O be|O shown|O .|O
Other|O codon|O 515|O mutations|O include|O W515A|O and|O W515R|O .|O
The|O mutual|O exclusivity|O of|O pairs|O of|O mutations|O was|O estimated|O with|O two|O -|O by|O -|O two|O contingencies|O tables|O and|O Fisher|O '|O s|O exact|O test|O .|O
Given|O the|O structural|O similarity|O between|O D|O -|O 2HG|O and|O alpha|O -|O KG|O ,|O D|O -|O 2HG|O is|O considered|O a|O putative|O oncometabolite|O by|O being|O a|O competitive|O inhibitor|O to|O alpha|O -|O KG|O -|O dependent|O dioxygenases|O .|O
In|O this|O study|O ,|O we|O aimed|O to|O further|O characterize|O this|O defined|O cohort|O of|O CMML|O patients|O by|O studying|O five|O additional|O genes|O :|O IDH1|O ,|O IDH2|O ,|O NPM1|O ,|O ASXL1|O and|O EZH2|O .|O
However|O ,|O treatment|O -|O related|O morbidity|O and|O mortality|O were|O higher|O in|O the|O high|O -|O dose|O cytarabine|O arm|O ;|O the|O 5|O -|O year|O OS|O rates|O were|O 33|O %|O in|O the|O high|O -|O dose|O arm|O compared|O with|O 25|O %|O with|O the|O standard|O dose|O .|O
This|O is|O evident|O from|O genomic|O studies|O on|O patient|O samples|O of|O myeloid|O malignancies|O ,|O as|O well|O as|O of|O T|O cell|O acute|O lymphoblastic|O leukaemia|O (|O T|O -|O ALL|O )|O ,|O in|O which|O mutations|O in|O PRC2|O components|O are|O more|O frequent|O than|O in|O myeloid|O malignancies|O .|O
ETO2|O ,|O a|O SCL|O associated|O protein|O with|O the|O potential|O for|O transcription|O repression|O ,|O is|O also|O absent|O from|O GATA1|O -|O repressed|O genes|O but|O ,|O unlike|O SCL|O ,|O fails|O to|O accumulate|O at|O GATA1|O -|O activated|O genes|O .|O
Signal|O transduction|O N|O -|O RAS|O ,|O K|O -|O RAS|O ,|O and|O H|O -|O RAS|O are|O three|O key|O members|O of|O the|O RAS|O family|O .|O
Therefore|O ,|O as|O shown|O in|O Figure|O 1a|O ,|O in|O total|O 81|O .|O 5|O %|O of|O cases|O harbored|O at|O least|O one|O molecular|O aberration|O (|O range|O :|O 1|O -|O 7|O )|O with|O a|O median|O of|O two|O genes|O being|O mutated|O (|O range|O :|O 1|O -|O 5|O )|O .|O
Whole|O -|O exome|O sequencing|O and|O targeted|O multiamplicon|O deep|O sequencing|O .|O
Patients|O with|O antecedent|O hematologic|O disease|O or|O treatment|O -|O related|O secondary|O leukemia|O are|O considered|O poor|O -|O risk|O ,|O unless|O they|O have|O favorable|O cytogenetics|O ,|O such|O as|O t|O (|O 8|O ;|O 21|O )|O ,|O inv|O (|O 16|O )|O ,|O t|O (|O 16|O ;|O 16|O )|O ,|O or|O t|O (|O 15|O ;|O 17|O )|O .|O
Hematopoiesis|O involves|O an|O elaborate|O regulatory|O network|O of|O transcription|O factors|O that|O coordinates|O the|O expression|O of|O multiple|O downstream|O genes|O ,|O and|O maintains|O homeostasis|O within|O the|O hematopoietic|O system|O through|O the|O accurate|O orchestration|O of|O cellular|O proliferation|O ,|O differentiation|O and|O survival|O .|O
Chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O is|O a|O clonal|O hematopoietic|O malignancy|O characterized|O by|O myeloproliferative|O or|O myelodysplastic|O features|O .|O
The|O randomized|O French|O ALFA|O -|O 9801|O study|O (|O N|O =|O 468|O )|O showed|O that|O idarubicin|O induction|O (|O the|O standard|O 12|O mg|O /|O m2|O x|O 3|O days|O or|O intensified|O with|O 12|O mg|O /|O m2|O x|O 4|O days|O )|O compared|O with|O high|O -|O dose|O daunorubicin|O (|O up|O to|O 80|O mg|O /|O m2|O )|O yielded|O a|O significantly|O higher|O CR|O rate|O in|O patients|O aged|O 50|O to|O 70|O years|O (|O 80|O %|O vs|O .|O 70|O %|O ,|O respectively|O ;|O P|O =|O .|O 03|O )|O .|O
Interestingly|O ,|O GATA2|O has|O been|O identified|O as|O a|O novel|O susceptibility|O gene|O for|O coronary|O artery|O disease|O .|O
These|O are|O broadly|O categorized|O into|O mutations|O involving|O epigenetic|O regulators|O (|O EZH2|O ,|O ASXL1|O ,|O TET2|O ,|O DNMT3A|O ,|O IDH1|O and|O IDH2|O )|O ,|O spliceosome|O components|O (|O SF3B1|O ,|O SRSF2|O ,|O U2AF35|O and|O ZRSR2|O )|O ,|O DNA|O -|O damage|O response|O genes|O (|O TP53|O )|O and|O transcription|O regulators|O and|O signaling|O molecules|O (|O JAK2|O ,|O KRAS|O ,|O NRAS|O ,|O NPM1|O and|O RUNX1|O )|O .|O
The|O BCL6|O /|O BCOR|O co|O -|O repressor|O complex|O plays|O an|O important|O role|O in|O early|O embryonic|O development|O .|O
Univariate|O analysis|O identified|O ASXL1|O (|O HR|O :|O 2|O .|O 0|O ,|O 95|O %|O CI|O :|O 1|O .|O 5|O -|O 2|O .|O 7|O ;|O P|O <|O 0|O .|O 0001|O )|O ,|O SRSF2|O (|O HR|O :|O 1|O .|O 6|O ,|O 95|O %|O CI|O :|O 1|O .|O 1|O -|O 2|O .|O 4|O ;|O P|O =|O 0|O .|O 01|O )|O ,|O EZH2|O (|O HR|O :|O 1|O .|O 9|O ,|O 95|O %|O CI|O :|O 1|O .|O 1|O -|O 3|O .|O 4|O ;|O P|O =|O 0|O .|O 03|O )|O and|O IDH1|O (|O HR|O :|O 2|O .|O 5|O ,|O 95|O %|O CI|O :|O 1|O .|O 1|O -|O 5|O .|O 6|O ;|O P|O =|O 0|O .|O 02|O )|O mutations|O as|O being|O prognostically|O detrimental|O for|O survival|O .|O
Morbidity|O and|O mortality|O in|O PV|O and|O ET|O is|O related|O to|O thrombophilia|O and|O ,|O along|O with|O PMF|O ,|O the|O progression|O to|O acute|O leukemia|O .|O
Less|O conspicuously|O ,|O SF3B1|O mutations|O were|O confined|O to|O 5|O -|O 7|O amino|O acid|O positions|O within|O the|O domains|O corresponding|O to|O exons|O 14|O -|O 15|O ,|O of|O which|O *|O 50|O %|O of|O the|O mutations|O were|O accounted|O for|O the|O K700E|O .|O
A|O mechanism|O that|O repairs|O damaged|O DNA|O throughout|O the|O cell|O cycle|O .|O
Of|O note|O ,|O Hoshino|O et|O al|O reported|O the|O generation|O and|O analysis|O of|O Gata2|O hypomorphic|O mutant|O mice|O that|O resembles|O human|O congenital|O anomalies|O of|O the|O kidney|O and|O urinary|O tract|O .|O
Most|O patients|O who|O received|O ruxolitinib|O had|O improvement|O in|O symptoms|O ;|O the|O majority|O of|O patients|O who|O received|O placebo|O had|O worsening|O of|O symptoms|O (|O Fig|O .|O 2B|O )|O .|O
The|O currently|O used|O scores|O for|O survival|O prognostication|O in|O PMF|O include|O IPSS|O ,|O DIPSS|O and|O DIPSS|O -|O plus|O ;|O the|O latter|O incorporates|O karyotype|O ,|O consistent|O with|O the|O major|O prognostic|O contribution|O of|O karyotype|O in|O other|O myeloid|O malignancies|O including|O AML|O and|O MDS|O .|O
In|O an|O analysis|O of|O patients|O with|O CBF|O AML|O treated|O on|O CALGB|O trials|O (|O n|O =|O 110|O )|O ,|O c|O -|O KIT|O mutations|O among|O patients|O with|O inv|O (|O 16|O )|O were|O associated|O with|O a|O higher|O cumulative|O incidence|O of|O relapse|O at|O 5|O years|O (|O 56|O %|O vs|O .|O 29|O %|O ;|O P|O =|O .|O 05|O )|O and|O decreased|O 5|O -|O year|O OS|O rate|O (|O 48|O %|O vs|O .|O 68|O %|O )|O compared|O with|O wild|O -|O type|O cKIT|O ;|O in|O multivariate|O analysis|O ,|O the|O presence|O of|O c|O -|O KIT|O mutations|O remained|O a|O significant|O predictor|O of|O decreased|O OS|O in|O the|O subgroup|O with|O inv|O (|O 16|O )|O .|O
The|O use|O of|O immunophenotyping|O and|O molecular|O markers|O to|O monitor|O minimal|O residual|O disease|O (|O MRD|O )|O in|O adult|O AML|O has|O not|O yet|O been|O incorporated|O into|O postremission|O monitoring|O strategies|O ,|O except|O in|O patients|O with|O APL|O .|O
GATA|O factors|O also|O act|O sequentially|O to|O regulate|O lineage|O determination|O during|O hematopoiesis|O by|O exerting|O variable|O repressive|O effects|O at|O the|O PU|O .|O 1|O locus|O .|O
Recently|O ,|O mutations|O in|O a|O gene|O encoding|O a|O spliceosomal|O protein|O ,|O SF3B1|O ,|O were|O discovered|O in|O a|O distinct|O form|O of|O MDS|O with|O ring|O sideroblasts|O .|O
In|O an|O international|O study|O of|O 1054|O patients|O with|O PMF|O ,|O the|O overall|O median|O survival|O was|O found|O to|O be|O 5|O .|O 8|O years|O ,|O but|O considerable|O variability|O was|O observed|O .|O
The|O cohesin|O complex|O presents|O a|O novel|O pathway|O affected|O by|O recurrent|O mutations|O in|O AML|O .|O
Secondary|O AML|O ,|O either|O related|O to|O prior|O myelodysplasia|O or|O prior|O chemotherapy|O ,|O also|O increases|O ,|O along|O with|O a|O higher|O rate|O of|O multidrug|O resistance|O protein|O expression|O .|O
In|O addition|O to|O the|O discovery|O in|O patients|O with|O myeloid|O malignancies|O of|O mutations|O in|O genes|O that|O primarily|O function|O in|O regulating|O DNA|O methylation|O or|O post|O -|O translational|O histone|O modifications|O ,|O various|O previously|O characterized|O class|O I|O and|O class|O II|O alleles|O have|O recently|O been|O found|O to|O affect|O the|O epigenome|O as|O part|O of|O their|O transforming|O activity|O .|O
METHODS|O .|O
Mutant|O SF3B1|O has|O been|O postulated|O to|O down|O -|O regulate|O several|O key|O gene|O networks|O essential|O in|O mitochondrial|O pathways|O .|O
Spleen|O Size|O .|O
Only|O 1|O patient|O with|O favorable|O cytogenetics|O had|O a|O mutation|O in|O a|O cohesin|O gene|O (|O SMC1A|O )|O ,|O whereas|O the|O majority|O of|O patients|O with|O cohesin|O gene|O mutations|O had|O intermediate|O risk|O cytogenetics|O ,|O most|O showing|O a|O normal|O karyotype|O (|O supplemental|O Tables|O 1|O and|O 2|O -|O 6|O )|O .|O
To|O determine|O the|O functional|O consequences|O of|O spliceosomal|O mutations|O on|O splicing|O ,|O we|O performed|O whole|O mRNA|O deep|O sequencing|O .|O
Table|O 3|O .|O Indications|O for|O JAK2|O and|O MPL|O Mutation|O Testing|O .|O
Among|O patients|O with|O FLT3|O -|O ITD|O and|O NK|O -|O AML|O ,|O median|O OS|O from|O the|O time|O of|O diagnosis|O ranged|O from|O 6|O to|O 12|O months|O .|O
Congenital|O neutropenia|O is|O a|O group|O of|O genetic|O disorders|O that|O involve|O chronic|O neutropenia|O and|O susceptibility|O to|O infections|O .|O
The|O NCCN|O Clinical|O Practice|O Guidelines|O in|O Oncology|O (|O NCCN|O Guidelines|O )|O are|O a|O statement|O of|O consensus|O of|O the|O authors|O regarding|O their|O views|O of|O currently|O accepted|O approaches|O to|O treatment|O .|O
Disclosures|O for|O the|O NCCN|O Acute|O Myeloid|O Leukemia|O Panel|O At|O the|O beginning|O of|O each|O NCCN|O Guidelines|O panel|O meeting|O ,|O panel|O members|O review|O all|O potential|O conflicts|O of|O interest|O .|O
Initial|O reports|O indicated|O a|O significantly|O better|O overall|O survival|O for|O SF3B1|O mutated|O cases|O compared|O to|O unmutated|O cases|O in|O MDS|O ,|O while|O other|O studies|O showed|O no|O significant|O impact|O of|O the|O mutations|O on|O survival|O .|O
However|O ,|O further|O studies|O are|O needed|O to|O analyze|O the|O stability|O of|O these|O markers|O ,|O as|O we|O also|O found|O 1|O patient|O in|O which|O the|O SMC1A|O mutation|O from|O the|O time|O of|O diagnosis|O was|O neither|O present|O during|O remission|O nor|O at|O the|O time|O of|O relapse|O .|O
Among|O the|O subgroup|O of|O patients|O aged|O 60|O to|O 65|O years|O (|O n|O =|O 299|O )|O ,|O an|O advantage|O with|O dose|O -|O escalated|O compared|O with|O standard|O -|O dose|O daunorubicin|O was|O observed|O with|O regard|O to|O rates|O of|O CR|O (|O 73|O %|O vs|O .|O 51|O %|O )|O ,|O 2|O -|O year|O EFS|O (|O 29|O %|O vs|O .|O 14|O %|O )|O ,|O and|O 2|O -|O year|O OS|O (|O 38|O %|O vs|O .|O 23|O %|O )|O .|O
Analysis|O from|O first|O referral|O may|O clearly|O lead|O to|O underestimation|O of|O survival|O .|O
Table|O 1|O .|O Characteristics|O of|O subjects|O with|O MDS|O showing|O 7q36|O .|O 1|O aberrations|O or|O EZH2|O mutations|O .|O
Transgenic|O reporter|O mouse|O analyses|O have|O shown|O that|O regulatory|O regions|O of|O the|O IS|O exon|O (|O 3|O .|O 1|O kb|O )|O recapitulate|O Gata2|O gene|O expression|O in|O the|O para|O -|O aortic|O splanchnopleura|O region|O and|O the|O yolk|O sac|O blood|O island|O of|O mid|O -|O gestation|O mice|O embryos|O .|O
Base|O -|O excision|O repair|O (|O BER|O )|O .|O
She|O was|O allografted|O and|O is|O still|O alive|O 1|O year|O later|O .|O
Epigenetic|O pathways|O are|O involved|O in|O manipulation|O of|O the|O level|O of|O DNA|O methylation|O and|O the|O modification|O of|O DNA|O or|O its|O protein|O interactions|O ,|O including|O methylation|O ,|O acetylation|O ,|O and|O phosphorylation|O of|O histone|O residues|O of|O nucleosomes|O around|O which|O the|O DNA|O double|O helix|O winds|O .|O
Treatment|O -|O related|O mortality|O rates|O were|O 6|O %|O and|O 17|O %|O ,|O respectively|O .|O
As|O initially|O presented|O elsewhere|O ,|O 81|O patients|O with|O CMML|O -|O 1|O (|O n|O =|O 45|O )|O or|O CMML|O -|O 2|O (|O n|O =|O 36|O )|O were|O collected|O and|O investigated|O (|O Supplementary|O Information|O 1|O )|O .|O
Patients|O with|O >|O 5|O %|O myeloblasts|O constituted|O those|O with|O advanced|O disease|O .|O
A|O recent|O study|O of|O patients|O with|O TET2|O mutations|O demonstrated|O that|O low|O 5hmC|O was|O an|O unfavorable|O prognostic|O marker|O in|O TET2|O -|O mutated|O MDS|O .|O
Other|O investigators|O described|O that|O trisomy|O 13|O and|O trisomy|O 21|O were|O associated|O with|O RUNX1|O mutations|O in|O AML|O .|O
Comparable|O 5|O -|O year|O DFS|O rates|O were|O reported|O in|O patients|O younger|O than|O 60|O years|O with|O normal|O karyotype|O after|O either|O 4|O cycles|O of|O intermediate|O -|O or|O high|O -|O dose|O cytarabine|O (|O 41|O %|O )|O or|O autologous|O HSCT|O (|O 45|O %|O )|O .|O
On|O the|O basis|O of|O the|O same|O phenomenon|O seen|O in|O alternative|O splicing|O analysis|O with|O the|O use|O of|O mRNAdeep|O sequencing|O of|O U2AF1|O mutants|O ,|O among|O the|O 3|O most|O frequently|O mutated|O spliceosomal|O genes|O ,|O U2AF1|O mutations|O might|O result|O in|O loss|O of|O function|O .|O
The|O lower|O mutation|O frequency|O in|O our|O study|O may|O be|O explained|O by|O our|O approach|O that|O we|O only|O considered|O mutations|O that|O could|O be|O validated|O by|O Sanger|O sequencing|O and|O therefore|O are|O present|O in|O at|O least|O 10|O %|O to|O 20|O %|O of|O all|O cells|O .|O
Consequently|O ,|O the|O '|O GATA|O factor|O switching|O '|O determines|O the|O beginning|O of|O erythroid|O differentiation|O (|O Fig|O .|O 4A|O )|O .|O
Hayakawa|O et|O al|O showed|O that|O endogenous|O GATA2|O is|O acetylated|O in|O HPCs|O by|O p300|O ,|O enhancing|O its|O DNA|O -|O binding|O activity|O and|O transactivating|O potential|O .|O
In|O particular|O ,|O studies|O of|O mouse|O haematopoietic|O development|O have|O revealed|O the|O dynamic|O regulation|O of|O specific|O target|O genes|O in|O the|O differentiation|O process|O .|O
These|O mutations|O were|O not|O strongly|O associated|O with|O clinical|O features|O such|O as|O cytopenias|O or|O blast|O proportion|O ,|O findings|O that|O are|O consistent|O with|O the|O observation|O that|O TET2|O mutations|O occur|O in|O diverse|O myeloid|O cancers|O ,|O including|O myeloproliferative|O neoplasms|O ,|O that|O are|O not|O characterized|O by|O defects|O in|O hematopoietic|O differentiation|O .|O
The|O use|O of|O aspirin|O ,|O hydroxyurea|O ,|O and|O phlebotomy|O for|O PV|O and|O ET|O ,|O and|O the|O use|O of|O androgens|O ,|O steroids|O ,|O chemotherapy|O ,|O and|O radiation|O therapy|O for|O PMF|O continues|O to|O be|O the|O mainstay|O of|O therapy|O .|O
A|O minority|O of|O patients|O present|O with|O variant|O translocations|O fusing|O RARA|O to|O other|O nuclear|O receptors|O such|O as|O promyelocytic|O leukaemia|O zinc|O finger|O (|O PLZF|O )|O .|O
Chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O is|O a|O clonal|O ,|O hematopoietic|O stem|O cell|O disorder|O ,|O with|O overlapping|O features|O of|O myelodysplastic|O syndromes|O (|O MDSs|O )|O and|O myeloproliferative|O neoplasms|O .|O
Besides|O FOG1|O binding|O ,|O GATA1|O recruits|O CBP|O /|O p300|O ,|O MED1|O ,|O and|O the|O chromatin|O remodeler|O BRG1|O to|O chromatin|O sites|O in|O a|O context|O -|O dependent|O manner|O .|O
Survival|O analysis|O of|O 112|O patients|O treated|O according|O to|O a|O uniform|O chemotherapy|O protocol|O showed|O that|O GATA2|O overexpression|O correlated|O with|O poor|O prognosis|O ,|O resulting|O in|O shorter|O overall|O and|O event|O -|O free|O survival|O .|O
Postremission|O Therapy|O :|O Patients|O who|O achieve|O a|O CR|O (|O including|O CRi|O )|O with|O standard|O induction|O chemotherapy|O may|O receive|O further|O consolidation|O with|O these|O agents|O .|O
Only|O studies|O in|O which|O both|O IDH1|O and|O IDH2|O were|O sequenced|O are|O included|O .|O Mutational|O frequencies|O of|O ASXL1|O are|O listed|O as|O reported|O in|O the|O original|O referenced|O manuscripts|O (|O this|O may|O include|O the|O controversial|O ASXL1|O pGly646fsX12|O variant|O (|O REF|O .|O 83|O )|O )|O .|O
Most|O of|O these|O methods|O typically|O do|O not|O achieve|O sensitivities|O of|O less|O than|O 5|O %|O of|O alleles|O (|O Table|O 4|O )|O .|O
She|O presented|O with|O aspergillosis|O during|O induction|O therapy|O and|O received|O several|O lines|O of|O chemotherapy|O because|O of|O a|O refractory|O disease|O .|O
BCORL1|O ,|O also|O located|O on|O chromosome|O X|O ,|O shares|O the|O similar|O functional|O activity|O .|O
NA|O ,|O not|O available|O in|O the|O original|O publication|O .|O
None|O had|O an|O earlier|O history|O of|O radiation|O exposure|O or|O chemotherapy|O .|O
Importantly|O ,|O clinical|O outcomes|O in|O patients|O with|O therapy|O -|O related|O AML|O have|O been|O shown|O to|O be|O significantly|O inferior|O (|O both|O in|O terms|O of|O relapse|O -|O free|O and|O overall|O survivals|O )|O compared|O with|O patients|O with|O de|O novo|O cases|O ,|O except|O those|O with|O the|O therapy|O -|O related|O acute|O promyelocytic|O leukemia|O (|O APL|O )|O subtype|O or|O the|O favorable|O -|O risk|O core|O binding|O factor|O (|O CBF|O )|O translocations|O .|O
Another|O option|O for|O patients|O who|O are|O medically|O fit|O is|O the|O purine|O nucleoside|O analogue|O clofarabine|O (|O currently|O FDA|O -|O approved|O only|O for|O the|O treatment|O of|O relapsed|O or|O refractory|O pediatric|O ALL|O )|O .|O
The|O guidelines|O consider|O recommendations|O for|O patients|O older|O or|O younger|O than|O 60|O years|O of|O age|O separately|O .|O
In|O humans|O ,|O however|O ,|O recent|O evidence|O indicates|O that|O acquisition|O of|O JAK2V617F|O may|O not|O be|O the|O primary|O oncogenic|O event|O and|O the|O relative|O predisposition|O to|O JAK2V617F|O mutation|O may|O be|O more|O contributory|O to|O disease|O phenotype|O .|O
Secondary|O end|O points|O included|O the|O durability|O of|O response|O ,|O changes|O in|O symptom|O burden|O (|O assessed|O by|O the|O total|O symptom|O score|O )|O ,|O and|O overall|O survival|O .|O
Historically|O ,|O in|O most|O large|O cooperative|O group|O trials|O ,|O daunorubicin|O has|O been|O the|O most|O commonly|O used|O anthracycline|O at|O doses|O of|O 45|O to|O 60|O mg|O /|O m2|O x|O 3|O days|O .|O
Its|O presence|O even|O appears|O to|O adversely|O override|O favorable|O genetic|O lesions|O .|O
Treatment|O with|O the|O BRD4|O inhibitor|O JQ|O .|O 1|O leads|O to|O a|O 2|O -|O fold|O decrease|O in|O cohesin|O occupancy|O at|O superenhancer|O sites|O and|O normalization|O of|O the|O expression|O of|O oncogenic|O drivers|O .|O
Furthermore|O ,|O activated|O Ras|O signaling|O may|O alter|O the|O expression|O of|O key|O identity|O genes|O ,|O which|O are|O then|O further|O dysregulated|O by|O cohesin|O inactivity|O .|O
Median|O follow|O -|O up|O time|O for|O survival|O was|O calculated|O according|O to|O the|O method|O of|O Korn|O .|O
The|O median|O DFS|O in|O patients|O who|O achieved|O a|O CR|O with|O low|O -|O dose|O cytarabine|O was|O 8|O months|O .|O
To|O avoid|O infections|O associated|O with|O neutropenia|O ,|O a|O large|O percentage|O of|O these|O patients|O are|O treated|O chronically|O with|O G|O -|O CSF|O to|O improve|O neutrophil|O production|O .|O
Findings|O from|O published|O reports|O on|O the|O prognostic|O effects|O of|O IDH1|O mutations|O have|O been|O inconsistent|O .|O
The|O panel|O members|O agreed|O that|O transplant|O -|O based|O options|O (|O either|O matched|O sibling|O or|O alternate|O donor|O allogeneic|O HSCT|O ,|O or|O 1|O -|O 2|O cycles|O of|O dose|O -|O intensive|O cytarabine|O followed|O by|O autologous|O HSCT|O )|O afforded|O a|O lower|O risk|O of|O relapse|O and|O a|O somewhat|O higher|O DFS|O as|O consolidation|O for|O most|O patients|O with|O intermediaterisk|O cytogenetics|O .|O
Although|O over|O 60|O genes|O have|O been|O recently|O identified|O ,|O there|O are|O 6|O genes|O (|O TET2|O ,|O SF3B1|O ,|O ASXL1|O ,|O SRSF2|O ,|O DNMT3A|O ,|O and|O RUNX1|O )|O that|O are|O consistently|O mutated|O in|O 10|O %|O or|O more|O of|O MDS|O patients|O .|O
These|O studies|O thus|O confirmed|O somatic|O mutations|O in|O five|O genes|O (|O NRAS|O ,|O KRAS|O ,|O BRAF|O ,|O JAK2|O ,|O and|O PTPN11|O )|O known|O to|O be|O mutated|O in|O patients|O with|O myelodysplastic|O syndromes|O and|O identified|O recurrent|O mutations|O in|O GNAS|O that|O have|O not|O been|O previously|O reported|O in|O hematologic|O cancers|O .|O
KEY|O POINTS|O .|O
EZH2|O encodes|O the|O histone|O methyltransferase|O that|O constitutes|O the|O catalytic|O unit|O of|O the|O polycomb|O repressive|O complex|O 2|O (|O PRC2|O )|O .|O
MDS|O is|O a|O clonal|O hematopoietic|O disorder|O resulting|O in|O ineffective|O hematopoiesis|O and|O frequently|O evolving|O to|O AML|O .|O
He|O was|O treated|O by|O HSCT|O and|O is|O still|O in|O complete|O remission|O 2|O .|O 5|O years|O after|O the|O transplantation|O .|O
EZH2|O ,|O SRSF2|O and|O IDH1|O /|O 2|O mutational|O frequencies|O were|O similar|O in|O patients|O with|O normal|O versus|O abnormal|O karyotype|O .|O
Their|O impact|O on|O clinical|O parameters|O should|O also|O be|O clarified|O .|O
Given|O the|O inconsistency|O among|O currently|O available|O CMML|O prognostic|O models|O ,|O their|O lack|O of|O strict|O adherence|O to|O the|O WHO|O classification|O system|O when|O selecting|O study|O patients|O and|O the|O discovery|O of|O molecular|O abnormalities|O potentially|O having|O an|O impact|O on|O survival|O ,|O we|O undertook|O the|O current|O study|O with|O 226|O single|O -|O center|O study|O patients|O strictly|O defined|O by|O the|O WHO|O ,|O fully|O annotated|O for|O karyotype|O and|O also|O analyzed|O for|O reportedly|O prognostic|O somatic|O mutations|O .|O
Altogether|O ,|O these|O findings|O reveal|O that|O GATA2|O is|O a|O critical|O transcription|O factor|O that|O coordinates|O cellular|O proliferation|O and|O maintains|O megakaryocyte|O identity|O in|O GATA1|O deficient|O or|O mutant|O cells|O .|O
It|O should|O be|O noted|O ,|O however|O ,|O that|O there|O are|O major|O differences|O in|O median|O OS|O between|O the|O same|O genotypic|O entities|O as|O estimated|O in|O the|O Mayo|O Clinic|O vs|O the|O present|O study|O :|O 2|O .|O 5|O vs|O 3|O .|O 2|O years|O in|O triple|O -|O negative|O ,|O 4|O .|O 1|O vs|O 9|O .|O 1|O years|O in|O MPL|O -|O mutant|O ,|O 4|O .|O 3|O vs|O 9|O .|O 2|O years|O in|O JAK2|O -|O mutant|O ,|O and|O 8|O .|O 2|O vs|O 17|O .|O 7|O years|O in|O CALR|O -|O mutant|O patients|O .|O
Another|O target|O of|O this|O circuit|O is|O EKLF|O ,|O whose|O expression|O at|O the|O progenitor|O stage|O is|O dependent|O on|O GATA2|O and|O SMAD5|O ;|O in|O contrast|O ,|O the|O maintenance|O of|O EKLF|O expression|O in|O committed|O erythroid|O cells|O is|O regulated|O by|O GATA1|O (|O Fig|O .|O 3|O )|O .|O
In|O our|O studies|O in|O myeloid|O malignancies|O ,|O the|O most|O commonly|O affected|O spliceosomal|O genes|O included|O SF3B1|O ,|O U2AF1|O ,|O and|O SRSF2|O .|O
For|O the|O European|O cohort|O ,|O median|O overall|O survival|O from|O time|O of|O diagnosis|O was|O 9|O .|O 7|O years|O (|O 95|O %|O CI|O :|O 7|O .|O 9|O -|O 12|O .|O 2|O )|O (|O Supplementary|O Figure|O S1A|O )|O ;|O the|O respective|O values|O for|O IPSS|O low|O ,|O intermediate|O -|O 1|O ,|O intermediate|O -|O 2|O and|O high|O -|O risk|O disease|O were|O 22|O .|O 8|O years|O (|O 95|O %|O CI|O :|O 12|O .|O 2|O -|O not|O reached|O )|O ,|O 10|O .|O 5|O years|O (|O 95|O %|O CI|O :|O 7|O .|O 12|O -|O 23|O .|O 7|O )|O ,|O 6|O .|O 2|O years|O (|O 95|O %|O CI|O :|O 5|O .|O 2|O -|O 9|O .|O 5|O )|O and|O 2|O .|O 5|O years|O (|O 95|O %|O CI|O :|O 1|O .|O 7|O -|O 2|O .|O 8|O )|O (|O P|O <|O 0|O .|O 0001|O )|O (|O Supplementary|O Figure|O S1B|O )|O .|O
As|O indicated|O above|O ,|O the|O two|O GATA2|O proteins|O described|O differ|O in|O exon|O 5|O .|O
The|O age|O of|O patients|O with|O mutations|O was|O younger|O than|O those|O without|O mutations|O (|O mean|O +|O =|O s|O .|O e|O .|O 66|O .|O 3|O +|O =|O 24|O years|O vs|O 71|O .|O 5|O +|O =|O 1|O .|O 6|O years|O ,|O P|O =|O 0|O .|O 055|O )|O .|O
Here|O ,|O we|O review|O how|O specific|O somatic|O alterations|O in|O epigenetic|O regulators|O lead|O to|O repatterning|O of|O the|O epigenome|O and|O contribute|O to|O myeloid|O leukaemogenesis|O .|O
The|O monocyte|O count|O was|O very|O low|O ,|O with|O a|O median|O value|O of|O 0|O .|O 05|O G|O /|O L|O (|O 25th|O percentile|O :|O 0|O .|O 03|O ;|O 75th|O percentile|O :|O 0|O .|O 17|O )|O .|O
Seven|O percent|O of|O 402|O patients|O with|O ET|O displayed|O a|O Y|O -|O (|O 6|O %|O of|O male|O patients|O )|O or|O +|O 8|O ,|O +|O 9|O ,|O 5q|O -|O ,|O 6|O -|O ,|O 20q|O -|O ,|O and|O abnormalities|O of|O chromosome|O 1|O and|O 11|O .|O
Ley|O and|O colleagues|O first|O identified|O somatic|O mutation|O of|O DNMT3A|O in|O adults|O with|O AML|O after|O whole|O -|O genome|O sequencing|O of|O a|O human|O sample|O of|O AML|O with|O normal|O cytogenetics|O .|O
In|O 2|O large|O observational|O studies|O ,|O therapy|O with|O hydroxyurea|O was|O not|O shown|O to|O contribute|O to|O an|O increased|O rate|O of|O transformation|O to|O acute|O myeloid|O leukemia|O or|O myelodysplastic|O syndrome|O in|O patients|O with|O PV|O or|O ET|O .|O
There|O were|O no|O transformations|O in|O the|O placebo|O group|O .|O
Cohesin|O complex|O mutations|O were|O almost|O always|O mutually|O exclusive|O (|O Figure|O 2A|O )|O .|O
Both|O univariate|O (|O P|O =|O 0|O .|O 0004|O and|O P|O =|O 0|O .|O 0001|O ,|O respectively|O )|O and|O multivariable|O (|O including|O karyotype|O and|O thrombocytopenia|O as|O covariates|O ;|O P|O =|O 0|O .|O 0002|O and|O P|O =|O 0|O .|O 02|O ,|O respectively|O )|O analysis|O for|O leukemia|O -|O free|O survival|O identified|O SRSF2|O and|O IDH1|O mutations|O as|O being|O significant|O .|O
Tandem|O GATA|O -|O E|O -|O box|O elements|O are|O found|O at|O the|O promoters|O of|O several|O erythroid|O expressed|O genes|O ,|O including|O the|O KLF1|O ,|O GATA1|O ,|O EPB|O ,|O and|O GYPA|O genes|O ,|O and|O in|O the|O HS2|O beta|O -|O globin|O locus|O control|O region|O .|O
There|O is|O increasing|O evidence|O implicating|O the|O Polycomb|O -|O repressive|O deubiquitylase|O (|O PR|O -|O DUB|O )|O complex|O ,|O which|O functions|O to|O deubiquitylate|O H2AK119|O ,|O in|O a|O range|O of|O human|O malignancies|O .|O
For|O the|O entire|O patient|O cohort|O ,|O the|O median|O DFS|O and|O OS|O were|O 37|O and|O 41|O weeks|O ,|O respectively|O ;|O patients|O experiencing|O a|O CR|O had|O a|O median|O OS|O of|O 72|O weeks|O .|O
Sequencing|O data|O were|O analyzed|O with|O Illumina|O CASAVA1|O .|O 7|O software|O and|O the|O human|O genome|O reference|O sequence|O hg19|O .|O
Figure|O 2|O .|O Kaplan|O -|O Meier|O estimates|O of|O (|O a|O )|O overall|O survival|O for|O CMML|O patients|O with|O and|O without|O RUNX1|O mutations|O (|O P|O =|O 0|O .|O 928|O )|O ,|O and|O (|O b|O )|O acute|O myeloid|O leukemia|O transformation|O for|O CMML|O patients|O with|O and|O without|O RUNX1|O mutations|O (|O P|O =|O 0|O .|O 175|O )|O ,|O C|O -|O terminal|O mutations|O vs|O those|O without|O mutation|O (|O P|O =|O 0|O .|O 022|O )|O .|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O .|O
Interestingly|O ,|O they|O found|O that|O Bmp4|O mRNA|O was|O reduced|O approximately|O 2|O -|O fold|O in|O these|O Gata2|O mutant|O mice|O ,|O and|O showed|O that|O GATA2|O is|O a|O direct|O regulator|O of|O Bmp4|O transcription|O .|O
Finally|O ,|O BCOR|O mutations|O in|O AML|O were|O often|O associated|O with|O a|O decrease|O in|O BCOR|O mRNA|O levels|O ,|O absence|O of|O full|O -|O length|O BCOR|O protein|O ,|O and|O lack|O or|O low|O expression|O of|O a|O truncated|O BCOR|O protein|O .|O
It|O is|O tasked|O with|O marking|O exon|O /|O intron|O boundaries|O with|O the|O capacity|O to|O functionally|O redefine|O splice|O sites|O ,|O leading|O to|O the|O formation|O of|O alternative|O transcripts|O .|O
On|O the|O other|O hand|O ,|O the|O same|O mutation|O was|O shown|O to|O promote|O splicing|O and|O exon|O skipping|O of|O a|O minigene|O reporter|O in|O 293T|O cells|O .|O
IDH1|O mutations|O have|O now|O also|O been|O identified|O in|O chondrosarcomas|O ,|O cholangiocarcinomas|O ,|O colorectal|O cancer|O and|O thyroid|O cancer|O ,|O and|O Mardis|O et|O al|O identified|O recurrent|O IDH1|O mutations|O in|O AML|O .|O
In|O a|O recent|O report|O that|O evaluated|O the|O ELN|O risk|O classification|O in|O a|O large|O cohort|O of|O patients|O ,|O those|O in|O the|O "|O Intermediate|O I|O "|O risk|O group|O (|O which|O includes|O all|O patients|O with|O NK|O -|O AML|O with|O FLT3|O abnormalities|O and|O those|O lacking|O both|O FLT3|O and|O NPM1|O mutations|O )|O ,|O relapse|O -|O free|O survival|O was|O more|O favorable|O with|O allogeneic|O HSCT|O (|O 94|O vs|O .|O 7|O .|O 9|O months|O without|O allogeneic|O HSCT|O )|O .|O
Mutations|O affecting|O spliceosomal|O genes|O that|O result|O in|O defective|O splicing|O are|O a|O new|O leukemogenic|O pathway|O .|O
An|O interpretive|O comment|O should|O be|O included|O ,|O indicating|O whether|O the|O observed|O mutation|O has|O been|O previously|O reported|O in|O MPNs|O or|O other|O malignancies|O or|O whether|O the|O mutation|O appears|O to|O be|O novel|O .|O
SNV|O and|O indel|O discovery|O was|O performed|O across|O all|O samples|O using|O standard|O parameters|O and|O a|O maximum|O coverage|O of|O 10000|O .|O
It|O was|O first|O cloned|O as|O an|O erythroid|O nuclear|O protein|O ,|O which|O binds|O to|O one|O of|O the|O enhancer|O regions|O of|O the|O globin|O genes|O .|O
Among|O the|O patients|O who|O underwent|O allogeneic|O HSCT|O ,|O myeloablative|O conditioning|O was|O used|O in|O 37|O %|O of|O patients|O ,|O whereas|O RIC|O was|O used|O in|O 61|O %|O .|O
Patients|O were|O randomly|O assigned|O in|O a|O 1|O :|O 1|O ratio|O to|O receive|O oral|O ruxolitinib|O phosphate|O tablets|O or|O matched|O placebo|O .|O
Patients|O with|O PV|O are|O considered|O low|O risk|O if|O they|O are|O <|O 60|O years|O old|O and|O have|O no|O history|O of|O thrombosis|O or|O are|O high|O risk|O if|O they|O are|O >|O =|O 60|O years|O old|O or|O have|O a|O history|O of|O thrombosis|O .|O
Finally|O ,|O disruption|O of|O the|O Gata4|O and|O Gata6|O genes|O results|O in|O early|O embryo|O lethality|O due|O to|O defects|O in|O heart|O tube|O formation|O and|O extraembryonic|O endoderm|O development|O ,|O respectively|O .|O
Reverse|O transcription|O was|O performed|O in|O a|O 20|O muL|O final|O volume|O containing|O 1|O mug|O RNA|O ,|O 0|O .|O 5|O mug|O random|O primers|O (|O 10|O mers|O )|O ,|O 10|O mM|O dithiothreitol|O ,|O 0|O .|O 5|O mM|O dNTPs|O ,|O 5|O units|O RNasin|O (|O Promega|O ,|O Madison|O ,|O WI|O )|O ,|O 50|O mM|O Tris|O -|O HCl|O (|O pH|O 8|O .|O 3|O )|O ,|O 75|O mM|O KCl|O ,|O 3|O mM|O MgCl2|O ,|O and|O 200|O units|O Moloney|O Murine|O Leukemia|O Virus|O reverse|O transcriptase|O .|O
In|O contrast|O ,|O GATA2|O is|O expressed|O at|O high|O levels|O during|O megakaryocyte|O differentiation|O [|O 145|O ]|O ,|O also|O suggesting|O a|O relevant|O role|O for|O GATA2|O in|O terminal|O thrombopoiesis|O .|O
In|O the|O absence|O of|O GATA1|O ,|O GATA2|O binding|O is|O associated|O with|O an|O undifferentiated|O state|O ,|O an|O intermediate|O level|O of|O PU|O .|O 1|O expression|O ,|O and|O a|O low|O -|O level|O expression|O of|O its|O downstream|O myeloid|O target|O genes|O .|O
It|O may|O also|O be|O possible|O to|O estimate|O mutant|O burden|O based|O on|O the|O allele|O frequency|O calculated|O from|O next|O -|O generation|O sequencing|O data|O ;|O however|O ,|O there|O has|O been|O only|O limited|O validation|O of|O the|O ability|O of|O next|O -|O generation|O sequencing|O to|O make|O this|O type|O of|O estimation|O .|O
Patient|O no|O .|O 8|O had|O Pro398Leu|O ,|O which|O is|O within|O the|O inhibitory|O domain|O (|O aa372|O -|O 411|O )|O found|O to|O keep|O the|O full|O transactivating|O potential|O of|O RUNX1|O .|O
Genotype|O -|O phenotype|O association|O .|O
The|O presence|O of|O reactive|O marrow|O fibrosis|O does|O not|O exclude|O a|O diagnosis|O of|O primary|O myelofribrosis|O in|O the|O presence|O of|O numerous|O other|O criteria|O .|O
Although|O the|O current|O evaluation|O of|O a|O suspected|O MDS|O includes|O clinical|O history|O ,|O peripheral|O blood|O value|O ,|O bone|O marrow|O morphology|O and|O architecture|O ,|O flow|O cytometry|O ,|O and|O cytogenetics|O study|O ,|O many|O cases|O of|O true|O MDS|O remain|O diagnostically|O challenging|O .|O
Regarding|O treatment|O ,|O TET2|O mutations|O appear|O to|O be|O a|O genetic|O predictor|O of|O response|O to|O azanucleosides|O [|O (|O 5|O -|O azacitidine|O (|O AZA|O )|O and|O decitabine|O (|O DAC|O )|O )|O ]|O ,|O primarily|O in|O higher|O -|O risk|O MDS|O ,|O although|O these|O observations|O require|O prospective|O validation|O .|O
Two|O patients|O in|O the|O ruxolitinib|O group|O had|O a|O transformation|O to|O AML|O during|O the|O study|O :|O one|O patient|O with|O 7|O %|O bone|O marrow|O blasts|O at|O baseline|O and|O a|O history|O of|O breast|O cancer|O had|O AML|O transformation|O after|O 8|O months|O in|O the|O study|O ;|O the|O second|O patient|O entered|O the|O study|O with|O 2|O %|O bone|O marrow|O blasts|O and|O a|O trisomy|O 8|O chromosomal|O abnormality|O at|O baseline|O and|O had|O AML|O transformation|O after|O 5|O months|O in|O the|O study|O .|O
After|O excluding|O 7|O polymorphisms|O and|O 9|O silent|O mutations|O ,|O 13|O different|O aberrations|O (|O Supplementary|O Table|O 4|O )|O were|O detected|O in|O IDH1|O (|O 1|O /|O 81|O ;|O 1|O .|O 2|O %|O )|O ,|O IDH2|O (|O 3|O /|O 81|O ;|O 3|O .|O 7|O %|O )|O ,|O NPM1|O (|O 1|O /|O 81|O ;|O 1|O .|O 2|O %|O )|O and|O EZH2|O (|O 9|O /|O 81|O ;|O 11|O .|O 1|O %|O )|O .|O
Similarly|O ,|O heterozygous|O ,|O somatic|O SF3B1|O mutations|O (|O E622D|O )|O were|O detected|O in|O a|O patient|O with|O refractory|O anemia|O with|O ring|O sideroblasts|O (|O RARS|O )|O associated|O with|O marked|O thrombocytosis|O (|O RARS|O -|O T|O ;|O Figure|O 1B|O )|O .|O
We|O identified|O mutated|O BCOR|O through|O whole|O -|O exome|O sequencing|O of|O a|O CN|O -|O AML|O patient|O who|O was|O selected|O for|O analysis|O because|O of|O lack|O of|O any|O known|O mutations|O .|O
The|O detrimental|O effect|O of|O ASXL1|O mutations|O has|O also|O been|O shown|O in|O MDS|O ,|O AML|O and|O CMML|O .|O
ASXL1|O mutations|O are|O common|O in|O myeloid|O malignancies|O ,|O including|O MDS|O ,|O AML|O ,|O myeloproliferative|O neoplasm|O and|O CMML|O .|O
Collectively|O ,|O deletions|O and|O point|O mutations|O of|O EZH2|O were|O present|O in|O 23|O %|O of|O the|O affected|O subjects|O .|O
At|O least|O 27|O clinically|O verified|O exon|O 12|O mutations|O have|O been|O identified|O to|O date|O ,|O including|O amino|O acid|O substitution|O ,|O deletions|O ,|O and|O duplications|O (|O Table|O 1|O )|O .|O
Prognostic|O risk|O stratification|O using|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O (|O P|O =|O 0|O .|O 17|O )|O ,|O MDAPS|O (|O P|O =|O 0|O .|O 2|O )|O and|O the|O G|O -|O MDAPS|O (|O 0|O .|O 32|O )|O demonstrated|O no|O difference|O between|O mutated|O and|O unmutated|O patients|O .|O
Biological|O impact|O of|O mutations|O .|O
Chun|O et|O al|O showed|O that|O GATA2|O is|O a|O target|O for|O SUMO|O modification|O and|O that|O PIASy|O enhances|O the|O SUMO|O conjugation|O of|O GATA2|O ,|O especially|O by|O SUMO2|O .|O
Numerical|O variables|O have|O been|O summarized|O by|O their|O median|O and|O range|O ,|O and|O categorical|O variables|O by|O count|O and|O relative|O frequency|O (|O %|O )|O of|O each|O category|O .|O
Estimates|O for|O general|O mutation|O detection|O indicate|O that|O approximately|O 1000|O -|O fold|O coverage|O is|O needed|O for|O a|O given|O base|O to|O achieve|O a|O 99|O %|O confidence|O of|O detecting|O more|O than|O 5|O %|O heterozygous|O mutant|O alleles|O .|O
When|O compared|O with|O other|O RNA|O splicing|O gene|O mutations|O that|O occur|O in|O MDS|O ,|O the|O incidence|O of|O ZRSR2|O mutation|O is|O much|O less|O ,|O occurring|O in|O only|O about|O 3|O %|O of|O patients|O ,|O precluding|O a|O formal|O ability|O to|O ascertain|O its|O prognostic|O significance|O .|O
DISCUSSION|O .|O
Two|O patients|O (|O patient|O numbers|O 5677|O and|O 6184|O )|O had|O infection|O profiles|O compatible|O with|O MonoMAC|O syndrome|O .|O
UTX|O .|O
The|O guidelines|O were|O developed|O by|O an|O expert|O panel|O from|O the|O Association|O for|O Molecular|O Pathology|O (|O AMP|O )|O based|O on|O the|O current|O literature|O and|O practices|O in|O the|O United|O States|O and|O Canada|O .|O
Furthermore|O ,|O using|O a|O mouse|O model|O of|O human|O GATA1|O mutations|O present|O in|O acute|O megakaryocytic|O leukemia|O with|O Down|O syndrome|O ,|O they|O demonstrated|O that|O GATA2|O overexpression|O contributes|O to|O aberrant|O megakaryocyte|O proliferation|O in|O the|O absence|O of|O full|O -|O length|O GATA1|O .|O
Nottingham|O et|O al|O reported|O that|O the|O GATA2|O ,|O FLI1|O ,|O and|O SCL|O complex|O are|O recruited|O to|O the|O mouse|O Runx1|O enhancer|O ,|O placing|O RUNX1|O directly|O downstream|O of|O these|O factors|O in|O the|O transcriptional|O network|O that|O governs|O HSC|O emergence|O .|O
For|O example|O ,|O in|O a|O specimen|O with|O 40|O %|O mutant|O alleles|O ,|O it|O is|O unclear|O whether|O the|O sample|O is|O actually|O composed|O of|O 40|O %|O cells|O with|O a|O monoallelic|O mutation|O or|O 20|O %|O cells|O with|O a|O biallelic|O mutation|O .|O
Bone|O marrow|O from|O patients|O with|O exon|O 12|O mutation|O often|O exhibits|O nonspecific|O morphology|O ,|O with|O isolated|O erythroid|O proliferation|O and|O absence|O of|O prominent|O megakaryocyte|O atypia|O and|O clustering|O .|O
A|O similar|O proportion|O of|O patients|O in|O each|O treatment|O arm|O received|O consolidation|O with|O a|O third|O chemotherapy|O cycle|O (|O 26|O %|O -|O 27|O %|O )|O ,|O autologous|O HSCT|O (|O 10|O %|O -|O 11|O %|O )|O ,|O and|O allogeneic|O HSCT|O (|O 27|O %|O -|O 29|O %|O )|O .|O
Recently|O ,|O Tripic|O et|O al|O investigated|O which|O proteins|O from|O among|O those|O known|O to|O be|O associated|O with|O GATA1|O ,|O might|O consistently|O distinguish|O active|O from|O repressive|O GATA1|O complexes|O .|O
Figure|O 2|O .|O Provisional|O diagnostic|O algorithm|O for|O neutrophilia|O and|O genetically|O informed|O treatment|O options|O .|O FISH|O probes|O for|O myeloid|O -|O associated|O cytogenetic|O abnormalities|O can|O be|O used|O to|O complement|O standard|O karyotype|O analysis|O to|O establish|O the|O presence|O of|O a|O clonal|O myeloid|O disorder|O .|O Cytogenetic|O /|O FISH|O or|O molecular|O evaluation|O of|O rearranged|O PDGFRA|O /|O B|O ,|O and|O FGFR1|O should|O also|O be|O considered|O if|O eosinophilia|O is|O present|O .|O Testing|O for|O JAK2|O V617F|O ,|O infrequently|O identified|O in|O CNL|O or|O atypical|O CML|O ,|O should|O also|O be|O considered|O .|O The|O list|O of|O relevant|O mutations|O ,|O including|O molecular|O abnormalities|O in|O complementary|O signaling|O pathways|O to|O CSF3R|O and|O SETBP1|O ,|O may|O expand|O over|O time|O .|O For|O patients|O who|O are|O CSF3R|O -|O mutation|O negative|O ,|O use|O of|O a|O JAK|O inhibitor|O (|O particularly|O if|O JAK2|O V617F|O positive|O )|O or|O SRC|O kinase|O inhibitor|O could|O be|O considered|O since|O mutations|O in|O the|O same|O or|O related|O signaling|O pathways|O may|O be|O present|O .|O
In|O conclusion|O ,|O BCOR|O and|O BCORL1|O add|O to|O the|O growing|O list|O of|O genes|O recurrently|O mutated|O in|O AML|O .|O
The|O negative|O regulatory|O domain|O ,|O which|O extends|O the|O amino|O acid|O residues|O 74|O -|O 235|O ,|O has|O no|O apparent|O homology|O to|O GATA1|O ,|O GATA4|O ,|O GATA5|O or|O GATA6|O ,|O but|O has|O 46|O %|O homology|O to|O the|O corresponding|O region|O of|O GATA3|O ,|O which|O has|O been|O reported|O as|O a|O transcription|O activation|O domain|O .|O
For|O exploratory|O purposes|O ,|O next|O we|O evaluated|O the|O prognostic|O influence|O of|O each|O gene|O in|O the|O cohesin|O complex|O separately|O in|O all|O patients|O ,|O although|O this|O analysis|O is|O limited|O by|O the|O small|O number|O of|O mutated|O patients|O .|O
In|O fact|O ,|O it|O has|O been|O found|O that|O GATA1|O defects|O give|O rise|O to|O pleiotropic|O hematopoietic|O disorders|O depending|O on|O which|O particular|O function|O is|O impaired|O .|O
Given|O that|O GATA2|O also|O has|O an|O essential|O role|O in|O mast|O cell|O development|O ,|O and|O the|O fact|O that|O FOG1|O represses|O GATA2|O expression|O ,|O it|O is|O possible|O that|O a|O cross|O -|O antagonistic|O regulatory|O loop|O may|O exist|O between|O GATA2|O and|O FOG1|O .|O
This|O result|O is|O consistent|O with|O Gayther|O '|O s|O study|O ,|O Chang|O '|O s|O study|O ,|O and|O our|O previous|O study|O of|O TSG101|O and|O FHIT|O ,|O in|O which|O aberrant|O transcriptions|O with|O different|O deletions|O were|O frequently|O identified|O .|O However|O ,|O PCR|O amplification|O of|O aberrant|O transcripts|O caused|O by|O pre|O -|O mRNA|O splicing|O that|O was|O less|O stringent|O in|O cancer|O cells|O than|O in|O normal|O tissues|O should|O be|O considered|O .|O
Recently|O ,|O GATA2|O has|O been|O identified|O as|O a|O new|O predisposing|O gene|O for|O familial|O AML|O /|O MDS|O .|O
As|O of|O writing|O ,|O there|O were|O no|O kits|O cleared|O by|O the|O FDA|O for|O clinical|O use|O in|O testing|O for|O JAK2|O or|O MPL|O mutations|O ;|O however|O ,|O it|O is|O possible|O that|O a|O companion|O diagnostic|O for|O the|O JAK2|O V617F|O mutation|O will|O be|O developed|O to|O detect|O the|O JAK2|O mutation|O and|O to|O quantify|O the|O response|O to|O targeted|O therapies|O .|O
During|O follow|O -|O up|O ,|O 157|O (|O 32|O .|O 5|O %|O )|O deaths|O were|O recorded|O in|O the|O European|O cohort|O and|O 246|O (|O 62|O %|O )|O in|O the|O Mayo|O cohort|O ;|O 75|O (|O 16|O %|O )|O and|O 46|O (|O 12|O %|O )|O leukemic|O transformations|O were|O documented|O in|O the|O European|O and|O Mayo|O cohort|O ,|O respectively|O .|O
In|O one|O study|O ,|O an|O association|O was|O found|O between|O IDH2|O mutations|O and|O poorer|O prognosis|O in|O the|O subgroup|O of|O patients|O with|O NK|O -|O AML|O with|O otherwise|O favorable|O risk|O (|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O )|O .|O
The|O presence|O of|O such|O a|O mutation|O would|O reclassify|O patients|O into|O the|O next|O highest|O IPSS|O risk|O group|O .|O
If|O no|O mass|O effect|O is|O seen|O ,|O cerebrospinal|O fluid|O (|O CSF|O )|O cytology|O should|O be|O sampled|O by|O LP|O .|O
Although|O the|O initial|O report|O did|O not|O break|O down|O remission|O duration|O by|O cytogenetic|O groups|O ,|O subsequent|O analysis|O showed|O a|O 5|O -|O year|O relapse|O -|O free|O survival|O (|O continuous|O CR|O measured|O from|O time|O of|O randomization|O )|O rate|O of|O 50|O %|O for|O CBF|O AML|O ,|O 32|O %|O for|O patients|O with|O normal|O karyotype|O ,|O and|O 15|O %|O for|O patients|O in|O other|O cytogenetic|O categories|O ,|O overall|O (|O P|O <|O .|O 001|O )|O .|O
The|O risk|O of|O malignant|O transformation|O was|O extremely|O high|O ,|O because|O 6|O of|O 14|O patients|O with|O GATA2|O mutations|O developed|O a|O refractory|O cytopenia|O with|O multilineage|O dysplasia|O and|O 4|O patients|O developed|O AML|O (|O Figure|O 2B|O )|O .|O
Furthermore|O ,|O the|O occupied|O sites|O pinpointed|O novel|O GATA|O factor|O target|O genes|O that|O highlight|O new|O GATA|O factor|O dependent|O cell|O regulatory|O pathways|O .|O
Mutations|O in|O genes|O of|O the|O cohesin|O complex|O are|O recurrent|O mutations|O in|O AML|O with|O a|O strong|O association|O with|O NPM1|O mutations|O .|O
Figure|O 2|O .|O Kaplan|O -|O Meier|O estimates|O of|O overall|O survival|O in|O patients|O of|O the|O European|O series|O depending|O on|O the|O mutational|O status|O (|O wild|O -|O type|O or|O mutated|O )|O of|O EZH2|O ,|O ASXL1|O ,|O SRSF2|O and|O IDH1|O or|O IDH2|O mutation|O is|O presented|O in|O (|O a|O )|O .|O The|O impact|O of|O mutations|O in|O EZH2|O ,|O ASXL1|O ,|O SRSF2|O and|O IDH1|O or|O IDH2|O on|O the|O cumulative|O risk|O of|O transformation|O to|O acute|O leukemia|O using|O a|O competitive|O risk|O analysis|O is|O shown|O in|O (|O b|O )|O .|O The|O P|O -|O values|O reported|O in|O each|O panel|O refer|O to|O the|O comparison|O of|O mutated|O and|O wild|O -|O type|O subjects|O .|O A|O comparison|O of|O overall|O survival|O by|O Kaplan|O -|O Meier|O estimates|O (|O c|O )|O and|O the|O cumulative|O risk|O of|O transformation|O to|O acute|O leukemia|O (|O d|O )|O in|O patients|O considered|O at|O '|O mutationally|O high|O -|O risk|O '|O (|O that|O is|O ,|O those|O mutated|O at|O least|O in|O one|O of|O ASXL1|O ,|O EZH2|O ,|O SRSF2|O ,|O IDH1|O or|O IDH2|O )|O versus|O '|O mutationally|O low|O -|O risk|O '|O (|O that|O is|O ,|O no|O mutation|O )|O is|O presented|O .|O
Figure|O 3|O .|O Cumulative|O incidence|O of|O leukemic|O transformation|O in|O PMF|O patients|O stratified|O according|O to|O their|O driver|O mutation|O .|O Vertical|O tick|O marks|O indicate|O right|O -|O censored|O patients|O .|O Triple|O -|O negative|O patients|O had|O higher|O incidence|O of|O leukemic|O transformation|O compared|O with|O both|O CALR|O -|O mutant|O and|O JAK2|O -|O mutant|O patients|O (|O maximum|O P|O value|O equal|O to|O .|O 043|O )|O .|O
Herein|O ,|O we|O review|O the|O clinical|O and|O pathological|O significance|O of|O these|O mutations|O as|O grouped|O by|O corresponding|O pathways|O that|O they|O dysregulate|O .|O
Treatment|O decisions|O for|O patients|O with|O significant|O reduction|O without|O hypoplasia|O or|O those|O with|O hypoplasia|O are|O deferred|O until|O the|O blood|O counts|O recover|O and|O a|O repeat|O marrow|O is|O performed|O to|O document|O remission|O status|O .|O
All|O amplicons|O from|O 1|O patient|O were|O pooled|O and|O randomly|O ligated|O (|O Quick|O Ligation|O Kit|O ,|O New|O England|O Biolabs|O ,|O Ipswich|O ,|O MA|O )|O .|O
PATIENTS|O AND|O METHODS|O .|O
Although|O DNMT1|O ,|O DNMT3B|O and|O DNMT3L|O have|O all|O been|O reported|O to|O be|O affected|O by|O rare|O somatic|O mutations|O in|O human|O malignancies|O ,|O DNMT3A|O is|O the|O only|O DNMT|O family|O member|O that|O is|O frequently|O mutated|O in|O myeloid|O malignancies|O .|O
Inhibition|O of|O Janus|O kinase|O 2|O or|O SRC|O kinase|O signaling|O downstream|O of|O mutated|O CSF3R|O is|O feasible|O and|O should|O be|O explored|O therapeutically|O .|O
Asxl1|O attenuation|O resulted|O in|O significant|O perinatal|O lethality|O ,|O although|O surviving|O mice|O had|O defects|O in|O B|O -|O lymphopoiesis|O and|O multiple|O constitutional|O developmental|O defects|O .|O
Despite|O a|O relatively|O high|O frequency|O of|O TET2|O mutations|O in|O MDS|O ,|O its|O clinical|O significance|O and|O pathogenesis|O have|O not|O been|O well|O defined|O .|O
Tumor|O Samples|O and|O Tumor|O Cell|O Lines|O .|O
The|O mean|O coverage|O of|O all|O amplicons|O was|O 2484|O reads|O per|O amplicon|O .|O
Examination|O of|O the|O bone|O marrow|O shows|O a|O myeloid|O hyperplasia|O with|O full|O maturation|O with|O <|O 5|O %|O myeloblasts|O (|O <|O 1|O %|O in|O the|O peripheral|O blood|O )|O .|O
RUNX1|O mutations|O have|O been|O described|O in|O the|O M0|O subtype|O of|O AML|O ,|O radiation|O -|O associated|O and|O chemotherapy|O -|O related|O MDS|O or|O AML|O ,|O or|O in|O patients|O with|O de|O novo|O high|O -|O risk|O MDS|O ;|O however|O ,|O only|O a|O small|O number|O of|O patients|O with|O CMML|O have|O been|O examined|O for|O RUNX1|O mutations|O ,|O and|O the|O frequency|O and|O patterns|O of|O RUNX1|O mutations|O in|O CMML|O remain|O to|O be|O defined|O .|O
Because|O of|O the|O strong|O association|O between|O NPM1|O mutations|O and|O genes|O in|O the|O cohesin|O complex|O ,|O we|O wanted|O to|O find|O out|O whether|O the|O cohesin|O mutations|O have|O an|O impact|O in|O the|O NPM1|O -|O mutated|O patient|O group|O .|O
Moreover|O ,|O these|O findings|O raise|O the|O question|O of|O whether|O other|O tyrosine|O and|O non|O -|O tyrosine|O kinases|O may|O localize|O to|O the|O nucleus|O and|O phosphorylate|O histones|O and|O other|O nuclear|O regulatory|O complexes|O .|O
More|O recently|O ,|O Challen|O et|O al|O carried|O out|O more|O extensive|O analysis|O in|O vivo|O by|O studying|O the|O effect|O of|O Haematopoietic|O -|O specific|O conditional|O Dnmt3a|O deletion|O on|O self|O -|O renewal|O in|O serial|O transplantation|O assays|O .|O
This|O mutation|O has|O also|O been|O found|O to|O be|O associated|O with|O wild|O -|O type|O CEBPA|O and|O the|O absence|O of|O FLT3|O abnormalities|O (|O eg|O ,|O FLT3|O -|O ITD|O or|O FLT3|O -|O TKD|O mutations|O )|O .|O
Diagnostic|O bone|O marrow|O or|O peripheral|O blood|O samples|O were|O analyzed|O from|O 389|O adult|O patients|O (|O aged|O 17|O -|O 60|O years|O )|O with|O de|O novo|O (|O n|O =|O 348|O )|O or|O secondary|O AML|O (|O n|O =|O 41|O ,|O and|O of|O these|O ,|O 35|O patients|O had|O antecedent|O myelodysplastic|O syndrome|O and|O 6|O patients|O had|O treatment|O -|O related|O secondary|O AML|O )|O with|O French|O -|O American|O -|O British|O classification|O M0|O -|O M2|O or|O M4|O -|O M7|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
GATA2|O mutation|O .|O
The|O discrepant|O findings|O from|O these|O studies|O may|O be|O a|O result|O of|O important|O differences|O between|O the|O studies|O in|O factors|O such|O as|O patient|O baseline|O characteristics|O ,|O presence|O of|O concurrent|O genetic|O lesions|O (|O eg|O ,|O NPM1|O ,|O CEBPA|O mutations|O )|O ,|O or|O inclusion|O of|O the|O APL|O subtypes|O .|O
Several|O reports|O have|O described|O the|O clinical|O impact|O of|O splicing|O factor|O mutations|O .|O
Genetic|O alterations|O of|O the|O cohesin|O complex|O genes|O in|O myeloid|O malignancies|O .|O
Upon|O induction|O of|O GATA1|O expression|O ,|O GATA1|O supplants|O these|O sites|O .|O
CONCLUSION|O .|O
EZH2|O mutations|O have|O also|O been|O reported|O in|O MDS|O /|O MPN|O and|O primary|O myelofibrosis|O ,|O but|O are|O less|O frequent|O in|O AML|O (|O 1|O .|O 8|O %|O )|O .|O
All|O the|O 81|O BM|O samples|O were|O re|O -|O evaluated|O and|O reclassified|O according|O to|O the|O World|O Health|O Organization|O system|O .|O
Changes|O in|O palpable|O spleen|O length|O in|O the|O ruxolitinib|O and|O placebo|O groups|O mirrored|O the|O changes|O in|O spleen|O volume|O .|O
Supportive|O Care|O for|O AML|O .|O
Moreover|O ,|O alternative|O splicing|O analysis|O showed|O that|O exon|O 9|O of|O FECH|O was|O skipped|O in|O U2AF1|O mutant|O cases|O but|O not|O in|O U2AF1|O WT|O cases|O ,|O including|O those|O with|O SF3B1|O mutations|O (|O supplemental|O Figure|O 8|O )|O .|O
Although|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O was|O prognostic|O on|O a|O univariate|O analysis|O ,|O it|O lost|O its|O prognostic|O impact|O on|O a|O multivariable|O analysis|O .|O
Recently|O ,|O Huang|O et|O al|O have|O dissected|O the|O function|O of|O GATA2|O in|O normal|O and|O aberrant|O megakaryopoiesis|O .|O
Table|O 6|O .|O Risk|O Stratification|O and|O Treatment|O in|O Primary|O Myelofibrosis|O .|O
Myelodysplastic|O syndromes|O (|O MDS|O )|O and|O related|O myeloid|O neoplasms|O are|O a|O heterogeneous|O group|O of|O intractable|O myeloid|O malignancies|O ,|O characterized|O by|O deregulated|O blood|O cell|O production|O with|O dysplastic|O cell|O morphology|O and|O a|O high|O propensity|O to|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
Regardless|O ,|O mutational|O profiling|O in|O PMF|O might|O clarify|O disease|O heterogeneity|O ,|O refine|O current|O prognostic|O models|O ,|O inform|O therapeutic|O decisions|O and|O provide|O clinical|O trials|O with|O a|O tool|O for|O better|O patient|O stratification|O and|O monitoring|O of|O the|O effects|O of|O novel|O drugs|O .|O
Indeed|O ,|O we|O observed|O a|O higher|O response|O rate|O in|O patients|O with|O cohesin|O mutations|O treated|O with|O azacitidine|O .|O
However|O ,|O the|O way|O in|O which|O BCOR|O and|O BCORL1|O mutations|O contribute|O to|O AML|O development|O is|O still|O not|O clear|O .|O
High|O frequency|O of|O GATA2|O mutations|O in|O patients|O with|O mild|O chronic|O neutropenia|O evolving|O to|O MonoMac|O syndrome|O ,|O myelodysplasia|O ,|O and|O acute|O myeloid|O leukemia|O .|O
Mutations|O of|O N|O -|O RAS|O and|O K|O -|O RAS|O have|O a|O higher|O incidence|O in|O patients|O with|O CMML|O ,|O 12|O .|O 3|O %|O and|O 14|O .|O 8|O %|O ,|O respectively|O .|O
Moreover|O ,|O the|O physiological|O requirement|O of|O GATA|O function|O in|O humans|O is|O further|O supported|O by|O the|O identification|O of|O GATA|O gene|O mutations|O associated|O with|O human|O disease|O .|O
In|O both|O studies|O ,|O these|O mutations|O were|O subsequently|O studied|O in|O larger|O series|O of|O AML|O patients|O .|O
Interestingly|O ,|O SF3B1|O mutations|O ,|O but|O not|O other|O splicing|O factor|O mutations|O ,|O have|O also|O been|O reported|O in|O 5|O -|O 15|O %|O of|O chronic|O lymphocytic|O leukemia|O (|O CLL|O )|O ,|O especially|O in|O high|O -|O risk|O cases|O .|O
INTRODUCTION|O .|O
Analysis|O of|O DNA|O from|O CD3|O +|O cells|O showed|O a|O much|O lower|O frequency|O of|O the|O base|O change|O (|O 2|O of|O 15|O reads|O )|O ,|O highlighting|O the|O somatic|O nature|O of|O this|O alteration|O .|O
In|O addition|O ,|O AML|O with|O molecular|O lesions|O such|O as|O mutated|O NPM1|O or|O CEBPA|O genes|O are|O considered|O provisional|O entities|O (|O further|O information|O on|O these|O genetic|O lesions|O is|O provided|O later|O )|O .|O
A|O complete|O remission|O was|O obtained|O ,|O but|O she|O developed|O a|O progressive|O loss|O of|O neutrophils|O ,|O monocytes|O ,|O B|O cells|O ,|O and|O NK|O cells|O associated|O with|O numerous|O infections|O (|O Table|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
ASXL1|O ,|O additional|O sex|O combs|O -|O like|O 1|O ;|O DNMT3A|O ,|O DNA|O methyltransferase|O 3A|O ;|O EZH2|O ,|O enhancer|O of|O zeste|O homologue|O 2|O ;|O NA|O ,|O data|O have|O not|O been|O reported|O .|O
Figure|O 1|O .|O Characterization|O of|O cohesin|O mutations|O in|O patients|O with|O myeloid|O disease|O .|O (|O A|O )|O Structure|O of|O the|O cohesin|O ring|O .|O (|O B|O )|O Position|O and|O disease|O subtype|O for|O identified|O cohesin|O mutations|O SMC3|O (|O i|O )|O ,|O STAG2|O (|O ii|O )|O ,|O and|O RAD21|O (|O iii|O )|O .|O No|O correlation|O was|O found|O with|O any|O structural|O motif|O ,|O and|O no|O mutational|O hotspots|O were|O identified|O .|O (|O C|O )|O Frequency|O of|O cohesin|O family|O gene|O mutations|O in|O each|O myeloid|O malignancy|O .|O (|O D|O )|O Distribution|O of|O cohesin|O family|O gene|O mutations|O identified|O across|O the|O patient|O cohort|O .|O
Our|O data|O further|O suggest|O that|O cohesin|O has|O a|O cooperative|O role|O in|O epigenetic|O regulation|O and|O transcriptional|O programming|O by|O virtue|O of|O the|O higher|O response|O rate|O in|O cohesin|O mutant|O MDS|O patients|O treated|O with|O HMAs|O .|O
In|O a|O multivariable|O analysis|O that|O included|O clinical|O features|O and|O other|O mutations|O ,|O mutations|O in|O five|O genes|O -|O TP53|O ,|O EZH2|O ,|O ETV6|O ,|O RUNX1|O ,|O and|O ASXL1|O -|O were|O independently|O associated|O with|O decreased|O overall|O survival|O .|O
There|O were|O 55|O CMML1|O and|O 26|O CMML2|O patients|O .|O
The|O SETBP1|O gene|O encodes|O a|O 170|O -|O kDa|O nuclear|O protein|O that|O binds|O SET|O and|O interacts|O with|O a|O tumor|O suppressor|O gene|O (|O PP2A|O )|O ,|O playing|O a|O critical|O role|O in|O cell|O proliferation|O .|O
DNA|O SEQUENCING|O .|O
Cohesin|O haploinsufficiency|O is|O thus|O the|O operative|O pathophysiologic|O mechanism|O ,|O a|O notion|O further|O supported|O by|O the|O mutual|O exclusivity|O of|O cohesin|O mutations|O :|O haploinsufficiency|O for|O one|O cohesin|O complex|O member|O may|O be|O sufficient|O to|O initiate|O the|O myeloid|O transformation|O pathway|O ,|O whereas|O a|O double|O hit|O would|O be|O deleterious|O .|O
Erik|O Vakil|O ;|O Ayalew|O Tefferi|O .|O
Clinical|O laboratories|O may|O choose|O to|O use|O either|O commercial|O detection|O kits|O or|O laboratory|O -|O developed|O tests|O .|O
We|O also|O identified|O three|O samples|O with|O activating|O mutations|O of|O amino|O acid|O R201|O in|O GNAS|O ,|O the|O gene|O encoding|O the|O Gsalpha|O subunit|O of|O the|O heterotrimeric|O Gs|O -|O protein|O complex|O .|O
The|O vast|O majority|O of|O mutations|O identified|O across|O cohesin|O proteins|O were|O heterozygous|O nonsense|O and|O frameshift|O events|O ,|O which|O would|O be|O anticipated|O to|O cause|O expression|O of|O a|O truncated|O protein|O .|O
The|O mutated|O genes|O most|O strongly|O associated|O with|O a|O specific|O karyotype|O group|O were|O TET2|O and|O TP53|O .|O
Clinical|O and|O cytogenetic|O correlates|O of|O mutations|O .|O
All|O patients|O received|O intensive|O ,|O response|O -|O adapted|O double|O induction|O and|O consolidation|O therapy|O .|O
However|O ,|O the|O percentage|O of|O patients|O achieving|O a|O CR|O who|O did|O not|O proceed|O to|O consolidation|O was|O twice|O as|O high|O in|O the|O high|O -|O dose|O cytarabine|O induction|O arm|O .|O
The|O analysis|O of|O global|O methylation|O levels|O by|O liquid|O chromatography|O -|O mass|O spectrometry|O (|O LC|O -|O MS|O )|O in|O DNMT3A|O -|O mutant|O AMLs|O did|O not|O reveal|O a|O difference|O in|O 5|O -|O methylcytosine|O (|O 5|O -|O mC|O )|O levels|O .|O
Association|O of|O cohesin|O gene|O mutations|O with|O clinical|O characteristics|O .|O
We|O failed|O to|O find|O a|O survival|O difference|O between|O CMML|O patients|O with|O RUNX1|O mutations|O and|O those|O without|O RUNX1|O mutations|O .|O
Although|O genome|O -|O wide|O mapping|O studies|O of|O 5|O -|O hmC|O in|O the|O haematopoietic|O system|O have|O not|O yet|O been|O reported|O ,|O genome|O -|O wide|O mapping|O of|O 5|O -|O hmC|O in|O embryonic|O stem|O cells|O has|O identified|O that|O 5|O -|O hmC|O is|O most|O often|O present|O at|O transcription|O start|O sites|O and|O within|O gene|O bodies|O .|O
Allogeneic|O Stem|O Cell|O Transplantation|O Allogeneic|O hematopoietic|O stem|O cell|O transplant|O (|O HCT|O )|O is|O currently|O the|O only|O therapy|O with|O curative|O potential|O for|O PMF|O ;|O however|O ,|O treatment|O -|O related|O mortality|O remains|O high|O .|O
When|O compared|O with|O patients|O with|O wild|O -|O type|O p53|O ,|O median|O OS|O in|O patients|O with|O the|O mutation|O was|O much|O shorter|O (|O 66|O versus|O 6|O months|O ;|O P|O <|O 0|O .|O 001|O )|O .|O
The|O PCR|O products|O were|O diluted|O 20|O -|O fold|O ,|O and|O 1|O muL|O of|O the|O diluted|O product|O was|O used|O for|O a|O second|O round|O of|O PCR|O for|O 35|O cycles|O using|O two|O nested|O primers|O ,|O M2u|O and|O M2d|O .|O
IDH1|O and|O IDH2|O mutations|O have|O also|O been|O reported|O in|O several|O hematopoietic|O malignancies|O such|O as|O MDS|O ,|O myeloproliferative|O neoplasm|O (|O MPN|O )|O ,|O AML|O (|O de|O novo|O or|O secondary|O to|O MDS|O or|O MPN|O )|O ,|O and|O CML|O in|O blast|O phase|O .|O
The|O algorithm|O can|O be|O accessed|O online|O at|O http|O :|O /|O /|O www|O .|O aml|O -|O score|O .|O org|O /|O .|O
Loss|O -|O of|O -|O function|O mutations|O in|O ASXL1|O have|O been|O identified|O in|O a|O range|O of|O myeloid|O malignancies|O ,|O most|O commonly|O in|O patients|O with|O MDS|O ,|O PMF|O or|O MDS|O /|O MPN|O overlap|O disorders|O .|O
This|O analysis|O suggested|O that|O RIC|O allogeneic|O HSCT|O was|O associated|O with|O improved|O relapse|O -|O free|O survival|O ,|O and|O the|O authors|O concluded|O that|O this|O approach|O remains|O of|O interest|O .|O
These|O findings|O strengthened|O the|O importance|O of|O deregulated|O epigenetic|O modifiers|O in|O myeloid|O malignancy|O pathogenesis|O which|O had|O already|O been|O suggested|O by|O the|O finding|O of|O recurrent|O translocations|O involving|O histone|O lysine|O acetyltransferases|O (|O for|O example|O ,|O lysine|O acetyltransferase|O 6A|O (|O KAT6A|O ;|O also|O known|O as|O MOZ|O )|O -|O nuclear|O receptor|O co|O -|O activator|O 2|O (|O NCOA2|O ;|O also|O known|O as|O TIF2|O )|O fusion|O )|O and|O methyltransferases|O (|O for|O example|O ,|O nucleoporin|O 98|O (|O NUP98|O )|O -|O nuclear|O receptor|O binding|O SET|O domain|O protein|O 1|O (|O NSD1|O )|O fusion|O and|O mixed|O -|O lineage|O leukaemia|O (|O MLL|O )|O translocations|O )|O .|O
It|O is|O possible|O that|O the|O mutations|O lead|O to|O distinct|O phenotypes|O by|O affecting|O different|O stages|O of|O splicing|O and|O /|O or|O by|O causing|O defective|O splicing|O of|O specific|O gene|O transcripts|O .|O
Prespecified|O analyses|O were|O conducted|O to|O cross|O -|O validate|O the|O modified|O MFSAF|O ,|O version|O 2|O .|O 0|O .|O
In|O our|O cohort|O ,|O we|O detected|O one|O case|O with|O a|O homozygous|O mutation|O pattern|O ,|O in|O detail|O ,|O a|O splice|O mutation|O before|O exon|O 17|O .|O
Furthermore|O ,|O high|O GATA2|O expression|O has|O been|O associated|O with|O myeloid|O neoplasias|O having|O 3q|O rearrangements|O .|O
Cohesin|O complex|O mutation|O ,|O mainly|O in|O STAG1|O (|O 1|O .|O 8|O %|O )|O ,|O STAG2|O (|O 1|O .|O 3|O %|O )|O ,|O and|O SMC3|O (|O 1|O .|O 3|O %|O )|O ,|O were|O detected|O in|O a|O total|O of|O 5|O .|O 9|O %|O of|O AML|O patients|O and|O associated|O with|O a|O low|O level|O expression|O of|O BAALC|O .|O
The|O mutation|O results|O in|O impaired|O function|O of|O the|O autoinhibitory|O region|O and|O subsequent|O ligand|O -|O independent|O thrombopoietin|O receptor|O activation|O .|O
A|O heterozygous|O missense|O mutation|O in|O U2AF1|O (|O Q157R|O )|O was|O found|O in|O a|O patient|O with|O refractory|O cytopenia|O with|O unilineage|O dysplasia|O (|O RCUD|O )|O and|O uniparental|O disomy|O of|O 2q|O (|O UPD2q|O ;|O Figure|O 1A|O )|O .|O
We|O show|O here|O that|O EZH2|O point|O mutations|O result|O in|O a|O similar|O adverse|O tendency|O in|O overall|O survival|O (|O P|O =|O 0|O .|O 076|O when|O measured|O from|O the|O date|O of|O diagnosis|O and|O P|O =|O 0|O .|O 026|O when|O measured|O from|O the|O time|O of|O bone|O marrow|O sampling|O )|O ,|O but|O a|O larger|O cohort|O from|O a|O prospective|O clinical|O trial|O should|O be|O analyzed|O to|O assess|O this|O properly|O .|O
Approximately|O half|O of|O the|O laboratories|O performed|O single|O replicates|O ,|O and|O half|O performed|O assays|O in|O duplicate|O .|O
In|O the|O group|O of|O NPM1|O -|O mutated|O AML|O patients|O (|O n|O =|O 137|O )|O ,|O OS|O and|O RFS|O were|O not|O influenced|O by|O the|O presence|O of|O mutations|O in|O the|O cohesin|O complex|O (|O OS|O :|O HR|O 1|O .|O 17|O ;|O 95|O %|O CI|O ,|O 0|O .|O 53|O -|O 2|O .|O 55|O ;|O P|O =|O .|O 7|O ;|O supplemental|O Figure|O 3C|O )|O and|O (|O RFS|O :|O HR|O 0|O .|O 85|O ;|O 95|O %|O CI|O ,|O 0|O .|O 34|O -|O 2|O .|O 12|O ;|O P|O =|O .|O 72|O ;|O supplemental|O Figure|O 3D|O )|O .|O
Mutations|O in|O the|O spliceosome|O machinery|O ,|O a|O novel|O and|O ubiquitous|O pathway|O in|O leukemogenesis|O .|O
A|O CNL|O patient|O with|O the|O CSF3R|O T618I|O membrane|O proximal|O mutation|O was|O treated|O with|O ruxolitinib|O and|O exhibited|O a|O marked|O ,|O durable|O decrease|O in|O white|O blood|O cell|O and|O absolute|O neutrophil|O counts|O and|O resolution|O of|O thrombocytopenia|O (|O initially|O reported|O as|O a|O 5|O -|O month|O response|O ,|O now|O still|O responding|O after|O 11|O months|O )|O .|O
These|O methods|O easily|O achieve|O analytical|O sensitivities|O of|O 1|O %|O mutant|O alleles|O .|O
A|O randomized|O phase|O III|O study|O has|O shown|O that|O in|O patients|O with|O neutropenia|O undergoing|O induction|O chemotherapy|O for|O AML|O or|O MDS|O ,|O posaconazole|O was|O significantly|O more|O effective|O in|O preventing|O invasive|O fungal|O infections|O than|O fluconazole|O or|O itraconazole|O ,|O and|O was|O associated|O with|O improved|O OS|O outcomes|O .|O
Two|O -|O hundred|O and|O twenty|O -|O six|O patients|O with|O WHO|O -|O defined|O CMML|O and|O who|O were|O seen|O at|O the|O Mayo|O Clinic|O from|O 1997|O to|O 2007|O were|O included|O in|O the|O current|O study|O .|O
The|O presence|O of|O STAG2|O mutation|O appeared|O to|O be|O associated|O with|O adverse|O clinical|O outcome|O and|O an|O increase|O in|O bone|O marrow|O blasts|O .|O
SUMMARY|O .|O
Because|O there|O was|O incomplete|O concordance|O ,|O it|O is|O important|O that|O laboratories|O participate|O in|O proficiency|O testing|O programs|O that|O include|O a|O wide|O spectrum|O of|O clinical|O laboratories|O .|O
Previous|O work|O in|O a|O zebrafish|O model|O identified|O runx|O dependence|O on|O rad21|O expression|O ,|O and|O given|O the|O high|O association|O of|O RUNX1|O mutations|O in|O cohesin|O mutant|O myeloid|O disease|O ,|O we|O queried|O if|O this|O relationship|O would|O be|O evident|O in|O our|O patient|O cohort|O .|O
Clinically|O ,|O patients|O with|O exon|O 12|O mutations|O typically|O present|O with|O isolated|O erythrocytosis|O and|O suppressed|O erythropoietin|O ,|O in|O contrast|O to|O the|O trilineage|O hyperplasia|O characteristic|O of|O patients|O with|O V617F|O mutation|O .|O
The|O 2008|O World|O Health|O Organization|O (|O WHO|O )|O definition|O of|O PMF|O includes|O JAK2|O (|O V617F|O )|O or|O MPL|O (|O W515|O )|O mutations|O as|O a|O major|O diagnostic|O criterion|O that|O unequivocally|O proves|O the|O clonal|O nature|O of|O the|O disease|O .|O
The|O complete|O overview|O of|O SNP|O array|O lesions|O has|O been|O published|O .|O
The|O disease|O poses|O a|O unique|O diagnostic|O challenge|O for|O both|O hematologists|O and|O pathologists|O because|O of|O its|O clinicopathologic|O diversity|O and|O its|O benign|O or|O malignant|O mimickers|O .|O
The|O Y252H|O mutation|O ,|O which|O is|O located|O in|O the|O extracellular|O domain|O of|O MPL|O ,|O confers|O hypersensitivity|O to|O thrombopoietin|O and|O increases|O the|O generation|O of|O megakaryocyte|O colonies|O in|O vitro|O and|O leads|O to|O increased|O thrombopoietin|O signaling|O and|O cell|O growth|O and|O survival|O .|O
If|O the|O LP|O is|O positive|O ,|O intrathecal|O chemotherapy|O with|O cytarabine|O or|O methotrexate|O is|O recommended|O ,|O given|O concurrently|O with|O systemic|O induction|O therapy|O .|O
ASXL1|O ,|O EZH2|O ,|O and|O UTX|O are|O members|O of|O pathways|O that|O control|O histone|O post|O -|O translational|O modifications|O .|O
Harada|O et|O al|O .|O observed|O that|O N|O -|O terminal|O mutations|O were|O highly|O associated|O with|O therapy|O -|O related|O MDS|O ,|O whereas|O C|O -|O terminal|O mutations|O of|O RUNX1|O preferentially|O occurred|O in|O de|O novo|O high|O -|O risk|O MDS|O or|O AML|O after|O antecedent|O de|O novo|O MDS|O .|O
The|O remainder|O are|O six|O novel|O missense|O mutants|O at|O RHD|O (|O nos|O .|O 1|O -|O 6|O )|O and|O one|O nonsense|O mutant|O ,|O Arg293X|O ,|O in|O three|O patients|O (|O nos|O .|O 14|O -|O 16|O )|O ;|O whether|O these|O mutants|O can|O induce|O RUNX1|O functional|O changes|O needs|O further|O investigation|O .|O
Using|O DNA|O sequencing|O ,|O we|O and|O others|O identified|O perturbation|O of|O TET2|O ,|O located|O at|O chromosome|O 4q24|O ,|O in|O 26|O %|O of|O the|O individuals|O with|O MDS|O .|O
Recurrent|O pneumonia|O was|O present|O in|O 5|O patients|O and|O severe|O and|O chronic|O warts|O and|O /|O or|O genital|O HPV|O was|O observed|O in|O 6|O patients|O .|O
BCORL1|O is|O also|O a|O transcriptional|O corepressor|O and|O functional|O studies|O have|O shown|O that|O it|O can|O bind|O to|O class|O II|O histone|O deacetylases|O (|O HDAC4|O ,|O HDAC5|O ,|O HDAC7|O )|O ,|O to|O interact|O with|O the|O CTBP1|O corepressor|O ,|O and|O to|O affect|O the|O repression|O of|O E|O -|O cadherin|O .|O
Notably|O ,|O the|O expression|O rate|O of|O Gata2|O was|O profoundly|O reduced|O in|O HSCs|O derived|O from|O Evi1|O -|O /|O -|O embryos|O .|O
However|O ,|O azoles|O should|O not|O be|O given|O during|O anthracycline|O chemotherapy|O because|O they|O impair|O drug|O metabolism|O and|O can|O increase|O toxicity|O .|O
The|O "|O protective|O effect|O "|O of|O SF3B1|O mutation|O on|O OS|O was|O lost|O in|O multivariate|O analysis|O ,|O including|O clinical|O variables|O such|O as|O International|O Prognostic|O Scoring|O System|O score|O .|O
In|O addition|O ,|O 5|O hemopoietic|O cell|O lines|O (|O HL60|O ,|O U937|O ,|O Raji|O ,|O KG|O -|O 1|O ,|O K562|O )|O and|O peripheral|O blood|O samples|O from|O 30|O normal|O control|O were|O also|O studied|O .|O
Impact|O of|O spliceosome|O mutations|O on|O clinical|O outcome|O .|O
Besides|O ,|O Bmp4|O transcripts|O are|O also|O concentrated|O along|O the|O ventral|O aspect|O of|O the|O dorsal|O aorta|O in|O E11|O .|O 5|O mouse|O embryos|O .|O
INCB018424|O is|O a|O JAK1|O /|O JAK2|O inhibitor|O ,|O and|O phase|O I|O /|O II|O studies|O involved|O 153|O patients|O with|O PMF|O or|O post|O -|O PV|O /|O ET|O MF|O ,|O 34|O patients|O with|O PV|O ,|O and|O 39|O with|O ET|O .|O
Indeed|O ,|O DNMT3A|O encodes|O a|O methyltransferase|O enzyme|O catalyzing|O the|O addition|O of|O methyl|O groups|O to|O CpG|O dinucleotides|O .|O
Gata2|O expression|O also|O rescued|O the|O embryonic|O lethal|O phenotype|O of|O the|O Gata1|O mutation|O .|O
Consolidation|O therapy|O in|O this|O trial|O would|O be|O either|O continuation|O of|O clofarabine|O or|O intermediate|O -|O dose|O cytarabine|O .|O
There|O was|O no|O significant|O difference|O between|O patients|O with|O or|O without|O a|O mutation|O in|O the|O cohesin|O complex|O with|O regard|O to|O gene|O expression|O of|O MN1|O ,|O ERG|O ,|O EVI1|O ,|O MLL5|O ,|O and|O WT1|O .|O
Results|O of|O MPL|O assays|O should|O be|O reported|O in|O a|O similar|O fashion|O as|O those|O described|O above|O for|O JAK2|O .|O
Aplastic|O anemia|O is|O characterized|O by|O a|O reduced|O number|O of|O HSCs|O and|O fatty|O replacement|O in|O the|O bone|O marrow|O .|O
Diagnosis|O .|O
Abnormalities|O in|O seven|O genes|O were|O significantly|O associated|O with|O poor|O overall|O survival|O in|O univariate|O analyses|O (|O Fig|O .|O 2|O ,|O and|O Fig|O .|O 4|O in|O the|O Supplementary|O Appendix|O )|O .|O
For|O the|O assessment|O of|O bone|O marrow|O fibrosis|O ,|O paraffin|O sections|O were|O stained|O with|O Gomori|O silver|O impregnation|O technique|O ,|O and|O fibrosis|O was|O assessed|O semiquantitatively|O following|O the|O European|O consensus|O guidelines|O .|O
Treatments|O are|O based|O on|O the|O risk|O profile|O of|O individual|O patients|O .|O
The|O cutoff|O date|O was|O July|O 1|O ,|O 2012|O .|O
What|O Are|O the|O Currently|O Known|O JAK2|O and|O MPL|O Mutations|O ?|O
In|O conclusion|O ,|O even|O though|O plentiful|O interesting|O data|O about|O GATA2|O have|O already|O been|O collected|O ,|O many|O questions|O remain|O that|O might|O stimulate|O future|O research|O .|O
For|O this|O strategy|O to|O be|O better|O used|O ,|O potential|O transplant|O options|O should|O be|O considered|O during|O induction|O therapy|O ,|O and|O unrelated|O donor|O options|O /|O searches|O explored|O earlier|O in|O the|O disease|O management|O .|O
Genes|O differentially|O expressed|O between|O these|O 2|O groups|O were|O then|O identified|O using|O the|O Bioconductor|O package|O limma|O and|O Benjamini|O -|O Hochberg|O adjusted|O (|O ie|O ,|O to|O correct|O for|O multiple|O hypothesis|O testing|O )|O P|O values|O of|O <|O =|O .|O 001|O ;|O specifically|O ,|O we|O used|O the|O limma|O pipeline|O of|O voom|O (|O )|O -|O -|O -|O >|O lmFit|O (|O )|O -|O -|O -|O >|O eBayes|O (|O )|O ,|O which|O can|O be|O applied|O to|O both|O microarray|O and|O RNA|O -|O sequencing|O data|O .|O
Pleotrophic|O and|O lineage|O -|O specific|O cytokines|O ,|O transcription|O factors|O ,|O bone|O marrow|O microenvironment|O ,|O and|O numerous|O signaling|O proteins|O play|O a|O vital|O function|O in|O promoting|O expansion|O and|O guiding|O the|O differentiation|O of|O progenitor|O cells|O .|O
A|O proficiency|O test|O for|O JAK2|O V617F|O is|O available|O from|O the|O College|O of|O American|O Pathologists|O (|O 2013|O Surveys|O and|O Anatomic|O Pathology|O Education|O Programs|O ,|O http|O :|O /|O /|O www|O .|O cap|O .|O org|O /|O apps|O /|O docs|O /|O proficiency|O _|O testing|O /|O 2013|O _|O surveys|O _|O catalog|O .|O pdf|O ,|O last|O accessed|O November|O 28|O ,|O 2012|O )|O .|O
CONCLUSION|O .|O
ASXL1|O ,|O SRSF2|O and|O EZH2|O mutations|O were|O independently|O associated|O with|O poor|O survival|O ,|O but|O only|O ASXL1|O mutations|O held|O their|O prognostic|O relevance|O (|O HR|O :|O 1|O .|O 4|O ;|O P|O =|O 0|O .|O 04|O )|O independent|O of|O the|O Dynamic|O IPSS|O (|O DIPSS|O )|O -|O plus|O model|O ,|O which|O incorporates|O cytogenetic|O risk|O .|O
The|O first|O study|O to|O identify|O this|O high|O -|O risk|O subgroup|O was|O HOVON|O .|O
Five|O hundred|O nanograms|O of|O this|O PCR|O product|O were|O hybridized|O to|O the|O SureSelect|O Human|O All|O Exon|O Kits|O Version|O 2|O (|O Agilent|O Technologies|O )|O ,|O covering|O 44|O Mb|O of|O the|O human|O exome|O during|O 24|O hours|O .|O
Although|O we|O identified|O 2|O mutant|O copies|O of|O U2AF1|O (|O 21q22|O .|O 3|O )|O in|O a|O sAML|O case|O with|O trisomy|O 21|O (|O supplemental|O Figure|O 2|O )|O ,|O all|O other|O 19|O cases|O of|O trisomy|O 21|O screened|O for|O this|O mutation|O were|O negative|O .|O
Use|O of|O growth|O factors|O may|O be|O a|O confounding|O factor|O in|O the|O interpretation|O of|O pathology|O results|O from|O bone|O marrow|O evaluations|O .|O
The|O different|O parental|O origins|O of|O the|O remaining|O chromosome|O 7|O within|O the|O same|O family|O led|O to|O the|O hypothesis|O of|O the|O existence|O of|O a|O "|O mutator|O gene|O "|O located|O outside|O of|O chromosome|O 7|O .|O
Emberger|O syndrome|O is|O an|O autosomal|O -|O dominant|O primary|O lymphedema|O with|O a|O predisposition|O to|O AML|O .|O
Using|O these|O four|O risk|O factors|O ,|O a|O new|O prognostic|O model|O for|O overall|O (|O high|O risk|O ,|O RR|O 4|O .|O 4|O ,|O 95|O %|O CI|O 2|O .|O 9|O -|O 6|O .|O 7|O ;|O intermediate|O risk|O ,|O RR|O 2|O .|O 0|O ,|O 95|O %|O CI|O 1|O .|O 4|O -|O 2|O .|O 9|O )|O and|O leukemia|O -|O free|O survival|O (|O high|O risk|O ,|O RR|O 4|O .|O 9|O ,|O 95|O %|O CI|O 1|O .|O 9|O -|O 12|O .|O 8|O ;|O intermediate|O risk|O ,|O RR|O 2|O .|O 6|O ,|O 95|O %|O CI|O 1|O .|O 1|O -|O 5|O .|O 9|O )|O performed|O better|O than|O other|O conventional|O risk|O models|O and|O was|O validated|O in|O an|O independent|O cohort|O of|O 268|O CMML|O patients|O .|O
Nucleotide|O positions|O are|O determined|O based|O on|O the|O cited|O sources|O .|O
These|O findings|O indicate|O that|O mutations|O in|O specific|O genes|O help|O explain|O the|O clinical|O heterogeneity|O of|O myelodysplastic|O syndromes|O and|O that|O the|O identification|O of|O these|O abnormalities|O would|O improve|O the|O prediction|O of|O prognosis|O in|O patients|O with|O myelodysplastic|O syndromes|O .|O
Figure|O 3|O .|O Kaplan|O -|O Meier|O estimates|O of|O overall|O survival|O in|O patients|O at|O '|O mutationally|O high|O -|O risk|O '|O compared|O with|O '|O mutationally|O low|O -|O risk|O '|O in|O the|O settings|O of|O IPSS|O categories|O ;|O a|O lowest|O and|O a|O highest|O IPSS|O category|O were|O considered|O ,|O the|O first|O including|O IPSS|O low|O plus|O Intermediate|O -|O 1|O ,|O the|O latter|O Intermediate|O -|O 2|O plus|O high|O -|O risk|O categories|O (|O a|O )|O .|O In|O (|O b|O )|O ,|O the|O cumulative|O risk|O of|O transformation|O to|O acute|O leukemia|O in|O the|O same|O patient|O populations|O as|O in|O (|O a|O )|O is|O shown|O .|O
Likewise|O ,|O little|O is|O known|O about|O the|O timing|O of|O DNMT3A|O mutations|O during|O disease|O evolution|O .|O
PMF|O .|O
Of|O the|O 53|O CMML|O patients|O who|O had|O cytogenetic|O examinations|O ,|O 30|O had|O normal|O karyotypes|O .|O
Both|O isoforms|O interact|O with|O the|O CtBP|O complex|O .|O
TET2|O is|O a|O putative|O tumor|O suppressor|O gene|O and|O mutational|O frequency|O is|O estimated|O at|O 16|O %|O for|O PV|O ,|O 5|O %|O for|O ET|O ,|O and|O 17|O %|O for|O PMF|O .|O
Patients|O who|O develop|O cerebellar|O toxicity|O should|O not|O be|O rechallenged|O with|O high|O -|O dose|O cytarabine|O in|O future|O treatment|O cycles|O .|O
Table|O 2|O describes|O the|O ASXL1|O mutational|O prevalence|O in|O 179|O patients|O with|O CMML|O .|O
Given|O the|O poor|O prognosis|O of|O these|O disorders|O ,|O the|O potential|O applicability|O of|O JAK|O or|O SRC|O kinase|O inhibitors|O is|O an|O important|O bench|O -|O tobedside|O implication|O of|O the|O discovery|O of|O activating|O CSF3R|O mutations|O .|O
A|O new|O GATA2|O transcript|O variant|O with|O an|O additional|O exon|O has|O been|O included|O recently|O in|O the|O NCBI|O database|O ;|O however|O ,|O no|O further|O information|O on|O this|O transcript|O has|O been|O reported|O .|O
We|O found|O a|O strong|O association|O between|O these|O mutations|O and|O mutations|O in|O NPM1|O .|O
Allogeneic|O HSCT|O in|O first|O CR|O was|O associated|O with|O significantly|O lower|O 3|O -|O year|O relapse|O (|O 32|O %|O vs|O .|O 81|O %|O ;|O P|O <|O .|O 001|O )|O and|O higher|O 3|O -|O year|O leukemia|O -|O free|O survival|O rates|O (|O 32|O %|O vs|O .|O 15|O %|O ;|O P|O <|O .|O 001|O )|O compared|O with|O the|O chemotherapy|O -|O only|O group|O .|O
We|O used|O the|O first|O cohort|O of|O 483|O European|O patients|O studied|O within|O 1|O year|O of|O diagnosis|O ,|O to|O select|O out|O which|O one|O of|O these|O mutations|O predicted|O worse|O outcome|O .|O
In|O contrast|O ,|O the|O membrane|O proximal|O mutations|O exhibit|O receptor|O activation|O in|O the|O complete|O absence|O of|O ligand|O ,|O suggesting|O distinct|O mechanisms|O of|O activation|O of|O these|O classes|O of|O CSF3R|O mutations|O .|O
Sequencing|O analyses|O have|O demonstrated|O that|O the|O SRSF2|O mutation|O appears|O to|O be|O an|O early|O event|O in|O the|O development|O of|O MDS|O ,|O perhaps|O making|O it|O a|O relevant|O therapeutic|O target|O .|O
Other|O options|O for|O this|O group|O include|O clinical|O trials|O or|O multiple|O courses|O (|O 3|O -|O 4|O )|O of|O high|O -|O dose|O cytarabine|O consolidation|O .|O
Details|O of|O the|O modeling|O strategy|O are|O provided|O in|O the|O Methods|O section|O in|O the|O Supplementary|O Appendix|O .|O
Study|O population|O and|O definitions|O .|O
The|O median|O follow|O -|O up|O was|O 4|O .|O 44|O years|O (|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 4|O .|O 12|O to|O 6|O .|O 19|O )|O ,|O during|O which|O time|O 332|O patients|O died|O and|O the|O data|O for|O 107|O were|O censored|O at|O the|O last|O date|O they|O were|O known|O to|O be|O alive|O .|O
In|O a|O more|O recent|O report|O ,|O Tet2|O -|O knockout|O mice|O developed|O a|O disease|O with|O MDS|O -|O like|O features|O including|O erythroid|O progenitor|O expansion|O .|O
When|O 310|O patients|O genotyped|O for|O these|O mutations|O were|O analyzed|O ,|O the|O presence|O of|O SF3B1|O mutations|O was|O associated|O with|O longer|O survival|O and|O U2AF1|O mutations|O with|O shorter|O survival|O ,|O whereas|O SRSF2|O mutations|O had|O no|O effect|O on|O survival|O .|O
However|O ,|O if|O neurologic|O symptoms|O (|O eg|O ,|O headache|O ,|O confusion|O ,|O altered|O sensory|O input|O )|O are|O present|O at|O diagnosis|O ,|O an|O initial|O CT|O /|O MRI|O should|O be|O performed|O to|O rule|O out|O the|O possibility|O of|O intracranial|O hemorrhage|O or|O presence|O of|O mass|O /|O lesion|O .|O
Single|O -|O agent|O use|O of|O any|O of|O these|O drugs|O have|O comparable|O response|O rates|O of|O approximately|O 20|O %|O that|O last|O 1|O -|O 2|O years|O .|O
In|O a|O joint|O study|O conducted|O by|O the|O Dutch|O -|O Belgian|O and|O Swiss|O cooperative|O groups|O (|O HOVON|O /|O SAKK|O )|O evaluating|O the|O correlation|O between|O cytogenetics|O and|O OS|O outcomes|O in|O patients|O aged|O 60|O years|O or|O younger|O with|O AML|O (|O N|O =|O 1975|O )|O ,|O the|O 4|O -|O year|O OS|O rate|O in|O patients|O with|O monosomal|O karyotype|O was|O 4|O %|O compared|O with|O 26|O %|O in|O those|O with|O complex|O karyotype|O (|O but|O without|O monosomal|O karyotype|O )|O .|O
Interestingly|O ,|O performing|O genome|O -|O wide|O microarray|O experiments|O in|O G1ME|O cells|O ,|O they|O identified|O four|O novel|O and|O direct|O targets|O of|O GATA2|O in|O megakaryocytes|O including|O conserved|O elements|O within|O intron|O 1|O of|O Hhex|O ,|O and|O Slamf1|O ,|O Sfpi1|O ,|O and|O Lmo2|O .|O
However|O there|O appear|O to|O be|O discrepancies|O in|O this|O impact|O among|O different|O studies|O .|O
These|O latter|O patients|O showed|O a|O higher|O incidence|O of|O leukemic|O transformation|O compared|O with|O both|O CALR|O -|O mutant|O (|O P|O =|O .|O 016|O )|O and|O JAK2|O -|O mutated|O patients|O (|O P|O =|O .|O 043|O )|O .|O
Based|O on|O studies|O with|O D|O .|O melanogaster|O homologues|O ,|O ASXL1|O is|O thought|O to|O associate|O with|O both|O repressive|O PcG|O and|O activating|O Trithorax|O complexes|O .|O
Mutations|O in|O histone|O -|O modifying|O enzymes|O EZH2|O mutations|O and|O genetic|O loss|O of|O PRC2|O function|O in|O myeloid|O malignancies|O .|O
Detection|O of|O JAK2|O and|O MPL|O mutations|O has|O been|O incorporated|O into|O routine|O diagnostic|O algorithms|O for|O these|O diseases|O .|O
The|O Gata2|O promoter|O responds|O to|O BMP4|O signaling|O ,|O which|O also|O initiates|O Fli1|O expression|O in|O Xenopus|O ,|O and|O as|O such|O BMP4|O -|O singnaling|O is|O another|O candidate|O initiator|O of|O the|O circuit|O .|O
CpG|O islands|O contain|O a|O high|O concentration|O of|O CpG|O sites|O and|O are|O frequently|O near|O promoter|O regions|O .|O
In|O addition|O to|O the|O known|O cytogenetic|O abnormalities|O ,|O we|O identified|O a|O single|O case|O with|O a|O focal|O deletion|O encompassing|O ETV6|O ,|O a|O gene|O that|O is|O recurrently|O involved|O in|O translocations|O in|O acute|O leukemia|O but|O is|O not|O known|O to|O be|O mutated|O in|O myelodysplastic|O syndromes|O (|O Fig|O .|O 3|O in|O the|O Supplementary|O Appendix|O )|O .|O
Whether|O Pro398Leu|O has|O a|O decreased|O transactivating|O ability|O requires|O further|O study|O .|O
Exploratory|O end|O points|O included|O changes|O in|O body|O weight|O and|O the|O JAK2V617F|O allele|O burden|O ,|O achievement|O of|O independence|O from|O transfusions|O ,|O and|O additional|O patient|O -|O reported|O outcomes|O (|O see|O the|O Supplementary|O Appendix|O )|O .|O
Western|O blot|O analysis|O demonstrated|O that|O protein|O levels|O of|O GATA2|O are|O lower|O in|O patients|O with|O aplastic|O anemia|O than|O those|O in|O normal|O subjects|O .|O
Intermediate|O -|O 1|O -|O risk|O patients|O who|O are|O transfusion|O dependent|O or|O with|O unfavorable|O cytogenetics|O ,|O intermediate|O -|O 2|O -|O risk|O patients|O ,|O and|O highrisk|O patients|O are|O candidates|O for|O investigational|O drug|O therapy|O or|O allogeneic|O stem|O cell|O transplantation|O .|O
Patients|O were|O eligible|O for|O the|O study|O if|O they|O were|O 18|O years|O of|O age|O or|O older|O and|O had|O primary|O myelofibrosis|O ,|O post|O -|O polycythemia|O vera|O myelofibrosis|O ,|O or|O post|O -|O essential|O thrombocythemia|O myelofibrosis|O according|O to|O 2008|O World|O Health|O Organization|O criteria|O ,|O with|O a|O life|O expectancy|O of|O 6|O months|O or|O longer|O ,|O an|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O score|O (|O see|O Table|O S1|O in|O the|O Supplementary|O Appendix|O ,|O available|O with|O the|O full|O text|O of|O this|O article|O at|O NEJM|O .|O org|O )|O of|O 2|O (|O intermediate|O -|O 2|O risk|O )|O or|O 3|O or|O more|O (|O high|O risk|O )|O ,|O an|O Eastern|O Cooperative|O Oncology|O Group|O performance|O status|O of|O 3|O or|O less|O (|O on|O a|O scale|O from|O 0|O to|O 5|O ,|O with|O higher|O scores|O indicating|O greater|O disability|O ;|O see|O the|O Supplementary|O Appendix|O for|O further|O details|O )|O ,|O less|O than|O 10|O %|O peripheral|O -|O blood|O blasts|O ,|O an|O absolute|O peripheral|O -|O blood|O CD34|O +|O cell|O count|O of|O more|O than|O 20x106|O per|O liter|O ,|O a|O platelet|O count|O of|O 100x109|O per|O liter|O or|O more|O ,|O and|O palpable|O splenomegaly|O (|O >|O =|O 5|O cm|O below|O the|O left|O costal|O margin|O )|O .|O
Finally|O ,|O the|O question|O of|O whether|O the|O recently|O characterized|O small|O molecular|O inhibitor|O of|O SF3B1|O might|O have|O a|O therapeutic|O role|O in|O the|O treatment|O of|O myeloid|O neoplasms|O with|O splicing|O factor|O mutations|O remains|O to|O be|O addressed|O .|O
Mutations|O in|O the|O analyzed|O genes|O were|O used|O as|O categorical|O variables|O .|O
Recently|O ,|O we|O identified|O high|O -|O frequency|O oncogenic|O mutations|O in|O the|O granulocyte|O -|O colony|O stimulating|O factor|O receptor|O (|O CSF3R|O )|O in|O CNL|O and|O in|O some|O patients|O with|O atypical|O chronic|O myeloid|O leukemia|O .|O
Cancer|O -|O associated|O mutations|O of|O IDH1|O and|O IDH2|O are|O heterozygous|O and|O occur|O at|O one|O of|O three|O highly|O conserved|O arginine|O residues|O :|O IDH1|O -|O R132|O ,|O IDH2|O -|O R172|O and|O IDH2|O -|O R140|O .|O
The|O subsequent|O analysis|O of|O the|O French|O Severe|O Chronic|O Neutropenia|O Registry|O allowed|O the|O identification|O of|O 6|O additional|O pedigrees|O and|O 10|O patients|O with|O 6|O different|O and|O not|O previously|O reported|O GATA2|O mutations|O (|O R204X|O ,|O E224X|O ,|O R330X|O ,|O A372T|O ,|O M388V|O ,|O and|O a|O complete|O deletion|O of|O the|O GATA2|O locus|O )|O .|O
Its|O estimated|O prevalence|O is|O more|O than|O 95|O %|O in|O PV|O ,|O 50|O %|O in|O ET|O ,|O and|O 50|O %|O in|O PMF|O ,|O and|O its|O value|O as|O a|O diagnostic|O marker|O is|O improved|O by|O a|O low|O prevalence|O in|O non|O -|O MPN|O myeloproliferative|O diseases|O .|O
Median|O survivals|O were|O 22|O months|O for|O CMML|O -|O 1|O and|O 14|O months|O for|O CMML|O -|O 2|O .|O
To|O explore|O whether|O these|O specific|O molecular|O assets|O associated|O with|O unique|O gene|O expression|O profiles|O ,|O we|O compared|O CD34|O +|O cells|O from|O 9|O mutationally|O high|O and|O 11|O mutationally|O low|O -|O risk|O patients|O ,|O randomly|O selected|O in|O the|O European|O cohort|O .|O
Other|O cytogenetic|O abnormalities|O included|O del20q|O -|O 5|O (|O 2|O %|O )|O ,|O +|O 21|O -|O 3|O (|O 1|O %|O )|O ,|O +|O 14|O -|O 2|O (|O 1|O %|O )|O ,|O +|O 11|O -|O 2|O (|O 1|O %|O )|O and|O isochromosome|O 17q|O -|O 2|O (|O 1|O %|O )|O .|O
Using|O a|O microarray|O screening|O approach|O ,|O miR|O -|O 144|O and|O miR|O -|O 451|O were|O identified|O as|O GATA1|O -|O regulated|O miRNAs|O .|O
Figure|O 5|O .|O Kaplan|O -|O Meier|O analysis|O of|O survival|O of|O PMF|O patients|O stratified|O according|O to|O their|O driver|O mutation|O and|O subdivided|O according|O to|O their|O IPSS|O risk|O .|O Vertical|O tick|O marks|O indicate|O right|O -|O censored|O patients|O .|O (|O A|O )|O "|O Lower|O "|O IPSS|O risk|O subgroup|O ,|O including|O patients|O with|O low|O or|O intermediate|O -|O 1|O IPSS|O risk|O :|O CALR|O -|O mutant|O patients|O had|O longer|O survival|O compared|O with|O either|O JAK2|O (|O V617F|O )|O -|O mutant|O (|O P|O =|O .|O 011|O )|O or|O triple|O -|O negative|O patients|O (|O P|O =|O .|O 001|O )|O .|O (|O B|O )|O "|O Higher|O risk|O "|O subgroup|O ,|O including|O patients|O with|O intermediate|O -|O 2|O or|O high|O IPSS|O risk|O :|O CALR|O -|O mutant|O patients|O had|O longer|O survival|O compared|O with|O the|O remaining|O genetic|O subgroups|O (|O maximum|O P|O value|O equal|O to|O .|O 023|O )|O .|O
Standard|O tumor|O lysis|O prophylaxis|O includes|O hydration|O with|O diuresis|O ,|O alkalinization|O of|O the|O urine|O ,|O and|O allopurinol|O administration|O or|O rasburicase|O treatment|O .|O
The|O risk|O of|O hemorrhage|O secondary|O to|O acquired|O von|O Willebrand|O syndrome|O may|O preclude|O the|O use|O of|O aspirin|O in|O patients|O with|O a|O ristocetin|O cofactor|O activity|O <|O 30|O %|O .|O
ETV6|O ,|O Ets|O variant|O 6|O ,|O is|O an|O ETS|O transcriptional|O repressor|O (|O locus|O of|O 12p13|O )|O and|O plays|O a|O critical|O role|O in|O embryogenesis|O and|O hematopoiesis|O .|O
ABSTRACT|O .|O
The|O prognostic|O value|O of|O JAK2V617F|O in|O PV|O and|O ET|O is|O yet|O to|O be|O established|O .|O
This|O probably|O relates|O to|O the|O partially|O non|O -|O overlapping|O roles|O of|O DNMT1|O ,|O DNMT3A|O and|O DNMT3B|O ,|O and|O suggests|O a|O possible|O unique|O role|O for|O DNMT3A|O in|O haematopoiesis|O .|O
Furthermore|O ,|O gene|O expression|O analysis|O of|O mutant|O megakaryocytes|O and|O erythroid|O progenitors|O showed|O significantly|O increased|O levels|O of|O GATA2|O ,|O indicating|O that|O FOG1|O /|O NuRD|O interaction|O is|O required|O for|O the|O earlier|O described|O '|O GATA|O switch|O '|O .|O
Patients|O with|O cohesin|O gene|O alterations|O had|O poor|O OS|O compared|O with|O patients|O without|O cohesin|O lesions|O (|O 27|O .|O 2|O vs|O 39|O .|O 9|O ;|O P|O =|O .|O 023|O )|O .|O
Furthermore|O ,|O GATA2|O suppresses|O adipocyte|O differentiation|O through|O direct|O inhibition|O of|O adipogenic|O factors|O ,|O including|O peroxisome|O proliferator|O -|O activated|O receptor|O -|O gamma|O (|O PPARy|O )|O ,|O indicating|O that|O fatty|O marrow|O replacement|O in|O patients|O with|O aplastic|O anemia|O can|O be|O explained|O by|O downregulation|O of|O GATA2|O and|O overexpression|O of|O PPARy|O .|O
All|O patients|O with|O CMML|O were|O managed|O with|O supportive|O care|O ,|O 45|O of|O them|O received|O low|O -|O dose|O cytarabine|O or|O an|O oral|O chemotherapeutic|O agent|O (|O hydroxyurea|O ,|O melphalan|O or|O 6|O -|O thioguanine|O )|O before|O transformation|O to|O AML|O .|O
Overall|O ,|O MPL|O W515L|O or|O W515K|O mutations|O are|O present|O in|O patients|O with|O PMF|O and|O ET|O at|O a|O frequency|O of|O approximately|O 5|O %|O and|O 3|O %|O ,|O respectively|O .|O
FLT3|O -|O ITD|O occurs|O in|O approximately|O 30|O %|O of|O cases|O and|O is|O more|O common|O than|O FLT3|O -|O TKD|O mutations|O ,|O which|O occur|O in|O approximately|O 10|O %|O of|O patients|O .|O
Thus|O ,|O the|O cohesin|O -|O complex|O is|O an|O essential|O structure|O during|O cell|O division|O .|O
In|O addition|O ,|O SF3B1|O are|O mutated|O in|O several|O solid|O cancers|O ,|O including|O breast|O ,|O bladder|O ,|O endometrial|O and|O other|O cancers|O ,|O although|O the|O mutation|O frequencies|O were|O low|O .|O
The|O Kaplan|O -|O Meier|O method|O and|O log|O -|O rank|O test|O were|O used|O to|O estimate|O the|O distribution|O of|O OS|O and|O RFS|O ,|O and|O to|O compare|O differences|O between|O survival|O curves|O ,|O respectively|O .|O
Baseline|O characteristics|O were|O similar|O in|O the|O two|O groups|O (|O Table|O 1|O )|O .|O
Similarly|O ,|O nearly|O one|O third|O of|O patients|O with|O RARS|O -|O T|O were|O found|O to|O have|O a|O JAK2|O mutation|O .|O
Mutations|O have|O been|O described|O previously|O in|O congenital|O neutropenia|O that|O is|O isolated|O (|O eg|O ,|O mutations|O of|O ELANE|O )|O ,|O associated|O with|O immunologic|O defects|O (|O eg|O ,|O mutations|O of|O CXCR4|O or|O WAS|O genes|O )|O ,|O or|O involves|O extra|O -|O hematopoietic|O manifestations|O ,|O the|O most|O frequent|O being|O HAX1|O (|O Kostmann|O disease|O )|O ,|O SDBS|O (|O Shwachman|O -|O Bodian|O -|O Diamond|O Syndrome|O )|O ,|O or|O G6PC3|O .|O
One|O patient|O had|O a|O silent|O mutation|O at|O RHD|O (|O no|O .|O 9|O )|O ,|O which|O had|O been|O reported|O earlier|O ;|O it|O is|O considered|O to|O have|O no|O effect|O on|O function|O .|O
This|O expressional|O change|O of|O GATA|O factors|O during|O cell|O differentiation|O is|O termed|O the|O '|O GATA|O factor|O switching|O '|O .|O
Overall|O ,|O we|O detected|O a|O GATA2|O mutation|O in|O 14|O white|O patients|O .|O
Figure|O 3|O .|O Janus|O kinase|O signalling|O affects|O the|O epigenome|O through|O direct|O and|O indirect|O activities|O .|O Janus|O kinase|O 1|O (|O JAK1|O )|O and|O JAK2|O have|O recently|O been|O shown|O to|O be|O able|O to|O enter|O the|O nucleus|O and|O to|O directly|O phosphorylate|O (|O P|O )|O tyrosine|O 41|O of|O histone|O H3|O (|O H3Y41|O )|O .|O At|O least|O one|O consequence|O of|O H3Y41|O phosphorylation|O is|O displaced|O binding|O of|O the|O repressive|O protein|O heterochromatin|O protein|O 1alpha|O (|O HP1alpha|O )|O from|O chromatin|O .|O The|O genome|O -|O wide|O effects|O of|O H3Y41|O phosphorylation|O and|O HP1alpha|O localization|O in|O contexts|O with|O and|O without|O JAK|O overactivity|O have|O yet|O to|O be|O published|O .|O Nor|O is|O it|O clear|O exactly|O how|O JAK1|O and|O JAK2|O enter|O the|O nucleus|O .|O In|O addition|O to|O phosphorylating|O H3Y41|O ,|O nuclear|O JAK2|O has|O been|O shown|O to|O phosphorylate|O protein|O arginine|O methyltransferase|O 5|O (|O PRMT5|O )|O .|O This|O thereby|O inhibits|O PRMT5|O activity|O and|O results|O in|O reduced|O histone|O H2A|O and|O H4|O arginine|O methyltransferase|O activity|O .|O Mutated|O forms|O of|O JAK2|O ,|O as|O seen|O most|O prominently|O in|O patients|O with|O myeloproliferative|O neoplasms|O ,|O result|O in|O increased|O kinase|O activity|O on|O the|O substrate|O PRMT5|O .|O H4R3me2|O ,|O histone|O H4|O dimethylated|O on|O arginine|O 3|O .|O
The|O 16|O specimens|O having|O a|O high|O rate|O of|O false|O -|O negative|O results|O tended|O to|O have|O lower|O JAK2|O allele|O burden|O in|O those|O laboratories|O doing|O quantitative|O assays|O ,|O suggesting|O that|O the|O false|O -|O negative|O results|O were|O mostly|O due|O to|O assays|O with|O lower|O analytical|O sensitivity|O .|O
Objective|O prognostic|O markers|O have|O yet|O to|O be|O established|O for|O PV|O and|O ET|O ,|O and|O the|O risk|O of|O thrombosis|O continues|O to|O be|O the|O main|O criteria|O for|O risk|O stratification|O .|O
Figure|O 3|O .|O Overall|O Survival|O .|O Kaplan|O -|O Meier|O estimates|O of|O overall|O survival|O ,|O including|O 4|O months|O of|O additional|O follow|O -|O up|O after|O the|O primary|O analysis|O ,|O are|O shown|O .|O There|O were|O 13|O deaths|O in|O the|O ruxolitinib|O group|O (|O 8|O .|O 4|O %|O )|O and|O 24|O deaths|O in|O the|O placebo|O group|O (|O 15|O .|O 6|O %|O )|O during|O a|O median|O follow|O -|O up|O period|O of|O 51|O weeks|O .|O Tick|O marks|O indicate|O censoring|O times|O for|O individual|O patients|O .|O
Studies|O of|O embryonic|O stem|O cells|O have|O demonstrated|O enrichment|O of|O 5|O -|O hmC|O in|O CpG|O dinucleotides|O near|O transcriptional|O start|O sites|O and|O in|O intragenic|O regions|O ,|O and|O 5|O -|O hmC|O placement|O in|O these|O regulatory|O regions|O is|O associated|O with|O increased|O gene|O expression|O .|O
There|O was|O an|O improvement|O of|O 50|O %|O or|O more|O in|O the|O total|O symptom|O score|O at|O 24|O weeks|O in|O 45|O .|O 9|O %|O of|O patients|O who|O received|O ruxolitinib|O as|O compared|O with|O 5|O .|O 3|O %|O of|O patients|O who|O received|O placebo|O (|O P|O <|O 0|O .|O 001|O )|O .|O
Only|O mutations|O in|O the|O TP53|O gene|O have|O been|O clearly|O associated|O with|O poor|O prognostic|O markers|O ,|O such|O as|O a|O complex|O karyotype|O (|O having|O three|O or|O more|O chromosomal|O abnormalities|O )|O ,|O and|O have|O been|O reported|O to|O independently|O predict|O survival|O among|O patients|O at|O intermediate|O risk|O ,|O as|O ascertained|O with|O the|O use|O of|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O .|O
The|O pathophysiology|O of|O MDS|O has|O not|O been|O well|O illustrated|O .|O
Genetic|O and|O functional|O studies|O have|O suggested|O that|O there|O are|O at|O least|O two|O classes|O of|O myeloid|O leukaemia|O disease|O alleles|O that|O contribute|O to|O haematopoietic|O transformation|O :|O class|O I|O alleles|O ,|O which|O confer|O a|O growth|O advantage|O by|O activating|O downstream|O effectors|O of|O various|O signalling|O pathways|O including|O members|O of|O the|O signal|O transducer|O and|O activator|O of|O transcription|O (|O STAT|O )|O ,|O PI3K|O and|O RAS|O -|O MAPK|O pathways|O ;|O and|O class|O II|O alleles|O ,|O which|O alter|O the|O expression|O of|O key|O transcriptional|O targets|O in|O myelopoiesis|O .|O
It|O is|O currently|O unknown|O whether|O 5|O -|O fC|O and|O 5|O -|O caC|O serve|O any|O function|O other|O than|O as|O oxidative|O by|O -|O products|O of|O 5|O -|O hmC|O and|O intermediates|O in|O DNA|O demethylation|O .|O
Re|O -|O evaluation|O using|O more|O sensitive|O techniques|O revealed|O higher|O frequencies|O :|O 95|O %|O to|O 97|O %|O in|O PV|O ,|O approximately|O 55|O %|O in|O ET|O ,|O and|O approximately|O 65|O %|O in|O PMF|O ,|O suggesting|O that|O insensitive|O assay|O methods|O (|O eg|O ,|O Sanger|O sequencing|O ,|O which|O has|O an|O analytic|O sensitivity|O of|O 20|O %|O )|O generated|O a|O significant|O number|O of|O false|O -|O negative|O results|O .|O
Recurrent|O hypomorphic|O cohesin|O defects|O and|O cohesin|O low|O expression|O were|O identified|O in|O a|O significant|O proportion|O of|O patients|O with|O MDS|O and|O AML|O .|O
MATERIALS|O AND|O METHODS|O .|O
Further|O analysis|O involves|O a|O JAK2V617|O PB|O mutation|O screen|O and|O measurement|O of|O a|O serum|O EPO|O level|O .|O
In|O addition|O ,|O they|O indicate|O that|O PMF|O genotypes|O should|O now|O be|O considered|O also|O in|O designing|O clinical|O trials|O on|O the|O use|O of|O novel|O drugs|O for|O treatment|O of|O PMF|O .|O
At|O the|O time|O of|O the|O prospectively|O defined|O data|O cutoff|O (|O median|O follow|O -|O up|O ,|O 32|O weeks|O )|O ,|O 134|O patients|O in|O the|O ruxolitinib|O group|O (|O 86|O .|O 5|O %|O )|O and|O 78|O in|O the|O placebo|O group|O (|O 50|O .|O 6|O %|O )|O were|O receiving|O the|O randomly|O assigned|O study|O drug|O .|O
Mutations|O in|O PTEN|O /|O MMAC1|O are|O most|O frequently|O found|O in|O advanced|O cancers|O .|O
IDH|O mutations|O commonly|O involve|O exon|O 4|O and|O affect|O three|O specific|O arginine|O residues|O :|O Arg132|O (|O IDH1|O )|O ,|O Arg172|O (|O IDH2|O )|O ,|O and|O Arg140|O (|O IDH2|O )|O .|O
JAK2|O exon|O -|O 12|O mutations|O are|O present|O in|O the|O majority|O of|O patients|O who|O were|O JAK2V617|O negative|O and|O 3|O %|O of|O patients|O with|O PV|O overall|O .|O
IDH1|O and|O IDH2|O :|O metabolic|O inputs|O .|O
In|O particular|O ,|O members|O of|O the|O jumonji|O -|O domain|O -|O containing|O (|O JMJC|O )|O family|O of|O histone|O lysine|O demethylases|O ,|O which|O demethylate|O lysines|O 9|O and|O 36|O of|O histone|O H3|O (|O H3K9|O and|O H3K36|O )|O ,|O have|O been|O shown|O to|O be|O inhibited|O by|O 2|O -|O HG|O .|O
In|O the|O recent|O report|O of|O the|O Cancer|O Genome|O Atlas|O Research|O Network|O ,|O no|O mutations|O in|O STAG1|O were|O detected|O ,|O whereas|O the|O mutation|O frequency|O in|O STAG2|O ,|O SMC1A|O ,|O SMC3|O ,|O and|O RAD21|O was|O slightly|O higher|O (|O 2|O .|O 5|O %|O -|O 3|O .|O 5|O %|O )|O .|O
Patients|O with|O DNMT3A|O mutations|O present|O with|O higher|O peripheral|O white|O blood|O cell|O counts|O and|O frequently|O also|O harbour|O nucleophosmin|O (|O NPM1|O )|O ,|O FMS|O -|O related|O tyrosine|O kinase|O 3|O (|O FLT3|O )|O and|O IDH1|O mutations|O .|O
A|O limitation|O of|O allele|O -|O specific|O qPCR|O is|O that|O ,|O in|O many|O cases|O ,|O signal|O is|O generated|O in|O the|O mutant|O PCR|O reaction|O at|O high|O CT|O counts|O even|O for|O known|O negative|O samples|O .|O
Hair|O follicles|O from|O 20|O of|O the|O 62|O AML|O patients|O were|O collected|O to|O evaluate|O constitutional|O DNA|O for|O LOH|O analysis|O .|O
Younger|O patients|O (|O age|O <|O 50|O years|O )|O who|O received|O high|O -|O dose|O cytarabine|O induction|O and|O consolidation|O in|O the|O SWOG|O trial|O had|O the|O best|O OS|O and|O DFS|O rates|O at|O 4|O years|O (|O 52|O %|O and|O 34|O %|O ,|O respectively|O )|O compared|O with|O those|O who|O received|O standard|O -|O dose|O induction|O and|O consolidation|O (|O 34|O %|O and|O 24|O %|O ,|O respectively|O )|O or|O standard|O induction|O with|O high|O -|O dose|O consolidation|O (|O 23|O %|O and|O 14|O %|O ,|O respectively|O )|O .|O
Patient|O pedigree|O 1|O samples|O were|O obtained|O after|O written|O informed|O consent|O in|O accordance|O with|O the|O Declaration|O of|O Helsinki|O and|O were|O stored|O at|O the|O HIMIP|O (|O Hematologie|O -|O Inserm|O Midi|O -|O Pyrenees|O )|O collection|O (|O declared|O to|O the|O Ministry|O of|O Higher|O Education|O and|O Research|O as|O DC|O 2008|O -|O 307|O collection|O 1|O )|O .|O
Both|O GATA1|O and|O GATA2|O bind|O the|O PU|O .|O 1|O gene|O at|O two|O highly|O conserved|O regions|O .|O
To|O avoid|O any|O misunderstanding|O ,|O we|O included|O information|O as|O to|O which|O cases|O were|O analyzed|O by|O whole|O exome|O sequencing|O in|O supplemental|O Table|O 2|O .|O
We|O believe|O that|O there|O is|O a|O major|O practical|O relevance|O of|O the|O observations|O from|O the|O current|O study|O in|O terms|O of|O disease|O prognostication|O and|O therapeutic|O decision|O making|O .|O
For|O instance|O ,|O SF3B1|O mutations|O may|O affect|O splicing|O of|O transcripts|O coding|O for|O proteins|O associated|O with|O iron|O handling|O in|O erythroid|O precursors|O ,|O leading|O to|O RS|O .|O
Our|O data|O indicate|O that|O the|O PTEN|O /|O MMAC1|O gene|O may|O not|O play|O a|O major|O role|O in|O AML|O .|O
Radiation|O of|O all|O blood|O products|O is|O advised|O in|O all|O patients|O receiving|O immunosuppressive|O therapy|O ,|O particularly|O for|O patients|O receiving|O fludarabine|O -|O based|O regimens|O and|O those|O undergoing|O HSCT|O .|O
IDH1|O and|O IDH2|O catalyse|O an|O essential|O step|O in|O the|O Krebs|O cycle|O that|O converts|O isocitrate|O to|O alpha|O -|O ketoglutarate|O in|O an|O NADP|O +|O -|O dependent|O manner|O .|O
Cytogenetics|O and|O SNP|O -|O A|O analyses|O .|O
Risk|O stratification|O in|O PV|O and|O ET|O is|O based|O on|O thrombotic|O risk|O ,|O and|O survival|O in|O PMF|O is|O estimated|O by|O the|O International|O Prognostic|O Scoring|O System|O .|O
In|O the|O current|O study|O ,|O we|O found|O aberrant|O PTEN|O /|O MMAC1|O RT|O -|O PCR|O products|O in|O 24|O %|O of|O AML|O patients|O ,|O 80|O %|O of|O hemopoietic|O cell|O lines|O ,|O and|O 13|O %|O of|O normal|O controls|O .|O
In|O our|O cases|O and|O in|O other|O cases|O reported|O with|O germline|O GATA2|O mutations|O ,|O no|O clear|O correlation|O between|O genotype|O and|O phenotype|O can|O be|O identified|O ,|O suggesting|O that|O these|O clinical|O presentations|O are|O a|O spectrum|O of|O the|O same|O disease|O .|O
GATA1|O ,|O GATA2|O and|O GATA3|O are|O expressed|O principally|O in|O hematopoietic|O cell|O lineages|O .|O
All|O complete|O blood|O count|O differentials|O and|O PB|O smears|O were|O evaluated|O for|O presence|O of|O circulating|O IMCs|O ,|O defined|O by|O the|O presence|O of|O any|O of|O the|O following|O cells|O in|O circulation|O :|O myeloblasts|O ,|O myelocytes|O ,|O metamyelocytes|O and|O promyelocytes|O .|O
Consistent|O with|O the|O coordinated|O changes|O in|O gene|O expression|O that|O occur|O during|O haematopoietic|O differentiation|O ,|O researchers|O have|O observed|O regular|O patterns|O of|O DNA|O methylation|O on|O differentiation|O into|O specific|O haematopoietic|O lineages|O .|O
The|O median|O age|O of|O diagnosis|O is|O 67|O years|O ,|O with|O 54|O %|O of|O patients|O diagnosed|O at|O 65|O years|O or|O older|O (|O and|O approximately|O a|O third|O of|O these|O diagnosed|O at|O >|O =|O 75|O years|O of|O age|O )|O .|O
The|O patients|O or|O their|O parents|O gave|O their|O written|O informed|O consent|O for|O genetic|O testing|O .|O
Online|O databases|O ,|O such|O as|O the|O Catalogue|O of|O Somatic|O Mutations|O in|O Cancer|O (|O COSMIC|O ;|O Catalogue|O of|O Somatic|O Mutations|O in|O Cancer|O ,|O http|O :|O /|O /|O cancer|O .|O sanger|O .|O ac|O .|O uk|O /|O cancergenome|O /|O projects|O /|O cosmic|O ,|O last|O accessed|O February|O 19|O ,|O 2013|O )|O and|O the|O Database|O of|O Single|O Nucleotide|O Polymorphisms|O (|O dbSNP|O ;|O National|O Center|O for|O Biotechnology|O Information|O ,|O http|O :|O /|O /|O www|O .|O ncbi|O .|O nlm|O .|O nih|O .|O gov|O /|O snp|O ,|O last|O accessed|O February|O 19|O ,|O 2013|O )|O ,|O are|O particularly|O useful|O for|O determining|O whether|O an|O uncommon|O abnormality|O has|O been|O previously|O reported|O .|O
Another|O patient|O (|O no|O .|O 21|O )|O had|O two|O frameshift|O mutations|O in|O RHD|O ;|O eight|O clones|O harbored|O 297|O _|O 298insGGAC|O resulting|O in|O Thr101fsX111|O and|O nine|O clones|O harbored|O 343|O _|O 344insGG|O resulting|O in|O Ala115fsX118|O ,|O the|O remaining|O one|O clone|O was|O wild|O type|O .|O
Earlier|O studies|O have|O shown|O that|O chromosomal|O translocations|O or|O mutations|O in|O the|O coding|O region|O of|O RUNX1|O ,|O especially|O in|O the|O Runt|O homology|O domain|O (|O RHD|O )|O (|O exons|O 3|O -|O 5|O )|O ,|O disrupt|O the|O function|O of|O RUNX1|O .|O
For|O this|O study|O ,|O we|O considered|O complete|O remission|O ,|O partial|O remission|O ,|O and|O hematologic|O improvement|O in|O any|O cell|O lineage|O as|O response|O and|O stable|O disease|O ,|O death|O ,|O progression|O ,|O or|O relapse|O during|O therapy|O as|O nonresponse|O .|O
PATIENTS|O AND|O METHODS|O .|O
Whether|O this|O pattern|O is|O due|O to|O an|O acquired|O uniparental|O disomy|O 7q|O as|O described|O as|O common|O abnormality|O in|O the|O literature|O for|O myelodysplastic|O /|O myeloproliferative|O neoplasm|O is|O not|O known|O .|O
The|O most|O prominent|O examples|O are|O from|O recent|O genome|O -|O wide|O and|O candidate|O -|O gene|O studies|O that|O have|O identified|O somatic|O alterations|O in|O genes|O that|O encode|O proteins|O regulating|O DNA|O methylation|O and|O post|O -|O translational|O histone|O modifications|O .|O
In|O this|O review|O ,|O we|O summarize|O the|O current|O knowledge|O regarding|O the|O biological|O properties|O and|O functions|O of|O the|O GATA2|O transcription|O factor|O in|O normal|O and|O malignant|O hematopoiesis|O .|O
Lee|O Moffitt|O Cancer|O Center|O in|O Tampa|O ,|O Florida|O (|O Supplementary|O Table|O 1|O and|O Supplementary|O figure|O two|O )|O .|O
These|O outcomes|O with|O dose|O -|O escalated|O daunorubicin|O seemed|O similar|O to|O those|O with|O idarubicin|O (|O 12|O mg|O /|O m2|O x|O 3|O days|O )|O from|O the|O ALFA|O -|O 9801|O study|O ,|O in|O which|O the|O 3|O -|O year|O EFS|O and|O OS|O rates|O were|O 30|O %|O and|O 40|O %|O ,|O respectively|O .|O
Fig|O .|O 3|O .|O Transcriptional|O network|O involved|O in|O hematopoietic|O stem|O cells|O emergence|O .|O Diagram|O showing|O the|O regulatory|O circuit|O among|O GATA2|O ,|O FLI1|O and|O SCL|O /|O TAL1|O .|O Solid|O lines|O represent|O direct|O binding|O interactions|O .|O Dotted|O lines|O represent|O indirect|O binding|O interactions|O .|O NOTCH1|O and|O BMP4|O signaling|O pathways|O might|O initiate|O GATA2|O and|O FLI1|O expression|O ,|O which|O then|O autoregulate|O each|O other|O and|O combine|O to|O initiate|O SCL|O transcription|O .|O Afterwards|O ,|O GATA2|O ,|O FLI1|O ,|O and|O the|O SCL|O complex|O are|O recruited|O to|O the|O RUNX1|O enhancer|O ,|O activating|O its|O transcription|O .|O BMP4|O transcription|O is|O dependent|O on|O GATA2|O .|O At|O the|O progenitor|O stage|O ,|O EKLF|O activation|O is|O also|O dependent|O on|O GATA2|O and|O SMAD5|O .|O
Genotyping|O of|O germ|O -|O line|O DNA|O from|O buccal|O swabs|O revealed|O that|O the|O mutations|O in|O these|O 10|O genes|O were|O somatic|O ,|O except|O for|O those|O in|O MET|O (|O E168D|O in|O three|O samples|O )|O ,|O EGFR|O (|O T790M|O in|O one|O sample|O )|O ,|O and|O CDH1|O (|O A617T|O in|O three|O samples|O )|O .|O
Table|O 3|O .|O Univariate|O and|O multivariable|O overall|O and|O leukemia|O -|O free|O survival|O analysis|O for|O 226|O patients|O with|O chronic|O myelomonocytic|O leukemia|O
Eighteen|O patients|O (|O 8|O %|O )|O had|O chromosomal|O translocations|O that|O did|O not|O fit|O into|O any|O specific|O category|O .|O
CBL|O mutations|O were|O detected|O in|O 18|O .|O 5|O %|O of|O patients|O with|O CMML|O and|O have|O been|O identified|O more|O generally|O in|O about|O 10|O %|O of|O patients|O with|O MDS|O /|O MPN|O .|O
Therefore|O ,|O in|O order|O to|O elucidate|O the|O role|O of|O PTEN|O /|O MMAC1|O in|O leukemogenesis|O ,|O 62|O AML|O cases|O ,|O 5|O hemopoietic|O cell|O lines|O ,|O and|O 30|O normal|O controls|O were|O studied|O .|O
SAMPLES|O FROM|O STUDY|O PATIENTS|O .|O
According|O to|O our|O preliminary|O results|O ,|O U2AF1|O mutations|O seem|O to|O be|O most|O commonly|O associated|O with|O ASXL1|O and|O TET2|O mutations|O ,|O whereas|O SF3B1|O can|O occur|O in|O the|O context|O of|O RUNX1|O mutations|O (|O data|O not|O shown|O )|O .|O
For|O the|O Mayo|O cohort|O ,|O median|O survival|O from|O time|O of|O referral|O was|O 5|O years|O and|O significantly|O different|O among|O DIPSS|O -|O plus|O risk|O groups|O (|O P|O <|O 0|O .|O 0001|O )|O ;|O the|O median|O survivals|O for|O low|O ,|O intermediate|O -|O 1|O ,|O intermediate|O -|O 2|O and|O high|O -|O risk|O groups|O were|O 18|O .|O 7|O ,|O 8|O .|O 3|O ,|O 5|O .|O 2|O and|O 2|O .|O 3|O years|O (|O Supplementary|O Figure|O S3|O )|O .|O
Mutations|O in|O one|O or|O more|O of|O these|O genes|O were|O present|O in|O 137|O of|O the|O 439|O patients|O (|O 31|O .|O 2|O %|O )|O .|O
Differences|O in|O survival|O were|O assessed|O using|O the|O log|O -|O rank|O test|O .|O
Notably|O ,|O we|O found|O that|O patients|O with|O C|O -|O terminal|O mutations|O had|O a|O significantly|O higher|O risk|O of|O AML|O transformation|O (|O P|O =|O 0|O .|O 023|O )|O and|O a|O shorter|O time|O to|O AML|O progression|O compared|O with|O mutation|O -|O negative|O patients|O (|O median|O 6|O .|O 8|O months|O vs|O 28|O .|O 3|O months|O ,|O P|O =|O 0|O .|O 022|O ,|O Figure|O 2b|O )|O ,|O whereas|O the|O N|O -|O terminal|O mutations|O had|O no|O influence|O on|O outcome|O (|O P|O =|O 0|O .|O 955|O for|O overall|O survival|O and|O P|O =|O 0|O .|O 759|O for|O time|O to|O AML|O progression|O )|O .|O
This|O latter|O condition|O is|O characterized|O by|O increased|O bone|O marrow|O cellularity|O ,|O multilineage|O dysplasia|O ,|O severe|O cytopenia|O involving|O high|O transfusion|O requirement|O ,|O unfavorable|O cytogenetics|O ,|O and|O poor|O survival|O .|O
We|O performed|O genomewide|O analysis|O of|O copy|O -|O number|O changes|O in|O a|O subgroup|O of|O 75|O samples|O ,|O using|O Affymetrix|O 6|O .|O 0|O SNP|O arrays|O .|O
Association|O of|O '|O mutationally|O high|O risk|O '|O status|O with|O a|O specific|O molecular|O signature|O .|O
In|O a|O phase|O 1|O -|O 2|O trial|O of|O ruxolitinib|O (|O INCB018424|O ,|O Incyte|O )|O ,|O a|O potent|O inhibitor|O of|O JAK1|O and|O JAK2|O ,|O patients|O with|O myelofibrosis|O had|O durable|O reductions|O in|O splenomegaly|O and|O improvements|O in|O myelofibrosis|O -|O related|O symptoms|O ,|O regardless|O of|O their|O status|O with|O respect|O to|O the|O JAK2V617F|O mutation|O .|O
National|O Cancer|O Institute|O Drug|O Dictionary|O :|O http|O :|O /|O /|O www|O .|O cancer|O .|O gov|O /|O drugdictionary|O .|O
The|O HR|O was|O 1|O .|O 83|O (|O 95|O %|O CI|O ,|O 1|O .|O 69|O -|O 1|O .|O 99|O ,|O P|O <|O .|O 001|O )|O ,|O that|O is|O ,|O there|O was|O a|O 1|O .|O 83|O -|O fold|O increase|O in|O hazard|O for|O a|O 1|O -|O point|O increase|O in|O the|O sum|O of|O weights|O .|O
However|O ,|O these|O mutations|O often|O occur|O together|O in|O the|O same|O patient|O ,|O and|O several|O are|O associated|O with|O established|O prognostic|O markers|O .|O
A|O recent|O analysis|O that|O evaluated|O the|O prognostic|O value|O of|O the|O ELN|O risk|O classification|O (|O based|O on|O data|O from|O the|O German|O AML96|O study|O )|O showed|O that|O for|O patients|O aged|O 60|O years|O and|O younger|O ,|O median|O relapse|O -|O free|O survival|O was|O shorter|O for|O the|O Intermediate|O I|O than|O for|O the|O Intermediate|O II|O group|O (|O 7|O .|O 9|O vs|O .|O 39|O .|O 1|O months|O ,|O respectively|O )|O .|O
Cross|O -|O sectional|O deep|O -|O sequencing|O analysis|O for|O clonal|O hierarchy|O demonstrated|O STAG2|O ,|O SMC3|O ,|O and|O RAD21|O mutations|O to|O be|O ancestral|O in|O 18|O %|O ,|O 18|O %|O ,|O and|O 47|O %|O of|O cases|O ,|O respectively|O ,|O and|O each|O expanded|O to|O clonal|O dominance|O concordant|O with|O disease|O transformation|O .|O
Since|O 1994|O ,|O multiple|O (|O 3|O -|O 4|O )|O cycles|O of|O high|O -|O dose|O cytarabine|O therapy|O have|O been|O the|O standard|O consolidation|O regimen|O for|O patients|O younger|O than|O 60|O years|O with|O either|O good|O -|O or|O intermediate|O -|O risk|O cytogenetics|O .|O
In|O this|O analysis|O ,|O the|O cohort|O was|O significantly|O separated|O into|O three|O prognostic|O risk|O groups|O ,|O that|O is|O ,|O at|O 3|O years|O 33|O .|O 9|O %|O of|O EZH2|O -|O mutated|O patients|O ,|O 49|O .|O 7|O %|O of|O EZH2|O /|O TET2|O wild|O -|O type|O patients|O and|O 89|O .|O 8|O %|O of|O TET2|O -|O mutated|O cases|O were|O alive|O (|O P|O <|O 0|O .|O 001|O )|O .|O
The|O activity|O of|O the|O GATA2|O transcription|O factor|O is|O also|O modulated|O by|O post|O -|O translational|O modifications|O such|O as|O phosphorylation|O ,|O acetylation|O ,|O sumoylation|O and|O ubiquitination|O .|O
The|O 2|O reads|O originated|O from|O contamination|O by|O a|O small|O amount|O of|O the|O mutated|O clone|O .|O
A|O few|O gene|O mutations|O are|O highly|O specific|O to|O MDS|O or|O myelodysplasia|O ,|O whereas|O a|O number|O of|O chimeric|O genes|O and|O other|O mutations|O ,|O including|O those|O in|O MPN1|O and|O CEBPA|O ,|O are|O highly|O specific|O to|O AML|O .|O
Identification|O of|O a|O germline|O GATA2|O R396Q|O mutation|O in|O pedigree|O 1|O .|O
Amplified|O DNA|O was|O used|O for|O mutation|O discovery|O .|O
In|O addition|O ,|O more|O recent|O work|O by|O Iwama|O and|O colleagues|O indicates|O that|O loss|O of|O BMI1|O results|O in|O a|O pathological|O haematopoiesis|O that|O mimics|O many|O aspects|O of|O human|O PMF|O .|O
The|O most|O widely|O used|O methods|O for|O the|O detection|O of|O V617F|O involve|O allele|O -|O specific|O qPCR|O .|O
The|O World|O Health|O Organization|O (|O WHO|O )|O ,|O first|O in|O 2001|O and|O again|O in|O 2008|O ,|O began|O reclassifying|O these|O disorders|O in|O light|O of|O evolving|O histologic|O ,|O cytogenetic|O ,|O and|O molecular|O information|O .|O
Of|O the|O 4|O RAD21|O mutated|O patients|O ,|O 3|O harbored|O a|O concomitant|O NPM1|O mutation|O ,|O and|O 1|O of|O the|O 2|O SMC1|O mutated|O patients|O was|O also|O NPM1|O mutated|O (|O supplemental|O Tables|O 2|O -|O 6|O )|O .|O
LOH|O analysis|O in|O the|O 10q23|O region|O and|O the|O RNA|O transcript|O of|O the|O PTEN|O /|O MMAC1|O gene|O in|O specimens|O from|O AML|O and|O hemopoietic|O cell|O lines|O were|O also|O examined|O .|O
Their|O involvement|O in|O AML|O emerged|O from|O in|O -|O solution|O whole|O -|O exome|O capture|O followed|O by|O massively|O parallel|O sequencing|O of|O paired|O leukemic|O cells|O at|O diagnosis|O and|O normal|O hematopoietic|O cells|O at|O the|O time|O of|O complete|O remission|O from|O patients|O with|O AML|O .|O
This|O international|O collaborative|O study|O ,|O approved|O by|O the|O individual|O center|O institutional|O review|O boards|O ,|O included|O 879|O patients|O with|O PMF|O diagnosed|O according|O to|O the|O 2008|O WHO|O criteria|O ;|O 1|O patients|O with|O the|O '|O prefibrotic|O '|O variant|O were|O excluded|O .|O
MDS|O comprise|O a|O heterogeneous|O group|O of|O acquired|O clonal|O hemato|O poietic|O disorders|O characterized|O by|O dysplasia|O of|O the|O myeloid|O ,|O erythroid|O and|O /|O or|O megakaryocytic|O lineages|O .|O
Overall|O ,|O in|O 40|O %|O of|O the|O subjects|O showing|O 7q36|O .|O 1|O aberrations|O or|O EZH2|O mutations|O ,|O TET2|O was|O affected|O as|O well|O .|O
The|O study|O was|O designed|O to|O enroll|O 240|O patients|O ,|O providing|O 97|O %|O power|O to|O detect|O a|O treatment|O difference|O in|O spleen|O -|O volume|O response|O at|O a|O two|O -|O sided|O alpha|O level|O of|O 0|O .|O 05|O ,|O assuming|O a|O response|O rate|O of|O 30|O %|O or|O more|O for|O ruxolitinib|O and|O a|O response|O rate|O of|O 10|O %|O or|O less|O for|O placebo|O .|O
We|O identified|O 2|O cases|O with|O germline|O known|O rare|O nonsynonymous|O alterations|O ,|O specifically|O a|O germline|O alteration|O in|O STAG1|O (|O p|O .|O E760D|O )|O with|O population|O allelic|O frequency|O of|O 0|O .|O 01|O ,|O and|O a|O novel|O alteration|O in|O WAPAL|O (|O p|O .|O G230V|O ;|O supplemental|O Table|O 4|O )|O .|O
Estey|O et|O al|O prospectively|O evaluated|O a|O protocol|O in|O which|O patients|O aged|O 50|O years|O and|O older|O with|O unfavorable|O cytogenetics|O would|O be|O evaluated|O for|O a|O RIC|O allogeneic|O HSCT|O .|O
Despite|O the|O optimism|O ,|O it|O is|O increasingly|O apparent|O that|O pathogenicity|O in|O BCR|O -|O ABL1|O -|O negative|O MPN|O is|O more|O complex|O than|O for|O chronic|O myeloid|O leukemia|O ,|O and|O a|O pathognomonic|O mutation|O may|O not|O be|O forthcoming|O .|O
To|O further|O clarify|O the|O significance|O of|O GATA2|O overexpression|O in|O AML|O ,|O our|O group|O has|O investigated|O for|O the|O first|O time|O the|O prevalence|O of|O GATA2|O overexpression|O by|O real|O -|O time|O RT|O -|O PCR|O in|O a|O large|O series|O of|O AML|O patients|O ,|O correlated|O the|O results|O to|O cytogenetics|O and|O other|O molecular|O markers|O ,|O and|O studied|O its|O prognostic|O relevance|O .|O
This|O model|O was|O also|O predictive|O of|O LT|O :|O high|O risk|O ,|O RR|O 4|O .|O 9|O (|O 95|O %|O CI|O 1|O .|O 9|O -|O 12|O .|O 8|O )|O and|O intermediate|O risk|O ,|O RR|O 2|O .|O 6|O (|O 1|O .|O 1|O -|O 5|O .|O 9|O )|O .|O
Compared|O with|O the|O very|O -|O low|O -|O risk|O category|O ,|O the|O estimated|O HR|O were|O 4|O .|O 2|O (|O 95|O %|O CI|O ,|O 1|O .|O 4|O -|O 12|O ,|O P|O =|O .|O 007|O )|O for|O the|O low|O risk|O ,|O 10|O .|O 2|O (|O 95|O %|O CI|O ,|O 3|O .|O 6|O -|O 28|O .|O 6|O ,|O P|O <|O .|O 001|O )|O for|O the|O intermediate|O risk|O ,|O 37|O .|O 5|O (|O 95|O %|O CI|O ,|O 13|O .|O 3|O -|O 105|O .|O 8|O ,|O P|O <|O .|O 001|O )|O for|O the|O high|O risk|O ,|O and|O 88|O .|O 6|O (|O 95|O %|O CI|O ,|O 30|O .|O 3|O -|O 259|O ,|O P|O <|O .|O 001|O )|O for|O the|O very|O -|O high|O -|O risk|O category|O .|O
It|O was|O also|O found|O to|O be|O an|O independent|O negative|O prognostic|O indicator|O for|O survival|O .|O
Mutations|O and|O prognosis|O in|O primary|O myelofibrosis|O .|O
These|O effects|O are|O thought|O to|O be|O secondary|O to|O the|O inhibition|O of|O active|O DNA|O methylation|O .|O
Patients|O with|O residual|O blasts|O without|O hypoplasia|O may|O receive|O additional|O standard|O -|O dose|O cytarabine|O with|O an|O anthracycline|O or|O mitoxantrone|O .|O
In|O a|O broad|O survey|O of|O mutations|O in|O 439|O primary|O DNA|O samples|O from|O patients|O with|O myelodysplastic|O syndromes|O ,|O we|O identified|O point|O mutations|O in|O 18|O genes|O ,|O including|O 2|O (|O ETV6|O and|O GNAS|O )|O that|O have|O not|O previously|O been|O reported|O to|O harbor|O mutations|O in|O such|O patients|O .|O
In|O spite|O of|O their|O similarities|O ,|O the|O BCOR|O and|O BCORL1|O proteins|O show|O a|O number|O of|O different|O features|O ,|O including|O their|O capability|O to|O interact|O with|O BCL6|O ,|O their|O expression|O levels|O in|O human|O tissues|O ,|O and|O their|O localization|O within|O subnuclear|O structures|O (|O Table|O 1|O )|O .|O
Erythrocytosis|O with|O a|O hemoglobin|O level|O >|O 18|O .|O 5|O g|O /|O dL|O in|O men|O and|O >|O 16|O .|O 5|O g|O /|O dL|O in|O women|O or|O a|O hemoglobin|O level|O >|O 17|O g|O /|O dL|O in|O men|O and|O >|O 15|O g|O /|O dL|O in|O women|O if|O representing|O a|O sustained|O increase|O of|O >|O =|O 2|O g|O /|O dL|O from|O baseline|O are|O consistent|O but|O not|O diagnostic|O for|O PV|O (|O Table|O 1|O )|O .|O
A|O deficit|O of|O monocytes|O ,|O B|O cells|O ,|O and|O NK|O cells|O was|O detected|O ,|O the|O T|O -|O cell|O count|O remained|O normal|O (|O Table|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
The|O Akaike|O information|O criterion|O (|O AIC|O )|O was|O applied|O to|O compare|O quality|O of|O models|O .|O
Blood|O count|O and|O BM|O examination|O were|O normal|O .|O
Category|O 3|O :|O Based|O upon|O any|O level|O of|O evidence|O ,|O there|O is|O major|O NCCN|O disagreement|O that|O the|O intervention|O is|O appropriate|O .|O
Considering|O the|O independent|O significance|O of|O driver|O mutations|O ,|O we|O developed|O a|O prognostic|O model|O that|O includes|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O in|O addition|O to|O the|O IPSS|O variables|O .|O
No|O difference|O in|O clinical|O outcome|O was|O seen|O for|O ASXL1|O -|O mutated|O patients|O versus|O ASXL1|O wild|O -|O type|O or|O taking|O different|O numbers|O of|O mutations|O into|O account|O .|O
For|O confirmation|O of|O the|O somatic|O nature|O of|O the|O mutations|O ,|O exons|O containing|O mutations|O were|O tested|O in|O nonclonal|O control|O DNA|O .|O
The|O prognostic|O value|O was|O only|O demonstrated|O for|O PMF|O when|O an|O "|O unfavorable|O "|O cytogenetic|O profile|O (|O complex|O karyotype|O ,|O +|O 8|O or|O abnormalities|O other|O than|O isolated|O +|O 9|O ,|O 13q|O -|O ,|O or|O 20q|O -|O )|O predicted|O inferior|O survival|O not|O already|O accounted|O for|O by|O the|O International|O Prognostic|O Scoring|O System|O for|O PMF|O .|O
TET2|O (|O ten|O -|O eleven|O translocation|O (|O TET|O )|O oncogene|O family|O member|O 2|O )|O .|O
Among|O these|O mutations|O ,|O it|O seems|O that|O AML|O patients|O under|O the|O age|O of|O 60|O with|O DNMT3A|O mutations|O have|O improved|O overall|O survival|O when|O treated|O with|O high|O -|O dose|O anthracycline|O chemotherapy|O ,|O whereas|O the|O other|O genetic|O subsets|O of|O patients|O mentioned|O here|O do|O not|O seem|O to|O benefit|O ,|O on|O average|O ,|O from|O dose|O -|O intensified|O induction|O therapy|O .|O
Various|O somatic|O mutations|O are|O involved|O in|O the|O pathogenesis|O of|O MDS|O .|O
cDNA|O PCR|O or|O DNA|O PCR|O assay|O with|O direct|O sequencing|O for|O RUNX1|O mutation|O analysis|O .|O
Patients|O who|O require|O 2|O cycles|O of|O chemotherapy|O to|O achieve|O a|O remission|O are|O likely|O to|O have|O more|O resistant|O disease|O and|O should|O be|O considered|O for|O a|O more|O intensive|O approach|O as|O initial|O consolidation|O whenever|O possible|O .|O
During|O the|O past|O decade|O ,|O a|O number|O of|O gene|O mutations|O have|O been|O identified|O in|O MDS|O .|O
Sixty|O -|O two|O specimens|O of|O bone|O marrow|O and|O /|O or|O peripheral|O blood|O were|O obtained|O from|O patients|O diagnosed|O with|O AML|O at|O the|O Kaohsiung|O Medical|O College|O Hospital|O from|O 1992|O through|O 1996|O .|O
In|O contrast|O ,|O mutations|O in|O other|O genes|O can|O lead|O to|O unsplicing|O of|O distinct|O genes|O and|O thereby|O result|O in|O particular|O phenotypic|O features|O .|O
HpaII|O tiny|O fragment|O enrichment|O by|O ligation|O -|O mediated|O PCR|O assay|O (|O HELP|O assay|O )|O .|O
Mechanistically|O ,|O partial|O loss|O of|O DNMT3A|O activity|O is|O thought|O to|O lead|O to|O hypomethylation|O ,|O but|O which|O methylated|O loci|O are|O altered|O and|O directly|O contribute|O to|O leukaemogenesis|O in|O DNMT3A|O -|O mutant|O or|O DNMT3A|O -|O haploinsufficient|O cells|O has|O not|O yet|O been|O delineated|O .|O
Actuarial|O survival|O curves|O were|O estimated|O by|O the|O method|O of|O Kaplan|O -|O Meier|O and|O compared|O by|O the|O log|O -|O rank|O test|O .|O
P|O -|O values|O <|O 0|O .|O 05|O were|O considered|O significant|O .|O
The|O number|O of|O patient|O -|O years|O of|O exposure|O was|O 105|O in|O the|O ruxolitinib|O group|O and|O 87|O in|O the|O placebo|O group|O ;|O study|O discontinuation|O and|O crossover|O to|O ruxolitinib|O accounted|O for|O lower|O exposure|O in|O the|O placebo|O group|O .|O
SUMMARY|O .|O
PCR|O was|O performed|O for|O 35|O cycles|O ,|O and|O then|O 5|O muL|O of|O each|O of|O the|O amplicons|O were|O denatured|O in|O 2|O muL|O denaturing|O solution|O (|O 95|O %|O formamide|O ,|O 10|O mM|O EDTA|O ,|O 0|O .|O 05|O %|O bromophenol|O blue|O ,|O 0|O .|O 05|O %|O xylenecyanol|O )|O at|O 95|O -|O -|O degrees|O -|O -|O C|O for|O 5|O min|O and|O thereafter|O directly|O placed|O on|O ice|O .|O
Five|O patients|O had|O frameshift|O mutations|O ,|O one|O at|O RHD|O and|O four|O in|O the|O C|O -|O terminal|O part|O ,|O all|O generating|O termination|O codons|O within|O the|O 3|O '|O -|O untranslated|O region|O .|O
The|O incidence|O of|O grade|O 3|O or|O 4|O toxicities|O after|O cycle|O 1|O was|O higher|O in|O the|O high|O -|O dose|O arm|O than|O in|O the|O intermediate|O -|O dose|O arm|O (|O 61|O %|O vs|O .|O 51|O %|O :|O P|O =|O .|O 005|O )|O ,|O but|O the|O incidence|O of|O 30|O -|O day|O mortality|O was|O the|O same|O in|O both|O arms|O (|O 10|O %|O )|O .|O
Christiansen|O et|O al|O .|O found|O that|O RUNX1|O mutations|O were|O significantly|O associated|O with|O monosomy|O 7|O or|O 7q|O -|O in|O therapy|O -|O related|O MDS|O .|O
Although|O the|O loss|O of|O TET|O enzyme|O activity|O would|O be|O predicted|O to|O increase|O DNA|O cytosine|O methylation|O and|O reduce|O 5|O -|O hmC|O levels|O ,|O studies|O of|O the|O effects|O of|O TET2|O mutations|O on|O global|O levels|O of|O methylation|O and|O 5|O -|O hmC|O in|O primary|O patient|O materials|O have|O yielded|O conflicting|O results|O .|O
In|O the|O analyses|O of|O change|O from|O baseline|O to|O week|O 24|O ,|O patients|O who|O discontinued|O the|O study|O drug|O or|O crossed|O over|O before|O week|O 24|O were|O counted|O as|O not|O having|O a|O response|O (|O for|O response|O measures|O of|O a|O reduction|O in|O spleen|O volume|O and|O symptom|O improvement|O )|O .|O
A|O total|O of|O 23|O .|O 2|O %|O of|O patients|O who|O received|O ruxolitinib|O and|O 14|O .|O 6|O %|O of|O patients|O who|O received|O placebo|O had|O bruising|O ;|O all|O events|O were|O grade|O 1|O or|O 2|O except|O for|O one|O grade|O 3|O event|O in|O the|O ruxolitinib|O group|O .|O
In|O contrast|O ,|O genetic|O susceptibility|O to|O MDS|O and|O /|O or|O AML|O is|O infrequent|O .|O
The|O rate|O of|O therapy|O -|O related|O MDS|O /|O AML|O is|O higher|O among|O patients|O with|O certain|O primary|O tumors|O ,|O including|O breast|O cancer|O ,|O gynecologic|O cancers|O ,|O and|O lymphomas|O (|O both|O nonHodgkin|O '|O s|O lymphoma|O and|O Hodgkin|O lymphoma|O )|O ,|O largely|O owing|O to|O the|O more|O leukemogenic|O cytotoxic|O agents|O that|O are|O commonly|O used|O in|O the|O treatment|O of|O these|O tumors|O .|O
These|O combinatorial|O mutations|O suggest|O a|O requirement|O for|O different|O therapeutic|O approaches|O tailored|O to|O the|O molecular|O profile|O of|O individual|O patients|O .|O
GATA1|O and|O GATA2|O are|O related|O essential|O transcription|O factors|O that|O govern|O the|O development|O of|O multiple|O hematopoietic|O cells|O .|O
His|O elder|O brother|O (|O patient|O number|O 6165|O ;|O P1|O ,|O III|O ,|O 2|O )|O ,|O 16|O years|O of|O age|O ,|O also|O had|O a|O history|O of|O chronic|O neutropenia|O with|O a|O chronic|O EBV|O replication|O in|O the|O gut|O and|O a|O severe|O respiratory|O distress|O syndrome|O requiring|O supplemental|O oxygen|O at|O age|O 14|O linked|O to|O pulmonary|O bronchiectasis|O .|O
A|O sample|O report|O for|O a|O quantitative|O JAK2|O V617F|O assay|O is|O presented|O as|O Table|O 5|O .|O
Low|O -|O dose|O radiation|O therapy|O (|O 100|O -|O 1000|O cGy|O in|O 5|O -|O 10|O fractions|O )|O also|O is|O effective|O at|O temporarily|O resolving|O symptoms|O associated|O with|O nonsplenic|O sites|O of|O extramedullary|O hematopoiesis|O .|O
The|O FAB|O classification|O (|O 1976|O )|O had|O set|O the|O threshold|O between|O high|O -|O grade|O MDS|O and|O AML|O at|O 30|O %|O blasts|O ,|O whereas|O the|O WHO|O classification|O lowered|O the|O threshold|O for|O diagnosing|O AML|O to|O 20|O %|O or|O more|O blasts|O ;|O this|O was|O based|O on|O the|O finding|O that|O the|O biologic|O behavior|O (|O and|O survival|O outcomes|O )|O of|O the|O FAB|O MDS|O subgroup|O of|O "|O refractory|O anemia|O with|O excess|O blasts|O in|O transformation|O (|O RAEB|O -|O T|O )|O "|O with|O 20|O %|O to|O 30|O %|O blasts|O was|O equally|O grim|O compared|O with|O that|O of|O patients|O with|O greater|O than|O 30|O %|O blasts|O .|O
The|O SF3B1|O gene|O ,|O which|O encodes|O subunit|O 1|O of|O the|O splicing|O factor|O 3b|O complex|O ,|O is|O located|O at|O the|O long|O arm|O of|O chromosome|O 2|O at|O position|O 33|O .|O 1|O (|O 2q33|O .|O 1|O )|O .|O
Myelodysplastic|O syndrome|O (|O MDS|O )|O is|O a|O clonal|O hematopoietic|O neoplasm|O characterized|O by|O peripheral|O cytopenia|O ,|O bone|O marrow|O dyspoiesis|O with|O or|O without|O excess|O blasts|O ,|O and|O >|O 30|O %|O transformation|O rate|O to|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
Frameshift|O mutations|O were|O validated|O by|O cloning|O and|O sequencing|O individual|O colonies|O (|O TOPO|O TA|O cloning|O ;|O Invitrogen|O )|O .|O
The|O median|O neutrophil|O count|O was|O 1|O .|O 5|O G|O /|O L|O (|O 25th|O percentile|O :|O 1|O .|O 2|O ;|O 75th|O percentile|O :|O 2|O .|O 0|O )|O ,|O although|O the|O count|O was|O mildly|O diminished|O ,|O all|O patients|O experienced|O at|O least|O once|O a|O neutropenia|O between|O 0|O .|O 5|O and|O 1|O .|O 2|O G|O /|O L|O .|O
Although|O initial|O studies|O demonstrated|O that|O these|O mutants|O lead|O to|O reduced|O enzymatic|O function|O with|O respect|O to|O alpha|O -|O ketoglutarate|O production|O ,|O the|O presence|O of|O focal|O ,|O recurrent|O heterozygous|O mutations|O suggested|O these|O might|O lead|O to|O an|O aberrant|O gain|O -|O of|O -|O function|O .|O
They|O showed|O that|O GATA2|O promotes|O megakaryopoiesis|O by|O driving|O progenitor|O cell|O proliferation|O and|O megakaryocytic|O lineage|O gene|O expression|O while|O suppressing|O myeloid|O gene|O expression|O .|O
This|O analysis|O indicates|O that|O evaluation|O of|O the|O mutation|O status|O of|O TP53|O ,|O EZH2|O ,|O ETV6|O ,|O RUNX1|O ,|O and|O ASXL1|O would|O add|O the|O most|O information|O to|O clinical|O prognostic|O scores|O as|O currently|O assessed|O in|O patients|O with|O myelodysplastic|O syndromes|O .|O
The|O CEBPA|O gene|O encodes|O for|O CCAAT|O /|O enhancer|O binding|O protein|O alpha|O (|O C|O /|O EBPalpha|O )|O ,|O a|O transcription|O factor|O that|O plays|O a|O key|O role|O in|O the|O differentiation|O of|O granulocytes|O .|O
Postinduction|O Therapy|O :|O Similar|O to|O younger|O patients|O ,|O older|O patients|O who|O receive|O standard|O cytarabine|O /|O anthracycline|O induction|O are|O evaluated|O with|O a|O bone|O marrow|O evaluation|O 7|O to|O 10|O days|O after|O completion|O of|O chemotherapy|O and|O categorized|O according|O to|O the|O presence|O of|O blasts|O or|O hypoplasia|O .|O
In|O another|O study|O ,|O TP53|O mutations|O occurred|O in|O 20|O %|O of|O low|O -|O risk|O MDS|O patients|O with|O del|O (|O 5q|O )|O at|O early|O disease|O stage|O ,|O suggesting|O that|O these|O patients|O may|O be|O at|O a|O particularly|O increased|O risk|O of|O leukemic|O evolution|O .|O
Table|O 2|O .|O Spectrum|O of|O ASXL1|O mutations|O in|O 179|O patients|O with|O WHO|O -|O defined|O chronic|O myelomonocytic|O leukemia|O .|O
We|O identified|O a|O total|O of|O 23|O patients|O (|O 5|O .|O 9|O %|O )|O with|O somatic|O mutations|O in|O 1|O of|O the|O cohesin|O genes|O .|O All|O gene|O mutations|O were|O mutually|O exclusive|O ,|O and|O STAG1|O (|O 1|O .|O 8|O %|O )|O ,|O STAG2|O (|O 1|O .|O 3|O %|O )|O ,|O and|O SMC3|O (|O 1|O .|O 3|O %|O )|O were|O most|O frequently|O mutated|O .|O
SIGNAL|O TRANSDUCTION|O .|O
In|O contrast|O ,|O TP53|O mutations|O were|O observed|O mainly|O in|O patients|O with|O intermediate|O -|O 2|O or|O high|O risk|O according|O to|O the|O IPSS|O (|O 79|O %|O )|O and|O were|O strongly|O associated|O with|O thrombocytopenia|O ,|O an|O elevated|O blast|O proportion|O ,|O and|O a|O complex|O karyotype|O .|O
In|O fact|O ,|O 4|O of|O 5|O patients|O with|O truncation|O mutations|O also|O had|O the|O T618I|O point|O mutation|O ,|O indicating|O that|O acquisition|O of|O both|O classes|O of|O mutations|O may|O be|O advantageous|O for|O tumor|O pathogenesis|O .|O
CGH|O analysis|O .|O
ONCOGENES|O .|O
Further|O ,|O the|O putative|O candidates|O were|O prioritized|O based|O on|O population|O genotypic|O frequency|O .|O
In|O another|O study|O ,|O ASXL1|O knockouts|O had|O a|O predilection|O for|O developing|O MDS|O /|O MPN|O .|O
The|O present|O study|O also|O highlights|O the|O frequent|O early|O myeloid|O transformation|O in|O patients|O carrying|O a|O GATA2|O mutation|O associated|O with|O a|O poor|O outcome|O linked|O to|O a|O refractory|O status|O of|O disease|O after|O initiation|O of|O chemotherapy|O .|O
5|O -|O hmC|O has|O been|O shown|O to|O block|O the|O binding|O of|O methyl|O -|O DNA|O -|O binding|O proteins|O that|O normally|O confer|O transcriptional|O silencing|O .|O
Ultimately|O ,|O comparison|O of|O TKI|O -|O treated|O patients|O to|O historical|O controls|O will|O help|O determine|O whether|O these|O therapies|O impact|O disease|O endpoints|O such|O as|O leukemia|O -|O free|O progression|O and|O overall|O survival|O .|O
Screening|O The|O usual|O indications|O for|O JAK2|O mutation|O testing|O include|O unexplained|O polycythemia|O ,|O neutrophilia|O ,|O or|O thrombocytosis|O (|O when|O secondary|O causes|O have|O been|O ruled|O out|O )|O ,|O because|O each|O may|O represent|O a|O MPN|O (|O Table|O 3|O )|O .|O
Table|O 5|O .|O Sample|O Report|O for|O Quantitative|O JAK2|O V617F|O Mutation|O Assay|O .|O
Among|O cases|O with|O an|O abnormal|O karyotype|O ,|O trisomy|O 8|O was|O more|O common|O in|O cohesin|O mutant|O patients|O (|O 19|O %|O vs|O 9|O %|O ;|O P|O =|O .|O 004|O ;|O supplemental|O Table|O 6|O )|O ,|O whereas|O 25|O /|O del|O (|O 5q|O )|O and|O 27|O /|O del|O (|O 7q|O )|O were|O less|O common|O (|O Table|O 1|O )|O .|O
There|O ,|O however|O ,|O was|O no|O difference|O in|O the|O distribution|O of|O ASXL1|O and|O spliceosome|O component|O mutations|O (|O Table|O 1|O )|O .|O
Myelodysplastic|O syndromes|O (|O MDS|O )|O and|O related|O myeloid|O neoplasms|O are|O a|O heterogeneous|O group|O of|O myeloid|O neoplasms|O ,|O which|O frequently|O terminate|O in|O acute|O myeloid|O leukemia|O (|O AML|O )|O .|O
In|O 2007|O ,|O additional|O mutations|O in|O exon|O 12|O of|O JAK2|O gene|O were|O found|O in|O a|O small|O percentage|O of|O PV|O patients|O .|O
The|O proximal|O first|O exon|O (|O IG|O exon|O )|O is|O utilized|O generally|O in|O various|O tissues|O .|O
Although|O none|O of|O the|O genetic|O abnormalities|O discussed|O earlier|O affect|O the|O initial|O course|O of|O AML|O treatment|O ,|O they|O provide|O prognostic|O information|O that|O may|O influence|O subsequent|O treatment|O decisions|O .|O
n|O =|O 42|O (|O mutants|O )|O ,|O 281|O (|O WT|O )|O .|O
Research|O into|O basic|O leukemia|O biology|O using|O banked|O samples|O from|O clinical|O trials|O may|O provide|O keys|O to|O altered|O cellular|O pathways|O ,|O which|O may|O lead|O to|O new|O treatment|O options|O .|O
RNA|O splicing|O is|O initiated|O by|O the|O recognition|O of|O 50|O splice|O site|O by|O a|O U1|O snRNP|O complex|O ,|O followed|O by|O the|O recruitment|O of|O a|O complex|O consisting|O of|O a|O U2AF35|O /|O 65|O heterodimer|O ,|O ZRSR2|O and|O an|O SR|O protein|O such|O as|O SRSF1|O or|O 2|O ,|O and|O other|O factors|O to|O recognize|O the|O 30|O splice|O site|O .|O
We|O observed|O that|O mutations|O of|O RUNX1|O ,|O TP53|O ,|O and|O NRAS|O were|O each|O strongly|O associated|O with|O severe|O thrombocytopenia|O (|O P|O <|O 0|O .|O 001|O for|O each|O gene|O )|O (|O Fig|O .|O 3A|O )|O .|O
Survival|O ranges|O from|O approximately|O 2|O to|O 11|O years|O ,|O depending|O on|O defined|O prognostic|O factors|O .|O
DNMT3A|O and|O DNA|O methylation|O .|O
NCCN|O ,|O in|O keeping|O with|O its|O commitment|O to|O public|O transparency|O ,|O publishes|O these|O disclosures|O for|O panel|O members|O ,|O staff|O ,|O and|O NCCN|O itself|O .|O
In|O contrast|O ,|O FLT3|O -|O TKD|O may|O be|O associated|O with|O an|O additional|O favorable|O prognosis|O in|O the|O presence|O of|O NPM1|O or|O CEBPA|O mutations|O .|O
When|O serial|O samples|O were|O analyzed|O ,|O we|O found|O that|O an|O U2AF1|O mutation|O detected|O at|O the|O sAML|O stage|O was|O present|O from|O initial|O MDS|O presentations|O ,|O suggesting|O an|O ancestral|O origin|O of|O this|O mutation|O (|O supplemental|O Figure|O 5|O )|O .|O
Data|O concerning|O the|O prognostic|O significance|O of|O DNMT3A|O mutations|O have|O thus|O far|O been|O conflicting|O .|O
AS|O ,|O allele|O -|O specific|O ;|O LNA|O ,|O locked|O nucleic|O acid|O ;|O RFLP|O ,|O restriction|O fragment|O length|O polymorphism|O .|O
In|O younger|O patients|O ,|O strategies|O for|O consolidation|O are|O based|O on|O the|O potential|O risk|O of|O relapse|O ,|O with|O higher|O -|O risk|O patients|O receiving|O more|O aggressive|O therapy|O .|O
Clinical|O phenotypes|O at|O diagnosis|O are|O reported|O in|O Table|O 1|O .|O
The|O changes|O in|O the|O total|O symptom|O score|O among|O patients|O with|O the|O JAK2V617F|O mutation|O were|O -|O 52|O .|O 6|O %|O (|O improvement|O )|O in|O the|O ruxolitinib|O group|O and|O 42|O .|O 8|O %|O (|O worsening|O )|O in|O the|O placebo|O group|O ,|O and|O the|O changes|O among|O those|O without|O the|O mutation|O were|O -|O 28|O .|O 1|O %|O and|O 37|O .|O 2|O %|O ,|O respectively|O (|O P|O =|O 0|O .|O 11|O for|O interaction|O )|O .|O
Cytomegalovirus|O (|O CMV|O )|O screening|O for|O potential|O HSCT|O candidates|O is|O left|O to|O institutional|O policies|O regarding|O provision|O of|O CMV|O -|O negative|O blood|O products|O to|O patients|O who|O are|O CMV|O -|O negative|O at|O time|O of|O diagnosis|O .|O
The|O most|O frequent|O genetic|O abnormalities|O detected|O using|O a|O sensitive|O next|O -|O generation|O amplicon|O deep|O -|O sequencing|O method|O were|O found|O in|O TET2|O with|O aberrations|O also|O seen|O in|O CBL|O ,|O RUNX1|O and|O RAS|O .|O
We|O studied|O 879|O PMF|O patients|O to|O determine|O the|O individual|O and|O combinatorial|O prognostic|O relevance|O of|O somatic|O mutations|O .|O
Higher|O analytical|O sensitivity|O may|O be|O achieved|O by|O using|O clamped|O PCR|O ,|O followed|O by|O nucleotide|O sequencing|O .|O
Finally|O ,|O PRC2|O -|O mediated|O transcriptional|O repression|O has|O also|O recently|O been|O identified|O as|O an|O important|O pathogenic|O event|O in|O acute|O promyelocytic|O leukaemia|O (|O APL|O )|O .|O
[|O SIDEBAR|O TEXT|O ]|O .|O
In|O addition|O to|O the|O eight|O subjects|O with|O EZH2|O point|O mutations|O ,|O the|O EZH2|O locus|O at|O 7q36|O .|O 1|O was|O entirely|O deleted|O at|O one|O allele|O in|O 22|O subjects|O by|O 7|O or|O 7q|O (|O micro|O )|O deletions|O .|O
Similar|O cytogenetic|O profiles|O in|O ET|O did|O not|O predominate|O in|O the|O older|O age|O group|O but|O were|O associated|O with|O palpable|O splenomegaly|O ;|O concurrent|O tobacco|O use|O ;|O venous|O thrombosis|O ;|O and|O anemia|O ,|O with|O a|O hemoglobin|O <|O 10|O g|O /|O dL|O .|O
Interestingly|O ,|O some|O laboratories|O obtained|O positive|O results|O with|O all|O four|O specimens|O ,|O whereas|O others|O obtained|O negative|O results|O with|O all|O four|O .|O
ABSTRACT|O .|O
The|O impact|O of|O the|O driver|O mutations|O on|O OS|O was|O independent|O of|O IPSS|O at|O diagnosis|O and|O of|O time|O -|O dependent|O DIPSS|O (|O maximum|O P|O value|O equal|O to|O .|O 033|O )|O .|O
Graubert|O et|O al|O has|O reported|O an|O increased|O risk|O of|O progression|O to|O secondary|O AML|O ,|O while|O other|O studies|O reported|O no|O effect|O of|O U2AF1|O mutations|O upon|O clinical|O outcome|O .|O depletion|O of|O cohesin|O may|O increase|O RUNX1|O expression|O ,|O forming|O the|O basis|O of|O leukemogenesis|O in|O these|O patients|O .|O
The|O most|O common|O grade|O 3|O or|O 4|O nonhematologic|O adverse|O events|O (|O abdominal|O pain|O ,|O fatigue|O ,|O and|O dyspnea|O )|O occurred|O more|O frequently|O in|O the|O placebo|O group|O .|O
The|O GATA2|O R396Q|O variation|O was|O not|O identified|O in|O the|O maternal|O grandparents|O '|O DNA|O ,|O but|O the|O NEK11|O D87Y|O variation|O was|O detected|O in|O the|O maternal|O grandfather|O '|O s|O DNA|O sample|O .|O
Additional|O value|O is|O also|O suggested|O for|O EZH2|O ,|O IDH1|O and|O SRSF2|O mutations|O .|O
M|O -|O C|O Kuo|O ;|O D|O -|O C|O Liang|O ;|O C|O -|O F|O Huang|O ;|O Y|O -|O S|O Shih|O ;|O J|O -|O H|O Wu|O ;|O T|O -|O L|O Lin|O ;|O L|O -|O Y|O Shih|O .|O
The|O PCR|O was|O performed|O on|O a|O DNA|O thermal|O cycler|O using|O a|O program|O consisting|O of|O 35|O cycles|O at|O 95|O -|O -|O degrees|O -|O -|O C|O for|O 30|O s|O ,|O 58|O -|O -|O degrees|O -|O -|O C|O for|O 30|O s|O and|O 68|O -|O -|O degrees|O -|O -|O C|O for|O 1|O min|O ,|O with|O an|O initial|O preheating|O at|O 94|O -|O -|O degrees|O -|O -|O C|O for|O 3|O min|O and|O a|O final|O step|O for|O 5|O min|O at|O 68|O -|O -|O degrees|O -|O -|O C|O .|O
Like|O JAK2|O and|O MPL|O mutations|O ,|O somatic|O mutations|O of|O CALR|O behave|O as|O driver|O mutations|O responsible|O for|O the|O myeloproliferative|O phenotype|O .|O
As|O low|O expression|O of|O these|O genes|O may|O have|O functionally|O equivalent|O consequences|O ,|O we|O defined|O a|O subset|O of|O patients|O with|O altered|O expression|O of|O the|O cohesin|O complex|O in|O an|O additional|O 15|O %|O of|O patients|O .|O
Similarly|O ,|O EZH2|O mutations|O are|O associated|O with|O worsened|O overall|O survival|O in|O PMF|O (|O TABLE|O 1|O )|O .|O
Mutations|O in|O epigenetic|O modifiers|O account|O for|O new|O classes|O of|O mutant|O disease|O alleles|O that|O contribute|O to|O the|O pathogenesis|O of|O myeloid|O malignancies|O in|O addition|O to|O the|O classical|O class|O I|O genes|O that|O affect|O proliferation|O and|O class|O II|O genes|O that|O affect|O differentiation|O .|O
Statistical|O analysis|O of|O clinical|O data|O .|O
Although|O a|O close|O relationship|O between|O SF3B1|O mutation|O and|O the|O presence|O of|O ring|O sideroblast|O subtype|O is|O well|O -|O established|O ,|O how|O the|O SF3B1|O mutation|O affects|O MDS|O clonal|O development|O or|O the|O formation|O of|O ring|O sideroblasts|O is|O still|O unclear|O .|O
HSCs|O in|O Evi1|O -|O /|O -|O embryos|O were|O markedly|O decreased|O in|O numbers|O ,|O showing|O defective|O self|O -|O renewing|O proliferation|O and|O repopulating|O capacity|O .|O
More|O evidence|O for|O the|O important|O role|O of|O GATA2|O in|O HSC|O arises|O from|O the|O finding|O that|O decreased|O expression|O of|O GATA2|O might|O be|O responsible|O for|O the|O pathogenesis|O and|O development|O of|O the|O clinical|O features|O of|O aplastic|O anemia|O .|O
Figure|O 2|O .|O Change|O in|O Symptom|O Scores|O .|O Panel|O A|O shows|O the|O results|O of|O an|O intention|O -|O to|O -|O treat|O analysis|O of|O the|O proportion|O of|O patients|O with|O at|O least|O a|O 50|O %|O reduction|O in|O the|O total|O symptom|O score|O over|O time|O (|O each|O value|O plotted|O represents|O the|O moving|O average|O for|O the|O previous|O 7|O days|O )|O .|O Patients|O who|O discontinued|O the|O study|O drug|O or|O for|O whom|O data|O were|O missing|O were|O considered|O not|O to|O have|O had|O a|O response|O .|O The|O majority|O of|O responses|O occurred|O rapidly|O ,|O within|O the|O first|O 4|O weeks|O after|O treatment|O .|O Only|O patients|O with|O baseline|O data|O were|O included|O in|O this|O analysis|O .|O Panel|O B|O shows|O the|O percent|O change|O from|O baseline|O in|O the|O total|O symptom|O score|O at|O week|O 24|O (|O in|O 129|O patients|O in|O the|O ruxolitinib|O group|O and|O 103|O patients|O in|O the|O placebo|O group|O )|O and|O at|O the|O last|O evaluation|O during|O receipt|O of|O the|O randomly|O assigned|O study|O drug|O (|O in|O 16|O patients|O in|O the|O ruxolitinib|O group|O and|O 42|O patients|O in|O the|O placebo|O group|O )|O .|O Five|O patients|O with|O a|O baseline|O score|O of|O 0|O ,|O 8|O patients|O with|O missing|O baseline|O values|O ,|O and|O 6|O patients|O with|O insufficient|O data|O after|O baseline|O are|O not|O included|O .|O Whereas|O most|O patients|O who|O received|O ruxolitinib|O had|O a|O reduction|O in|O the|O total|O symptom|O score|O ,|O the|O majority|O of|O patients|O who|O received|O placebo|O had|O a|O worsening|O of|O symptoms|O (|O worsening|O in|O the|O total|O symptom|O score|O of|O >|O =|O 150|O %|O is|O shown|O as|O 150|O %|O )|O .|O Panel|O C|O shows|O the|O mean|O percent|O change|O in|O the|O score|O for|O each|O symptom|O in|O the|O modified|O Myelofibrosis|O Symptom|O Assessment|O Form|O ,|O version|O 2|O .|O 0|O .|O All|O symptoms|O improved|O in|O the|O ruxolitinib|O group|O and|O worsened|O in|O the|O placebo|O group|O (|O P|O <|O 0|O .|O 01|O for|O all|O comparisons|O with|O placebo|O )|O .|O T|O bars|O denote|O standard|O errors|O .|O
The|O guidelines|O are|O intended|O to|O establish|O a|O helpful|O reference|O for|O laboratory|O professionals|O in|O the|O selection|O of|O methodologies|O ,|O validation|O of|O procedures|O ,|O and|O interpretation|O of|O results|O in|O JAK2|O and|O MPL|O testing|O .|O
One|O recent|O study|O showed|O that|O coincidence|O of|O EZH2|O and|O TET2|O mutations|O occurred|O in|O 35|O %|O of|O patients|O with|O MDS|O /|O AML|O and|O also|O demonstrated|O that|O an|O EZH2|O mutation|O augments|O the|O repopulating|O capacity|O of|O hematopoietic|O stem|O cells|O and|O causes|O myeloid|O proliferation|O .|O
Fig|O .|O 2|O .|O Schematic|O RNA|O Splicing|O .|O Adopted|O and|O modified|O according|O to|O Cazzola|O M|O et|O al|O .|O Blood|O 2013|O ;|O 121|O :|O 260|O -|O 269|O and|O Yoshida|O K|O et|O al|O .|O Nature|O ,|O 2011|O ,|O 478|O :|O 64|O -|O 69|O .|O (|O A|O )|O Human|O pre|O -|O mRNA|O consists|O of|O exon|O and|O intron|O sequences|O .|O During|O RNA|O splicing|O process|O ,|O introns|O are|O removed|O and|O exons|O are|O retained|O and|O formed|O mature|O mRNA|O with|O normal|O sequences|O .|O The|O RNA|O splicing|O is|O performed|O in|O spliceosome|O where|O resides|O a|O macromolecular|O structure|O composed|O of|O 5|O '|O -|O snRNAs|O associated|O with|O proteins|O to|O form|O particles|O termed|O snRNPs|O .|O The|O outcomes|O of|O mutation|O vary|O according|O to|O mutated|O sites|O and|O components|O ,|O which|O could|O lead|O to|O retention|O of|O intron|O (|O s|O )|O ,|O truncation|O or|O missing|O of|O exon|O (|O s|O )|O ,|O as|O well|O as|O increased|O or|O decreased|O pre|O -|O mRNA|O level|O .|O (|O B|O )|O There|O are|O 2|O classes|O of|O introns|O :|O the|O majority|O is|O U2|O type|O and|O the|O rare|O is|O U12|O type|O ,|O which|O will|O be|O catalyzed|O by|O 2|O different|O spliceosomes|O ,|O U2|O -|O orU12|O -|O dependent|O spliceosomes|O .|O The|O key|O signal|O sequences|O are|O located|O the|O donor|O site|O (|O DS|O )|O (|O arrow|O points|O to|O 5|O '|O end|O of|O the|O intron|O )|O ,|O the|O branch|O site|O (|O BS|O )|O (|O arrow|O points|O to|O near|O the|O 3|O '|O end|O )|O ,|O and|O the|O splice|O acceptor|O site|O (|O AS|O )|O (|O arrow|O points|O to|O 3|O '|O end|O )|O .|O In|O the|O major|O U2|O -|O dependent|O spliceosome|O ,|O the|O 5|O '|O donor|O site|O is|O recognized|O by|O the|O U1|O snRNP|O ,|O whereas|O the|O branch|O site|O is|O recognized|O by|O the|O U2|O snRNP|O .|O RNA|O splicing|O is|O complicated|O and|O requires|O many|O components|O .|O It|O begins|O with|O the|O recruitment|O of|O U1|O snRNP|O to|O the|O 5|O '|O SS|O .|O Two|O U2|O auxiliary|O factors|O are|O needed|O to|O bind|O different|O sites|O .|O The|O large|O one|O ,|O U2A65|O ,|O along|O with|O SF1|O ,|O binds|O the|O branch|O point|O sequence|O (|O BPS|O )|O and|O its|O downstream|O polypyrimidine|O tract|O while|O the|O smaller|O subunit|O ,|O U2AF35|O ,|O binds|O to|O the|O AG|O dinucleotide|O of|O the|O 3|O '|O SS|O ,|O interacting|O with|O both|O U2AF65|O and|O a|O SR|O protein|O ,|O such|O as|O SRSF2|O .|O ZRSR2|O is|O also|O required|O for|O RNA|O splicingby|O interacting|O with|O U2AF|O and|O SRSF2|O proteins|O .|O After|O the|O recognition|O of|O the|O 3|O '|O SS|O ,|O U2|O snRNP|O ,|O together|O with|O SF3A1|O and|O SF3B1|O ,|O is|O recruited|O to|O the|O 3|O '|O SS|O to|O generate|O the|O splicing|O complex|O .|O Mutation|O of|O U2AF|O ,|O SRSF2|O ,|O SF3B1|O or|O ZESR2|O involving|O in|O RNA|O splicing|O results|O in|O abnormal|O mRNA|O pattern|O e|O .|O g|O .|O ,|O intron|O retention|O ,|O truncation|O of|O exon|O due|O to|O cryptic|O splice|O site|O or|O missing|O exon|O .|O Pre|O -|O mRNA|O level|O can|O be|O either|O increased|O or|O decreased|O .|O Note|O :|O I|O =|O intron|O ,|O E|O (|O 1|O ,|O 2|O ,|O 3|O )|O =|O exon|O 1|O ,|O 2|O ,|O 3|O ;|O snRNps|O =|O small|O nuclear|O ribonucleoproteins|O .|O
The|O role|O of|O TET2|O in|O the|O classification|O of|O MPN|O is|O limited|O because|O TET2|O mutations|O have|O been|O identified|O in|O most|O other|O myeloid|O malignancies|O .|O
Herein|O ,|O we|O discuss|O the|O potential|O impact|O of|O these|O findings|O for|O the|O classification|O and|O treatment|O of|O these|O disorders|O .|O
Of|O special|O interest|O in|O our|O study|O was|O EZH2|O ,|O that|O localizes|O to|O chromosome|O 7q36|O ,|O proposed|O to|O function|O as|O an|O oncogene|O or|O a|O tumor|O suppressor|O gene|O in|O different|O diseases|O .|O
The|O increasing|O use|O of|O next|O -|O generation|O sequencing|O technologies|O applied|O to|O the|O study|O of|O cancer|O genomes|O is|O making|O a|O remarkable|O contribution|O to|O our|O knowledge|O of|O the|O molecular|O landscape|O of|O CN|O -|O AML|O .|O
This|O technique|O was|O chosen|O for|O its|O high|O -|O throughput|O detection|O of|O recurrent|O oncogene|O mutations|O limited|O to|O well|O -|O characterized|O locations|O .|O
One|O patient|O displayed|O four|O mutations|O (|O ASXL1|O ,|O SRSF2|O ,|O EZH2|O and|O IDH2|O )|O and|O four|O patients|O displayed|O three|O mutations|O (|O two|O displayed|O ASXL1|O ,|O SRSF2|O and|O EZH2|O and|O two|O others|O displayed|O ASXL1|O ,|O SRSF2|O and|O IDH1|O mutations|O )|O .|O
For|O patients|O younger|O than|O 60|O years|O who|O have|O experienced|O a|O relapse|O ,|O enrollment|O in|O clinical|O trials|O is|O considered|O an|O appropriate|O strategy|O and|O is|O a|O strongly|O preferred|O option|O by|O the|O panel|O .|O
IDENTIFICATION|O OF|O NEW|O SOMATIC|O MUTATIONS|O .|O
In|O order|O to|O examine|O prognostic|O relevance|O of|O mutations|O detected|O at|O the|O time|O of|O initial|O diagnosis|O and|O further|O validate|O their|O value|O when|O encountered|O at|O time|O of|O tertiary|O center|O referral|O ,|O we|O used|O two|O independent|O patient|O cohorts|O .|O
The|O larger|O form|O is|O a|O protein|O of|O 480|O amino|O acids|O (|O 50|O .|O 5|O kDa|O )|O ;|O the|O shorter|O form|O ,|O encoded|O by|O the|O transcript|O variant|O of|O 3263|O base|O pairs|O ,|O has|O 466|O amino|O acids|O and|O presents|O a|O smaller|O exon|O 5|O (|O 49|O .|O 1|O kDa|O )|O .|O
She|O developed|O a|O disseminated|O Mycobacterium|O avium|O complex|O infection|O and|O later|O an|O AML|O M4|O subtype|O .|O
Table|O 1|O .|O JAK2|O Mutations|O in|O Myeloproliferative|O Neoplasms|O .|O
Molecular|O profiling|O of|O chronic|O myelomonocytic|O leukemia|O reveals|O diverse|O mutations|O in|O >|O 80|O %|O of|O patients|O with|O TET2|O and|O EZH2|O being|O of|O high|O prognostic|O relevance|O .|O
Patients|O and|O experimental|O samples|O .|O
Approximately|O 45|O %|O of|O patients|O will|O be|O JAK2V617|O negative|O and|O alternative|O diagnoses|O that|O may|O mimic|O ET|O should|O be|O considered|O ,|O including|O CML|O ,|O prefibrotic|O PMF|O ,|O and|O PV|O .|O
Many|O of|O the|O newer|O treatment|O strategies|O are|O designed|O to|O work|O more|O gradually|O using|O agents|O that|O may|O allow|O expression|O of|O tumor|O suppressor|O genes|O (|O eg|O ,|O a|O methyltransferase|O inhibitor|O such|O as|O decitabine|O or|O 5|O -|O azacytidine|O )|O or|O increase|O apoptosis|O (|O eg|O ,|O histone|O deacetylase|O inhibitors|O )|O .|O
However|O ,|O we|O also|O noted|O reduced|O expression|O of|O cohesin|O genes|O in|O patients|O without|O mutations|O ,|O including|O 15|O %|O of|O lower|O -|O and|O higher|O -|O risk|O MDS|O patients|O with|O reduced|O expression|O of|O STAG2|O and|O RAD21|O .|O
The|O results|O can|O be|O better|O clarified|O by|O incorporating|O a|O disclaimer|O in|O the|O exon|O 12|O test|O report|O :|O This|O test|O does|O not|O include|O testing|O for|O the|O more|O common|O JAK2|O V617F|O (|O exon|O 14|O ,|O c|O .|O 1849G|O >|O T|O )|O mutation|O .|O
Splice|O site|O mutations|O can|O cause|O activation|O of|O a|O nearby|O cryptic|O splice|O site|O (|O upstream|O or|O downstream|O of|O the|O normal|O site|O )|O ,|O omission|O of|O the|O whole|O exon|O ,|O or|O intron|O retention|O ,|O any|O of|O which|O can|O lead|O to|O frameshifts|O and|O premature|O stop|O codons|O that|O will|O trigger|O nonsense|O -|O mediated|O decay|O and|O haploinsufficiency|O .|O
We|O found|O that|O C|O -|O terminal|O mutations|O were|O associated|O with|O a|O significantly|O higher|O risk|O of|O AML|O transformation|O compared|O with|O those|O without|O mutations|O .|O
The|O former|O had|O a|O lower|O AIC|O value|O (|O 1744|O .|O 5|O vs|O 1764|O .|O 3|O )|O ,|O indicating|O a|O better|O quality|O for|O the|O given|O set|O of|O data|O .|O
It|O is|O known|O that|O GATA|O factors|O interact|O with|O simple|O DNA|O motifs|O (|O WGATAR|O )|O to|O regulate|O critical|O processes|O ,|O including|O hematopoiesis|O .|O
TET2|O and|O DNA|O hydroxymethylation|O .|O
Statistical|O analysis|O .|O
Results|O were|O analyzed|O with|O CNAG|O (|O Version|O 3|O .|O 0|O )|O or|O Genotyping|O Console|O (|O Affymetrix|O )|O .|O
Recently|O ,|O a|O putative|O tumor|O suppressor|O gene|O ,|O PTEN|O /|O MMAC1|O ,|O has|O been|O identified|O at|O chromosome|O 10q23|O .|O 3|O .|O
A|O high|O allele|O burden|O in|O PV|O and|O ET|O is|O associated|O with|O progression|O to|O myelofibrosis|O .|O
The|O mutational|O status|O of|O RUNX1|O was|O also|O correlated|O with|O the|O clinicohematological|O characteristics|O in|O our|O patients|O with|O CMML|O at|O initial|O diagnosis|O .|O
Unexpectedly|O ,|O S34F|O U2AF35|O mutant|O -|O transduced|O HeLa|O cells|O showed|O severely|O suppressed|O cell|O growth|O rather|O than|O enhanced|O cell|O proliferation|O ,|O accompanied|O by|O apoptosis|O and|O G2|O /|O M|O arrest|O .|O
Jerald|O Z|O .|O Gong|O ;|O James|O R|O .|O Cook|O ;|O Timothy|O C|O .|O Greiner|O ;|O Cyrus|O Hedvat|O ;|O Charles|O E|O .|O Hill|O ;|O Megan|O S|O .|O Lim|O ;|O Janina|O A|O .|O Longtine|O ;|O Daniel|O Sabath|O ;|O Y|O .|O Lynn|O Wang|O .|O
For|O the|O false|O -|O negative|O ,|O false|O -|O positive|O ,|O and|O no|O -|O consensus|O results|O ,|O there|O appeared|O to|O be|O no|O correlation|O between|O the|O discordant|O results|O and|O assay|O methodology|O .|O
Chronic|O neutrophilic|O leukemia|O (|O CNL|O )|O is|O a|O rare|O myeloproliferative|O neoplasm|O ,|O with|O only|O ~|O 200|O patients|O reported|O to|O date|O ,|O mostly|O culled|O from|O case|O reports|O and|O small|O case|O series|O .|O
Thus|O ,|O identification|O of|O new|O molecular|O factors|O involved|O in|O these|O malignancies|O would|O be|O fundamental|O to|O improve|O HSC|O -|O based|O anti|O -|O leukemic|O therapies|O and|O to|O prevent|O leukemia|O progression|O .|O
The|O median|O time|O to|O AML|O transformation|O in|O patients|O with|O RUNX1|O mutations|O was|O 23|O .|O 3|O months|O compared|O with|O 28|O .|O 3|O months|O for|O those|O without|O RUNX1|O mutations|O (|O P|O =|O 0|O .|O 175|O ,|O Figure|O 2b|O )|O .|O
The|O amplicons|O were|O purified|O using|O a|O gel|O extraction|O kit|O (|O Geneclean|O III|O Kit|O ,|O Bio101|O ,|O Inc|O .|O ,|O Vista|O ,|O CA|O )|O and|O then|O sequenced|O using|O SequiTherm|O EXCEL|O II|O DNA|O Sequencing|O Kit|O (|O Epientre|O Technologies|O ,|O Madison|O ,|O WI|O )|O .|O The|O sequencing|O primers|O were|O the|O same|O as|O those|O used|O for|O the|O PCR|O -|O SSCP|O .|O
RUNX1|O mutation|O -|O positive|O patients|O were|O younger|O and|O had|O a|O higher|O BM|O blast|O percentage|O than|O did|O mutation|O -|O negative|O patients|O ,|O but|O the|O difference|O did|O not|O reach|O statistical|O significance|O .|O
Four|O patients|O ,|O which|O concomitantly|O harbored|O an|O EZH2|O and|O TET2|O mutation|O ,|O were|O added|O into|O the|O EZH2|O -|O mutated|O group|O ,|O as|O EZH2|O mutations|O are|O believed|O to|O be|O an|O early|O event|O in|O the|O disease|O process|O and|O precede|O the|O sequential|O acquisition|O of|O TET2|O mutations|O and|O because|O EZH2|O mutations|O remained|O significant|O in|O the|O multivariate|O analyses|O in|O contrast|O to|O TET2|O (|O Supplementary|O Information|O 2|O )|O .|O
Patient|O -|O designated|O intermediate|O -|O 1|O risk|O but|O who|O are|O transfusion|O dependent|O or|O have|O an|O unfavorable|O karyotype|O are|O managed|O as|O high|O risk|O (|O Table|O 6|O )|O .|O
Yildrim|O et|O al|O found|O that|O the|O nucleosome|O remodelling|O and|O deacetylase|O (|O NURD|O )|O complex|O member|O methyl|O -|O CpG|O binding|O domain|O protein|O 3|O (|O MBD3|O )|O specifically|O recognizes|O 5|O -|O hmC|O in|O embryonic|O stem|O cells|O and|O represses|O the|O transcription|O of|O genes|O marked|O by|O 5|O -|O hmC|O .|O
Similarly|O ,|O for|O patients|O younger|O than|O 50|O years|O who|O received|O high|O -|O dose|O cytarabine|O at|O the|O 3|O -|O g|O /|O m2|O dose|O schedule|O for|O consolidation|O ,|O the|O rates|O of|O treatment|O -|O related|O deaths|O (|O 4|O %|O vs|O .|O 0|O %|O )|O and|O grade|O 3|O or|O greater|O neurologic|O toxicity|O (|O 16|O %|O vs|O .|O 0|O %|O )|O were|O higher|O than|O for|O those|O who|O received|O the|O standard|O dose|O .|O
Epigenetic|O modifiers|O provide|O new|O targets|O for|O therapeutic|O intervention|O .|O
A|O heterozygous|O nonsense|O GATA2|O R330X|O mutation|O (|O c|O .|O 988C|O >|O T|O ,|O supplemental|O Figure|O 1|O )|O was|O identified|O .|O
These|O are|O observations|O in|O highly|O artificial|O systems|O ;|O no|O information|O about|O abnormal|O splicing|O is|O available|O for|O other|O splicing|O factor|O mutants|O .|O
Ethnic|O differences|O among|O cohorts|O might|O also|O be|O a|O reason|O for|O the|O distinct|O frequency|O of|O RUNX1|O mutations|O between|O ours|O and|O earlier|O studies|O .|O
In|O a|O large|O SWOG|O study|O ,|O patients|O younger|O than|O 65|O years|O (|O N|O =|O 665|O )|O were|O randomized|O to|O receive|O high|O -|O dose|O cytarabine|O (|O 2|O g|O /|O m2|O every|O 12|O hours|O x|O 6|O days|O for|O a|O total|O of|O 24|O g|O /|O m2|O ;|O patients|O aged|O <|O 50|O years|O were|O initially|O randomized|O to|O receive|O 3|O g|O /|O m2|O at|O the|O above|O schedule|O before|O the|O high|O -|O dose|O arm|O was|O redefined|O to|O 2|O g|O /|O m2|O because|O of|O toxicity|O concerns|O )|O or|O standard|O -|O dose|O cytarabine|O (|O 200|O mg|O /|O m2|O /|O d|O x|O 7|O days|O )|O ;|O patients|O in|O both|O treatment|O arms|O also|O received|O daunorubicin|O (|O 45|O mg|O /|O m2|O /|O d|O x|O 3|O days|O )|O .|O
The|O youngest|O brother|O (|O patient|O number|O 6224|O ;|O P1|O ,|O III|O ,|O 5|O )|O ,|O 5|O years|O of|O age|O ,|O presented|O with|O recurrent|O fever|O and|O chronic|O EBV|O replication|O in|O the|O blood|O .|O
The|O durability|O of|O spleen|O response|O and|O survival|O were|O analyzed|O with|O the|O use|O of|O the|O Kaplan|O -|O Meier|O method|O .|O
The|O median|O ,|O lower|O ,|O and|O upper|O interquartile|O values|O depict|O the|O distribution|O of|O quantitative|O variables|O .|O
To|O determine|O the|O coverage|O of|O genomic|O intervals|O ,|O the|O data|O were|O processed|O with|O BEDTools|O and|O analyzed|O in|O R|O .|O
Blood|O and|O medullar|O tests|O were|O normal|O except|O for|O a|O mild|O B|O -|O cell|O deficiency|O .|O
Karyotype|O risk|O designation|O and|O CMML|O risk|O stratification|O were|O according|O to|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O ,|O the|O MDAPS|O and|O the|O G|O -|O MDAPS|O ,|O respectively|O .|O
Alternatively|O ,|O because|O DNMT3A|O functions|O as|O an|O oligomer|O ,|O AML|O -|O associated|O mutations|O may|O result|O in|O dominant|O -|O negative|O inhibition|O of|O the|O wild|O -|O type|O enzyme|O .|O
NuRD|O proteins|O can|O be|O detected|O not|O only|O at|O repressed|O genes|O but|O also|O at|O most|O genes|O activated|O by|O GATA1|O .|O
Quantitative|O tests|O for|O JAK2|O V617F|O allele|O have|O been|O used|O to|O determine|O the|O depth|O of|O clinical|O remission|O and|O to|O guide|O adoptive|O immunotherapy|O ,|O such|O as|O donor|O lymphocyte|O infusion|O .|O
Clinical|O effect|O of|O driver|O mutations|O of|O JAK2|O ,|O CALR|O ,|O or|O MPL|O in|O primary|O myelofibrosis|O .|O
ASXL1|O has|O few|O well|O -|O characterized|O domains|O ,|O but|O it|O does|O have|O a|O conserved|O carboxyl|O -|O terminal|O PHD|O domain|O and|O a|O putative|O DNA|O -|O binding|O domain|O and|O is|O not|O thought|O to|O possess|O enzymatic|O activity|O .|O
The|O median|O follow|O -|O up|O of|O the|O study|O population|O was|O 3|O .|O 5|O years|O (|O range|O ,|O 0|O .|O 1|O -|O 30|O .|O 8|O years|O )|O .|O
Adverse|O effects|O of|O splenectomy|O in|O patients|O with|O PMF|O include|O bleeding|O ,|O thrombosis|O ,|O thrombocytopenia|O ,|O leukocytosis|O ,|O increased|O circulating|O blasts|O ,|O and|O hepatomegaly|O .|O
Of|O these|O ,|O ASXL1|O ,|O SRSF2|O and|O EZH2|O mutations|O inter|O -|O independently|O predicted|O shortened|O survival|O .|O
The|O adjusted|O VAF|O of|O STAG2|O ,|O RAD21|O ,|O and|O SMC3|O mutations|O were|O significantly|O lower|O than|O those|O for|O other|O concomitantly|O present|O TET2|O gene|O mutations|O (|O P|O =|O .|O 01|O )|O .|O
In|O patients|O for|O whom|O the|O cause|O of|O neutrophilia|O is|O not|O easily|O discernible|O ,|O the|O incorporation|O of|O CSF3R|O mutation|O testing|O can|O be|O a|O useful|O point|O -|O of|O -|O care|O diagnostic|O to|O evaluate|O for|O the|O presence|O of|O a|O clonal|O myeloid|O disorder|O ,|O as|O well|O as|O the|O potential|O for|O genetically|O informed|O therapy|O (|O Figure|O 2|O )|O .|O
Thus|O ,|O high|O GATA2|O levels|O would|O silence|O FOG1|O expression|O in|O maturing|O mast|O cells|O ,|O leading|O to|O enhanced|O GATA2|O expression|O and|O further|O FOG1|O repression|O .|O
Of|O patients|O with|O splanchnic|O vein|O thrombosis|O ,|O 31|O %|O were|O found|O to|O have|O associated|O JAK2|O mutations|O and|O often|O had|O a|O latent|O MPN|O ,|O with|O the|O most|O common|O site|O of|O thrombosis|O occurring|O in|O the|O portal|O venous|O system|O .|O
In|O all|O analyses|O ,|O P|O -|O values|O were|O two|O -|O tailed|O and|O values|O <|O 0|O .|O 05|O were|O considered|O statistically|O significant|O .|O
GATA2|O expression|O has|O a|O broad|O distribution|O among|O hematopoietic|O cells|O ,|O with|O a|O particularly|O prominent|O expression|O in|O early|O progenitors|O ,|O as|O well|O as|O in|O megakaryocytes|O and|O in|O mast|O cell|O lineages|O .|O
At|O present|O ,|O the|O only|O treatment|O modality|O with|O curative|O potential|O is|O allogeneic|O stem|O cell|O transplantation|O ,|O but|O this|O particular|O treatment|O is|O still|O associated|O with|O a|O high|O rate|O of|O mortality|O and|O morbidity|O .|O
Prognostically|O significant|O somatic|O mutations|O occurred|O in|O patients|O in|O all|O risk|O groups|O .|O
One|O approach|O to|O the|O integration|O of|O mutational|O -|O analysis|O results|O into|O the|O IPSS|O would|O be|O to|O include|O a|O variable|O for|O mutations|O in|O one|O or|O more|O of|O these|O five|O prognostic|O genes|O (|O Fig|O .|O 4|O )|O .|O
The|O Spanish|O cytogenetic|O risk|O stratification|O system|O analyzed|O the|O role|O of|O karyotype|O in|O patients|O with|O CMML|O .|O
However|O ,|O no|O evidence|O shows|O that|O dysplasia|O represents|O an|O independent|O risk|O factor|O ,|O because|O it|O is|O frequently|O linked|O to|O poor|O -|O risk|O cytogenetics|O .|O
On|O the|O contrary|O ,|O PMF|O with|O nonmutated|O JAK2|O ,|O CALR|O ,|O or|O MPL|O has|O a|O poor|O prognosis|O with|O a|O particularly|O high|O risk|O of|O leukemic|O transformation|O ,|O as|O shown|O by|O a|O study|O of|O the|O Mayo|O Clinic|O and|O by|O the|O present|O work|O .|O
Furthermore|O ,|O GATA2|O gene|O expression|O is|O determined|O by|O multiple|O cis|O -|O regulatory|O elements|O spread|O over|O a|O wide|O range|O of|O the|O mouse|O genome|O .|O
These|O data|O suggest|O that|O therapeutic|O targeting|O of|O the|O EGLN|O family|O may|O also|O demonstrate|O efficacy|O in|O the|O treatment|O of|O IDH|O -|O mutant|O disease|O .|O
Functional|O analyses|O demonstrated|O that|O this|O single|O mutation|O was|O sufficient|O to|O reduce|O FOG1|O binding|O to|O GATA1|O and|O to|O inhibit|O the|O ability|O of|O GATA1|O to|O rescue|O erythroid|O differentiation|O in|O the|O G1E|O murine|O cell|O line|O .|O
Mutations|O of|O GATA2|O described|O previously|O are|O highly|O heterogeneous|O (|O supplemental|O Table|O 3|O )|O ,|O ranging|O from|O the|O creation|O of|O a|O stop|O codon|O (|O R337X|O )|O ,|O a|O frameshift|O mutation|O scattered|O over|O the|O whole|O coding|O frame|O (|O R78|O ,|O G81|O ,|O L105|O ,|O A194|O ,|O G200|O ,|O D259|O ,|O N317|O ,|O L332|O and|O A341|O )|O ,|O deletions|O (|O ranging|O from|O large|O deletions|O encompassing|O the|O whole|O GATA2|O locus|O to|O smaller|O deletions|O such|O as|O codons|O 1|O -|O 290|O ,|O codons|O 340|O -|O 381|O ,|O codons|O 341|O -|O 346|O ,|O and|O codons|O 362|O -|O 365|O or|O T355|O )|O ,|O and|O point|O mutations|O (|O located|O close|O to|O the|O second|O zinc|O finger|O domain|O with|O the|O exception|O of|O P254L|O :|O P304H|O ,|O C319SC|O ,|O T344M|O ,|O T354M|O ,|O L359V|O ,|O R361L|O ,|O R362Q|O ,|O N371K|O ,|O C373R|O ,|O R396W|O ,|O R396Q|O ,|O and|O R398W|O )|O .|O
A|O claim|O of|O intellectual|O property|O rights|O has|O been|O made|O for|O the|O list|O of|O mutated|O genes|O with|O independent|O prognostic|O significance|O identified|O in|O this|O analysis|O .|O
As|O shown|O recently|O by|O us|O and|O by|O others|O ,|O the|O clinical|O course|O of|O MPNs|O is|O profoundly|O influenced|O not|O only|O by|O the|O founding|O driver|O mutations|O but|O also|O by|O subclonal|O events|O .|O
Hematologic|O abnormalities|O are|O based|O on|O laboratory|O values|O .|O The|O data|O shown|O are|O for|O events|O of|O the|O worst|O grade|O during|O the|O study|O ,|O regardless|O of|O whether|O this|O grade|O was|O a|O change|O from|O the|O baseline|O grade|O .|O
Highly|O sensitive|O qPCR|O for|O JAK2|O V617F|O may|O have|O value|O in|O followup|O of|O patients|O with|O primary|O and|O secondary|O myelofibrosis|O after|O allogeneic|O stem|O cell|O transplantation|O .|O
MDS|O is|O one|O of|O the|O most|O frequent|O hematopoietic|O malignancies|O ,|O particularly|O in|O the|O elderly|O .|O
We|O also|O found|O that|O C|O -|O terminal|O mutations|O of|O RUNX1|O in|O CMML|O predicted|O an|O increased|O risk|O and|O shorter|O time|O to|O AML|O transformation|O .|O
These|O studies|O show|O that|O monosomal|O karyotype|O ,|O independent|O of|O other|O unfavorable|O cytogenetic|O factors|O ,|O confers|O very|O poor|O prognosis|O in|O both|O young|O and|O older|O patients|O with|O AML|O .|O
Total|O genomic|O DNA|O was|O isolated|O and|O extracted|O from|O bone|O marrow|O or|O peripheral|O blood|O leukocyte|O of|O the|O subjects|O as|O described|O previously|O .|O
We|O have|O already|O examined|O the|O unique|O switching|O profile|O that|O the|O expression|O profile|O of|O GATA1|O and|O GATA2|O shows|O during|O erythroid|O differentiation|O (|O Fig|O .|O 2|O )|O .|O
Most|O improvements|O in|O recent|O years|O have|O been|O in|O the|O treatment|O of|O patients|O with|O APL|O ,|O which|O serves|O as|O a|O paradigm|O for|O understanding|O how|O the|O biology|O of|O the|O disease|O can|O inform|O treatment|O .|O
Truncated|O CSF3R|O may|O lack|O the|O di|O -|O leucine|O internalization|O motif|O ,|O resulting|O in|O an|O increase|O in|O cell|O surface|O expression|O of|O the|O receptor|O .|O
The|O somatic|O deletions|O and|O mutations|O of|O PTEN|O /|O MMAC1|O gene|O were|O identified|O in|O several|O cancer|O cell|O lines|O and|O primary|O cancers|O including|O glioma|O ,|O breast|O ,|O endometrium|O ,|O prostate|O ,|O thyroid|O ,|O and|O malignant|O melanoma|O .|O
We|O report|O here|O that|O EZH2|O ,|O located|O at|O 7q36|O .|O 1|O ,|O is|O frequently|O targeted|O in|O MDS|O .|O Analysis|O of|O EZH2|O deletions|O ,|O missense|O and|O frameshift|O mutations|O strongly|O suggests|O that|O EZH2|O is|O a|O tumor|O suppressor|O .|O
ASXL1|O belongs|O to|O the|O enhancer|O of|O trithorax|O and|O polycomb|O gene|O family|O and|O is|O mutated|O in|O 33|O %|O of|O CMML|O .|O
cDNA|O was|O fragmented|O with|O Covaris|O ,|O profiled|O with|O Agilent|O Bioanalyzer|O ,|O and|O subjected|O to|O Illumina|O library|O preparation|O with|O NEBNext|O reagents|O (|O New|O England|O Biolabs|O )|O .|O
The|O study|O was|O approved|O by|O the|O Institutional|O Review|O Board|O ,|O Chang|O Gung|O Memorial|O Hospital|O .|O
A|O recent|O large|O -|O scale|O study|O of|O ETV6|O rearrangements|O in|O myeloid|O malignancies|O identified|O a|O low|O frequency|O of|O occurrence|O (|O 0|O .|O 5|O %|O ,|O 51|O of|O 9550|O patients|O )|O ,|O comprising|O 1|O .|O 1|O %|O of|O AML|O (|O 40|O of|O 3798|O )|O and|O 0|O .|O 2|O %|O of|O MDS|O (|O 6|O of|O 3375|O )|O patients|O .|O
It|O has|O already|O been|O suggested|O that|O NPM1|O is|O an|O early|O event|O in|O leukemogenesis|O .|O
Another|O mechanism|O of|O GATA2|O action|O seems|O to|O be|O the|O activation|O of|O SCL|O after|O GATA2|O binding|O to|O its|O promoter|O ,|O controlling|O progenitor|O cell|O survival|O in|O primitive|O hematopoiesis|O .|O
All|O the|O patients|O with|O PV|O no|O longer|O required|O phlebotomy|O after|O treatment|O ,|O but|O only|O 13|O %|O of|O patients|O with|O ET|O had|O a|O reduction|O of|O platelets|O to|O <|O 400|O x|O 109|O /|O L|O .|O
From|O a|O total|O of|O 23|O putative|O mutations|O in|O cohesin|O genes|O ,|O the|O somatic|O status|O could|O be|O confirmed|O in|O 16|O by|O analyzing|O remission|O samples|O or|O T|O -|O cells|O (|O CD3|O +|O CD11b|O -|O CD14|O -|O CD3|O +|O )|O ,|O which|O were|O purified|O from|O diagnostic|O samples|O by|O flow|O cytometry|O (|O supplemental|O Tables|O 2|O -|O 6|O )|O .|O
Of|O note|O ,|O for|O the|O most|O frequently|O mutated|O genes|O ,|O that|O is|O ,|O EZH2|O ,|O ASXL1|O ,|O TET2|O ,|O RAS|O and|O CBL|O various|O pairwise|O analyses|O were|O performed|O between|O wild|O -|O type|O /|O wild|O -|O type|O ,|O mutated|O /|O wild|O -|O type|O ,|O wild|O -|O type|O /|O mutated|O and|O mutated|O /|O mutated|O combinations|O .|O
The|O primers|O for|O all|O exons|O of|O the|O cohesin|O genes|O are|O listed|O in|O supplemental|O Table|O 1|O ,|O available|O on|O the|O Blood|O Web|O site|O .|O
These|O data|O suggest|O the|O possibility|O that|O loss|O -|O of|O -|O function|O cohesin|O mutations|O alter|O transcriptional|O orchestration|O of|O differentiation|O /|O proliferation|O and|O may|O have|O a|O role|O in|O clonal|O evolution|O and|O tumorigenesis|O .|O
Several|O informative|O clinical|O prognostic|O tools|O exist|O for|O the|O risk|O stratification|O of|O MDS|O ,|O but|O it|O has|O become|O apparent|O that|O incorporation|O of|O genetic|O mutations|O may|O further|O enhance|O the|O efficacy|O of|O current|O clinical|O tools|O .|O
The|O NCCN|O AML|O Panel|O convenes|O annually|O to|O update|O recommendations|O for|O the|O diagnosis|O and|O treatment|O of|O AML|O in|O adults|O .|O
Associations|O between|O gene|O mutations|O are|O represented|O by|O a|O Circos|O diagram|O (|O Figure|O 1|O )|O .|O
It|O should|O also|O be|O noted|O that|O future|O trials|O might|O involve|O treatments|O conceived|O for|O specific|O genetic|O subgroups|O .|O
RESULTS|O .|O
They|O owe|O their|O name|O to|O their|O ability|O to|O bind|O the|O consensus|O DNA|O sequence|O (|O A|O /|O T|O )|O GATA|O (|O A|O /|O G|O )|O through|O two|O highly|O conserved|O zinc|O finger|O (|O ZnF|O )|O domains|O .|O
Genotyping|O of|O 953|O mutations|O representing|O 111|O genes|O was|O performed|O on|O amplified|O DNA|O with|O the|O use|O of|O iPlex|O extension|O -|O chemistry|O methods|O (|O Sequenom|O )|O and|O mass|O spectrometry|O ,|O as|O previously|O described|O for|O the|O complete|O set|O of|O OncoMap|O assays|O .|O
Cumulative|O risk|O of|O thrombosis|O according|O to|O JAK2|O ,|O CALR|O ,|O and|O MPL|O mutation|O status|O .|O
In|O a|O review|O of|O data|O from|O adult|O patients|O treated|O on|O a|O phase|O III|O SWOG|O /|O ECOG|O intergroup|O study|O (|O N|O =|O 609|O )|O ,|O the|O 5|O -|O year|O survival|O rates|O for|O those|O with|O favorable|O ,|O intermediate|O -|O risk|O ,|O and|O unfavorable|O cytogenetics|O were|O 55|O %|O ,|O 38|O %|O ,|O and|O 11|O %|O ,|O respectively|O .|O
Gorica|O Nikoloski|O ;|O Saskia|O M|O C|O Langemeijer|O ;|O Roland|O P|O Kuiper|O ;|O Ruth|O Knops|O ;|O Marion|O Massop|O ;|O Evelyn|O R|O L|O T|O M|O Tonnissen|O ;|O Adrian|O van|O der|O Heijden|O ;|O Theresia|O N|O Scheele|O ;|O Peter|O Vandenberghe|O ;|O Theo|O de|O Witte|O ;|O Bert|O A|O van|O der|O Reijden|O ;|O Joop|O H|O Jansen|O .|O
Notably|O ,|O mutations|O in|O EZH2|O were|O associated|O with|O impaired|O survival|O in|O MDS|O but|O not|O with|O an|O increased|O risk|O of|O transformation|O to|O AML|O ;|O these|O data|O suggest|O a|O differential|O role|O for|O PRC2|O function|O in|O acute|O and|O chronic|O myeloid|O malignancies|O ,|O which|O is|O supported|O by|O the|O current|O absence|O of|O reported|O EZH2|O mutations|O in|O de|O novo|O AML|O .|O
Therefore|O ,|O these|O molecular|O markers|O have|O not|O been|O incorporated|O into|O the|O risk|O categorization|O schema|O in|O the|O current|O guidelines|O .|O
Figure|O 1|O .|O Leukaemia|O -|O associated|O mutations|O in|O the|O DNA|O methylation|O and|O demethylation|O pathway|O .|O The|O process|O of|O DNA|O methylation|O and|O the|O enzymes|O involved|O are|O shown|O .|O Enzymes|O known|O to|O be|O affected|O by|O somatic|O mutations|O in|O myeloid|O leukaemia|O are|O marked|O with|O an|O asterisk|O .|O The|O catalytic|O domain|O of|O the|O TET|O family|O of|O methylcytosine|O dioxygenases|O is|O contained|O within|O the|O conserved|O carboxyl|O -|O terminal|O region|O .|O TET1|O and|O TET3|O each|O contain|O an|O amino|O -|O terminal|O CxxC|O zinc|O -|O finger|O domain|O that|O is|O probably|O responsible|O for|O DNA|O binding|O ;|O by|O contrast|O ,|O TET2|O does|O not|O possess|O a|O CxxC|O domain|O ,|O consistent|O with|O a|O likely|O requirement|O for|O other|O proteins|O to|O direct|O TET2|O localization|O within|O the|O genome|O .|O There|O are|O splice|O variants|O of|O TET2|O that|O do|O not|O contain|O the|O carboxyl|O -|O terminal|O catalytic|O domain|O ;|O the|O function|O of|O these|O variants|O ,|O which|O are|O abundantly|O expressed|O in|O haematopoietic|O cells|O ,|O are|O not|O yet|O understood|O .|O Although|O it|O is|O not|O yet|O clear|O whether|O 5|O -|O hydroxymethylcytosine|O (|O 5|O -|O hmC|O )|O is|O consistently|O associated|O with|O activation|O and|O /|O or|O repression|O of|O transcription|O ,|O 5|O -|O hmC|O has|O been|O shown|O to|O specifically|O recruit|O at|O least|O one|O protein|O -|O binding|O complex|O subunit|O -|O the|O nucleosome|O remodelling|O and|O deacetylase|O (|O NURD|O )|O complex|O member|O methyl|O -|O CpG|O binding|O domain|O protein|O 3|O (|O MBD3|O )|O -|O to|O repress|O the|O transcription|O of|O genes|O marked|O by|O 5|O -|O hmC|O .|O Currently|O 5|O -|O carboxylcytosine|O ,|O 5|O -|O formylcytosine|O ,|O and|O 5|O -|O hydroxymethyluracil|O are|O only|O known|O to|O be|O by|O -|O products|O of|O 5|O -|O hmC|O in|O DNA|O demethylation|O ,|O but|O no|O specific|O functions|O have|O been|O described|O .|O 2|O -|O HG|O ,|O 2|O -|O hydroxyglutarate|O ;|O alpha|O -|O KG|O ,|O alpha|O -|O ketoglutarate|O ;|O AID|O ,|O activation|O -|O induced|O cytidine|O deaminase|O ;|O BER|O ,|O base|O -|O excision|O repair|O ;|O DNMT3A|O ,|O DNA|O methyltransferase|O 3A|O ;|O IDH|O ,|O isocitrate|O dehydrogenase|O ;|O NADP|O +|O ,|O nicotinamide|O adenine|O dinucleotide|O phosphate|O ;|O SAH|O ,|O S|O -|O adenosylhomocysteine|O ;|O SAM|O ,|O S|O -|O adenosylmethionine|O ;|O TDG|O ,|O thymine|O DNA|O glycosylase|O .|O
First|O ,|O overall|O JAK2|O V617F|O mutation|O testing|O was|O reproducible|O among|O the|O laboratories|O performing|O this|O testing|O .|O
Thus|O ,|O NPM1|O mutation|O confers|O favorable|O prognosis|O only|O in|O the|O absence|O of|O FLT3|O -|O ITD|O .|O
RESULTS|O .|O
Methods|O .|O
Although|O mutations|O of|O R140|O in|O IDH2|O exclusively|O result|O in|O the|O substitution|O of|O arginine|O to|O glutamine|O (|O IDH2|O -|O R140Q|O )|O ,|O mutations|O affecting|O IDH1|O -|O R132|O or|O IDH2|O -|O R172|O consist|O of|O a|O broader|O range|O of|O amino|O -|O acid|O substitutions|O (|O IDH1|O -|O R132H|O ,|O IDH1|O -|O R132C|O ,|O IDH2|O -|O R172K|O ,|O IDH2|O -|O R172M|O and|O IDH2|O -|O R172S|O )|O .|O
She|O had|O additional|O infections|O such|O as|O pulmonary|O aspergillosis|O ,|O recurrent|O oral|O herpes|O ,|O and|O onychomycosis|O infections|O .|O
In|O this|O international|O collaborative|O project|O ,|O we|O studied|O two|O independent|O cohorts|O of|O patients|O with|O PMF|O in|O order|O to|O clarify|O the|O prognostic|O relevance|O of|O newly|O described|O mutations|O ,|O including|O TET2|O ,|O CBL|O ,|O IDH1|O or|O IDH2|O ,|O ASXL1|O ,|O EZH2|O ,|O DNMT3A|O and|O SRSF2|O .|O
The|O cohesin|O complex|O includes|O SMC1|O ,|O SMC3|O ,|O SCC1|O /|O RAD21|O ,|O SCC3|O /|O STAG|O ,|O WPL1|O ,|O and|O PDS5B|O .|O
The|O new|O genetics|O of|O chronic|O neutrophilic|O leukemia|O and|O atypical|O CML|O :|O implications|O for|O diagnosis|O and|O treatment|O .|O
This|O indicates|O that|O deregulation|O of|O EZH2|O in|O cancer|O may|O not|O be|O generalized|O into|O one|O simple|O mechanism|O .|O
Patients|O were|O randomized|O to|O treatment|O with|O an|O "|O intermediate|O -|O dose|O "|O cytarabine|O regimen|O (|O cycle|O 1|O :|O cytarabine|O ,|O 200|O mg|O /|O m2|O x|O 7|O days|O +|O idarubicin|O ,|O 12|O mg|O /|O m2|O x|O 3|O days|O ;|O cycle|O 2|O :|O cytarabine|O ,|O 1|O g|O /|O m2|O every|O 12|O hours|O x|O 6|O days|O +|O amsacrine|O ,|O 120|O mg|O /|O m2|O x|O 3|O days|O )|O [|O 12|O g|O /|O m2|O cytarabine|O ]|O or|O a|O "|O high|O -|O dose|O "|O cytarabine|O regimen|O (|O cycle|O 1|O :|O cytarabine|O ,|O 1|O g|O /|O m2|O every|O 12|O hours|O x|O 5|O days|O +|O idarubicin|O ,|O 12|O mg|O /|O m2|O x|O 3|O days|O ;|O cycle|O 2|O :|O cytarabine|O ,|O 2|O g|O /|O m2|O every|O 12|O hours|O x|O 4|O days|O +|O amsacrine|O ,|O 120|O mg|O /|O m2|O x|O 3|O days|O )|O [|O 26|O g|O /|O m2|O cytarabine|O ]|O .|O
Figure|O 5|O .|O Proposed|O updated|O model|O of|O myeloid|O malignancy|O pathogenesis|O based|O on|O mutational|O data|O from|O patient|O samples|O .|O The|O myeloid|O malignancies|O have|O previously|O been|O thought|O to|O be|O induced|O by|O mutations|O in|O genes|O that|O normally|O promote|O increased|O growth|O or|O enhance|O survival|O (|O so|O -|O called|O class|O I|O genetic|O alterations|O )|O in|O concert|O with|O co|O -|O occurring|O mutations|O in|O genes|O that|O are|O normally|O involved|O in|O haematopoietic|O differentiation|O (|O so|O -|O called|O class|O II|O genetic|O alterations|O )|O .|O Mutations|O in|O class|O I|O genes|O consist|O of|O activating|O mutations|O in|O genes|O such|O as|O FMS|O -|O related|O tyrosine|O kinase|O 3|O (|O FLT3|O )|O ,|O NRAS|O ,|O KRAS|O and|O KIT|O .|O These|O class|O I|O alterations|O are|O rarely|O co|O -|O occurring|O ,|O which|O is|O consistent|O with|O their|O overlapping|O function|O in|O myeloid|O malignancy|O transformation|O .|O This|O is|O visually|O depicted|O using|O primary|O data|O from|O patients|O with|O acute|O myeloid|O leukaemia|O (|O AML|O )|O in|O the|O form|O of|O a|O Circos|O diagram|O .|O Recently|O ,|O a|O series|O of|O mutually|O exclusive|O mutations|O that|O affect|O DNA|O hydroxymethylation|O have|O been|O found|O in|O patients|O with|O myeloid|O malignancies|O ;|O these|O include|O tet|O methylcytosine|O dioxygenase|O 2|O (|O TET2|O )|O ,|O isocitrate|O dehydrogenase|O 1|O (|O IDH1|O )|O or|O IDH2|O mutations|O ,|O and|O potentially|O other|O heretofore|O unidentified|O disease|O alleles|O .|O Class|O II|O mutations|O occur|O in|O genes|O that|O are|O involved|O in|O regulating|O the|O chromatin|O state|O (|O such|O as|O mixed|O -|O lineage|O leukaemia|O (|O MLL|O )|O and|O additional|O sex|O combs|O -|O like|O 1|O (|O ASXL1|O )|O )|O or|O DNA|O methylation|O (|O such|O as|O DNA|O methyltransferase|O 3A|O (|O DNMT3A|O )|O )|O ;|O again|O ,|O these|O mutations|O rarely|O co|O -|O occur|O ,|O which|O is|O consistent|O with|O redundant|O roles|O in|O oncogenic|O transformation|O .|O Moreover|O ,|O functional|O data|O of|O several|O genes|O in|O this|O new|O class|O of|O epigenetic|O modifier|O mutation|O have|O been|O found|O to|O affect|O both|O cellular|O proliferation|O as|O well|O as|O cellular|O differentiation|O (|O for|O example|O ,|O translocations|O in|O MLL|O as|O well|O as|O loss|O -|O of|O -|O function|O mutations|O in|O TET2|O )|O .|O On|O this|O basis|O ,|O a|O revised|O model|O of|O myeloid|O malignancy|O pathogenesis|O is|O depicted|O here|O ,|O in|O which|O mutations|O in|O class|O I|O ,|O class|O II|O and|O in|O two|O novel|O classes|O of|O epigenetic|O modifier|O genes|O co|O -|O occur|O to|O promote|O myeloid|O transformation|O .|O CBF|O ,|O CCAAT|O -|O binding|O factor|O ;|O CEBPA|O ,|O CCAAT|O /|O enhancer|O binding|O protein|O -|O alpha|O ;|O NPM1|O ,|O nucleophosmin|O ;|O RUNX1|O ,|O runt|O -|O related|O transcription|O factor|O 1|O .|O
Clinical|O outcome|O in|O the|O total|O cohort|O of|O AML|O patients|O according|O to|O cohesin|O gene|O mutation|O status|O .|O
The|O spectrum|O of|O gene|O mutations|O in|O MDS|O and|O related|O myeloid|O neoplasms|O includes|O mutations|O involving|O classical|O signaling|O molecules|O ,|O such|O as|O NRAS|O /|O KRAS|O ,|O PTNP11|O ,|O NF1|O ,|O c|O -|O CBL|O ,|O JAK2|O ,|O and|O FLT3|O ,|O and|O those|O involving|O hematopoietic|O transcription|O factors|O ,|O such|O as|O RUNX1|O ,|O ETV6|O ,|O and|O CEBPA|O ,|O together|O with|O TP53|O and|O other|O tumor|O suppressor|O genes|O .|O
Ninety|O patients|O (|O 40|O %|O )|O had|O SRSF2|O mutations|O ,|O 13|O (|O 6|O %|O )|O had|O SF3B1|O mutations|O and|O 20|O (|O 9|O %|O )|O had|O U2AF35|O mutations|O .|O
On|O a|O multivariable|O analysis|O ,|O independent|O prognostic|O factors|O included|O older|O age|O ,|O poor|O performance|O status|O ,|O thrombocytopenia|O ,|O anemia|O ,|O increased|O BM|O blasts|O ,|O leukocytosis|O (|O >|O 20|O x|O 109|O /|O l|O )|O ,|O chromosome|O 7|O or|O complex|O cytogenetic|O abnormalities|O and|O a|O prior|O history|O of|O red|O blood|O cell|O transfusions|O .|O
All|O of|O these|O patterns|O were|O found|O in|O our|O AML|O patients|O .|O Sequencing|O of|O the|O normal|O -|O sized|O RT|O -|O PCR|O products|O amplified|O from|O the|O AML|O specimens|O ,|O cell|O lines|O ,|O and|O normal|O controls|O showed|O wild|O -|O type|O PTEN|O /|O MMAC1|O transcripts|O except|O in|O the|O U937|O line|O (|O 4|O -|O base|O insertion|O )|O (|O data|O not|O shown|O )|O .|O
Moreover|O ,|O ASXL1|O directly|O interacts|O with|O the|O PRC2|O complex|O in|O reciprocal|O co|O -|O immunoprecipitation|O experiments|O .|O
In|O the|O present|O study|O ,|O we|O identified|O GATA2|O mutations|O as|O a|O cause|O of|O congenital|O mild|O neutropenia|O associated|O with|O a|O high|O risk|O of|O leukemic|O transformation|O .|O
In|O particular|O ,|O 11|O /|O 21|O alterations|O were|O observed|O in|O this|O CMML|O cohort|O .|O
Monocytosis|O is|O frequently|O associated|O with|O neutropenia|O .|O
The|O new|O risk|O stratification|O incorporating|O molecular|O data|O along|O with|O cytogenetics|O is|O summarized|O in|O the|O guidelines|O (|O see|O "|O Risk|O Status|O Based|O on|O Cytogenetics|O and|O Molecular|O Abnormalities|O ,|O "|O on|O page|O 995|O )|O .|O
Single|O -|O fraction|O irradiation|O (|O 100|O cGy|O )|O of|O the|O lungs|O may|O be|O effective|O for|O pulmonary|O hypertension|O and|O 400|O cGy|O for|O extremity|O pain|O associated|O with|O PMF|O .|O
In|O striking|O contrast|O ,|O the|O SCL|O complex|O was|O depleted|O at|O sites|O where|O GATA1|O functions|O as|O a|O repressor|O .|O
Mutations|O of|O two|O or|O more|O genes|O were|O present|O in|O 79|O samples|O (|O 18|O .|O 0|O %|O )|O (|O Fig|O .|O 1|O ,|O and|O Table|O 6|O in|O the|O Supplementary|O Appendix|O )|O .|O
In|O contrast|O ,|O most|O patients|O who|O received|O placebo|O had|O progressive|O splenomegaly|O and|O worsening|O of|O myelofibrosis|O -|O related|O symptoms|O .|O
SRSF2|O mutations|O were|O reported|O to|O be|O associated|O with|O poor|O prognosis|O in|O univariate|O analysis|O ,|O but|O may|O not|O be|O an|O independent|O prognostic|O predictor|O .|O
The|O MonoMAC|O syndrome|O is|O characterized|O by|O a|O severe|O deficiency|O of|O monocytes|O ,|O B|O -|O lymphocytes|O ,|O and|O natural|O killer|O (|O NK|O )|O cells|O ,|O along|O with|O nontuberculous|O mycobacterial|O ,|O fungal|O ,|O and|O viral|O infections|O and|O an|O autosomal|O -|O dominant|O transmission|O in|O most|O cases|O .|O
Cenersen|O ,|O an|O antisense|O oligonucleotide|O complementary|O to|O TP53|O ,|O suppresses|O mutant|O p53|O expression|O and|O restores|O impaired|O erythropoiesis|O in|O patients|O with|O del|O (|O 5q|O )|O MDS|O .|O
Importantly|O ,|O cohesin|O genes|O can|O also|O affect|O transcription|O independently|O of|O CCCTC|O -|O binding|O factor|O .|O
Somatic|O mutations|O of|O the|O PTEN|O /|O MMAC1|O gene|O have|O been|O identified|O in|O a|O number|O of|O cancer|O cell|O lines|O and|O primary|O cancers|O ,|O and|O most|O frequently|O found|O in|O advanced|O cancers|O .|O
Accordingly|O ,|O whereas|O the|O outcome|O of|O patients|O with|O IPSS|O /|O DIPSS|O -|O plus|O high|O -|O risk|O disease|O may|O not|O be|O affected|O by|O the|O presence|O of|O ASXL1|O mutations|O ,|O the|O apparently|O lower|O -|O risk|O patients|O might|O not|O fare|O as|O well|O as|O expected|O ,|O an|O observation|O that|O might|O affect|O therapeutic|O decisions|O .|O
The|O authors|O compared|O the|O results|O of|O RIC|O allogeneic|O HSCT|O with|O those|O from|O matched|O subjects|O receiving|O conventional|O -|O dose|O chemotherapy|O .|O
Interestingly|O ,|O cohesin|O genes|O have|O been|O found|O to|O bind|O to|O CCCTC|O -|O binding|O factor|O ,|O a|O sequence|O -|O specific|O transcription|O factor|O that|O is|O known|O to|O interact|O with|O NPM1|O in|O addition|O to|O regulating|O tumor|O suppressor|O loci|O .|O
Matched|O unrelated|O BM|O transplantation|O was|O performed|O and|O was|O complicated|O by|O a|O grade|O 4|O cutaneous|O GVHD|O requiring|O intensive|O immunosuppressive|O therapy|O .|O
The|O overall|O survival|O of|O patients|O with|O RUNX1|O mutations|O did|O not|O differ|O from|O those|O without|O mutations|O (|O median|O 15|O .|O 7|O months|O vs|O 12|O .|O 8|O months|O ,|O P|O =|O 0|O .|O 928|O ,|O Figure|O 2a|O )|O .|O
Recurrent|O mutations|O in|O SETBP1|O were|O recently|O identified|O in|O 25|O %|O of|O aCML|O patients|O .|O
On|O the|O opposite|O ,|O triple|O -|O negative|O patients|O were|O older|O ,|O had|O lower|O hemoglobin|O level|O ,|O lower|O platelet|O count|O ,|O and|O higher|O IPSS|O risk|O (|O P|O values|O in|O Table|O 1|O )|O .|O
Abbreviations|O :|O AVWS|O =|O acute|O von|O Willebrand|O syndrome|O ;|O Hct|O =|O hematocrit|O ;|O PV|O =|O polycythemia|O vera|O .|O
First|O ,|O whole|O exome|O assembly|O was|O nonredundantly|O mapped|O with|O the|O reference|O genome|O hg19|O .|O
2|O -|O HG|O is|O present|O at|O markedly|O elevated|O levels|O in|O the|O serum|O of|O patients|O with|O AML|O harbouring|O IDH1|O or|O IDH2|O mutations|O ,|O suggesting|O that|O 2|O -|O HG|O could|O be|O a|O biomarker|O for|O IDH|O -|O mutant|O AML|O .|O
The|O recent|O shortages|O of|O several|O chemotherapy|O agents|O have|O raised|O the|O question|O of|O how|O best|O to|O use|O cytarabine|O .|O
Although|O some|O studies|O showed|O no|O prognostic|O effect|O of|O IDH1|O mutations|O on|O OS|O when|O considering|O all|O IDH|O mutations|O (|O IDH1|O and|O IDH2|O combined|O )|O or|O in|O the|O overall|O patient|O population|O ,|O IDH1|O mutations|O seemed|O to|O be|O associated|O with|O significantly|O worse|O outcomes|O in|O the|O subgroup|O of|O patients|O with|O NK|O -|O AML|O with|O favorable|O -|O or|O intermediate|O -|O risk|O disease|O .|O
Subsequent|O analysis|O has|O confirmed|O this|O finding|O ,|O showing|O an|O overall|O frequency|O of|O ASXL1|O mutation|O ranging|O from|O 14|O .|O 4|O %|O to|O 20|O .|O 7|O %|O of|O MDS|O .|O
After|O interruption|O of|O ruxolitinib|O therapy|O ,|O myelofibrosis|O -|O related|O symptoms|O gradually|O returned|O to|O baseline|O levels|O .|O
One|O -|O hundred|O and|O twenty|O -|O three|O (|O 54|O %|O )|O patients|O had|O at|O least|O one|O of|O the|O three|O spliceosome|O mutations|O .|O
All|O of|O these|O parameters|O were|O available|O for|O 780|O patients|O in|O this|O cohort|O after|O excluding|O 200|O pAML|O TCGA|O cases|O and|O 80|O patients|O with|O incomplete|O clinical|O details|O .|O
Other|O .|O
However|O ,|O their|O effects|O on|O RNA|O splicing|O have|O been|O evaluated|O only|O in|O a|O very|O limited|O context|O .|O
Next|O ,|O the|O analytic|O algorithm|O within|O DNAnexus|O called|O all|O the|O positions|O that|O vary|O from|O a|O reference|O genome|O .|O
Patients|O .|O
ABSTRACT|O .|O
Elisa|O Rumi|O ,|O Daniela|O Pietra|O ,|O Cristiana|O Pascutto|O ,|O Paola|O Guglielmelli|O ,|O Alejandra|O Martinez|O -|O Trillos|O ,|O Ilaria|O Casetti|O ;|O Dolors|O Colomer|O ;|O Lisa|O Pieri|O ;|O Marta|O Pratcorona|O ;|O Giada|O Rotunno|O ;|O Emanuela|O Sant|O '|O Antonio|O ;|O Marta|O Bellini|O ;|O Chiara|O Cavalloni|O ;|O Carmela|O Mannarelli|O ;|O Chiara|O Milanesi|O ;|O Emanuela|O Boveri|O ;|O Virginia|O Ferretti|O ;|O Cesare|O Astori|O ;|O Vittorio|O Rosti|O ;|O Francisco|O Cervantes|O ;|O Giovanni|O Barosi|O ;|O Alessandro|O M|O .|O Vannucchi|O ;|O Mario|O Cazzola|O ;|O on|O behalf|O of|O the|O Associazione|O Italiana|O per|O la|O Ricerca|O sul|O Cancro|O Gruppo|O Italiano|O Malattie|O Mieloproliferative|O Investigators|O .|O
AML|O patients|O were|O classified|O according|O to|O French|O -|O American|O -|O British|O criteria|O as|O follows|O :|O M1|O ,|O ten|O patients|O ;|O M2|O ,|O fourteen|O ;|O M3|O ,|O fifteen|O ;|O M4|O ,|O eleven|O ;|O M5|O ,|O eight|O ;|O M6|O ,|O four|O patients|O .|O
This|O error|O can|O be|O easily|O avoided|O by|O restricting|O exon|O 12|O testing|O only|O to|O a|O reflex|O test|O .|O
The|O contamination|O was|O confirmed|O by|O flow|O cytometric|O analysis|O after|O magnetic|O bead|O sorting|O .|O
Identification|O of|O the|O underlying|O genetic|O aberrations|O in|O MDS|O may|O promote|O proper|O classification|O and|O prognostication|O of|O disease|O and|O ,|O eventually|O ,|O the|O development|O of|O targeted|O therapy|O .|O
8|O .|O 1|O .|O GATA2|O MUTATIONS|O IN|O CHRONIC|O MYELOID|O LEUKEMIA|O .|O
Also|O ,|O patients|O with|O low|O 5|O -|O hmC|O levels|O showed|O hypomethylation|O relative|O to|O controls|O at|O the|O majority|O of|O differentially|O methylated|O CpG|O sites|O .|O
The|O ETV6|O mutation|O appears|O also|O to|O be|O associated|O with|O adverse|O clinical|O outcomes|O in|O patients|O with|O MDS|O (|O hazard|O ratio|O =|O 2|O .|O 04|O ;|O 95|O %|O CI|O :|O 1|O .|O 08|O -|O 3|O .|O 86|O )|O .|O
ABSTRACT|O .|O
The|O results|O showed|O aberrant|O PTEN|O /|O MMAC1|O transcripts|O in|O 15|O of|O the|O 62|O (|O 24|O %|O )|O AML|O patients|O ,|O 4|O of|O the|O 5|O cell|O lines|O (|O 80|O %|O )|O ,|O and|O 4|O of|O the|O 30|O (|O 13|O %|O )|O normal|O controls|O .|O
In|O a|O CALGB|O trial|O ,|O the|O subgroup|O of|O patients|O aged|O 60|O years|O or|O younger|O (|O n|O =|O 156|O )|O who|O received|O standard|O -|O dose|O cytarabine|O -|O daunorubicin|O induction|O therapy|O and|O 4|O courses|O of|O high|O -|O dose|O cytarabine|O consolidation|O (|O 3|O g|O /|O m2|O every|O 12|O hours|O on|O days|O 1|O ,|O 3|O ,|O and|O 5|O ,|O per|O course|O )|O experienced|O a|O 4|O -|O year|O DFS|O rate|O of|O 44|O %|O .|O
In|O a|O second|O example|O ,|O one|O assay|O reported|O a|O specimen|O positive|O for|O JAK2|O V617F|O that|O was|O reported|O negative|O in|O all|O other|O laboratories|O ;|O however|O ,|O that|O specimen|O was|O found|O to|O have|O a|O JAK2|O exon|O 12|O mutation|O ,|O which|O is|O mutually|O exclusive|O with|O the|O V617F|O mutation|O .|O
As|O our|O study|O shows|O ,|O somatic|O mutations|O in|O several|O genes|O are|O associated|O with|O distinct|O effects|O on|O cytopenias|O ,|O blast|O proportion|O ,|O the|O likelihood|O of|O co|O -|O occurrence|O with|O other|O molecular|O lesions|O ,|O and|O overall|O survival|O .|O
Initially|O ,|O we|O performed|O whole|O exome|O sequencing|O of|O 15|O index|O cases|O with|O various|O forms|O of|O myeloid|O malignancies|O and|O identified|O distinct|O somatic|O mutations|O in|O genes|O encoding|O components|O of|O the|O spliceosomal|O machinery|O (|O supplemental|O Table|O 1|O ,|O available|O on|O the|O Blood|O Web|O site|O ;|O see|O the|O Supplemental|O Materials|O link|O at|O the|O top|O of|O the|O online|O article|O )|O .|O
Study|O eligibility|O criteria|O included|O availability|O of|O PB|O smear|O ,|O BM|O histology|O and|O cytogenetic|O information|O at|O the|O time|O of|O referral|O to|O the|O Mayo|O Clinic|O .|O
Table|O 1|O .|O Biologic|O and|O clinical|O presentations|O of|O patients|O with|O GATA2|O mutations|O .|O
However|O ,|O in|O another|O recent|O study|O ,|O IDH2|O mutation|O (|O restricted|O to|O IDH2|O -|O R140|O )|O was|O associated|O with|O improved|O survival|O among|O the|O overall|O study|O population|O ,|O and|O among|O the|O subgroup|O of|O patients|O with|O favorable|O risk|O (|O intermediate|O -|O risk|O AML|O with|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O )|O .|O
Less|O prominently|O ,|O SRSF2|O mutations|O were|O more|O frequently|O found|O in|O CMML|O (|O 30|O .|O 7|O -|O 47|O %|O )|O than|O in|O other|O subtypes|O of|O myeloid|O neoplasms|O .|O
Figure|O 3|O .|O Proportions|O of|O Patients|O with|O Mutations|O ,|O According|O to|O Platelet|O Count|O ,|O Blast|O Percentage|O ,|O and|O Hemoglobin|O Level|O .|O Data|O are|O shown|O for|O the|O platelet|O count|O (|O Panel|O A|O )|O ,|O percentage|O of|O blasts|O in|O bone|O marrow|O aspirate|O (|O Panel|O B|O )|O ,|O and|O hemoglobin|O level|O (|O Panel|O C|O )|O at|O the|O time|O of|O bone|O marrow|O sample|O collection|O .|O The|O numbers|O in|O parentheses|O along|O the|O x|O axis|O indicate|O the|O number|O of|O patients|O with|O a|O mutation|O in|O the|O gene|O (|O patients|O could|O have|O >|O 1|O mutated|O gene|O )|O .|O Mutations|O in|O NRAS|O ,|O TP53|O ,|O and|O RUNX1|O were|O significantly|O associated|O with|O severe|O thrombocytopenia|O (|O defined|O as|O <|O 50|O ,|O 000|O platelets|O per|O cubic|O millimeter|O )|O (|O P|O <|O 0|O .|O 001|O for|O each|O comparison|O )|O (|O Panel|O A|O )|O and|O elevated|O blast|O percentage|O (|O defined|O as|O >|O =|O 5|O %|O )|O (|O P|O <|O 0|O .|O 001|O ,|O P|O =|O 0|O .|O 005|O ,|O and|O P|O =|O 0|O .|O 003|O for|O mutations|O in|O the|O three|O genes|O ,|O respectively|O )|O (|O Panel|O B|O )|O .|O
They|O investigated|O the|O role|O and|O target|O genes|O of|O EVI1|O in|O hematopoiesis|O using|O Evi1|O -|O /|O -|O mice|O ,|O which|O died|O at|O embryonic|O day|O 10|O .|O 5|O .|O
With|O the|O exception|O of|O GATA5|O ,|O null|O mutations|O for|O each|O of|O the|O GATA|O genes|O results|O in|O embryonic|O lethality|O in|O mice|O ,|O showing|O they|O are|O crucial|O transcriptional|O regulators|O in|O cell|O development|O .|O
The|O emerging|O realization|O of|O the|O molecular|O diversity|O of|O MDS|O parallels|O the|O clinical|O and|O phenotypic|O heterogeneity|O of|O this|O disease|O .|O
Regulators|O of|O DNA|O methylation|O (|O such|O as|O TET2|O ,|O IDH1|O ,|O IDH2|O and|O DNMT3A|O )|O and|O of|O histone|O modifications|O (|O such|O as|O MLL|O translocations|O ,|O ASXL1|O and|O EZH2|O )|O are|O targeted|O by|O somatic|O alterations|O in|O a|O significant|O subset|O of|O patients|O with|O myeloid|O malignancies|O .|O
Serial|O samples|O were|O obtained|O for|O 38|O patients|O .|O
Of|O note|O ,|O no|O case|O revealed|O the|O Tyr641|O mutation|O as|O described|O in|O follicular|O and|O diffuse|O large|O B|O -|O cell|O lymphomas|O of|O germinal|O center|O origin|O suggesting|O a|O different|O oncogenic|O mechanism|O in|O these|O diseases|O .|O
Among|O the|O 3|O older|O patients|O ,|O 2|O had|O presented|O severe|O vascular|O complications|O ,|O 1|O with|O a|O lethal|O aortic|O dissection|O at|O the|O age|O of|O 36|O (|O patient|O number|O 7107|O )|O and|O 1|O cardiac|O infarct|O at|O the|O age|O of|O 50|O in|O a|O woman|O without|O risk|O factors|O (|O patient|O number|O 5593|O )|O .|O
The|O G|O -|O MDAPS|O was|O developed|O for|O patients|O with|O de|O novo|O MDS|O ,|O secondary|O MDS|O and|O CMML|O and|O identified|O older|O age|O ,|O poor|O performance|O status|O ,|O thrombocytopenia|O ,|O anemia|O ,|O increased|O BM|O blasts|O ,|O leukocytosis|O ,|O chromosome|O 7|O or|O complex|O cytogenetic|O abnormalities|O and|O transfusion|O dependence|O as|O independent|O factors|O associated|O with|O a|O shorter|O OS|O .|O
The|O basis|O for|O phenotypic|O differences|O between|O CSF3R|O mutation|O -|O positive|O CNL|O and|O aCML|O may|O relate|O to|O multiple|O factors|O .|O
Patients|O without|O JAK2|O (|O V617F|O )|O were|O evaluated|O for|O MPL|O exon|O 10|O mutations|O using|O a|O high|O -|O resolution|O melt|O assay|O or|O Sanger|O sequencing|O .|O
Interestingly|O ,|O they|O also|O found|O high|O GATA2|O occupancy|O and|O relatively|O low|O GATA1|O at|O one|O of|O the|O cis|O -|O regulatory|O elements|O that|O controls|O FOG1|O expression|O ,|O which|O is|O normally|O occupied|O by|O GATA1|O in|O erythroid|O cells|O .|O
Clinical|O presentation|O and|O disease|O course|O .|O
Besides|O these|O somatic|O mutations|O in|O the|O cohesin|O complex|O ,|O in|O our|O analysis|O ,|O we|O also|O identified|O 3|O unannotated|O SNPs|O (|O supplemental|O Table|O 7|O )|O .|O
Patients|O who|O underwent|O allogeneic|O stem|O cell|O transplantation|O were|O censored|O at|O the|O time|O of|O transplant|O .|O
It|O is|O also|O possible|O that|O the|O phenotypic|O features|O are|O related|O to|O the|O transcriptional|O spectrum|O of|O cells|O in|O which|O the|O mutations|O occur|O .|O
It|O has|O been|O reported|O that|O ectopic|O expression|O of|O GATA2|O promotes|O erythroblast|O proliferation|O while|O it|O blocks|O erythroid|O terminal|O differentiation|O .|O
Allogeneic|O transplantation|O may|O result|O in|O favorable|O long|O -|O term|O outcomes|O in|O selected|O patients|O ,|O particularly|O when|O undertaken|O in|O the|O chronic|O phase|O of|O disease|O .|O
In|O 2005|O ,|O several|O groups|O simultaneously|O described|O a|O point|O mutation|O in|O codon|O 617|O of|O the|O protein|O tyrosine|O kinase|O gene|O Janus|O kinase|O 2|O (|O JAK2|O )|O in|O BCR|O -|O ABL1|O -|O negative|O myeloproliferative|O neoplasms|O (|O MPN|O )|O .|O
A|O phase|O I|O /|O II|O study|O that|O investigated|O TG101348|O in|O 59|O patients|O with|O PMF|O or|O post|O -|O PV|O /|O ET|O MF|O reported|O that|O 67|O %|O of|O patients|O achieved|O resolution|O of|O leukocytosis|O ,|O thrombocytosis|O ,|O and|O constitutional|O symptoms|O ,|O and|O decreased|O splenomegaly|O ,|O whereas|O 44|O %|O achieved|O >|O 50|O %|O reduction|O in|O JAK2V617F|O allelic|O burden|O .|O
All|O patients|O provided|O written|O informed|O consent|O .|O
Moreover|O ,|O molecular|O defects|O have|O the|O potential|O to|O serve|O as|O biomarkers|O and|O probably|O are|O more|O suitable|O for|O the|O identification|O of|O therapy|O targets|O and|O responsiveness|O /|O refractoriness|O to|O treatment|O .|O
Seventy|O -|O four|O of|O 617|O patients|O (|O 12|O %|O )|O progressed|O to|O blast|O phase|O (|O leukemic|O transformation|O )|O ,|O including|O 43|O of|O 399|O subjects|O (|O 11|O %|O )|O with|O JAK2|O mutation|O ,|O 17|O of|O 140|O (|O 12|O %|O )|O with|O CALR|O mutation|O ,|O 3|O of|O 25|O (|O 12|O %|O )|O with|O MPL|O mutation|O ,|O and|O 11|O of|O 53|O triple|O -|O negative|O subjects|O (|O 21|O %|O )|O .|O
The|O cytogenetic|O risk|O categories|O adopted|O by|O these|O guidelines|O are|O primarily|O based|O on|O analyses|O of|O large|O datasets|O from|O major|O cooperative|O group|O trials|O (|O see|O "|O Risk|O Status|O Based|O on|O Cytogenetics|O and|O Molecular|O Abnormalities|O ,|O "|O page|O 995|O )|O .|O
The|O mutations|O have|O been|O found|O to|O be|O related|O to|O RNA|O slicing|O ,|O transcription|O regulation|O ,|O DNA|O methylation|O ,|O histone|O modification|O ,|O DNA|O repair|O /|O tumor|O suppressor|O ,|O signal|O transduction|O ,|O and|O the|O cohesion|O complex|O .|O
Cytogenetic|O assessment|O was|O done|O in|O 54|O of|O 62|O cases|O ,|O none|O had|O a|O chromosome|O 10|O or|O 10q|O deletion|O .|O
Two|O patients|O had|O transformation|O to|O acute|O myeloid|O leukemia|O ;|O both|O were|O in|O the|O ruxolitinib|O group|O .|O
To|O get|O a|O better|O understanding|O of|O when|O mutations|O in|O the|O cohesin|O complex|O occur|O during|O clonal|O evolution|O ,|O we|O evaluated|O the|O allelic|O burden|O of|O mutations|O in|O the|O cohesin|O complex|O .|O
In|O fact|O ,|O FOG1|O -|O deficient|O mice|O display|O erythropoietic|O defects|O that|O largely|O mimic|O those|O found|O in|O Gata1|O -|O null|O mice|O .|O
For|O patients|O with|O NKAML|O ,|O the|O remission|O rates|O are|O 40|O %|O to|O 50|O %|O with|O cytarabine|O combined|O with|O idarubicin|O ,|O daunorubicin|O or|O mitoxantrone|O .|O
The|O United|O Kingdom|O National|O Cancer|O Research|O Institute|O AML|O 14|O trial|O randomized|O 217|O older|O patients|O (|O primarily|O age|O >|O 60|O years|O ;|O de|O novo|O AML|O ,|O n|O =|O 129|O ;|O secondary|O AML|O ,|O n|O =|O 58|O ;|O high|O -|O risk|O MDS|O ,|O n|O =|O 30|O )|O unfit|O for|O chemotherapy|O to|O receive|O either|O low|O -|O dose|O cytarabine|O subcutaneously|O (|O 20|O mg|O twice|O daily|O for|O 10|O consecutive|O days|O ,|O every|O 4|O -|O 6|O weeks|O )|O or|O hydroxyurea|O (|O given|O to|O maintain|O target|O WBC|O counts|O <|O 10|O ,|O 000|O /|O mcL|O )|O .|O
Given|O the|O diversity|O of|O known|O MPL|O mutations|O ,|O the|O precise|O mutation|O detected|O should|O be|O reported|O using|O HGVS|O -|O standard|O nucleotide|O and|O amino|O acid|O nomenclature|O .|O
KEY|O POINTS|O .|O
Patients|O with|O any|O cohesin|O complex|O mutation|O had|O lower|O BAALC|O expression|O levels|O .|O
However|O ,|O we|O had|O examined|O a|O large|O number|O of|O Chinese|O patients|O with|O de|O novo|O AML|O and|O had|O found|O that|O RUNX1|O mutations|O ,|O except|O for|O AML|O -|O M0|O subtype|O ,|O were|O rarely|O present|O (|O data|O not|O shown|O )|O .|O
GATA1|O is|O the|O founding|O member|O of|O the|O GATA|O family|O .|O
Splicing|O factor|O mutations|O in|O myelodysplasia|O .|O
DISCUSSION|O .|O
A|O total|O of|O 51|O %|O of|O all|O patients|O had|O at|O least|O one|O point|O mutation|O ,|O including|O 52|O %|O of|O the|O patients|O with|O normal|O cytogenetics|O .|O
Overall|O ,|O in|O our|O cohort|O of|O 81|O cases|O ,|O only|O 15|O (|O 18|O .|O 5|O %|O )|O remained|O in|O which|O no|O mutation|O was|O detectable|O .|O
Genomic|O DNA|O and|O RNA|O were|O extracted|O from|O frozen|O BM|O mononuclear|O cells|O as|O described|O earlier|O .|O
We|O did|O not|O find|O a|O difference|O in|O the|O risk|O of|O AML|O transformation|O between|O CMML1|O and|O CMML2|O (|O P|O =|O 0|O .|O 146|O )|O .|O
The|O 2|O mutations|O in|O SMC1A|O were|O both|O missense|O mutations|O (|O Figure|O 1|O and|O supplemental|O Table|O 6|O )|O .|O
PV|O .|O
However|O ,|O recent|O studies|O have|O demonstrated|O a|O novel|O role|O for|O JAK2|O in|O epigenetic|O regulation|O .|O
SRSF2|O .|O
Activating|O mutations|O of|O FLT3|O and|O RAS|O genes|O are|O of|O class|O I|O ,|O whereas|O RUNX1|O mutation|O is|O of|O class|O II|O .|O
Karyotype|O identified|O a|O complete|O monosomy|O 7|O leading|O to|O the|O diagnosis|O of|O unclassifiable|O MDS|O (|O MDS|O -|O U|O )|O .|O
Over|O the|O past|O 3|O decades|O ,|O the|O classification|O system|O for|O AML|O has|O evolved|O from|O the|O French|O American|O British|O (|O FAB|O )|O system|O ,|O which|O relied|O on|O cytochemical|O stains|O and|O morphology|O to|O separate|O AML|O from|O acute|O lymphoblastic|O leukemia|O (|O ALL|O )|O and|O to|O categorize|O the|O disease|O based|O on|O degree|O of|O myeloid|O and|O monocytic|O differentiation|O ,|O to|O the|O system|O developed|O by|O the|O WHO|O .|O
Results|O were|O concordant|O for|O 26|O of|O the|O 66|O specimens|O (|O ie|O ,|O the|O same|O results|O were|O obtained|O by|O all|O participating|O laboratories|O )|O ,|O with|O 21|O positive|O and|O 5|O negative|O .|O
As|O previously|O observed|O in|O ET|O ,|O JAK2|O (|O V617F|O )|O appears|O to|O be|O highly|O thrombophilic|O also|O in|O patients|O with|O PMF|O ,|O indicating|O that|O this|O mutation|O likely|O causes|O thrombosis|O through|O multiple|O mechanisms|O ,|O including|O activation|O of|O platelets|O and|O granulocytes|O .|O
Acute|O myeloid|O leukemia|O (|O AML|O )|O remains|O the|O most|O common|O form|O of|O acute|O leukemia|O among|O adults|O and|O accounts|O for|O the|O largest|O number|O of|O annual|O deaths|O due|O to|O leukemias|O in|O the|O United|O States|O .|O
TP53|O .|O
Mutations|O in|O multiple|O genes|O were|O associated|O with|O overall|O survival|O in|O univariate|O analyses|O (|O Table|O 1|O )|O .|O
Sixteen|O ASXL1|O mutations|O were|O novel|O and|O have|O not|O been|O reported|O to|O date|O (|O Table|O 2|O )|O .|O
Importantly|O ,|O they|O occurred|O at|O a|O higher|O frequency|O (|O about|O 17|O %|O ;|O 14|O of|O 82|O cases|O )|O in|O the|O subset|O of|O CN|O -|O AML|O devoid|O of|O NPM1|O ,|O CEBPA|O ,|O FLT3|O -|O ITD|O ,|O and|O MLLPTD|O mutations|O ,|O and|O mostly|O also|O lacking|O IDH1|O mutations|O .|O
The|O patterns|O of|O the|O 32|O mutations|O consisted|O of|O 9|O missense|O mutations|O ,|O 7|O nonsense|O mutations|O ,|O 15|O frameshift|O mutations|O and|O 1|O silent|O mutation|O .|O
Statistical|O analyses|O were|O performed|O using|O SPSS|O version|O 14|O .|O 0|O .|O 1|O (|O SPSS|O Inc|O .|O ,|O Chicago|O ,|O IL|O ,|O USA|O )|O .|O
Neither|O of|O these|O genetic|O mutations|O is|O available|O for|O testing|O outside|O of|O the|O research|O setting|O .|O
For|O instance|O ,|O Eed|O +|O /|O -|O mice|O develop|O severe|O ,|O lethal|O myeloid|O and|O lymphoid|O proliferation|O .|O
In|O an|O analysis|O of|O outcomes|O between|O 2|O different|O strategies|O for|O matched|O sibling|O allogeneic|O HSCT|O ,|O outcomes|O in|O younger|O patients|O (|O age|O <|O =|O 50|O years|O ;|O n|O =|O 35|O )|O receiving|O conventional|O myeloablative|O allogeneic|O HSCT|O were|O compared|O with|O those|O in|O older|O patients|O (|O age|O >|O 50|O years|O ;|O n|O =|O 39|O )|O receiving|O RIC|O allogeneic|O HSCT|O .|O
The|O gene|O contains|O a|O JmjC|O domain|O and|O encodes|O an|O H3K27|O demethylase|O .|O
Table|O 4|O .|O Risk|O Stratification|O and|O Treatment|O in|O Polycythemia|O Vera|O .|O
A|O lower|O allelic|O burden|O in|O PMF|O is|O associated|O with|O decreased|O leukemic|O -|O free|O survival|O and|O an|O inferior|O prognosis|O .|O
In|O addition|O ,|O homeostatic|O control|O of|O self|O -|O renewal|O versus|O differentiation|O is|O required|O to|O maintain|O hematopoiesis|O throughout|O life|O .|O
In|O sum|O ,|O most|O of|O the|O available|O results|O suggest|O that|O SF3B1|O mutations|O convey|O better|O survival|O in|O the|O cohort|O of|O whole|O myeloid|O malignancies|O ,|O including|O RARS|O and|O RCMD|O -|O RS|O .|O
Besides|O ,|O the|O human|O GATA2|O protein|O contains|O two|O putative|O SUMOylation|O sites|O :|O MKME|O (|O amino|O acids|O 221|O -|O 224|O )|O and|O MKKE|O (|O amino|O acids|O 388|O -|O 391|O )|O .|O
Six|O of|O 7|O mutations|O in|O STAG1|O were|O missense|O mutations|O ,|O while|O one|O patient|O showed|O a|O frameshift|O mutation|O (|O Figure|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
The|O presence|O (|O vs|O .|O the|O absence|O )|O of|O mutations|O of|O ASXL1|O carried|O a|O more|O modest|O hazard|O ratio|O for|O death|O (|O 1|O .|O 38|O [|O 95|O %|O CI|O ,|O 1|O .|O 00|O to|O 1|O .|O 89|O ]|O )|O ,|O but|O ASXL1|O ,|O as|O the|O second|O most|O commonly|O mutated|O gene|O identified|O in|O this|O study|O ,|O contributed|O additional|O risk|O to|O the|O greatest|O number|O of|O patients|O .|O
Similar|O techniques|O were|O used|O for|O analyzing|O the|O Mayo|O samples|O for|O mutations|O found|O to|O be|O prognostically|O relevant|O in|O the|O European|O cohort|O :|O ASXL1|O ,|O SRSF2|O ,|O EZH2|O ,|O IDH1|O and|O IDH2|O (|O see|O Supplementary|O Methods|O and|O Supplementary|O Table|O S1|O for|O details|O )|O .|O
TET2|O mutations|O can|O be|O observed|O as|O an|O early|O ,|O probably|O disease|O -|O initiating|O event|O in|O patients|O with|O MPN|O ,|O and|O can|O also|O be|O observed|O as|O a|O later|O disease|O event|O in|O patients|O with|O MPN|O whose|O disease|O transforms|O to|O AML|O (|O BOX|O 1|O )|O .|O
This|O model|O was|O validated|O in|O an|O independent|O cohort|O of|O 268|O CMML|O patients|O at|O the|O H|O .|O Lee|O Moffitt|O Cancer|O Center|O ,|O in|O Tampa|O ,|O Florida|O .|O
Figure|O 7|O .|O Kaplan|O -|O Meier|O analysis|O of|O survival|O of|O PMF|O patients|O stratified|O according|O to|O their|O genotype|O ,|O as|O it|O was|O known|O in|O different|O time|O periods|O .|O (|O A|O )|O OS|O of|O the|O whole|O population|O of|O PMF|O patients|O :|O the|O genetic|O basis|O of|O MPNs|O was|O unknown|O before|O 2005|O ,|O and|O therefore|O no|O genotypic|O subgroup|O could|O be|O defined|O .|O (|O B|O )|O PMF|O patients|O stratified|O according|O to|O JAK2|O or|O MPL|O mutation|O status|O :|O these|O mutant|O genes|O where|O identified|O in|O 2005|O and|O 2006|O ,|O respectively|O .|O (|O C|O )|O PMF|O patients|O stratified|O according|O to|O JAK2|O ,|O CALR|O ,|O or|O MPL|O mutation|O status|O :|O somatic|O mutations|O of|O calreticulin|O were|O identified|O in|O 2013|O .|O
Sixteen|O of|O 30|O RUNX1|O mutation|O -|O positive|O CMML|O patients|O (|O 53|O %|O )|O progressed|O to|O AML|O compared|O with|O 17|O of|O 51|O RUNX1|O mutationnegative|O patients|O (|O 33|O %|O )|O (|O P|O =|O 0|O .|O 102|O )|O .|O
Alternative|O regimens|O incorporating|O intermediate|O doses|O of|O cytarabine|O (|O 1|O .|O 5|O -|O 2|O g|O /|O m2|O )|O may|O also|O be|O reasonable|O in|O this|O group|O .|O
She|O suffered|O from|O a|O chronic|O genital|O papillomavirus|O infection|O evolving|O to|O carcinoma|O .|O
His|O rationale|O was|O based|O on|O similarities|O in|O the|O trilineage|O proliferation|O of|O hematopoietic|O stem|O cells|O and|O disease|O phenotypes|O .|O
The|O e19|O /|O a2|O type|O BCR|O /|O ABL|O mRNA|O transcript|O (|O p230|O )|O that|O was|O initially|O reported|O as|O the|O molecular|O basis|O for|O some|O cases|O of|O CNL|O is|O instead|O now|O considered|O related|O to|O an|O uncommon|O neutrophilic|O variant|O of|O CML|O .|O
As|O indicated|O above|O ,|O GATA2|O regulates|O its|O own|O transcription|O by|O binding|O to|O its|O promoter|O and|O working|O as|O an|O enhancer|O .|O
7|O .|O IDENTIFYING|O GATA2|O -|O REGULATED|O TARGET|O GENES|O .|O
For|O confirmation|O of|O somatic|O mutations|O ,|O we|O analyzed|O paired|O germline|O DNA|O from|O CD3|O +|O lymphocytes|O .|O
Intermediate|O -|O 1|O -|O risk|O patients|O who|O have|O anemia|O should|O be|O treated|O with|O either|O erythropoietin|O stimulating|O agents|O ,|O testosterone|O enanthate|O (|O 400|O -|O 600|O mg|O intramuscularly|O /|O week|O )|O ,|O fluoxymesterone|O (|O 10|O mg|O orally|O ,|O 3|O times|O a|O day|O [|O t|O .|O id|O .|O ]|O )|O ,|O prednisone|O (|O 0|O .|O 5|O -|O 1|O .|O 0|O mg|O /|O kg|O /|O day|O )|O ,|O danazol|O (|O 600|O mg|O /|O day|O )|O ,|O thalidomide|O (|O 50|O -|O 200|O mg|O /|O day|O )|O ,|O or|O lenalidomide|O (|O 10|O mg|O /|O day|O )|O .|O
Recently|O ,|O a|O putative|O tumor|O suppressor|O gene|O ,|O PTEN|O /|O MMAC1|O ,|O has|O been|O identified|O at|O chromosome|O 10q23|O .|O 3|O ,|O which|O encodes|O a|O 403|O amino|O acid|O dual|O -|O specificity|O phosphatase|O containing|O a|O region|O of|O homology|O to|O tensin|O and|O auxillin|O .|O
ASXL1|O gene|O sequencing|O was|O limited|O to|O 179|O patients|O ,|O 150|O with|O CMML|O -|O 1|O and|O 29|O with|O CMML|O -|O 2|O ,|O because|O of|O limited|O availability|O of|O DNA|O .|O
Demonstration|O of|O exon|O 12|O mutation|O in|O these|O patients|O is|O particularly|O helpful|O for|O ruling|O out|O reactive|O erythrocytosis|O .|O
Scheuremann|O et|O al|O identified|O that|O the|O PR|O -|O DUB|O consists|O of|O BRCA1|O -|O associated|O protein|O 1|O (|O BAP1|O )|O and|O ASXL1|O to|O deubiquitylate|O H2AK119|O (|O FIG|O .|O 2|O )|O .|O
For|O patients|O younger|O than|O 50|O years|O who|O received|O high|O -|O dose|O cytarabine|O at|O the|O 3|O -|O g|O /|O m2|O dose|O schedule|O for|O induction|O ,|O the|O rates|O of|O treatment|O -|O related|O deaths|O (|O 10|O %|O vs|O .|O 5|O %|O )|O and|O grade|O 3|O or|O greater|O neurologic|O toxicity|O (|O 16|O %|O vs|O .|O 2|O %|O )|O were|O higher|O than|O for|O those|O who|O received|O the|O standard|O dose|O .|O
The|O beads|O were|O then|O added|O to|O the|O Flow|O Chip|O for|O sequencing|O in|O the|O SOLiD|O system|O (|O Life|O Technologies|O ,|O Darmstadt|O ,|O Germany|O )|O ,|O and|O sequenced|O according|O to|O the|O manufacturer|O '|O s|O protocol|O (|O Life|O Technologies|O )|O .|O
In|O contrast|O ,|O SF3B1|O mutations|O are|O associated|O with|O generally|O good|O prognosis|O ,|O compatible|O with|O their|O association|O with|O RARS|O ,|O which|O has|O a|O protracted|O clinical|O course|O .|O
Genomic|O DNA|O Preparation|O .|O
Figure|O 1|O .|O Location|O and|O type|O of|O mutations|O in|O genes|O of|O the|O cohesin|O complex|O in|O 389|O patients|O with|O AML|O ,|O and|O associations|O of|O gene|O mutations|O in|O the|O AML|O patient|O cohort|O outlined|O by|O a|O Circos|O diagram|O .|O
Mutations|O in|O PRC2|O components|O do|O not|O seem|O to|O be|O mutually|O exclusive|O .|O
These|O observations|O suggest|O an|O untapped|O resource|O of|O genetic|O alterations|O for|O disease|O prognostication|O and|O warrant|O the|O inclusion|O of|O mutation|O screening|O for|O ASXL1|O ,|O EZH2|O ,|O SRSF2|O and|O IDH1|O as|O laboratory|O correlative|O studies|O in|O future|O clinical|O trials|O and|O prospective|O observational|O studies|O .|O
Five|O of|O the|O samples|O resulted|O in|O failed|O amplifications|O in|O more|O than|O one|O laboratory|O ,|O and|O these|O had|O very|O low|O DNA|O concentrations|O .|O
INTRODUCTION|O .|O
More|O studies|O are|O needed|O to|O prove|O the|O findings|O .|O
Current|O genetic|O and|O functional|O data|O suggest|O that|O mutations|O in|O epigenetic|O modifiers|O fall|O into|O at|O least|O two|O novel|O classes|O :|O one|O set|O of|O mutations|O that|O affect|O DNA|O hydroxymethylation|O (|O including|O TET2|O ,|O IDH1|O and|O IDH2|O )|O ,|O and|O a|O second|O set|O that|O directly|O regulate|O DNA|O methylation|O and|O /|O or|O the|O histone|O state|O (|O including|O MLL|O ,|O ASXL1|O and|O DNMT3A|O )|O .|O
Statistical|O Analysis|O .|O
Conditional|O deletion|O of|O Ezh2|O in|O the|O haematopoietic|O compartment|O results|O in|O B|O -|O lymphoid|O defects|O without|O alterations|O of|O stem|O or|O progenitor|O cell|O function|O or|O of|O myelopoiesis|O in|O vivo|O .|O
In|O fact|O ,|O most|O of|O the|O cis|O -|O acting|O regulatory|O motifs|O for|O the|O Gata2|O mouse|O gene|O reside|O within|O a|O single|O yeast|O artificial|O chromosome|O (|O YAC|O )|O clone|O (|O 250|O kb|O long|O )|O ,|O since|O Gata2|O -|O deficient|O mice|O may|O be|O rescued|O from|O embryonic|O lethality|O with|O this|O Gata2|O -|O YAC|O transgene|O .|O
Murine|O models|O have|O demonstrated|O that|O mutations|O in|O TET2|O are|O sufficient|O to|O induce|O a|O myeloid|O neoplasm|O by|O increased|O hematopoietic|O stem|O cell|O self|O -|O renewal|O and|O myeloid|O transformation|O .|O
Patients|O who|O received|O initial|O chemotherapy|O and|O experienced|O a|O CR|O had|O a|O 45|O %|O DFS|O rate|O ,|O compared|O with|O 10|O %|O for|O patients|O who|O did|O not|O experience|O response|O to|O chemotherapy|O before|O transplantation|O .|O
CSF3R|O is|O known|O to|O signal|O downstream|O through|O both|O Janus|O kinase|O (|O JAK|O )|O and|O SRC|O tyrosine|O kinase|O pathways|O ,|O and|O the|O 2|O classes|O of|O CSF3R|O mutations|O that|O we|O observed|O exhibit|O different|O downstream|O signaling|O and|O kinase|O inhibitor|O sensitivities|O .|O
Analysis|O of|O splicing|O patterns|O in|O 35|O U2AF1|O target|O genes|O has|O revealed|O that|O mutations|O are|O associated|O with|O dysregulation|O of|O cell|O cycle|O and|O RNA|O processing|O .|O
Thirty|O -|O three|O patients|O had|O progressed|O to|O AML|O ,|O which|O was|O defined|O as|O the|O presence|O of|O >|O =|O 20|O %|O blasts|O in|O BM|O or|O peripheral|O blood|O .|O
These|O findings|O strongly|O suggest|O that|O ,|O although|O BCOR|O and|O BCORL1|O are|O homologous|O genes|O ,|O they|O encode|O for|O proteins|O that|O are|O likely|O to|O play|O distinctly|O different|O roles|O in|O normal|O human|O cells|O .|O
Two|O variations|O ,|O GATA2|O R396Q|O (|O c|O .|O 1187G|O A|O ;|O supplemental|O Figure|O 1|O )|O and|O NEK11|O D87Y|O ,|O both|O genes|O located|O on|O the|O chromosome|O 3|O that|O are|O separated|O by|O 2|O .|O 7|O Mb|O ,|O were|O identified|O in|O the|O mother|O and|O in|O the|O 3|O children|O '|O s|O samples|O but|O were|O absent|O in|O the|O father|O '|O s|O sample|O .|O
EZH2|O .|O
For|O samples|O harboring|O multiple|O mutations|O ,|O cloning|O analysis|O was|O carried|O out|O to|O clarify|O whether|O the|O mutations|O were|O on|O the|O same|O allele|O or|O on|O different|O alleles|O .|O
Also|O ,|O U2AF35|O mutations|O were|O associated|O with|O poor|O prognosis|O or|O higher|O risk|O of|O progression|O to|O AML|O in|O univariate|O analysis|O in|O some|O series|O but|O not|O in|O others|O .|O
In|O the|O ruxolitinib|O group|O ,|O 62|O .|O 7|O %|O of|O patients|O with|O a|O reduction|O in|O spleen|O volume|O of|O 35|O %|O or|O more|O had|O improvement|O of|O 50|O %|O or|O more|O in|O spleen|O -|O related|O symptoms|O (|O as|O indicated|O by|O the|O sum|O of|O MFSAF|O scores|O for|O abdominal|O discomfort|O ,|O pain|O under|O the|O ribs|O on|O the|O left|O side|O ,|O and|O a|O feeling|O of|O fullness|O [|O early|O satiety|O ]|O )|O ;|O however|O ,|O this|O level|O of|O improvement|O also|O occurred|O in|O 46|O .|O 9|O %|O of|O patients|O with|O a|O reduction|O in|O spleen|O volume|O of|O less|O than|O 35|O %|O .|O
PcG|O proteins|O operate|O in|O at|O least|O two|O distinct|O complexes|O ,|O PRC1|O and|O PRC2|O ,|O with|O a|O third|O PcG|O complex|O identified|O in|O Drosophila|O melanogaster|O (|O the|O pleiohomeotic|O repressive|O complex|O )|O .|O
Statistical|O analyses|O were|O performed|O using|O Stata|O 12|O .|O 1|O (|O StataCorp|O LP|O )|O software|O .|O
Screening|O for|O JAK2V617F|O may|O help|O increase|O clinical|O suspicion|O of|O MPN|O and|O may|O be|O diagnostic|O in|O PV|O ,|O and|O eliminate|O the|O need|O for|O bone|O marrow|O biopsy|O (|O Figure|O 2|O )|O .|O
Several|O genes|O have|O been|O implicated|O on|O chromosome|O 5|O ,|O but|O the|O relevant|O genes|O on|O chromosome|O 7|O have|O remained|O elusive|O .|O
Restoration|O of|O either|O Evi1|O or|O Gata2|O expression|O in|O these|O cells|O prevented|O the|O failure|O of|O in|O vitro|O maintenance|O and|O proliferation|O of|O the|O HSC|O Evi1|O -|O /|O -|O population|O .|O
They|O display|O the|O typical|O WHIM|O -|O associated|O dysfunctions|O of|O the|O CXCR4|O chemokine|O receptor|O pathway|O without|O mutations|O of|O CXCR4|O that|O are|O frequent|O in|O WHIM|O syndrome|O .|O
JAK2V617F|O is|O a|O tyrosine|O kinase|O gain|O -|O of|O -|O function|O mutation|O in|O exon|O 14|O that|O results|O from|O a|O guanine|O -|O to|O -|O thymine|O transversion|O at|O nucleotide|O 1849|O with|O substitution|O of|O valine|O to|O phenylalanine|O at|O codon|O 617|O .|O
The|O OS|O of|O cohesin|O -|O mutated|O patients|O with|O a|O related|O donor|O was|O similar|O compared|O with|O patients|O without|O a|O related|O donor|O (|O OS|O :|O HR|O 0|O .|O 54|O ;|O 95|O %|O CI|O ,|O 0|O .|O 06|O -|O 4|O .|O 8|O ;|O P|O =|O .|O 58|O ;|O supplemental|O Figure|O 4A|O -|O B|O )|O ,|O suggesting|O that|O cohesin|O gene|O mutations|O did|O not|O influence|O the|O outcome|O of|O allogeneic|O transplantation|O .|O
To|O examine|O the|O potential|O association|O of|O cohesin|O complex|O mutations|O with|O other|O somatic|O defects|O ,|O cases|O with|O mutated|O cohesin|O complex|O genes|O were|O compared|O with|O WT|O .|O
Clinical|O suspicion|O of|O PV|O is|O most|O often|O raised|O in|O the|O context|O of|O elevated|O peripheral|O blood|O (|O PB|O )|O counts|O .|O
ET|O should|O be|O suspected|O in|O patients|O who|O present|O with|O a|O platelet|O count|O >|O =|O 450|O x|O 109|O /|O L|O and|O when|O clinical|O evidence|O of|O reactive|O thrombocytosis|O is|O not|O obvious|O (|O Table|O 2|O )|O .|O
Three|O other|O samples|O appeared|O to|O have|O adequate|O DNA|O but|O still|O resulted|O in|O failed|O amplification|O in|O more|O than|O one|O laboratory|O .|O
5|O .|O POST|O -|O TRANSCRIPTIONAL|O REGULATION|O OF|O GATA2|O .|O
In|O our|O series|O ,|O GATA2|O was|O overexpressed|O in|O 37|O .|O 4|O %|O of|O cases|O (|O 97|O /|O 259|O )|O ,|O showing|O that|O this|O might|O a|O recurrent|O event|O in|O AML|O .|O
Disruption|O of|O expression|O of|O transcription|O factors|O regulating|O proliferation|O ,|O survival|O and|O differentiation|O of|O myeloid|O progenitors|O is|O directly|O linked|O to|O acute|O myeloid|O leukemogenesis|O .|O
To|O study|O the|O germline|O genotype|O ,|O immunoselected|O CD3|O +|O lymphocytes|O were|O used|O .|O
Compared|O with|O PMF|O patients|O ,|O those|O with|O the|O myelodysplastic|O syndrome|O associated|O with|O bone|O marrow|O fibrosis|O have|O more|O profound|O cytopenia|O and|O lower|O circulating|O CD34|O -|O positive|O cell|O count|O .|O
HpaII|O digests|O 5|O '|O -|O CCGG|O -|O 3|O '|O sites|O when|O the|O cytosine|O in|O the|O central|O CpG|O dinucleotide|O is|O unmethylated|O ,|O whereas|O MspI|O digests|O methylated|O and|O unmethylated|O DNA|O at|O those|O sites|O .|O
The|O GATA2|O protein|O ,|O like|O other|O vertebrate|O GATA|O transcription|O factors|O ,|O contains|O a|O conserved|O DNA|O -|O binding|O domain|O composed|O of|O two|O multifunctional|O ZnF|O domains|O (|O N|O -|O ZnF|O and|O C|O -|O ZnF|O )|O of|O the|O Cys|O -|O X2|O -|O Cys|O -|O X17|O -|O Cys|O -|O X2|O -|O Cys|O type|O .|O
These|O observations|O were|O confirmed|O in|O subsequent|O studies|O ,|O although|O splicing|O factor|O mutations|O seem|O to|O be|O rare|O in|O pediatric|O myeloid|O neoplasms|O ,|O including|O juvenile|O myelomonocytic|O leukemia|O .|O
A|O stringent|O algorithm|O was|O applied|O for|O the|O identification|O of|O SNP|O -|O A|O lesions|O .|O
Other|O mutations|O ,|O including|O those|O in|O LUC7L2|O ,|O ZRSR2|O ,|O and|O PRPF8|O ,|O appear|O to|O be|O less|O prevalent|O ,|O and|O ,|O because|O of|O the|O small|O number|O of|O positive|O cases|O within|O the|O already|O large|O cohort|O studied|O ,|O we|O were|O unable|O to|O establish|O whether|O these|O mutations|O correlated|O with|O characteristic|O phenotypic|O features|O and|O survival|O .|O
Additional|O investigations|O may|O include|O bone|O marrow|O biopsy|O that|O demonstrate|O trilineage|O myeloproliferation|O and|O /|O or|O the|O presence|O of|O endogenous|O erythroid|O colonies|O on|O peripheral|O smear|O .|O
When|O expressed|O in|O HeLa|O cells|O ,|O the|O S34F|O U2AF35|O allele|O induces|O global|O defects|O of|O splicing|O ,|O causing|O abnormal|O retention|O of|O intronic|O sequences|O in|O a|O wide|O variety|O of|O mature|O mRNA|O species|O .|O
Mutations|O in|O the|O cohesin|O gene|O family|O members|O (|O mainly|O STAG1|O ,|O STAG2|O ,|O SMC3|O ,|O SMC1A|O ,|O PDS5B|O ,|O and|O RAD21|O )|O have|O been|O recently|O reported|O in|O myeloid|O neoplasms|O .|O
One|O patient|O each|O had|O trisomy|O 13|O and|O trisomy|O 21|O in|O the|O whole|O cohort|O of|O CMML|O patients|O ;|O it|O is|O of|O note|O that|O both|O patients|O harbored|O RUNX1|O mutations|O .|O
Mutations|O in|O DNMT3A|O have|O been|O shown|O to|O confer|O adverse|O overall|O survival|O in|O patients|O with|O cytogenetically|O defined|O intermediate|O -|O risk|O AML|O ,|O and|O mutations|O in|O TET2|O confer|O adverse|O overall|O survival|O in|O this|O risk|O -|O subset|O of|O AML|O regardless|O of|O FLT3|O mutational|O status|O .|O
However|O ,|O the|O demonstrated|O oncogenecity|O in|O transgenic|O mice|O provides|O a|O reasonable|O rationale|O for|O JAK2|O inhibition|O as|O a|O targeted|O treatment|O strategy|O .|O
Analytical|O Sensitivity|O .|O
DISCUSSION|O .|O
However|O ,|O when|O the|O four|O mutations|O were|O considered|O individually|O ,|O only|O ASXL1|O mutations|O retained|O their|O significance|O in|O the|O context|O of|O IPSS|O (|O HR|O :|O 2|O .|O 02|O ;|O P|O <|O 0|O .|O 001|O )|O .|O
Based|O on|O intent|O -|O to|O -|O treat|O analysis|O ,|O patients|O randomized|O to|O the|O ambulatory|O arm|O had|O a|O significantly|O higher|O 2|O -|O year|O DFS|O rate|O (|O 28|O %|O vs|O .|O 17|O %|O ;|O P|O =|O .|O 04|O )|O and|O OS|O rate|O (|O from|O time|O of|O CR|O ;|O 56|O %|O vs|O .|O 37|O %|O ;|O P|O =|O .|O 04|O )|O compared|O with|O the|O single|O course|O of|O intense|O chemotherapy|O consolidation|O .|O
To|O account|O for|O the|O morphologic|O and|O cytogenetic|O diversity|O of|O these|O neoplasms|O ,|O a|O well|O -|O annotated|O cohort|O of|O 1060|O patients|O with|O myeloid|O malignancies|O including|O MDS|O (|O n|O =|O 386|O )|O ,|O myeloproliferative|O neoplasms|O (|O MPNs|O )|O (|O n|O =|O 55|O )|O ,|O MDS|O /|O MPNs|O (|O n|O =|O 169|O )|O ,|O and|O AML|O (|O n|O =|O 450|O )|O were|O analyzed|O for|O cohesin|O gene|O mutational|O status|O ,|O gene|O expression|O ,|O and|O therapeutic|O and|O survival|O outcomes|O .|O
During|O our|O search|O for|O new|O molecular|O lesions|O associated|O with|O MDS|O ,|O we|O identified|O somatic|O mutations|O affecting|O various|O components|O of|O the|O spliceosomal|O machinery|O ,|O similar|O to|O previous|O reports|O .|O
Patient|O -|O specific|O barcodes|O and|O sequencing|O primers|O P1|O and|O P2|O were|O ligated|O to|O these|O fragments|O .|O
The|O allele|O burden|O varies|O greatly|O (|O between|O 1|O %|O and|O 100|O %|O )|O from|O patient|O to|O patient|O at|O the|O time|O of|O first|O diagnosis|O ,|O and|O low|O levels|O of|O JAK2|O V617F|O are|O not|O uncommon|O .|O
His|O younger|O brother|O (|O patient|O number|O 7109|O ;|O P4|O ,|O III|O ,|O 3|O )|O presented|O at|O the|O age|O of|O 15|O with|O severe|O meningococcal|O infection|O associated|O with|O mild|O hematologic|O abnormalities|O and|O an|O identical|O GATA2|O mutation|O .|O
ZRSR2|O encodes|O a|O protein|O associated|O with|O the|O U2|O auxiliary|O factor|O heterodimer|O .|O
However|O ,|O a|O number|O of|O critical|O issues|O remain|O unsolved|O :|O what|O is|O the|O molecular|O mechanism|O for|O these|O mutations|O to|O contribute|O to|O MDS|O pathogenesis|O ,|O to|O what|O extent|O the|O deregulated|O RNA|O splicing|O could|O be|O involved|O in|O that|O process|O ,|O what|O is|O the|O molecular|O nature|O of|O the|O predicted|O gain|O -|O of|O -|O functions|O ,|O and|O what|O are|O the|O targets|O of|O these|O genes|O .|O
Of|O 7|O patients|O with|O STAG1|O mutations|O ,|O 3|O patients|O also|O showed|O an|O NPM1|O mutation|O .|O
This|O model|O identified|O four|O subgroups|O of|O patients|O with|O median|O survivals|O of|O 24|O ,|O 15|O ,|O 8|O and|O 5|O months|O respectively|O .|O
In|O an|O analysis|O of|O data|O from|O pediatric|O and|O adult|O patients|O with|O AML|O (|O N|O =|O 1612|O )|O enrolled|O on|O the|O United|O Kingdom|O Medical|O Research|O Council|O (|O UK|O MRC|O )|O AML|O 10|O trial|O ,|O the|O 5|O -|O year|O survival|O rates|O for|O those|O with|O favorable|O ,|O intermediaterisk|O ,|O and|O poor|O -|O risk|O cytogenetics|O were|O 65|O %|O ,|O 41|O %|O ,|O and|O 14|O %|O ,|O respectively|O .|O
Using|O an|O enhanced|O sequence|O -|O specific|O approach|O to|O examine|O methylation|O status|O ,|O IDH|O -|O mutant|O AMLs|O were|O found|O to|O have|O a|O unique|O methylation|O profile|O that|O is|O distinct|O from|O AMLs|O arising|O from|O MLL|O translocations|O .|O
Christiansen|O et|O al|O .|O observed|O that|O RUNX1|O mutations|O in|O chemotherapyrelated|O MDS|O were|O associated|O with|O a|O shorter|O time|O to|O AML|O transformation|O ,|O and|O missense|O mutations|O had|O a|O shorter|O survival|O than|O those|O with|O frameshift|O or|O nonsense|O patterns|O .|O
In|O this|O regard|O ,|O the|O value|O of|O Bournemouth|O ,|O Lille|O and|O the|O International|O Prognostic|O Scoring|O Systems|O (|O IPSS|O )|O is|O limited|O ,|O as|O they|O were|O designed|O primarily|O for|O patients|O with|O MDS|O ,|O excluding|O CMML|O patients|O with|O a|O proliferative|O phenotype|O .|O
The|O reason|O of|O rapid|O AML|O progression|O in|O patients|O with|O C|O -|O terminal|O mutation|O is|O unclear|O .|O
A|O number|O of|O prognostic|O systems|O are|O either|O based|O on|O the|O old|O French|O -|O American|O -|O British|O classification|O of|O CMML|O (|O Bournemouth|O ,|O Modified|O Bournemouth|O and|O Lille|O )|O or|O are|O not|O primarily|O designed|O for|O CMML|O (|O IPSS|O ,|O revised|O IPSS|O and|O G|O -|O MDAPS|O )|O .|O
Some|O studies|O in|O the|O overall|O AML|O population|O and|O in|O patients|O with|O intermediate|O risk|O reported|O no|O significant|O effect|O of|O DNMT3A|O mutations|O on|O survival|O outcomes|O ,|O whereas|O other|O studies|O have|O shown|O a|O negative|O prognostic|O effect|O in|O the|O overall|O population|O or|O specific|O subgroups|O .|O
In|O 2008|O ,|O the|O World|O Health|O Organization|O expanded|O the|O classification|O of|O myeloproliferative|O disorders|O based|O on|O increasing|O amounts|O of|O molecular|O and|O cytogenetic|O data|O .|O
Antithrombotic|O efficacy|O of|O hydroxyurea|O in|O ET|O is|O well|O established|O and|O is|O recommended|O for|O all|O highrisk|O patients|O .|O
No|O difference|O in|O OS|O was|O observed|O between|O patients|O with|O type|O 1|O and|O those|O with|O type|O 2|O CALR|O mutation|O (|O P|O =|O .|O 235|O )|O ,|O and|O between|O patients|O with|O type|O 2|O CALR|O mutation|O and|O those|O with|O JAK2|O (|O V617F|O )|O (|O P|O =|O .|O 311|O )|O .|O
For|O those|O cases|O in|O which|O a|O sample|O was|O collected|O after|O diagnosis|O ,|O the|O IPSS|O risk|O was|O recalculated|O on|O the|O basis|O of|O clinical|O variables|O at|O the|O time|O of|O sample|O collection|O .|O
Expression|O signatures|O associated|O with|O cohesin|O defects|O .|O
Table|O 5|O .|O Risk|O Stratification|O and|O Treatment|O in|O Essential|O Thrombocythemia|O .|O
In|O clinical|O practice|O ,|O neutrophilia|O most|O commonly|O relates|O to|O leukemoid|O reactions|O due|O to|O chronic|O infections|O ,|O inflammatory|O diseases|O ,|O or|O various|O types|O of|O malignancies|O .|O
INTRODUCTION|O .|O
On|O the|O other|O hand|O ,|O Yuasa|O et|O al|O reported|O that|O the|O oncogenic|O transcription|O factor|O EVI1|O regulates|O hematopoietic|O stem|O cell|O proliferation|O through|O GATA2|O .|O
In|O this|O disease|O ,|O GATA2|O is|O a|O marker|O predictive|O of|O poor|O outcome|O .|O
The|O prognostic|O strength|O of|O mutations|O to|O predict|O transformation|O into|O AML|O was|O evaluated|O in|O the|O framework|O of|O competing|O risks|O ;|O that|O is|O ,|O the|O cumulative|O incidence|O of|O progression|O to|O AML|O was|O calculated|O by|O taking|O AML|O -|O unrelated|O death|O as|O competing|O risk|O .|O
In|O Wu|O '|O s|O study|O ,|O U2AF1|O mutation|O was|O found|O to|O be|O an|O independent|O poor|O -|O risk|O factor|O for|O OS|O in|O all|O patients|O (|O P|O =|O 0|O .|O 030|O )|O and|O could|O predict|O a|O shorter|O time|O -|O to|O -|O leukemia|O transformation|O in|O younger|O patients|O (|O P|O =|O 0|O .|O 020|O )|O ,|O particularly|O in|O lower|O -|O risk|O MDS|O patients|O .|O
Patients|O carrying|O a|O CALR|O mutation|O had|O a|O lower|O risk|O of|O thrombosis|O than|O those|O carrying|O JAK2|O (|O V617F|O )|O (|O P|O =|O .|O 021|O )|O ,|O whereas|O no|O significant|O difference|O was|O observed|O by|O comparing|O the|O other|O genotypic|O subgroups|O .|O
In|O mammals|O ,|O the|O GATA|O family|O is|O composed|O of|O six|O members|O that|O have|O been|O divided|O into|O two|O subfamilies|O on|O the|O basis|O of|O their|O spatial|O and|O temporal|O expression|O patterns|O .|O
Treatment|O with|O ATRA|O results|O in|O a|O loss|O of|O PRC2|O recruitment|O by|O PLZF|O -|O RARalpha|O while|O PRC1|O -|O mediated|O gene|O repression|O persists|O in|O an|O ATRA|O -|O insensitive|O manner|O .|O
Analysis|O was|O performed|O in|O 483|O European|O patients|O and|O the|O seminal|O observations|O were|O validated|O in|O 396|O Mayo|O Clinic|O patients|O .|O
The|O median|O age|O at|O the|O diagnosis|O of|O MDS|O or|O AML|O was|O 15|O years|O (|O range|O ,|O 7|O -|O 35|O )|O .|O
Median|O survival|O was|O significantly|O shorter|O in|O the|O mutationally|O high|O -|O risk|O compared|O with|O the|O low|O -|O risk|O category|O (|O 81|O versus|O 148|O months|O ;|O P|O <|O 0|O .|O 0001|O )|O (|O Figure|O 2c|O )|O .|O
He|O underwent|O HSCT|O with|O a|O matched|O unrelated|O donor|O in|O April|O 2012|O .|O
However|O ,|O outcomes|O in|O favorable|O -|O risk|O patients|O who|O have|O c|O -|O KIT|O mutations|O are|O more|O similar|O to|O those|O of|O patients|O with|O intermediate|O -|O risk|O karyotype|O ,|O and|O these|O patients|O should|O be|O considered|O for|O either|O clinical|O trials|O targeted|O toward|O the|O molecular|O abnormality|O or|O consolidation|O strategies|O similar|O to|O those|O used|O in|O the|O intermediate|O -|O risk|O group|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
After|O adjusting|O for|O age|O ,|O the|O risk|O of|O leukemic|O transformation|O remained|O higher|O in|O triple|O -|O negative|O patients|O compared|O with|O JAK2|O -|O mutant|O patients|O (|O P|O =|O .|O 04|O )|O ,|O whereas|O the|O significance|O of|O the|O difference|O between|O triple|O -|O negative|O and|O CALR|O -|O mutant|O patients|O was|O borderline|O (|O P|O =|O .|O 052|O )|O .|O
For|O older|O patients|O (|O age|O >|O 60|O years|O )|O with|O AML|O ,|O the|O panel|O recommends|O using|O patient|O performance|O status|O ,|O in|O addition|O to|O adverse|O features|O (|O eg|O ,|O unfavorable|O cytogenetics|O and|O therapy|O -|O related|O AML|O or|O prior|O MDS|O )|O and|O comorbid|O conditions|O ,|O to|O select|O treatment|O options|O rather|O than|O relying|O on|O a|O patient|O '|O s|O chronologic|O age|O alone|O .|O
The|O degree|O of|O functional|O redundancy|O between|O GATA1|O and|O GATA2|O in|O the|O erythroid|O -|O megakaryocyte|O differentiation|O pathway|O remains|O the|O subject|O of|O active|O investigation|O .|O
The|O JAK2|O gene|O maps|O to|O chromosome|O band|O 9p24|O and|O encodes|O a|O tyrosine|O kinase|O protein|O composed|O of|O 1132|O amino|O acids|O .|O
GATA2|O might|O be|O this|O putative|O mutator|O gene|O suggested|O by|O Minelli|O et|O al|O GATA2|O mutation|O could|O act|O as|O a|O preleukemic|O event|O followed|O by|O an|O overt|O transformation|O due|O to|O the|O loss|O of|O genes|O located|O in|O the|O long|O arm|O of|O chromosome|O 7|O .|O
For|O qualitative|O JAK2|O V617F|O testing|O ,|O the|O report|O should|O clearly|O indicate|O a|O final|O analytic|O result|O (|O eg|O ,|O JAK2|O V617F|O mutation|O DETECTED|O or|O JAK2|O V617F|O mutation|O NOT|O DETECTED|O )|O .|O
C|O -|O ZnF|O is|O essential|O for|O GATA1|O function|O ,|O since|O it|O is|O responsible|O for|O the|O recognition|O of|O the|O GATA|O consensus|O sequence|O and|O consequent|O binding|O to|O DNA|O .|O
The|O study|O was|O conducted|O in|O accordance|O with|O the|O International|O Conference|O on|O Harmonization|O guidelines|O for|O Good|O Clinical|O Practice|O .|O
To|O provide|O quantitative|O information|O on|O the|O relevance|O of|O results|O ,|O 95|O %|O confidence|O intervals|O (|O CIs|O )|O of|O odds|O ratios|O (|O OR|O )|O and|O hazard|O ratios|O (|O HR|O )|O were|O computed|O .|O
CALR|O -|O mutant|O ET|O and|O CALR|O -|O mutant|O PMF|O have|O a|O relatively|O indolent|O clinical|O course|O compared|O with|O the|O respective|O JAK2|O -|O mutant|O disorders|O .|O
Subsequently|O ,|O we|O studied|O the|O effect|O of|O the|O most|O common|O spliceosomal|O mutations|O on|O clinical|O outcomes|O .|O
Statistical|O analyses|O were|O performed|O with|O the|O statistical|O software|O package|O SPSS|O 20|O .|O 0|O (|O IBM|O Corp|O .|O ,|O Armonk|O ,|O NY|O )|O .|O
All|O factors|O of|O Table|O 2|O were|O therefore|O included|O in|O the|O new|O prognostic|O model|O ,|O here|O defined|O as|O clinical|O -|O molecular|O prognostic|O model|O .|O
In|O this|O latter|O subgroup|O ,|O presence|O of|O IDH1|O or|O mutations|O was|O associated|O with|O significantly|O increased|O 3|O -|O year|O OS|O rate|O compared|O with|O patients|O with|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O and|O without|O IDH1|O or|O IDH2|O mutations|O (|O 89|O %|O vs|O .|O 31|O %|O ;|O P|O <|O .|O 0001|O )|O .|O
The|O cytogenetic|O risk|O group|O is|O defined|O according|O to|O Medical|O Research|O Council|O criteria|O .|O
As|O shown|O in|O Figure|O 1A|O ,|O CALR|O -|O mutant|O patients|O had|O a|O lower|O cumulative|O incidence|O of|O anemia|O compared|O with|O JAK2|O -|O mutant|O (|O P|O <|O .|O 001|O )|O ,|O MPL|O -|O mutant|O (|O P|O =|O .|O 004|O )|O ,|O and|O triple|O -|O negative|O patients|O (|O P|O <|O .|O 001|O )|O .|O
This|O explains|O ,|O at|O least|O in|O part|O ,|O the|O lack|O of|O efficacy|O of|O ATRA|O in|O PLZF|O -|O RARalpha|O -|O positive|O APL|O (|O FIG|O .|O 4|O )|O .|O
Although|O initial|O studies|O identified|O metabolic|O alterations|O in|O samples|O of|O IDH|O -|O mutant|O AML|O and|O glioma|O ,|O the|O mechanism|O by|O which|O these|O mutations|O contribute|O to|O malignant|O transformation|O was|O not|O known|O .|O
Although|O ,|O traditionally|O ,|O histomorphology|O -|O based|O schemes|O have|O been|O applied|O to|O subclassify|O patients|O with|O MDS|O ,|O this|O approach|O is|O unlikely|O to|O be|O reflective|O of|O the|O underlying|O pathogenesis|O .|O
The|O NPM1|O mutation|O has|O been|O shown|O to|O be|O associated|O NK|O -|O AML|O with|O a|O reported|O frequency|O of|O 48|O %|O to|O 53|O %|O .|O
PMF|O .|O
These|O SUMOylation|O consensus|O sequences|O are|O conserved|O among|O GATA|O family|O members|O .|O
However|O ,|O in|O CN|O -|O AML|O patients|O ,|O in|O patients|O with|O mutated|O NPM1|O ,|O and|O in|O the|O NPM1|O mutated|O /|O FLT3|O wild|O -|O type|O subgroup|O of|O patients|O ,|O cohesin|O mutations|O had|O no|O impact|O on|O outcome|O .|O
On|O a|O multivariable|O analysis|O ,|O only|O increased|O AMC|O (|O >|O 10|O x|O 109|O /|O l|O ,|O RR|O 2|O .|O 5|O ,|O 95|O %|O CI|O 1|O .|O 7|O -|O 3|O .|O 8|O )|O ,|O presence|O of|O circulating|O IMC|O (|O RR|O 2|O .|O 0|O ,|O 95|O %|O CI|O 1|O .|O 4|O -|O 2|O .|O 7|O )|O ,|O decreased|O hemoglobin|O (|O <|O 10|O g|O /|O dl|O ,|O RR|O 1|O .|O 6|O ,|O 99|O %|O CI|O 1|O .|O 2|O -|O 2|O .|O 2|O )|O and|O decreased|O platelet|O count|O (|O <|O 100|O x|O 109|O /|O l|O ,|O RR|O 1|O .|O 4|O ,|O 99|O %|O CI|O 1|O .|O 0|O -|O 1|O .|O 9|O )|O retained|O significance|O .|O
Another|O recent|O study|O evaluating|O treatment|O in|O older|O patients|O (|O age|O 60|O -|O 70|O years|O )|O compared|O outcomes|O between|O RIC|O allogeneic|O HSCT|O (|O reported|O to|O the|O Center|O for|O International|O Blood|O and|O Marrow|O Transplant|O Research|O ;|O n|O =|O 94|O )|O and|O standard|O chemotherapy|O induction|O and|O postremission|O therapy|O from|O the|O CALGB|O studies|O (|O n|O =|O 96|O )|O .|O
Other|O options|O for|O consolidation|O strategies|O include|O one|O or|O more|O cycles|O of|O high|O -|O dose|O cytarabine|O followed|O by|O autologous|O HSCT|O or|O allogeneic|O HSCT|O from|O matched|O sibling|O or|O unrelated|O donors|O .|O
The|O incidence|O of|O monosomal|O karyotype|O increased|O with|O age|O ,|O from|O 4|O %|O in|O patients|O aged|O 30|O years|O or|O younger|O to|O 20|O %|O in|O those|O older|O than|O 60|O years|O .|O
Nevertheless|O the|O potential|O mechanisms|O of|O pathogenesis|O remain|O largely|O unknown|O .|O
TRANSCRIPTION|O REGULATION|O .|O
Also|O ,|O proinflammatory|O cytokines|O that|O play|O an|O important|O role|O in|O myelofibrosis|O signal|O through|O JAK|O 1|O (|O JAK1|O )|O and|O JAK2|O .|O
Statistical|O analysis|O .|O
The|O significance|O of|O these|O differences|O remains|O to|O be|O elucidated|O .|O Whether|O the|O aberrant|O transcripts|O in|O these|O candidate|O tumor|O suppressor|O genes|O are|O important|O in|O leukemogenesis|O or|O are|O merely|O the|O consequence|O of|O splicing|O infidelity|O in|O leukemic|O cells|O needs|O further|O investigation|O .|O
In|O our|O cohort|O of|O CMML|O patients|O ,|O the|O Mayo|O prognostic|O model|O outperformed|O the|O MDAPS|O ,|O G|O -|O MDAPS|O and|O the|O Spanish|O cytogenetic|O risk|O models|O .|O
Peripheral|O blood|O mononuclear|O cells|O from|O 30|O healthy|O volunteers|O were|O used|O to|O assess|O the|O frequency|O of|O germline|O single|O nucleotide|O variants|O (|O SNVs|O )|O .|O
On|O the|O other|O hand|O ,|O low|O levels|O (|O 1|O %|O )|O of|O the|O mutant|O JAK2|O have|O been|O reported|O in|O ET|O patients|O (|O as|O determined|O using|O allele|O -|O specific|O loop|O -|O mediated|O amplification|O assay|O )|O .|O
ABSTRACT|O .|O
Fig|O .|O 1|O .|O RT|O -|O PCR|O analysis|O of|O the|O expression|O of|O the|O PTEN|O /|O MMAC1|O gene|O .|O (|O A|O )|O Abnormal|O transcripts|O are|O noted|O in|O AML|O patients|O (|O cases|O 10|O ,|O 22|O ,|O 24|O ,|O 35|O ,|O and|O 72|O )|O and|O normal|O controls|O (|O N6|O ,|O N7|O ,|O N10|O ,|O N16|O )|O .|O (|O B|O )|O Abnormal|O transcripts|O in|O cell|O lines|O .|O Lane|O 1|O ,|O U937|O ;|O lane|O 2|O ,|O Raji|O ;|O lane|O 3|O ,|O HL60|O ;|O lane|O 4|O ,|O KG|O -|O 1|O ;|O lane|O 5|O ,|O K562|O .|O M|O represents|O pGem|O marker|O .|O
Abbreviations|O :|O HCT|O =|O hematopoietic|O stem|O cell|O transplant|O ;|O IPSS|O =|O international|O prognostic|O scoring|O system|O ;|O PMF|O =|O primary|O myelofibrosis|O .|O
Extramedullary|O presentation|O ,|O including|O central|O nervous|O system|O (|O CNS|O )|O disease|O ,|O is|O uncommon|O in|O patients|O with|O AML|O .|O
These|O percentages|O are|O similar|O to|O those|O reported|O in|O published|O epidemiologic|O studies|O of|O patients|O with|O myelodysplastic|O syndromes|O .|O
Although|O a|O gain|O -|O of|O -|O function|O mutation|O of|O EZH2|O (|O Try641|O )|O has|O been|O identified|O in|O follicular|O lymphoma|O (|O 7|O .|O 2|O %|O )|O and|O germinal|O center|O B|O -|O cell|O subtype|O diffuse|O large|O B|O -|O cell|O lymphoma|O (|O 21|O .|O 7|O %|O )|O ,|O loss|O -|O of|O -|O function|O mutations|O in|O EZH2|O have|O been|O found|O in|O MDS|O and|O MDS|O /|O MPN|O .|O
In|O 2008|O ,|O the|O Global|O MDAPS|O (|O G|O -|O MDAPS|O )|O was|O developed|O for|O patients|O with|O de|O novo|O MDS|O ,|O secondary|O MDS|O and|O CMML|O (|O n|O =|O 1915|O )|O .|O
Patient|O number|O 5758|O (|O P4|O ,|O III|O ,|O 1|O )|O presented|O with|O numerous|O and|O extensive|O warts|O associated|O with|O a|O mild|O neutropenia|O since|O the|O age|O of|O 6|O ,|O a|O profound|O monocytopenia|O ,|O and|O deficiencies|O of|O B|O cells|O and|O NK|O cells|O (|O Table|O 1|O and|O supplemental|O Table|O 2|O )|O .|O
Overall|O and|O leukemia|O -|O free|O survival|O correlates|O of|O mutations|O .|O
Primary|O analysis|O was|O performed|O on|O OS|O .|O
Targeted|O gene|O panels|O assessed|O by|O next|O -|O generation|O sequencing|O are|O increasingly|O being|O used|O in|O clinical|O laboratories|O .|O
The|O mononuclear|O cells|O from|O BM|O samples|O were|O obtained|O by|O Ficoll|O -|O Hypaque|O density|O gradient|O centrifugation|O (|O 1|O .|O 077|O g|O /|O ml|O ;|O cryofetal|O bovine|O ;|O Amersham|O Pharmacia|O ,|O Buckinghamshire|O ,|O UK|O )|O and|O preserved|O in|O 10|O %|O dimethylsulfoxide|O and|O 20|O %|O serum|O at|O -|O 70|O -|O -|O Degree|O -|O -|O C|O or|O in|O liquid|O nitrogen|O until|O test|O .|O
The|O mutations|O consisted|O of|O 9|O missense|O ,|O 1|O silent|O ,|O 7|O nonsense|O and|O 15|O frameshift|O mutations|O .|O
The|O only|O notable|O difference|O was|O that|O patients|O with|O the|O SF3B1|O mutations|O had|O a|O higher|O percentage|O of|O BM|O ring|O sideroblast|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O lower|O median|O WBC|O (|O P|O =|O 0|O .|O 04|O )|O and|O a|O lower|O ALC|O (|O P|O =|O 0|O .|O 045|O )|O .|O
Furthermore|O ,|O we|O performed|O a|O survival|O analysis|O taking|O both|O EZH2|O and|O TET2|O mutations|O into|O account|O ,|O as|O TET2|O -|O mutated|O patients|O showed|O a|O better|O survival|O in|O our|O first|O analysis|O (|O Figure|O 1c|O )|O .|O
Another|O option|O for|O this|O group|O is|O 1|O to|O 2|O cycles|O of|O high|O -|O dose|O cytarabine|O -|O based|O consolidation|O followed|O by|O autologous|O HSCT|O ,|O if|O allogeneic|O transplant|O is|O not|O an|O available|O option|O .|O
In|O the|O subgroup|O of|O patients|O with|O CN|O -|O AML|O (|O n|O =|O 201|O )|O ,|O we|O identified|O 16|O patients|O with|O mutations|O in|O the|O cohesin|O complex|O (|O 8|O %|O )|O .|O
The|O exception|O is|O an|O MDS|O subtype|O ,|O refractory|O anemia|O with|O ring|O sideroblasts|O and|O thrombocytosis|O ,|O in|O which|O the|O frequency|O of|O JAK2V617F|O mutation|O is|O estimated|O to|O be|O 50|O %|O .|O
4|O .|O 1|O .|O THE|O '|O GATA|O SWITCH|O '|O DURING|O ERYTHROID|O DIFFERENTIATION|O .|O
The|O U2AF1|O /|O U2AF35|O gene|O is|O located|O at|O 21q22|O .|O 3|O and|O encodes|O U2|O auxiliary|O factor|O protein|O ,|O which|O recognizes|O the|O AG|O splice|O acceptor|O dinucleotide|O at|O the|O 3|O end|O of|O introns|O during|O RNA|O splicing|O .|O
Patients|O with|O mutations|O of|O these|O genes|O ,|O as|O compared|O with|O patients|O who|O did|O not|O have|O such|O mutations|O ,|O were|O also|O more|O likely|O to|O have|O an|O elevated|O blast|O percentage|O (|O Fig|O .|O 3B|O )|O ,|O but|O the|O two|O groups|O did|O not|O differ|O significantly|O with|O respect|O to|O neutropenia|O or|O anemia|O (|O Fig|O .|O 3C|O )|O .|O
The|O Mayo|O prognostic|O model|O was|O then|O validated|O in|O an|O independent|O cohort|O of|O 268|O patients|O with|O WHO|O -|O defined|O CMML|O at|O the|O H|O .|O
We|O did|O not|O observe|O widespread|O defective|O splicing|O ,|O but|O rather|O distinct|O changes|O in|O specific|O introns|O ,|O as|O seen|O in|O RUNX1|O ,|O that|O would|O functionally|O have|O the|O same|O effect|O as|O RUNX1|O mutations|O .|O
The|O function|O of|O hematopoietic|O GATA|O factors|O has|O been|O extensively|O examined|O ,|O and|O various|O in|O vivo|O experimental|O approaches|O have|O been|O explored|O to|O assess|O their|O activity|O in|O an|O integrated|O context|O .|O
In|O another|O cohort|O ,|O mutated|O STAG2|O was|O found|O in|O 6|O %|O of|O patients|O with|O MDS|O ,|O both|O low|O -|O grade|O (|O RCMD|O )|O and|O high|O -|O grade|O (|O RAEB|O )|O .|O
Similarly|O ,|O overall|O survival|O was|O significantly|O worse|O for|O CMML|O patients|O with|O SETBP1|O mutations|O .|O
Figure|O 2|O .|O Comparison|O of|O the|O Mayo|O prognostic|O model|O for|O CMML|O ,|O with|O the|O MD|O Anderson|O model|O ,|O Global|O MD|O Anderson|O model|O and|O the|O Spanish|O cytogenetic|O risk|O -|O stratification|O system|O .|O
The|O Kaplan|O -|O Meier|O method|O was|O used|O to|O analyze|O survival|O outcomes|O (|O OS|O )|O of|O subgroups|O characterized|O by|O the|O presence|O of|O mutant|O versus|O wild|O -|O type|O (|O WT|O )|O variants|O of|O specific|O spliceosome|O -|O associated|O gene|O mutations|O with|O the|O log|O -|O rank|O test|O (|O JMP9|O ;|O SAS|O Institute|O )|O .|O
Other|O relevant|O genes|O were|O assessed|O for|O frequently|O occurring|O mutations|O or|O expression|O levels|O as|O previously|O described|O (|O ie|O ,|O FLT3|O -|O ITD|O ,|O nucleophosmin1|O [|O NPM1|O ]|O ,|O DNMT3A|O ,|O IDH1|O ,|O IDH2|O ,|O and|O MLL5|O )|O .|O
In|O vivo|O studies|O demonstrated|O the|O induction|O of|O PV|O -|O ,|O ET|O -|O ,|O and|O PMF|O -|O like|O diseases|O in|O JAK2V617F|O -|O positive|O transgenic|O mice|O and|O the|O relative|O disease|O phenotypes|O could|O be|O partially|O anticipated|O by|O allelic|O burden|O .|O
ETV6|O .|O
Consequently|O ,|O GATA2|O expression|O is|O also|O regulated|O by|O GATA2|O itself|O and|O GATA1|O .|O
The|O cDNA|O PCR|O was|O carried|O out|O in|O an|O Expand|O Long|O Template|O PCR|O system|O (|O Roche|O ,|O Mannheim|O ,|O Germany|O )|O ,|O which|O is|O composed|O of|O buffer|O 3|O with|O a|O unique|O enzyme|O mix|O containing|O a|O mixture|O of|O Taq|O DNA|O polymerase|O and|O Tgo|O DNA|O polymerase|O (|O 1|O .|O 25|O U|O in|O 25|O ml|O )|O ;|O the|O latter|O is|O a|O thermostable|O DNA|O polymerase|O with|O proofreading|O activity|O .|O
Among|O STAG2|O sequence|O alterations|O ,|O 62|O out|O of|O 63|O predicted|O loss|O of|O function|O ,|O including|O frameshift|O (|O n|O =|O 19|O )|O ,|O splice|O site|O (|O n|O =|O 10|O )|O ,|O and|O /|O or|O nonsense|O (|O n|O =|O 33|O )|O mutations|O .|O
By|O contrast|O ,|O PRC1|O is|O more|O appropriately|O thought|O of|O as|O a|O collection|O of|O different|O complexes|O on|O the|O basis|O of|O genomic|O duplication|O of|O the|O core|O PRC1|O complex|O between|O D|O .|O melanogaster|O and|O mammalian|O evolutionary|O development|O .|O
This|O increased|O cellular|O proliferation|O may|O be|O relevant|O to|O the|O pathobiology|O of|O aCML|O .|O
The|O survival|O outcome|O for|O patients|O with|O unfavorable|O cytogenetics|O was|O poor|O ,|O with|O a|O median|O OS|O of|O only|O 10|O months|O in|O both|O treatment|O arms|O .|O
RT|O -|O PCR|O and|O cDNA|O Sequencing|O Analysis|O .|O
When|O the|O Gata2|O promoter|O region|O was|O analyzed|O ,|O they|O found|O that|O EVI1|O directly|O binds|O to|O the|O Gata2|O promoter|O as|O an|O enhancer|O ,|O showing|O that|O Gata2|O is|O one|O of|O critical|O targets|O for|O EVI1|O and|O that|O transcription|O factors|O regulate|O the|O HSC|O pool|O hierarchically|O .|O
Using|O these|O four|O independent|O risk|O factors|O ,|O we|O prepared|O the|O Mayo|O prognostic|O model|O for|O CMML|O ,|O consisting|O of|O three|O risk|O categories|O :|O low|O risk|O (|O 0|O risk|O factors|O )|O ,|O intermediate|O risk|O (|O one|O risk|O factor|O )|O and|O high|O risk|O (|O two|O or|O more|O risk|O factors|O )|O ,|O with|O median|O survivals|O of|O 32|O ,|O 18|O .|O 5|O and|O 10|O months|O ,|O respectively|O (|O Figure|O 2|O )|O .|O
The|O prevalence|O of|O grade|O 3|O or|O 4|O anemia|O peaked|O after|O approximately|O 8|O to|O 12|O weeks|O of|O ruxolitinib|O therapy|O ,|O subsequently|O decreasing|O to|O levels|O similar|O to|O those|O in|O patients|O who|O received|O placebo|O .|O
RUNX1|O mutations|O have|O been|O described|O in|O chemotherapyrelated|O MDS|O ,|O MDS|O of|O atomic|O bomb|O survivors|O or|O in|O de|O novo|O MDS|O ,|O whereas|O RUNX1|O mutations|O were|O rarely|O reported|O in|O CMML|O .|O
Of|O note|O ,|O in|O the|O vast|O majority|O of|O cases|O the|O remaining|O DNMT3A|O allele|O remains|O wild|O -|O type|O ,|O suggesting|O that|O DNMT3A|O haploinsufficiency|O is|O sufficient|O to|O contribute|O to|O myeloid|O transformation|O .|O
The|O familial|O segregation|O of|O the|O GATA2|O R396Q|O mutation|O (|O GATA2|O gene|O location|O according|O to|O hg19|O ,|O chr3|O :|O 128|O .|O 2|O Mb|O )|O in|O pedigree|O 1|O was|O investigated|O using|O 4|O highly|O polymorphic|O short|O tandem|O repeats|O (|O STRs|O )|O ,|O 2|O of|O which|O were|O centromeric|O to|O GATA2|O (|O D3S3606|O and|O D3S3607|O ,|O located|O at|O chr3|O :|O 127|O .|O 2|O Mb|O and|O chr3|O :|O 127|O .|O 3|O Mb|O ,|O respectively|O )|O and|O 2|O of|O which|O were|O telomeric|O to|O GATA2|O (|O D3S1587|O and|O D3S1292|O located|O at|O chr3|O :|O 130|O .|O 8|O Mb|O and|O chr3|O :|O 131|O .|O 6|O Mb|O ,|O respectively|O )|O .|O
Mutations|O of|O the|O MPL|O gene|O occur|O in|O BCR|O -|O ABL1|O -|O negative|O MPN|O .|O
Given|O the|O fact|O that|O both|O GATA1|O and|O GATA2|O have|O key|O roles|O in|O controlling|O the|O proliferation|O and|O differentiation|O of|O hematopoietic|O cells|O ,|O defects|O arising|O from|O mutations|O in|O these|O genes|O have|O long|O been|O suspected|O as|O possible|O contributions|O to|O hematopoietic|O disorders|O ,|O including|O leukemia|O .|O
In|O 2003|O ,|O the|O International|O Working|O Group|O for|O the|O Diagnosis|O and|O Standardization|O of|O Response|O Criteria|O accepted|O the|O cytochemical|O and|O immunophenotypic|O criteria|O of|O WHO|O as|O the|O standard|O for|O diagnosing|O AML|O ,|O including|O the|O reporting|O of|O dysplasia|O according|O to|O morphology|O .|O
Recommendations|O for|O induction|O chemotherapy|O in|O patients|O with|O AML|O consider|O age|O 60|O years|O as|O a|O therapeutic|O divergence|O point|O .|O
Based|O on|O the|O protocol|O -|O specified|O final|O analysis|O of|O the|O primary|O end|O point|O (|O OS|O )|O ,|O decitabine|O was|O associated|O with|O a|O statistically|O nonsignificant|O trend|O for|O increased|O median|O OS|O compared|O with|O physician|O '|O s|O choice|O (|O 7|O .|O 7|O vs|O .|O 5|O months|O ;|O HR|O ,|O 0|O .|O 85|O ;|O 95|O %|O CI|O ,|O 0|O .|O 69|O -|O 1|O .|O 04|O ;|O P|O =|O .|O 10|O )|O .|O
Reports|O of|O quantitative|O JAK2|O V617F|O assays|O should|O include|O a|O statement|O of|O qualitative|O results|O (|O eg|O ,|O JAK2|O V617F|O mutation|O DETECTED|O )|O ,|O as|O well|O as|O a|O statement|O of|O quantitative|O allele|O burden|O .|O
Fig|O .|O 1|O .|O Epigenetic|O regulations|O -|O simplified|O DNA|O methylation|O /|O histone|O modification|O .|O Adopted|O and|O modified|O based|O on|O Li|O KK|O et|O al|O .|O ,|O Semin|O Hematol|O 2013|O ;|O 50|O :|O 48|O -|O 60|O and|O http|O :|O /|O /|O www|O .|O activemotif|O .|O com|O /|O stem|O -|O cell|O -|O identity|O .|O (|O A|O )|O DNA|O methylation|O is|O regulated|O by|O DNMT3|O as|O hemi|O -|O methylated|O form|O and|O maintained|O by|O DNMT1|O to|O full|O -|O methylated|O DNA|O .|O Mutations|O (|O red|O fond|O )|O impair|O DNA|O methylation|O .|O (|O B|O )|O DNMTs|O add|O methyl|O group|O in|O C5|O (|O carbon|O 5|O )|O position|O of|O cytosines|O to|O produce|O 5mC|O ,|O while|O TETs|O catalyze|O 5mC|O to|O 5hmC|O ,|O then|O some|O other|O factors|O turn|O 5hmC|O back|O to|O cytosine|O .|O (|O C|O )|O There|O are|O two|O polycomb|O repressive|O complexes|O ,|O 1|O and|O 2|O ,|O and|O constitute|O totally|O different|O components|O as|O shown|O .|O PRC2|O is|O incorporated|O to|O chromatin|O which|O allows|O trimethylation|O of|O histone|O H3|O Lys27|O by|O EZH2|O .|O The|O consequence|O of|O trimethylation|O of|O Lys27|O is|O to|O recruit|O PRC1|O via|O CBX|O .|O PRC1|O interacts|O with|O nonadjacent|O regions|O of|O chromatin|O that|O further|O represses|O gene|O expression|O the|O function|O of|O H2AK119ub1|O is|O to|O repress|O transcript|O elongation|O by|O RNA|O polymerase|O II|O .|O The|O ASXL1|O gene|O regulates|O epigenesis|O through|O interaction|O with|O PRC2|O while|O the|O PRC2|O complex|O serves|O to|O put|O 1|O -|O 3|O methyl|O groups|O on|O the|O 27th|O lysine|O residue|O of|O histone|O H3|O (|O H3K27|O )|O .|O Mutations|O in|O ASXL1|O and|O EZH2|O alter|O Polycomb|O functions|O so|O as|O to|O cause|O inappropriate|O differentiation|O and|O perpetual|O self|O -|O renewal|O of|O cancer|O stem|O cells|O .|O (|O For|O interpretation|O of|O the|O references|O to|O color|O in|O this|O figure|O legend|O ,|O the|O reader|O is|O referred|O to|O the|O web|O version|O of|O this|O article|O .|O )|O
Results|O .|O
Ongoing|O investigations|O are|O trying|O to|O identify|O the|O molecular|O basis|O of|O PMF|O with|O nonmutated|O JAK2|O ,|O CALR|O ,|O or|O MPL|O ,|O and|O to|O better|O define|O the|O distinctive|O features|O of|O these|O patients|O .|O
Also|O ,|O EZH2|O and|O ASXL1|O mutations|O were|O neither|O associated|O with|O CMML|O subtype|O ,|O dysplastic|O /|O myeloproliferative|O characteristics|O ,|O age|O ,|O karyotype|O ,|O white|O blood|O cell|O count|O ,|O platelets|O count|O ,|O hemoglobin|O or|O gender|O (|O Supplementary|O Information|O 2|O )|O .|O
Besides|O ,|O it|O has|O been|O shown|O that|O the|O hematopoietic|O GATA|O factors|O interact|O with|O multiple|O transcription|O factors|O ,|O coactivators|O and|O co|O -|O repressors|O ,|O regulating|O the|O expression|O of|O several|O lineage|O -|O specific|O genes|O .|O
Following|O the|O identification|O of|O IDH1|O and|O DNMT3A|O mutations|O ,|O this|O strategy|O has|O recently|O led|O to|O the|O discovery|O that|O two|O homologous|O genes|O ,|O i|O .|O e|O .|O BCOR|O and|O BCORL1|O ,|O are|O recurrently|O mutated|O in|O AML|O .|O
The|O recurrent|O mutation|O of|O U2AF1|O is|O a|O missense|O mutation|O affecting|O the|O serine|O at|O codon|O 34|O (|O Ser34|O )|O (|O 8|O .|O 7|O %|O of|O de|O novo|O MDS|O )|O .|O
Clonal|O hierarchy|O analysis|O rarely|O identified|O cohesin|O mutations|O in|O founding|O clones|O ;|O rather|O ,|O cohesins|O were|O present|O in|O subclones|O that|O underwent|O clonal|O expansion|O over|O time|O .|O
Associated|O morbidities|O .|O
Thus|O ,|O in|O early|O erythroid|O progenitors|O GATA2|O binds|O to|O GATA|O motifs|O that|O reside|O in|O five|O discrete|O regions|O within|O the|O GATA2|O gene|O (|O -|O 77|O ,|O -|O 3|O .|O 9|O ,|O -|O 2|O .|O 8|O ,|O -|O 1|O .|O 8|O and|O +|O 9|O .|O 5|O kb|O from|O the|O IS|O exon|O )|O .|O
Moreover|O ,|O overexpression|O of|O particular|O genes|O has|O been|O associated|O with|O prognosis|O in|O AML|O ,|O making|O it|O possible|O to|O identify|O patients|O with|O different|O risks|O of|O relapse|O within|O cytogenetic|O risk|O groups|O .|O
We|O then|O analyzed|O the|O categorical|O clinical|O -|O molecular|O score|O as|O a|O covariate|O in|O a|O Cox|O survival|O regression|O model|O .|O
This|O results|O in|O decreased|O global|O arginine|O methylation|O of|O the|O PRMT5|O targets|O histone|O H2A|O and|O histone|O H4|O and|O in|O altered|O haematopoietic|O progenitor|O cell|O expansion|O and|O erythroid|O differentiation|O .|O
The|O differential|O counts|O were|O within|O the|O normal|O range|O without|O evident|O myeloid|O cytologic|O abnormalities|O .|O
The|O molecular|O pathogenesis|O of|O cancers|O including|O leukemias|O involves|O a|O stepwise|O accumulation|O of|O mutations|O affecting|O both|O cellular|O oncogenes|O and|O tumor|O suppressor|O genes|O .|O
Activating|O mutations|O of|O FLT3|O or|O RAS|O gene|O in|O CMML|O patients|O with|O RUNX1|O mutations|O .|O
Allele|O burden|O may|O also|O be|O reported|O in|O semiquantitative|O fashion|O (|O eg|O ,|O >|O 50|O %|O to|O 75|O %|O mutant|O alleles|O )|O .|O
Such|O nonmutated|O cohesin|O low|O expressors|O have|O been|O described|O in|O both|O AML|O and|O Ewing|O sarcoma|O cell|O lines|O .|O
One|O patient|O (|O patient|O number|O 6183|O )|O presented|O with|O an|O urethral|O malposition|O that|O was|O corrected|O at|O the|O age|O of|O 2|O ,|O and|O 1|O patient|O (|O patient|O number|O 6225|O )|O presented|O with|O a|O thigh|O fibroma|O at|O the|O age|O of|O 3|O .|O
Table|O 1|O .|O 2008|O World|O Health|O Organization|O Diagnostic|O Criteria|O for|O Polycythemia|O Vera|O .|O
Patient|O number|O 5593|O (|O P3|O ,|O II|O ,|O 2|O )|O developed|O chronic|O neutropenia|O at|O the|O age|O of|O 30|O associated|O with|O numerous|O HPV|O -|O induced|O warts|O since|O age|O of|O 14|O years|O .|O
MASS|O -|O SPECTROMETRIC|O GENOTYPING|O .|O
Somatic|O loss|O of|O function|O of|O HDAC8|O impairs|O SMC3|O deacetylation|O ,|O leading|O to|O decreased|O cohesin|O occupancy|O and|O altered|O transcriptional|O programs|O ,|O underscoring|O a|O role|O for|O cohesin|O in|O gene|O regulation|O .|O
As|O a|O result|O ,|O defects|O in|O the|O expression|O levels|O or|O the|O activity|O of|O these|O transcription|O factors|O are|O intimately|O linked|O to|O hematopoietic|O disorders|O ,|O including|O leukemia|O .|O
Heritable|O GATA2|O mutations|O are|O associated|O with|O deafness|O ,|O lymphedema|O ,|O mononuclear|O cytopenias|O ,|O susceptibility|O to|O infections|O ,|O familial|O myelodysplasia|O (|O MDS|O )|O ,|O and|O AML|O .|O
A|O subset|O of|O these|O patients|O had|O mutations|O in|O cohesin|O complex|O members|O and|O reduced|O expression|O of|O STAG2|O /|O RAD21|O /|O SMC3|O ;|O indeed|O ,|O we|O noted|O that|O most|O patients|O with|O cohesin|O mutations|O had|O reduced|O expression|O of|O the|O entire|O cohesin|O complex|O .|O
A|O similar|O high|O mutation|O burden|O was|O also|O detected|O in|O RUNX1|O (|O median|O 46|O .|O 7|O %|O )|O ,|O TET2|O (|O median|O 44|O .|O 6|O %|O )|O and|O CBL|O (|O median|O 42|O .|O 5|O %|O )|O ,|O whereas|O the|O burden|O was|O low|O in|O RAS|O pathway|O alterations|O ,|O that|O is|O ,|O NRAS|O (|O median|O 11|O .|O 1|O %|O )|O ,|O KRAS|O (|O median|O 27|O %|O )|O or|O JAK2|O V617F|O mutations|O (|O median|O 6|O .|O 9|O %|O )|O .|O
Clinical|O Effect|O of|O Point|O Mutations|O in|O Myelodysplastic|O Syndromes|O .|O
European|O cohort|O .|O
V|O Grossmann|O ;|O A|O Kohlmann|O ;|O C|O Eder|O ;|O C|O Haferlach|O ;|O W|O Kern|O ;|O NCP|O Cross|O ;|O T|O Haferlach|O ;|O S|O Schnittger|O .|O
The|O use|O of|O these|O parameters|O led|O to|O the|O definition|O of|O the|O International|O Prognostic|O Scoring|O System|O (|O IPSS|O )|O ,|O which|O identifies|O 4|O prognostic|O groups|O with|O substantially|O different|O survival|O in|O PMF|O .|O
However|O ,|O there|O are|O few|O studies|O analyzing|O the|O role|O of|O GATA2|O in|O hematological|O malignancies|O .|O
The|O most|O -|O effective|O alternative|O treatments|O to|O hydroxyurea|O in|O PV|O and|O ET|O are|O INF|O -|O alpha|O and|O busulfan|O .|O
Clinicopathologic|O characteristics|O of|O aCML|O include|O splenomegaly|O and|O a|O neutrophilic|O leukocytosis|O with|O left|O shift|O and|O prominent|O granulocytic|O dysplasia|O (|O eg|O ,|O hypogranular|O and|O hypolobated|O neutrophils|O ,|O abnormal|O chromatin|O clumping|O ,|O pseudo|O -|O Pelger|O -|O Hoet|O neutrophils|O )|O .|O
However|O ,|O the|O context|O that|O determines|O these|O opposite|O activities|O is|O not|O clear|O .|O
Figure|O 1|O .|O Somatic|O spliceosomal|O gene|O (|O U2AF1|O ,|O SF3B1|O ,|O SRSF2|O ,|O LUC7L2|O ,|O PRPF8|O ,|O and|O ZRSR2|O )|O mutations|O as|O detected|O by|O next|O -|O generation|O sequencing|O (|O NGS|O )|O and|O Sanger|O sequencing|O technologies|O .|O (|O A|O )|O With|O the|O use|O of|O an|O NGS|O -|O based|O whole|O exome|O sequencing|O analysis|O of|O whole|O BM|O DNA|O from|O a|O patient|O with|O refractory|O cytopenia|O with|O unilineage|O dysplasia|O (|O left|O )|O ,|O a|O mutation|O of|O U2AF1|O (|O 21q22|O .|O 3|O )|O at|O position|O 44514|O 777|O (|O T|O >|O C|O )|O was|O detected|O in|O 13|O of|O 18|O reads|O .|O Analysis|O of|O DNA|O from|O CD3|O +|O cells|O showed|O a|O much|O lower|O frequency|O of|O the|O base|O change|O (|O 2|O of|O 15|O reads|O ;|O right|O )|O ,|O highlighting|O the|O somatic|O nature|O of|O this|O alteration|O .|O The|O finding|O was|O confirmed|O by|O Sanger|O sequencing|O .|O Arrows|O and|O bars|O indicate|O the|O specific|O nucleotide|O and|O predicted|O codon|O ,|O respectively|O .|O It|O should|O be|O noted|O that|O U2AF1|O is|O expressed|O from|O the|O minus|O strand|O ;|O therefore|O ,|O the|O NGS|O presentation|O (|O top|O panels|O )|O is|O complementally|O reversed|O in|O comparison|O to|O the|O Sanger|O sequencing|O results|O (|O middle|O panels|O )|O .|O This|O heterozygous|O somatic|O mutation|O results|O in|O the|O predicted|O nucleotide|O change|O 470|O A|O >|O G|O in|O exon|O 6|O of|O the|O coding|O region|O ,|O which|O lead|O to|O the|O amino|O acid|O change|O Q157R|O in|O the|O second|O zinc|O finger|O domain|O .|O In|O the|O entire|O cohort|O ,|O 27|O mutations|O were|O observed|O in|O 26|O patients|O ,|O including|O a|O whole|O gene|O deletion|O .|O All|O 26|O missense|O mutations|O were|O located|O in|O 1|O of|O the|O 2|O zinc|O finger|O domains|O (|O ZNFs|O )|O ;|O 2|O residues|O ,|O S34|O or|O Q157|O ,|O were|O frequently|O affected|O (|O bottom|O panels|O )|O .|O RRM|O indicates|O RNA|O recognition|O motif|O .|O (|O B|O )|O With|O the|O use|O of|O an|O NGS|O analysis|O of|O a|O patient|O with|O CMML|O (|O middle|O left|O )|O ,|O a|O mutation|O of|O SF3B1|O (|O 2q33|O .|O 1|O )|O at|O position|O 198|O 267|O 491|O (|O C|O >|O G|O )|O was|O detected|O in|O 9|O of|O 24|O reads|O .|O The|O somatic|O nature|O of|O this|O alteration|O was|O confirmed|O by|O an|O analogous|O analysis|O of|O the|O CD3|O +|O fraction|O ,|O with|O the|O change|O being|O less|O frequent|O (|O 2|O of|O 23|O ;|O middle|O right|O )|O .|O The|O mutation|O was|O confirmed|O by|O Sanger|O sequencing|O (|O bottom|O )|O .|O This|O heterozygous|O somatic|O mutation|O results|O in|O the|O nucleotide|O change|O 1866|O G|O >|O T|O in|O exon|O 14|O of|O SF3B1|O ,|O resulting|O in|O the|O amino|O acid|O change|O E622D|O in|O the|O HSH155|O domain|O .|O Analysis|O of|O the|O entire|O cohort|O identified|O mutations|O in|O 33|O patients|O ,|O including|O a|O case|O with|O a|O whole|O gene|O deletion|O .|O (|O C|O )|O Further|O screening|O by|O NGS|O led|O to|O the|O detection|O of|O a|O nonsense|O mutation|O (|O R27X|O )|O in|O LUC7L2|O (|O 7q34|O ;|O top|O )|O which|O participates|O in|O the|O recognition|O of|O splice|O donor|O sites|O in|O association|O with|O the|O U1|O snRNP|O spliceosomal|O subunit|O ,|O and|O a|O missense|O mutation|O (|O M1307I|O )|O in|O PRPF8|O (|O 17p13|O .|O 3|O ;|O bottom|O )|O which|O is|O a|O large|O U5|O snRNP|O -|O specific|O protein|O essential|O for|O pre|O -|O mRNA|O splicing|O .|O RS|O indicates|O serine|O /|O arginine|O -|O rich|O domain|O ;|O U5|O 2|O -|O snRNA|O bdg|O ,|O U5|O -|O snRNA|O binding|O site|O 2|O ;|O and|O MPN|O ,|O Mpr1p|O ,|O Pad1p|O N|O -|O terminal|O domain|O .|O (|O D|O )|O Mutations|O of|O SRSF2|O ,|O an|O arginine|O /|O serine|O -|O rich|O splicing|O factor|O ,|O were|O detected|O in|O 29|O cases|O among|O the|O entire|O cohort|O ,|O including|O 2|O whole|O gene|O deletions|O and|O a|O microdeletion|O within|O the|O gene|O (|O top|O )|O .|O All|O mutations|O were|O heterozygous|O and|O affected|O P95|O .|O The|O somatic|O nature|O of|O the|O P95R|O mutation|O was|O confirmed|O with|O whole|O BM|O and|O T|O -|O cell|O rich|O fraction|O DNAs|O (|O bottom|O )|O .|O (|O E|O )|O Anonsense|O mutation|O (|O W153X|O )|O was|O found|O in|O ZRSR2|O ,|O another|O arginine|O /|O serine|O -|O rich|O splicing|O regulatory|O factor|O ,|O in|O a|O case|O of|O CMML|O .|O ZRSR2|O is|O located|O at|O Xp22|O .|O 2|O ,|O and|O the|O nonsense|O mutation|O was|O hemizygous|O in|O this|O male|O case|O (|O BM|O )|O .|O
ABSTRACT|O .|O
Allele|O heterozygosity|O is|O more|O common|O in|O ET|O compared|O with|O homozygosity|O in|O PV|O and|O PMF|O ,|O which|O is|O thought|O to|O result|O from|O mitotic|O recombination|O .|O
About|O one|O -|O third|O of|O AML|O patients|O harbor|O well|O -|O defined|O chromosomal|O translocations|O and|O are|O included|O as|O a|O distinct|O entity|O named|O "|O AML|O with|O recurrent|O genetic|O abnormalities|O "|O in|O the|O 2008|O World|O Health|O Organization|O (|O WHO|O )|O classification|O of|O myeloid|O neoplasms|O .|O
Candidate|O mutations|O detected|O in|O whole|O -|O genome|O -|O -|O amplified|O DNA|O were|O validated|O with|O the|O use|O of|O nonamplified|O DNA|O (|O see|O the|O Methods|O section|O ,|O Table|O 4|O ,|O and|O Fig|O .|O 1|O in|O the|O Supplementary|O Appendix|O )|O .|O
To|O modulate|O GATA|O -|O mediated|O transcription|O ,|O the|O FOG1|O protein|O is|O believed|O to|O recruit|O other|O transcriptional|O co|O -|O factors|O to|O the|O GATA1|O /|O FOG1|O complex|O .|O
One|O of|O the|O major|O regulatory|O protein|O degradation|O pathways|O is|O the|O ubiquitin|O -|O proteasome|O pathway|O ,|O in|O which|O the|O poly|O -|O ubiquitination|O of|O target|O protein|O is|O the|O trigger|O for|O degradation|O .|O
Decisions|O regarding|O the|O use|O and|O choice|O of|O antibiotics|O to|O prevent|O and|O treat|O infections|O should|O be|O made|O by|O the|O individual|O institutions|O based|O on|O the|O prevailing|O organisms|O and|O their|O drug|O resistance|O patterns|O .|O
The|O Dusseldorf|O score|O classified|O patients|O into|O three|O risk|O categories|O ,|O with|O median|O survivals|O of|O 93|O (|O low|O )|O ,|O 26|O (|O intermediate|O )|O and|O 11|O (|O high|O )|O months|O ,|O respectively|O .|O
Improvements|O in|O symptoms|O were|O measured|O with|O the|O use|O of|O the|O modified|O MFSAF|O ,|O version|O 2|O .|O 0|O ,|O diary|O ,|O a|O tool|O designed|O specifically|O to|O assess|O symptoms|O of|O myelofibrosis|O .|O
Further|O investigation|O is|O needed|O to|O determine|O which|O role|O the|O cohesin|O -|O complex|O fulfills|O in|O AML|O and|O whether|O cohesin|O mutations|O have|O clinical|O implications|O .|O
Karyotypes|O were|O established|O from|O bone|O marrow|O (|O BM|O )|O aspiration|O using|O standard|O procedures|O and|O described|O according|O to|O the|O International|O System|O for|O Human|O Cytogenetic|O Nomenclature|O .|O
However|O ,|O in|O low|O -|O risk|O MDS|O ,|O patients|O with|O SF3B1|O mutations|O showed|O a|O tendency|O toward|O better|O prognosis|O (|O P|O =|O .|O 09|O )|O ,|O whereas|O those|O with|O SRSF2|O mutations|O had|O worse|O survival|O .|O
Mutational|O analysis|O .|O
Risk|O of|O leukemia|O was|O significantly|O increased|O in|O EZH2|O -|O (|O P|O =|O 0|O .|O 03|O )|O ,|O ASXL1|O -|O (|O P|O <|O 0|O .|O 0001|O )|O ,|O SRSF2|O -|O (|O P|O =|O 0|O .|O 007|O )|O and|O IDH1|O -|O or|O IDH2|O -|O (|O P|O <|O 0|O .|O 0001|O )|O mutated|O patients|O (|O Figure|O 2b|O )|O .|O
High|O -|O dose|O cytarabine|O ,|O when|O used|O as|O part|O of|O induction|O therapy|O ,|O may|O substitute|O for|O intrathecal|O chemotherapy|O because|O it|O crosses|O the|O blood|O -|O brain|O barrier|O ;|O the|O CSF|O must|O then|O be|O reassessed|O after|O completion|O of|O induction|O therapy|O ,|O and|O further|O therapy|O should|O be|O given|O as|O appropriate|O .|O
Even|O among|O the|O subgroup|O with|O favorable|O karyotypes|O ,|O those|O with|O therapy|O -|O related|O AML|O tend|O to|O do|O less|O well|O .|O
JH2|O ,|O which|O resides|O upstream|O to|O JH1|O ,|O is|O structurally|O similar|O to|O JH1|O but|O functions|O as|O a|O pseudokinase|O domain|O that|O negatively|O regulates|O basal|O activity|O of|O the|O kinase|O domain|O and|O receptor|O -|O induced|O activation|O of|O the|O catalytic|O function|O .|O
These|O mRNAs|O code|O for|O two|O proteins|O with|O the|O same|O translation|O start|O site|O ,|O located|O at|O exon|O 2|O .|O
Cantor|O et|O al|O found|O that|O FOG1|O expression|O in|O mast|O cell|O precursors|O blocks|O their|O maturation|O into|O mast|O cells|O ,|O demonstrating|O that|O repression|O of|O FOG1|O is|O a|O critical|O step|O for|O mast|O cell|O development|O .|O
Co|O -|O occurrence|O of|O U2AF1|O mutations|O with|O ASXL1|O and|O DNMT3A|O mutations|O have|O been|O noted|O as|O well|O .|O
Table|O 2|O .|O 2008|O World|O Health|O Organization|O Diagnostic|O Criteria|O for|O Essential|O Thrombocythemia|O .|O
A|O recent|O retrospective|O study|O based|O on|O data|O in|O older|O patients|O (|O age|O 50|O -|O 70|O years|O )|O with|O AML|O compared|O outcomes|O in|O patients|O who|O underwent|O allogeneic|O HSCT|O (|O either|O myeloablative|O conditioning|O or|O RIC|O ;|O n|O =|O 152|O )|O and|O those|O who|O did|O not|O receive|O HSCT|O in|O first|O CR|O (|O chemotherapy|O only|O ;|O n|O =|O 884|O )|O .|O
Recent|O mechanistic|O studies|O have|O revealed|O specific|O molecular|O hallmarks|O that|O distinguished|O these|O unoccupied|O elements|O from|O a|O highly|O restricted|O subset|O of|O occupied|O composite|O elements|O .|O
In|O conclusion|O ,|O ruxolitinib|O was|O associated|O with|O reductions|O in|O splenomegaly|O and|O symptoms|O that|O are|O prominent|O manifestations|O of|O myelofibrosis|O and|O appeared|O to|O be|O associated|O with|O an|O improvement|O in|O overall|O survival|O .|O
Fluorescence|O in|O situ|O hybridization|O testing|O for|O BCR|O -|O ABL1|O and|O PDGFRA|O /|O B|O was|O negative|O in|O all|O cases|O .|O
The|O 10|O -|O year|O cumulative|O incidence|O of|O thrombosis|O was|O 18|O .|O 3|O %|O (|O 95|O %|O confidence|O interval|O [|O CI|O ]|O ,|O 13|O .|O 3|O -|O 24|O .|O 1|O )|O in|O patients|O carrying|O JAK2|O (|O V617F|O )|O ,|O 13|O .|O 6|O %|O (|O 95|O %|O CI|O ,|O 6|O .|O 9|O -|O 22|O .|O 7|O )|O in|O those|O with|O CALR|O mutation|O ,|O 17|O .|O 9|O %|O (|O 95|O %|O CI|O ,|O 4|O .|O 1|O -|O 39|O .|O 6|O )|O in|O those|O with|O MPL|O mutation|O ,|O and|O 16|O .|O 2|O %|O (|O 95|O %|O CI|O ,|O 6|O .|O 3|O -|O 30|O .|O 1|O )|O in|O triple|O -|O negative|O subjects|O (|O Figure|O 2|O )|O .|O
As|O previously|O mentioned|O ,|O FLT3|O -|O TKD|O in|O the|O presence|O of|O FLT3|O -|O ITD|O or|O occurring|O with|O t|O (|O 15|O ;|O 17|O )|O /|O PML|O -|O RARA|O seems|O to|O be|O associated|O with|O poorer|O prognosis|O .|O
Allogeneic|O HCT|O is|O also|O potentially|O curative|O in|O PV|O and|O ET|O ,|O but|O the|O already|O high|O rates|O of|O long|O -|O term|O survival|O with|O these|O diseases|O preclude|O the|O use|O of|O aggressive|O therapy|O with|O a|O high|O risk|O of|O mortality|O .|O
Connelly|O et|O al|O identified|O five|O single|O nucleotide|O polymorphisms|O in|O GATA2|O that|O were|O significantly|O associated|O with|O early|O -|O onset|O coronary|O arterydisease|O .|O
Postremission|O Surveillance|O and|O Salvage|O Therapy|O for|O AML|O .|O
If|O a|O quantitative|O assay|O is|O clinically|O indicated|O to|O achieve|O precise|O mutant|O levels|O or|O to|O monitor|O allele|O burden|O ,|O there|O will|O be|O a|O need|O for|O quantitative|O standards|O to|O accurately|O quantify|O the|O allele|O burden|O and|O to|O assess|O the|O sensitivity|O and|O dynamic|O range|O of|O the|O assay|O .|O
The|O Wilcoxon|O signed|O -|O rank|O test|O was|O applied|O to|O compare|O measures|O of|O quantitative|O variables|O repeated|O in|O different|O phases|O of|O the|O disease|O .|O
Future|O work|O to|O dissect|O these|O potential|O functions|O of|O ASXL1|O and|O BAP1|O in|O a|O haematopoietic|O -|O specific|O mammalian|O context|O are|O of|O importance|O to|O the|O field|O .|O
In|O AML|O ,|O SETBP1|O overexpression|O is|O significantly|O associated|O with|O reduced|O survival|O ,|O indicating|O that|O SETBP1|O may|O be|O relevant|O to|O leukemia|O oncogenesis|O .|O
The|O procedures|O followed|O were|O in|O accordance|O with|O the|O Helsinki|O Declaration|O of|O 1975|O ,|O as|O revised|O in|O 2000|O ,|O and|O samples|O were|O obtained|O after|O patients|O had|O provided|O written|O informed|O consent|O .|O
We|O identified|O somatic|O mutations|O in|O 18|O genes|O ,|O including|O two|O ,|O ETV6|O and|O GNAS|O ,|O that|O have|O not|O been|O reported|O to|O be|O mutated|O in|O patients|O with|O myelodysplastic|O syndromes|O .|O
Cytogenetic|O analysis|O was|O performed|O successfully|O in|O 53|O patients|O .|O
In|O contrast|O to|O JAK2|O mutations|O ,|O MPL|O mutations|O were|O found|O less|O frequently|O in|O PMF|O and|O ET|O ,|O and|O may|O be|O present|O in|O either|O JAK2|O mutation|O -|O positive|O or|O mutation|O -|O negative|O cases|O .|O
GATA2|O is|O phosphorylated|O in|O HPCs|O through|O the|O MAPK|O signal|O transduction|O pathway|O in|O response|O to|O IL|O -|O 3|O .|O
We|O assigned|O each|O factor|O an|O integer|O weight|O according|O to|O the|O corresponding|O HR|O in|O the|O multivariable|O -|O Cox|O regression|O (|O Table|O 2|O )|O :|O weight|O 1|O for|O presence|O of|O constitutional|O symptoms|O ,|O peripheral|O blood|O blasts|O >|O =|O 1|O %|O ,|O hemoglobin|O <|O 10|O g|O /|O dL|O ,|O and|O presence|O of|O JAK2|O mutation|O ;|O weight|O 2|O for|O MPL|O mutation|O or|O nonmutated|O JAK2|O ,|O CALR|O ,|O and|O MPL|O ,|O WBC|O count|O >|O 25|O x|O 109|O /|O L|O ,|O and|O age|O >|O 65|O years|O .|O
Cytogenetic|O findings|O were|O divided|O into|O three|O categories|O ,|O namely|O ,|O good|O (|O normal|O ,|O -|O Y|O ,|O del|O [|O 5q|O ]|O ,|O del|O [|O 20q|O ]|O )|O ,|O poor|O (|O complex|O or|O chromosome|O 7|O anomalies|O )|O and|O intermediate|O (|O all|O other|O abnormalities|O )|O ,|O according|O to|O the|O criteria|O developed|O by|O the|O International|O MDS|O Risk|O Analysis|O Workshop|O .|O
Collectively|O ,|O these|O studies|O suggest|O that|O RIC|O allogeneic|O HSCT|O is|O a|O feasible|O treatment|O option|O for|O patients|O aged|O 60|O years|O and|O older|O ,|O particularly|O those|O in|O first|O CR|O with|O minimal|O comorbidities|O and|O who|O have|O an|O available|O donor|O .|O
The|O primary|O end|O point|O was|O reached|O in|O 41|O .|O 9|O %|O of|O patients|O in|O the|O ruxolitinib|O group|O as|O compared|O with|O 0|O .|O 7|O %|O in|O the|O placebo|O group|O (|O P|O <|O 0|O .|O 001|O )|O .|O
Proficiency|O testing|O for|O JAK2|O V617F|O is|O now|O standard|O ,|O and|O it|O is|O likely|O that|O MPL|O codon|O 515|O mutations|O will|O be|O added|O in|O the|O future|O .|O
TET2|O mutations|O occur|O in|O 10|O -|O 20|O %|O of|O cases|O of|O MPN|O and|O MDS|O and|O in|O 7|O -|O 23|O %|O of|O cases|O of|O AML|O (|O TABLE|O 1|O )|O .|O
As|O shown|O in|O Figure|O 1|O and|O Table|O 1|O ,|O seven|O patients|O had|O eight|O missense|O mutations|O at|O RHD|O and|O one|O patient|O had|O a|O missense|O mutation|O at|O the|O C|O -|O terminal|O region|O ,|O all|O resulting|O in|O single|O amino|O -|O acid|O substitutions|O .|O
The|O guidelines|O note|O that|O RIC|O allogeneic|O HSCT|O is|O considered|O an|O additional|O option|O for|O patients|O aged|O 60|O years|O and|O older|O for|O the|O following|O situations|O :|O 1|O )|O as|O postremission|O therapy|O in|O those|O experiencing|O a|O CR|O to|O induction|O therapy|O ,|O or|O 2|O )|O as|O treatment|O of|O induction|O failure|O (|O in|O the|O context|O of|O a|O clinical|O trial|O )|O only|O in|O patients|O with|O low|O -|O volume|O disease|O .|O
In|O 2008|O ,|O the|O WHO|O revised|O the|O diagnostic|O and|O response|O criteria|O for|O AML|O to|O include|O additional|O recurrent|O genetic|O abnormalities|O created|O by|O reciprocal|O translocations|O /|O inversions|O ,|O and|O a|O new|O provisional|O category|O for|O some|O of|O the|O molecular|O markers|O that|O have|O been|O found|O to|O have|O prognostic|O impact|O .|O
Epigenetic|O roles|O for|O class|O I|O and|O class|O II|O genes|O .|O
Median|O follow|O -|O up|O was|O 3|O .|O 7|O years|O (|O range|O 0|O -|O 27|O .|O 9|O )|O for|O the|O European|O and|O 3|O .|O 4|O years|O (|O range|O 0|O -|O 26|O )|O for|O the|O Mayo|O cohorts|O .|O
=|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O =|O `|O
Our|O analysis|O showed|O a|O similar|O expression|O profile|O in|O patients|O with|O STAG2|O mutations|O or|O patients|O with|O reduced|O expression|O of|O cohesin|O complex|O members|O (|O Figure|O 6A|O )|O .|O
Mutational|O Analysis|O of|O PTEN|O /|O MMAC1|O by|O PCR|O -|O SSCP|O and|O Direct|O Sequencing|O .|O
This|O abnormality|O of|O ABCB7|O protein|O induced|O by|O SF3B1|O mutation|O could|O explain|O the|O mechanism|O that|O results|O in|O the|O ring|O -|O sideroblast|O phenotype|O .|O
Two|O patients|O had|O biallelic|O heterozygous|O mutations|O .|O
In|O univariate|O analysis|O ,|O significant|O risk|O factors|O for|O survival|O included|O anemia|O ,|O thrombocytopenia|O ,|O increased|O levels|O of|O white|O blood|O cells|O ,|O absolute|O neutrophils|O ,|O absolute|O monocyte|O count|O (|O AMC|O )|O ,|O absolute|O lymphocytes|O ,|O peripheral|O blood|O and|O bone|O marrow|O blasts|O ,|O and|O presence|O of|O circulating|O immature|O myeloid|O cells|O (|O IMCs|O )|O .|O
More|O than|O one|O quarter|O (|O 26|O %|O )|O of|O the|O samples|O with|O at|O least|O one|O TET2|O mutation|O had|O two|O distinct|O TET2|O mutations|O ,|O suggesting|O that|O biallelic|O loss|O of|O wild|O -|O type|O TET2|O contributes|O to|O the|O pathogenesis|O of|O myelodysplastic|O syndromes|O in|O some|O cases|O .|O
A|O hypercellular|O bone|O marrow|O is|O observed|O with|O a|O myeloid|O hyperplasia|O and|O prominent|O granulocytic|O dysplasia|O ,|O although|O multilineage|O dysplasia|O may|O be|O present|O .|O
The|O frequency|O of|O type|O 1|O mutation|O in|O patients|O with|O PMF|O was|O significantly|O higher|O than|O that|O previously|O reported|O by|O us|O in|O patients|O with|O ET16|O (|O 72|O %|O vs|O 46|O %|O ,|O P|O <|O .|O 001|O )|O .|O
Patients|O of|O 2|O of|O the|O pedigrees|O described|O herein|O (|O P3|O and|O P5|O )|O have|O a|O syndrome|O related|O to|O the|O WHIM|O syndrome|O ,|O although|O the|O BM|O myelokathexis|O feature|O was|O missing|O .|O
To|O the|O best|O of|O our|O knowledge|O ,|O mutations|O of|O RUNX1|O have|O only|O been|O described|O in|O two|O patients|O with|O CMML|O .|O
We|O then|O analyzed|O the|O effect|O of|O these|O mutations|O in|O more|O clinically|O uniform|O subgroups|O to|O more|O precisely|O determine|O their|O clinical|O consequences|O .|O
Figure|O 1|O .|O Schematic|O illustration|O of|O RUNX1b|O mutations|O in|O 30|O patients|O with|O CMML|O .|O CMML|O ,|O chronic|O myelomonocytic|O leukemia|O .|O
One|O laboratory|O found|O a|O third|O specimen|O positive|O for|O W515L|O ,|O but|O the|O mutation|O was|O not|O detected|O in|O the|O other|O two|O laboratories|O that|O tested|O this|O specimen|O .|O
The|O inclusions|O criteria|O of|O the|O registry|O are|O :|O neutrophil|O count|O lower|O than|O 0|O .|O 5|O G|O /|O L|O observed|O at|O least|O 3|O times|O in|O a|O period|O of|O 3|O months|O or|O a|O neutrophil|O count|O lower|O than|O 1|O G|O /|O L|O observed|O at|O least|O 3|O times|O in|O a|O period|O of|O 3|O months|O associated|O with|O infection|O .|O
Granulocyte|O JAK2|O (|O V617F|O )|O mutation|O status|O and|O mutant|O allele|O burden|O were|O assessed|O using|O a|O quantitative|O polymerase|O chain|O reaction|O -|O based|O allelic|O discrimination|O assay|O on|O a|O Rotor|O -|O Gene|O 6000|O real|O -|O time|O analyzer|O (|O Qiagen|O )|O ,|O as|O previously|O described|O .|O
Risk|O scores|O were|O calculated|O according|O to|O the|O International|O Prognostic|O Scoring|O System|O .|O
The|O value|O of|O cellular|O markers|O as|O a|O complement|O to|O histologic|O classification|O was|O first|O validated|O in|O CML|O with|O the|O discovery|O of|O the|O Philadelphia|O chromosome|O and|O the|O characterization|O of|O the|O oncogenic|O BCR|O -|O ABL1|O fusion|O protein|O .|O
Interestingly|O ,|O more|O recent|O data|O suggests|O that|O cohesin|O genes|O have|O additional|O functions|O within|O the|O cell|O such|O as|O double|O -|O strand|O DNA|O repair|O and|O regulation|O of|O transcription|O .|O
For|O the|O moment|O ,|O no|O prognostic|O information|O is|O available|O concerning|O BCORL1|O mutations|O and|O this|O needs|O to|O be|O clarified|O .|O
RESULTS|O .|O
IDH1|O is|O a|O cytosolic|O enzyme|O ,|O whereas|O IDH2|O is|O found|O in|O mitochondria|O .|O
Facing|O a|O patient|O with|O PMF|O ,|O his|O or|O her|O genetic|O lesion|O must|O now|O be|O taken|O into|O account|O carefully|O because|O this|O has|O an|O impact|O on|O clinical|O decision|O -|O making|O .|O
AM|O Vannucchi|O ;|O TL|O Lasho|O ;|O P|O Guglielmelli|O ;|O F|O Biamonte|O ;|O A|O Pardanani|O ;|O A|O Pereira|O ;|O C|O Finke|O ;|O J|O Score|O ;|O N|O Gangat|O ;|O C|O Mannarelli|O ;|O RP|O Ketterling|O ;|O G|O Rotunno|O ;|O RA|O Knudson|O ;|O MC|O Susini|O ;|O RR|O Laborde|O ;|O A|O Spolverini|O ;|O A|O Pancrazzi|O ;|O L|O Pieri|O ;|O R|O Manfredini|O ;|O E|O Tagliafico|O ;|O R|O Zini|O ;|O A|O Jones|O ;|O K|O Zoi|O ;|O A|O Reiter|O ;|O A|O Duncombe|O ;|O D|O Pietra|O ;|O E|O Rumi|O ;|O F|O Cervantes|O ;|O G|O Barosi|O ;|O M|O Cazzola|O ;|O NCP|O Cross|O ;|O A|O Tefferi|O .|O
The|O differential|O use|O of|O these|O two|O exons|O was|O first|O described|O in|O GATA1|O and|O subsequently|O in|O GATA2|O and|O GATA3|O .|O
The|O use|O of|O next|O -|O generation|O sequencing|O and|O mass|O spectrometry|O has|O subsequently|O revealed|O genetic|O abnormalities|O ,|O which|O have|O been|O verified|O in|O 20|O -|O 25|O %|O of|O patients|O with|O MDS|O and|O in|O 30|O -|O 60|O %|O of|O patients|O with|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O .|O
Patients|O whose|O performance|O status|O would|O make|O them|O poor|O candidates|O for|O the|O standard|O antineoplastic|O regimens|O may|O still|O be|O able|O to|O participate|O in|O clinical|O trials|O using|O epigenetic|O agents|O designed|O to|O target|O this|O underserved|O patient|O population|O .|O
INTRODUCTION|O .|O
Transplant|O should|O be|O considered|O only|O if|O the|O patient|O has|O entered|O remission|O or|O in|O the|O context|O of|O a|O clinical|O trial|O .|O
Nested|O PCR|O was|O carried|O out|O using|O primers|O flanking|O the|O full|O coding|O sequence|O of|O the|O PTEN|O /|O MMAC1|O cDNA|O ,|O as|O shown|O in|O Table|O I|O .|O
Treatment|O -|O related|O mortality|O at|O 100|O days|O was|O 18|O %|O ,|O 19|O %|O ,|O and|O 35|O %|O respectively|O .|O
Common|O to|O all|O eukaryotes|O ,|O this|O mechanism|O allows|O for|O generating|O a|O large|O diversity|O of|O protein|O species|O in|O the|O face|O of|O limited|O set|O of|O genes|O by|O alternative|O splicing|O .|O
About|O half|O of|O all|O grade|O 3|O or|O 4|O adverse|O events|O of|O anemia|O in|O the|O ruxolitinib|O group|O occurred|O during|O the|O first|O 8|O weeks|O of|O therapy|O .|O
Figure|O 2|O .|O Schematic|O representation|O of|O MPL|O gene|O and|O mutation|O hot|O spots|O .|O Locations|O of|O reported|O mutations|O are|O indicated|O by|O colored|O triangles|O :|O red|O triangles|O for|O W515L|O and|O W515K|O ,|O and|O black|O triangles|O for|O other|O SNP|O variant|O mutations|O .|O Representative|O codon|O numbers|O are|O marked|O above|O exon|O boxes|O .|O CP|O ,|O cytoplasmic|O domain|O ;|O DCR|O -|O NRD|O ,|O distal|O cytokine|O receptor|O domain|O -|O negative|O regulatory|O domain|O ;|O PCR|O -|O LBR|O ,|O proximal|O cytokine|O receptor|O domain|O -|O ligand|O binding|O region|O ;|O TM|O ,|O transmembrane|O domain|O .|O
CALR|O -|O mutant|O patients|O had|O a|O significantly|O longer|O large|O -|O splenomegaly|O -|O free|O survival|O compared|O with|O the|O remaining|O patients|O with|O PMF|O (|O P|O <|O .|O 001|O ,|O data|O not|O shown|O )|O .|O
LOH|O Analysis|O .|O
One|O laboratory|O tested|O only|O a|O subset|O of|O the|O specimens|O .|O
Considering|O the|O CMML|O -|O 1|O and|O CMML|O -|O 2|O category|O (|O Supplementary|O Figure|O 1|O )|O ,|O a|O significant|O prognostic|O difference|O was|O detectable|O for|O CMML|O -|O 2|O (|O P|O =|O 0|O .|O 009|O )|O but|O not|O more|O for|O CMML|O -|O 1|O (|O P|O =|O 0|O .|O 063|O )|O .|O
In|O addition|O ,|O one|O laboratory|O provided|O formalin|O -|O fixed|O ,|O paraffin|O -|O embedded|O sections|O of|O spleen|O from|O a|O patient|O with|O polycythemia|O vera|O .|O
Our|O results|O showed|O that|O 72|O %|O of|O RUNX1|O mutations|O in|O CMML|O were|O located|O at|O the|O N|O -|O terminal|O region|O and|O 28|O %|O at|O the|O C|O -|O terminal|O region|O .|O
In|O a|O prespecified|O analysis|O of|O biomarkers|O ,|O patients|O who|O received|O ruxolitinib|O had|O mean|O reductions|O in|O the|O JAK2V617F|O allele|O burden|O of|O 10|O .|O 9|O %|O at|O week|O 24|O and|O 21|O .|O 5|O %|O at|O week|O 48|O ;|O patients|O who|O received|O placebo|O had|O a|O mean|O increase|O of|O 3|O .|O 5|O %|O at|O week|O 24|O and|O 6|O .|O 3|O %|O at|O week|O 48|O (|O Fig|O .|O S6|O in|O the|O Supplementary|O Appendix|O )|O .|O
These|O complexes|O serve|O an|O important|O function|O that|O is|O conserved|O throughout|O vertebrate|O development|O ,|O in|O which|O PcG|O protein|O complexes|O initiate|O and|O maintain|O transcriptional|O silencing|O through|O specific|O post|O -|O translational|O histone|O modifications|O .|O
An|O additional|O post|O hoc|O analysis|O showed|O an|O improvement|O of|O 50|O %|O or|O more|O in|O nonabdominal|O symptoms|O (|O night|O sweats|O ,|O bone|O or|O muscle|O pain|O ,|O and|O pruritus|O )|O in|O 58|O .|O 6|O %|O of|O patients|O with|O reductions|O in|O spleen|O volume|O of|O 35|O %|O or|O more|O and|O in|O 54|O .|O 1|O %|O of|O patients|O with|O reductions|O in|O spleen|O volume|O of|O less|O than|O 35|O %|O .|O
Two|O -|O sided|O P|O values|O <|O .|O 05|O were|O considered|O significant|O in|O the|O primary|O analysis|O and|O indicators|O for|O a|O trend|O in|O all|O additional|O analyses|O .|O
Future|O experience|O with|O these|O agents|O will|O inform|O whether|O complete|O hematologic|O remissions|O and|O indepth|O molecular|O responses|O are|O realized|O ,|O similar|O to|O experience|O with|O TKIs|O in|O CML|O and|O PDGFRA|O /|O B|O -|O rearranged|O myeloid|O neoplasms|O associated|O with|O eosinophilia|O .|O
Interestingly|O ,|O among|O patients|O with|O AML|O ,|O ASXL1|O mutations|O seem|O to|O occur|O in|O an|O age|O -|O dependent|O manner|O and|O are|O more|O enriched|O in|O AML|O from|O an|O antecedent|O haematological|O disorder|O rather|O than|O in|O de|O novo|O AML|O .|O
DNMT3A|O mutations|O are|O enriched|O in|O patients|O with|O cytogenetically|O defined|O intermediate|O -|O risk|O AML|O and|O in|O patients|O with|O class|O M4|O or|O M5|O AML|O (|O as|O defined|O by|O the|O French|O -|O American|O -|O British|O (|O FAB|O )|O classification|O system|O )|O .|O
Because|O of|O the|O strong|O association|O between|O NPM1|O and|O cohesin|O mutations|O ,|O the|O allelic|O ratio|O of|O mutated|O and|O wild|O -|O type|O NPM1|O was|O compared|O with|O the|O allelic|O ratio|O of|O mutated|O and|O wild|O -|O type|O cohesin|O genes|O .|O
Because|O the|O maternal|O grandfather|O had|O no|O clinical|O or|O biologic|O phenotypes|O ,|O we|O focused|O our|O analysis|O on|O the|O GATA2|O R396Q|O mutation|O .|O
Routine|O screening|O LPs|O are|O not|O warranted|O at|O the|O time|O of|O diagnosis|O in|O patients|O with|O AML|O .|O
Germline|O point|O mutations|O of|O RUNX1|O (|O runt|O -|O related|O transcription|O factor|O 1|O )|O were|O first|O described|O in|O familial|O platelet|O disorders|O evolving|O to|O AML|O .|O
All|O RT|O -|O PCR|O products|O were|O then|O subjected|O to|O direct|O sequencing|O analysis|O .|O
Protein|O tyrosine|O phosphatases|O have|O been|O thought|O to|O play|O a|O role|O in|O tumor|O suppression|O due|O to|O antagonize|O the|O activity|O of|O the|O protein|O tyrosine|O kinase|O .|O
These|O adverse|O events|O were|O manageable|O ,|O as|O evidenced|O by|O the|O low|O discontinuation|O rate|O (|O one|O patient|O in|O each|O group|O for|O each|O event|O )|O .|O
Symptoms|O and|O Other|O Patient|O -|O Reported|O Outcomes|O .|O
It|O is|O conceivable|O that|O identified|O inactivating|O mutations|O of|O this|O gene|O may|O comprise|O a|O mechanism|O of|O altered|O histone|O demethylation|O ,|O leading|O to|O a|O transcriptional|O repression|O of|O tumor|O suppressor|O genes|O .|O
This|O is|O in|O line|O with|O recent|O investigations|O showing|O that|O Drosophila|O E|O (|O z|O )|O as|O well|O as|O other|O PRC1|O and|O PRC2|O components|O may|O exert|O tumor|O suppressor|O activity|O by|O silencing|O the|O mitogenic|O JAK|O -|O STAT|O and|O Notch|O signaling|O pathways|O .|O
Although|O the|O presence|O of|O FLT3|O -|O TKD|O mutations|O has|O been|O shown|O to|O be|O associated|O with|O shorter|O remission|O durations|O (|O eg|O ,|O decreased|O DFS|O )|O and|O decreased|O OS|O outcomes|O in|O some|O studies|O ,|O other|O studies|O have|O reported|O no|O impact|O of|O FLT3|O -|O TKD|O on|O prognosis|O or|O even|O a|O favorable|O outcome|O on|O OS|O with|O FLT3|O -|O TKD|O mutations|O .|O
Adapted|O from|O Tefferi|O et|O al|O .|O
Pathway|O mutations|O involving|O the|O RNA|O splicing|O machinery|O .|O
Additional|O JAK2|O mutations|O have|O now|O been|O described|O on|O exon|O 12|O ,|O with|O N542|O -|O E543|O being|O the|O most|O common|O .|O
Other|O alpha|O -|O ketoglutarate|O -|O dependent|O oxygenases|O include|O enzymes|O involved|O in|O hypoxia|O sensing|O ,|O collagen|O biosynthesis|O ,|O lipid|O biosynthesis|O and|O DNA|O and|O RNA|O demethylation|O .|O
Table|O 1|O .|O Clinical|O and|O laboratory|O features|O and|O subsequent|O events|O in|O 226|O patients|O with|O World|O Health|O Organization|O defined|O chronic|O myelomonocytic|O leukemia|O .|O
ANC|O indicates|O absolute|O neutrophil|O count|O ;|O ALC|O ,|O absolute|O lymphocyte|O count|O ;|O AMC|O ,|O absolute|O monocyte|O count|O ;|O Hb|O ,|O hemoglobin|O ;|O HSCT|O ,|O hematopoietic|O stem|O cell|O transplantation|O ;|O MDS|O ,|O myelodysplastic|O syndrome|O ;|O AML|O ,|O acute|O myeloid|O leukemia|O ;|O CR|O ,|O complete|O remission|O ;|O and|O HPV|O ,|O human|O papillomavirus|O .|O
There|O is|O a|O lack|O of|O standardization|O among|O the|O variety|O of|O qualitative|O and|O quantitative|O methods|O available|O to|O detect|O the|O range|O of|O molecular|O alterations|O in|O JAK2|O and|O MPL|O .|O
A|O study|O has|O reported|O that|O mutational|O inactivation|O of|O STAG2|O resulted|O in|O abnormal|O chromosomal|O ploidy|O in|O human|O cancer|O .|O
TET2|O .|O
The|O mean|O hemoglobin|O level|O in|O patients|O who|O received|O ruxolitinib|O reached|O a|O nadir|O of|O 95|O g|O per|O liter|O after|O approximately|O 8|O to|O 12|O weeks|O of|O therapy|O (|O Fig|O .|O S8|O in|O the|O Supplementary|O Appendix|O )|O ,|O with|O an|O increase|O by|O week|O 24|O to|O a|O new|O steady|O state|O (|O 101|O g|O per|O liter|O )|O .|O
Pretreatment|O samples|O from|O all|O patients|O were|O studied|O centrally|O by|O G|O -|O and|O R|O -|O banding|O analysis|O .|O
We|O aimed|O to|O identify|O the|O prevalence|O of|O mutations|O in|O CMML|O ,|O identify|O any|O associations|O between|O them|O ,|O as|O well|O as|O their|O correlation|O with|O morphology|O ,|O cytogenetics|O and|O survival|O .|O
Safety|O .|O
Combination|O therapy|O with|O thalidomide|O and|O prednisone|O or|O lenalidomide|O and|O prednisone|O is|O associated|O with|O higher|O response|O rates|O ,|O 40|O %|O and|O 30|O %|O ,|O respectively|O ,|O and|O decreased|O toxicity|O .|O
Traditional|O therapies|O for|O PV|O and|O ET|O remain|O effective|O ,|O but|O the|O treatments|O and|O prognosis|O for|O PMF|O are|O comparatively|O poor|O .|O
They|O also|O had|O a|O lower|O risk|O of|O thrombosis|O compared|O with|O patients|O carrying|O JAK2|O (|O V617F|O )|O .|O
Long|O -|O term|O haematopoietic|O stem|O cell|O (|O LT|O -|O HSC|O )|O .|O
From|O September|O 2009|O through|O April|O 2010|O ,|O a|O total|O of|O 309|O patients|O were|O enrolled|O :|O 155|O were|O randomly|O assigned|O to|O ruxolitinib|O ,|O and|O 154|O were|O randomly|O assigned|O to|O placebo|O .|O
The|O epigenetic|O regulator|O gene|O UTX|O (|O KDM6A|O )|O ,|O ubiquitously|O transcribed|O X|O chromosome|O tetratricopeptide|O repeat|O protein|O ,|O is|O found|O on|O chromosome|O Xp11|O .|O 2|O .|O
The|O gene|O encoded|O tumor|O protein|O TP53|O binds|O directly|O to|O DNA|O and|O determines|O whether|O the|O damaged|O DNA|O undergoes|O repair|O and|O apoptosis|O .|O
Fig|O .|O 1|O .|O GATA2|O genomic|O and|O protein|O structure|O .|O Schematic|O representation|O of|O the|O GATA2|O human|O gene|O and|O protein|O .|O The|O GATA2|O locus|O has|O 6|O exons|O (|O dark|O grey|O )|O .|O A|O new|O transcript|O form|O with|O 7|O exons|O has|O recently|O added|O to|O online|O databases|O .|O The|O 5|O and|O 3|O untranslated|O region|O are|O shown|O in|O light|O grey|O .|O Arrows|O indicate|O transcription|O start|O sites|O from|O the|O IS|O and|O IG|O first|O exons|O .|O The|O encoded|O protein|O has|O two|O transactivation|O domains|O (|O TAD|O )|O ,|O a|O negative|O regulatory|O domain|O (|O NRD|O )|O ,|O a|O nuclear|O localization|O signal|O (|O NLS|O )|O and|O two|O zinc|O finger|O (|O ZnF|O )|O domains|O .|O Phosphorilation|O (|O P|O )|O ,|O acetylation|O (|O Ac|O )|O SUMOylation|O (|O S|O )|O and|O ubiquitination|O (|O U|O )|O sites|O are|O shown|O .|O Protein|O interactions|O through|O the|O GATA2|O N|O -|O ZnF|O and|O C|O -|O ZnF|O domains|O are|O also|O shown|O .|O
This|O suggests|O a|O crucial|O role|O for|O epigenetic|O modifiers|O in|O the|O regulation|O of|O normal|O haematopoiesis|O and|O illustrates|O how|O the|O loss|O of|O normal|O epigenetic|O functionality|O can|O contribute|O to|O leukaemogenesis|O .|O
In|O addition|O to|O these|O newly|O defined|O ,|O high|O -|O frequency|O mutations|O in|O SETBP1|O and|O CSF3R|O ,|O other|O recurrent|O mutations|O in|O a|O variety|O of|O genes|O including|O NRAS|O ,|O IDH2|O ,|O and|O CBL|O have|O recently|O been|O described|O in|O aCML|O at|O lower|O frequencies|O .|O
Such|O a|O splicing|O abnormality|O was|O more|O prominent|O in|O cases|O with|O SRSF2|O mutations|O but|O not|O detected|O in|O the|O cases|O with|O SF3B1|O mutations|O or|O WT|O spliceosomal|O genes|O .|O
Mutations|O have|O been|O found|O in|O different|O types|O of|O disease|O .|O
There|O was|O no|O clear|O pattern|O in|O these|O events|O to|O suggest|O a|O specific|O withdrawal|O effect|O (|O Tables|O S5|O and|O S6|O in|O the|O Supplementary|O Appendix|O )|O .|O
PV|O .|O
An|O international|O randomized|O phase|O III|O study|O by|O Fenaux|O et|O al|O compared|O the|O hypomethylating|O agent|O 5|O -|O azacytidine|O with|O conventional|O care|O (|O best|O supportive|O care|O ,|O low|O -|O dose|O cytarabine|O ,|O or|O intensive|O chemotherapy|O )|O in|O patients|O with|O MDS|O (|O N|O =|O 358|O )|O .|O
The|O main|O end|O points|O were|O overall|O and|O leukemia|O -|O free|O survival|O .|O
In|O the|O subgroup|O of|O patients|O younger|O than|O 60|O years|O with|O favorable|O -|O risk|O AML|O (|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O )|O in|O a|O study|O of|O patients|O with|O NK|O -|O AML|O ,|O IDH1|O mutation|O was|O associated|O with|O a|O significantly|O decreased|O 5|O -|O year|O DFS|O rate|O (|O 42|O %|O vs|O .|O 59|O %|O ;|O P|O =|O .|O 046|O )|O and|O trend|O for|O decreased|O OS|O rate|O (|O 50|O %|O vs|O .|O 63|O %|O )|O compared|O with|O patients|O who|O had|O wild|O -|O type|O IDH|O .|O
At|O the|O time|O of|O CMML|O diagnosis|O ,|O DNA|O from|O BM|O or|O PB|O was|O extracted|O using|O conventional|O methods|O .|O
Please|O Note|O :|O
The|O color|O -|O space|O reads|O were|O aligned|O with|O NovoalignCS|O and|O genotyped|O with|O GATK|O '|O s|O Unified|O Genotyper|O .|O
Conceptually|O ,|O mutations|O of|O spliceosomal|O proteins|O could|O result|O in|O defective|O splicing|O ,|O including|O intron|O retention|O ,|O altered|O splice|O site|O recognition|O ,|O or|O altered|O alternative|O splicing|O .|O
Equally|O disturbing|O is|O the|O increasing|O incidence|O of|O treatment|O -|O related|O myelodysplasia|O and|O acute|O leukemia|O in|O survivors|O of|O tumors|O of|O childhood|O and|O young|O adulthood|O .|O
Carmen|O Vicente|O ;|O Ana|O Conchillo|O ;|O Maria|O A|O .|O Garcia|O -|O Sanchez|O ;|O Maria|O D|O .|O Odero|O .|O
Differences|O in|O the|O mutational|O spectrum|O and|O clinical|O correlates|O of|O TET2|O and|O IDH1|O or|O IDH2|O mutations|O in|O myeloid|O malignancies|O might|O be|O explained|O by|O the|O range|O of|O 2|O -|O oxoglutarate|O -|O dependent|O enzymes|O that|O are|O impaired|O by|O IDH1|O and|O IDH2|O mutations|O compared|O with|O TET2|O mutations|O ,|O which|O only|O directly|O affect|O the|O function|O of|O TET2|O .|O
In|O a|O murine|O model|O ,|O N|O -|O RAS|O mutation|O led|O to|O aberrant|O GM|O -|O CSF|O signaling|O in|O myelomonocytic|O precursors|O ,|O perhaps|O contributing|O to|O the|O development|O of|O CMML|O ,|O possibly|O via|O hyperactivation|O of|O GMCSF|O -|O STAT5|O pathway|O .|O
Similarly|O ,|O U2AF26|O mutations|O resulted|O in|O an|O alteration|O of|O RUNX1|O splicing|O (|O supplemental|O Figure|O 7|O )|O .|O
Identification|O of|O GATA2|O mutations|O is|O critical|O for|O the|O management|O of|O these|O patients|O .|O
Test|O Validation|O and|O Proficiency|O Testing|O
Mutations|O or|O deletions|O in|O tumor|O -|O related|O genes|O are|O frequently|O accompanied|O by|O loss|O of|O the|O remaining|O allele|O or|O alleles|O (|O loss|O of|O heterozygosity|O ,|O LOH|O )|O ,|O leading|O to|O the|O inactivation|O of|O these|O tumor|O suppressor|O genes|O ,|O which|O is|O thought|O to|O be|O involved|O in|O a|O multi|O -|O step|O accumulation|O of|O gene|O alterations|O crucial|O to|O leukemogenesis|O .|O
Knockdown|O of|O LMO2|O selectively|O impairs|O activation|O but|O not|O repression|O by|O GATA1|O .|O
The|O median|O age|O at|O the|O last|O follow|O -|O up|O was|O 18|O years|O (|O range|O ,|O 7|O -|O 56|O )|O .|O
Trithorax|O .|O
Pairwise|O comparisons|O of|O variables|O were|O performed|O for|O exploratory|O purposes|O using|O the|O Kolmogorov|O -|O Smirnov|O test|O and|O Student|O t|O test|O for|O continuous|O variables|O and|O the|O x|O -|O squared|O test|O for|O categorical|O variables|O .|O
Clinical|O features|O of|O cases|O harboring|O cohesin|O complex|O gene|O mutations|O .|O
The|O application|O of|O high|O -|O throughput|O molecular|O technologies|O ,|O including|O high|O -|O density|O single|O nucleotide|O polymorphism|O arrays|O (|O SNP|O -|O As|O )|O and|O new|O sequencing|O technologies|O has|O led|O to|O the|O improved|O characterization|O of|O genomic|O lesions|O such|O as|O chromosomal|O aberrations|O and|O of|O somatic|O mutations|O affecting|O specific|O classes|O of|O genes|O ,|O including|O signal|O transducers|O (|O eg|O ,|O CBL|O )|O ,|O apoptotic|O genes|O (|O eg|O ,|O TP53|O and|O RAS|O )|O ,|O genes|O involved|O in|O epigenetic|O regulation|O of|O DNA|O (|O eg|O ,|O DNMT3A|O ,|O IDH1|O /|O 2|O ,|O and|O TET2|O )|O ,|O and|O histone|O modifiers|O (|O eg|O ,|O EZH2|O ,|O UTX|O ,|O and|O ASXL1|O )|O .|O
Mutations|O in|O exon|O 13|O ,|O exon|O 15|O ,|O and|O exon|O 14|O other|O than|O V617F|O are|O exceptionally|O rare|O ,|O and|O are|O observed|O in|O a|O broader|O variety|O of|O disease|O types|O .|O
Secondary|O end|O points|O included|O the|O duration|O of|O the|O reduction|O in|O spleen|O volume|O ;|O the|O proportion|O of|O patients|O with|O a|O reduction|O in|O the|O total|O symptom|O score|O of|O 50|O %|O or|O more|O from|O baseline|O to|O week|O 24|O ,|O as|O assessed|O with|O the|O modified|O Myelofibrosis|O Symptom|O Assessment|O Form|O (|O MFSAF|O )|O ,|O version|O 2|O .|O 0|O (|O see|O the|O Supplementary|O Appendix|O )|O ;|O the|O change|O in|O the|O total|O symptom|O score|O from|O baseline|O to|O week|O 24|O ;|O and|O overall|O survival|O .|O
There|O is|O a|O dearth|O of|O follow|O -|O up|O information|O for|O MPL|O mutation|O analysis|O ,|O likely|O because|O of|O the|O low|O number|O of|O cases|O identified|O to|O date|O .|O
It|O is|O not|O yet|O clear|O whether|O these|O differences|O in|O results|O are|O due|O to|O the|O differences|O in|O the|O diseases|O studied|O (|O AML|O versus|O MDS|O )|O or|O in|O the|O platforms|O used|O to|O assess|O alterations|O in|O methylation|O ,|O which|O may|O not|O accurately|O distinguish|O between|O 5|O -|O mC|O and|O 5|O -|O hmC|O .|O
In|O our|O study|O ,|O high|O ALC|O ,|O although|O prognostic|O in|O a|O univariate|O analysis|O ,|O lost|O its|O prognostic|O significance|O on|O a|O multi|O variable|O analysis|O .|O
Screening|O of|O GATA2|O mutations|O in|O patients|O with|O mild|O chronic|O neutropenia|O associated|O with|O monocytopenia|O may|O be|O important|O .|O
Even|O with|O this|O "|O low|O -|O intensity|O "|O treatment|O approach|O ,|O induction|O death|O occurred|O in|O 26|O %|O of|O patients|O ,|O and|O overall|O prognosis|O remained|O poor|O for|O older|O patients|O who|O cannot|O tolerate|O intensive|O chemotherapy|O regimens|O .|O
In|O mice|O ,|O Gata2|O is|O expressed|O in|O primitive|O hematopoietic|O cells|O and|O its|O level|O gradually|O declines|O during|O cell|O maturation|O into|O different|O blood|O cell|O lineages|O .|O
Assays|O with|O adequate|O analytic|O sensitivity|O are|O required|O for|O the|O sensitive|O detection|O of|O JAK2|O V617F|O ,|O because|O the|O mutation|O may|O be|O present|O in|O a|O small|O fraction|O of|O the|O neoplastic|O clonal|O cell|O population|O .|O
Next|O -|O generation|O amplicon|O deep|O -|O sequencing|O data|O were|O analyzed|O using|O Sequence|O Pilot|O version|O 3|O .|O 4|O (|O JSI|O Medical|O Systems|O ,|O Kippenheim|O ,|O Germany|O )|O .|O
N|O -|O RAS|O and|O K|O -|O RAS|O .|O
RESULTS|O .|O
A|O recent|O large|O retrospective|O study|O involved|O 289|O patients|O with|O PMF|O receiving|O HCT|O from|O either|O HLA|O -|O matched|O identical|O siblings|O (|O 162|O patients|O )|O ,|O HLA|O -|O matched|O nonidentical|O family|O members|O (|O 26|O patients|O )|O or|O HLA|O -|O matched|O unrelated|O individuals|O (|O 101|O patients|O )|O .|O
Several|O groups|O have|O found|O that|O PML|O -|O RARalpha|O physically|O interacts|O with|O PRC2|O and|O that|O repression|O of|O PML|O -|O RARalpha|O target|O genes|O occurs|O in|O association|O with|O PRC2|O -|O mediated|O histone|O modifications|O (|O FIG|O .|O 4|O )|O .|O
The|O initial|O evaluation|O of|O AML|O has|O 2|O objectives|O .|O
A|O recent|O study|O of|O 132|O patients|O non|O -|O RARS|O -|O T|O MDS|O demonstrated|O that|O the|O JAK2|O V617F|O mutation|O was|O apparently|O associated|O with|O lower|O progression|O to|O AML|O and|O a|O trend|O to|O better|O overall|O survival|O .|O
The|O Kaplan|O -|O Meier|O analysis|O was|O used|O to|O evaluate|O survival|O .|O
Patients|O initially|O treated|O with|O high|O -|O dose|O cytarabine|O and|O who|O have|O significant|O residual|O blasts|O 7|O to|O 10|O days|O after|O completion|O of|O induction|O chemotherapy|O are|O considered|O to|O have|O experienced|O induction|O failure|O .|O
The|O GATA|O family|O of|O nuclear|O regulatory|O proteins|O serves|O as|O a|O prototype|O for|O the|O action|O of|O lineage|O -|O restricted|O transcription|O factors|O .|O
Significant|O clustering|O was|O noted|O for|O SRSF2|O with|O both|O IDH1|O (|O P|O =|O 0|O .|O 0002|O )|O and|O IDH2|O (|O P|O =|O 0|O .|O 0009|O )|O mutations|O .|O
The|O terms|O heterozygous|O and|O homozygous|O have|O been|O used|O in|O the|O literature|O to|O describe|O cases|O with|O allele|O burdens|O of|O <|O 50|O %|O and|O >|O =|O 50|O %|O ,|O respectively|O ,|O but|O this|O terminology|O is|O potentially|O misleading|O .|O
Similarly|O ,|O all|O mutations|O of|O SF3B1|O and|O SRSF2|O were|O heterozygous|O ,|O and|O patients|O with|O somatic|O UPD2q33|O .|O 1|O or|O UPD17q25|O (|O regions|O containing|O SF3B1|O and|O SRSF2|O ,|O respectively|O )|O did|O not|O harbor|O homozygous|O mutations|O of|O the|O associated|O genes|O .|O
INTRODUCTION|O .|O
In|O our|O cohort|O ,|O STAG1|O followed|O by|O STAG2|O and|O SMC3|O mutations|O were|O the|O most|O frequently|O mutated|O genes|O in|O the|O cohesin|O complex|O ,|O whereas|O SMC1A|O mutations|O were|O rare|O events|O .|O
Studies|O have|O shown|O that|O FLT3|O -|O TKD|O mutations|O can|O occur|O in|O a|O subgroup|O of|O patients|O with|O the|O prognostically|O favorable|O NPM1|O or|O CEBPA|O mutations|O .|O
In|O an|O Australian|O Leukemia|O Study|O Group|O trial|O ,|O patients|O younger|O than|O 60|O years|O were|O randomized|O (|O N|O =|O 301|O )|O to|O receive|O either|O high|O -|O dose|O cytarabine|O (|O 3|O g|O /|O m2|O every|O 12|O hours|O on|O days|O 1|O ,|O 3|O ,|O 5|O ,|O and|O 7|O for|O a|O total|O of|O 24|O g|O /|O m2|O )|O or|O standard|O cytarabine|O therapy|O (|O 100|O mg|O /|O m2|O /|O d|O x|O 7|O days|O via|O continuous|O infusion|O )|O ;|O patients|O in|O both|O arms|O received|O daunorubicin|O (|O 50|O mg|O /|O m2|O on|O days|O 1|O -|O 3|O )|O and|O etoposide|O (|O 75|O mg|O /|O m2|O /|O d|O x|O 7|O days|O )|O .|O
This|O Review|O focuses|O on|O somatic|O genetic|O alterations|O that|O result|O in|O malignant|O myeloid|O transformation|O by|O affecting|O DNA|O cytosine|O methylation|O and|O hydroxymethylation|O as|O well|O as|O histone|O methylation|O ,|O acetylation|O ,|O ubiquityation|O and|O phosphorylation|O .|O
TET2|O mutations|O lead|O to|O increased|O self|O renewal|O of|O hematopoietic|O stem|O cells|O and|O myeloid|O hyperplasia|O .|O
Recent|O work|O suggests|O that|O ASXL1|O mutations|O are|O bona|O fide|O loss|O -|O of|O -|O function|O mutations|O ,|O and|O that|O ASXL1|O loss|O results|O in|O loss|O of|O the|O transcriptionally|O repressive|O H3K27|O trimethylation|O .|O
GATA1|O and|O GATA2|O are|O expressed|O principally|O in|O hematopoietic|O lineages|O ,|O and|O have|O essential|O roles|O in|O the|O development|O of|O multiple|O hematopoietic|O cells|O ,|O including|O erythrocytes|O and|O megakaryocytes|O .|O
Histograms|O of|O log2|O expression|O values|O were|O then|O used|O to|O identify|O cutoffs|O that|O defined|O low|O expression|O of|O STAG2|O ,|O RAD21|O ,|O and|O SMC3|O as|O compared|O with|O the|O cohort|O of|O healthy|O donors|O .|O
ABSTRACT|O .|O
Further|O studies|O will|O clarify|O the|O whole|O alteration|O of|O mRNA|O splicing|O profiles|O induced|O by|O spliceosomal|O gene|O mutations|O .|O
Discordant|O results|O were|O categorized|O as|O false|O negative|O if|O more|O than|O 15|O laboratories|O obtained|O a|O positive|O result|O and|O as|O false|O positive|O if|O more|O than|O 15|O laboratories|O obtained|O negative|O results|O for|O a|O given|O specimen|O .|O
BM|O smears|O were|O available|O at|O baseline|O for|O 4|O patients|O .|O
Across|O myelofibrosis|O subtypes|O (|O primary|O myelofibrosis|O ,|O post|O -|O polycythemia|O vera|O myelofibrosis|O ,|O and|O post|O -|O essential|O thrombocythemia|O myelofibrosis|O )|O ,|O patients|O who|O received|O ruxolitinib|O had|O a|O decrease|O in|O spleen|O volume|O and|O improvement|O in|O the|O total|O symptom|O score|O ;|O patients|O receiving|O placebo|O had|O increases|O in|O spleen|O volume|O (|O P|O =|O 0|O .|O 52|O for|O interaction|O )|O and|O worsening|O of|O the|O total|O symptom|O score|O (|O P|O =|O 0|O .|O 46|O for|O interaction|O )|O (|O Fig|O .|O
The|O clinical|O and|O laboratory|O features|O of|O CNL|O include|O hepato|O /|O splenomegaly|O ,|O persistent|O neutrophilic|O leukocytosis|O with|O minimal|O left|O shift|O often|O characterized|O by|O toxic|O granulation|O and|O Dohle|O o|O bodies|O ,|O and|O elevated|O leukocyte|O alkaline|O phosphatase|O and|O vitamin|O B12|O levels|O .|O
Response|O is|O then|O categorized|O as|O complete|O response|O or|O induction|O failure|O .|O
In|O the|O past|O four|O decades|O ,|O cytogenetic|O and|O candidate|O -|O gene|O studies|O have|O identified|O recurrent|O somatic|O alterations|O in|O patients|O with|O myeloid|O malignancies|O ,|O including|O myeloproliferative|O neoplasms|O (|O MPNs|O )|O ,|O myelodysplastic|O syndrome|O (|O MDS|O )|O and|O acute|O myeloid|O leukaemia|O (|O AML|O )|O .|O
The|O PCR|O reactions|O were|O carried|O out|O for|O 35|O cycles|O under|O the|O following|O conditions|O :|O 1|O .|O 5|O min|O at|O 94|O -|O -|O Degree|O -|O -|O C|O for|O denaturation|O ,|O 1|O .|O 5|O min|O at|O 52|O -|O -|O 56|O -|O -|O Degree|O -|O -|O C|O for|O annealing|O ,|O 2|O min|O at|O 72|O -|O -|O Degree|O -|O -|O C|O for|O extension|O ,|O and|O a|O final|O extension|O at|O 72|O -|O -|O Degree|O -|O -|O C|O for|O 5|O min|O .|O
Conclusive|O evidence|O associating|O specific|O aberrant|O epigenetic|O profiles|O and|O somatic|O mutations|O with|O targeted|O therapy|O or|O with|O predictive|O value|O for|O standard|O therapy|O is|O lacking|O for|O the|O majority|O of|O cases|O .|O
In|O addition|O ,|O detailed|O studies|O of|O the|O genomic|O methylation|O landscape|O of|O AML|O have|O identified|O distinct|O profiles|O that|O can|O subclassify|O patients|O based|O on|O methylation|O patterns|O and|O a|O core|O set|O of|O genes|O that|O are|O commonly|O methylated|O in|O AML|O cells|O compared|O with|O normal|O haematopoietic|O cells|O .|O
ET|O .|O
ABSTRACT|O .|O
The|O allele|O burden|O may|O be|O expressed|O as|O a|O ratio|O of|O mutant|O (|O mut|O )|O to|O wild|O -|O type|O (|O wt|O )|O alleles|O ,|O or|O more|O commonly|O ,|O as|O a|O percentage|O of|O mutated|O JAK2|O alleles|O ,|O calculated|O as|O (|O JAK2mut|O )|O /|O (|O JAK2mut|O +|O JAK2wt|O )|O x100|O .|O
Subsequent|O analysis|O of|O the|O French|O Severe|O Chronic|O Neutropenia|O Registry|O allowed|O the|O identification|O of|O 10|O additional|O patients|O with|O GATA2|O mutations|O in|O 6|O pedigrees|O with|O unexplained|O mild|O neutropenia|O in|O at|O least|O 1|O patient|O of|O the|O pedigree|O .|O
The|O methodology|O summary|O should|O include|O source|O information|O regarding|O any|O commercial|O primers|O and|O probes|O used|O ,|O and|O it|O must|O include|O a|O statement|O of|O assay|O sensitivity|O .|O
Mutations|O in|O the|O cohesin|O gene|O complex|O .|O
Although|O these|O findings|O reveal|O novel|O insights|O into|O noncanonical|O functions|O of|O JAK2|O ,|O many|O questions|O remain|O .|O
In|O AML|O ,|O ETV6|O mutation|O caused|O a|O loss|O of|O repressor|O activity|O ,|O suggesting|O that|O ETV6|O might|O have|O tumor|O suppressor|O features|O .|O
How|O the|O SETBP1|O mutation|O regulates|O proliferative|O signaling|O remains|O unknown|O .|O
However|O ,|O the|O function|O of|O hematopoietic|O GATA|O factors|O should|O be|O examined|O in|O an|O integrated|O context|O in|O order|O to|O fully|O understand|O their|O regulation|O .|O
Moreover|O ,|O although|O PU|O .|O 1|O can|O inhibit|O GATA2|O expression|O ,|O the|O generation|O of|O mast|O cells|O requires|O cooperated|O functions|O of|O GATA2|O and|O PU|O .|O 1|O .|O
In|O 2005|O ,|O it|O was|O observed|O that|O many|O patients|O with|O "|O classic|O BCR|O -|O ABL1|O -|O negative|O "|O MPDs|O (|O PV|O ,|O ET|O ,|O and|O PMF|O ;|O Figure|O 1|O )|O carried|O the|O somatic|O mutation|O JAK2V617F|O ,|O which|O had|O important|O implications|O for|O classification|O ,|O diagnosis|O ,|O and|O potential|O targeted|O therapy|O .|O
In|O contrast|O ,|O CSF3R|O membrane|O proximal|O mutations|O strongly|O activate|O the|O JAK|O /|O signal|O transducer|O and|O activator|O of|O transcription|O pathway|O and|O are|O sensitive|O to|O JAK|O kinase|O inhibitors|O such|O as|O ruxolitinib|O .|O
Patients|O completed|O the|O MFSAF|O every|O night|O ;|O this|O electronic|O diary|O was|O used|O to|O evaluate|O symptoms|O of|O night|O sweats|O ,|O itching|O ,|O abdominal|O discomfort|O ,|O pain|O under|O the|O ribs|O on|O the|O left|O side|O ,|O a|O feeling|O of|O fullness|O (|O early|O satiety|O )|O ,|O muscle|O or|O bone|O pain|O ,|O and|O inactivity|O .|O
Best|O supportive|O care|O includes|O red|O cell|O and|O platelet|O transfusions|O to|O alleviate|O symptoms|O of|O anemia|O and|O thrombocytopenia|O ;|O prophylactic|O antibiotic|O and|O antifungal|O drugs|O to|O reduce|O the|O risk|O of|O infection|O ;|O and|O hydroxyurea|O for|O management|O of|O leukocytosis|O .|O
Analysis|O of|O a|O large|O series|O of|O CN|O -|O AML|O patients|O suggests|O that|O BCOR|O mutations|O may|O confer|O a|O poorer|O prognosis|O .|O
The|O cumulative|O incidence|O of|O anemia|O ,|O thrombocytopenia|O ,|O marked|O leukocytosis|O ,|O thrombotic|O events|O ,|O and|O leukemic|O transformation|O was|O estimated|O with|O a|O competing|O risk|O approach|O ,|O considering|O death|O for|O any|O cause|O as|O a|O competing|O event|O .|O
The|O CBL|O (|O Casitas|O B|O -|O lineage|O lymphoma|O )|O gene|O ,|O located|O at|O 11q23|O .|O 3|O ,|O encodes|O a|O protein|O with|O E3|O ubiquitin|O ligase|O activity|O that|O is|O thought|O to|O be|O a|O negative|O regulator|O of|O receptor|O tyrosine|O kinase|O (|O RTK|O )|O signaling|O driving|O the|O oncogenesis|O pathway|O .|O
Age|O >|O 65|O years|O old|O ,|O hemoglobin|O level|O <|O 10|O g|O /|O dL|O ,|O leukocyte|O count|O >|O 25|O x|O 109|O /|O L|O ,|O circulating|O blasts|O >|O =|O 1|O %|O ,|O and|O the|O presence|O of|O constitutional|O symptoms|O are|O considered|O negative|O predictive|O risk|O factors|O by|O the|O International|O Prognostic|O Scoring|O System|O .|O
Patients|O who|O receive|O high|O -|O dose|O cytarabine|O should|O be|O closely|O monitored|O for|O changes|O in|O renal|O function|O ,|O because|O renal|O dysfunction|O is|O highly|O correlated|O with|O increased|O risk|O of|O cerebellar|O toxicity|O .|O
A|O large|O German|O trial|O has|O revealed|O additional|O molecular|O prognostic|O markers|O for|O patients|O with|O NK|O -|O AML|O .|O
In|O ET|O and|O PMF|O ,|O JAK2|O V617F|O mutations|O and|O /|O or|O MPL|O exon|O 10|O mutations|O are|O present|O in|O approximately|O 60|O %|O to|O 70|O %|O of|O patients|O ,|O with|O no|O other|O well|O -|O defined|O ,|O recurrent|O JAK2|O or|O MPL|O mutations|O found|O in|O the|O remaining|O patients|O .|O
Mutation|O descriptors|O are|O not|O translated|O into|O the|O standard|O HGVS|O nomenclature|O ,|O to|O avoid|O misinterpretation|O .|O
However|O ,|O the|O spectrum|O of|O these|O mutations|O overlaps|O largely|O with|O that|O in|O AML|O ,|O complicating|O the|O understanding|O of|O MDS|O -|O specific|O pathogenesis|O that|O discriminates|O MDS|O from|O AML|O .|O
Eight|O of|O the|O 33|O TP53|O mutant|O samples|O (|O 24|O .|O 2|O %|O )|O had|O abnormalities|O of|O chromosome|O 17|O (|O P|O <|O 0|O .|O 001|O )|O ,|O suggesting|O that|O mutation|O and|O chromosomal|O loss|O are|O frequently|O found|O together|O ,|O abrogating|O the|O activity|O of|O wildtype|O TP53|O .|O
The|O dose|O was|O adjusted|O for|O lack|O of|O efficacy|O or|O excess|O toxicity|O as|O specified|O in|O the|O protocol|O (|O see|O the|O Supplementary|O Appendix|O )|O .|O
Overall|O ,|O SF3B1|O mutations|O were|O less|O prevalent|O in|O patients|O with|O advanced|O forms|O of|O MDS|O ,|O indicating|O that|O mutation|O of|O this|O factor|O does|O not|O contribute|O to|O progression|O (|O Figure|O 2A|O )|O .|O
Importantly|O ,|O conditional|O TET2|O loss|O in|O the|O haematopoietic|O compartment|O leads|O to|O the|O development|O of|O myeloid|O leukaemia|O ,|O most|O accurately|O characterized|O as|O CMML|O .|O
In|O contrast|O to|O the|O V617F|O mutation|O ,|O which|O involves|O one|O amino|O acid|O codon|O ,|O exon|O 12|O mutations|O affect|O a|O larger|O region|O ,|O spanning|O codons|O 533|O to|O 547|O .|O
Clinical|O evolution|O .|O
Category|O 2A|O :|O Based|O upon|O lower|O -|O level|O evidence|O ,|O there|O is|O uniform|O NCCN|O consensus|O that|O the|O intervention|O is|O appropriate|O .|O
CMML|O is|O characterized|O by|O persistent|O peripheral|O blood|O (|O PB|O )|O monocytosis|O >|O 1|O x|O 109|O /|O l|O ,|O absence|O of|O the|O BCR|O -|O ABL1|O fusion|O ,|O absence|O of|O rearrangements|O of|O the|O PDGFRA|O or|O PDGFRB|O genes|O ,|O absence|O of|O >|O =|O 20|O %|O myeloblasts|O or|O promonocytes|O in|O the|O blood|O and|O bone|O marrow|O (|O BM|O )|O and|O presence|O of|O dysplasia|O in|O one|O or|O more|O myeloid|O lineages|O .|O
However|O ,|O based|O on|O the|O substantial|O difference|O in|O relapse|O -|O free|O survival|O data|O between|O the|O Intermediate|O I|O and|O Intermediate|O II|O groups|O defined|O by|O ELN|O ,|O the|O NCCN|O has|O continued|O to|O place|O NK|O -|O AML|O with|O FLT3|O -|O ITD|O mutations|O in|O the|O unfavorable|O risk|O group|O rather|O than|O the|O intermediate|O risk|O group|O (|O see|O "|O Risk|O Status|O Based|O on|O Cytogenetics|O and|O Molecular|O Abnormalities|O ,|O "|O on|O page|O 995|O )|O .|O
The|O majority|O of|O GATA2|O mutations|O have|O been|O identified|O in|O MDS|O /|O AML|O ,|O Emberger|O ,|O or|O MonoMAC|O syndrome|O patients|O .|O
THE|O COHESIN|O COMPLEX|O .|O
Adverse|O events|O of|O grade|O 3|O or|O higher|O developed|O in|O 8|O of|O 49|O patients|O in|O the|O ruxolitinib|O group|O (|O 16|O .|O 3|O %|O )|O and|O in|O 7|O of|O 54|O patients|O in|O the|O placebo|O group|O (|O 13|O .|O 0|O %|O )|O after|O interruption|O of|O the|O study|O drug|O and|O in|O 12|O of|O 21|O patients|O in|O the|O ruxolitinib|O group|O (|O 57|O .|O 1|O %|O )|O and|O 17|O of|O 37|O patients|O in|O the|O placebo|O group|O (|O 45|O .|O 9|O %|O )|O after|O discontinuation|O .|O
Under|O normal|O circumstances|O ,|O the|O CSF3R|O ligand|O ,|O granulocyte|O -|O colony|O stimulating|O factor|O (|O G|O -|O CSF|O )|O ,|O promotes|O growth|O and|O survival|O of|O myeloid|O precursor|O cells|O ,|O ultimately|O leading|O to|O differentiation|O of|O these|O myeloid|O precursors|O into|O neutrophils|O .|O
Allele|O -|O specific|O qPCR|O also|O allows|O for|O quantification|O of|O the|O mutant|O as|O a|O percentage|O of|O all|O of|O the|O JAK2|O alleles|O ,|O as|O an|O estimate|O of|O disease|O burden|O .|O
This|O region|O was|O shared|O by|O 13|O out|O of|O 14|O subjects|O with|O deletions|O ,|O as|O well|O as|O by|O the|O two|O subjects|O with|O UPD|O ,|O and|O encompassed|O two|O genes|O ,|O CUL1|O and|O EZH2|O (|O Fig|O .|O 1a|O and|O Supplementary|O Fig|O .|O 1|O )|O .|O
In|O addition|O ,|O they|O do|O not|O carry|O JAK2|O (|O V617F|O )|O ,|O which|O is|O instead|O found|O in|O two|O -|O thirds|O of|O PMF|O patients|O .|O
Adverse|O effects|O were|O reported|O in|O 89|O %|O of|O patients|O ,|O and|O treatment|O was|O stopped|O in|O 24|O %|O due|O to|O toxicity|O .|O
TET1|O ,|O but|O not|O TET2|O ,|O can|O recruit|O Polycomb|O repressive|O complexes|O (|O PRCs|O )|O through|O direct|O binding|O to|O the|O trans|O criptional|O regulator|O SIN3A|O .|O
Moreover|O ,|O GATA2|O inhibits|O the|O erythroid|O differentiation|O through|O the|O regulation|O of|O EPO|O ,|O which|O is|O the|O major|O growth|O factor|O that|O controls|O the|O red|O blood|O cell|O production|O through|O the|O promotion|O of|O survival|O ,|O proliferation|O and|O differentiation|O of|O the|O erythroid|O progenitors|O in|O the|O bone|O marrow|O .|O
ETV6|O mutation|O was|O recently|O found|O in|O the|O patients|O with|O MDS|O transformed|O to|O chronic|O myelomonocytic|O leukemia|O .|O
In|O the|O Italian|O report|O ,|O transformation|O to|O acute|O leukemia|O occurred|O in|O 22|O patients|O (|O 40|O %|O )|O ,|O with|O a|O median|O time|O from|O diagnosis|O of|O 18|O months|O .|O
White|O blood|O cells|O can|O be|O obtained|O by|O simply|O performing|O a|O red|O blood|O cell|O lysis|O procedure|O .|O
However|O ,|O GATA2|O and|O GATA3|O replacement|O strains|O displayed|O significant|O thrombocytopenia|O ,|O with|O 2|O to|O 3|O -|O fold|O reductions|O in|O platelet|O counts|O .|O
Laboratory|O tests|O for|O these|O mutations|O have|O become|O standard|O in|O assessing|O clinically|O suspected|O BCR|O -|O ABL1|O -|O negative|O MPN|O .|O
ABSTRACT|O .|O
In|O addition|O ,|O the|O expression|O of|O IDH1|O or|O IDH2|O mutants|O in|O mouse|O bone|O -|O marrow|O -|O derived|O cells|O induced|O the|O expression|O of|O markers|O associated|O with|O immature|O (|O less|O differentiated|O )|O cells|O ,|O a|O phenotype|O that|O is|O similar|O to|O Tet2|O -|O knockdown|O or|O Tet2|O -|O knockout|O cells|O .|O
Average|O depth|O was|O 124x|O .|O
The|O 4|O -|O year|O DFS|O rate|O for|O patients|O receiving|O consolidation|O with|O 3|O g|O /|O m2|O of|O high|O -|O dose|O cytarabine|O was|O 44|O %|O ,|O with|O a|O 5|O %|O treatment|O -|O related|O mortality|O rate|O and|O a|O 12|O %|O incidence|O of|O severe|O neurologic|O toxicity|O .|O
Overall|O ,|O these|O mutations|O appeared|O to|O be|O more|O prevalent|O in|O refractory|O anemia|O with|O excess|O blasts|O type|O II|O (|O 23|O %|O )|O than|O in|O refractory|O anemia|O with|O excess|O blasts|O (|O RAEB|O )|O type|O I|O (|O 14|O %|O )|O and|O MDS|O unclassifiable|O (|O 14|O %|O )|O and|O were|O not|O observed|O in|O MDS|O with|O isolated|O del|O (|O 5q|O )|O .|O
[|O END|O OF|O ABSTRACT|O ]|O .|O
In|O vitro|O studies|O have|O shown|O that|O short|O hairpin|O RNA|O (|O shRNA|O )|O -|O mediated|O silencing|O of|O TET2|O expression|O leads|O to|O impaired|O haematopoietic|O differentiation|O .|O
To|O examine|O the|O clinical|O effects|O of|O mutations|O in|O patients|O with|O myelodysplastic|O syndromes|O ,|O we|O evaluated|O all|O 439|O samples|O for|O all|O the|O genes|O identified|O above|O ,|O as|O well|O as|O a|O set|O of|O 13|O genes|O previously|O reported|O to|O be|O mutated|O in|O hematologic|O cancers|O .|O
Finally|O ,|O a|O U2|O snRNP|O complex|O replaces|O SF1|O bound|O to|O the|O branchpoint|O sequence|O with|O one|O of|O its|O subcomponent|O ,|O SF3B1|O ,|O to|O establish|O a|O splicing|O A|O complex|O (|O Fig|O .|O 1|O )|O .|O
We|O evaluated|O the|O prognostic|O relevance|O of|O several|O clinical|O and|O laboratory|O parameters|O in|O 226|O Mayo|O Clinic|O patients|O with|O chronic|O myelomonocytic|O leukemia|O (|O CMML|O )|O :|O 152|O (|O 67|O %|O )|O males|O and|O median|O age|O 71|O years|O .|O
A|O recent|O study|O demonstrated|O that|O this|O specific|O mutation|O is|O one|O of|O the|O important|O biomarkers|O for|O response|O to|O DNTMIs|O .|O
Eight|O patients|O had|O nine|O frameshift|O mutations|O at|O the|O N|O -|O terminal|O region|O resulting|O in|O truncation|O of|O the|O proteins|O .|O
Patients|O were|O also|O randomized|O to|O receive|O all|O -|O trans|O retinoic|O acid|O (|O ATRA|O )|O or|O no|O ATRA|O .|O
Data|O from|O 3|O large|O studies|O have|O identified|O monosomal|O karyotypes|O (|O defined|O as|O having|O >|O =|O 2|O autosomal|O monosomies|O ,|O or|O a|O single|O monosomy|O with|O additional|O structural|O abnormalities|O )|O as|O a|O subset|O of|O unfavorable|O cytogenetic|O prognosticators|O .|O
In|O patients|O older|O than|O 60|O years|O ,|O no|O major|O difference|O was|O observed|O (|O 9|O .|O 6|O vs|O .|O 11|O .|O 6|O months|O ,|O respectively|O )|O .|O
Congenital|O neutropenia|O is|O a|O group|O of|O genetic|O disorders|O that|O involve|O chronic|O neutropenia|O and|O susceptibility|O to|O infections|O .|O
CSF3R|O and|O SETBP1|O mutational|O overlap|O .|O
For|O a|O qPCR|O assay|O ,|O the|O threshold|O for|O a|O positive|O result|O must|O be|O determined|O ,|O because|O of|O cross|O -|O amplification|O of|O the|O wild|O -|O type|O allele|O .|O
Even|O though|O these|O measures|O are|O integrated|O into|O the|O IPSS|O ,|O TP53|O mutations|O remained|O strongly|O associated|O with|O shorter|O overall|O survival|O after|O adjustment|O for|O IPSS|O risk|O group|O (|O P|O <|O 0|O .|O 001|O )|O ,|O indicating|O that|O these|O mutations|O adversely|O affect|O survival|O through|O other|O means|O (|O Fig|O .|O 5|O in|O the|O Supplementary|O Appendix|O )|O .|O
Twenty|O -|O seven|O patients|O died|O during|O follow|O -|O up|O ,|O with|O a|O cumulative|O nonrelapse|O mortality|O at|O 1|O year|O of|O 16|O %|O .|O
Mutation|O analysis|O was|O performed|O by|O sequencing|O the|O nine|O exons|O and|O adjacent|O intronic|O splice|O -|O junction|O regions|O of|O PTEN|O /|O MMAC1|O .|O
The|O 5|O -|O year|O cumulative|O rate|O of|O relapse|O risk|O was|O also|O similar|O between|O treatment|O arms|O (|O 39|O %|O vs|O .|O 27|O %|O ,|O respectively|O )|O .|O
Furthermore|O ,|O Pimanda|O et|O al|O described|O a|O regulatory|O circuit|O among|O GATA2|O ,|O FLI1|O and|O SCL|O /|O TAL1|O ,|O leading|O to|O the|O notion|O that|O switching|O on|O the|O GATA2|O /|O FLI1|O /|O SCL|O triad|O could|O be|O a|O prerequisite|O for|O specifying|O HSCs|O .|O
Reported|O P|O -|O values|O are|O two|O -|O sided|O and|O not|O corrected|O for|O multiple|O testing|O .|O
Most|O initial|O treatment|O decisions|O for|O AML|O are|O based|O on|O age|O ,|O history|O of|O prior|O myelodysplasia|O or|O cytotoxic|O therapy|O ,|O and|O performance|O status|O .|O
Five|O SNVs|O were|O identified|O further|O and|O confirmed|O by|O classic|O Sanger|O sequencing|O :|O EPHB6|O T483P|O ,|O GATA2|O R396Q|O ,|O IMPG2|O P1161L|O ,|O NEK11|O D87Y|O ,|O and|O TTN|O P4737R|O .|O
Almost|O all|O patients|O receiving|O ruxolitinib|O had|O some|O degree|O of|O reduction|O in|O spleen|O volume|O (|O Fig|O .|O 1B|O )|O .|O
The|O monthly|O prevalence|O of|O grade|O 3|O or|O 4|O anemia|O and|O the|O proportion|O of|O patients|O requiring|O transfusions|O (|O 1|O or|O more|O units|O of|O red|O cells|O )|O also|O followed|O a|O pattern|O that|O was|O consistent|O with|O changes|O in|O the|O hemoglobin|O level|O over|O time|O (|O Fig|O .|O
In|O addition|O ,|O mutations|O in|O specific|O epigenetic|O modifiers|O including|O DNMT3A|O and|O MLL|O predict|O benefit|O from|O dose|O -|O intensified|O induction|O therapy|O with|O daunorubicin|O ,|O which|O suggests|O that|O these|O mutant|O disease|O alleles|O affect|O the|O response|O to|O classical|O cytotoxic|O therapies|O .|O
The|O majority|O of|O the|O ZRSR2|O mutated|O cases|O were|O male|O ,|O in|O which|O single|O mutations|O resulted|O in|O complete|O loss|O of|O functions|O .|O
The|O intersection|O of|O ASXL1|O -|O bound|O genomic|O regions|O -|O as|O identified|O by|O chromatin|O immunoprecipitation|O followed|O by|O high|O -|O throughput|O sequencing|O (|O ChIP|O -|O seq|O )|O -|O and|O gene|O expression|O profiling|O resulted|O in|O the|O identification|O of|O specific|O targets|O of|O ASXL1|O ,|O including|O the|O HOXA|O cluster|O of|O genes|O ,|O the|O expression|O of|O which|O increases|O with|O ASXL1|O loss|O or|O mutation|O .|O
A|O total|O of|O 38|O .|O 2|O %|O of|O the|O patients|O had|O IPSS|O intermediate|O -|O 2|O -|O risk|O disease|O ,|O and|O 61|O .|O 2|O %|O had|O high|O -|O risk|O disease|O .|O
Traditional|O allele|O -|O specific|O PCR|O and|O allele|O -|O specific|O qPCR|O assays|O have|O also|O been|O used|O ,|O but|O these|O assays|O are|O limited|O to|O assessing|O specific|O mutations|O .|O
Figure|O 1|O .|O Mutations|O and|O Cytogenetic|O Abnormalities|O in|O 223|O Samples|O with|O at|O Least|O One|O Mutation|O .|O Mutations|O in|O the|O 11|O most|O frequently|O mutated|O gene|O groups|O are|O shown|O by|O colored|O bars|O .|O Each|O column|O represents|O 1|O of|O the|O 223|O samples|O with|O a|O mutation|O in|O one|O or|O more|O of|O the|O genes|O listed|O .|O Darker|O bars|O indicate|O samples|O with|O two|O or|O more|O distinct|O mutations|O in|O that|O gene|O group|O .|O The|O karyotype|O of|O each|O of|O the|O 223|O samples|O is|O also|O shown|O .|O
Of|O the|O 5|O patients|O with|O STAG2|O mutations|O ,|O 2|O patients|O were|O female|O and|O 3|O were|O male|O .|O
In|O addition|O ,|O the|O GATA2|O protein|O contains|O putative|O modification|O motifs|O ,|O through|O which|O cellular|O signals|O can|O regulate|O the|O stability|O of|O GATA2|O in|O hematopoietic|O cells|O .|O
S505N|O mutation|O has|O been|O associated|O with|O familial|O autosomal|O dominant|O thrombocytosis|O .|O
The|O reduction|O in|O spleen|O volume|O was|O durable|O with|O continued|O therapy|O (|O Fig|O .|O 1C|O )|O .|O
The|O clinical|O and|O prognostic|O implications|O of|O DNMT3A|O mutations|O in|O chronic|O myeloid|O malignancies|O are|O not|O yet|O clarified|O .|O
Monocytosis|O and|O basophilia|O are|O not|O prominent|O (|O <|O 2|O %|O peripheral|O blood|O basophils|O ,|O <|O 10|O %|O peripheral|O blood|O monocytes|O )|O ,|O and|O the|O leukocyte|O alkaline|O phosphatase|O level|O may|O be|O low|O ,|O normal|O ,|O or|O increased|O ,|O therefore|O lacking|O diagnostic|O utility|O .|O
Environmental|O factors|O that|O have|O long|O been|O established|O to|O increase|O the|O risks|O of|O myelodysplastic|O syndromes|O (|O MDS|O )|O and|O AML|O include|O prolonged|O exposure|O to|O petrochemicals|O ;|O solvents|O such|O as|O benzene|O ;|O pesticides|O ;|O and|O ionizing|O radiation|O .|O
Harada|O et|O al|O .|O found|O that|O patients|O with|O de|O novo|O or|O secondary|O MDS|O /|O AML|O carrying|O RUNX1|O mutations|O had|O a|O significantly|O poorer|O overall|O survival|O than|O those|O without|O mutations|O .|O
The|O possible|O role|O of|O PRC1|O alterations|O in|O myeloid|O malignancies|O .|O
The|O cohesin|O complex|O is|O composed|O of|O 2|O long|O structural|O maintenance|O proteins|O ,|O SMC1A|O and|O SMC3|O ,|O which|O heterodimerize|O at|O the|O hinge|O domain|O ,|O forming|O a|O closed|O loop|O by|O binding|O at|O the|O alpha|O -|O klesin|O end|O to|O RAD21|O and|O adapter|O proteins|O STAG1|O /|O STAG2|O .|O
Both|O patients|O with|O SMC1A|O mutations|O were|O male|O .|O
Currently|O ,|O various|O driver|O mutations|O identified|O in|O MDS|O represent|O genes|O involved|O in|O pathways|O important|O in|O epigenetic|O regulation|O ,|O including|O chromatin|O modification|O and|O DNA|O methylation|O ,|O transcriptional|O regulation|O ,|O DNA|O repair|O /|O tumor|O suppressor|O ,|O signal|O transduction|O ,|O RNA|O splicing|O machinery|O ,|O and|O the|O cohesion|O complex|O (|O Table|O 1|O )|O .|O
Interestingly|O ,|O these|O mutations|O appeared|O to|O co|O -|O occur|O in|O patients|O who|O had|O RUNX1|O and|O DNMT3A|O mutations|O and|O were|O associated|O with|O inferior|O OS|O and|O higher|O risk|O of|O leukemic|O transformation|O .|O
Fig|O .|O 3|O .|O (|O A|O )|O SSCP|O analysis|O of|O PTEN|O /|O MMAC1|O exon|O 5|O .|O Altered|O mobility|O band|O (|O arrowhead|O )|O present|O in|O PCR|O products|O amplified|O from|O the|O leukemia|O cell|O line|O U937|O DNA|O is|O seen|O in|O lane|O 3|O .|O (|O B|O )|O The|O result|O of|O sequencing|O of|O the|O altered|O band|O shows|O a|O 4|O -|O bp|O (|O CCCG|O )|O insertion|O at|O nucleotide|O 1423|O .|O
Two|O cases|O showed|O a|O complex|O deletion|O from|O exons|O 1|O to|O 8|O but|O retained|O 21|O bp|O of|O exon|O 7|O (|O Fig|O .|O 2|O )|O .|O
SF3B1|O mutations|O are|O commonly|O associated|O with|O myeloid|O neoplasms|O expressing|O ring|O sideroblasts|O .|O
Notably|O ,|O these|O salvage|O treatment|O options|O are|O aggressive|O regimens|O intended|O for|O appropriate|O patients|O who|O can|O tolerate|O such|O therapies|O ;|O for|O other|O patents|O ,|O less|O aggressive|O treatment|O options|O may|O include|O low|O -|O dose|O cytarabine|O or|O hypomethylating|O agents|O .|O
All|O the|O reactions|O were|O repeated|O at|O least|O three|O times|O with|O controls|O .|O
Gene|O expression|O profiling|O .|O
By|O contrast|O ,|O mutations|O in|O IDH1|O or|O IDH2|O seem|O to|O be|O significantly|O associated|O with|O mutations|O in|O NPM1|O ,|O and|O NPM1|O -|O IDH1|O or|O NPM1|O -|O IDH2|O co|O -|O mutant|O patients|O comprise|O a|O subset|O of|O intermediate|O -|O risk|O AML|O with|O remarkably|O favourable|O clinical|O outcome|O .|O
However|O ,|O we|O could|O not|O detect|O a|O significant|O difference|O in|O OS|O when|O subgroups|O with|O RS|O were|O analyzed|O separately|O ,|O perhaps|O because|O of|O low|O number|O of|O WT|O cases|O .|O
Aberrations|O of|O EZH2|O at|O chromosome|O 7q36|O .|O 1|O were|O detected|O in|O 29|O bone|O marrow|O samples|O from|O 126|O individuals|O with|O MDS|O .|O Genomic|O sequencing|O of|O the|O coding|O region|O and|O the|O splice|O donor|O and|O acceptor|O sites|O revealed|O missense|O mutations|O ,|O donor|O -|O splice|O -|O site|O mutations|O ,|O deletions|O and|O insertions|O ,|O predicting|O amino|O acid|O substitutions|O and|O truncations|O .|O
Median|O OS|O was|O 17|O .|O 7|O years|O in|O CALR|O -|O mutant|O ,|O 9|O .|O 2|O years|O in|O JAK2|O -|O mutant|O ,|O 9|O .|O 1|O years|O in|O MPL|O -|O mutant|O ,|O and|O 3|O .|O 2|O years|O in|O triple|O -|O negative|O patients|O ,|O as|O shown|O in|O Figure|O 4|O .|O
Full|O sequencing|O of|O JAK2|O and|O MPL|O ,|O as|O well|O as|O other|O genes|O relevant|O for|O MPNs|O ,|O may|O be|O performed|O in|O this|O manner|O .|O
In|O terms|O of|O prognostic|O significance|O ,|O N|O -|O RAS|O mutation|O does|O not|O appear|O to|O independently|O affect|O survival|O in|O MDS|O ,|O although|O it|O is|O linked|O to|O severe|O thrombocytopenia|O .|O
For|O example|O ,|O DNMT3A|O ,|O TET2|O ,|O IDH1|O /|O 2|O and|O ASXL1|O are|O among|O most|O frequent|O targets|O of|O gene|O mutations|O in|O both|O MDS|O and|O normal|O karyotype|O AML|O .|O
In|O aCML|O ,|O the|O majority|O of|O SETBP1|O mutations|O are|O located|O in|O a|O 14|O amino|O acid|O stretch|O that|O is|O also|O mutated|O in|O Schinzel|O -|O Giedion|O syndrome|O ,|O a|O rare|O genetic|O disease|O characterized|O by|O congenital|O malformations|O ,|O mental|O retardation|O ,|O and|O a|O high|O prevalence|O of|O epithelial|O tumors|O .|O
Outside|O the|O hematopoietic|O system|O ,|O GATA2|O collaborates|O in|O the|O development|O of|O the|O endothelial|O cells|O ,|O adipocytes|O ,|O and|O the|O nervous|O system|O .|O
Mutational|O frequencies|O of|O ASXL1|O are|O listed|O as|O reported|O in|O the|O original|O referenced|O manuscripts|O (|O this|O may|O include|O the|O controversial|O ASXL1|O pGly646fsX12|O variant|O (|O REF|O .|O 83|O )|O )|O .|O
Abnormal|O RNA|O splicing|O caused|O by|O splicing|O factor|O mutations|O .|O
No|O consensus|O result|O was|O obtained|O with|O four|O of|O the|O specimens|O .|O
Notably|O ,|O however|O ,|O in|O patients|O with|O CBF|O AML|O who|O were|O treated|O with|O postremission|O therapy|O with|O high|O -|O dose|O cytarabine|O ,|O the|O presence|O of|O c|O -|O KIT|O mutations|O resulted|O in|O poorer|O outcomes|O .|O
The|O outcome|O once|O the|O MDS|O or|O the|O AML|O occurred|O was|O extremely|O poor|O :|O none|O of|O the|O patients|O treated|O only|O by|O chemotherapy|O was|O alive|O in|O contrast|O to|O the|O 6|O patients|O receiving|O HSCT|O (|O Table|O 1|O )|O .|O
Fig|O .|O 3|O .|O The|O cohesin|O complex|O .|O Adopted|O and|O modified|O based|O on|O Ocampo|O -|O Hafalla|O M|O T|O ,|O and|O Uhlmann|O F|O J|O .|O Cell|O Sci|O 2011|O ;|O 124|O :|O 685|O -|O 691|O .|O SCC|O family|O members|O include|O SA1|O and|O SA2|O in|O vertebrate|O ,|O which|O are|O encoded|O by|O STAG1|O and|O STAG2|O .|O The|O cohesin|O complex|O is|O composed|O of|O ATP|O -|O bound|O proteins|O including|O SMC1|O ,|O SMC3|O ,|O and|O SCC1|O forming|O an|O embracing|O ring|O .|O Pds5|O ,|O Scc3|O and|O Wpl1|O proteins|O interact|O with|O the|O ring|O and|O modulate|O its|O function|O .|O Cohesin|O is|O loaded|O on|O the|O chromosomes|O prior|O to|O DNA|O replication|O with|O the|O help|O of|O Scc2|O /|O Scc4|O cohesin|O loader|O .|O During|O loading|O reaction|O ,|O the|O ATP|O bound|O between|O SMC3|O /|O SMC1|O head|O domains|O is|O hydrolyzed|O ,|O which|O is|O catalyzed|O by|O the|O Scc2|O -|O Scc4|O complex|O .|O Once|O the|O new|O complex|O is|O formed|O ,|O cohesin|O is|O enabled|O to|O encircle|O the|O DNA|O ,|O which|O allows|O translocation|O of|O cohesin|O rings|O along|O the|O DNA|O in|O response|O to|O transcription|O ,|O leading|O to|O their|O accumulation|O between|O convergent|O gene|O pairs|O (|O RNA|O -|O polymerase|O -|O II|O -|O transcribed|O genes|O and|O their|O direction|O of|O transcription|O )|O .|O During|O DNA|O replication|O it|O is|O acetylated|O by|O Eco1|O acetyltransferase|O .|O The|O release|O of|O cohesin|O from|O DNA|O happens|O at|O the|O beginning|O of|O the|O anaphase|O and|O SCC1|O subunit|O is|O cleaved|O by|O separase|O ,|O a|O protease|O .|O Cohesin|O is|O deacetylated|O by|O Hos1|O deacetylase|O and|O released|O from|O chromosomes|O .|O Mutations|O in|O cohesin|O complex|O will|O lead|O to|O abnormal|O mitosis|O or|O meiosis|O .|O Note|O :|O *|O frequent|O mutation|O site|O .|O
The|O commonly|O used|O MDAPS|O was|O developed|O on|O a|O cohort|O of|O 213|O CMML|O patients|O and|O identified|O four|O risk|O groups|O based|O on|O the|O hemoglobin|O level|O ,|O presence|O of|O IMC|O ,|O ALC|O and|O BM|O blasts|O .|O
ASXL1|O mutations|O in|O epigenetic|O repatterning|O and|O myeloid|O transformation|O .|O
Patient|O number|O 6184|O (|O P2|O ,|O II|O ,|O 1|O )|O was|O diagnosed|O at|O the|O age|O of|O 13|O with|O an|O AML|O M5|O .|O
In|O another|O study|O ,|O IDH|O mutations|O (|O IDH1|O and|O IDH2|O combined|O )|O were|O associated|O with|O significantly|O inferior|O 5|O -|O year|O relapse|O -|O free|O survival|O rates|O (|O 37|O %|O vs|O .|O 67|O %|O ;|O P|O =|O .|O 02|O )|O and|O OS|O rates|O (|O 41|O %|O vs|O .|O 65|O %|O ;|O P|O =|O .|O 03|O )|O in|O the|O subgroup|O of|O patients|O with|O favorable|O -|O risk|O AML|O (|O normal|O karyotype|O with|O NPM1|O mutation|O without|O FLT3|O -|O ITD|O )|O .|O
Instead|O ,|O the|O mutations|O are|O tumorigenic|O by|O alteration|O of|O the|O catalytic|O activity|O of|O the|O enzymes|O ,|O resulting|O in|O accumulation|O of|O D|O -|O 2|O -|O hydroxyglutarate|O (|O D|O -|O 2HG|O )|O as|O the|O reduction|O product|O of|O alpha|O -|O KG|O .|O
MPLW515L|O results|O from|O a|O guanine|O -|O to|O -|O thymine|O transversion|O at|O nucleotide|O 1544|O ,|O with|O substitution|O of|O tryptophan|O to|O leucine|O at|O codon|O 515|O .|O
Patients|O who|O received|O at|O least|O 4|O cycles|O of|O treatment|O were|O assessed|O by|O modified|O International|O Working|O Group|O criteria|O .|O
ELN|O classifies|O patients|O with|O t|O (|O 9|O ;|O 11|O )|O (|O p22|O ;|O q23|O )|O ,|O MLLT3|O -|O MLL|O and|O other|O cytogenetic|O abnormalities|O that|O fall|O into|O neither|O the|O favorable|O or|O adverse|O category|O into|O the|O "|O Intermediate|O II|O "|O group|O .|O
Although|O activation|O of|O tyrosine|O kinase|O pathways|O is|O a|O shared|O theme|O among|O myeloproliferative|O neoplasms|O ,|O the|O pathogenetic|O basis|O of|O chronic|O neutrophilic|O leukemia|O (|O CNL|O )|O has|O remained|O elusive|O .|O
Cohesin|O mutations|O likely|O represent|O secondary|O events|O in|O clonal|O hierarchy|O and|O contribute|O to|O clonal|O transformation|O .|O
Current|O treatments|O for|O BCR|O -|O ABL1|O -|O negative|O MPN|O are|O considered|O noncurative|O and|O focus|O primarily|O on|O reducing|O the|O risk|O of|O complications|O .|O
Treatment|O for|O PMF|O is|O dependent|O on|O both|O the|O absolute|O risk|O category|O and|O the|O presence|O of|O anemia|O ,|O splenomegaly|O ,|O or|O both|O .|O
How|O Should|O the|O Results|O of|O JAK2|O and|O MPL|O Mutation|O Testing|O Be|O Reported|O ?|O
In|O this|O study|O ,|O we|O analyzed|O a|O large|O cohort|O of|O patients|O with|O CMML|O to|O define|O the|O prevalence|O and|O types|O of|O RUNX1|O mutations|O .|O
The|O adverse|O effect|O of|O chromosome|O 7|O and|O 7q|O deletions|O on|O the|O prognosis|O of|O individuals|O with|O MDS|O is|O well|O known|O .|O
Sequences|O were|O compared|O to|O the|O reference|O genomic|O sequence|O NT|O _|O 007914|O .|O 15|O and|O the|O deduced|O protein|O sequences|O were|O compared|O to|O reference|O NP|O _|O 004447|O .|O 2|O .|O In|O subjects|O 44|O and|O 104|O ,|O the|O 7q|O deletion|O that|O was|O identified|O on|O the|O SNP|O array|O was|O missed|O by|O karyotype|O analysis|O .|O In|O subject|O 43|O ,|O the|O 7q|O deletion|O that|O was|O revealed|O by|O karyotype|O analysis|O was|O not|O detected|O by|O a|O SNP|O array|O analysis|O .|O
A|O between|O -|O group|O comparison|O of|O adverse|O events|O reported|O after|O interruption|O or|O permanent|O discontinuation|O of|O the|O study|O drug|O showed|O no|O clear|O pattern|O of|O a|O specific|O withdrawal|O effect|O .|O
Prognostic|O scores|O were|O analyzed|O as|O both|O a|O fixed|O and|O a|O time|O -|O dependent|O covariate|O .|O
We|O did|O not|O find|O major|O differences|O between|O CALR|O -|O mutant|O patients|O with|O the|O 52|O -|O bp|O deletion|O (|O type|O 1|O mutation|O )|O and|O those|O with|O the|O 5|O -|O bp|O insertion|O (|O type|O 2|O mutation|O )|O .|O
As|O in|O our|O previous|O study|O of|O TSG101|O ,|O the|O abnormal|O transcripts|O may|O result|O from|O aberrant|O RNA|O splicing|O as|O evidenced|O by|O the|O presence|O of|O both|O these|O aberrant|O transcripts|O and|O normal|O full|O length|O transcripts|O in|O all|O specimens|O examined|O .|O
Furthermore|O ,|O patients|O with|O mutant|O TP53|O and|O a|O complex|O karyotype|O had|O a|O paucity|O of|O mutations|O in|O other|O genes|O ,|O suggesting|O that|O this|O group|O could|O be|O considered|O to|O have|O a|O distinct|O molecular|O subclass|O of|O myelodysplastic|O syndromes|O with|O a|O unique|O pathogenic|O mechanism|O .|O
The|O potential|O prognostic|O value|O of|O IDH|O ,|O EZH2|O and|O SRSF2|O mutations|O in|O PMF|O were|O previously|O suggested|O by|O single|O center|O studies|O .|O
Cohesin|O mutations|O were|O significantly|O associated|O with|O RUNX1|O ,|O Ras|O -|O family|O oncogenes|O ,|O and|O BCOR|O and|O ASXL1|O mutations|O and|O were|O most|O prevalent|O in|O high|O -|O risk|O MDS|O and|O secondary|O AML|O .|O
The|O SWOG|O /|O ECOG|O trial|O reported|O a|O 5|O -|O year|O survival|O rate|O (|O from|O time|O of|O CR|O )|O of|O 44|O %|O with|O allogeneic|O HSCT|O (|O n|O =|O 18|O ;|O 61|O %|O underwent|O HSCT|O )|O and|O 13|O %|O with|O autologous|O HSCT|O (|O n|O =|O 20|O ;|O 50|O %|O underwent|O HSCT|O )|O among|O the|O subgroup|O of|O patients|O with|O unfavorable|O cytogenetics|O ;|O moreover|O ,|O the|O 5|O -|O year|O survival|O rate|O was|O similar|O between|O those|O allocated|O to|O autologous|O HSCT|O and|O those|O intended|O for|O chemotherapy|O consolidation|O alone|O (|O 13|O %|O and|O 15|O %|O ,|O respectively|O )|O .|O
P|O -|O values|O <|O 0|O .|O 05|O were|O considered|O significant|O .|O
Low|O -|O risk|O patients|O with|O platelet|O counts|O >|O 1000|O x|O 109|O /|O L|O are|O considered|O separately|O (|O Table|O 4|O )|O .|O
Interestingly|O ,|O in|O this|O latter|O study|O ,|O non|O -|O R882|O DNMT3A|O mutations|O were|O significantly|O associated|O with|O poorer|O outcomes|O in|O patients|O younger|O than|O 60|O years|O (|O but|O not|O R882|O mutations|O )|O ;|O in|O contrast|O ,|O in|O patients|O aged|O 60|O years|O and|O older|O ,|O DNMT3A|O -|O R882|O mutations|O (|O but|O not|O non|O -|O R882|O mutations|O )|O were|O associated|O with|O significantly|O decreased|O DFS|O (|O 3|O -|O year|O rate|O ,|O 3|O %|O vs|O .|O 21|O %|O ;|O P|O =|O .|O 006|O )|O and|O OS|O (|O 3|O -|O year|O rate|O ,|O 4|O %|O vs|O .|O 24|O %|O ;|O P|O =|O .|O 01|O )|O .|O
To|O evaluate|O the|O role|O of|O the|O PTEN|O /|O MMAC1|O gene|O in|O leukemia|O ,|O bone|O marrow|O and|O /|O or|O peripheral|O blood|O from|O 62|O acute|O myeloid|O leukemia|O (|O AML|O )|O patients|O ,|O 5|O hemopoietic|O cell|O lines|O (|O HL60|O ,|O U937|O ,|O Raji|O ,|O KG|O -|O 1|O ,|O K562|O )|O ,|O and|O 30|O normal|O controls|O were|O analyzed|O .|O
Leukemic|O cells|O from|O peripheral|O blood|O or|O bone|O marrow|O were|O collected|O from|O patients|O at|O diagnosis|O ,|O and|O genomic|O DNA|O was|O extracted|O ,|O whole|O genome|O amplified|O (|O GenomePlex|O whole|O genome|O amplification|O kit|O ,|O Sigma|O -|O Aldrich|O ,|O Seelze|O ,|O Germany|O )|O and|O polymerase|O chain|O reaction|O amplified|O for|O 119|O amplicons|O with|O not|O more|O than|O 5|O amplicons|O per|O well|O using|O standard|O conditions|O .|O
The|O genetic|O ,|O epigenetic|O and|O functional|O data|O suggest|O that|O TET2|O and|O IDH|O mutations|O form|O a|O novel|O mutational|O complementation|O group|O in|O myeloid|O leukaemia|O ,|O and|O indicate|O that|O mutational|O studies|O may|O identify|O additional|O disease|O alleles|O that|O alter|O DNA|O hydroxymethylation|O in|O different|O malignancies|O .|O
Effects|O of|O spliceosomal|O mutations|O on|O spliceosomal|O function|O .|O
[|O ARTICLE|O ]|O .|O
Mechanisms|O underlying|O the|O function|O of|O these|O regulators|O are|O highly|O stringent|O ,|O as|O deviations|O in|O their|O expression|O ,|O chromatin|O site|O selection|O ,|O and|O protein|O -|O protein|O interactions|O elicit|O catastrophic|O phenotypes|O .|O
In|O addition|O ,|O in|O supplemental|O Table|O 1|O ,|O we|O clarified|O the|O mutational|O status|O of|O spliceosomal|O genes|O .|O
In|O this|O study|O ,|O they|O dissect|O the|O function|O of|O GATA2|O in|O normal|O and|O aberrant|O megakaryopoiesis|O ,|O showing|O that|O GATA2|O promotes|O megakaryopoiesis|O by|O driving|O progenitor|O cell|O proliferation|O and|O megakaryocytic|O lineage|O gene|O expression|O ,|O while|O suppressing|O myeloid|O gene|O expression|O .|O
In|O this|O situation|O ,|O it|O is|O necessary|O for|O the|O laboratory|O to|O establish|O the|O minimal|O amount|O of|O signal|O needed|O to|O confidently|O call|O a|O sample|O positive|O .|O
This|O process|O is|O termed|O the|O '|O GATA|O switch|O '|O .|O
However|O ,|O the|O prognostic|O value|O of|O ETV6|O translocation|O has|O not|O been|O fully|O investigated|O in|O myeloid|O neoplasms|O .|O
The|O cumulative|O incidence|O of|O thrombocytopenia|O was|O significantly|O lower|O in|O CALR|O -|O mutant|O patients|O compared|O with|O the|O remaining|O ones|O (|O P|O =|O .|O 001|O )|O ,|O whereas|O no|O significant|O difference|O was|O observed|O between|O triple|O -|O negative|O and|O JAK2|O -|O mutant|O (|O P|O =|O .|O 292|O )|O or|O MPL|O -|O mutant|O patients|O (|O P|O =|O .|O 627|O )|O (|O Figure|O 1B|O )|O .|O
In|O a|O study|O using|O direct|O sequencing|O ,|O lower|O frequencies|O of|O the|O JAK2|O V617F|O were|O found|O in|O all|O three|O classical|O MPN|O entities|O :|O 65|O %|O in|O PV|O ,|O 23|O %|O in|O ET|O ,|O and|O 30|O %|O in|O PMF|O .|O
The|O functional|O differences|O between|O these|O proteins|O have|O not|O been|O studied|O in|O detail|O ,|O but|O this|O might|O be|O of|O interest|O since|O the|O shorter|O protein|O lacks|O part|O of|O the|O C|O -|O ZnF|O domain|O .|O
Statistical|O methods|O .|O
In|O our|O analysis|O ,|O the|O allelelic|O burden|O of|O mutations|O in|O the|O cohesin|O genes|O were|O very|O similar|O to|O that|O observed|O for|O NPM1|O mutations|O .|O
The|O prognostic|O relevance|O of|O RUNX1|O mutations|O in|O CMML|O has|O not|O been|O determined|O earlier|O .|O
High|O expression|O of|O GATA2|O in|O AML|O was|O first|O reported|O by|O Shimamoto|O et|O al|O ,|O who|O found|O it|O in|O 87|O %|O of|O cases|O (|O 54|O /|O 62|O )|O using|O RT|O -|O PCR|O .|O
In|O this|O Review|O we|O discuss|O recent|O genetic|O and|O functional|O data|O implicating|O mutations|O in|O epigenetic|O modifiers|O ,|O including|O tet|O methylcytosine|O dioxygenase|O 2|O (|O TET2|O )|O ,|O isocitrate|O dehydrogenase|O 1|O (|O IDH1|O )|O ,|O IDH2|O ,|O additional|O sex|O combs|O -|O like|O 1|O (|O ASXL1|O )|O ,|O enhancer|O of|O zeste|O homologue|O 2|O (|O EZH2|O )|O and|O DNA|O methyltransferase|O 3A|O (|O DNMT3A|O )|O ,|O in|O the|O pathogenesis|O of|O MPN|O ,|O MDS|O and|O AML|O ,|O and|O discuss|O how|O this|O knowledge|O is|O leading|O to|O novel|O clinical|O ,|O biological|O and|O therapeutic|O insights|O .|O
Table|O 1|O .|O Clinical|O characteristics|O of|O patients|O participating|O in|O this|O study|O .|O
Abnormalities|O in|O cytosine|O methylation|O may|O result|O from|O mutations|O in|O TET2|O ,|O DNMT3A|O ,|O and|O IDH1|O /|O 2|O .|O
However|O ,|O very|O few|O WGATAR|O motifs|O are|O occupied|O in|O genomes|O .|O
Genes|O that|O belong|O to|O the|O cohesin|O complex|O in|O somatic|O vertebrate|O cells|O are|O SMC1A|O ,|O SMC3|O ,|O RAD21|O (|O SCC1|O )|O ,|O STAG2|O (|O SA|O -|O 2|O )|O ,|O and|O STAG1|O (|O SA|O -|O 1|O )|O ;|O these|O genes|O form|O a|O ring|O structure|O that|O regulates|O chromosome|O segregation|O during|O meiosis|O and|O mitosis|O .|O
There|O are|O two|O different|O mRNA|O transcripts|O with|O 3484|O and|O 3263|O base|O pairs|O (|O Fig|O .|O 1|O )|O .|O
Traditional|O therapeutic|O options|O ,|O including|O splenectomy|O ,|O have|O limited|O benefit|O .|O
Sequencing|O of|O large|O cohorts|O has|O identified|O mutations|O and|O deletions|O in|O MDS|O (|O 8|O %|O ,|O 18|O /|O 224|O )|O ,|O CMML|O (|O 10|O %|O ,|O 9|O /|O 88|O )|O ,|O and|O AML|O (|O 12|O %|O ,|O 19|O /|O 157|O )|O patients|O .|O
He|O died|O suddenly|O at|O the|O age|O of|O 36|O from|O aortic|O dissection|O .|O
In|O line|O with|O these|O observations|O ,|O the|O current|O study|O identifies|O additional|O submicroscopic|O genetic|O changes|O ,|O such|O as|O ASXL1|O mutations|O ,|O which|O cluster|O with|O normal|O karyotype|O and|O yet|O portend|O a|O poor|O prognosis|O .|O
Together|O ,|O these|O results|O demonstrate|O that|O the|O SCL|O complex|O is|O a|O crucial|O regulator|O of|O the|O positive|O transcriptional|O activity|O of|O GATA1|O and|O GATA2|O in|O several|O hematopoietic|O lineages|O ,|O probably|O by|O modulating|O the|O activity|O of|O GATA1|O cofactors|O to|O specify|O transcriptional|O activation|O .|O
In|O the|O subgroup|O of|O these|O patients|O with|O AML|O ,|O a|O significant|O survival|O benefit|O was|O found|O with|O 5|O -|O azacytidine|O compared|O with|O conventional|O care|O regimens|O ,|O with|O a|O median|O OS|O of|O 24|O .|O 5|O versus|O 16|O months|O (|O hazard|O ratio|O [|O HR|O ]|O ,|O 0|O .|O 47|O ;|O 95|O %|O CI|O ,|O 0|O .|O 28|O -|O 0|O .|O 79|O ;|O P|O =|O .|O 005|O )|O .|O
Four|O nonsense|O mutations|O were|O located|O in|O the|O RHD|O that|O generate|O termination|O codons|O resulting|O in|O truncated|O RUNX1|O proteins|O .|O
A|O risk|O -|O assessment|O system|O to|O evaluate|O the|O prognosis|O of|O newly|O diagnosed|O patients|O with|O myelodysplastic|O syndrome|O (|O MDS|O )|O .|O
Second|O ,|O and|O more|O importantly|O ,|O emerging|O genetic|O data|O suggest|O that|O there|O are|O additional|O classes|O of|O mutations|O that|O commonly|O occur|O in|O patients|O with|O myeloid|O malignancies|O .|O
It|O will|O soon|O be|O possible|O for|O clinicians|O to|O detect|O a|O broad|O range|O of|O point|O mutations|O in|O peripheral|O blood|O with|O the|O use|O of|O sensitive|O genotyping|O methods|O ,|O which|O will|O not|O only|O improve|O prognostication|O in|O myelodysplastic|O syndromes|O but|O also|O facilitate|O the|O diagnosis|O of|O these|O disorders|O ,|O the|O evaluation|O of|O disease|O progression|O ,|O and|O the|O monitoring|O of|O response|O to|O treatment|O .|O
This|O includes|O decreased|O expression|O of|O signaling|O effectors|O (|O NRAS|O ,|O JAK1|O ,|O and|O CBL|O )|O and|O reduced|O expression|O of|O HIF1A|O ,|O suggesting|O a|O novel|O mechanism|O of|O transformation|O for|O patients|O with|O myeloid|O malignancies|O characterized|O by|O alterations|O in|O the|O cohesin|O complex|O .|O
This|O led|O to|O metabolic|O studies|O that|O showed|O that|O mutant|O IDH|O proteins|O acquire|O a|O neomorphic|O enzymatic|O activity|O that|O converts|O alpha|O -|O ketoglutarate|O to|O 2|O -|O hydroxyglutarate|O (|O 2|O -|O HG|O )|O .|O
In|O general|O ,|O supportive|O care|O measures|O may|O include|O the|O use|O of|O blood|O products|O or|O transfusion|O support|O ,|O tumor|O lysis|O prophylaxis|O ,|O neurologic|O assessments|O ,|O antiinfective|O prophylaxis|O ,|O and|O use|O of|O growth|O factors|O .|O
In|O addition|O ,|O the|O mutation|O status|O of|O the|O RUNX1|O gene|O was|O also|O correlated|O with|O the|O clinicohematological|O features|O and|O outcome|O in|O CMML|O patients|O to|O determine|O its|O clinical|O and|O prognostic|O relevance|O .|O
Studies|O that|O compared|O hydroxyurea|O with|O anagrelide|O and|O with|O pipobroman|O also|O showed|O no|O difference|O in|O leukemogenic|O potential|O between|O these|O drugs|O .|O
Stata|O Version|O 10|O software|O was|O used|O for|O all|O statistical|O analyses|O .|O
These|O candidate|O alterations|O were|O subtracted|O by|O the|O results|O of|O CD3|O +|O peripheral|O blood|O DNA|O and|O subsequently|O validated|O with|O Sanger|O sequencing|O (|O see|O "|O Sanger|O sequencing|O analysis|O "|O )|O .|O
Because|O a|O familial|O MDS|O /|O AML|O was|O suspected|O in|O pedigree|O 1|O ,|O we|O looked|O for|O a|O putative|O germline|O mutation|O .|O
One|O patient|O (|O no|O .|O 26|O )|O had|O 780|O _|O 797|O duplication|O and|O 798|O T|O >|O C|O ;|O cloning|O analysis|O revealed|O that|O the|O mutations|O were|O located|O on|O the|O same|O allele|O ,|O which|O resulted|O in|O frameshift|O and|O a|O stop|O at|O codon|O 460|O .|O
Patients|O with|O PML|O -|O RARA|O or|O t|O (|O 15|O ;|O 17|O )|O -|O positive|O AML|O were|O excluded|O from|O these|O trials|O .|O
A|O comparison|O of|O clinicohematological|O features|O between|O CMML|O patients|O with|O and|O without|O RUNX1|O mutations|O was|O carried|O out|O (|O Supplementary|O Table|O 2|O )|O .|O
LOH|O analysis|O in|O our|O 20|O AML|O cases|O (|O all|O lacked|O chromosome|O 10|O or|O 10q|O deletions|O )|O with|O hair|O follicle|O constitutional|O DNA|O showed|O that|O regions|O defined|O by|O markers|O D10S215|O ,|O D10S541|O ,|O D10S579|O ,|O and|O AFM086|O were|O intact|O in|O both|O alleles|O .|O
Mutations|O in|O codon|O 132|O of|O IHD1|O (|O Arg132|O )|O and|O codon|O 172|O of|O IHD2|O (|O Arg172|O )|O appear|O to|O be|O associated|O with|O shorter|O OS|O ;|O however|O ,|O Arg140Q|O mutations|O in|O IHD2|O were|O not|O linked|O to|O poor|O prognosis|O in|O MDS|O .|O
Of|O the|O patients|O with|O RUNX1|O mutations|O ,|O 11|O had|O normal|O karyotypes|O with|O one|O partial|O tandem|O duplication|O of|O MLL|O ;|O trisomy|O 13|O ,|O trisomy|O 21|O ,|O monosomy|O 7|O and|O complex|O anomaly|O were|O detected|O in|O one|O patient|O each|O ,|O and|O none|O had|O -|O 5|O /|O 5q|O -|O (|O Table|O 1|O )|O .|O
Systematic|O screening|O studies|O found|O that|O such|O mutations|O do|O not|O only|O occur|O as|O sole|O abnormalities|O but|O are|O often|O found|O in|O combination|O ,|O probably|O contributing|O to|O the|O phenotypic|O heterogeneity|O found|O in|O MDS|O .|O
MPL|O .|O
Thus|O ,|O in|O addition|O to|O basic|O cytogenetic|O analysis|O ,|O new|O molecular|O markers|O help|O to|O refine|O prognostics|O groups|O ,|O particularly|O in|O patients|O with|O a|O normal|O karyotype|O .|O
Patient|O number|O 7015|O (|O P6|O ,|O II|O ,|O 2|O )|O ,|O born|O from|O healthy|O parents|O ,|O presented|O with|O several|O warts|O in|O the|O extremities|O and|O on|O the|O forehead|O at|O the|O age|O of|O 4|O .|O
When|O compared|O with|O the|O cohesin|O WT|O cohort|O ,|O cooccurring|O mutations|O in|O RUNX1|O (|O P|O =|O .|O 0001|O )|O ,|O Ras|O -|O family|O oncogenes|O (|O P|O =|O .|O 0001|O )|O ,|O BCOR|O (|O n|O =|O 15|O ;|O P|O =|O .|O 003|O )|O ,|O and|O ASXL1|O (|O P|O =|O .|O 03|O )|O were|O significantly|O enriched|O in|O patients|O with|O cohesin|O mutations|O (|O Figure|O 2|O and|O supplemental|O Table|O 7|O )|O .|O
